<SEC-DOCUMENT>0000950170-24-102919.txt : 20240903
<SEC-HEADER>0000950170-24-102919.hdr.sgml : 20240903
<ACCEPTANCE-DATETIME>20240903171045
ACCESSION NUMBER:		0000950170-24-102919
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		57
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240903
DATE AS OF CHANGE:		20240903

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ascendis Pharma A/S
		CENTRAL INDEX KEY:			0001612042
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36815
		FILM NUMBER:		241274978

	BUSINESS ADDRESS:	
		STREET 1:		TUBORG BOULEVARD 12
		CITY:			HELLERUP
		STATE:			G7
		ZIP:			DK-2900
		BUSINESS PHONE:		45 70 22 22 44

	MAIL ADDRESS:	
		STREET 1:		TUBORG BOULEVARD 12
		CITY:			HELLERUP
		STATE:			G7
		ZIP:			DK-2900
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asnd-20240630.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-09-03T15:57:07.2512+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2023" xmlns:asnd="http://ascendispharma.com/20240630" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>6-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_98362920-f219-4adb-b411-a5a3fe50f58e" name="dei:EntityCentralIndexKey" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880">0001612042</ix:nonNumeric><ix:nonNumeric id="F_7ebee0fe-bbcb-4462-81d3-e43c11577328" name="dei:CurrentFiscalYearEndDate" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880">--12-31</ix:nonNumeric><ix:nonNumeric id="F_7ca06285-1a8e-42b6-956d-23c8742508e2" name="dei:DocumentPeriodEndDate" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" format="ixt:date-monthname-day-year-en">June 30, 2024</ix:nonNumeric><ix:nonNumeric id="F_305bcc60-4e3b-458d-a481-cdf96e35a5ca" name="dei:AmendmentFlag" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880">false</ix:nonNumeric><ix:nonNumeric id="F_dca34ce8-4341-49df-91ec-43789a7c6bc8" name="dei:DocumentFiscalPeriodFocus" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880">Q2</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="asnd-20240630.xsd"/></ix:references><ix:resources><xbrli:context id="C_80565c4e-bb31-49b2-b787-63ca7487b354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82679e63-57f7-42c8-af63-f3c54a3a76ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84865da0-8e28-4c64-b919-2fa941621732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_875630a8-6b06-4d56-b547-543891791c57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89622b42-c78f-4d8c-aa28-7a988bd5583e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">asnd:SalesRebatesAndProductReturnsInUSMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8de101c2-a4a1-4558-b6d8-6845ebd51060"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ef04b98-f458-48b5-892e-fb3c6e17fd2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f91e2fa-63c3-4b7c-88ab-ee542b10c21b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_916a1d45-ad20-4d5e-8c65-dfd11d9b937b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99311e47-32a5-474d-8dac-f41409c83e74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a1ee37c-f52e-4fe7-a481-ffe9c8b8f6b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f234091-2f5a-43d2-b9cb-77a8e49084d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9fd79df1-50c6-4d41-901d-c77df4998cd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a078a24b-80df-47b2-af27-cd002780edca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-29</xbrli:startDate><xbrli:endDate>2023-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a15defaa-f932-466b-bc51-1a68ece7b752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3ac4f0f-c190-458b-a628-87ada275b688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6a141f6-eee5-4acc-a932-da5764785d72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a74af470-e599-4a1e-b963-cdf93c8f8ad0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7df51f1-e149-4eba-96d2-8116875f09ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_abf9a434-e689-4daf-8c60-5e8e573deaff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af63688c-aa98-486a-a73c-5ac60c4f9e6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1459f92-4bdf-48d9-b032-4c65da483b6d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1b4d1e4-24f6-4c89-914e-0c15eb61bcdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesYorvipathMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">asnd:EventsAfterReportingPeriodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1cd9cb9-4b1b-4fea-bbde-9d3bc31d8f4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-29</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2b88484-8cd6-44b7-aec7-488f08ce60a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3eeeb63-6bc6-460d-8c2e-19abe3bd08c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b41da24d-bd30-42f4-a704-1d5714f18704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5bd486e-1131-4c51-9d6b-ba25b8052be8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b5e24c58-8391-46c0-963b-15580b32b822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b745985a-29e1-4fcb-919b-47749840575a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">asnd:SalesRebatesAndProductReturnsInUSMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba212868-8b66-4623-81ce-a65efa8cb9e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd7c5f8f-6386-4bcb-a667-86ed3c7b0c33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">asnd:EventsAfterReportingPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be47076c-c5c2-4398-803d-95bcc128d86b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_becea9f1-8ea3-4a3f-b92c-d1e19a63174b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bfc109b6-0267-4568-8f44-fa14915ce2e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2fcb3f0-5af6-4d4d-b93c-dd673702d997"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4bb41a9-9897-48ff-97d9-d9e4c2fc4102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5bb9cca-7e70-46d1-a292-8e9d545f5c33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c5d652d5-d799-43f6-903b-d2389a4f9c48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7b94f2c-5166-4906-bd69-2ea999d9fd53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8cfaab1-fe5c-43f9-98a6-b5e0e36fcb12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce698de3-cc8b-45e2-bf70-a5c86942e92e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cf326443-9fc3-4acd-8a7b-d10a15c9c639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cf8bec94-85c6-4446-9f8d-25c797b23040"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfd8955d-eb7e-4148-9713-3f97e5f71e44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cff9af56-3621-49bb-95fa-62e774a90dc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d001d487-d74a-42b7-827b-045eca711447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:RoyaltiesAndMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d23709e8-9e0d-4985-a23d-111331fe0a1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d2e575be-2a92-4dca-9d69-cce91f677a27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4a58637-2055-42b3-8157-1d28bda0cf03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d4d49cb8-932e-432f-a338-771c043ea715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5ac3b5c-e60f-478e-83cf-eddc448b6227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5d1312c-4638-41e8-a0fb-c5a22dd1c28e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d66908c6-a5fa-467c-9047-36af0a5ab839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">asnd:EventsAfterReportingPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d75b971a-1f5c-45c3-9cf0-b42af670311f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9e73adc-e2fa-4a69-a5e0-c417bc7c2b6e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9f93835-5fdc-4307-9a1f-a342ff26fcd1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da85c345-157f-4aeb-af0c-84f018bd921c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dbce7df2-7245-4497-93d8-ee51d52959af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dca280d3-48db-4166-b87b-1d80627ed422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dff101ac-1dfc-4e89-bbe4-f6d1091007b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e47ee6ea-6244-4fae-841d-df097dd0610e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e661bb05-fc48-440a-941f-d142682c6c26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6982966-8271-4e1c-b818-503cfb91de1c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6cdfa0f-6832-4fea-9068-94b3c87d8f1f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e94750b4-4124-4fd8-8705-f5583e219191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ea6471ce-cfa4-4d71-8f75-d5e623498d8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb095a6e-1284-4325-9346-7b0d477b86e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed967469-6caa-47a7-ad87-51a13e77b2b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee58604e-a45e-405b-aac6-1e95591f95f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee64b1a5-0ac7-4bae-bf54-7e5e49b1964e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eea519f3-ad46-4ee7-85b0-8608cf3c21c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0e8016e-5734-4177-91b0-d52b46d6a142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f87b4034-74cf-4447-b713-7401524f3969"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9148b7d-21b7-44df-8bda-8e6396f928c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb30e055-a4bd-4504-a481-e7270ff2a4d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc29bc9d-a605-4ae9-bbea-0edd6dc89dde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe41fa87-a9a5-445e-889a-4a84ce27e626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01332415-aee7-4777-a043-a57648e597b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04baf03f-f9bb-4f2a-83ab-f0cc09cff3da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0566eec3-61b9-4678-9b3a-a122291dbee2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08eccbc8-30a4-467c-8814-e3da8f51a6a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0901f291-b6cf-4be5-8d74-9686996cf492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0a89dad9-4f70-4ce9-b6cb-3b23f0d335f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0be81193-83e1-496a-b2bd-963e7a3ae019"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cea65b1-8e2e-4700-abec-c50d25040dcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d563d87-8d91-4eb6-a982-541081c3f97a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:RoyaltiesAndMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d721657-d4bf-491a-b07d-d4d0a337317b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0eaa7d1b-df57-4e29-a988-3e72ff479760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f31b8c9-3f3e-45ff-b2dc-b529c435f24b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0fda0982-6a94-4187-a702-171d557879fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11cc6832-e075-4630-91b6-6f66a1b43e2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_120df43c-ac40-4949-bdf1-72d7e1be8540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12efaec8-00be-4d5b-a2c1-d97f9f8f9802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_17f53fa0-ac0d-4634-a8a3-82386070a977"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_187cae39-2542-4e99-8ed4-2163bbbdd410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_18a4bc8c-4933-49e5-bb82-fff50688e62b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a075a8f-0d93-49ae-991b-20bf71825ac3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1eee9ac4-42e3-4c2a-b3db-f3d552da0c91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-29</xbrli:startDate><xbrli:endDate>2024-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ff24599-9bec-4004-890e-f2cabcf62656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_225597ce-7a29-4ac4-bf28-15c7db56cb1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22691430-ca22-41f0-9568-18019e721ba9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_226b71fb-e2f1-440b-9ce0-1b02d378af1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24e1c394-8155-4ccd-9e4a-59d9e1ec986d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26726fd6-ee62-4142-bc95-a08f61caedc3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_276506bc-fed9-44d5-bde0-317663083ca8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d38989e-7833-45b0-ae39-4b7e1ff91a47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32e6f681-0344-457f-8a03-21f7d9f10b40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34124e79-d811-40a9-b5d7-6e45ec01b712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34afc0af-3b75-4c01-8ab1-e8ee319238ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_398210cf-1fd9-4c1e-939e-e91ca03161c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39a0db7a-f4cf-4e59-a617-6a1e70c6bcfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b38ee1f-0d21-4c30-b4e6-b4a0842378c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d46e5dc-bcc4-472a-9b45-7da68fed384e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44cab9aa-2fd6-48de-9166-d81f187ddff5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44d7ff3b-a312-4758-9d5a-9853401406cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45be4da6-fe2a-4d4e-95dc-772befc84731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4875ac0d-47d5-4a79-b057-425d568f5baf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49e1466f-2be7-41f1-9dd9-ebfd767c7ab0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4bfef56a-6c92-4668-b539-a03819e7ccb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c6f70b1-9efa-4bae-96b1-ae13a04d5ec3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">asnd:ForeignCurrencyConversionOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d022a29-849f-49c1-8fcf-8bc1ea086dfc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e7c4bb8-3ee7-41bc-9070-e5a4f8998df8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f8a6e8b-b214-487d-a30f-ae5d8fab47d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_515c180b-f403-4c76-ab33-f262096366f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51bb1848-afba-426b-b5e1-8227d0a04edf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5233396e-84c8-4084-9018-ab624a6eebc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_539b6d7b-9d56-47fe-9068-c2dcb0874079"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53d2ec13-fbb3-43f3-8664-1c7545479049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5578ada0-929b-48b2-bebc-ff63e89ab5f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_567228fa-89e0-4f5f-91c5-10eec549d109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">asnd:EventsAfterReportingPeriodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58b82036-71f0-4630-b251-42c9dc52172f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59fa5ae0-47b2-46af-9d0c-e8a4358f7f81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a7beea2-de57-4790-91d5-5d1200eacac6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a94d79c-4291-4d0a-b8bb-268dad9a101c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ad1bdbd-dc10-4a8c-b928-7615e2fbcdc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b082919-9fbb-47d2-96d1-56d15ab71d5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60329ad0-04b9-486e-902b-e170a080d6a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_607615b8-3c2e-4bf2-ae45-963ac837db9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60e20bc2-5206-4d1b-b79b-82ec729f7143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64ff6bf5-a7fc-4f5e-87e7-121d85ebad42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68b6a5ee-4fe8-4f12-a551-652ec2097752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6be2f049-eb3c-45d2-b25b-1ce6e49e5a4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70a9c3db-ba5b-4b53-9757-db806da4769e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_73c5c8ba-1fdd-4912-bbd7-e04f001ad88b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_74b79d5a-c86f-4a0e-b7fd-c61544cc9d20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_755b6ff2-16af-4b77-aef3-7e63b09f7644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_756073fe-efcc-4ad7-914c-18bd04b9013e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c55eeb6-4f32-446b-889f-4e47524ee405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d3624fd-d503-4996-b6ea-8dbd9da04208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d5f46e4-3795-445e-9938-80e373d5b80d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f8c7ce5-86c4-4f44-b5a8-e85f28bd20e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="U_Agreement"><xbrli:measure>asnd:Agreement</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>asnd:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Days"><xbrli:measure>asnd:Days</xbrli:measure></xbrli:unit><xbrli:unit id="U_XBB"><xbrli:measure>iso4217:XBB</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_DkkPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:DKK</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_CommercialCustomer"><xbrli:measure>asnd:CommercialCustomer</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Multiple"><xbrli:measure>asnd:Multiple</xbrli:measure></xbrli:unit><xbrli:unit id="U_EurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_13751f10-8ccb-4870-982f-e026f2425cce" fromRefs="F_524f7c83-ae41-47ce-8c40-f85ecc391045 F_5b333498-0653-46a4-872f-fc79e7006884 F_8a589942-865c-4e8d-8663-eb005469b812 F_084333b3-53b3-4ef1-99d1-28a4da53ed19"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9ad1a90d-8cff-4b98-acea-9a4e46db3f0e" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">6-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">REPORT OF FOREIGN PRIVATE ISSUER</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PURSUANT TO SECTION 13a-16 OR 15d-16</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the month of September, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a7f23a8-94c1-406f-8456-378dbdeee588" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2024</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Commission File Number: 001-36815</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e54b22d-eced-4fb9-abc7-8fd5889dc140" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Ascendis Pharma A/S</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact Name of Registrant as Specified in Its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Tuborg Boulevard 12</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">DK-2900 Hellerup</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Form 20-F  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">                Form 40-F  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INCORPORATION BY REFERENCE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-228576, 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-254101, 333-261550, 333-270088 and 333-277519) and Form F-3 (Registration Numbers 333-209336, 333-211511, 333-216882, 333-223134, 333-225284, and 333-256571) of Ascendis Pharma A/S (the &#8220;Company&#8221;) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="border-top:0.75pt solid #000000;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Information Contained in this Form 6-K Report</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This report contains the Company&#8217;s Unaudited Condensed Consolidated Interim Financial Statements as of and for the period ended June 30, 2024, including Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the period presented therein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:1.333%;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.347%;"/>
    <td style="width:1.02%;"/>
    <td style="width:3.061%;"/>
    <td style="width:45.571%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Ascendis Pharma A/S</span></p></td>
   </tr>
   <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: September 3, 2024</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Michael Wolff Jensen</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Michael Wolff Jensen</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Executive Vice President, Chief Legal Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="toc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TABLE OF CONTENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:2.525%;"/>
    <td style="width:92.465%;"/>
    <td style="width:5.01%;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidate_nterim_financia"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unaudited Condensed Consolidated Interim Financial Statements &#8211; June 30, 2024</span><span style="color:#0000ff;white-space:pre-wrap;min-width:fit-content;"> </span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2.</span></p></td>
    <td style="text-indent:12pt;vertical-align:bottom;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#managements_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="padding-left:0.1in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASCENDIS PHARMA A/S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="condensed_consolidate_nterim_financia"><span id="tx355617_1"></span><span id="index"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:98.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:91.837%;"/>
    <td style="width:8.163%;"/>
   </tr>
   <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Page</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unaudited_cond_consol_interim__of_profit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unaudited Condensed Consolidated Interim Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) for the Three and Six Months Ended June 30, 2024 and 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;F-2</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#un_cond_co_int_st_of_financial_position"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unaudited Condensed Consolidated Interim Statements of Financial Position as of June 30, 2024 and December 31, 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;F-3</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#una_cons_inter_state_of_chan_in_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unaudited Condensed Consolidated Interim Statements of Changes in Equity at June 30, 2024 and 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;F-4</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unaudited_co_consolid_interim_cash_flow"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Unaudited Condensed Consolidated Interim Cash Flow Statements for the Six Months Ended June 30, 2024 and 2023</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;F-5</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="text-indent:12pt;vertical-align:top;"><p style="text-indent:-12pt;padding-left:12pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Notes to the Unaudited Condensed Consolidated Interim Financial Statements</span></a></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;F-6</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="unaudited_cond_consol_interim__of_profit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Conden</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">sed Consolidated Interim Statements of Profit or (Loss)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and Other Comprehensive Income or (Loss) for the Three and Six Months Ended June 30, 2024 and 2023</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.208%;"/>
    <td style="width:1.141%;"/>
    <td style="width:5.143%;"/>
    <td style="width:1.141%;"/>
    <td style="width:1%;"/>
    <td style="width:8.487%;"/>
    <td style="width:1%;"/>
    <td style="width:1.141%;"/>
    <td style="width:1%;"/>
    <td style="width:8.487%;"/>
    <td style="width:1%;"/>
    <td style="width:1.141%;"/>
    <td style="width:1%;"/>
    <td style="width:8.487%;"/>
    <td style="width:1%;"/>
    <td style="width:1.141%;"/>
    <td style="width:1%;"/>
    <td style="width:8.487%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Notes</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Consolidated Statement of Profit or (Loss)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98dbc364-ef81-418d-86c1-ba8422eb810a" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,998</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f1ea7a4-3763-4312-b3d8-12895e907f51" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,393</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3710bc06-a3ba-47cc-9ea2-6f91a79e203a" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,892</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_adb08bb3-72a9-4eff-be34-0fd7a272d99f" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,982</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of sales</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d9b81726-d120-484e-9b75-2974d9008fe2" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:CostOfSales" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,465</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cdd65880-d55f-4e25-9f7c-31e862fd43ec" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:CostOfSales" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,929</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b4de2e3b-575b-4f32-a953-203fb5229819" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:CostOfSales" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,034</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b7814773-1117-4d58-a09c-fd2c939de656" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:CostOfSales" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,551</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Gross profit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_503b48fa-4421-472a-9882-d2c489a33187" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:GrossProfit" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,533</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c70a4b04-adb7-4397-b7bd-86c2a59d232b" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:GrossProfit" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,464</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c2b5d20f-08e5-4692-853a-5c532157f016" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:GrossProfit" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">112,858</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_0992e5cf-b455-43e6-925d-9a0a8cb43b98" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:GrossProfit" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ce7ec23-6cf3-45ed-92ba-4eef2d904d3c" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,478</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f843dff4-4de0-4a37-ad54-d380b5a12d78" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">105,021</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0474ab13-33bd-4409-aae6-477a1c9bb521" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">154,165</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1765de0-81e9-42a3-b35d-46a0a3106402" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">211,134</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_880bf0f2-147d-4dbc-9b0e-ee680f0526b7" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,312</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcd39260-b5ad-4ebd-8147-3bbaf8fa1441" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,281</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90c0918c-d7b3-47f7-b2ba-bb16f9718ffd" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,095</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5c4b6087-a8d7-4465-a221-32fc70b163af" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">136,820</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating profit/(loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_445e53de-b802-4023-925b-204b45224f28" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:ProfitLossFromOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">133,257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_33c90628-0f26-4fb7-942a-6ae9e3942539" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:ProfitLossFromOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">140,838</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_f994be03-cade-4910-bd47-38048edc4d21" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ProfitLossFromOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">182,402</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c03a027d-fe8a-4498-952e-2ba30414b7f9" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ProfitLossFromOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">284,523</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share of profit/(loss) of associates</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83bc2bbc-4e6c-450f-8719-3414e9a17f40" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,322</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fcff9022-0471-46c0-a9c8-f6f52afde1df" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,451</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d5335e4b-f6bc-4c66-8d8f-01e87ef9cbbb" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,118</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_839ec1e9-d020-4774-a096-8b33518e934e" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,677</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_437d35fc-678c-4834-b89a-647857d95c00" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,052</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6697fe97-553c-4537-a4ac-6821f4f2a88b" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,761</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_895edca5-5468-45c3-a8b8-f73343d97508" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,395</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_178be397-491e-4911-9423-2fde84217078" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,374</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ee008f0-0e7c-489e-9130-4362f7245f87" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,624</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5d3db34f-d2fe-4817-a50f-d24d4ce0b26c" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,334</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d927dbd4-278e-4be6-8061-efcc25b4acba" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,553</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a0e8d50c-e098-4fda-b6ed-ad0076d3bcb3" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,652</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Profit/(loss) before tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_f7594020-ce76-4a44-88d8-f5d29f170602" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,151</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_345e32ad-3d9c-4af2-9520-9c65666b22dc" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,862</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_d501fa2e-83da-43b1-a374-69a5d5e3b0d7" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">237,678</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_99959afa-b96d-4c0b-87fd-cd9b3e5a6daf" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">231,478</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income taxes/(expenses)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ad151a7-70ca-408e-ab99-8c3ee662087e" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">229</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0c1b3d04-89bb-47a0-b665-0c9902564342" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">429</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e76093a-a0c9-4256-b53f-2490cf141a3f" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,737</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb931759-5d3a-44ee-b368-6a6b360cc1a2" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">868</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_cfd192f8-0e83-4573-8df0-52bee0245fc7" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,380</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_8533e4ac-f5fc-4d5b-b064-a41743ee4c55" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,433</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_b46e7905-a9ef-4e45-8fa4-dae79ce5ea02" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_78a3339a-4e32-478b-82d0-83767d399274" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">232,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Attributable to owners of the Company</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c258d69-ca59-48d9-a8e7-2a8d410a0c19" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,380</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7c822d8d-5321-4d60-a36a-93cadaf09876" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,433</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57503442-4fa2-4b91-bd25-8db48b715624" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dc21e1cd-531a-4cb4-aa30-1a01e9f949f8" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">232,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Basic and diluted earnings/(loss) per share</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#8364;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7b7123d3-ba86-48ae-b983-f4e475cc20d2" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:BasicEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_3fd4c353-2970-41d8-b1a0-e761bff6735d" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:DilutedEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.91</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#8364;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_155d219f-8ef0-4eaa-8f56-f70fb7cacaf3" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:BasicEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_96578553-0cee-427e-8fb4-d701811757f2" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:DilutedEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.16</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#8364;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f910941-e329-4329-baa7-68465982599a" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:BasicEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e044379b-3224-4148-abd5-a60452218101" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DilutedEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">4.21</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">&#8364;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5ce5cc44-f3f2-4ac9-98e2-d0f31e515fe6" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:BasicEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_22f96721-0f62-46a8-a284-2c2708009d83" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:DilutedEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">4.14</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Number of shares used for calculation (basic and diluted) </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5b333498-0653-46a4-872f-fc79e7006884" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:WeightedAverageShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">57,345,613</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_084333b3-53b3-4ef1-99d1-28a4da53ed19" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:WeightedAverageShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">56,218,257</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8a589942-865c-4e8d-8663-eb005469b812" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:WeightedAverageShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">57,114,435</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_524f7c83-ae41-47ce-8c40-f85ecc391045" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:WeightedAverageShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">56,155,441</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Consolidated Statement of Comprehensive Income or (Loss)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_45b757b7-778e-406c-ae2b-99006c099b87" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,380</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_a8c66272-f922-4bb2-b02e-ec8e0ca28725" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">121,433</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_9ed5816d-bb29-4f43-a267-8b187c072a87" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_0e09851d-0036-41d4-af2d-366a32416fa2" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">232,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other comprehensive income/(loss)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;min-width:fit-content;">Items that may be reclassified subsequently to profit or (loss):</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exchange differences on translating foreign operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ab3c8ec-5199-4fc0-bab2-a240c4d54b26" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b35158f8-1e43-492c-a571-363f41449508" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,016</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce62f9e9-201b-4f24-805d-85e6cec0c893" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb983484-bf90-48e9-9796-6ad988bcd361" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other comprehensive income/(loss) for the period, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_fdc6d627-c930-41f9-b236-1f88567da079" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_2ab05e23-64e1-4e9a-97e3-30815aab9077" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,016</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_db96393e-6583-49bb-9998-982cfeb2d010" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_7421433f-dcb2-4643-b003-eec50cb04de7" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total comprehensive income/(loss) for the period, net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_8a33915e-c247-45a4-b684-07c592f1b780" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,365</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_f57004ff-987f-46f2-a6fa-b676b9765e31" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">122,449</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_461a8c3d-8b35-4446-961c-1180c33f0321" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,337</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_890e7ed1-ce7c-4eb8-94a3-c139895240a8" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Attributable to owners of the Company</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d30afef2-2872-4d34-97c8-b5862e25147e" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">109,365</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4b44f1be-24ab-465b-9738-d1d92a511d59" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">122,449</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_85bf780b-18bb-4df4-b69b-f228ee24c810" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,337</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4a304574-a392-4a7a-9145-59abb63c5092" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8pt;font-family:Times New Roman;transform-origin:top left;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_13751f10-8ccb-4870-982f-e026f2425cce" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and June 30, 2023, a total of </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_236e0152-c612-4210-ae4c-9b7995743eb0" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:NumberOfWarrantsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,107,875</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4dbc0000-8b55-4dd2-b312-32fab65e4a1b" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="asnd:NumberOfWarrantsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,866,241</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> warrants outstanding, respectively, each carrying the right to subscribe for one ordinary share, and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5190953-aff8-4d00-8523-7dc220eecf74" contextRef="C_abf9a434-e689-4daf-8c60-5e8e573deaff" name="asnd:PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">575,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> convertible senior notes which can potentially be converted into </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a5b285fc-669d-45da-a1c4-bad41bed4f43" contextRef="C_64ff6bf5-a7fc-4f5e-87e7-121d85ebad42" name="asnd:NumberOfWarrantsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,456,785</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares, can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the periods presented. </span></ix:footnote></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="tx355617_4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Condensed Consol</span><span id="un_cond_co_int_st_of_financial_position"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">idated Interim Statements of Financial Position</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:61.488%;"/>
    <td style="width:1.5%;"/>
    <td style="width:6.699%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:12.138%;"/>
    <td style="width:1%;"/>
    <td style="width:1.02%;"/>
    <td style="width:1%;"/>
    <td style="width:12.138%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Notes</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,<br/>2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-current assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ec5dfb78-b7c7-49e7-9448-c5a264379a58" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,186</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e57b3a9-8415-4520-b190-e7623aa77a8b" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,419</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property, plant and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6686650c-5b23-4186-b9f5-c0e5db8ed12b" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">104,041</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd576b10-7e04-442f-b95a-46b778291a84" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,634</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investment in associates</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_748db188-92fe-4278-a346-3137854bce05" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:InvestmentsInAssociates" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,564</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9dc19c89-9bf1-49f4-a7c1-5e3d7ae71023" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:InvestmentsInAssociates" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,686</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14cecb2f-06cb-4fd6-aa2f-fda59e2f5320" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:OtherNoncurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,186</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_233ee51a-aad9-4832-ad75-b10f6b9e9200" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:OtherNoncurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,127</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_5d2ed3cf-6352-4055-913f-e9a4e6510165" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:NoncurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">130,977</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_e657ec17-8454-43a1-88d8-54894f39488b" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:NoncurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,866</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current assets</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ddf6618-af50-4ec2-bf8e-597af3d5da4d" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:Inventories" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,199</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dc349cc-2616-47e9-9d87-5b4ce08ffc77" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:Inventories" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,931</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08f8b877-cf65-4968-82cd-9199cd1f24cf" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CurrentTradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,163</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_67abc51f-3bcb-4f46-83db-eb370da16f59" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentTradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,874</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51322fdd-e1ab-444b-82cc-097dd46ce565" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CurrentTaxAssetsCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,841</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1967865c-c743-4421-aa13-6d4bd424ec09" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentTaxAssetsCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">802</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfb6fdc3-41e6-4374-ad84-4fc63b348c9c" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:OtherCurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,679</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c97d3a3-4fb6-4b41-860c-543a94f30be5" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:OtherCurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,097</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepayments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bceb0a5d-2672-4353-b448-3137cf8239e1" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CurrentPrepayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,743</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_700359cb-1f36-4eea-9927-994eaeb60ffa" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentPrepayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,578</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10081e95-7dee-4f9c-b819-bd02f863f53c" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:MarketableSecurities1" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_49564e5c-380a-4e0f-8662-ab6867d57b24" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="asnd:MarketableSecurities1" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,275</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6378753c-31a0-4fe8-adab-c383c13d42cb" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,696</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1ea4e60-53d4-4e7d-b845-1a989bde68de" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_ed950255-5eab-44df-bc7b-ac5eb46c323e" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">627,321</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_44dffc56-8fa3-443c-b2a6-4e7632e6014d" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">702,721</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total assets</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_64022296-31c9-4bc0-a13a-4bed75e0612c" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:Assets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">758,298</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_fa26f540-87ab-4661-910d-3b5d76a9c04d" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:Assets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">825,587</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">  </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity and liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share capital</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">8</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d37dc391-8738-4cda-bc35-a7fd02b556ba" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:IssuedCapital" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,819</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4468caae-728d-4f21-84e9-903706d21fb8" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:IssuedCapital" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,749</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Distributable equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3b9f2286-8740-4dbe-b79d-a8b4d704c6b0" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:DistributableEquity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">328,952</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_729541c0-268c-4e4e-9f85-a9a6598f58b6" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="asnd:DistributableEquity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">153,446</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total equity</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">4</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_9aafd48e-5a97-4054-94fb-bf0f4f678b4f" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">321,133</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_7a50cee2-f81a-4c0f-9457-ae618f65b38d" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145,697</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Non-current liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2, 10</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8097d2a4-90c1-4949-9388-b3fd707c4e5a" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:LongtermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">219,052</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3158cf98-5517-43b7-b02e-e56e57bb504c" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:LongtermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,996</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c107a77-c10e-4085-a2dd-6afe44b3d82d" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:NoncurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_91592c61-ac7a-4a8c-b02f-4a7d390f9fa6" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:NoncurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,949</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Deferred tax liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65d873f0-2a15-4658-a406-e1d69db292e6" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:DeferredTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,644</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1af6c97d-a6df-4125-8a82-6404e0e630cf" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:DeferredTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,830</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c43442be-486a-4f81-865d-c9494312ec06" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:NoncurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">231,696</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_57f697bb-02ca-4ba1-a9e0-60565488b080" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:NoncurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">234,775</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Current liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Convertible notes, matures in April 2028</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2, 10</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba71a074-3159-403f-a9c3-8c121f66028e" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:ShorttermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">432,190</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_41aa71c5-385e-434f-96a1-ef39cddad894" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:ShorttermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">407,095</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Derivative liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2, 10</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a61611a6-0669-4796-a221-fe8d8775b222" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CurrentDerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,059</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_10a4d01f-45ce-4892-8284-1013ef13b263" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentDerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_f033e3de-3d02-46df-9570-a8f387bb6490" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:ConvertibleNotesCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">591,249</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_4db275dc-86a6-4799-91c1-bcc3b23e5975" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="asnd:ConvertibleNotesCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">550,391</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;min-width:fit-content;">Other current liabilities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2, 10</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_056e797e-2c05-4db7-a993-dd344b5ce128" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:OtherShortTermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,397</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_391a6cde-2c4a-42d1-81ef-fbe85b4890c4" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="asnd:OtherShortTermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,174</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bddcbac3-ee19-4e9a-a7db-fe52df162c6a" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,293</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d098eeb5-066d-4cdc-88c8-c4c91af0542a" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,184</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3075070-9217-4c64-94b6-72efde8be358" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,527</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a783ab8c-b33f-4cb5-a0d3-db14a43cba75" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,566</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">10</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_96fdc6a5-d144-4e93-96c6-294a6fb72acb" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:OtherCurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,411</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_612a2e7c-8e09-4c3f-917c-5f33528ebeb8" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:OtherCurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,176</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income tax payables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8f10b3a2-b96c-4713-9158-32a3bd8b8953" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CurrentTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,090</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ce9e534c-d8db-4ce7-abee-d76dcf664ac1" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,299</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Provisions</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">3</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70af1a0e-26bc-4b04-a927-070e546790be" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">106,768</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_197f6a85-94fe-465c-a124-57b8fda7252c" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,719</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_8146482c-44ef-4e73-b09f-5a8e7ca871a6" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:OtherCurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">256,486</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_8bbbf781-28ad-479c-86a6-3344dba03d2e" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:OtherCurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">186,118</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_5fed9d14-4a81-40dd-8b00-9c1197645472" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">847,735</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_74ee0fa5-ceef-4f77-8881-1d42c5515e22" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">736,509</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_79eca445-a392-42ea-960e-484398badb85" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:Liabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,079,431</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_cf9e20cb-43d0-4ec4-8a31-4e0f524a15f5" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:Liabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">971,284</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total equity and liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:middle;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_fc2f364c-b3c5-41e0-a467-66fc7a68fb7c" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:EquityAndLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">758,298</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_366def8c-0803-4cb0-945b-8ff5c883022a" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:EquityAndLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">825,587</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="tx355617_5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited </span><span id="una_cons_inter_state_of_chan_in_equity"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Interim Statements of Changes in Equity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.808%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.481%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Distributable Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Share<br/>Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Share<br/>Premium</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Treasury<br/>Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Foreign<br/>Currency<br/>Translation<br/>Reserve</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="22" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity at January 1, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_9fc41c57-50ab-4eeb-be27-7df032cf79a2" contextRef="C_539b6d7b-9d56-47fe-9068-c2dcb0874079" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,749</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_8b0d8596-89a8-4c61-9240-5e500836ddb6" contextRef="C_18a4bc8c-4933-49e5-bb82-fff50688e62b" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,123,074</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_00ce142d-a16e-4c32-8717-5394fdfef3c1" contextRef="C_34afc0af-3b75-4c01-8ab1-e8ee319238ab" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_cb34fba0-e86c-4cda-9404-9620f9a120c2" contextRef="C_60329ad0-04b9-486e-902b-e170a080d6a9" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">721</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c339653c-a4a2-41eb-9149-4ecd827dc523" contextRef="C_11cc6832-e075-4630-91b6-6f66a1b43e2c" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,277,095</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_6aae2350-73b0-4ae2-9bb0-c5d226bdc001" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145,697</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cb3ce5bb-2db1-4632-9ace-7aadc9e7a282" contextRef="C_8f91e2fa-63c3-4b7c-88ab-ee542b10c21b" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_6bc96047-4c11-42d7-963d-fec7a484d62d" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income/(loss), net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a2b30796-42b5-4530-9e67-6812a98bb4c1" contextRef="C_08eccbc8-30a4-467c-8814-e3da8f51a6a7" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_479d5a18-f519-4d50-a88a-71288a73a0cd" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total comprehensive income/(loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_994137d0-45a2-4489-ac08-1f5fa2613322" contextRef="C_08eccbc8-30a4-467c-8814-e3da8f51a6a7" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">78</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_bce4c34e-1251-4a5d-b4e7-6839ca99272a" contextRef="C_8f91e2fa-63c3-4b7c-88ab-ee542b10c21b" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_77c5f1af-ad65-440a-a6a6-f39d0a27b5ec" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,337</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Transactions with Owners</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based payment (Note 7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0592f7a8-8532-45e6-a5c3-5dfaa6f1014c" contextRef="C_8f91e2fa-63c3-4b7c-88ab-ee542b10c21b" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,327</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_ecaf0144-4186-4b78-bf4a-bfb7feb3677e" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,327</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transfer under stock incentive programs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f6399d61-491a-4e4b-b364-a1fb1545b658" contextRef="C_58b82036-71f0-4630-b251-42c9dc52172f" name="asnd:TransferOfTreasury" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6b31a518-b051-45af-9364-4b2f855bd7c7" contextRef="C_8f91e2fa-63c3-4b7c-88ab-ee542b10c21b" name="asnd:TransferOfTreasury" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capital increase</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8217269-1869-456e-9e9c-913b5d826261" contextRef="C_607615b8-3c2e-4bf2-ae45-963ac837db9f" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">70</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_59e83e16-76fe-45d6-a45f-0f9e8e5e441b" contextRef="C_4d022a29-849f-49c1-8fcf-8bc1ea086dfc" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,504</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_048a55cf-c22a-4351-90f1-5dca978ebbff" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,574</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity at June 30, 2024</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_59c04b3d-87a8-4d77-b0cd-b2cef1a11590" contextRef="C_eb095a6e-1284-4325-9346-7b0d477b86e0" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,819</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_24f5c7a1-d264-4c6e-81e5-ca47e8f2ee70" contextRef="C_80565c4e-bb31-49b2-b787-63ca7487b354" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,144,578</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_72cbbbd7-c550-420d-9a09-0630ab0306a8" contextRef="C_68b6a5ee-4fe8-4f12-a551-652ec2097752" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_ef115822-0cf1-45a6-97c3-c017b8ee8d11" contextRef="C_17f53fa0-ac0d-4634-a8a3-82386070a977" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">799</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_691a9b98-89b3-4633-8f77-01a033313daa" contextRef="C_fe41fa87-a9a5-445e-889a-4a84ce27e626" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,474,211</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_8d8243e4-9993-4ce7-abf8-e24865d510ae" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">321,133</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.808%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:6.941%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:7.481%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Distributable Equity</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Share<br/>Capital</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Share<br/>Premium</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Treasury<br/>Shares</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Foreign<br/>Currency<br/>Translation<br/>Reserve</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="22" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity at January 1, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_460bc0d6-f87d-4110-b074-5fcb2d67e17c" contextRef="C_e6cdfa0f-6832-4fea-9068-94b3c87d8f1f" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,675</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_31b382a9-bb13-469c-aeca-7001c89918a9" contextRef="C_dbce7df2-7245-4497-93d8-ee51d52959af" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,112,863</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_822c4751-2e5a-4950-88df-5b10030e37ca" contextRef="C_a3ac4f0f-c190-458b-a628-87ada275b688" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_a91a6645-aadf-4c1f-9c04-0e72b3aefd3d" contextRef="C_fb30e055-a4bd-4504-a481-e7270ff2a4d0" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,452</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_33d5b95c-77c0-4fa9-98bd-79737240fe45" contextRef="C_225597ce-7a29-4ac4-bf28-15c7db56cb1a" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,860,493</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_739151e3-b9c3-467c-ab38-eadd564c8378" contextRef="C_875630a8-6b06-4d56-b547-543891791c57" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">263,348</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b71d08c7-eaae-43b7-946b-a39ca4bc5175" contextRef="C_a15defaa-f932-466b-bc51-1a68ece7b752" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">232,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_fdbe50e7-e444-466e-bad6-51c67a42e6b7" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">232,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive income/(loss), net of tax</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ad28e8d3-e2fa-489b-9552-f3ecf32aa2e7" contextRef="C_9f234091-2f5a-43d2-b9cb-77a8e49084d4" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_99fd2b31-bf5c-445d-945e-bceeb5cb0e1d" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total comprehensive income/(loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_e16e837e-b59f-437b-9130-5331850473c0" contextRef="C_9f234091-2f5a-43d2-b9cb-77a8e49084d4" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,803</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c5fecdb3-03e3-49c2-a2a6-154a303a1a4d" contextRef="C_a15defaa-f932-466b-bc51-1a68ece7b752" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">232,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_702e98e7-7623-4b9f-bcf7-00b1f7806ac1" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">234,149</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Transactions with Owners</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based payment (Note 7)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3f803551-1191-4ac6-96b8-119c41987aaa" contextRef="C_a15defaa-f932-466b-bc51-1a68ece7b752" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,568</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_3f284b2b-4c96-405b-8e07-f60ab229ab57" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,568</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capital increase</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3e46ffdf-6f21-4902-8ee0-74ab0debd762" contextRef="C_5578ada0-929b-48b2-bebc-ff63e89ab5f2" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">24</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b57fc59e-f854-408c-88bf-eae2e36afa82" contextRef="C_4e7c4bb8-3ee7-41bc-9070-e5a4f8998df8" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,050</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_25486fde-6391-4820-9417-4fdaaaaf54ce" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,074</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Equity at June 30, 2023</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c5dcd651-a6d4-4d53-95e6-d0f7c9649a4b" contextRef="C_c8cfaab1-fe5c-43f9-98a6-b5e0e36fcb12" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,699</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_82556213-f429-4713-ae26-5200d7447d69" contextRef="C_5ad1bdbd-dc10-4a8c-b928-7615e2fbcdc2" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,114,913</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_0e3a96a5-28f0-4fa6-b8f6-c8bf6de8e73f" contextRef="C_7d3624fd-d503-4996-b6ea-8dbd9da04208" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_2d6361b1-6957-400b-b13f-71cb8a8e4c6f" contextRef="C_af63688c-aa98-486a-a73c-5ac60c4f9e6e" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,649</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_d8f00593-e0c7-4197-83bb-53840525fff0" contextRef="C_398210cf-1fd9-4c1e-939e-e91ca03161c0" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,059,271</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_b0e5ee10-858b-41d3-b67c-9403b6c9d003" contextRef="C_f87b4034-74cf-4447-b713-7401524f3969" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,841</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="tx355617_6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unaudited Condensed </span><span id="unaudited_co_consolid_interim_cash_flow"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Consolidated Interim Cash Flow Statements for the</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Six Months Ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.967%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:13.357%;"/>
    <td style="width:1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:1%;"/>
    <td style="width:13.357%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Operating activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_7f6c6dc6-f450-4192-abe7-f0fd45908744" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">240,415</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_652c1ada-451d-4bdd-9818-bf2b866af0e9" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">232,346</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reversal of finance income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0a6d1e16-72f3-4004-b840-fc34542353de" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,395</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5504240-8005-43a7-85d7-6b30904d70e3" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,374</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reversal of finance expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fa050aca-0ad4-4d12-a7a5-4831ed1cbf8f" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,553</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90980bf1-9caa-44b2-968e-cdaa2c0c4440" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,652</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reversal of (gain)/loss on disposal of property, plant and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_668d5afc-9514-4452-9891-2fa1e04d0def" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_33fc0f80-dd23-4801-9919-806e640f8428" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">21</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Reversal of income taxes (expenses)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_83b46eea-ba2f-4b09-ace9-0963b3c2382a" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,737</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5501057-57b2-40a7-bac2-bcd194f50253" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">868</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Adjustments for non-cash items:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-cash consideration relating to revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70761ef7-b344-454b-ae7b-4e72c1be3e19" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:AdjustmentsForNonCashConsiderationRegardingRevenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,639</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20521aaf-6ce9-4ddc-b4a8-effa2c322875" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="asnd:AdjustmentsForNonCashConsiderationRegardingRevenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,203</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share of profit/(loss) of associates</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef93ee45-d8d4-4668-8939-8bac0e47fe8f" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,118</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_26326ffd-0040-4d03-ac99-68f5bb1b0ea2" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,677</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Share-based payment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2c44a051-01ad-4b26-a88c-542b8feba250" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,327</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4f79fc31-0931-40b2-9138-b2adf489a1c5" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,568</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_79b471bd-656b-476f-aaee-d30801226116" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:AdjustmentsForDepreciationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,632</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a6df18a4-44bc-4fbc-ae1d-efdd26f472a3" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:AdjustmentsForDepreciationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,969</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08c67643-8e54-4f53-b0be-bf1b2ab3ca3f" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:AdjustmentsForAmortisationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">233</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4420d0fa-212c-4b44-9326-082486c6a76d" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:AdjustmentsForAmortisationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">222</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Changes in working capital:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dfd7536d-2550-4b06-adcb-ecaf02bdfc9a" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">42,268</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a7b1c824-acd1-4b88-9499-bd6294f2e33f" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">37,246</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Receivables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0dd8aba2-a098-4a28-95fe-818d0fbaf213" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">22,747</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eff9ab59-d17c-4563-90a5-1eddb5149f22" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,715</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepayments</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5379d9e-6927-4610-943c-634bb46ed161" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,867</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80a7397a-4e5a-47a6-b302-6fc80d9c0641" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,779</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Contract liabilities (deferred income)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_979148be-220b-40ca-8c1e-01968b12c62b" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">840</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1fdd8e73-7404-4d8b-8ae7-da2b4d7267bd" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9,118</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade payables, accrued expenses and other payables</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d7e25e97-60fa-4b57-91d5-959a577024cb" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">10,571</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6a2689c0-f7cd-4c46-92fa-6dc1b7fb1aef" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,316</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Increase/(decrease) in provisions</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ef53d1e2-7a53-46d9-bf27-705492289901" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:AdjustmentsForProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,276</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_947069b7-8cd5-4421-bade-223a994bcf19" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:AdjustmentsForProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,625</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows generated from/(used in) operations</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c09a2cfd-0304-4f92-8d69-0fbd6a236aeb" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:CashFlowsFromUsedInOperations" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">158,223</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_2c5a3b45-4fb5-4adf-a2ac-567df7bdc050" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:CashFlowsFromUsedInOperations" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">299,863</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance income received</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4fd6f3f3-1645-4e82-86e6-5aa5432086a6" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,265</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87ee3d6a-a2bc-4835-8406-ace6ddec1a7a" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,403</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance expenses paid</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_08508d55-5e49-4002-a4c5-735fd3da2600" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,714</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_42ea8ae3-bbd4-4882-94e3-2908d13f0927" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,746</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Income taxes received/(paid)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ebaf1fb5-4664-4fad-8a69-13453a03c4f3" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,218</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d32837d7-3472-40ee-847c-183ed4723df6" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">966</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from/(used in) operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_1888c207-cd13-4fe9-9ef5-cdc49a6e786c" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">162,890</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_8aed7a61-2d25-480c-a701-070305b2f585" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">300,172</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Investing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Acquisition of property, plant and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0659db9d-1e88-4e83-b7d8-2d096d257b23" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">541</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80814f24-7c66-4cb1-b467-d29632a2449d" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,529</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from disposal of property, plant and equipment</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c0f1face-a15a-4dfc-bf0d-549717c34b29" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">950</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Settlement of marketable securities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e23a25db-4031-4326-9051-ace8623aace5" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,354</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_273283fa-f594-4917-a222-71e320938297" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">259,132</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from/(used in) investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c184583c-6bde-4d18-b630-6111b84fbdfe" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,763</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_76238698-11b3-465e-ad1c-124c5373e749" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,603</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financing activities</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Repayment of borrowings</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_16eaa617-c712-4102-bcc6-caa5df1138ad" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,606</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d7e6ef7-e5fd-4ec3-a34f-0ef3a0f0e99e" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,085</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Proceeds from exercise of warrants</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6ea529bc-90d3-4386-8221-4568c26783ff" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,574</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cbf2e55d-e28b-4f7b-ad00-0a584609c694" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,074</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from/(used in) financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c2d0a497-6c56-4583-91ff-836c07313c4b" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,968</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_df0a64c9-34f9-46c5-abe8-9b940ad3e189" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,011</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Increase/(decrease) in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_cec4ed8b-92ef-4706-875f-39f3c065ab0b" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">139,159</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_eb4630d9-3118-449e-bda3-09f3e15fcd19" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">45,580</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents at January 1</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b37acba8-ce53-40cb-9be5-7ba254a9d1a3" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,164</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8786a2ef-4bb7-461e-888b-1348ac679e8a" contextRef="C_875630a8-6b06-4d56-b547-543891791c57" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,767</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Effect of exchange rate changes on balances held in foreign currencies</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e5aedce7-d069-44f8-89a6-9e5b085e2cfb" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,691</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f770c00e-b640-4032-b2c7-c9ab2eb4685f" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,965</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and cash equivalents at June 30</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_dc7c7945-a3ae-4ab7-b21f-7adb96730cf5" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,696</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_fdfc6f2c-fad9-4510-b5ad-a71571ee2a29" contextRef="C_f87b4034-74cf-4447-b713-7401524f3969" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">394,222</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and cash equivalents include:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Bank deposits</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_007be83f-b1bc-43d8-b7e9-e4895a7076e9" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:BalancesWithBanks" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,696</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_800448db-8c6f-4170-b528-f48e01a40dd9" contextRef="C_f87b4034-74cf-4447-b713-7401524f3969" name="ifrs-full:BalancesWithBanks" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">394,222</ix:nonFraction></span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash and cash equivalents at June 30</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c8b7e0c2-0441-4493-a65c-0753c5e72494" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,696</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_4d9adb36-a948-4a60-a2f1-65c93a4ec761" contextRef="C_f87b4034-74cf-4447-b713-7401524f3969" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">394,222</ix:nonFraction></span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Notes to the Unaudited Condensed Consolidated Interim Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da6d93fe-a7d9-4278-a059-5e5f72f3d01a" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="notes"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">te 1&#8212;General Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ascendis Pharma A/S, together with its subsidiaries, is applying its innovative TransCon technology platform to build a leading, fully integrated, global biopharma company focused on making a meaningful difference in patients&#8217; lives. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to Ascendis Pharma A/S and its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The address of the Company&#8217;s registered office is Tuborg Boulevard 12, DK-2900, Hellerup, Denmark.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 2, 2015, the Company completed an initial public offering which resulted in the listing of American Depositary Shares (&#8220;ADSs&#8221;), representing the Company&#8217;s ordinary shares, under the symbol &#8220;ASND&#8221; in the United States on The Nasdaq Global Select Market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) approved these unaudited condensed consolidated interim financial statements on September 3, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_94fed202-9a8c-4631-b9cf-dee524f254f6" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 2&#8212;Summary of Material Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_351ced3b-d51a-4eaf-ba8a-b94a9ff2df9b" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Preparation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#8220;Interim Financial Reporting.&#8221; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#8220;IFRS&#8221;) have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements for the year ended December 31, 2023, and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board (the &#8220;IASB&#8221;) and as adopted by the European Union (the &#8220;EU&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting policies applied are consistent with those of the previous financial year. A description of the accounting policies is provided in the Accounting Policies section of the audited consolidated financial statements as of and for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_612845fe-148b-45cf-a6ac-5379954a2ad2" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New and Amended Standards and Interpretations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has applied amendments to paragraphs 69 to 76 of IAS 1, &#8220;Presentation of Financial Statements,&#8221; which was effective for annual reporting periods beginning on or after January 1, 2024, and must be applied retrospectively. The amendments to IAS 1 specify the requirements for classifying liabilities as current or non-current. The amendments clarify:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">What is meant by a right to defer settlement;  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That a right to defer must exist at the end of the reporting period; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That classification is unaffected by the likelihood that an entity will exercise its deferral right; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The convertible senior notes (&#8220;convertible notes&#8221;) include an embedded equity conversion option which is not deemed closely related to the financial liability and was initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div></div></ix:exclude><ix:exclude>
       <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since the embedded derivative is not an equity instrument under IFRS, the amendments require the convertible notes (presented as part of borrowings in the statement of financial position) and derivative liabilities, presented as non-current liabilities at December 31, 2023, to be presented as current liabilit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ies. The amendments require presentation of the convertible notes as current liabilities even though: the initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c7ac5bd5-37c5-4e92-b02f-effdc9ad70c0" contextRef="C_26726fd6-ee62-4142-bc95-a08f61caedc3" name="asnd:ConversionPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">166.34</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per ADS is not met; the conversion would not require cash settlement; and, the convertible notes do not mature until </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fca6d885-ce32-4c0a-b993-5a28531c612e" contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405" name="ifrs-full:BorrowingsMaturity"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further details, including (cash) maturity analysis are provided in Note 10, &#8220;Financial Assets and Liabilities.&#8221; On December 31, 2023, the carrying amount of convertible notes and derivative liabilities were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7dd0405a-8ce9-4b9a-ad77-1a390bdf5195" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">407.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9aa50244-0811-4adc-8fe0-c3f16292bfa7" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:NoncurrentDerivativeFinancialLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">143.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparative amounts have been reclassified to reflect the change to presentation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 31, 2023, lease liabilities were presented separately in the consolidated statements of financial position. At December 31, 2023, carrying amount of lease liabilities was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_90058f23-603e-4b6a-901a-8bfd28352b0d" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:NoncurrentLeaseLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">84.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcfc9770-e525-439e-9a5a-63941c848a13" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentLeaseLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, for non-current liabilities and current liabilities, respectively. Since March 31, 2024, lease liabilities are presented as part of borrowings in the consolidated statements of financial position. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparative amounts have been reclassified to reflect the change in presentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, since March 31, 2024, borrowings comprise convertible notes, royalty funding liabilities, and lease liabilities. The change to presentation had no other impact on the unaudited condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The applied amendments had no other impact on the unaudited condensed consolidated interim financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other amendments apply for the first time in 2024, but do not have an impact on the unaudited condensed consolidated interim financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New International Financial Reporting Standards Not Yet Effective</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these unaudited condensed consolidated interim financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2024, the IASB issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS 18&#8221;), which replaces IAS 1, &#8220;Presentation in Financial Statements.&#8221; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Discontinued operations.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements are not expected to be affected by other new or amended standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34ea192b-0647-4853-bb1d-09c9d40e05ba" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 3&#8212;Significant Accounting Judgements and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the application of the Company&#8217;s accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Judgements, estimates and assumptions applied are based on historical experience and other factors that are relevant, and which are available at the reporting date. Uncertainty concerning estimates and assumptions could result in outcomes that require a material adjustment to assets and liabilities in future periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed consolidated interim financial statements do not include all disclosures for significant accounting judgements, estimates and assumptions, that are required in the annual consolidated financial statements, and therefore should be read in conjunction with the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively. While the application of critical accounting estimates is subject to material estimation uncertainties, management&#8217;s ongoing revisions of critical accounting estimates and underlying assumptions have, except for revenue and provisions, as described below, not revealed any material impact in any of the periods presented in the unaudited condensed consolidated interim financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no other changes to the application of significant accounting judgements, or estimation uncertainties regarding accounting estimates compared to December 31, 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue and Provisions - Change in Accounting Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue includes provision for a variety of sales deductions such as prompt pay discounts, shelf stock adjustments and applicable sales rebates attributable to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangement. Provisions for sales deductions attributed to commercial arrangements are recognized when the related sales takes place and measured using the expected value method. Payable amounts for commercial arrangements are generally settled within 90-180 days from the transaction date. Provisions for unsettled sales deductions under commercial arrangements are estimated on the basis of a percentage of sales as defined by individual agreements and contracts. Further inputs to the calculations are based on payer channel mix, current contract prices under eligible programs and current inventory levels in the distribution channels. Inputs to the calculations are subject to estimation and assumptions and are based on historical experience and other factors that are relevant, and which are available at the reporting date. These estimates and assumptions are subject to material uncertainties and could result in outcomes that require a material adjustment in future periods.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue for the three months ended June 30, 2024, was negatively impacted by an adjustment to prior periods estimates and assumptions for sales deductions of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d8b8809-0971-4cc2-b03c-44655f03468e" contextRef="C_226b71fb-e2f1-440b-9ce0-1b02d378af1b" name="ifrs-full:Revenue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, where &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_64de9b44-81b8-40c4-8e56-9486bd921213" contextRef="C_f9148b7d-21b7-44df-8bda-8e6396f928c6" name="ifrs-full:Revenue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_18ff54b8-98aa-4209-a986-718a2780593b" contextRef="C_74b79d5a-c86f-4a0e-b7fd-c61544cc9d20" name="ifrs-full:Revenue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were attributable to the three months ended March 31, 2024 and periods prior to January 1, 2024, respectively. The adjustment was primarily attributable to a different payer and rebate mix than anticipated, and which provisions for prior periods were based upon.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total provisions for the year ended, December 31, 2023 and six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_57a7573f-fd9b-4f54-bee5-77d9ad327cf1" contextRef="C_89622b42-c78f-4d8c-aa28-7a988bd5583e" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd2b00b3-b2a1-47c0-8359-20882df4b7dc" contextRef="C_b745985a-29e1-4fcb-919b-47749840575a" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">106.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0cacb66-64a9-442b-a8d7-2b8627fda1a6" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:SignificantEventsInTheReportingPeriodTextBlock" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 4&#8212;Significant Events in the Reporting Period</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eyconis, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 29, 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, Inc. (&#8220;Eyconis&#8221;), a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de37c6ad-8b81-4bf6-846b-d67b40c6bf31" contextRef="C_1eee9ac4-42e3-4c2a-b3db-f3d552da0c91" name="asnd:CapitalCommitmentFromInvestors" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">150</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s consideration for the granting of such rights, the Company received, as consideration, approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1f2d8ea0-3b60-4cbe-9d46-5fd2c9fc26fb" contextRef="C_1eee9ac4-42e3-4c2a-b3db-f3d552da0c91" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">42</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership of Eyconis&#8217; on a non-diluted basis. In addition, various development and administrative services were provided to Eyconis and invoiced during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2024. Further details regarding Eyconis are provided in Note 5, &#8220;Revenue.&#8221;</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Development</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, the unaudited condensed consolidated interim statements of financial position presented a negative balance of equity of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5581d3f6-891a-4d8c-ae35-d148fbe858cc" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:Equity" unitRef="U_EUR" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">321.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Under Danish corporate law, as Ascendis Pharma A/S, the parent company of the Company holds a positive balance of equity, the Company is currently not subject to legal or regulatory requirements to re-establish the balance of equity. There is no direct impact from the negative balance of equity to the liquidity and capital resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on its current operating plan, the Company believes that the existing capital resources as of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, will be sufficient to meet projected cash requirements for at least twelve months from the date of this report. However, the Company's operating plan may change as a result of many factors that are currently unknown, and the Company may need to seek additional funds sooner than planned. Further details regarding borrowings including maturity analysis are provided in Note 10, &#8220;Financial Assets and Liabilities.&#8221;</span></p></ix:nonNumeric></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c115d53c-edbc-4b27-b6c7-7d7fdda23a84" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DisclosureOfRevenueExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 5&#8212;Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca438c0a-bed9-4a6a-a320-6473580cd2de" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss in the following amounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.09%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.418%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.418%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.418%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:9.658%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Revenue</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sale of commercial products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_603bb92e-709c-4eec-9059-9c8ed9a4f8e3" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d56c8880-93f4-4fbe-9664-45c4b78ba2a6" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,895</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6299e340-39e2-4536-89d8-c0b38b66e347" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,888</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e3a7b342-caf7-4c45-8d6e-bfc0408e289e" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,446</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rendering of services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d4d7bd9c-9d3a-412a-a13a-f463f8192e17" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:RevenueFromRenderingOfServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,740</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bb2f3055-8081-4d4f-8602-8aee38e29b39" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:RevenueFromRenderingOfServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e74e02b9-082d-417d-9013-e6b790447f05" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:RevenueFromRenderingOfServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,364</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4bdd628c-dae0-4574-97bb-e8e783d55d74" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:RevenueFromRenderingOfServices" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,079</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sale of clinical supply</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cacbe074-8404-4e51-a14d-20e51b544741" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:RevenueFromSaleOfClinicalSupply" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eba61058-bfaa-4d1c-840f-9962c84c510c" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="asnd:RevenueFromSaleOfClinicalSupply" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">254</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Licenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3ca87ef6-0039-4cf4-bca1-5c881c101fb4" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:LicenceFeeIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">869</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d43d043c-0cc5-48ea-bfe1-67da545c13cc" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:LicenceFeeIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">589</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_56217779-677e-44db-b414-9203f1504752" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:LicenceFeeIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,639</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aecbcf64-e712-4fb4-9b8b-ceb7a56d0dcf" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:LicenceFeeIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,203</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_879af9e1-f01a-448f-bc50-edcba4fd2a02" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,998</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_a890cf5b-7de5-4d18-a7ac-1acd33d8715f" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,393</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_9a81ffcf-9138-433e-99f6-eb08c6c2ccb9" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,892</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_6ec6c79a-3faf-41f0-ac1f-bb78c152d80e" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,982</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Attributable to</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial customers</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2cc12900-aa04-43da-8b8a-24106ff2abaa" contextRef="C_9fd79df1-50c6-4d41-901d-c77df4998cd3" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,389</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_80484b7e-b2a7-49bc-ac22-32368b5c15db" contextRef="C_53d2ec13-fbb3-43f3-8664-1c7545479049" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,895</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bae8e089-eddf-44e2-a27a-5affb20bdee7" contextRef="C_e94750b4-4124-4fd8-8705-f5583e219191" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,888</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2020dd1a-525a-4159-b4c1-33856d524a49" contextRef="C_ee58604e-a45e-405b-aac6-1e95591f95f0" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,446</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration partners and license agreements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11e4b67d-2e0c-4113-a07b-2c1bd035eef6" contextRef="C_0a89dad9-4f70-4ce9-b6cb-3b23f0d335f1" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,609</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65b0367b-20ab-411d-b36b-3a36e820c2c5" contextRef="C_5b082919-9fbb-47d2-96d1-56d15ab71d5f" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,498</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f83f949a-2f1e-4c08-842e-ff100d13de84" contextRef="C_cf326443-9fc3-4acd-8a7b-d10a15c9c639" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,004</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1d8054a-362b-4ee2-a7fe-d9bba52f9798" contextRef="C_bfc109b6-0267-4568-8f44-fa14915ce2e1" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,536</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_bb586705-cfea-4683-9f35-c2eb57f8d2ff" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,998</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c52f8690-15a8-4a8c-8dfb-520d6ad6b9d7" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,393</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_cd0ab485-da5d-4024-8e01-958878d8576d" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,892</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_55fd0275-b49e-4dc5-8bc0-ad06e9f4411d" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,982</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Specified by timing of recognition</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recognized over time</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0e7cc327-4eee-46bd-9243-81f7a9c80e41" contextRef="C_d23709e8-9e0d-4985-a23d-111331fe0a1e" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,740</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_74e7f2f3-69c4-4b6e-af26-d8c66dc80ca0" contextRef="C_39a0db7a-f4cf-4e59-a617-6a1e70c6bcfc" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_073d9472-17e8-4e15-87e2-dc8da688ffda" contextRef="C_a6a141f6-eee5-4acc-a932-da5764785d72" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,364</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98038a6c-657a-4542-83e6-1495decf2be7" contextRef="C_04baf03f-f9bb-4f2a-83ab-f0cc09cff3da" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,079</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recognized at a point in time</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b353522e-2665-4e38-948d-977cf9f43c26" contextRef="C_22691430-ca22-41f0-9568-18019e721ba9" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,258</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_89ff7632-6752-421d-9d7e-1391f4443755" contextRef="C_ba212868-8b66-4623-81ce-a65efa8cb9e5" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,484</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ca9030bd-05d6-4d36-81a8-a6cf973b7975" contextRef="C_ea6471ce-cfa4-4d71-8f75-d5e623498d8f" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">123,528</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9799a0ac-7dc8-4cfb-b4d0-bb258b638929" contextRef="C_45be4da6-fe2a-4d4e-95dc-772befc84731" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,903</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_9c37371b-9dc5-4256-b443-6df80be2f007" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,998</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_27e87f00-c365-4928-813c-2a219743c5b5" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,393</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_75ceaee0-d2ef-43a7-abeb-86dcc1dc0198" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,892</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_0e444f45-9b9e-47bd-ad3b-3da8edc8ea37" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,982</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Specified per geographical area</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Europe</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6cc79f97-5d71-4b1c-aef6-c813ff0a7275" contextRef="C_515c180b-f403-4c76-ab33-f262096366f4" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,082</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f66412b0-ec39-49e8-b041-c1da6dda0cb7" contextRef="C_755b6ff2-16af-4b77-aef3-7e63b09f7644" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,649</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">North America</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ff188f5e-5995-4410-8f90-5c386aaca90d" contextRef="C_4875ac0d-47d5-4a79-b057-425d568f5baf" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,394</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ccf20ce-a2b8-4bb9-9f83-b5b00f59e1d8" contextRef="C_6be2f049-eb3c-45d2-b25b-1ce6e49e5a4a" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,758</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4ac78517-13c6-4414-8dc3-2c3b27d8f9e9" contextRef="C_0901f291-b6cf-4be5-8d74-9686996cf492" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">122,075</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1594ff9-fb55-4cd1-aae9-b69b00f792dd" contextRef="C_12efaec8-00be-4d5b-a2c1-d97f9f8f9802" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,828</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Asia</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5be656b4-d1e8-4a59-ba52-d370b651ed30" contextRef="C_e661bb05-fc48-440a-941f-d142682c6c26" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,522</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a09dba4d-796a-46d6-b22b-7972003518ef" contextRef="C_cfd8955d-eb7e-4148-9713-3f97e5f71e44" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b089e65e-0192-4d7c-91e8-fe79f47eea74" contextRef="C_c2fcb3f0-5af6-4d4d-b93c-dd673702d997" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,168</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3746a52a-bf9f-4f77-9ad3-3c2bb5fb057c" contextRef="C_da85c345-157f-4aeb-af0c-84f018bd921c" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,154</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_12b8cf28-e197-4c28-ba29-4fb0a76417d4" contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,998</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_edfdba6b-0b5b-410f-b16d-8cd09e8d8279" contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,393</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_8a3b92d2-3edb-4ee3-95b6-32b66953d3ce" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">131,892</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_ee1af5a1-1010-4022-8918-f9b204c87c84" contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">80,982</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commercial Customers</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue to commercial customers primarily relates to sale of SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (lonapegsomatropin-tcgd), primarily in the U.S. market, which is sold to specialty pharmacies and specialty distributors. In addition, the Company began shipping SKYTROFA to customers in Germany in September 2023. In November 2023, TransCon PTH received regulatory approval in the EU and European Economic Area countries and is marketed as YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(palopegteriparatide). In August 2024, TransCon PTH received regulatory approval in the U.S. and will be marketed in the U.S. as YORVIPATH. The Company began shipping YORVIPATH to customers in Europe in the first quarter of 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three and six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_04254acf-8e04-44f3-85b5-0b600845e497" contextRef="C_9fd79df1-50c6-4d41-901d-c77df4998cd3" name="asnd:NumberOfCommercialCustomers" unitRef="U_CommercialCustomer" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_4610c87a-a4c1-4d3b-9738-7b9131dd5b62" contextRef="C_e94750b4-4124-4fd8-8705-f5583e219191" name="asnd:NumberOfCommercialCustomers" unitRef="U_CommercialCustomer" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_6d650873-1f88-4554-87b1-74637f84fd1c" contextRef="C_53d2ec13-fbb3-43f3-8664-1c7545479049" name="asnd:NumberOfCommercialCustomers" unitRef="U_CommercialCustomer" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_386935d2-8844-4cc9-8d66-09afb7f9dcb5" contextRef="C_ee58604e-a45e-405b-aac6-1e95591f95f0" name="asnd:NumberOfCommercialCustomers" unitRef="U_CommercialCustomer" decimals="0" format="ixt-sec:numwordsen">four</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> commercial customers, each represented more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1058137-e6e9-4923-8d7c-1714135f2a57" contextRef="C_becea9f1-8ea3-4a3f-b92c-d1e19a63174b" name="ifrs-full:PercentageOfEntitysRevenue" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b246a375-e4cc-44a5-916d-245ccbb1599f" contextRef="C_be47076c-c5c2-4398-803d-95bcc128d86b" name="ifrs-full:PercentageOfEntitysRevenue" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_5bdf9612-1abc-4724-a55b-31a6dc83caa3" contextRef="C_8de101c2-a4a1-4558-b6d8-6845ebd51060" name="ifrs-full:PercentageOfEntitysRevenue" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7e1dd1a1-ed1e-418d-8046-7c8a35ff054d" contextRef="C_d2e575be-2a92-4dca-9d69-cce91f677a27" name="ifrs-full:PercentageOfEntitysRevenue" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of sales to commercial customers.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Partners and License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue attributable to collaboration partners and license agreements relates to Eyconis, Teijin Limited and VISEN Pharmaceuticals. Under the collaboration agreements, we provide various research and development services which are invoiced to collaboration partners. Revenue for these activities is presented as part of &#8220;Rendering of services.&#8221; Employment costs related to these activities are presented as Research and Development Costs in the consolidated statement of profit or loss.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eyconis, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 29, 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophth</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">almology assets globally, together with a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4e202a3c-7913-4be4-b0e7-361eeb5a71c1" contextRef="C_1eee9ac4-42e3-4c2a-b3db-f3d552da0c91" name="asnd:CapitalCommitmentFromInvestors" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">150</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received, as consideration, an equity position in the newly formed company. In addition, the Company is eligible to receive development, regulatory, and sales milestone payments, plus single digit royalties on global net sales of commercialized products, if any.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is expected to provide various research and development services, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, revenue from &#8220;Licenses&#8221; of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dce02b37-cfec-4a90-b6f9-4520cc5f38db" contextRef="C_1ff24599-9bec-4004-890e-f2cabcf62656" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million relates to non-cash upfront payment through an equity position in Eyconis, which is allocated to transfer of the Company&#8217;s intellectual property (&#8220;IP&#8221;) adjusted for internal profit. Internal profit relates to the Company&#8217;s share of the non-cash upfront payment whic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">h is recognized as part of &#8220;Investment in associates&#8221; and recognized as revenue from &#8220;Licenses&#8221; as the IP is amortized in the associate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6fc30d4e-6c59-4302-9922-1a6dcd10a5c7" contextRef="C_0d563d87-8d91-4eb6-a982-541081c3f97a" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> revenue from royalties or milestones has been recognized under the Eyconis agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Teijin Limited</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 29, 2023, the Company entered into an exclusive license agreement with Teijin Limited (the &#8220;Teijin Agreement&#8221;) for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease (the &#8220;Licensed Products&#8221;) in Japan. Under the terms of the Teijin Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b3ac1ef4-1df1-4366-b10c-6b7c60ea89f9" contextRef="C_a078a24b-80df-47b2-af27-cd002780edca" name="asnd:UpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with additional development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cd5f64b8-5a1e-41cc-9eab-6cd7b44163c9" contextRef="C_a078a24b-80df-47b2-af27-cd002780edca" name="asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">175</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and commercial milestones. In addition, the Company is eligible to receive royalties on net sales of the Licensed Products in Japan, of up to mid-20&#8217;s percent.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the Company will provide clinical and commercial supply, and development services for joint activities, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024, none of the Licensed Products have received marketing authorization in Japan. The Licensed Products are patent protected, where future activities do not affect their existing stand-alone functionalities. Accordingly, all three licenses have been classified as &#8220;right-to-use&#8221; licenses, with revenue recognized at a point in time, where the licensee is granted access to the IP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f21235be-bd3f-468e-9d0f-dcd362a1c652" contextRef="C_34124e79-d811-40a9-b5d7-6e45ec01b712" name="asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">175</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million are recognized as revenue when the milestone criteria specific to the Licensed Product are met. Royalty and commercial milestone income is recognized as revenue when the subsequent product sales occur.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d377bfd3-7d65-4b95-9358-febb3f4193ff" contextRef="C_d001d487-d74a-42b7-827b-045eca711447" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> revenue from royalties o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">r milestones has been recognized under the Teijin Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">VISEN Pharmaceuticals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from collaboration partners and license agreements also includes license income, rendering of services and sale of clinical supply under three licenses agreements with VISEN Pharmaceuticals, which were entered into in 2018.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_221c7309-08ed-44df-af64-4fecc46ed0c1" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 6&#8212;Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is managed and operated as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e7b65b04-d7d1-4860-b95f-150a4bf3157b" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:NumberOfReportableOperatingSegments" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> business unit. Accordingly, no additional information on business segments or geographical areas is disclosed apart from revenue on geographical areas as disclosed in Note 5 &#8220;Revenue.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Revenue is specified on geographical areas according to the location of the customer.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_df571c75-5544-4177-8ea2-2417587da809" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 7&#8212;Share-based Payment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As an incentive to the senior management, other employees, members of the Board and select consultants, Ascendis Pharma A/S has established warrant programs, a Restricted Stock Unit (&#8220;RSU&#8221;) program adopted in December 2021, and a Performance Stock Unit (&#8220;PSU&#8221;) program adopted in February 2023, which are all classified as equity-settled share-based payment transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-based Compensation Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation costs are determined using the grant date fair value and are recognized over the vesting period as research and development costs, selling, general and administrative expenses, or cost of sales. For the three and six months ended June 30, 2024 and 2023, share-based compensation costs recognized in the unaudited condensed consolidated interim statement of profit or loss were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7f60ada7-4d17-4b61-83d3-c13b2645cb2c" contextRef="C_a7df51f1-e149-4eba-96d2-8116875f09ad" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efdda4e1-f807-450c-b3c9-f4ef4e07802b" contextRef="C_e47ee6ea-6244-4fae-841d-df097dd0610e" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">43.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8e37e066-d378-4761-919b-d48388e79483" contextRef="C_187cae39-2542-4e99-8ed4-2163bbbdd410" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">19.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a511cb03-60e7-4c93-b26c-3ae406e162a3" contextRef="C_01332415-aee7-4777-a043-a57648e597b0" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs are granted by the Board to members of senior management, certain other employees and certain members of the Board (the &#8220;RSU-holders&#8221;). In addition, RSUs may be granted to select consultants.</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One RSU represents a right for the RSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting, if the vesting conditions are met. RSUs granted vest over three years with 1/3 of the RSUs vesting on each anniversary date from the date of grant, and require RSU-holders to be employed, appointed as member of the Board, or retained as a consultant (the &#8220;service conditions&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PSUs are granted by the Board to certain members of senior management (the &#8220;PSU-holders&#8221;). In addition, PSUs may be granted to other employees, select consultants and members of the Board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One PSU represents a right for the PSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting. PSUs vest in a manner similar to the service conditions of the RSUs. For the March 2023 PSU grant, in addition to service conditions, vesting is also contingent upon achievement of performance-based targets as determined by the Board, provided that no more than 10% of each tranche may be directly attributable to accomplishment of financial results achieved in the financial year prior to the vesting date. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_870c275a-7ac6-4340-bb5d-dab858cbee3b" contextRef="C_2d38989e-7833-45b0-ae39-4b7e1ff91a47" name="ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the March 2024 PSU grants, in addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_98f4f13f-701e-476e-bb8e-78a2a10d618c" contextRef="C_b2b88484-8cd6-44b7-aec7-488f08ce60a9" name="asnd:PercentageOfVestingRightsForShareBasedPaymentArrangement" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, nor will it result in additional grants. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs and PSUs generally cease to vest from the date of termination of employment or Board membership, as applicable, whereas unvested RSUs or PSUs will forfeit. The Board may at its discretion and on an individual basis decide to deviate from the vesting conditions, including deciding to accelerate vesting in the event of termination of employment or Board membership, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All RSUs and PSUs are expected to be settled at the time of vesting by treasury shares that are ADSs repurchased by the Company. The Company may at its sole discretion choose to make a cash settlement instead of delivering ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSU and PSU Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a50602e9-cd71-4a1b-a83c-4446ad22c0b6" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies the number of RSUs and PSUs granted and outstanding at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.162%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.162%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.242%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Restricted Stock Units</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Performance Stock Units</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Number)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c60f13ad-da26-4901-b409-804483f94432" contextRef="C_ed967469-6caa-47a7-ad87-51a13e77b2b5" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">576,625</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c9a5fe9e-4aa1-47dc-b121-a690dcc99bbc" contextRef="C_c5d652d5-d799-43f6-903b-d2389a4f9c48" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">105,023</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7935c04-218e-4706-83cb-dba8538c1bfd" contextRef="C_ce698de3-cc8b-45e2-bf70-a5c86942e92e" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">681,648</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a4a44c91-22ca-483c-82a8-bc7342d2607f" contextRef="C_7d5f46e4-3795-445e-9938-80e373d5b80d" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">717,980</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_834831ce-2b82-4354-865b-7b066a4f43ab" contextRef="C_5a94d79c-4291-4d0a-b8bb-268dad9a101c" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">92,655</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_00b49ceb-2d72-4f5d-9a29-d52ddb0ae832" contextRef="C_5a7beea2-de57-4790-91d5-5d1200eacac6" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">810,635</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transferred during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_70b9bc34-fe50-44bb-becf-27d120fd4873" contextRef="C_7d5f46e4-3795-445e-9938-80e373d5b80d" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" sign="-" format="ixt:num-dot-decimal">176,317</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6f1c9a15-2823-4506-a59e-06957fe82897" contextRef="C_5a94d79c-4291-4d0a-b8bb-268dad9a101c" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" sign="-" format="ixt:num-dot-decimal">35,007</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5e615e90-9305-48a1-9fc6-a27e6e21edfd" contextRef="C_5a7beea2-de57-4790-91d5-5d1200eacac6" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" sign="-" format="ixt:num-dot-decimal">211,324</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e61fdea3-ffdc-4d6d-98c3-9677a697d61c" contextRef="C_7d5f46e4-3795-445e-9938-80e373d5b80d" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">63,309</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_14360b7e-df4a-46f7-bb3e-ca34be10f6b5" contextRef="C_5a94d79c-4291-4d0a-b8bb-268dad9a101c" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">4,830</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2d9fc024-25db-41c8-baec-3b742cdecd4d" contextRef="C_5a7beea2-de57-4790-91d5-5d1200eacac6" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">68,139</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_2b3acdec-d5a6-4d0c-9e7d-a97e82c4865d" contextRef="C_3b38ee1f-0d21-4c30-b4e6-b4a0842378c6" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">1,054,979</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_58220995-7498-4862-be32-42bb37c050cd" contextRef="C_d9f93835-5fdc-4307-9a1f-a342ff26fcd1" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">157,841</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_dbeb3dc4-d370-4bf8-b04b-00bb48df9f3c" contextRef="C_d5d1312c-4638-41e8-a0fb-c5a22dd1c28e" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">1,212,820</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Specified by vesting year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_503112f0-ed65-4f84-bef5-578df9feb1bd" contextRef="C_f0e8016e-5734-4177-91b0-d52b46d6a142" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">35,843</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f1b19c22-c53c-4c0e-8ff5-1d626a05f555" contextRef="C_d5ac3b5c-e60f-478e-83cf-eddc448b6227" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c07340b8-9036-4454-96a4-64db57724239" contextRef="C_eea519f3-ad46-4ee7-85b0-8608cf3c21c0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">35,843</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_aef2cc4d-2c81-4cb6-affe-7521fb5d54ff" contextRef="C_4f8a6e8b-b214-487d-a30f-ae5d8fab47d4" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">393,254</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d987460-53da-47aa-a997-47038fdc3279" contextRef="C_49e1466f-2be7-41f1-9dd9-ebfd767c7ab0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">63,478</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2543a93-932b-4b42-9f54-1aa65aececb9" contextRef="C_0be81193-83e1-496a-b2bd-963e7a3ae019" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">456,732</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7d34d8da-29b1-45f5-8076-a26648532f5a" contextRef="C_51bb1848-afba-426b-b5e1-8227d0a04edf" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">393,612</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2943e75-a069-45be-b536-ed21c548f99c" contextRef="C_c7b94f2c-5166-4906-bd69-2ea999d9fd53" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">63,478</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_de4fb3e3-3b6a-424a-87b9-c37ed7feff19" contextRef="C_1a075a8f-0d93-49ae-991b-20bf71825ac3" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">457,090</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cb7fb75-beb0-4a59-8507-2f967190066a" contextRef="C_5233396e-84c8-4084-9018-ab624a6eebc0" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">232,270</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ea46ab5-8012-4282-9bf1-30618f940966" contextRef="C_c4bb41a9-9897-48ff-97d9-d9e4c2fc4102" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">30,885</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_704a992a-6933-4acc-a860-438262004823" contextRef="C_b5e24c58-8391-46c0-963b-15580b32b822" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">263,155</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_13392e19-9475-4230-a96f-ddefc3288652" contextRef="C_3b38ee1f-0d21-4c30-b4e6-b4a0842378c6" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">1,054,979</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_4272e50d-11b0-4ea7-98b2-adbc8959b6e2" contextRef="C_d9f93835-5fdc-4307-9a1f-a342ff26fcd1" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">157,841</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_ed062bcf-06cb-4c7d-99e6-7c7bcbcf26f1" contextRef="C_d5d1312c-4638-41e8-a0fb-c5a22dd1c28e" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">1,212,820</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to all employees, members of the Board and select consultants. Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5d3c5ba-1875-480f-8f36-062d13124a0f" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:ParValuePerShare" unitRef="U_DkkPerShare" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The exercise price is fixed at the fair market value of the Company&#8217;s ordinary shares at the time of grant as determined by the Board. Vested warrants may be exercised in two or four annual exercise periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div></ix:exclude><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d1f079c-b3c5-48d9-9cc5-a469bf6f6278" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies the warrant activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Warrants</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Number)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a1a7129a-3efa-4bd3-a133-1c9df9423ce3" contextRef="C_0f31b8c9-3f3e-45ff-b2dc-b529c435f24b" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">6,523,784</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f96a85e8-2e1e-45d5-9fdb-7bab6d52d58d" contextRef="C_0f31b8c9-3f3e-45ff-b2dc-b529c435f24b" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">86.38</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9e0e919c-e250-4233-a218-4d0520f3d3f9" contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">197,855</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ac0d7dcf-0a6c-4edb-a504-d424877b292e" contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">130.74</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a77ea8be-cf29-4673-af66-61795dc7fe65" contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">524,045</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7fa7f8bb-ad78-4f09-aef0-f2d6db48464a" contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">39.85</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_fb1030e0-16dd-46a5-9296-1f28b63189c7" contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">89,719</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_52e6b50e-acd1-4e9c-84e6-0fe9665e3b25" contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">108.71</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_23aa26df-6096-46d4-9c2d-7d9f0a694ae1" contextRef="C_dca280d3-48db-4166-b87b-1d80627ed422" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">6,107,875</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_4c878589-58e5-4d8c-a980-7f73d7aa9d70" contextRef="C_dca280d3-48db-4166-b87b-1d80627ed422" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">91.16</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vested at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_137e4396-e520-4b29-98f5-16e60ca34518" contextRef="C_dca280d3-48db-4166-b87b-1d80627ed422" name="asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">5,088,475</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_1aee1670-6090-40e1-8748-a6f0dae4a071" contextRef="C_dca280d3-48db-4166-b87b-1d80627ed422" name="asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">86.49</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exercise prices of outstanding warrants under the Company&#8217;s warrant programs range from &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9f63e5a2-7f1a-4276-b1ca-8169626577d1" contextRef="C_32e6f681-0344-457f-8a03-21f7d9f10b40" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_b67f9313-a2c2-46a0-b631-2903fa43f4d7" contextRef="C_73c5c8ba-1fdd-4912-bbd7-e04f001ad88b" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">145.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> depending on the grant dates.</span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7909469f-785d-451c-ab31-2eed86a423b9" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 8&#8212;Share Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The share capital of Ascendis Pharma A/S consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_468fbeac-eb69-458d-8f63-8b1cfb3da616" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">58,231,484</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fully paid shares at a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2dff0aba-e057-4dc1-b646-24f639d9a238" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:ParValuePerShare" unitRef="U_DkkPerShare" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all in the same share class.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e8a65c2-70a3-433b-af5a-ebe0e12439eb" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:DisclosureOfInformationAboutTreasurySharesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 9&#8212;Treasury Shares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c9c3b362-cf4a-490c-8bbf-f8f55304b321" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DisclosureOfTreasurySharesExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development in the holding of treasury shares is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.162%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.162%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:11.241999999999999%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nominal<br/>values</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Holding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Holding in<br/>% of total<br/>outstanding<br/>shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Number)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Treasury shares</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4afc5eed-d802-43f8-b9c5-d77d93370708" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="asnd:TreasurySharesOfNominalValue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4309f52d-4362-401e-8025-5568cde89d4b" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="asnd:NumberOfTreasurySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,093,054</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bd8b6e67-2610-4ae5-8a44-ad49810838cf" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e596d16c-dc2f-48fd-b4ad-01f2809aa52d" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d03de79a-4aee-4698-920b-e1a1bc1edeba" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">211,324</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8c7408da-fc0d-49aa-9aca-8c16b03b62ab" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_010e3a82-2986-4100-a10b-dc502c291019" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:TreasurySharesOfNominalValue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_40223127-a271-4456-a6c8-ebae3aed51be" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:NumberOfTreasurySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">881,730</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_f2e2dc94-aa5d-4bb0-ac85-fe76e3df21ca" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee6eb23d-3494-44a3-aa55-f65c9e889631" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 10&#8212;Financial Assets and Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_8550a9d9-76fb-42ff-9f5c-67f690702000" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies financial assets and liabilities:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,<br/>2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets by category</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade receivables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f7fd87df-52cc-4562-a616-7fe68119565e" contextRef="C_3d46e5dc-bcc4-472a-9b45-7da68fed384e" name="ifrs-full:TradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,163</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_11550ed9-9c7a-4e70-8ec9-8ac5483da083" contextRef="C_99311e47-32a5-474d-8dac-f41409c83e74" name="ifrs-full:TradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,874</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables (excluding income tax and indirect tax receivables)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5663040c-649e-4c74-a6cd-312855fc26f7" contextRef="C_3d46e5dc-bcc4-472a-9b45-7da68fed384e" name="ifrs-full:OtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,062</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_435fb513-1019-424f-ba3c-bb33cb4c78ad" contextRef="C_99311e47-32a5-474d-8dac-f41409c83e74" name="ifrs-full:OtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,909</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_cf35c72a-4373-43ea-a824-98a99163c918" contextRef="C_99311e47-32a5-474d-8dac-f41409c83e74" name="asnd:MarketableSecurities1" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,275</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1f57a57-370f-4068-9c6c-4247578c7a35" contextRef="C_3d46e5dc-bcc4-472a-9b45-7da68fed384e" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">258,696</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a55f1910-d7d8-449e-8952-537b06bb78c4" contextRef="C_99311e47-32a5-474d-8dac-f41409c83e74" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,164</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_64b6863c-dc3e-4c58-9391-0cb21676d76e" contextRef="C_3d46e5dc-bcc4-472a-9b45-7da68fed384e" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">312,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_47a48f00-e64b-4933-bc10-a46645cacce5" contextRef="C_99311e47-32a5-474d-8dac-f41409c83e74" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,222</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_d19b9dbc-fec7-47f7-80a4-8538e54303ba" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">312,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_054cd00f-9eae-4f72-b5f4-17b29d9915d8" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,222</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0ba793b2-33ca-4a2f-8719-7fe143583def" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:NoncurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,186</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_496393e3-86d9-4436-84c4-cae065043ea3" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:NoncurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,127</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ee0926cd-9523-449c-8d43-f0ea66c96dcb" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">310,735</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6c3e317a-53a6-4d29-b292-ea0c0bbf57a0" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">437,095</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_97d91939-9aad-4d54-9b92-af5770b98f9b" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">312,921</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_de72fbdf-88fb-468c-b375-c493bea70237" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">439,222</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities by category</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_510c6212-1c64-4e56-ba63-dfd05dc722ec" contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">432,190</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c557fc9-17af-4237-a852-f57d28b654b2" contextRef="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">407,095</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_456a6929-e3b0-4d73-8e44-15c2ff53e3ec" contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">144,547</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e1101d4d-7a6a-49f4-82a8-c7e61da5de90" contextRef="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,377</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_50baa6a1-c667-465f-9bd3-29ac20c8b5c2" contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,902</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8ba00d9-5e48-430d-84a5-b95bcbddca65" contextRef="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,793</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_95612129-43c7-4636-a8af-c9462ad49561" contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,527</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_da1d15ad-d31d-4e3d-85be-c4db734348c3" contextRef="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,566</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities (excluding income tax, indirect tax, and employee related payables)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f23ec902-027f-4900-94c7-80d99125367d" contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb" name="ifrs-full:OtherFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">302</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_608be36f-de9c-4b45-83ec-39026994a582" contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">772,468</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c1003ce9-7a92-4900-af85-88f01b3744d6" contextRef="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">738,831</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c2f1a640-a6c2-4852-950f-1e09064c7346" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,059</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_38454091-81da-4285-afba-81610f6027af" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_bd265e47-3fc8-402c-8dc0-f87715df3fcc" contextRef="C_44d7ff3b-a312-4758-9d5a-9853401406cc" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,059</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_a7039271-e737-40c3-9cec-8496475c7c1b" contextRef="C_0fda0982-6a94-4187-a702-171d557879fc" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_b65d0834-a024-4d7a-80a2-820cd3c66110" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">931,527</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_3ddaec2d-e1b5-4e4a-8df9-ef0a86a28397" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">882,127</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d72884bc-bd6d-403f-b524-957594a4b2da" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:NoncurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">219,052</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c1da0a35-346a-4b03-b972-887e03d9389b" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:NoncurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,996</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7305639e-9902-4de5-b8ce-4889efcef82a" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:CurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">712,475</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bc0f8e39-12e3-44c2-9f57-cc9061230585" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:CurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">659,131</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_01c5733b-885c-4258-93f7-5001781baef3" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">931,527</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_f4a73b18-07f0-4391-9145-030b1f7b6fb2" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">882,127</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Senior Notes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, the Company issued an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_026ff4f7-b73e-4ac6-a80e-0b25e6ada46f" contextRef="C_ee64b1a5-0ac7-4bae-bf54-7e5e49b1964e" name="ifrs-full:NotionalAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">575.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of fixed rate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c5e445f1-6b2b-4ad6-95d5-400dc26df798" contextRef="C_c5bb9cca-7e70-46d1-a292-8e9d545f5c33" name="ifrs-full:BorrowingsInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% convertible notes. The net proceeds from the offering of the convertible notes were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_377dc136-56a4-4b83-a2fb-038a24573caf" contextRef="C_b1cd9cb9-4b1b-4fea-bbde-9d3bc31d8f4d" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">557.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdce358e-42af-4d1e-ad60-39247daaad83" contextRef="C_b1cd9cb9-4b1b-4fea-bbde-9d3bc31d8f4d" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">503.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million) after deducting the initial purchasers&#8217; discounts and commissions and offering expenses. The convertible notes rank equally in right of payment with all future senior unsecured indebtedness. Unless earlier converted or redeemed, the convertible notes will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2e987b0c-67f8-4a2b-8862-d2f512e68cf7" contextRef="C_b1cd9cb9-4b1b-4fea-bbde-9d3bc31d8f4d" name="ifrs-full:BorrowingsMaturity"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The convertible notes accrue interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_4c3da444-10ca-4fe6-bbc0-e7c48fcae9f0" contextRef="C_120df43c-ac40-4949-bdf1-72d7e1be8540" name="ifrs-full:BorrowingsInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their convertible notes at their option into the Company&#8217;s ordinary shares represented by ADSs, together, if applicable, with cash in lieu of any fractional ADS, at the then-applicable conversion rate. The initial conversion rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a8c864b5-e48a-4513-8605-1d4a466cb264" contextRef="C_fc29bc9d-a605-4ae9-bbea-0edd6dc89dde" name="asnd:ConversionRatePerNote" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">6.0118</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ADSs per $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_63da02c9-9f54-4b13-a197-1f33c3673b41" contextRef="C_276506bc-fed9-44d5-bde0-317663083ca8" name="ifrs-full:NotionalAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> principal amount of convertible notes, which represents an initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0440487c-1dff-4969-a0c2-0acb743b0fa9" contextRef="C_26726fd6-ee62-4142-bc95-a08f61caedc3" name="asnd:ConversionPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">166.34</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per ADS. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The convertible notes will be optionally redeemable, in whole or in part (subject to certain limitations), at the Company&#8217;s option at any time, and from time to time, on or after </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_62f47ea8-6a0c-42d4-8f60-79f2a5f506ce" contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405" name="asnd:BorrowingsRedemptionPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 7, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_10248c2d-7a2d-4a68-b3c9-de8ee346faac" contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405" name="asnd:BorrowingsConditionForRedemption"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">but only if the last reported sale price per ADS exceeds </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f3267a1a-51e2-4cc8-aaff-4602ba9a20be" contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405" name="asnd:BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the conversion price on (i) each of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_22f058de-d9e7-4ae1-ad5e-70eb56ebc18e" contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405" name="asnd:BorrowingsThresholdTradingDaysForRedemption" unitRef="U_Days" decimals="0" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> trading days, whether or not consecutive, during the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_06e0a776-7e30-4e33-b623-c68251aba831" contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405" name="asnd:BorrowingsThresholdConsecutiveTradingDaysForRedemption" unitRef="U_Agreement" decimals="0" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2024, the carrying amount of the convertible notes was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_fe231fb8-d28a-43bb-8743-79046dfb9e53" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">432.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and the fair value was approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0f09f721-8021-4145-95a4-651e0df06cc5" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:FairValueOfConvertibleNotes" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">412.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Fair value cannot be measured based on quoted prices in active markets or other observable input, and accordingly the fair value was measured by using an estimated market rate for an equivalent non-convertible instrument.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div></ix:exclude><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ae853543-53eb-40f4-a661-4a8d3665ff8c" contextRef="C_b41da24d-bd30-42f4-a704-1d5714f18704" name="asnd:FundingReceivedInExchangeOfRoyaltyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Agreement&#8221;) with Royalty Pharma (the &#8220;Purchaser&#8221;). The net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d03ad2f9-9742-4e25-ad61-0b4cec2e670b" contextRef="C_8ef04b98-f458-48b5-892e-fb3c6e17fd2b" name="asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">146.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_87e7ece2-69cc-4e8b-84ac-98f2deb39dc4" contextRef="C_8ef04b98-f458-48b5-892e-fb3c6e17fd2b" name="asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">136.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million) after deducting offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Royalty Pharma Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_5cb347ac-9dc0-4c11-bfaf-86717e875c9c" contextRef="C_82679e63-57f7-42c8-af63-f3c54a3a76ef" name="asnd:FundingReceivedInExchange" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Purchase Price&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ed3d6b36-2643-46ab-b8c5-bf5abeba26bd" contextRef="C_82679e63-57f7-42c8-af63-f3c54a3a76ef" name="asnd:ExchangeRateForPercentageOfRevenueToRoyaltyPayment" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty on net U.S. SKYTROFA revenue, beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70317e4b-0935-4475-8e25-712fd9cb4615" contextRef="C_82679e63-57f7-42c8-af63-f3c54a3a76ef" name="asnd:RoyaltyPaymentBeginningPeriod" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Revenue Interest Payments&#8221;). The Revenue Interest Payments to the Purchaser will cease upon reaching a multiple of the Purchase Price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e05785d9-338d-41a8-af3c-86071fce475b" contextRef="C_b5bd486e-1131-4c51-9d6b-ba25b8052be8" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="3" format="ixt:num-dot-decimal">1.925</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">x, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_efd0b992-588e-4c86-9f2f-d0c4bfb2016e" contextRef="C_dff101ac-1dfc-4e89-bbe4-f6d1091007b7" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">x if the Purchaser receives Revenue Interest Payments in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44f57d4b-43c0-4930-bb02-4aa9c56f597c" contextRef="C_b41da24d-bd30-42f4-a704-1d5714f18704" name="asnd:RoyaltyPaymentEndingPeriod" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Royalty Pharma Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9ae44f1f-be9f-4a2a-ab50-a9c6cb56949c" contextRef="C_e6982966-8271-4e1c-b818-503cfb91de1c" name="asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" unitRef="U_XBB" scale="0" decimals="3" format="ixt:num-dot-decimal">1.925</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> times the Purchase Price minus the Revenue Interest Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to December 31, 2028, and the Company has paid the Purchaser Revenue Interest Payments equal to the Purchase Price as of the date of the buy-out notice, then the buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_af6c6bd8-1287-4577-8175-92372ab28383" contextRef="C_e6982966-8271-4e1c-b818-503cfb91de1c" name="asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" unitRef="U_XBB" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> times the Purchase Price minus the Revenue Interest Payments paid to the Purchaser as of the effective date of the buy-out notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2024, the carrying amount of the royalty funding liabilities was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_042612f6-e227-4306-a9dc-90b610deaca9" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:CarryingAmountOfRoyaltyFundingLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">144.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and the fair value was approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_583336e0-ccc0-4599-97cd-40d3090057df" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:FairValueOfRoyaltyFundingLiabilities" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">147.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Fair value cannot be measured based on quoted prices in active markets or other observable input, and accordingly the fair value was measured by using an estimated market rate for an equivalent instrument.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivative Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value cannot be measured based on quoted prices in active markets or other observable inputs, and accordingly, derivative liabilities are measured by using the Black-Scholes option pricing model. Fair value of the option is calculated, applying the following assumptions: (1) conversion price; (2) the Company&#8217;s share price; (3) maturity of the option; (4) a risk-free interest rate equaling the effective interest rate on a U.S. government bond with the same lifetime as the maturity of the option; (5) no payment of dividends; and (6) an expected volatility using the Company&#8217;s share price </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_838b9f50-3903-4d7c-bc6b-c7bc62fd1190" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:SharePriceAppliedForValuation" unitRef="U_EurPerShare" decimals="INF" format="ixt:num-dot-decimal">49.89</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_a08c5e72-fd2d-4726-a809-9a7be69ddce3" contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242" name="asnd:SharePriceAppliedForValuation" unitRef="U_EurPerShare" decimals="INF" format="ixt:num-dot-decimal">50.47</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of June 30, 2024 and December 31, 2023, respectively).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional description of fair values, refer to the following section &#8220;Fair Value Measurement.&#8221;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sensitivity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3cbd6228-982e-46cb-8731-b74247be4f72" contextRef="C_0d721657-d4bf-491a-b07d-d4d0a337317b" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% relative increase in volatility, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7e4da763-af5d-4159-a73c-b60ec8f95ba3" contextRef="C_4c6f70b1-9efa-4bae-96b1-ae13a04d5ec3" name="asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_82f45fb9-fe32-4b89-a74c-0d8fd2cf8a3e" contextRef="C_0d721657-d4bf-491a-b07d-d4d0a337317b" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% relative decrease in volatility indicates the opposite impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly, on June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_20fb71f4-2e3a-44e6-96c9-a144a8bbca15" contextRef="C_70a9c3db-ba5b-4b53-9757-db806da4769e" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% increase in the share price, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e8b67f61-e61e-4204-aabf-b197c6d360cd" contextRef="C_60e20bc2-5206-4d1b-b79b-82ec729f7143" name="asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7bc7cf52-3a39-4d3c-8ba8-ff1ef2e2920f" contextRef="C_70a9c3db-ba5b-4b53-9757-db806da4769e" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% decrease in the share price indicates the opposite impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the short-term maturity for cash and cash equivalents, receivables and trade payables, their fair value approximate carrying amount. Fair value of lease liabilities are not disclosed. Fair value compared to carrying amount of marketable securities, convertible notes, royalty funding liabilities and derivative liabilities, and their level in the fair value hierarchy is summarized in the following table, where:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is based on valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.</span></p><ix:exclude><div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div></div></ix:exclude><ix:exclude>
     <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div></ix:exclude><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da445236-dd8f-4b3b-ad42-f9607c89c45f" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;"/>
        <td style="width:1.08%;"/>
        <td style="width:9.96%;"/>
        <td style="width:1.08%;"/>
        <td style="width:9.96%;"/>
        <td style="width:1.08%;"/>
        <td style="width:9.96%;"/>
        <td style="width:1.08%;"/>
        <td style="width:9.96%;"/>
        <td style="width:1.08%;"/>
        <td style="width:9.96%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value level</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(1-3)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_dcaeb48a-9f24-4dbb-80a6-c4d5ce3effa6" contextRef="C_d75b971a-1f5c-45c3-9cf0-b42af670311f" name="asnd:MarketableSecuritiesExplanatory" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,275</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_bdff43d4-b0f2-4814-9659-599ef7d01520" contextRef="C_b3eeeb63-6bc6-460d-8c2e-19abe3bd08c0" name="asnd:MarketableSecuritiesExplanatory" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,266</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_9ec8e1d1-4212-435c-9d83-2e8c5dc91482" contextRef="C_756073fe-efcc-4ad7-914c-18bd04b9013e" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,275</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_73e985e6-b789-4ada-b5c2-452f68028031" contextRef="C_d4d49cb8-932e-432f-a338-771c043ea715" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,266</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb948724-06b2-402c-b582-96b022e45522" contextRef="C_916a1d45-ad20-4d5e-8c65-dfd11d9b937b" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">432,190</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_421770e5-a7b0-451a-8372-1afa8b1099b2" contextRef="C_24e1c394-8155-4ccd-9e4a-59d9e1ec986d" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">412,122</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_24cbc5b7-4e94-4247-a12a-71e1ca54cf76" contextRef="C_b1459f92-4bdf-48d9-b032-4c65da483b6d" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">407,095</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c3beec9-e4d3-4a80-a0d6-44cdcea61021" contextRef="C_d9e73adc-e2fa-4a69-a5e0-c417bc7c2b6e" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">385,410</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_eb94babb-ad21-471a-a35c-124935818df0" contextRef="C_916a1d45-ad20-4d5e-8c65-dfd11d9b937b" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">144,547</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_43619246-3d33-4dc9-be77-c9d7588eaf11" contextRef="C_24e1c394-8155-4ccd-9e4a-59d9e1ec986d" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">147,345</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9d8739f2-0b82-458b-97f8-c2058a3a87c3" contextRef="C_b1459f92-4bdf-48d9-b032-4c65da483b6d" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">138,377</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_192d5df5-93a5-4f69-8528-be6e03d13473" contextRef="C_d9e73adc-e2fa-4a69-a5e0-c417bc7c2b6e" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,975</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_bc3fcf19-4a96-4f0a-b92f-a049d6bc04a8" contextRef="C_9a1ee37c-f52e-4fe7-a481-ffe9c8b8f6b1" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">576,737</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_a614f6ae-1af8-4283-adf4-27cee6b20161" contextRef="C_0eaa7d1b-df57-4e29-a988-3e72ff479760" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">559,467</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c7deea54-3af8-400e-b177-5899b5fca295" contextRef="C_756073fe-efcc-4ad7-914c-18bd04b9013e" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">545,472</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_cb2119bf-147c-44b7-8a0d-760ca357685b" contextRef="C_d4d49cb8-932e-432f-a338-771c043ea715" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">529,385</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_6df4096f-b916-4a1c-b01a-c82888942fda" contextRef="C_916a1d45-ad20-4d5e-8c65-dfd11d9b937b" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,059</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_3d1a78c5-d607-4a3f-999f-2d47e05dc1d9" contextRef="C_24e1c394-8155-4ccd-9e4a-59d9e1ec986d" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,059</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c692ff1d-3666-4e77-8a06-29d3d5b5e9b0" contextRef="C_b1459f92-4bdf-48d9-b032-4c65da483b6d" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_05a30498-7f46-4868-b545-ec889d61bc4c" contextRef="C_d9e73adc-e2fa-4a69-a5e0-c417bc7c2b6e" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_c2f362ce-60da-4a4a-89fb-41c2d387e144" contextRef="C_9a1ee37c-f52e-4fe7-a481-ffe9c8b8f6b1" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,059</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_602e7ae4-5879-4ef1-847e-a14b07d05b84" contextRef="C_0eaa7d1b-df57-4e29-a988-3e72ff479760" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,059</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_bccf65c0-096f-4f27-9447-86daa600e374" contextRef="C_756073fe-efcc-4ad7-914c-18bd04b9013e" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_1f7b7d92-672d-4a8b-9d85-2cdc636bd9b3" contextRef="C_d4d49cb8-932e-432f-a338-771c043ea715" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66a12e92-d402-4f51-9e5f-b5ce5925f2e1" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies movements in level 3 fair value measurements:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
        <td style="width:1.16%;"/>
        <td style="width:1%;"/>
        <td style="width:13.357%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_057a4418-ebfc-467e-870f-1aca9e5d651a" contextRef="C_84865da0-8e28-4c64-b919-2fa941621732" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_7ca808c0-a9d7-49da-9fe4-0cf68ce7a9e0" contextRef="C_4bfef56a-6c92-4668-b539-a03819e7ccb0" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,950</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remeasurement recognized in finance (income) or expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_209993cc-b612-4b18-97d3-6cf1bf784ba1" contextRef="C_cff9af56-3621-49bb-95fa-62e774a90dc9" name="asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,763</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_2636cb5a-1b60-4878-9678-b76e5b2078bc" contextRef="C_7f8c7ce5-86c4-4f44-b5a8-e85f28bd20e0" name="asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">71,565</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_5c2020e5-0a8c-4632-86aa-f3dfce8b71c1" contextRef="C_59fa5ae0-47b2-46af-9d0c-e8a4358f7f81" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">159,059</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_4615756f-e294-44a5-a020-ca4ef6a5c5dd" contextRef="C_44cab9aa-2fd6-48de-9166-d81f187ddff5" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,385</ix:nonFraction></span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Maturity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_66065812-b64b-4b44-8225-c2f882e45d41" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="asnd:MaturityAnalysisForFinancialLiabilitiesTextBlock" escape="true" continuedAt="F_66065812-b64b-4b44-8225-c2f882e45d41_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the unaudited condensed consolidated statements of financial position at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Further details regarding classification of convertible notes as current liabilities in the consolidated statement of financial position are provided in Note 2, &#8220;Summary of Material Accounting Policies,&#8221; section &#8220;New and Amended Standards and Interpretations.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_66065812-b64b-4b44-8225-c2f882e45d41_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.42%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.04%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.04%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.04%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.04%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:1%;"/>
        <td style="width:8.42%;"/>
        <td style="width:1%;"/>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&lt; 1 year</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1-5 years</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&gt;5 years</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>contractual<br/>cash-flows</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_db7f052e-1be1-445e-8dfa-e46320ed4609" contextRef="C_a74af470-e599-4a1e-b963-cdf93c8f8ad0" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,902</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_402fda8f-b1d1-48d2-aec9-ef02e267f202" contextRef="C_d4a58637-2055-42b3-8157-1d28bda0cf03" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">759,073</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_51c4eb81-373d-4cfe-b344-bc05836ac77e" contextRef="C_0566eec3-61b9-4678-9b3a-a122291dbee2" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,700</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0362f06b-2086-4374-a52b-969fb5d6c252" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">816,675</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d88bb79d-5c76-48d2-a5b7-06960895214a" contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">576,737</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d028ae51-7016-454f-bf58-cf762bc37f79" contextRef="C_a74af470-e599-4a1e-b963-cdf93c8f8ad0" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,802</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_0469068d-c1f2-4182-a236-6ce375a4e06d" contextRef="C_d4a58637-2055-42b3-8157-1d28bda0cf03" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,632</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_ba1fb194-a04b-41f3-8a8c-a5a0cfce1879" contextRef="C_0566eec3-61b9-4678-9b3a-a122291dbee2" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,312</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_116e09fe-ce08-4110-916e-b1b32f3f2927" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">110,746</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_722c6cf1-6afa-44b2-9ca4-5282d859acc1" contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,902</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_9c29c396-b5d7-4a52-8ace-ef0b601c8d31" contextRef="C_a74af470-e599-4a1e-b963-cdf93c8f8ad0" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,829</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_8ea05236-b6c8-44fb-9d07-87244d30ba29" contextRef="C_d4a58637-2055-42b3-8157-1d28bda0cf03" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_d1aacdf8-23ef-4c40-b1b1-e955b6967b5f" contextRef="C_0566eec3-61b9-4678-9b3a-a122291dbee2" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_069a0d85-da9f-408c-9ad8-704d7bf7180f" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,829</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_1a6c844f-93e9-432d-86ea-5e44512d16ba" contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,829</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_a8d43160-e5bc-413b-9565-b06d25826373" contextRef="C_a74af470-e599-4a1e-b963-cdf93c8f8ad0" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">133,533</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_b76ca1ef-2f0d-4ed7-865f-372d9ff70344" contextRef="C_d4a58637-2055-42b3-8157-1d28bda0cf03" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">810,705</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_f0a242aa-e68e-4092-b04c-233bd8698f46" contextRef="C_0566eec3-61b9-4678-9b3a-a122291dbee2" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,012</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_45873b33-f3b9-447a-8855-094e046bba02" contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040" name="asnd:ContractualUndiscountedCashflowOfFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,027,250</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><ix:nonFraction id="F_53a1d97d-24d2-4068-b93c-cfbf40c36ae0" contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">772,468</ix:nonFraction></span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b5702332-9da7-440b-b26a-919982b71fec" contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 11&#8212;Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2024, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_28d2d5fb-ea93-46c6-96b7-23d17824b2d4" contextRef="C_d66908c6-a5fa-467c-9047-36af0a5ab839" name="asnd:FundingReceivedInExchangeOfRoyaltyPayments" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">150</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Yorvipath Agreement&#8221;) with Royalty Pharma (the &#8220;Purchaser&#8221;). Under the terms of the Yorvipath Agreement, Purchaser has agreed to provide the Company an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_65032f9c-bb84-450a-9330-bd1fef8606cb" contextRef="C_b1b4d1e4-24f6-4c89-914e-0c15eb61bcdc" name="asnd:FundingReceivedInExchange" unitRef="U_USD" scale="6" decimals="-6" format="ixt:num-dot-decimal">150</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Purchase Amount&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_e50e6447-1b45-44b8-98ce-dfbfb196ba48" contextRef="C_b1b4d1e4-24f6-4c89-914e-0c15eb61bcdc" name="asnd:ExchangeRateForPercentageOfRevenueToRoyaltyPayment" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty on net U.S. YORVIPATH revenue (the &#8220;Royalty Payments&#8221;). The Royalty Payments to the Purchaser will cease upon reaching a multiple of the Purchase Amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_c8c0f6ef-c6cd-405a-b8fe-dba7b7607061" contextRef="C_bd7c5f8f-6386-4bcb-a667-86ed3c7b0c33" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="1" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">x, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"><ix:nonFraction id="F_f458af5d-5c70-44c3-880d-0a40dbc5bf30" contextRef="C_567228fa-89e0-4f5f-91c5-10eec549d109" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">x if the Purchaser receives royalties in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee1c405c-8ffc-4356-a23d-4eb010f5ca0c" contextRef="C_d66908c6-a5fa-467c-9047-36af0a5ab839" name="asnd:RoyaltyPaymentEndingPeriod" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Yorvipath Agreement includes certain buy-out options under various terms and conditions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No other events have occurred after the balance sheet date that would influence the evaluation of these unaudited condensed consolidated interim financial statements.</span></p></ix:nonNumeric></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ASCENDIS PHARMA A/S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="managements_discussion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MANAGEMENT&#8217;S DISCUS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SION AND ANALYSIS OF FINANCIAL CONDITION AND</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RESULTS OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report and the section contained in our Annual Report on Form 20-F for the year ended December 31, 2023&#8211; &#8220;Item 5. Operating and Financial Review and Prospects.&#8221; The following discussion is based on our financial information prepared in accordance with International Accounting Standard 34, &#8220;Interim Financial Reporting.&#8221; Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#8220;IFRS&#8221;) have been condensed or omitted. IFRS as issued by the International Accounting Standards Board, and as adopted by the European Union, might differ in material respects from generally accepted accounting principles in other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This report contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals for our product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the commercial availability of our approved products, in the United States, European countries, and related patient support services; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the commercialization of our products and product candidates, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our commercialization, marketing and manufacturing capabilities of our products and product candidates and associated devices; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope, timing, progress, results and costs of developing our product candidates or any other future product candidates, and conducting preclinical studies and clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our pursuit of oncology as our second independent therapeutic area of focus and our development of a pipeline of product candidates related to oncology; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Eyconis, Inc.&#8217;s ability to develop, manufacture, and commercialize TransCon ophthalmology assets globally;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the potential market opportunities and patient populations for our products and product candidates, if approved for commercial use; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding the potential advantages of our products and product candidates over existing therapies;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential benefits of using our products and product candidates in combination with each other and other therapies; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to enter into new collaborations; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations with regard to the ability to develop additional product candidates using our TransCon technologies and submit Investigational New Drug Applications (&#8220;INDs&#8221;) or similar for such product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations with regard to our current and future collaboration partners to pursue the development of our product candidates and submit INDs or similar for such product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our development plans with respect to our products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our pursuit of additional indications for TransCon hGH; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the implementation of our business model and strategic plans for our business, our products and product candidates and technologies, including global commercialization strategies; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our products and product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our expectations regarding our ability to apply our technology platform and algorithm for product innovation to develop highly differentiated product candidates to address unmet medical needs;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to apply our TransCon technology platform to build a leading, fully integrated, global biopharma company;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our use of our TransCon technologies to create new and potentially best-in-class therapies;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to achieve our goals for Vision 2030; </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">estimates of our expenses, future revenue, capital requirements, needs for additional financing and ability to obtain additional capital; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our financial performance; </span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to attract and hire qualified personnel;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">developments and projections relating to market conditions, competitors and the industry;</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the impact of international economic, political, legal, compliance, social and business factors, including inflation, geopolitical conflicts and energy shortages; and</span></div></div>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the effects on our business of pandemics and the ongoing conflicts in the region surrounding Ukraine and Russia and between Israel and Hamas.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">These forward-looking statements are based on senior management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this report may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section in our Annual Report on Form 20-F for the year ended December 31, 2023 &#8212; &#8220;Item 3.D. Risk Factors.&#8221; You are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this report. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. Given these risks and uncertainties, you are cautioned not to rely on such forward-looking statements as predictions of future events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">You should read this report and the documents that we reference in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect. You should also review the factors and risks we describe in the reports we will file or submit from time to time with the Securities and Exchange Commission after the date of this report. We qualify all of our forward-looking statements by these cautionary statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are applying our innovative TransCon technology platform to build a leading, fully integrated, global biopharma company focused on making a meaningful difference in patients&#8217; lives. Guided by our core values of Patients, Science, and Passion, we use our TransCon technologies to create new and potentially best-in-class therapies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our Vision</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As announced in January 2024, Vision 2030 is our vision to achieve blockbuster status for multiple products and expand our engine for future innovation. This includes:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Be the Leading Endocrinology Rare Disease Company</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Achieve blockbuster status (&gt;$1B) for each of TransCon PTH, TransCon hGH, and TransCon CNP through worldwide commercialization</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Be the leader in growth disorders and hypoparathyroidism, pursuing clinical conditions, innovative life cycle management, and complementary patient offerings</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Expand pipeline with Endocrinology Rare Disease blockbuster product opportunities</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Create Value in Additional Therapeutic Areas through Innovative Business Models</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Obtain accelerated approval in oncology with registrational trials ongoing</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursue TransCon product opportunities in &gt;$5B indications</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maximize value creation of these product opportunities through collaboration with therapeutic area market leaders</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Differentiate with Ascendis Fundamentals</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outperform industry drug development benchmarks with Ascendis&#8217; product innovation algorithm</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Remain independent as a profitable biopharma through lean and flexible ways of working</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Let our values Patients, Science, Passion drive our decisions to success</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our products and product candidates combine our TransCon technologies with clinically validated parent drugs or pathways, with the goal of optimizing safety, efficacy, tolerability and convenience.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We apply these technologies using our algorithm with the goal of creating product candidates with the potential to be best-in-class. Using this approach, we plan to expand our pipeline with Endocrinology Rare Disease product opportunities in large addressable markets. In addition, our vision is to pursue TransCon product opportunities in &gt;$5B indications in other therapeutic areas and maximize value creation of these product opportunities through collaboration with therapeutic area market leaders. We believe our approach to product innovation may reduce the risks associated with traditional drug development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ascendis Algorithm for Product Innovation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img148560552_0.jpg" alt="img148560552_0.jpg" style="width:720px;height:173px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">When we apply our TransCon technologies to clinically validated parent drugs or pathways, we may benefit from established clinical safety and efficacy data, which we believe increases the probability of success compared to traditional drug development. As illustrated above, our algorithm for product innovation focuses on identifying indications that have an unmet medical need, have a clinically validated parent drug or pathway, are suitable to our TransCon technologies, have potential for creating a clearly differentiated product, have a potential established development pathway, and have the potential to address a large market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Program Summaries</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We currently have two marketed products and a diversified portfolio of four product candidates in clinical development in the areas of Endocrinology Rare Disease and Oncology, and we are working to apply our TransCon technology platform in additional therapeutic areas such as the glucagon-like peptide 1 (&#8220;GLP-1&#8221;) class, where we believe we have designed a potentially best-in-class, once-monthly program.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Our first marketed product was SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (lonapegsomatropin-tcgd), developed as TransCon Growth Hormone (&#8220;TransCon hGH&#8221;), which has received regulatory approval in the United States for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone, also known as growth hormone deficiency (&#8220;GHD&#8221;). TransCon hGH has been commercially available for prescription in the United States under its brand name SKYTROFA (lonapegsomatropin-tcgd) since October 2021. In addition, TransCon hGH was granted marketing authorization in the European Union (&#8220;EU&#8221;), Norway, Iceland, Lichtenstein and Great Britain (covering England, Wales, Scotland) as SKYTROFA (lonapegsomatropin), a once-weekly subcutaneous injection for the treatment of children and adolescents ages 3 to 18 years with growth failure due to insufficient secretion of endogenous growth hormone. SKYTROFA has been commercially available for prescription in Germany since September 2023.</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">3</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Our second marketed product is YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (palopegteriparatide), developed as TransCon PTH. In the EU, Norway, Iceland, Lichtenstein and Great Britain (covering England, Wales, Scotland), YORVIPATH has been granted marketing authorization as a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. YORVIPATH has been commercially available for prescription in Germany and Austria since January 2024. In the U.S., TransCon PTH received regulatory approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the treatment of hypoparathyroidism in adults in August 2024 under the brand name YORVIPATH. We are completing manufacturing of commercial product for the U.S. market and anticipate initial supply will be available in the first quarter of 2025. We are in dialogue with the FDA about commercialization of existing manufactured products, which if agreed, could be introduced in the U.S. in the fourth quarter of 2024.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Endocrinology Rare Disease Pipeline </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#8211; We are further developing two product candidates in our Endocrinology Rare Disease portfolio spanning multiple indications and geographies. These product candidates are TransCon hGH for adult GHD and Turner syndrome and TransCon CNP (navepegritide) for infants and children with achondroplasia. Through our strategic collaboration, Teijin Limited is developing and, if approved, plans to commercialize TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan. In addition, through our strategic investment, VISEN Pharmaceuticals (&#8220;VISEN&#8221;) is developing and, if approved, plans to commercialize TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare diseases in Greater China. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Oncology Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; In Oncology, we are leveraging our TransCon technologies with the goal of enhancing the anti-tumor effects of clinically-validated parent drugs and pathways and to provide sustained modulation of tumor microenvironments and activate cytotoxic immune cells. We have initiated clinical development of two product candidates: TransCon TLR7/8 Agonist, an investigational, long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (&#8220;TLR&#8221;) 7 and 8 for intratumoral delivery, and TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(onvapegleukin alfa) for systemic delivery, which is designed for prolonged exposure to an IL-2 variant that selectively activates the IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with minimal binding to IL-2R&#945;. Our clinical development program for these product candidates also includes evaluation of each of them as a potential combination therapy.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon Products and Product Candidates Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other than the rights we have granted to VISEN, Teijin Limited, and Eyconis as noted in this report, we hold worldwide rights to our TransCon technologies and, other than our royalty financing arrangements with Royalty Pharma as noted in this report, we owe no third-party royalty or milestone payment obligations with respect to our TransCon technologies, TransCon hGH, TransCon PTH or any of our other product candidates. The following chart lists our approved products and product candidates.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img148560552_1.jpg" alt="img148560552_1.jpg" style="width:720px;height:306px;"/>&#160;</p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In the U.S., SKYTROFA is indicated for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In the EU, SKYTROFA is indicated for growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In the U.S., YORVIPATH is indicated for the treatment of hypoparathyroidism in adults.</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">In the EU, the therapeutic indication for YORVIPATH is a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Pivotal ApproaCH Trial (NCT05598320).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">foresiGHt Trial (NCT05171855).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New InsiGHTS Trial (NCT05690386).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">reACHin Trial (NCT06079398).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">COACH Trial (NCT06433557). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">VISEN Pharmaceuticals&#8217; Phase 3 trial. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Japanese riGHt Trial.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PaTHway China.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">PaTHway Japan.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">14.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ACcomplisH China.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">15.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">transcendIT-101 Trial (NCT04799054). </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">16.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">BelieveIT-201 Trial (NCT05980598).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">17.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IL-Believe Trial (NCT05081609).</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain an intellectual property portfolio comprising over 300 issued patents and over 550 patent applications as of December 31, 2023, which includes patents and patent applications applicable to our products and product candidates with claims directed to composition of matter, process, formulation and/or methods-of-use for our products and product candidates, including a product-specific device and core TransCon technologies. Other than the rights we have granted to VISEN, Teijin Limited, and Eyconis as noted in this report, we hold worldwide rights to our TransCon technologies and, other than our royalty financing arrangements with Royalty Pharma as noted in this report, we owe no third-party royalty or milestone payment obligations with respect to our TransCon technologies, TransCon hGH, TransCon PTH, or any of our other product candidates. While our TransCon prodrugs may incorporate already approved parent drugs, TransCon hGH, TransCon PTH and each of our other product candidates are new molecular entities and therefore eligible to be granted new intellectual property rights, including new composition of matter patents.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Global Commercialization Strategy</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are establishing a global presence to commercialize TransCon product and product candidates, if approved, to address patients' unmet medical needs.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the U.S., we have established a multi-faceted organization to support the ongoing commercialization of SKYTROFA, which will also serve as the foundation for future Endocrinology Rare Disease product launches in the U.S., including YORVIPATH.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In Europe, we are expanding our presence by building integrated organizations in select countries, which we call Europe Direct, beginning with Germany, where we have launched SKYTROFA and YORVIPATH. We are establishing commercial infrastructure in other Europe Direct country clusters, including DACH (Germany, Austria, Switzerland), France &amp; BeNeLux (Belgium, the Netherlands, and Luxembourg), Iberia (Portugal and Spain), Italy, Nordics (Denmark, Norway, Sweden, Iceland, Finland), and the United Kingdom &amp; Ireland.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Beyond the U.S. and Europe Direct, we are expanding global reach for our Endocrinology Rare Disease programs through exclusive distribution agreements with geographic market leaders, which we call International Markets. As of June 30, 2024, we have established five such regional agreements:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Specialised Therapeutics Asia Pte Ltd. (Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam) </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Er-Kim &#304;lac Sanayi ve Ticaret A.S (Central &amp; Eastern Europe and Turkey) </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Vector Pharma FZCO (Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar, and Bahrain) </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Neopharm (Israel) 1996 Ltd (Israel)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pendopharm, a division of Pharmascience Inc. (Canada)</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">5</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Finally, we are making our products commercially available in select markets through exclusive license agreements with partners with local development and commercialization expertise and infrastructure. In China, VISEN has exclusive license rights to develop and commercialize TransCon hGH, TransCon PTH, and TransCon CNP. In Japan, Teijin Limited has exclusive license rights to develop and commercialize TransCon hGH, TransCon PTH, and TransCon CNP.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon Technologies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our TransCon technologies are designed to combine the benefits of conventional prodrug and sustained release technologies to solve the fundamental limitations seen in other approaches to extending duration of a drug&#8217;s action in the body, with the goal of developing highly differentiated product candidates based on efficacy, safety, tolerability and convenience. In addition to retaining the original mode of action of the parent drug and potentially supporting dosing frequency from daily up to six months or more, we believe that predictable release over time can improve treatment safety and efficacy, increase the likelihood of clinical development success, and provide intellectual property benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon molecules can have up to three components: a parent drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from clearance. When injected into the body, physiologic pH and temperature conditions initiate the release of the active, unmodified parent drug in a predictable release manner.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Depending upon the type of TransCon carrier we employ, we can design our TransCon prodrugs for sustained localized or systemic delivery.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img148560552_2.jpg" alt="img148560552_2.jpg" style="width:624px;height:232px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TransCon Technology Components</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TransCon Carriers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our TransCon technologies incorporate two carrier platforms that can be used to provide sustained localized or systemic drug exposure. These biocompatible carrier platforms include our TransCon systemic carriers and TransCon localized carriers (self-eliminating hydrogels). Our carriers inactivate and protect the drug through a shielding effect, which may prevent rapid excretion and degradation of the parent drug and enable benefits that include improved injection site tolerability, reduced systemic adverse effects, and low immunogenicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Systemic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Our TransCon systemic carriers are used to provide systemic drug exposure and are based on soluble compounds such as methoxypolyethylene glycol (&#8220;mPEG&#8221;) or other natural or synthetic polymers. Prodrugs created using our systemic carriers are readily absorbed into the bloodstream after administration, thus minimizing exposure of the subcutaneous tissue to active drug, which we believe may improve injection site tolerability. TransCon hGH, TransCon PTH, and TransCon CNP utilize mPEG as a carrier molecule. mPEG is widely used to improve the pharmacokinetic or pharmacodynamic properties of marketed therapeutics. Below is an illustration of our systemic carrier:</span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">6</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img148560552_3.jpg" alt="img148560552_3.jpg" style="width:464px;height:152px;"/>&#160;</p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Localized</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> &#8211; Our TransCon localized carriers include TransCon hydrogels based on PEG, hyaluronic acid, or other biopolymers. TransCon hydrogel is designed to self-eliminate to soluble, biocompatible molecules after the drug payload has been released. When applied for localized delivery, the TransCon hydrogel enables the release of a parent drug at high local concentrations within the target area while minimizing systemic exposure. We believe this may widen the therapeutic window for parent drugs that suffer from significant systemic side effects and toxicities, facilitating the development of highly efficacious product candidates with improved safety and tolerability profiles. Below is an illustration of our hydrogel carrier: </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img148560552_4.jpg" alt="img148560552_4.jpg" style="width:448px;height:163px;"/>&#160;</p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2023, we announced the development of a novel TransCon prolongation technology. This new TransCon technology may support expansion of TransCon technology into new therapeutic areas.</span></div></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TransCon Linkers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our reversible TransCon linkers are designed to enable the transient conjugation of a broad range of therapeutics, including proteins, peptides and small molecules, to our TransCon carriers. We have a large library of TransCon linkers that may be applicable to various types of parent drugs, and that can be tailored to potentially achieve half-life extension enabling daily, weekly, monthly, and half-yearly dosing and to customize the potential pharmacokinetic profile for each individual product candidate with the goal of optimizing the potential therapeutic effect. TransCon linkers are self-cleaving through a process called intra-molecular assisted cleavage, which causes the linker to release the unmodified parent drug. We can tailor the release properties of the linker to a given therapeutic indication and parent drug by modifying the linker structures. We believe the self-cleaving process of our linker avoids many of the shortcomings of conventional prodrug technologies, which often depend on metabolic processes, such as enzymatic degradation, to convert the prodrug into the active drug. The rate of metabolic conversion of prodrugs in these types of processes may differ between patients, and even within different tissues in the same patient. As a result, conventional prodrugs do not always offer predictable release of the parent drug. Our TransCon linkers are designed to predictably release an unmodified active parent drug at predetermined rates governed by physiological pH and temperature conditions, which are tightly regulated in the body. Consequently, we believe we can design our prodrugs to release the unmodified parent drug at predictable rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Parent Drugs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our TransCon technologies are applicable across a broad range of therapeutic classes and are currently used to create potentially best-in-class long-acting product candidates based on proteins, peptides and small molecules. By primarily focusing on biological targets that have been clinically validated, we can leverage available knowledge regarding a target&#8217;s activity. Based on this selective approach, we know what drug levels must be maintained in the body for optimal efficacy and safety, and we can design the release half-life and dosing frequency of our TransCon prodrugs to maintain these levels to achieve the desired pharmacological effect. We move a product candidate into development after it demonstrates the desired profile in non-clinical models. Furthermore, based on the established translational relationships between preclinical animal models and clinical efficacy, we believe experimental results generated in animal models are highly predictive of clinical results and reduce the development risk for our TransCon prodrugs. This strategy is designed to reduce risk and increase productivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This approach has enabled us to develop two approved products and generate a pipeline of product candidates designed to address significant unmet medical needs and to become potential sources of significant revenue for our company. Because our TransCon technologies leverage clinically validated parent drugs or pathways, we believe we may benefit from a higher development and regulatory success rate compared to development of drug compounds without established biology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon Products &#8211; Endocrinology Rare Disease</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TransCon Growth Hormone (hGH)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Opportunity for Recombinant Human Growth Hormone</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Growth hormone deficiency is a serious orphan disease that affects both children and adults. Children with GHD are characterized by short stature, metabolic and cardiovascular abnormalities, cognitive deficiencies, and poor quality of life. GHD in adults is associated with increased adiposity, or fat mass, as well as psychiatric-cognitive, cardiovascular, muscular, metabolic and skeletal abnormalities. In childhood and adolescence, growth hormone plays an essential role in normal longitudinal growth, muscle and bone strength, and distribution of body fat. In adults, growth hormone contributes to body composition, cardiovascular function, and bone health. The current standard of care for GHD has been daily subcutaneous injections of somatropin, a recombinant human growth hormone (&#8220;hGH&#8221;). These daily hGH therapies have been shown to be safe and well-tolerated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In both therapy-compliant children and adults with GHD, daily subcutaneous injections of hGH result in improved body composition parameters, bone density, cardiovascular outcomes and quality of life. Growth hormone-deficient children who are fully adherent to their daily hGH treatment regimen may achieve a height in adulthood that is comparable to that of their family members and national norms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite the demonstrated benefits of daily hGH therapy, many GHD patients are not adequately treated, and adherence continues to be a challenge, as reported in a 2021 paper published by Kaplowitz et al. (Kaplowitz P, Manjelievskaia J, Lopez-Gonzalez L, et al. Economic burden of growth hormone deficiency in a US pediatric population. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">J Manag Care Spec Pharm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> 2021; 27(8):1118-1128). The observational retrospective cohort analysis utilized administrative claims data from two databases on over 20,000 pediatric patients diagnosed with GHD. Approximately 68% of commercial patients and approximately 63% of Medicaid patients received daily growth hormone treatment, whereas approximately 32% of commercial patients and approximately 37% of Medicaid patients were untreated. In addition, mean adherence as measured by proportions of days covered which is defined as the number of days covered by any daily growth hormone prescription during the follow-up period was approximately 60% in the commercial cohort and approximately 50% in the Medicaid cohort. Only 32% of commercial and 18% of Medicaid patients reported adherence rates greater than 80%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For adult patients with GHD, underdiagnosis and undertreatment are also a concern. Untreated adult GHD (&#8220;AGHD&#8221;) patients can experience reduced quality of life and increased risk of morbidity and mortality. A retrospective cohort study presented at ENDO 2023 analyzed an electronics health records database and selected adult patients with suspected AGHD. Of the 51,588 patients with suspected AGHD, fewer than 4% were treated with growth hormone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since the introduction of hGH in 1981, a number of the world&#8217;s largest pharmaceutical companies have developed and marketed daily-administered hGH products. All currently marketed daily hGH products in the United States &#8211; Norditropin</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Novo Nordisk A/S), Humatrope</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Eli Lilly and Company), Genotropin</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Pfizer Inc.), Zomacton</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Ferring Pharmaceuticals, Inc.) and Omnitrope</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Sandoz GmbH) &#8211; contain unmodified somatropin (hGH) and are administered by subcutaneous injections. The global market for daily hGH products is largely composed of products from Novo Nordisk, Pfizer, Eli Lilly, Sandoz, and Merck KGaA, which together account for most of the global market share.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Primary indications for hGH in children are GHD, idiopathic short stature, chronic kidney disease, Prader-Willi syndrome, small for gestational age, and Turner syndrome. In adults, primary indications for hGH include GHD and AIDS-induced weight loss. We estimate pediatric indications comprise up to 90% of the current total hGH market, of which approximately half is for pediatric GHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Competitive Landscape for Long-Acting Growth Hormone Therapies</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since the 1990s, the pharmaceutical industry has employed various approaches to develop long-acting growth hormone products to reduce the burden of daily injections on patients and increase patient compliance with the dosing regimen. These approaches generally fall into two categories: unmodified somatropin (hGH) and permanent modification of growth hormone:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Unmodified somatropin (hGH): Two long-acting growth hormone products using encapsulation technologies previously received regulatory approval in the U.S. and Europe but were subsequently discontinued due to commercial challenges. These include Nutropin Depot</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, formerly marketed by Genentech, and Somatropin Biopartners, developed by LG Life Sciences and Biopartners GmbH. Nutropin Depot was approved in 1999 and later withdrawn; Somatropin Biopartners (LB03002), was approved by the European Medicines Agency (&#8220;EMA&#8221;) in 2013, and later withdrawn. We believe that the lack of market acceptance was a result of the various safety and tolerability issues that tend to arise with encapsulation technologies. </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Permanent modification of growth hormone: Modification technologies prolong activity in the body by creating analogs of growth hormone through permanent modification of the growth hormone molecule. This modification may alter the molecular size and interaction with the growth hormone receptor and/or change the natural association affinity to endogenous proteins, as well as the distribution in the body. These changes may alter and reduce the efficacy of these drugs compared to unmodified daily somatropin (hGH) and may also negatively impact the drug&#8217;s safety. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Novo Nordisk received regulatory approval in various countries and regions including the U.S., Japan, and EU for once-weekly somapacitan (SOGROYA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) for replacement of endogenous growth hormone in adult patients with GHD and pediatric patients with GHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pfizer (in collaboration with OPKO Health Inc.) received regulatory approval of once-weekly somatrogon (NGENLA) in various countries and regions including the U.S., Japan, and EU for pediatric GHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A permanently PEGylated long-acting growth hormone developed by GeneScience Pharmaceuticals Co., Ltd. (Jintrolong</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) is available in China and the Somatropin Biopartners product (LB03002) is available in Korea. Other experimental growth hormone therapies based on permanent modification are in different stages of clinical development by various companies, including Genexine Inc., I-MAB, and JCR Pharmaceuticals Co., Ltd.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Solution: TransCon hGH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon hGH is a prodrug composed of somatropin that is transiently bound to a carrier by a proprietary linker. TransCon hGH is administered once weekly and is designed to maintain the same mode of action as daily therapies by providing sustained release of active, unmodified somatropin, the same recombinant growth hormone molecule used in the daily hGH therapies that are the current standard of care.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">9</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TransCon Growth Hormone (hGH) for pediatric GHD</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon hGH, marketed under the brand name SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(lonapegsomatropin-tcgd), received regulatory approval in the U.S. for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone, also known as GHD. SKYTROFA has been commercially available for prescription in the United States since October 2021. In the EU, Norway, Iceland, Lichtenstein and Great Britain (covering England, Wales, Scotland), we received marketing authorization for TransCon hGH &#8211; known by its brand name SKYTROFA (lonapegsomatropin) &#8211; as a once-weekly subcutaneous injection for the treatment of children and adolescents ages 3 to 18 years with growth failure due to insufficient secretion of endogenous growth hormone. SKYTROFA has been commercially available for prescription in Germany since September 2023.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, we announced topline results from the completed enliGHten Trial, an open-label extension trial evaluating the long-term safety and efficacy of TransCon hGH as a once-weekly treatment for children and adolescents with growth hormone deficiency. The enliGHten Trial enrolled 298 participants (mean age 10.3 years) from the Phase 3 heiGHt Trial of treatment-na&#239;ve pediatric GHD patients and the Phase 3 fliGHt Trial of pediatric GHD patients switching from daily somatropin treatment. Patients in these trials received a total of up to 6 years of treatment with TransCon hGH. At the time of the enliGHten Trial closure, 81 participants were designated as treatment completers, based on their physician&#8217;s determination that treatment for pediatric GHD was no longer required. Of these treatment completers, 59% met or exceeded their average parental height standard deviation score (&#8220;SDS&#8221;), with mean TransCon hGH treatment duration of 3.2 years.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical Trial of TransCon hGH in Japanese Pediatric GHD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In our ongoing Phase 3 riGHt Trial, we are evaluating TransCon hGH as a treatment in Japanese children with GHD. The primary objective of the riGHt Trial is to evaluate and compare the annualized height velocity of approximately 40 Japanese prepubertal children with GHD treated with once-weekly TransCon hGH to that of children treated with a commercially available daily hGH formulation at 52 weeks. Enrollment in the riGHt trial was completed during the fourth quarter of 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Proprietary Auto-injector</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SKYTROFA includes the SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Auto-Injector and cartridges. The auto-injector provides for room temperature storage, includes an empty-all design, and is expected to last for at least four years. The device enables a single, low-volume injection of less than 0.6 mL for the majority of patients with a thin, 31-gauge needle that is only 4 millimeters in length, which is comparable to needles used to administer daily hGH. We are also working on strategies that will enable the auto-injector to integrate with the digital healthcare system, including Bluetooth connectivity features to allow for easy tracking of dosing adherence over time.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img148560552_5.jpg" alt="img148560552_5.jpg" style="width:205px;height:345px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Figure: Our state-of-the-art auto-injector is designed to improve treatment compliance for children with GHD.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">10</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon Product Candidates &#8211; Endocrinology Rare Diseases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TransCon Growth Hormone (hGH) for Other Indications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development in Adults</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, we announced positive topline results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled (double-blind) and active-controlled (open-label) trial to compare the efficacy and safety of TransCon hGH with placebo and daily hGH in adults with GHD. The trial aims to evaluate the metabolic benefits of TransCon hGH in adults, with the primary objective to evaluate change in trunk fat percentage.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The foresiGHt Trial evaluated 259 adults with GHD aged 23 to 80 years old, randomized 1:1:1, titrated to receive a target fixed dose of TransCon hGH, placebo, or daily hGH based on age and oral estrogen intake, with approximately equivalent hGH mg/week for TransCon hGH and daily hGH.</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon hGH demonstrated superiority on its primary efficacy endpoint at Week 38:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change from baseline in trunk percent fat as measured by dual x-ray absorptiometry (TransCon hGH -1.67% vs. placebo +0.37%, LS mean difference = -2.04%, p &lt; 0.0001)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon hGH demonstrated superiority on its key secondary efficacy endpoints at Week 38:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change from baseline in total body lean mass (TransCon hGH +1.60 kg vs placebo -0.10 kg, LS mean difference = 1.70 kg, p &lt; 0.0001)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change from baseline in trunk fat mass (TransCon hGH -0.48 kg vs placebo +0.22 kg, LS mean difference = -0.70 kg, p = 0.0053)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exploratory post-hoc analysis at Week 38 demonstrated comparable treatment effect of TransCon hGH and daily hGH on target tissues. For patients with average IGF-1 SDS levels &#8804; 1.75 at Week 38:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change from baseline in trunk percent fat (TransCon hGH -2.42% vs. daily hGH -2.59%)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change from baseline in total body lean mass (TransCon hGH +1.70 kg vs daily hGH +1.37 kg)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Change from baseline in trunk fat mass (TransCon hGH -0.90 kg vs daily hGH -0.94 kg)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily hGH.</span></div></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We plan to submit a supplemental Biologics License Application (&#8220;BLA&#8221;) to the FDA for adult GHD in the third quarter of 2024.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Development Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, we initiated the Phase 2 New InsiGHTS Trial in the U.S. to evaluate TransCon hGH in Turner syndrome. In this trial, we are evaluating higher doses of TransCon hGH and daily hGH for Turner syndrome compared to doses for pediatric or adult GHD. Topline results from New InsiGHTS are expected in the fourth quarter of 2024. In addition, we are investigating other potential indications for TransCon hGH where we believe a long-acting hGH therapy may offer benefits to patients with rare growth disorders, including in combination with our TransCon CNP product candidate.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TransCon PTH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Opportunity in Hypoparathyroidism</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Hypoparathyroidism is a rare endocrine disease characterized by insufficient levels of parathyroid hormone (&#8220;PTH&#8221;). Most patients with hypoparathyroidism develop the condition following damage to or accidental removal of the parathyroid glands during thyroid surgery. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%); other etiologies include autoimmune disorders, genetic disorders such as autosomal dominant hypocalcemia type 1, and idiopathic causes. Conventional therapy with oral calcium and active vitamin D (also called calcitriol) does not effectively address the short-term symptoms, long-term complications, or quality-of-life impacts of hypoparathyroidism.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Short-term symptoms include weakness, severe muscle cramps (tetany), abnormal sensations such as tingling, burning and numbness (paresthesia), memory loss, impaired judgment, and headache. Patients often experience decreased quality of life, and, over the long term, prolonged use of conventional therapy may increase risk of major complications, such as calcium deposits in the brain, blood vessels, eye, and other soft tissues. According to a recent systematic literature review, chronic hypoparathyroidism treated with conventional therapy is associated with higher rates of renal complications compared to the general population, such as nephrolithiasis (up to 36%), nephrocalcinosis (up to 38%), and chronic kidney disease (up to 41%).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Hypoparathyroidism also poses a high burden on the healthcare system despite current conventional therapy. For example, one survey of 374 patients showed that 72% experienced more than ten symptoms in the preceding twelve months, with symptoms experienced for a mean of 13 &#177; 9 hours a day. Other studies showed that 79% of hypoparathyroidism cases require hospitalizations and that patients with the disease have a four-fold increase in the risk of renal disease compared to healthy controls. Patients often experience decreased quality of life. We conducted a survey of 42 patients which found that 100% of patients reported negative psychological impacts, interference with daily life and impact on physical functioning from hypoparathyroidism, and that 76% were either no longer able to work or experienced interference with work productivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 2022 Guidelines from the Second International Workshop addressing the prevention, diagnosis, and management of hypoparathyroidism was published in September 2022 in the Journal of Bone and Mineral Research and authored by leading clinicians from North America, Europe, and Asia. The authors suggest consideration of PTH replacement therapy in patients whose hypoparathyroidism is inadequately controlled with conventional therapy. Inadequate control is considered to be any one of the following: symptomatic hypocalcemia, hyperphosphatemia, renal insufficiency, hypercalciuria, or poor quality of life. In addition, the guideline indicates that individuals with poor compliance, malabsorption or who are intolerant of large doses of calcium and active vitamin D may also benefit from PTH replacement therapy. Based on this current guideline, we believe PTH replacement therapy could be applicable to most patients with hypoparathyroidism.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2015, NATPARA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (parathyroid hormone) for injection was approved in the U.S. for once-daily subcutaneous injection as an adjunct to vitamin D and calcium in patients with hypoparathyroidism. NATPARA was voluntarily recalled in September 2019 in the U.S. and is now only available to a limited number of patients through a Special Use Program offered by its manufacturer, Takeda. In October 2022, Takeda announced that it will discontinue manufacturing NATPARA/NATPAR globally by the end of 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are also aware of several academic groups and companies working on making longer-acting agonists of the PTH receptor. In addition, other companies and groups are developing or commercializing therapies for hypoparathyroidism, including Calcilytix (a BridgeBio company), Entera Bio, Extend Biosciences, Massachusetts General Hospital, Amolyt Pharma (acquired by AstraZeneca), and MBX Biosciences.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Teriparatide, PTH (1-34), approved since 2002 for the treatment of osteoporosis, has sometimes been used for treatment of hypoparathyroidism using multiple daily injections, despite not being approved for this indication. Clinical research conducted by the U.S. National Institutes of Health in subjects receiving continuous exposure to PTH (1-34), administered by an infusion pump, demonstrated simultaneous normalization of sCa and urinary calcium, as well as normalization of bone turnover.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We estimate hypoparathyroidism affects over 250,000 patients in the U.S. and Europe. In the U.S., we estimate hypoparathyroidism affects approximately 70,000 to 90,000 patients, including 4,000 to 5,000 patients who we estimate have previously been treated with PTH therapy. In Germany, we estimate hypoparathyroidism affects approximately 70,000 patients. Outside of Germany, we estimate hypoparathyroidism affects over 100,000 patients in the rest of Europe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Solution: TransCon PTH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon PTH (palopegteriparatide) is a prodrug of PTH (1-34) that is designed to be dosed once-daily to achieve and maintain a steady concentration of PTH in the bloodstream within the normal range. TransCon PTH is designed to provide PTH in the physiological range for 24 hours per day, thereby more fully addressing aspects of the disease, including normalizing serum and urinary calcium and serum phosphate levels.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">By providing steady levels of PTH in the physiological range, we believe TransCon PTH can address the fundamental limitations of PTH therapies with short half-life molecules and become a highly differentiated therapy for hypoparathyroidism.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">12</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TransCon Parathyroid Hormone (PTH) for adults with hypoparathyroidism</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, TransCon PTH received regulatory approval in the EU and European Economic Area and is marketed as YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(palopegteriparatide), a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. In April 2024, TransCon PTH received regulatory approval in Great Britain as a PTH replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. In August 2024, the U.S. FDA approved TransCon PTH for the treatment of hypoparathyroidism in adults.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are completing manufacturing of commercial product for the U.S. market and anticipate initial supply will be available in the first quarter of 2025. We are in dialogue with the FDA about commercialization of existing manufactured products, which if agreed, could be introduced in the U.S. in the fourth quarter of 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we announced that YORVIPATH is commercially available in Germany and Austria, and we began shipping to customers in February. In April 2024, we announced that the United Kingdom&#8217;s Medicines &amp; Healthcare products Regulatory Agency granted YORVIPATH orphan drug status.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development of TransCon PTH for Adult Hypoparathyroidism</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ongoing Phase 3 PaTHway Trial, Phase 3 PaTHway Japan Trial, and Phase 2 PaTH Forward Trial continue in the open-label extension portion to collect long-term data.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2024, we announced 2-year results from a post-hoc analysis of the our Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function in adults with chronic hypoparathyroidism treated with TransCon PTH. The post-hoc analysis examined the impact of treatment with TransCon PTH on renal function using estimated glomerular filtration rate (&#8220;eGFR&#8221;) through Week 104 (n=76) of PaTHway, a Phase 3 double-blind, placebo-controlled trial of 82 dosed adults with chronic hypoparathyroidism randomized 3:1 (TransCon PTH:placebo; both arms initially co-administered with conventional therapy of active vitamin D and oral calcium), with a 26-week blinded period followed by an ongoing 156-week open-label extension period. Across both treatment arms, TransCon PTH treatment resulted in a mean eGFR increase of 8.9 mL/min/1.73m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (p&lt;0.0001) from baseline at Week 52, sustained at Week 104 with a mean change from baseline of 9.0 mL/min/1.73m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (p&lt;0.0001). Treatment was generally well-tolerated, with no new safety signals.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:85.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:17.204%;"/>
    <td style="width:18.899%;"/>
    <td style="width:7.484%;"/>
    <td style="width:14.121%;"/>
    <td style="width:6.731%;"/>
    <td style="width:14.121%;"/>
    <td style="width:7.06%;"/>
    <td style="width:14.38%;"/>
   </tr>
   <tr style="height:18.15pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="8" style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">eGFR* Change from Baseline by Study Arm</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #eeece1;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #eeece1;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Baseline</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 26</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 52</span></p></td>
    <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 104</span></p></td>
   </tr>
   <tr style="height:9pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Study Arm</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">eGFR</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(mL/min/1.73m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>N</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mean</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(p value)</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>N</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mean<br/>(p value)</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>N</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Mean<br/>(p value)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="3" style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TransCon PTH / TransCon PTH</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">eGFR &lt; 60<br/></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+11.4<br/>(p=0.0002)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+11.5<br/>(p=0.0003)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+13.4<br/>(p&lt;0.0001)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">eGFR &#8805; 60</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">41</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+6.3<br/>(p=0.0002)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+8.6<br/>(p&lt;0.0001)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+6.9<br/>(p&lt;0.0001)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">All</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">60</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+7.9</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(p&lt;0.0001)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">59</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+9.3<br/>(p&lt;0.0001)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+8.9<br/>(p&lt;0.0001)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="3" style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Placebo<br/>(first 26 weeks) / TransCon PTH**</span></p></td>
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">eGFR &lt; 60</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+0.1<br/>(p=0.9877)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+11.7<br/>(p=0.0018)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+15.6<br/>(p=0.0067)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">eGFR &#8805; 60</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-2.4<br/>(p=0.3280)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+6.5<br/>(p=0.0199)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+7.6<br/>(p=0.0121)</span></p></td>
   </tr>
   <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">All</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-1.9</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(p=0.3468)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+7.6</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(p=0.0014)</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18</span></p></td>
    <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">+9.4<br/>(p=0.0006)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">*eGFR (an assessment of kidney filtering capacity) was calculated by the trial&#8217;s central lab using the Modification of Diet in Renal Disease Study Group (MDRD) equation (Levey, Ann Intern Med 2006). An eGFR level &lt;60 mL/min/1.73m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">is considered the threshold for impaired kidney function.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">**Patients in the placebo arm switched to TransCon PTH following the Week 26 visit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">13</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon PTH treatment was associated with clinically meaningful increases (&#8805; 5 mL/min/1.73 m2) in eGFR within 26 weeks that were sustained through Week 104 of PaTHway:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:86.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.16%;"/>
    <td style="width:11.56%;"/>
    <td style="width:11.56%;"/>
    <td style="width:11.3%;"/>
    <td style="width:12.76%;"/>
    <td style="width:15.78%;"/>
    <td style="width:16.88%;"/>
   </tr>
   <tr style="height:22.2pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="7" style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Proportion of Participants (%) with &#8805; 5 and &#8805; 10 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Increases in eGFR <br/>from Baseline through Week 104*</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="4" style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">eGFR Change from Baseline</span></p></td>
    <td colspan="6" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">All Participants</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TransCon PTH / TransCon PTH<br/>(n=61)</span></p></td>
    <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Placebo (first 26 weeks) / TransCon PTH** <br/>(n=21)</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 26</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 52</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 104</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 26</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 52</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 104</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Placebo</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Switch to PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Switch to PTH</span></p></td>
   </tr>
   <tr style="height:8.4pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;5 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;min-width:fit-content;">2</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">61%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">62%</span></p></td>
   </tr>
   <tr style="height:10.2pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">43%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38%</span></p></td>
   </tr>
   <tr style="height:11.1pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="7" style="padding-top:0.02in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;padding-right:0.03in;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:17.25pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
    <td rowspan="4" style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">eGFR Change from Baseline</span></p></td>
    <td colspan="6" style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Participants with Baseline eGFR &lt; 60 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TransCon PTH / TransCon PTH<br/>&#160;(n=19)</span></p></td>
    <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Placebo (first 26 weeks) / TransCon PTH** <br/>(n=4)</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 26</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 52</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 104</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 26</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 52</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Week 104</span></p></td>
   </tr>
   <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Placebo</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Switch to PTH</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Switch to PTH</span></p></td>
   </tr>
   <tr style="height:9.3pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;5 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">74%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">100%</span></p></td>
   </tr>
   <tr style="height:9.75pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;10 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">42%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">53%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">0%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75%</span></p></td>
    <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">75%</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">*Percentages were calculated based on all participants. Patients who did not have an eGFR assessment at the visit were still included in the denominator.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">**Patients in the placebo arm switched to TransCon PTH following the Week 26 visit.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2023, we announced one-year (Week 52) data from the open-label extension (&#8220;OLE&#8221;) portion of the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism. PaTHway is a Phase 3 trial of TransCon PTH with a placebo-controlled 26-week blinded portion and a 156-week OLE portion, designed to evaluate the long-term efficacy and safety of TransCon PTH as a potential hormone therapy for adult patients diagnosed with hypoparathyroidism. Of the 82 study participants dosed, 79 completed blinded treatment and entered the OLE, and 78 (59 TransCon PTH/TransCon PTH, 19 placebo/TransCon PTH) completed Week 52. The data showed that treatment with TransCon PTH resulted in sustained improvements through Week 52, as well as safety and tolerability similar to that reported for the initial 26-week blinded portion of the trial. As of June 30, 2024, 74 out of 79 patients continue in the OLE and have exceeded two years of follow-up in the PaTHway Trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 8, 2023, we announced topline data from PaTHway Japan, a single-arm Phase 3 trial to evaluate the safety, tolerability, and efficacy of TransCon PTH in adults with hypoparathyroidism. The study achieved its primary objective, with topline results consistent with our trials in North America and the EU. Twelve out of thirteen patients met the primary multi-component endpoint, which was defined as serum calcium levels in the normal range (8.3&#8211;10.6 mg/dL) and independence from conventional therapy (no active vitamin D and &#8804;600 mg/day of calcium). In this trial, TransCon PTH was generally well-tolerated, with no discontinuations related to study drug. As of March 31, 2024, 12 patients continue in the ongoing 3-year extension portion of the PaTHway Japan Trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2022, the FDA allowed us to initiate a U.S. expanded access program (&#8220;EAP&#8221;) for TransCon PTH for eligible adult patients with hypoparathyroidism with prior PTH treatment experience. This EAP program is ongoing.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2022, we announced new Week 110 data from the Phase 2 PaTH Forward Trial showing that long-term therapy with TransCon PTH provided a durable response in adult patients with hypoparathyroidism, as evidenced by maintenance of normal mean serum calcium levels and 93% of patients achieving independence from conventional therapy (no active vitamin D and &#8804;600 mg/day of calcium). Fifty-seven subjects exceeded three years of follow-up in the PaTH Forward Trial. As of June 30, 2024, 56 out of the 59 patients originally enrolled in the trial continued in the OLE portion and have exceeded four years of follow-up. Three patients withdrew from the trial for reasons unrelated to safety or efficacy of the study drug.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">14</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, we announced that top-line data from the randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism demonstrated statistically significant higher proportion of participants treated with TransCon PTH achieved the primary multi-component endpoint compared to placebo. The primary endpoint, defined as serum calcium levels in the normal range (8.3&#8211;10.6 mg/dL) and independence from conventional therapy (no active vitamin D and &#8804;600 mg/day of calcium) with no increase in prescribed study drug within the 4 weeks prior to the Week 26 visit, was achieved by 78.7% of TransCon PTH-treated patients (48 of 61), compared to 4.8% for patients (1 of 21) in control group (p-value &lt;0.0001). In addition, all key pre-specified secondary endpoints were met with statistical significance. TransCon PTH was generally well tolerated, with no discontinuations related to study drug. Three patients discontinued during the treatment period, two from the placebo arm and one from the TransCon PTH arm. TransCon PTH-treated patients showed a mean decrease in 24-hour urine calcium excretion into the normal range.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2020, we announced top-line data from the four-week fixed dose, double-blinded portion of PaTH Forward, a global Phase 2 trial evaluating the safety, tolerability and efficacy of TransCon PTH in adult subjects with hypoparathyroidism. A total of 59 subjects were randomized in a blinded manner to receive fixed doses of TransCon PTH at 15, 18 or 21 &#181;g/day or placebo for four weeks using a ready-to-use prefilled pen injector planned for commercial presentation. All doses of TransCon PTH were well-tolerated, and no serious or severe treatment-related adverse events (&#8220;TEAEs&#8221;), were observed at any point. No treatment-emergent adverse events led to discontinuation of study drug, and the overall incidence of TEAEs was comparable between TransCon PTH and placebo. Additionally, there were no drop-outs during the four-week fixed dose period.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2018, we were granted Orphan Drug Designation (&#8220;ODD&#8221;) by the FDA, for TransCon PTH for the treatment of hypoparathyroidism. In October 2020, we were granted Orphan designation (&#8220;OD&#8221;) by the European Commission (&#8220;EC&#8221;) for TransCon PTH for the treatment of hypoparathyroidism. In July 2021, the Ministry of Health, Labour and Welfare in Japan granted ODD to TransCon PTH for the treatment of hypoparathyroidism.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TransCon CNP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Opportunity in Achondroplasia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Achondroplasia is the most common genetic form of skeletal dysplasia leading to disproportionate short stature and is associated with a well-delineated range of clinical complications and manifestations, occurring in about one in 10,000 to 30,000 newborns or approximately 250,000 worldwide. Achondroplasia results in severe skeletal complications and comorbidities including spinal stenosis due to premature fusion of the foramen magnum, sleep apnea, chronic ear infections, and muscular complications. Patients often face multiple surgeries to alleviate its many complications. There is significant unmet need for treatments that ameliorate complications and improve quality of life in achondroplasia.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Achondroplasia is primarily caused by gain-of-function variants of the FGFR3 gene resulting in constitutive activation of FGFR3 that leads to an imbalance in the effects of the FGFR3 and C-type natriuretic peptide (&#8220;CNP&#8221;) signaling pathways. In achondroplasia, mutations in FGFR3 result in constitutive activation, suppressing the proliferation and differentiation of chondrocytes resulting in improper cartilage to bone conversion in the growth plate, and dysfunction in the skeletal muscle. Preclinical and clinical data show that the CNP pathway helps to counteract the effects of the FGFR3 mutation downstream.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2021, BioMarin Pharmaceutical Inc.&#8217;s VOXZOGO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (vosoritide) was approved by the FDA and is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. Other companies that are developing therapies for achondroplasia include QED Therapeutics (a BridgeBio company), Sanofi, Ribomic, Tyra Biosciences, and ProLynx.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">15</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Changing the Treatment Paradigm of Achondroplasia</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical manifestations of achondroplasia are associated with significant, potentially life-threatening complications and reduced quality of life. While achondroplasia has historically been considered a growth disorder, secondary manifestations beyond linear growth, including reduced muscle strength and stamina, suggest that achondroplasia is also a muscle disorder.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img148560552_6.jpg" alt="img148560552_6.jpg" style="width:624px;height:221px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">ACH-AE: Increased incidence of Achondroplasia-related Adverse Events.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">HRQoL: Reduced Health-Related Quality of Life; Height; Reduced height. Muscle Strength/Stamina; Reduced muscular functionality, including reduced strength and stamina.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Solution: TransCon CNP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon CNP (navepegritide) is an investigational prodrug of CNP administered once weekly and designed to provide sustained release of active CNP supporting continuous exposure for the treatment of achondroplasia. TransCon CNP is designed to provide effective shielding of CNP from neutral endopeptidase degradation in subcutaneous tissue and the blood compartment, minimize binding of CNP to the NPR-C receptor to decrease clearance, reduce binding of CNP to the NPR-B receptor in the cardiovascular system to avoid hypotension, and release unmodified CNP, which is small enough in size to allow effective penetration into growth plates. Shorter-acting CNP and CNP analogs in development have resulted in high Cmax levels that may cause adverse cardiovascular events. We believe the therapeutically sustained release of TransCon CNP offers advantages that may mitigate this issue, leading to more constant CNP exposure at lower Cmax to correlate with better therapeutic outcomes.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Development of TransCon CNP for Achondroplasia</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our ongoing pivotal ApproaCH Trial, ACcomplisH Trial, our long-term extension trial AttaCH and COACH, are evaluating the safety and efficacy of TransCon CNP in children with achondroplasia. The ongoing reACHin Trial is evaluating the safety, tolerability, and efficacy of TransCon CNP in infants with achondroplasia (aged 0 to &lt; 2 years at the time of randomization).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we announced our plan to submit an Investigational New Drug (&#8220;IND&#8221;) application or similar in the fourth quarter of 2024 to initiate a trial to evaluate TransCon CNP in adults with achondroplasia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In December 2023, we announced new analyses demonstrating benefits beyond linear growth from the blinded and ongoing OLE portions of ACcomplisH, a Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial of TransCon CNP in children ages 2-10 years with achondroplasia. In the trial, all 57 patients have now completed one year of treatment with TransCon CNP at 100 &#181;g/kg/week, the dose agreed with regulatory agencies for the active arm in our pivotal ApproaCH Trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We analyzed available data for patients who only received TransCon CNP at the 100 &#181;g/kg/week dose in either blinded or OLE part and were treated for one year (n=19), compared to those administered placebo for one year (n=15). Results showed that these TransCon CNP-treated patients (data available for 9-16 patients) showed significant improvements in health-related quality of life and disease impacts compared to those receiving placebo (data available for 5-13 patients).</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">16</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Assessments were performed with the SF-10 (a 10-item non-disease specific survey of a child&#8217;s functional health and well-being that is validated in children ages 5 years and older) and the Achondroplasia Child Experience Measure (&#8220;ACEM&#8221;) a condition-specific clinical outcome measure that assesses the impact of achondroplasia on a child&#8217;s health-related quality of life, with statistically significant improved outcome in TransCon CNP-treatment versus placebo for:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SF-10 Physical Summary (p=0.002, ages 5 years and older)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACEM Daily Living Function (p=0.047)</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ACEM Emotional Well-being (p=0.045)</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img148560552_7.jpg" alt="img148560552_7.jpg" style="width:624px;height:264px;"/>&#160;</p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The 46 children switching from placebo or a lower dose of TransCon CNP to the 100 &#181;g/kg/week dose in the OLE demonstrated improved growth after one year of treatment, similar to the growth benefits seen in the 11 children treated with 100 &#181;g/kg/week in the one-year randomized, double-blind period of ACcomplisH.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">While the CNP pathway may restore normal growth and skeletal muscle function, delayed initiation of therapy could lead to a permanent height deficit. Clinical use of daily growth hormone injection has consistently demonstrated growth improvements in children with achondroplasia, including catch up growth, however without reports of benefits beyond linear growth. We believe use of TransCon hGH and TransCon CNP together once per week could enable catch up growth beyond normal growth while maintaining benefits on skeletal muscle of continuous CNP exposure. During the fourth quarter of 2023, we filed a Clinical Trial Application for COACH, a Phase 2 open-label single-arm trial evaluating TransCon CNP and TransCon hGH in children with achondroplasia (age 2 to 11 years). The primary objective is to evaluate the treatment effect on linear growth and safety. Secondary objectives are to evaluate treatment effect on quality of life, radiological endpoints, physical functioning, and body composition. The trial plans to enroll approximately 18 patients (treatment na&#239;ve, n=12; prior treatment with TransCon CNP (100 &#181;g/kg/week) for at least 1 year, n=6). Week 26 topline data from the COACH Trial are expected in the second quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the third quarter of 2023, we filed an IND amendment with the FDA to initiate reACHin, a Phase 2, multicenter, double-blind, randomized, placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 &#956;g/kg of TransCon CNP once-weekly for 52 weeks in infants with achondroplasia, aged 0 to &lt; 2 years at the time of randomization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, we announced completion of enrollment in ApproaCH with a total of 84 subjects randomized. U.S. and EU regulatory agencies have endorsed ApproaCH, a global randomized, double-blind, placebo-controlled trial in children ages 2&#8211;11 years with achondroplasia, as a pivotal Phase 3 trial. The primary endpoint of the trial is annualized growth velocity at 52 weeks with additional endpoints analyzing achondroplasia-related co-morbidities and quality of life. Topline results from the ApproaCH trial are expected in the third quarter of 2024. In addition, we intend to use the results from ApproaCH in connection with a planned NDA submission to the FDA for TransCon CNP for children with achondroplasia (age 2-11 years) in the first quarter of 2025.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2022, we announced topline results from ACcomplisH, a Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial evaluating the safety and efficacy of once-weekly TransCon CNP compared to placebo in children with achondroplasia aged two to ten years old.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">17</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The ACcomplisH Trial evaluated 57 children with achondroplasia aged 2 to 10 years old, randomized in a 3:1 ratio to receive either sequential ascending doses of once-weekly TransCon CNP (6 &#181;g/kg/week, 20 &#181;g/kg/week, 50 &#181;g/kg/week, 100 &#181;g/kg/week) or placebo for 52 weeks. The trial met its primary objectives, demonstrating that TransCon CNP at 100 &#181;g/kg/week (n=11) was superior to placebo (n=15) on the primary efficacy endpoint of annualized growth velocity (&#8220;AGV&#8221;) at 52 weeks (p=0.0218). All 57 randomized children completed the blinded portion of ACcomplisH and continued in the OLE portion of ACcomplisH at the 100 &#181;g/kg/week dose. As of June 30, 2024, the first 41 patients completed the OLE portion of the ACcomplisH Trial and transitioned into the Phase 2 AttaCH Trial, a multicenter, long-term, open label extension and 40 continue treatment; 14 patients continue in OLE portion of ACcomplisH.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional highlights:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon CNP demonstrated a consistent dose-dependent increase in AGV across the four dose groups.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Mean improvements in AGV for TransCon CNP-treated patients were consistent across age groups &lt;5 years and &gt;5 years, with dose response established.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon CNP at 100 &#181;g/kg/week improved change in achondroplasia-specific height SDS compared to placebo (p=0.0283).</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon CNP was generally well tolerated, with no discontinuations.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No serious adverse events (&#8220;SAEs&#8221;) related to treatment were reported; two unrelated SAEs were reported.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Injections were generally well tolerated with low frequency of injection site reactions (&#8220;ISRs&#8221;):</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">11 mild ISRs (in 8 patients) out of &gt;2,000 injections.</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investigator-assessed achondroplasia-related AEs were less frequently reported among participants receiving TransCon CNP (31%; 13/42) compared with placebo (60%; 9/15).</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In 2019, we initiated the ACHieve Study, a five-year, multi-center natural history study designed to gain insight into the experiences of pediatric patients with achondroplasia. ACHieve is designed to evaluate growth velocity, body proportionality, and comorbidities over time in children with achondroplasia up to eight years old. No study medication was administered in the ACHieve Study. The study ended in the first quarter of 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In February 2019, we were granted ODD by the FDA for TransCon CNP for the treatment of achondroplasia. In July 2020, we received OD from the EC for TransCon CNP for the treatment of achondroplasia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon Product Candidates&#8212;Oncology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Opportunity in Oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cancer continues to be one of the leading causes of mortality. Improved understanding of the cellular and molecular mechanisms involved in anti-tumor immune responses has fueled the rapid growth of immuno-oncology therapeutics. Immune checkpoint inhibitors, such as anti-PD-(L)1 and anti-CTLA-4 antibodies, have provided new therapeutic options for patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Despite recent advances, a high need for new treatment options remains for patients who do not respond or respond inadequately to current therapies. In addition to insufficient efficacy, many current treatments are limited by toxicities that result in dose reductions, treatment discontinuations, or long-term health risks to patients.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe that one approach to improving efficacy while limiting adverse events is to create long-acting product candidates using our sustained systemic release TransCon technology, allowing for more consistent circulating drug levels and potentially avoiding high peak concentrations that are often associated with toxicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Another approach is to target the drug activity into tumors via intratumoral injection using our sustained localized release TransCon hydrogel technology, aiming for high activity in the tumor microenvironment while limiting systemic adverse events. While one intratumoral treatment has been approved for the local treatment of recurrent melanoma, the overall success of intratumoral treatments has been limited to date. This is likely partly due to lack of prolonged intratumoral exposure of active drug levels, resulting in the potential need for more frequent dosing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Our Solution: TransCon Technologies for Oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe prolonging the therapeutic activity and targeting the drug activity to the relevant cell types and tissues have the potential to improve treatment outcomes. We believe TransCon is well-suited to improve cancer treatments given the large number of validated targets with known limitations. By applying our unique algorithm for product innovation to clinically validated targets and pathways, we believe TransCon has the potential to improve outcomes currently limited by suboptimal efficacy and systemic toxicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We believe TransCon technologies may have the potential to increase the efficacy of small molecules, peptides and proteins without increasing toxicity, which could offer the potential to treat more patients with new combination and multi-agent regimens that would not otherwise be feasible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are currently investigating two clinical-stage product candidates designed to activate the patient&#8217;s own immune system to eradicate malignant cells. We believe our approach, if successfully developed, has the potential to improve the efficacy of systemically administered, clinically validated therapies while limiting adverse effects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly, with the potential to achieve sustained local release at predictable levels, we believe TransCon hydrogel product candidates may allow for improved efficacy and reduced dosing frequency of intratumorally administered therapies, potentially enabling treatments of multiple tumor types, including those that cannot be easily accessed for frequent injection.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Development of TransCon Product Candidates in Oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our TransCon product candidates in oncology are designed to provide sustained systemic or intratumoral administration, which we believe could provide potent and durable anti-tumor efficacy. Our nonclinical studies have shown sustained activation of cytotoxic immune cells that resulted in robust anti-tumor responses by TransCon product candidates using infrequent administration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Two of our oncology product candidates, TransCon TLR7/8 Agonist and TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, are now in clinical development. In addition, we believe that a combination of TransCon TLR7/8 Agonist and TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> may have the potential to produce greater anti-tumor activity than either candidate alone.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TransCon TLR7/8 Agonist for sustained localized release</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon TLR7/8 Agonist is an investigational long-acting prodrug, designed for sustained intratumoral release of resiquimod, a small molecule agonist of TLR 7 and 8. It is designed to provide sustained and potent activation of the innate immune system in the tumor and tumor draining lymph node for weeks following a single intratumoral injection and to have a low risk of systemic toxicity. The transcendIT-101 Trial, a Phase 1/2 clinical trial to evaluate the safety and efficacy of TransCon TLR7/8 Agonist in locally advanced or metastatic solid tumors, alone or in combination with pembrolizumab, has completed dose escalation and is enrolling patients in four indication-specific cohorts where increased TLR7/8 activity has potential to improve innate and adaptive immune activation and host defense against cancers: head and neck squamous cell carcinoma (HNSCC), HPV-associated cancers, melanoma, and cutaneous squamous cell carcinoma (cSCC). Initial data from these cohorts are expected by the end of 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, we announced additional follow-up from the transcendIT-101 Trial indicating further clinical activity in patients receiving TransCon TLR7/8 Agonist as monotherapy or in combination with pembrolizumab. Enrollment continues in the Phase 2 portion of transcendIT-101 at the recommended Phase 2 dose (&#8220;RP2D&#8221;). Updated clinical data indicate intratumoral TransCon TLR7/8 Agonist was generally well tolerated as monotherapy or when used in combination with pembrolizumab. In addition, monotherapy confirmed response in injected and non-injected tumors was observed, indicating abscopal effect and ability to induce systemic immune effects.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2022, we announced new data (cutoff date of September 21, 2022) from the dose-escalation portion of transcendIT-101. All 23 of the patients enrolled in the dose escalation portion of the trial had advanced or metastatic solid tumors that had progressed on prior treatments, 9 in the monotherapy cohort (intratumoral TransCon TLR7/8 Agonist alone) and 14 in the combination therapy cohort (intratumoral TransCon TLR7/8 Agonist plus the check-point inhibitor pembrolizumab). Two dose levels were evaluated: 0.3 mg/lesion and 0.5 mg/lesion. The RP2D was declared at 0.5 mg/lesion for up to two lesions, which is being evaluated in four indication specific cohorts.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">19</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Symbol',serif;font-style:italic;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Symbol',serif;font-style:italic;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> for sustained systemic release</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (onvapegleukin alfa) is an investigational long-acting prodrug designed to improve cancer immunotherapy through sustained release of an IL-2 variant that selectively activates IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, with minimal binding to IL-2R&#945;. The IL-Believe Trial, a Phase 1/2 clinical trial to evaluate the safety and efficacy of TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> in locally advanced or metastatic solid tumors, alone or in combination with pembrolizumab or standard of care chemotherapy, has completed dose escalation and is enrolling patients in multiple indication-specific dose expansion cohorts, including platinum-resistant ovarian cancer (PROC), cervical cancer, melanoma, non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC) at the RP2D. Initial data from these cohorts are expected by the end of 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2024, we reported interim results from our ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g.</span><span style="color:#58595b;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Data included the first presentation of Phase 2 dose expansion Cohort 4 (TransCon IL-2 &#946;&#8260;&#947; in combination with TransCon TLR7/8 Agonist) in post anti-PD-1 melanoma and new analyses of patients from dose escalation cohorts with prior disease progression on checkpoint inhibitors, along with biomarker studies correlating cytotoxic immune cell expansion and clinical benefit. As of the April 16, 2024, data cutoff, confirmed clinical responses were observed in 40% (two out of five) of efficacy-evaluable patients from Cohort 4, suggesting potential synergy of our two novel immunotherapy agents in patients who did not derive sufficient benefit from checkpoint inhibitors. Of efficacy-evaluable patients with prior disease progression on checkpoint inhibitors to date in the IL-Believe Trial, confirmed clinical responses (per RECIST v1.1) were observed in 45% (five out of eleven) administered TransCon IL-2 &#946;/&#947; doses &#8805;80 &#956;g/kg every 3 weeks, suggesting clinical benefit in treatment-resistant settings (monotherapy (n=4): 1 confirmed partial response (&#8220;PR&#8221;) in colorectal cancer; combination with pembrolizumab (n=2): 1 confirmed complete response and 1 confirmed PR in small-cell lung cancer; combination with TransCon TLR7/8 Agonist (n=5): 2 confirmed PRs in melanoma). In this trial, TransCon IL-2 &#946;&#8260;&#947; alone or in combination with pembrolizumab or TransCon TLR7/8 Agonist was generally well tolerated with no new safety signals.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">During the fourth quarter of 2023, the first patient was dosed with the combination of TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and TransCon TLR7/8 Agonist in the post PD-1 melanoma dose expansion cohort in the IL-Believe Trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In October 2023, we announced new and updated data from the ongoing IL-Believe Trial. Forty-six patients were enrolled into dose escalation cohorts: 25 to monotherapy and 21 to combination therapy. As of the August 15, 2023, data cutoff, anti-tumor clinical responses were observed with TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> monotherapy (colorectal cancer with PR) or in combination with pembrolizumab (small cell lung cancer, one with confirmed PR and one ongoing with unconfirmed complete response) in heavily pre-treated patients who previously progressed on checkpoint inhibitors. TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> every three weeks was generally well-tolerated, with no meaningful effect on Tregs and eosinophils.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, we announced completion of Phase 1 dose escalation in combination with pembrolizumab of the IL-Believe Trial with a total of 21 patients enrolled and RP2D determined at 120 &#181;g/kg IV every three weeks. Twenty-one patients were enrolled.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In May 2023, we announced completion of the Phase 1 monotherapy dose escalation of the IL-Believe Trial with RP2D determined at 120 &#181;g/kg IV every three weeks with 25 heavily pre-treated patients enrolled and a median of four prior lines of systemic therapies.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Other Development Plans</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To further evaluate safety and anti-tumor efficacy of TransCon TLR7/8 Agonist and TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, we are also evaluating these product candidates as neoadjuvant therapy in the ongoing randomized Phase 2 BelieveIT-201 trial in resectable locally advanced head and neck squamous cell carcinoma.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strategic Collaborations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We also engage in strategic collaborations to further leverage our TransCon technologies in certain geographies with market-leading biopharmaceutical companies. These collaborations aim to make promising treatment options available to more patients and to further monetize both our TransCon technologies and our internal product candidates, particularly into therapeutic areas where we believe a partner may have more expertise, capability, and capital. In addition, we may choose to pursue a collaboration to develop and market our internal, wholly owned product candidates in geographic markets outside our core focus areas of the United States and Europe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, we announced that we entered into an exclusive license agreement with Teijin Limited for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan. Under the terms of the agreement with Teijin Limited, we received an upfront payment of $70 million, with additional development and regulatory milestones of up to $175 million, transfer pricing and commercial milestones. In addition, we are eligible to receive royalties on net sales in Japan, of up to mid-20&#8217;s percent, varying by product.</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">20</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Strategic Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">VISEN Pharmaceuticals</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2018, we announced the formation of VISEN, a company established to develop and commercialize our endocrinology rare disease therapies in the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;). In connection with the formation of VISEN, we granted VISEN exclusive rights to develop and commercialize certain product candidates based on our proprietary TransCon technologies, including TransCon hGH, TransCon PTH and TransCon CNP, in Greater China for use in all human indications, subject to certain exceptions. As consideration for the rights granted to VISEN, we received 50% ownership in the outstanding shares of VISEN and concurrently with the rights we granted to VISEN, entities affiliated with Vivo Capital and Sofinnova Ventures purchased shares in VISEN for an aggregate purchase price of $40 million in cash. In January 2021, we invested additional $12.5 million in VISEN as part of VISEN&#8217;s $150 million Series B financing. Following the Series B financing, we retained 43.93% of VISEN&#8217;s issued and outstanding shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In August 2024, VISEN announced topline data from the 26-week randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway China Trial of Palopegteriparatide (TransCon PTH) in adults with chronic hypoparathyroidism. A statistically significantly higher proportion of patients treated with palopegteriparatide achieved the primary multi-component endpoint compared to placebo (p-value &lt;0.0001). Palopegteriparatide was generally safe and well-tolerated, with no discontinuations related to study drug. Results were consistent with those announced by Ascendis Pharma for its palopegteriparatide Phase 3 trial.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2024, VISEN announced that the BLA for lonapegsomatropin (TransCon hGH) was accepted by the China National Medical Products Administration. Lonapegsomatropin is the first once-weekly administrated growth hormone approved by both the FDA and EMA for the treatment of pediatric GHD.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2023, VISEN announced topline results from the Phase 2 ACcomplisH China Trial in children with achondroplasia aged 2 to 10 years. The trial met its primary objectives, demonstrating that TransCon CNP at 100 &#181;g/kg/week was superior to placebo on the primary efficacy endpoint of AGV at 52 weeks (p=0.018).</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In November 2022, VISEN announced data from its pivotal Phase 3 study of TransCon hGH in children with GHD in China. The trial achieved its primary endpoint; patients treated with TransCon hGH demonstrated greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone with comparable safety and tolerability to daily growth hormone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In June 2022, VISEN announced it had completed enrollment of the Phase 3 PaTHway China Trial of TransCon PTH.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Market Opportunity in China</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">China is the second largest pharmaceutical market in the world after the United States and represents one of the fastest growing pharmaceutical markets worldwide. In recent years, the Chinese government has initiated a number of regulatory reforms that are expected to accelerate drug development, as well as drive growth and demand for new therapeutics in China. In addition to joining an international organization that standardizes regulations for clinical development, the National Medical Products Administration has introduced initiatives such as fast track review for drugs for unmet medical needs and adopted new rules that streamline the drug approval process in China for global companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The purpose of our investment in VISEN is to support our strategy to extend our endocrinology rare disease portfolio globally and establish a presence in China in partnership with collaborators who have significant experience and knowledge of the biopharmaceutical opportunity in China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Rights Agreements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under three exclusive license agreements, each effective November 7, 2018, and as amended January 4, 2021, between the Company and VISEN (collectively, the &#8220;Rights Agreements&#8221;), VISEN must use diligent efforts to develop and commercialize licensed products in Greater China. Additionally, we and VISEN will conduct certain research and development activities allocated to the respective party under a research and technical development plan, and VISEN will reimburse us for costs of conducting such activities, including costs of our personnel committed to performing such activities in Greater China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We entered into a clinical supply agreement with VISEN in 2018 to provide product supply for use in conducting clinical trials in Greater China. Additionally, during 2023, we entered into a commercial supply agreement governing commercial supply of licensed product (TransCon hGH) to VISEN on the terms and conditions set forth in the Rights Agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">21</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the Rights Agreements, we agreed not to research, develop, or commercialize competing products in Greater China, and VISEN agreed not to grant certain rights under its interest in any inventions or intellectual property arising out of the activities conducted under the Rights Agreements to third-parties, in each case, under the terms and conditions specified in the Rights Agreements. We will have the right to exploit inventions and intellectual property arising out of the activities conducted under the Rights Agreements outside of Greater China. Additionally, we granted VISEN a right of first negotiation to develop and commercialize certain of our endocrinology products in Greater China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Rights Agreements continue in effect for as long as a valid claim of a licensed patent exists in Greater China. VISEN may terminate a Rights Agreement for convenience, for uncured material breach by us of a Rights Agreement and for our bankruptcy or insolvency-related events. We may terminate a Rights Agreement for certain specified material breaches thereof by VISEN, in the event VISEN undergoes a change of control in favor of a competitor, if VISEN challenges the validity of any of the licensed patents and for VISEN&#8217;s bankruptcy or insolvency-related events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Amended and Restated Shareholders Agreement</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In connection with the Company&#8217;s investment in VISEN, on January 8, 2021, the Company entered into an Amended and Restated Shareholders Agreement (the &#8220;Amended Shareholders Agreement&#8221;), amending and restating the Shareholders Agreement dated November 7, 2018, between the Company and the parties set forth therein (the &#8220;Shareholders Agreement&#8221;). In addition to rights previously granted under the Shareholders Agreement, under the Amended Shareholders Agreement, the Company has the right to designate two individuals for election to the board of directors of VISEN, which individuals are Jan M&#248;ller Mikkelsen and Michael Wolff Jensen. In addition, VISEN has agreed that certain specified events (including certain liquidation events) shall require the approval of (i) shareholders of VISEN holding at least 50% of VISEN&#8217;s Series B preferred shares, (ii) shareholders of VISEN holding at least 60% of VISEN&#8217;s Series A preferred shares and/or (iii) certain members of VISEN&#8217;s board of directors. The Amended Shareholders Agreement can be terminated by written agreement among the holders of at least 60% of VISEN&#8217;s Series A preferred shares and at least 50% of VISEN&#8217;s Series B preferred shares.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eyconis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In January 2024, we announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with a $150 million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, we will be eligible to receive development, regulatory, and sales milestone payments, plus single digit royalties on global net sales of commercialized products, if any. Eyconis will initially be based in Redwood City, California, and certain employees of Ascendis have joined the newly formed company.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">22</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial Highlights (unaudited)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.09%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.418%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.418%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.418%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.658%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,998</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">47,393</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">131,892</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,982</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Gross profit</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,533</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,464</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112,858</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,431</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157,790</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">175,302</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">295,260</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">347,954</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating profit/(loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(133,257</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(140,838</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(182,402</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(284,523</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(109,380</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(121,433</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(240,415</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(232,346</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash flows from/(used in) operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(61,307</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(153,128</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(162,890</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(300,172</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Operating expenses comprise research and development costs and selling, general and administrative expenses.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Compared to the three and six months ended June 30, 2023, revenue for the three and six months ended June 30, 2024, primarily benefited from continued demand growth for SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (lonapegsomatropin-tcgd) in the U.S., non-cash license revenue related to our exclusive license agreement with Eyconis in January 2024, and launch of YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (palopegteriparatide) in Europe, partly offset by a negative adjustment to prior periods estimates and assumptions for sales deductions related to sale of SKYTROFA.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating loss for the three and six months ended June 30, 2024, represented a decrease of &#8364;7.6 million and &#8364;102.1 million, compared to the same period last year, primarily attributable to lower operating expenses. In addition, the six months ended June 30, 2024 was positively impacted by higher revenue from commercial sales and from non-cash license revenue of &#8364;25.6 million related to our exclusive license agreement with Eyconis in January 2024.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We had a net loss of &#8364;240.4 million for the six months ended June 30, 2024, compared to a net loss of &#8364;232.3 million for the same period last year. Total equity presented a negative balance of &#8364;321.1 million as of June 30, 2024, compared to a negative balance of &#8364;145.7 million as of December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further details about our results of operations and cash flows are described in the following sections.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparison of the Three and Six Months Ended June 30, 2024 and 2023 (unaudited)</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue for the three and six months ended June 30, 2024, were &#8364;36.0 million and &#8364;131.9 million, representing a decrease of &#8364;11.4 million and an increase of &#8364;50.9 million, compared to the same period last year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The &#8364;50.9 million increase for the six months ended June 30, 2024 was primarily attributable to sales of SKYTROFA, recognition of non-cash license revenue of &#8364;25.6 million related to our exclusive license agreement with Eyconis in January 2024, and the launch of YORVIPATH, which we began shipping to customers in Europe in the first quarter of 2024. Revenue for the six months ended June 30, 2024, was negatively impacted by an adjustment to estimates and assumptions for sales deductions of &#8364;7.6 million, which were attributable to periods prior to January 1, 2024. The adjustment was primarily attributable to a different payer and rebate mix than anticipated, and which provisions for prior periods were based upon.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The &#8364;11.4 million decrease for the three months ended June 30, 2024, was primarily driven by a negative adjustment to prior periods estimates and assumptions for sales deductions of &#8364;27.1 million, where &#8364;19.5 million and &#8364;7.6 million were attributable to the three months ended March 31, 2024 and periods prior to January 1, 2024, respectively, partly offset by increased sales of SKYTROFA and the launch of YORVIPATH. In addition, the three months ended June 30, 2024 was negatively impacted by lower revenue of &#8364;6.9 million, associated with delivering of services under our license and collaboration agreements.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development in quarterly revenue from sale of commercial products was as follows:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.043%;"/>
    <td style="width:1.399%;"/>
    <td style="width:12.792%;"/>
    <td style="width:1.399%;"/>
    <td style="width:12.792%;"/>
    <td style="width:1.399%;"/>
    <td style="width:12.792%;"/>
    <td style="width:1.399%;"/>
    <td style="width:12.792%;"/>
    <td style="width:1.399%;"/>
    <td style="width:12.792%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="9" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended,</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="9" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Sale of commercial products</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">35,895</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">46,968</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">64,249</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">66,499</span></p></td>
    <td style="border-top:0.5pt solid #ffffff03;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:0.5pt solid #000000;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">31,389</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">23</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cost of Sales</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cost of sales for the three and six months ended June 30, 2024, was &#8364;11.5 million and &#8364;19.0 million, representing a decrease of &#8364;1.5 million and an of increase &#8364;1.5 million, compared to the same period last year. This development was primarily attributable to higher volume of commercial sales for the three and six months ended June 30, 2024, offset by lower costs associated with delivering of services under our license and collaboration agreements compared to the same period last year.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Research and Development Costs</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies external project costs on the development pipeline and other research and development costs.</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.34%;"/>
    <td style="width:1.22%;"/>
    <td style="width:11.196%;"/>
    <td style="width:1.22%;"/>
    <td style="width:11.196%;"/>
    <td style="width:1.22%;"/>
    <td style="width:11.196%;"/>
    <td style="width:1.22%;"/>
    <td style="width:11.196%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="3" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">External project costs</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TransCon hGH</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,491</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,882</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,308</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,888</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TransCon PTH</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,876</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,100</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(442)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,614</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TransCon CNP</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,515</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,473</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,259</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">24,418</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TransCon IL-2 &#223;/&#947;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,973</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,532</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,937</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,728</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TransCon TLR7/8 Agonist</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,290</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,081</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,199</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,574</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ophthalmology</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,038</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,759</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other project costs </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;min-width:fit-content;">(1)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">736</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,959</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">544</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total external project costs</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">44,881</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">60,142</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">77,220</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">123,525</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Other research and development costs</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee costs</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,513</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,002</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">64,779</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,583</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other costs</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,675</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,758</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,518</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,203</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,409</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,119</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,648</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,823</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total other research and development costs</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">38,597</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">44,879</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">76,945</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">87,609</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total research and development costs</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">83,478</span></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">105,021</span></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">154,165</span></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">211,134</span></p></td>
   </tr>
  </table>
  <div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">For the three and six months ended June 30, 2023, other project costs of &#8364;3.8 million and &#8364;6.6 million were reclassified to Ophthalmology and TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Symbol',serif;min-width:fit-content;">g,</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> with &#8364;3.0 million and &#8364;4.8 million respectively and &#8364;0.8 million and &#8364;1.8 million, respectively. </span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D costs for the three and six months ended June 30, 2024, were &#8364;83.5 million and &#8364;154.2 million, representing a decrease of &#8364;21.5 million and &#8364;57.0 million, compared to the same period last year. This decrease was primarily due to:</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Maturity of our endocrinology rare disease pipeline, especially regarding TransCon hGH and TransCon PTH. In addition, the six months ended June 30, 2024 includes reversal (income) of prior period write-downs of pre-launch inventories for TransCon PTH of &#8364;10.6 million due to the launch of YORVIPATH in the EU in the first quarter of 2024;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Lower product development activities on our TransCon TLR7/8 Agonist and TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> programs, partly offset by increased clinical trial activities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ceassation of ophthalmology expenses, including employee costs, due to the grant of exclusive rights to develop and commercialize TransCon ophthalmology to Eyconis in January 2024; partly offset by higher costs for TransCon CNP, including write-downs on pre-launch inventories.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development in quarterly external project costs was as follows:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.848%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.322%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.322%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.322%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.322%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.862%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">External project costs</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TransCon hGH</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,882</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,892</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,197</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,816</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,491</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TransCon PTH</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,100</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,600</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,366</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,319</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,876</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TransCon CNP</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,473</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,627</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,570</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,744</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,515</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-family:'Symbol',serif;min-width:fit-content;">b/g</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,532</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,279</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,987</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,964</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,973</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TransCon TLR7/8 Agonist</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,081</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,843</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,066</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,910</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,290</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Ophthalmology</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,038</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,543</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,419</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other project costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">129</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">353</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,224</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">736</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total external project costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">60,142</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">73,913</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">48,958</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">32,339</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">44,881</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">24</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Selling, General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies selling, general and administrative expenses:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.09%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.418%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.418%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.418%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.658%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Selling, general and administrative expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,409</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,225</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,951</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,698</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,886</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,876</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,683</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">76,449</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,017</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,180</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,462</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,673</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total selling, general and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">74,312</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">70,281</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">141,096</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">136,820</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses for the three and six months ended June 30, 2024, were &#8364;74.3 million and &#8364;141.1 million, representing an increase of &#8364;4.0 million and &#8364;4.3 million, compared to the same period last year. This increase was primarily due to higher employee costs, including the impact from commercial expansion. Other costs decreased primarily due to lower pre-launch and other administrative costs, partly offset by higher costs related to the European launch activities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development in quarterly SG&amp;A expenses was as follows:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.848%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.322%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.322%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.322%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.322%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.862%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="18" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Selling, general and administrative expenses</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Employee costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,225</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,381</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,627</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">33,543</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,409</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other costs</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,876</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,132</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,016</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,795</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,886</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Depreciation</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,180</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,101</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,332</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,445</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,017</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total selling, general and administrative expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">70,281</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">63,614</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">63,975</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">66,783</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">74,312</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">25</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Finance Income and Finance Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies the result of net finance income and expenses, further disaggregated into cash and non-cash items:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.09%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.418%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.418%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.418%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:9.658%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="14" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net finance income/(expenses)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance income</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,052</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,761</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,395</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">80,374</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance expenses</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(19,624</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(9,334</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(58,553</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18,652</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total net finance income/(expenses)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">29,428</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">26,427</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(44,158</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">61,722</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Specified in cash and non-cash items</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Cash items</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance income received</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,677</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,524</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,265</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,403</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Finance expenses paid</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,837</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(6,841</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,714</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,746</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Non-cash items</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remeasurement gain/(loss) of financial liabilities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,375</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,384</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,620</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,565</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Currency gain/(loss)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(4,791</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,085</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,411</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">563</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Amortization charges, accruals and other items</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(7,996</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(2,725</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(21,678</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(11,063</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total net finance income/(expenses)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">29,428</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">26,427</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(44,158</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">61,722</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development in non-cash items was primarily due to remeasurement of financial liabilities, which influenced especially the six months ended June 30, 2024. The increase in amortization charges, accruals and other items primarily relates to amortization charges and interests on royalty funding liabilities, which we entered into in September 2023. In addition, the development in currency gain/(loss) was primarily driven by conversion of U.S. dollar denominated monetary positions into Euro, primarily cash and cash equivalents, convertible notes and royalty funding liabilities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">26</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our liquidity and capital resources comprise cash and cash equivalents, which as of June 30, 2024, amounted to &#8364;258.7 million.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our expenditures primarily relate to continued development of our endocrinology rare disease and oncology therapeutic areas, the commercialization of SKYTROFA and YORVIPATH, and expenses made in anticipation of potential future product launches. We manage our liquidity risk by maintaining adequate cash reserves and banking facilities in line with our cash-forecasts. We monitor the risk of a shortage of funds through liquidity planning tools, to ensure sufficient funds are available to settle liabilities as they become due.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, the unaudited condensed consolidated interim statements of financial position presented a negative balance of equity of &#8364;321.1 million. Under Danish corporate law, as Ascendis Pharma A/S, the parent company of the Company holds a positive balance of equity, the Company is currently not subject to legal or regulatory requirements to re-establish the balance of equity. There is no direct impact from the negative balance of equity to the liquidity and capital resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on our current operating plan, we believe that our existing capital resources as of June 30, 2024, will be sufficient to meet our projected cash requirements for at least twelve months from the date of this report. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Historically, we have funded our operations primarily through issuance of preference shares, ordinary shares (including public offerings and exercise of warrants), convertible debt securities, payments to us made under collaboration agreements, and our royalty funding agreement. Including our initial public offering, since February 2015, we have completed public offerings of American Depositary Shares (&#8220;ADSs&#8221;) with net proceeds of $2,256.6 million (or &#8364;1,968.4 million at the time of the offerings).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, we issued an aggregate principal amount of $575.0 million of fixed rate 2.25% convertible notes. The coupon interest is payable semi-annually. Unless earlier converted or redeemed, the convertible notes will mature on April 1, 2028. We used $116.7 million (&#8364;105.3 million) of the net proceeds from the offering in March 2022 to repurchase 1,000,000 ADSs representing our ordinary shares. The holding of treasury shares is disclosed in Note 9, &#8220;Treasury Shares.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, we entered into a $150.0 million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Agreement&#8221;) with Royalty Pharma (the &#8220;Purchaser&#8221;). Under the terms of the Royalty Pharma Agreement, in exchange for the Purchaser&#8217;s payment of a cash purchase price of $150.0 million at closing (the &#8220;Purchase Price&#8221;), we have agreed to sell to the Purchaser its right to receive payment in full of 9.15% on net U.S. SKYTROFA revenue, beginning on January 1, 2025 (the &#8220;Revenue Interest Payments&#8221;). The Revenue Interest Payments to the Purchaser will cease upon reaching a multiple of the Purchase Price of 1.925x, or 1.65x if the Purchaser receives Revenue Interest Payments in that amount by December 31, 2031. The Royalty Pharma Agreement includes a buy-out option under various terms and conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2024, we entered into a $150.0 million capped synthetic royalty funding agreement (the &#8220;Yorvipath Agreement&#8221;) with the Purchaser. Under the terms of the Yorvipath Agreement, in exchange for the Purchaser&#8217;s payment of a cash purchase price of $150.0 million at closing (the &#8220;Purchase Amount&#8221;), we have agreed to sell to the Purchaser its right to receive payment in full of 3% on net U.S. YORVIPATH revenue (the &#8220;Revenue Payments&#8221;). The Revenue Payments to the Purchaser will cease upon reaching a multiple of the Purchase Amount of 2.0x, or 1.65x if the Purchaser receives Revenue Payments in that amount by December 31, 2029. The Yorvipath Agreement includes a buy-out option under various terms and conditions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further details regarding our borrowings are provided in Note 10, &#8220;Financial Assets and Liabilities.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional description of our cash requirements, public offerings, expense structure and commitments, refer to &#8220;Item 5B. Liquidity and Capital Resources,&#8221; set forth in our Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 7, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our future funding requirements will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we are able to generate product revenue from sales of our products;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the manufacturing, selling and marketing costs associated with our products and product candidates, if approved, including the cost and timing of building our sales and marketing capabilities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the timing, receipt, and amount of sales of, or royalties on, TransCon hGH, TransCon PTH, and any future products; </span></div></div>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">27</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the sales price and the availability of adequate third-party coverage and reimbursement for our products and product candidates, if approved; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs related to manufacturing of our products and product candidates, including the timing of when we incur such costs;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our ability to collect payments which are due to us from customers and collaboration partners (if any), which in turn is impacted by the financial standing of any such customers and collaboration partners; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the progress, timing, scope, results and costs of our preclinical studies and clinical trials and manufacturing activities for our product candidates that have not been licensed, including the ability to enroll patients in a timely manner for clinical trials; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the time and cost necessary to obtain regulatory approvals for our product candidates and the costs of post-marketing studies that could be required by regulatory authorities; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the cash requirements of any future acquisitions or discovery of product candidates; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the number and scope of preclinical and discovery programs that we decide to pursue or initiate; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the potential acquisition and in-licensing of other technologies, products or assets; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the time and cost necessary to respond to technological and market developments, including further development of our TransCon technologies; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the achievement of development, regulatory and commercial milestones resulting in the payment to us from collaboration partners of contractual milestone payments and the timing of receipt of such payments, if any; </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">our progress in the successful commercialization and co-promotion of our products and product candidates, if approved, and our efforts to develop and commercialize our other existing product candidates;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the market opportunities and patient populations for our products and product candidates, if approved, including with respect to TransCon PTH, and our ability to obtain market acceptance of our products and product candidates, if approved;</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of our product candidates; and</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the extent to which we purchase ADSs prior to settlement for such shares under our equity incentive plans.</span></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional funds may not be available if we need them or on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, scale back or cease our research and development and commercialization activities, preclinical studies and clinical trials.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes our cash flows for the six months ended June 30, 2024 and 2023:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.431%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.162%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.162%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:1%;"/>
    <td style="width:11.242%;"/>
    <td style="width:1%;"/>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Change</span></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Cash flows from/(used in)</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(162,890</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(300,172</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">137,282</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Investing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,763</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">257,603</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(249,840</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Financing activities</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,968</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(3,011</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,979</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Net increase/(decrease) in cash and cash equivalents</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(139,159</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(45,580</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(93,579</span></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">28</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from / (used in) Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash flows used in operating activities for the six months ended June 30, 2024, were &#8364;162.9 million, representing a decrease of &#8364;137.3 million compared to the same period last year. This improvement is primarily related to higher commercial revenue and reduced operating expenditures, and to further adjustment for changes to non-operating financial income and expenses, taxes and non-cash items of total &#8364;82.6 million. In addition, the change in cash flows from operations was positively impacted by working capital balances with &#8364;54.6 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from / (used in) Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from investing activities for the six months ended June 30, 2024, were &#8364;7.8 million, representing a decrease of &#8364;249.8 million compared to the same period last year. This decrease was primarily attributable to &#8364;251.8 million higher net settlements of marketable securities in 2023 in line with our liquidity management strategy.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Cash Flows from / (used in) Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cash flows from financing activities for the six months ended June 30, 2024 were &#8364;16.0 million, representing an increase of &#8364;19.0 million compared to the same period last year. This increase was primarily attributable to increased warrant exercise activity of &#8364;19.5 million.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Off-balance Sheet Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have not entered into any off-balance sheet arrangements or any holdings in variable interest entities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Qualitative Disclosures about Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our activities expose us to financial risks of changes in foreign currency exchange rates, inflation rates and interest rates. We do not enter into derivative financial instruments to manage our exposure to such risks. Further, we are exposed to credit risk, equity risk and liquidity risk. For a description of our exposure to liquidity risks, including risks associated with the royalty funding liabilities and processes for managing these risks, please refer to &#8220;Liquidity and Capital Resources,&#8221; set forth above, and maturity analysis for non-derivative financial liabilities provided in Note 10, &#8220;Financial Assets and Liabilities.&#8221;</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Foreign Currency Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the U.S. Dollar. While we generate revenue in Euro, a significant portion of our revenue is denominated in U.S. Dollars. Similarly, a significant portion of our operating expenses are denominated in U.S. Dollars. In addition, our outstanding convertible notes and royalty funding liabilities are denominated in U.S. Dollar. We seek to minimize our exchange rate risk by maintaining cash positions in the currencies in which we expect to incur the majority of our future expenses and we make payments from those positions.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Interest Rate Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Outstanding convertible notes comprise a 2.25% coupon fixed rate structure. In addition, the interest rate on lease liabilities is fixed at the lease commencement date. Future indebtedness, including those related to lease arrangements, if any, may be subject to higher interest rates. In addition, future interest income from interest-bearing bank deposits may fall short of expectations due to changes in interest rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Derivative liabilities are measured at fair value through profit or loss. Accordingly, since the fair value is exposed from the development in interest rates, the profit or loss is exposed to volatility from such development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Inflation Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Inflation affects us as our vendors may pass on any increased costs to us and accordingly increase our R&amp;D costs, SG&amp;A expenses and cost of manufacturing. We do not believe that inflation had a material impact on our results of operation for the three and six months ended June 30, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">    </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">29</span></p></div></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We have adopted an investment policy with the primary purpose of preserving capital, fulfilling our liquidity needs and diversifying the risks associated with cash, cash equivalents and marketable securities. Our investment policy establishes minimum ratings for institutions with which we hold cash, cash equivalents and marketable securities, as well as rating and concentration limits for marketable securities held. All material counterparties are considered creditworthy. While the concentration of credit risk may be significant, the credit risk for each individual counterpart is considered to be low. Our exposure to credit risk primarily relates to cash and cash equivalents. The credit risk on our bank deposits is limited because the counterparties holding significant deposits are banks with high credit-ratings (minimum A3/A-) assigned by international credit-rating agencies.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We maintain the majority of our cash and cash equivalents in accounts with major financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. The banks are reviewed on a regular basis and deposits may be transferred during the year to mitigate credit risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In order to mitigate the concentration of credit risks on bank deposits and to preserve capital, a portion of the bank deposits may be placed into marketable securities. Our investment policy, approved by the Board, only allows investment in marketable securities having investment grade credit-ratings, assigned by international credit-rating agencies. As of June 30, 2024, we do not hold marketable securities.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On each reporting date, we consider the risk of expected credit loss on bank deposits and marketable securities, if any, including the hypothetical impact arising from the probability of default, which is considered in conjunction with the expected loss caused by default by banks or securities with similar credit-ratings and attributes. In line with previous periods, this assessment did not reveal a material impairment loss, and accordingly no provision for expected credit loss has been recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are exposed from the development in our share price, when remeasuring derivative liabilities at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes and are measured at fair value through profit or loss. Fair value cannot be measured based on quoted prices in active markets, or other observable input, and accordingly, derivative liabilities are measured by using the Black-Scholes option pricing model, where the pricing is exposed from changes in our share price. Sensitivity analysis over derivative liabilities is disclosed in Note 10, &#8220;Financial Assets and Liabilities.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div class="page-node-content"><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">30</span></p></div></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img148560552_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148560552_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #A Z@# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@U8RISA\2.FG6IU/@DF6****@U"BBB@ HHHH .U%':B@#+U'_7CZ53JYJ/\
MKQ]*IUP5/C9#W$I*6DK,04E+24@"BBB@!**** $-!H-!I )1110 J=3]#3:<
MG4_0TVA@!I#2FD-2 E%%% A****0"&B@T4 )1112 2E7[P^M)2K]X?6@ ;[S
M?6FTYOO-]:;0 E%%%2 E%%%  :2E-)0 E%%%(0@)'0XIP=@<AC^=-HH E%U.
M.DSCZ&IGU"Z1L+,PX%5.U.D^_P#@*:G)+1A<MKJ]XO60'ZBI%URY'W@A_"LV
MDJE6J+[0[LUQK\@/S0KCZU*-?3O ?P-81HJEB:JZAS,Z$:[;_P 2./UJ5=9L
MV_B8?45S-)5+&5$/F9UBZG9OTG'X@U(+VV;I/'_WU7'TE4L;/JD'.SM1+&W2
M13]#3\@]ZX?<?4T\3RJ,"1A]#5K'=XCYSM:*XU;ZZ0?+._XM4JZK>K_RW8_6
MJ6.AU0<Z.MHKF?[;O%5#N4Y'.5IP\0W ZQH?K5K&4A\Z.DHK 7Q$W\4 _ U*
MGB*(_>A9?QS5K%4GU#F1M45E+K]H3R)!^%2KK5B?^6I'U4U:KTG]I#YD:%%5
M%U.S;_EX0?4XJ5;JW?[LT9^C"J4XO9A=$U%-$B'HZGZ&G58PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF[C5I-/UV93EH&QN7TXZBND
MKBM=_P"0Q-^'\JXL=.4(*4=[D3=D=C#/'<1++$P9&Z$5)7$Z9J4NGRY'S1'[
MR5V%M<Q7<*RQ-E3^E:8?$QK+S'&5R:BBBNDH**** "BBB@ HHHH **** "BB
MB@ HI"0H))  Y)/:O-?%WQ*6 O8:"RO(,K)=8R%_W?4^]:4Z4JCM$QK5X48\
MTV=CK_BK2O#L6;V?,Q&4@3EV_#M]37EVM_$S6-2+QV.+"W/ V',A'NW;\*XV
M::6YF>:>1Y97.6=SDD_6F5Z=+"0AJ]6>#B,PJU=(Z(?++)<2F6:1Y)#R6=B2
M?Q-,HHKJ.$****!!1110 5-:W=S8S"6TN)8)!T:)RI_2H:*!IVU1Z!H?Q3U"
MT*Q:M$+R$<>:@"R#^A_2O3](US3M=M?/T^Y25?XEZ,GL1U%?.%6+&_NM-NTN
MK*=X)TZ.A_GZBN2KA(3UCHST,/F-2GI/5?B?3%%</X/^(-OK12QU+9;ZAT5N
MB2_3T/M7<5YDZ<H.TCWJ5:%6/-!A1114&@=J*.U% &7J/^O'TJG5S4?]>/I5
M.N"I\;(>XE)2TE9B"DI:2D 4444 )1110 AH-!H-(!**** %3J?H:;3DZGZ&
MFT, -(:4TAJ0$HHHH$)1112 0T4&B@!****0"4J_>'UI*5?O#ZT #?>;ZTVG
M-]YOK3: $HHHJ0$HHHH #24II* $HHHI"$HHHH .U.D^_P#@*;VITGW_ ,!2
MZ ,I*6DI (:*#10 4E+24@"D-+2&@!****0 :2E-)2$/;[D?T-1U(WW(_H:C
MIL I*6DJ0$-%!HH *,GU-%(:0"AV7[K$?2GK<SJ>)I/^^C49I*+M; 6AJ=ZO
M2YD_.I1K=^O2;\QFL^BK56:VDPNS67Q#>C[VQO\ @-3IXCGV%GAC/..,UA4[
M_E@?]ZKCB:J^T/F9O+XF&?FMN/9JF'B6V_BBD'TQ7,4E4L9674.=G6KX@L3U
M9U^JU,FLV#])P/J"*XLT5:Q]7R'SL[E-2LG^[<QG\:F%Q"W25#_P(5P%(#@Y
M%6LQEUB/VAZ&&!Z$'Z&EKSX2R#I(X_&I5OKM!A;B0?1JM9BNL0]H=Y17$+K%
M^G2Y<_7FI4\0:@O616^JBK684^J8^='945R:^)KP'E(B/I4R^*9!]ZV4_1L5
M:QU%]1\Z.FHKGU\4Q?QVS#Z-4R>)K-OO)(OU JUBZ+^T',C:KBM=_P"0Q-^'
M\JZ%/$.GO_RT8?537-:O/'<:G++$VY#C!_"N7'583II1=]29M-%05>L+^6QF
M#H<J?O*>AJB*D%>="3B[HA'<VEW%>0B2(_4=P:GKBK.[ELYA)&?J.Q%=99WL
M5[%O0X8?>7N*]K#XE559[FL97+-%%%=104444 %%%% !1110 4C,%4LQ  &2
M3VI:\P^)7B\H7T&PDP<?Z5(IZ?[ _K6E*FZDN5&.(KQHP<Y&;XZ\>/J<DFEZ
M5*5LE.V69>LQ]!_L_P ZX"BBO:ITXTX\L3Y>M6G6GSS"BBBK,@HHHH ****
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M#2TAH 2BBBD &DI324A#V^Y']#4=2-]R/Z&HZ; *2EI*D!#10:* "D-+2&D
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M]Q*2EI*S$-D!,3@<DJ0/RKD;?2;Y%TZ 0,L%W!''>YX\ORSGGZCBNPI*<9-
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M= B[J,T3S21K"H<-S(#UJA2M]X_6DI3DY.[ YRZT^[FM-71(W!EO5E48&9$
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M[0.=W52*Z#OC//I4-U<I:6TD\F=B#)V]:B-:6BL*YD);3IJH:.WDVFX9W$J
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M***]<^="BBB@#8U+P]+INAZ9JCW"2)?J2L84@I@=SWK'ZG &2>PKT+7-+O\
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M?2J=7-1_UX^E4Z\VI\;&]Q*2EI*S$%)2TE( HHHH 2BBB@!#0:#0:0"4444
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MHHH 2BBB@!#0:#0:0"4444 *G4_0TVG)U/T--H8 :0TII#4@)1110(2BBBD
MAHH-% "4444@$I5^\/K24J_>'UH &^\WUIM.;[S?6FT )1114@)1110 &DI3
M24 )1112$)1110 =J=)]_P# 4WM3I/O_ ("ET 924M)2 0T4&B@ I*6DI %(
M:6D- "4444@ TE*:2D(>WW(_H:CJ1ON1_0U'38!24M)4@(:*#10 4AI:0T@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ':BCM10 VBBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
' HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img148560552_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148560552_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (A!/\# 2(  A$! Q$!_\0
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M_P!!>Y_[Z%'_  FGB3_H,7/_ 'T*PJ*/9P[(/;5?YG]YN_\ ":>)/^@Q<_\
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ML4=<YP0<$4XJE)V21$Y8B"3DWKYFS_PFGB3_ *#%S_WT*/\ A-/$G_08N?\
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M_A-/$G_08N?^^A75?#WQ%J^J>*5@OM0FGB$#ML<\9XKSBNT^%W_(XC_KW?\
MI65>$53DTC?"U:CK13D]^Y%\2_\ D=;G_KE'_P"@BJ'A#6K+0]2NIK]+AX)[
M1[<B *6&XKSR0.@-=CXT\$:UK?B6:^LHX6@=$4%I #D#!XKG_P#A6/B3_GC;
M_P#?X5$*E)TE&3Z&M6C76(E.$7N^A4-SX2LY[6ZTT:V9X;B.0BY\K:5# G[O
M.<#BKTOB_3WO?$\PAN=NJP". %5RIVX^;YN/PS3/^%8^)/\ GC;_ /?X4?\
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M*C'!.<YX]*G_ .%8^)/^>-O_ -_A1_PK'Q)_SQM_^_PHO0[_ -;_ *ARXO\
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MXSQ6\7>*8]=@M[>WNM1GBC;>WVU(5PV,<"-1Z]S^%3?\*Q\2?\\;?_O\*/\
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M"&0_W4F7/ZXJ#_A!/$G_ $#?_(\?_P 53]K3[H3P]5?9?W'.T5T7_"">)/\
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MNP&0?8=L&MGAWS63_IG*L9'D3DM=;V\CU"BO.[O5O$4USXEFMM<AMH-)D+)
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MHWOK_P "XEBXN?+;3_@V/0Z*\XA\5:Q<Z?'#%>QK<7FLO9QW;1*PBC&W&
MQYXSU_4,\52:S'X4O;>ZUVUNGM[I$D:V #NC=%D4?<.><#.10L.[I-@\9'E<
MHINWH>E45P&N7?BS2KE?-U"Y&GQ1#=>6NG1S;V'+M(I;* >HXP*[BRN4O+&"
MYBE65)8U=9$4J&!&<@'D?0U$J;BD[WN:TZRG)QLTUW)Z***S-@HHHH ****
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ML**QM(N+H:OJFG7%T]TMMY3QRR(JOAU.0=H ."OIWK+\0:K>12:D;"^O"]G
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M-%?7U[?QRP^24N)%"A3UX0*"3_>.3QP14*>&HOM<=S<:C?W4L<#VZ&9TX1@
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MIN+AY(4BA$TE^D-MD$[H&+?O",YZ1R'MVK(9]3>&,M<0S7'_  D3)&SHP52
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M4_:G_/3]*-J?\]/TH"PRBG[4_P">GZ4;4_YZ?I0%AE%/VI_ST_2C:G_/3]*
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MP1D?0\B@">BBB@ HHHH **** "BH(KRWFN[BUCDS-;[?-7!^7<,CGH>G:IZ
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MZ2US&;R.%91R0<!!P", AAN&#TIVFV=W-K-E%#J<\!&BPLTJQQL[?.V!RNW
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M8E_OG\J?,A<DCG9- MS;Z?%;SSVSV"[()8MA8+MVD$,I4Y&.W45#;^%[2W4
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MF3]CUS_H+VG_ ( G_P".4?8]<_Z"]I_X G_XY6M11SO^D@]FO/[V9/V/7/\
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M_0;M/_ #_P"SHV^)/^@W:?\ @!_]G6E11S>2^Y!R^;^]_P"9F[?$G_0;M/\
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M!NT_\ /_ +.C;XD_Z#=I_P" '_V=:5%'-Y+[D'+YO[W_ )F;M\2?]!NT_P#
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M_0;M/_ #_P"SHV^)/^@W:?\ @!_]G6E11S>2^Y!R^;^]_P"9F[?$G_0;M/\
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M!NT_\ /_ +.C;XD_Z#=I_P" '_V=:5%'-Y+[D'+YO[W_ )F;M\2?]!NT_P#
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M>9Y6X;MN<;L=<9XS0!)1110!D5D:OXHT?0IXX=2O/(DD7>H\IVR,X_A!K7K
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MP/#8\1B?4AKQB,?G?Z(4V_=R<].WW<9YZYK?H&R&ZNH;*TENKB01PQ(7=SV
MZTEG>0:A:175K)YD,HRC8(R/H>16'XIG>=[#28;>2Y-Q,)9X8BH8PQD,?O$
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M:;'K=I;:A<I;6_V-Q,T[.]NSR@,N]B3@J <$GKZ'%-\1 V=GK>GP7=Q<6O\
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M(&"AP&*9R3M4#.*+A8[BBN)E.H+'964VH@*VKK"5M;UY'2,Q.3$\F%8G/KR
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MC[0TLG5FPB@#)[ =!T%6B3'XW54.%FTYFD '4I(NTG_OMZ L;=%%% @HHHH
M**** "BBB@ HHHH *?-_KG^IIE/F_P!<_P!30/H9>HZLNGW5K;+:7%S/=;_+
M2'8/N@$Y+LH[TR#6A/-/;&PNXKR%%D^S2>7N="<!E(<J1D'OVJAKL,D_B70H
MX[F6V8BX_>1!2P^5?[RD?I57Q)I*6?A[5+N2YN+NZECC0S3E<A XPH"JH R2
M>G>D.R.MHKB=1MY$UN;P\BM]FU6X2[) X6,9,PS[E%_[^55U'['Y.N"ZV_\
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MH **** "BBB@ HHHH **** "BBB@ I\W^N?ZFF4^;_7/]30/H,HHHH$%%%%
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M_P#H9M0_[]0__$4?V%J?_0S:A_WZA_\ B*W:*/:/^D@]C'S^]_YF%_86I_\
M0S:A_P!^H?\ XBC^PM3_ .AFU#_OU#_\16[11[1_TD'L8^?WO_,PO["U/_H9
MM0_[]0__ !%']A:G_P!#-J'_ 'ZA_P#B*W:*/:/^D@]C'S^]_P"9A?V%J?\
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M+YZY8D @ 9YR&'YCUHYV'LEY_>RI_8VH?]#!??\ ?N+_ .)H_L;4/^A@OO\
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MH,KN'FRJN1G&>3TS2S:A96UHEU/>6\5L^-LSRJJ-GD8).#FCG8>RCY_>S/\
M[&U#_H8+[_OW%_\ $T?V-J'_ $,%]_W[B_\ B:TH;VTN658+J&5FC$JA) Q*
M$X##';(/-/AGBN8EE@E26-ONNC!@?H11SL/91\_O9E?V-J'_ $,%]_W[B_\
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M[]Q?_$TK:/J!<D^(;XG/_/.+_P")K8I6^\:.=_TA^SCY_>S%_L;4/^A@OO\
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MM"VH06^G126]U;8TN!6EM['S9I7"G,19E*Q@''##OU%=SL?^ZWY4;'_NM^5
M7.#TJUN[:U\,>?:7*F*TN8)!Y#$QLVT*& ' .#R>*=HD,^D_V7=7UC=M%_92
MVX"6SR-%(&)8%0"PR"O.,?+S7=;'_NM^5&Q_[K?E18+G$Z)I5U;ZGH;W%I(B
M107;*"F1 '<%$)' .TXQ]1VJ.!+^RL[:,6LL""^N_P#2!9-/);H7)&Q #C<"
M1NP1['-=UL?^ZWY4;'_NM^5%@NS@=.M+TQ0E[6]S_P )!]HS/#M<QF,_.P4
M#D\XZ'BN\IVQ_P"ZWY4;'_NM^5,3U&T4[8_]UORHV/\ W6_*@+#:*=L?^ZWY
M4;'_ +K?E0%AM%.V/_=;\J-C_P!UORH"PVBG;'_NM^5&Q_[K?E0%AM%.V/\
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M=)10 N]O[Q_.C>W]X_G244 +O;^\?SHWM_>/YTE% "[V_O'\Z-[?WC^=)10
MN]O[Q_.C>W]X_G244 +O;^\?SHWM_>/YTE% "[V_O'\Z-[?WC^=)10 N]O[Q
M_.C>W]X_G244 +O;^\?SHWM_>/YTE% "[V_O'\ZLV9)E.23Q56K-E_K3]*4M
MBH?$7J***S-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1<+$=%2;(O\ GJ?^^:-D7_/4_P#?-%PL1TK?>-/V1?\ /4_]\TK)%N/[T_\
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MY11169N%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKN&#SUI7"QW=07MY;Z?9RW=U)Y<$2[G?!.!]!S7%ZU=W&FQZW:6VH7*6UO\
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MR G< 2,$G/K770LSP1LZ[7906&,8.*8FA]%%% @HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I6^\:2E;[QH&9NHZLNGW5K;+:7%S/=;_+
M2'8/N@$Y+LH[U5E\36]M%=M=V=W;2VJ+(\$@0LR,=H92K%2,\=>U5]=ADG\2
MZ%''<RVS$7'[R(*6'RK_ 'E(_2JGB72$M?#FJW4EU<W5U-''&9IBH94#C"J%
M50!DD].II#21UU%<9?Q6FAZK?I:616V_L@RR06Q,9D*OC)(YS@G+=<5FZ?\
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MP4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;H5/F$="W'./>M#SC_<C_P"^11YQ_N1_]\B@#)NM&@FL8;"!8K:R24/)!%$
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MB\U%?RY5VNF1G##L1W%2UY[INFV<WB/Q1JEQ:RW-Q8SEX$21E(.PD[0#]XX
M_ 8K)\+S:>?&>DW.DH+:&YCE2>-/-(5MF[RV=SAR#@\ #IUZTKARGK%%>.6.
MFV]MX6TC6XA(NH#5%C$OF-PFYOE S@#O^)JUK1L=/\:37 *:I?-=!OLSK<PW
M*'(VK&P^0@<$$]NE%Q\IWNJ^*;/2[\6"VM]?7FSS'ALH?-:->Q;D8_\ U>HJ
M[H^L6>NZ<E[8R%HV.UE889&[J1ZC-<O_ &G;^%?&&LSZSOAM]0$4EO=>6SJV
MT;2F0"<CT]![BJNN:@VI^#K.ZCTZYL=*>]!NXXUVLUN227 '\+9!/N>XY)<5
MCT&BO)9/LW]C^)SH7G?\(]]GCV;]^SSMRYV;^>G7\/:MC2--M]&\9Z*+(2)]
MMTYGN=TC-YC8SN.3US^%%PY3LKK6+>TUFPTN1)3/>B0QLH&T;!DYYS^AJ35-
M4L]'L)+V^E$<"=3C))[ #N:Y;Q580:GXU\.6=R',$J7(<(Y4L-F<9'.#C!]L
MUS\%G<1:-=1VD$MS:Z-XA,@ME)9C$IZ =_7\2:+C21V6G^,[&]U&"QFL]0L)
MK@$P?;8/+$OLIR?\^^*T+#7+;45U%H8YE%A.\$N\ 99.I7!Z?7%<=)XBEUGQ
M9IKZ'J;WEN9E,ML-/&;:/@.3(RY&>>GKUZ5%I.A?VG-XGN/[5U2T\O4K@>7:
M7'EHW.<D8Y/:BX61W>CZK!K>E0:C;)(D,P)59  PP2.<$^E7JYKX?_\ (C:9
M_NR?^C&KI::)>X4444""BBB@# \-^&1X>GU*07TMR+R;S '&-G)]^3SR>,X'
M%;]%% V[F!KMO>ZCJNG6=J!%% WVR2>6$O'N4X1>"N3DDXS_  @UC7NF:O$=
M<L/+%RM_&EVC00M'&7# 21\LP#,H'4\\UW%%%@N<CKS0ZSH]TEII-X9-D*%Y
M+-HR5\U3Y>& 8X )X! ]:37]+N[K4=2CL[9MLNF1H-J[5D*RDE,],[>,>]=?
M118+G':@DFK7,ES86%U#'%I4\,GFV[1,Y8#9&%(!;!!/&1SUYJ1M.N0?#L=K
M \#QV,T32",@0L8EQN../F_45UM%%@N<1#&SOX6M4TJ[BFL)=EPS6S*L6(RK
M?/C:P9AG*D@\9ZBG6^G7$/A#2\V4I^SWWVBYMQ&=[H)'/W>K'E6QWQQ7:T4K
M#N<!XAC:XM==U%;29;*;['&$EB,;3NLJY.Q@#T(7) SCT%3:W;S:I#K%U8:?
M=)$VFBW"M;M&\LF[( 0@$[1QG'? Z5V5Y9V]_;&WN8_,B+*Q7)'*L&'3W J>
MBP7.(\0_;[@ZY;);7,7FQE8H[2QWF[R@ 9Y2I4 <C:-K<<'.*2]@FAA9[>&^
M6ZFM8/,MI=/^T6]WA" C8&4.>#EEQZ'K7<446"YQERFHQ7>JW)TX.\DUF27M
MVF5,( SJ@Y<J?3Z]JL>&H[L>(]5GF^W213P0;+B[MA"92N\'@*N,9Z$9Q@],
M&NKHIV"YSC0S'7]>@C;9<75C$;=B?0.OX88C\ZJ(8I?#::>FCW:WEO82Q_-:
M%1$WE[2 QP&W'@;-V>OO7426D$MU!<NF9H PC8,1@-U''4' X/H#VJ:BPKG*
M+82PR^&Q%:.BPV4L<NV,C9F->#QQDCOWK%BTC4IM)MX$M)UD_L-8BKH5RPE!
M,9)X!(!&#ZUZ+12L/F.*O,ZEK1N+33+R.,://"7DM'C^8X*QX('(YZ<<\9YJ
M2YT^XAT_PS*$O(8;2';,+6 221.44!MA5LX.X' R,_6NQHIV"YQ?]F;SI\L,
M.I3(^M+<R-=PJAXC<>9L51M&0.6 .>>X)V](@EAUW7F:%HX9+B)XR5PK_ND#
M$>O(Y]ZV:*+"N<#XD34+JUUJTCMKJ-G9O+M[2QW"Y&%/F23$$'@$  JW&.3B
MK6H%K2+Q"U]9W$_VZW1H76W9E*B+&UB!A-K9/S8ZY]:[2LVZT#3;VYEGGAD+
MS!1*%G=$E Z;U5@K>G(/'%*P[G+VMK/;RP7,\NHQP3Z9;QQ/9VJW'W5^9&!C
M<KR01T!Y]*FEL$L+6R-M_;%K*MGY2L]DMTK('SY4B(#@X/;:,'KP179JH50J
M@  8 ':EHL%S-L;B>W\/0SW=EY4T=N&>UMDS@@?=11GZ 5CZ5++J-\;^[6YB
MU-XV2VBEL9O)M%/.,LJAF.!N.1GH..O544Q7,U(-;#J7U#3V3(W!;%P2/8^<
M<?E5:X@F;QI8SB)S"ME,K2!3M!+)@$],\'\JVZ* N8VHP2OXFT25(G:.,7&]
MPI(7*C&3VS32#)XW5D&1#IS"4CL7D&T'_OAZVZAAM(+>6>6-,23MOD8DDL<8
M'7H,#ITH"Y-1110(**** "BBB@ HHHH **** "E;[QI*5OO&@9AZQI U/6M)
M>>TBN;. 3><)55E!*C;\IZ\BF:UH<1\,WMAI-A!$\VTB*%%C#'<,D]!T%;U%
M%@N<]JUEJK:O<WFG(F_^S6BA=RN/-WY P>^.A(QGK6=;Z1J$FOI=R6-V]N;2
M>&0ZA>*Q=VP<%4+*B'I\@[?=&!GLJ*+!<XM=$U2[MKJQA2]L+&>T:-H+VY2=
M4D*@*(R"S!1@YR0.>!5_2].?[?9S3:1>PR0(Q:6YU)I51BN"(UWMD')Y(7CW
MXKI:*+!<P?$/]JSO#9V=K<-9R FYFMGC$F/[B[W7&>[=NU:>F(D6GQ11V,EE
M'&-B0.5)4#I]UF'ZU;HH"Y!;V-I:/*]M:P0M,VZ1HXPI<^IQU/)J>BB@0444
M4 %%%% !1110 IZ"J>IZ=!JVFW%A<[O)G0HQ0X(]Q[@\U</04E RCI&E6^B:
M5!IUH7,,((4N<L<DDD_B35ZBB@1RNH:3J1O-7O;2$&X$MO/9Y< 2,B;6'7C(
M+#G'6HI/#-UMO+5 "DFBK:+,6&&FW.23WY+ DX[UU]%%AW.1DL]5O[ZVE?3)
M+>.'3IK<^9+&29&"X VL>..OUR!WC.C:DEN(A9LYDT 6)*R)A)0K<'+=R0,C
M(_#FNRHHL%SFK#2;R&?4WD@QYVGV\$9W*<NJ.&'7CDCVJFEAK45KI]M+;W<D
M$.GPQ^5:W*0XG52&\UPP?:,C[A(X/!KL:*+!<XW3='U.SMO#HDLV9K2VN()P
MLB?(7V[3RW(^7MD^U.TC3=4T4:?<G3WN6&FI:2PQ2QAXW5BV?F8*0=V.#V[U
MV%%*P[G*:1H5]9:CI4T\:[8HKIIBK@B-Y9 X4=SW&0.WO4,>FZS;6<<*Q70@
M:]N7G2TEC69D9RR89B, ]\$-R*[&BG85SB]/T34XXH1+9O'C6_MFU[@2E8C'
MC)8DDD'@]_KUKM*** ;N%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "K-E_K3]*K59LO\ 6GZ4
MI;%0^(O450NM$TZ]G,]Q;"20@ MN8?R-0?\ ",Z/_P ^2_\ ?;?XU-H]S5N?
M1+[_ /@&M163_P (SH__ #Y+_P!]M_C1_P (SH__ #Y+_P!]M_C1:/?^OO"\
M^R^__@&M163_ ,(SH_\ SY+_ -]M_C1_PC.C_P#/DO\ WVW^-%H]_P"OO"\^
MR^__ (!K45D_\(SH_P#SY+_WVW^-'_",Z/\ \^2_]]M_C1:/?^OO"\^R^_\
MX!K45D_\(SH__/DO_?;?XT?\(SH__/DO_?;?XT6CW_K[PO/LOO\ ^ :U%9/_
M  C.C_\ /DO_ 'VW^-'_  C.C_\ /DO_ 'VW^-%H]_Z^\+S[+[_^ :U%9/\
MPC.C_P#/DO\ WVW^-'_",Z/_ ,^2_P#?;?XT6CW_ *^\+S[+[_\ @&M163_P
MC.C_ //DO_?;?XT?\(SH_P#SY+_WVW^-%H]_Z^\+S[+[_P#@&M163_PC.C_\
M^2_]]M_C1_PC.C_\^2_]]M_C1:/?^OO"\^R^_P#X!K45D_\ ",Z/_P ^2_\
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M^-%H]_P_X(7J=E]__ -FBL;_ (131/\ GQ7_ +^-_C1_PBFB?\^*_P#?QO\
M&BT>_P"'_!"]3LOO_P" ;-%8W_"*:)_SXK_W\;_&C_A%-$_Y\5_[^-_C1:/?
M\/\ @A>IV7W_ / -FBL;_A%-$_Y\5_[^-_C1_P (IHG_ #XK_P!_&_QHM'O^
M'_!"]3LOO_X!LT5C?\(IHG_/BO\ W\;_ !H_X131/^?%?^_C?XT6CW_#_@A>
MIV7W_P# -FBL;_A%-$_Y\5_[^-_C1_PBFB?\^*_]_&_QHM'O^'_!"]3LOO\
M^ ;-%8W_  BFB?\ /BO_ '\;_&C_ (131/\ GQ7_ +^-_C1:/?\ #_@A>IV7
MW_\  -FBL;_A%-$_Y\5_[^-_C1_PBFB?\^*_]_&_QHM'O^'_  0O4[+[_P#@
M&S16-_PBFB?\^*_]_&_QH_X131/^?%?^_C?XT6CW_#_@A>IV7W_\ V:*QO\
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M^_C?XT6CW_#_ ((7J=E]_P#P#9HK&_X131/^?%?^_C?XT?\ "*:)_P ^*_\
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M%8W_  BFB?\ /BO_ '\;_&C_ (131/\ GQ7_ +^-_C1:/?\ #_@BO4[+[_\
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M\:/^$4T3_GQ7_OXW^-%H]_P_X(7J=E]__ -H]!25CGPIHF!_H*_]_'_QI/\
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M7_OXW^-'_"*:)_SXK_W\;_&BT>_X?\$+U.R^_P#X!LT5C?\ "*:)_P ^*_\
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MKB6. -'&<X!+9X!/3OQTK/A\':T;2UT2YOK)M%MK@2JZ(PN'4$D*?X1R>O\
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M)-$2YMOLD,T<S[([DN'^0'#C ^8?B.>#6CKEH]PME(GG,8KN%MD9.TCS%R6
MZX /7@=:@M]#OAJ>GWEYJB3BRC>-$2VV;]R@%F.X_-P.@ ]A6[3$SE[*U9?$
M2O\ 9)DO!<7#75R8B%DA.?+7S.C8!C&T'C:>!BNHHHH!BGH*KWMY;Z?9RW=W
M*(H(EW.Y!.!^%6#T%5[RSM[^SEM+J(2P2J4=#W!_E]: &V%_:ZG8Q7EG,);>
M491P",\X[\]0:LU6L+"UTRQBL[.$16\0PB DXYSWYZDU9H$88N+O5=7OK6"\
MDL[:R*1EH41GDD90QY=6 4 CMDGOVJKJ5_JVCV%D;F03RG4$A+01@M/$0< J
M1@,>AQ@9[@5>DL;^SU6ZO=.6WF2["F:&XD:/:ZC:&5@K=5 !!'8'/:JK:)J,
M\=K)=7:2W(U!+R5=S>7&H7&R//8?ADDGBD42S^(8#:3M(E[9RV]S%#+'MC,@
M+E=O=E*G/4'.,]Z&\4VRO.397OV>WN?LTUQL78C[@O\ >W$9(Y /6J^H^'KN
M[N=2DCD@ NKBUE3<QX$1&[/'7CC^E+/X?NY-$U6R$D/F7=ZUQ&2QP%+JV#QU
MP#1J&A<U#Q FG"XD?3KZ2VML>;<(B!%]<;F!;'?:#^E:ZL&4,IR",BN0UOPO
MJ&JMJ*LME<&X)^S7%U*Y-LI5?E2/:54Y7[P(/.2#C!ZNVC:*UAC?&Y4"G!R,
M@4Q.Q+1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JS9?ZT_2JU6;+_ %I^
ME*6Q4/B+U%%%9G0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% &7Y8_OI^='EC^^GYTRJ=WJNG:>ZI>ZA:VSL,
MJLTRH2/49-:G,7_+']]/SH\L?WT_.J5GJ5CJ(<V5[;7.S&_R95?;GIG!XZ&K
M5 #_ "Q_?3\Z/+']]/SIE% #_+']]/SH\L?WT_.HI)$BC:21U1$!9F8X  ZD
MFJ]GJ5CJ(<V5[;7.S&_R95?;GIG!XZ&@"[Y8_OI^='EC^^GYTRB@!_EC^^GY
MT>6/[Z?G4,TT5O"\T\B11(,L[L%51ZDGI2QR)-$DL3J\;@,K*<A@>A![B@"7
MRQ_?3\Z/+']]/SK/N-8TRTN/L]SJ-G#/Q^[DG56YZ<$YJP]U;Q7$5O)/$D\V
M?+B9P&? R<#J<4 6/+']]/SH\L?WT_.JPNK=KIK59XC<*N]H@XWA?4CKCWJ:
M@!_EC^^GYT>6/[Z?G3** '^6/[Z?G1Y8_OI^=,HH ?Y8_OI^='EC^^GYTRB@
M!_EC^^GYT>6/[Z?G3** '^6/[Z?G1Y8_OI^=4[S4;'3U1KV\M[8.<*9I53=]
M,FBSU"RU!&>RO+>Y53AFAD#@'WP: +GEC^^GYT>6/[Z?G3*BDN8(9%CEFC1V
M5F568 D+U('H,C/UH L>6/[Z?G1Y8_OI^=112QS1)+$ZR1NH9'0Y# ]"#W%*
M64,JE@"W0$]: )/+']]/SH\L?WT_.H))X87C665$:5ML89@"YQG ]3@&I* '
M^6/[Z?G1Y8_OI^=12RQPQ/+*ZQQHI9W<X"@=23V%5[/4K#4=_P!BO;:Y\O&_
MR)5?;GIG!XZ'\J +OEC^^GYT>6/[Z?G5=+JWDMOM*3Q-!@MYJN"N!U.>E5KC
M6=+M!&;G4K.'S5#Q^9.J[U/<9/(]Z -'RQ_?3\Z/+']]/SJ"WN(+N!9[::.:
M%_NR1L&5OH14E #_ "Q_?3\Z/+']]/SIE% #_+']]/SH\L?WT_.F44 /\L?W
MT_.CRQ_?3\Z910 _RQ_?3\Z/+']]/SIE% #_ "Q_?3\Z/+']]/SIE% #_+']
M]/SH\L?WT_.F44 /\L?WT_.CRQ_?3\Z910 _RQ_?3\Z/+']]/SIE% #_ "Q_
M?3\Z/+']]/SIE% #_+']]/SH\L?WT_.F44 /\L?WT_.CRQ_?3\Z910 _RQ_?
M3\Z/+']]/SIE% #_ "Q_?3\Z/+']]/SIE% #_+']]/SH\L?WT_.F44 /\L?W
MT_.E:,;C\Z?G4=*WWC0 [RQ_?3\Z/+']]/SK/OM5M-.D@CN&E\R?=Y:10/*S
M;>3P@)XS4 \0Z9Y%S,T\D:VP4S++!)&Z!N =K*&P?7% &OY8_OI^='EC^^GY
MTRB@!_EC^^GYT>6/[Z?G3** '^6/[Z?G1Y8_OI^=4;W4K73_ "A<.^^4D1QQ
M1-([8&3A5!.!W..*EM;J"]M8[FVE66&0;D=>A% %GRQ_?3\Z/+']]/SK+BUJ
MSF-YM,NVT8([>4QW$]-@'+>G Y[9JU9727UC;WD081SQ+*H<8(##(S[\T 6O
M+']]/SH\L?WT_.F44 /\L?WT_.CRQ_?3\Z910 _RQ_?3\Z/+']]/SIE% $AC
M&!\Z?G2>6/[Z?G33T%)0#'^6/[Z?G1Y8_OI^=,HH ?Y8_OI^='EC^^GYU!-/
M%;Q&6>5(HP0"[L% R<#D^Y J2@!_EC^^GYT>6/[Z?G3** '^6/[Z?G1Y8_OI
M^=,HH ?Y8_OI^='EC^^GYTRB@!_EC^^GYT>6/[Z?G3** '^6/[Z?G1Y8_OI^
M=,HH ?Y8_OI^='EC^^GYTRB@!_EC^^GYT>6/[Z?G3** '^6/[Z?G1Y8_OI^=
M,HH ?Y8_OI^='EC^^GYTRB@!_EC^^GYT>6/[Z?G3** '^6/[Z?G1Y8_OI^=,
MHH ?Y8_OI^='EC^^GYTRB@!_EC^^GYT>6/[Z?G3** '^6/[Z?G1Y8_OI^=,H
MH ?Y8_OI^='EC^^GYTRB@!_EC^^GYT>6/[Z?G3** '^6/[Z?G1Y8_OI^=,HH
M ?Y8_OI^='EC^^GYTRB@!_EC^^GYT>6/[Z?G3** '^6/[Z?G1Y8_OI^=,HH
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M !5FR_UI^E5JLV7^M/TI2V*A\1>HHHK,Z HHHH **** "BBB@ HHHH ****
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M;38;P6<NH6D=TQ"B%IE#DGH-N<\YJ'5]<LM(M;AY;BW^TQP/-';/,$>7:"<
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MSQW&?3/*D_YYO_WR:/*D_P">;_\ ?)I6&FSS^VT3[?XITEM0TQIK5-#C1C/
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M'*4&]%Z*<<@58\J3_GF__?)H\J3_ )YO_P!\FF#N,HI_E2?\\W_[Y-'E2?\
M/-_^^30*S&44_P J3_GF_P#WR:/*D_YYO_WR: LQE%/\J3_GF_\ WR:/*D_Y
MYO\ ]\F@+,913_*D_P">;_\ ?)H\J3_GF_\ WR: LQE%/\J3_GF__?)H\J3_
M )YO_P!\F@+,913_ "I/^>;_ /?)H\J3_GF__?)H"S&44_RI/^>;_P#?)H\J
M3_GF_P#WR: LQE%/\J3_ )YO_P!\FCRI/^>;_P#?)H"S&4K?>-.\J3_GF_\
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M_ODT>5)_SS?_ +Y- 68RBG^5)_SS?_ODT>5)_P \W_[Y- 68RBG^5)_SS?\
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M<1*00V .Y'/'O1<+,Z+)]:,GUK%_M.1=0U6&ULGFGMVA&&N2$;<N<\\( .N
M<^A-)H?B!=8N[VVQ:[[4(V^UNA/&X;/1MHY&#D8]* LS;R?6C)]:**!!D^M&
M3ZT44 &3ZT9/K110 9/K1D^M%% !D^M&3ZT44 &3ZT9/K110 9/K1D^M%% !
MD^M&3ZT44 &3ZT9/K110 9/K1D^M%% !D^M&3ZT44 &3ZT9/K110 9/K1D^M
M%% !D^M&3ZT44 &3ZTK$[C24K?>- Q,GUHR?6N7\3113:_H:3:=_:"'[1FWV
MHV?E7G#D+Q]:R=8T^6UTC6[J#31IED\$2+:90;Y X)?"$JO! ZY..:+CL=]D
M^M&3ZU@#5-2M+ZYLKUK!Y%LOM22*&AC3#$,')+?*.#NXXSQ5*R\37DFJ&T#6
M]^K6DDT3V]M) KNA VJS%@X.?O+Q1<5F=9D^M&3ZUR=KXJECMKV:]GM))+6U
M\Z2T6"2WG1L [2CD[EY'S#'T.:LZ7K6I3ZC;V]S TD<Z$NZ:?/ (& S@M)PP
M/(SQSVYX+A9G1Y/K1D^M8^N6NE;5U#6,2V]NA"P2@/&6.,'9CYG[#ZFE\,V]
MS:Z#!'=*Z-EF2)SEHHRQ*(3[+@>W3M0'0U5E1Y'C612Z8W*&Y7/3([4D4T<\
M2RPRK)&W1T;(/XBL)]#G)U>&T=+-+MXV$NW?OX^?.&!R>1G(//%7/#UG<Z?H
MD%K="-9(RPVQIM"C<<#&3_.@#4R?6C)]:**!!D^M&3ZT44 &3ZT9/K110 I)
MP.:3)]:4]!5/5-1@TC3+B_N0YA@7<P09)]A0,MY/K1D^M4=(U6WUO2H-1M X
MAF!*AQAA@D$'\0:O4 &3ZT9/K6!&KZSK>I0W$US';63)%'%!,\.YB@8NQ0@G
M[P &<>V:JZN-1T>PT^..[FNW.I(D0+[&>,@XC=OXN>I/4=030%CJ<GUHR?6N
M:N]?=;:ZCO+(I<6MU!$Z073!2)&7:P< ''/((&<8Z&E?Q/<HMY<'35^Q6EV;
M667[1\Y^8+N5=N".1U(_&BX69TF3ZT9/K7.ZYXEFT02RRVEL+=/N>?>B.6?&
M-WEIM.[&>Y'\B>@1Q)&KKT8 B@!V3ZT9/K110(,GUHR?6BB@ R?6C)]:** #
M)]:,GUHHH ,GUHR?6BB@ R?6C)]:** #)]:,GUHHH ,GUHR?6BB@ R?6C)]:
M** #)]:,GUHHH ,GUHR?6BB@ R?6C)]:** #)]:,GUHHH ,GUHR?6BB@ R?6
MC)]:** #)]:,GUHHH ,GUHR?6BB@ R?6C)]:** #)]:LV?\ K3]*K59LO]:?
MI2EL5#XB]11169T!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!D50UO3/[9T6ZT[SO)\]-OF;=VWGTR,UM_81
M_P ]/TH^PC_GI^E:<R,.21RUSX<^T2:&WVK;_93 X\O/FX4#U^7I[U0U7P9-
MJ.IZC<Q:Q+;P:A$L<\(@5R=JX7#GD+G!('7GGICN/L(_YZ?I1]A'_/3]*5T/
MED<K9>&S::U9:B;O>;;3EL3&(L;L'._.>/I^M48O"%W:^&XM(M=9$861VD9[
M*.5)58YP4?/0XYSZ\=,=Q]A'_/3]*/L(_P">GZ470<LCB8? UM%X=73&O)?/
M2X-U'=1H$,<O8JHX X''\NUC3O#=Y'JC:AJ^M3:C,(3 B"(0H$/WLJIPV>/R
M[X&.N^PC_GI^E'V$?\]/THN@Y9'!P>!7C\BSFUF>;1K>;SHK$Q*"""2 9,Y(
MR3QBK,OA#S+#7;7[=C^U9S-N\K_5<YQC=\WZ5V?V$?\ /3]*/L(_YZ?I1=!R
MR,=M-AFT?^S;@"6$P"%^,;AC&?:N=A\&WJO:07'B*[FTRTE$D-L(@C@+]T&0
M')Q]/ICC'=?81_ST_2C["/\ GI^E%T+ED<JGAB WNNS7,OGPZLL:O%LQY852
M.#DY/.<X&,5F6G@3[+HMGIW]I%_L^HK?^88,;L#&W&[]?TKO?L(_YZ?I1]A'
M_/3]*+H?+(IT5<^PC_GI^E'V$?\ /3]*?,A<DBG15S["/^>GZ4?81_ST_2CF
M0<DBG15S["/^>GZ4?81_ST_2CF0<DBG15S["/^>GZ4?81_ST_2CF0<DC-@M+
M:U:5K>WBB:9R\AC0*78]2<=3[U-5S["/^>GZ4?81_P ]/THYD')(Y^_T.#5-
M4M[F^$=Q;01LJ6LL09=[$?.<]>!@#%49_"%D]Q=&U*6=M=6ZQ206\04;U;<D
M@QQD?3FNN^PC_GI^E'V$?\]/THN@Y9'+W>BZCJ-C-;7VJQL'$>T0VNQ05<,6
M(+$DG&." /2GZCX>BU.]N9IIV5)[1;;:J\J0Y<,#]2.,=JZ7["/^>GZ4?81_
MST_2BZ#ED<K)H%U>-)+J6H)/-]DDM86BM_+5-XPSD;CEC@=P..E3/H*2-I?F
M3;X[*!X&0I_K0R!3WXZ>_6ND^PC_ )Z?I1]A'_/3]*+H.61R,7AR\6;2Q+JB
MR6VFR;H8_L^'9=I4!VW8) (Y '?CGB5/#>S0K73TO"L]I-Y\-P(^C[F(RN>1
M\Q!&?RKJ?L(_YZ?I1]A'_/3]*5T/ED<+KVA7;:3J-PTS7.HW3VR V\!41HDJ
MGY4RQXRS$DG\ *N7?AJXU*WOOMVH(]U<VWV9)([?8D29R?EW$DD]3GTZ5UWV
M$?\ /3]*/L(_YZ?I1=!RR./O_"\UU<:H\-]%"NHILE=K;?,J[0I57W#"G'3!
MZG&.H??>';J^L!827UN]IY*1E)[(2%&"[2\9W#:2/4-@_E76_81_ST_2C["/
M^>GZ470<LCD+KPFEP+H"Z!$SV[JDT7F)^Z &'&1O![CBK6EZ)/8ZK=:A/>I.
M]Q$D92.#RT383C:-QP,'H<\]^PZ7["/^>GZ4?81_ST_2BZ#ED4Z*N?81_P ]
M/TH^PC_GI^E/F0N213HJY]A'_/3]*/L(_P">GZ4<R#DD4Z*N?81_ST_2C["/
M^>GZ4<R#DD4Z*N?81_ST_2C["/\ GI^E',@Y)%.BKGV$?\]/TH^PC_GI^E',
M@Y)%.BKGV$?\]/TH^PC_ )Z?I1S(.213HJY]A'_/3]*/L(_YZ?I1S(.213HJ
MY]A'_/3]*/L(_P">GZ4<R#DD4Z*N?81_ST_2C["/^>GZ4<R#DD4Z*N?81_ST
M_2C["/\ GI^E',@Y)%.BKGV$?\]/TH^PC_GI^E',@Y)%.BKGV$?\]/TH^PC_
M )Z?I1S(.213HJY]A'_/3]*/L(_YZ?I1S(.213HJY]A'_/3]*/L(_P">GZ4<
MR#DD4Z5OO&K?V$?\]/TI#9$DG>/RHYD')(R9]/BN-0M+UV<26H<( 1@[P <\
M>U&IZ?%JNGRV4[.L<H 8H0#P0>,@^E:WV)O[X_*C[$W]\?E1S(.21@:CH-GJ
M<\TMP9<S6IM6"L  I;=D<=<C_P"M42>'8O[26_N-0OKFX6)X=SNJ_(V.!L5<
M$8R",'GJ>,=)]B;^^/RH^Q-_?'Y470<LCFT\.0.VZ^N[O4,0M HNF7"HV WW
M57).!R<GBI[+2#9RQ,VI7]PD*;(HYI%"J, <[5!<X'5L^O7FMW[$W]\?E1]B
M;^^/RHN@Y9'/ZEH::E?VUX;VZ@DM@?+$8C903_%AT8;O>K]K#);PB.2ZEN6S
MGS)0@8_]\J!^E:/V)O[X_*C[$W]\?E1=!R2*E%6_L3?WQ^5'V)O[X_*CF0<D
MBI15O[$W]\?E1]B;^^/RHYD')(J45;^Q-_?'Y4?8F_OC\J.9!R2*E%6_L3?W
MQ^5'V)O[X_*CF0<DBJ>@IDL4<T3Q2HLD;J5='&0P/4$=Q5W[$V/OC\J/L3?W
MQ^5',@Y)%"&"*VA2&")(HD&%1%"JH]@.E25;^Q-_?'Y4?8F_OC\J.9!R2,"?
M2[A-2FOM.NX[>6X55G2:$RHY7A6 #*0V..N".W>JJ>&@L<!>\:2Y%\M[/,T8
M_>N!C  /RC& .N,=ZZG[$W]\?E1]B;^^/RHN@Y9'+7OAO[9/?2?:]GVJ>WEQ
MY>=OE$<=><X_#WI9?#GFZ3J-C]JQ]LNC<[_+^YEE;;C//W<9XKJ/L3?WQ^5'
MV)O[X_*BZ#ED<=?^%);QM46*_BA3423+(;7?,!M "A]WW,J.,=,@$=1T4$9A
MMXHBP8H@4D#&<#TJ_P#8F_OC\J/L3?WQ^5%T'+(J45;^Q-_?'Y4?8F_OC\J.
M9!R2*E%6_L3?WQ^5'V)O[X_*CF0<DBI15O[$W]\?E1]B;^^/RHYD')(J45;^
MQ-_?'Y4?8F_OC\J.9!R2*E%6_L3?WQ^5'V)O[X_*CF0<DBI15O[$W]\?E1]B
M;^^/RHYD')(J45;^Q-_?'Y4?8F_OC\J.9!R2*E%6_L3?WQ^5'V)O[X_*CF0<
MDBI15O[$W]\?E1]B;^^/RHYD')(J45;^Q-_?'Y4?8F_OC\J.9!R2*E%6_L3?
MWQ^5'V)O[X_*CF0<DBI15O[$W]\?E1]B;^^/RHYD')(J45;^Q-_?'Y4?8F_O
MC\J.9!R2*E%6_L3?WQ^5'V)O[X_*CF0<DBI15O[$W]\?E1]B;^^/RHYD')(J
M45;^Q-_?'Y4?8F_OC\J.9!R2*E%6_L3?WQ^5'V)O[X_*CF0<DBI15O[$W]\?
ME1]B;^^/RHYD')(J59LO]:?I3OL3?WQ^5206YA<L6!XQ2;5AQBTQTEU;Q/LD
MGC1O1F --^W6G_/U#_WV*X[Q-_R&Y/\ =7^59%>-5S*4)N'+L1*NTVK'I'VZ
MT_Y^H?\ OL4?;K3_ )^H?^^Q7F]%9_VK+^47UA]CTC[=:?\ /U#_ -]BC[=:
M?\_4/_?8KS>BC^U9?RA]8?8](^W6G_/U#_WV*/MUI_S]0_\ ?8KS>BC^U9?R
MA]8?8](^W6G_ #]0_P#?8H^W6G_/U#_WV*\WHH_M67\H?6'V/2/MUI_S]0_]
M]BC[=:?\_4/_ 'V*\WHH_M67\H?6'V/2/MUI_P _4/\ WV*/MUI_S]0_]]BO
M-Z*/[5E_*'UA]CTC[=:?\_4/_?8H^W6G_/U#_P!]BO-Z*/[5E_*'UA]CTC[=
M:?\ /U#_ -]BC[=:?\_4/_?8KS>BC^U9?RA]8?8](^W6G_/U#_WV*/MUI_S]
M0_\ ?8KS>BC^U9?RA]8?8](^W6G_ #]0_P#?8H^W6G_/U#_WV*\WHH_M67\H
M?6'V/2/MUI_S]0_]]BC[=:?\_4/_ 'V*\WHH_M67\H?6'V/2/MUI_P _4/\
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M[5E_*'UA]CTC[=:?\_4/_?8H^W6G_/U#_P!]BO-Z*/[5E_*'UA]CTC[=:?\
M/U#_ -]BC[=:?\_4/_?8KS>BC^U9?RA]8?8](^W6G_/U#_WV*/MUI_S]0_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M11]5H_RA[.'8Q/\ A&X?^?B3\A1_PC</_/Q)^0K;JM=7\%G+;13,0]S+Y40
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M*VZ*/JM'^4/9P[&)_P (W#_S\2?D*/\ A&X?^?B3\A6W11]5H_RA[.'8Q/\
MA&X?^?B3\A1_PC</_/Q)^0K;HH^JT?Y0]G#L8G_"-P_\_$GY"C_A&X?^?B3\
MA6W11]5H_P H>SAV,3_A&X?^?B3\A1_PC</_ #\2?D*VZ*/JM'^4/9P[&)_P
MC</_ #\2?D*/^$;A_P"?B3\A6W11]5H_RA[.'8Q/^$;A_P"?B3\A1_PC</\
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M%'_".:?_ ,]+G_OI?\*U:*/JU'^5![./8R_^$<T__GI<_P#?2_X4G_".:?\
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MGN [1H!U" ;CGIW'Y_6IH9&EA1WB>%F&3&Y!9?8X)'Y$T?5J/\J#V<>QF_\
M".:?_P ]+G_OI?\ "C_A'-/_ .>ES_WTO^%:M%'U:C_*@]G'L97_  CFG_\
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MS3_^>ES_ -]+_A6K11]6H_RH/9Q[&5_PCFG_ //2Y_[Z7_"C_A'-/_YZ7/\
MWTO^%:M%'U:C_*@]G'L97_".:?\ \]+G_OI?\*/^$<T__GI<_P#?2_X5JT4?
M5J/\J#V<>QE?\(YI_P#STN?^^E_PH_X1S3_^>ES_ -]+_A6K11]6H_RH/9Q[
M&5_PCFG_ //2Y_[Z7_"C_A'-/_YZ7/\ WTO^%:M%'U:C_*@]G'L97_".:?\
M\]+G_OI?\*TM(TZWT]Y1 TK&0#.\@],^@]Z?4]K_ *P_2KI4*<9IQCJ5&$4[
MI%NL+Q3_ ,>=E_U^Q_UK=I&8*I9B H&22> *ZJL.>#B6U='"W=E!-#K]VX8S
M07),3!B-IW<\5+?O;OJ6_5C,5:S0VA7=R^!G&.^?7_"NOM[RUNBPM[F&8K][
MRY V/RJ>N3ZHFKQ?X>O^?X$\AYW+YO\ 8ND>;Y?V+;)GSM_E[]S==G.<=/Q]
MZLS@#2]&%[,9K<3M\T8?_5\<<@-C&?PZ5W=4[ZQ@N9;>XGD9/LK^:I! 'XY[
M5+P;2=G?1+[K?Y"Y#CG\P:9JATKS?[,,L>W.[&W!W^^,XS[4EN&&@:L8IH&M
M2BXCA$NU6R.F\=QUY]*[A+NVD9%2XB9I%W(%<$L/4>HITD\4)02RHA=MJ!F
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M(****0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_N?K5.'4+*XMGN8+RWE@CSOE20,JXY.2#@8JIHVOV&N6J2VL\1=@S>3YBEU
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %':BB@ HHHH
G**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H[T44 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img148560552_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148560552_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %< Z@# 2(  A$! Q$!_\0
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MXQ_Z&34/^_G_ -:N:HHY(]@.E_X6%XQ_Z&34/^_G_P!:C_A87C'_ *&34/\
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M/_ :/_"N(8%&*L"K X(/8TE/V4.R+.X_X6_XX_Z#"?\ @-'_ (4?\+?\<?\
M083_ ,!H_P#"N'HH]E#L@.X_X6_XX_Z#"?\ @-'_ (4?\+?\<?\ 083_ ,!H
M_P#"N'HH]E#L@.X_X6_XX_Z#"?\ @-'_ (4?\+?\<?\ 083_ ,!H_P#"N,^S
M3_93=>2_V</Y?FX^7=C.,^N*A)P"?2CV4.R"YW/_  M_QQ_T&$_\!H_\*/\
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M&CS:AJ[VMYX8LK+294<1J0JW$6%RK9!W$YKG6\0Z39:SHTFF:<?L>FN&9Y%
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MI%8V%OIME<WDELEQ<SW<7F9+\A5!X  K/U&]T.VT-M+TJ*2YFED#S7UQ$$8
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M5TEA?Z7-X/ET>^N9[:=+K[3$Z0^8K_+C:>>/K7.,"4([D4T:4E9OU.K\??\
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M[ZK_ .!"_P#Q-'_"B/"7_/?5?_ A?_B:/K5,+'SC17T=_P *(\)?\]]5_P#
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M0O\ \31]:IA8^<:*^CO^%$>$O^>^J_\ @0O_ ,31_P *(\)?\]]5_P# A?\
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M .!"_P#Q-'_"B/"7_/?5?_ A?_B:?UJF:V/G&BOH[_A1'A+_ )[ZK_X$+_\
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M<%+='SDS%F+,2S$Y))R2:2OH[_A1'A+_ )[ZK_X$+_\ $T?\*(\)?\]]5_\
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MKC_B7_R*L/\ V$;3_P!'+785;^!?/] "BBBH Y#P+_Q\>*?^P[<?R2NOKD/
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M[/"1^H;^E--_/;_\?EFZH.LL!\Q?Q&-P_*@"_13(9HKB)989%DC;HRG(-/H
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M=1GPUHYMH;<6$8BA=GB521L9NI!!X-8$^N:S<6\-S9NOV>[NI?)2)$,QMT&
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M* "BBB@ HHHH Y#QU_Q\>%O^P[;_ ,GKKZY#QU_Q\>%O^P[;_P GKKZN7PH
MHHHJ ./^%_\ R(-G_P!=[G_T?)785Q_PO_Y$&S_Z[W/_ */DKL*NI\; ****
M@ HHHH **** "J5U=R>=]CLPK7)&YF;[L2_WF]3Z#O\ 2I+ZZ^R6ID5=\C$)
M&F?O.> /\]J+*T%I!M9M\KG?+(>KL>I_H!V % "6MA%:L9,M+<./GFDY9O\
M >PXJU15/4=3M=*MA/=R;$+!1@9/^>]"5]$.,7)V6Y8N)X[6!YYFVQH,L<9J
MM%JUA-'+)'=(4B^^W0+7">(_%POUQ9"0V07#,'&7/#9"C.1@=_7I5,7-XUI<
M?80L=M<@-*9&VD;N=@R,9X)S@=:Z8X=M7>AZ=/+9."E/1L].M;N"]@$UO()(
MST8"JDEC):.9]. 4DY>V)PDGT_NM[]#W]:Y?0-1O%U"&%#^YF5&VL.&!') ]
M1]>!VKN:QJ0Y'8XL10=&?*0VMS'=PB6(G&2&5A@JPZ@CL14U9UV/L%T+].(G
M(2Y';'0/]1T/M]!6C4& 445%=7"6EM)/)G:@S@=3Z >YZ4 0WEXT+)! @ENI
M/N)G 4=V8]E'Z]!26NGK%)]HG<SW1&#*P^[[*/X1_DYHL+9XD>>XP;J?YI2/
MX?11[#I^9[TFJ:E#I6G37DW*Q#.T'DD\ 4";MJ7:*Y%?'41C1C9$%EW;?-!.
M/RKI[*[BOK.*YA.4D&1[5$:D9.R9,:D9_"R>BJEUJ=E99%Q=11L!DJS#-<^W
MC>)6/^A$)R06E )'KC%$JD8[L)581W9N3V#)*US8LL-P>64_<E_WAZ_[0Y^O
M2IK.\6[C8[&CE0[98F^\C>GN/0]Q531=9&L13.(&A\M@N&.<Y&?2I-0C:W==
M1A!+Q#$JC_EI'W'U'4?B.]5&2DKHJ,E)71H44B.LB*Z$,K#(([BEIC"BBB@
MHHHH **** .0\0_\E&\&?2^_]%+11XA_Y*-X,^E]_P"BEHJY;+T_5@)X6_Y'
M;QI_U]6__HD5V%<?X6_Y';QI_P!?5O\ ^B17843W^[\@(+NRM=0MVM[RWCGA
M;JDBAA^M4IM"L_[%NM+LHTLH;A&1C#&!U&"?<XK4HJ *,VCZ=<V4%G<6<,T$
M  B21 0N!@8].*?_ &98>;;R_8X ]NI2%A&,QJ1@@>@]JMT4 9\&AZ5;1S1P
MZ=:QI.,2JL0PX]#[>U6FM+9W=V@C9GC\IR5&63^Z?;D\5-10!6.GV15U-I"5
M>(0L"@P4'13[#)XI;.QM-/A\FSMHK>/.XK&H4$^O%6** *$6AZ3!<BYBTVT2
M<$L)%A4,">^<=:>^DZ=+?K?R65NUVN,3&,%ACIS5RB@"NMC:(ZNMM$&5VD4A
M!D.WWF^IR<FGI:V\4TTT<,:R38\UU4 O@8&3WXJ6B@"A!HFEVJSK!I]M&LZE
M90L0 <>A]O:DU'28=1-DLC;8;6=9Q&%&&*@[0?8$@_A6A10 4444 %! (P>0
M:** ,^#0=(M93)!IEI$Y4J62%02#U'3H:=:Z-IME#+%;6%O%',,2*L8 <>A]
M1[5=!))!&!0&!Z4 9_\ 8&D?8C9_V;:_9B^\QB(8W>OU]ZGATVQMQ&(;2",1
M%C&$C VDC!(],U:HH SI-!TB4H9-,M&,:A$S"ORJ.@''2I4TG3H[]K]+*W6[
M;K,(QN/OGUJY10!2BT?3(+HW,5A;).6+^8L0#9/4Y_$TM[I6GZBR->V5O<,@
M(4RQAMH/7&:N44 5)=+L)K%;&2R@:U7&V'RQM7'3 [4L6FV4*0I%:0HL*LL0
M5 -@/4#TSWJU10!7-A9F"&$VL)B@96B0H,1D="!VQ4=WI.GWT\<UW96\\L?W
M'DC#$=ZN44 1K!%')+)'&B22X+N%Y8@8!/KQ531]+BT?3([.)B^TLSR$ %V8
MDECCU)J_10 4444 <?\ $O\ Y%6'_L(VG_HY:["N/^)?_(JP_P#81M/_ $<M
M=A5OX%\_T ****@#D/ O_'QXI_[#MQ_)*Z^N0\"_\?'BG_L.W'\DKKZNI\0!
M1114 %%%% !1110!'!<17*%X7#J&*DCU'!%$\*W$>QBP&Y6!4X.001_*J%S"
M]M>PRV2 O(3YD6XJK#DD^@.3^M.>\O8I4\RS7RVX^63<=Q.!V]\_A0!)?EI%
M6&  W7WXR3PA'<^W;\:BL+*2UM%$#+'N^8HZ$\XQR<Y[5-;M*TEV[1A)<@*,
MYXVC'ZDU4?[-]@\R%E-W_ 2?WAD]#W^H]* -&&8R%DD39*OWESD?4'N*@;4%
M>\FLH$W7,2AB&.% /0YI;EG2ZMWCB#RD,I&[''&?UQ4"2W']IR'[( WDK_RT
M'J: '0:=/#?R7<E_/('.[R"?D7C& /3OS5JUNX[R(R1AU )4AUP<C@\?7(_"
MJT-[=O-)"]EAU)(P_!7. <^^*J:7:7NGV<P:WC-P[.P?S-P(R2H/YT ;=%-3
M<8UWXWX&<=,TZ@ HHHH *A%U 9)4\P!HB X/&,]*I:]I(US2VL&F:)'EC9F4
M<[5<,0,\<XQSFGZ9I4.GV5O"51Y8D"F7;RV!@'ZXH J:7K)NM3NK6:T:V8*)
M-S-D."S*N..X3..H-;,DB1)N=@J^IJ&ZN+>*/$_S*YV%0N[)]"*J*@L$-W<_
MZH*68L<^0,=O; YH JV.J3:EJ)W8M8K>1DVEC_I (^5AD#Y>N.^0?QVI)HXE
M#.X / ]ZS$UZRN+F*",--'*0%D1<@-D\,/X<8[U!X:T9M(MWB-TUPBA8D#KR
MFW.<'/0DD^V<4 1Z'<--<3.X-LOFM\C9Q/D#$@R.!@<#ZUM730^25E; ; &.
M3GM@>M3,H92" ?8C(K.T?2CI<,J--YQ>0R!BN"N?X1_LCH!V&!0!):2L92;H
M&.=AM53T('<=LGKC_"K$EPD+[9#C=]P#DM^%221I*A210RGJ"*HZ;$K0%V+&
M3</G8Y;H.,GM0!?1BR E2I/8]12T44 %%%% !1110!R'CK_CX\+?]AVW_D]=
M?7(>.O\ CX\+?]AVW_D]=?5R^% %%%%0!Q_PO_Y$&S_Z[W/_ */DKL*X_P"%
M_P#R(-G_ -=[G_T?)785=3XV 4445 !1110 4444 4''VC644\I:Q[_^!MD#
M\@&_[ZJ_5*R :\OY.YF"_@$7_$U=H *\YUV]N;R\:43.%9O)\HD;$1AM//J2
MO8?C7HU>7^(3:'5KB:#)MH6\G!)"QN<Y(QG(SGBNC#).1Z6613J/0?J'EP1_
M9X[>,/;2+*3&N5;CL!P&QC/UIIO[YWGB>.WM[B=R"G0QJ%['!'))_/M2HLBZ
M;<7$<Z%Y5C)B:,=_PYR,<\<FK%K:WVNW#))Y:KD&.$<>6!W8>_?'/>NG1+4]
M*\8QO+9=?N_4T?#&AS?:4U!B844#;'\W#8PV,GOW/?M7:U#:PFWM8X6D+E!C
M<1BIJX:DW-W9X6(K2K3YF-DC66)XW&Y'4JP/<&JNENS6*QR-NDA8PL?4J<9_
M$8/XU<JC9_+?:@@Z>:K?FB_X5!@7JH78^T:C:6W\*9G<>NW 7]3G_@-7ZI0_
M-K-TQ_AAC4?FQ/\ 2@"[7FOCN%;76O-/F$7,0/\ JRRD X(ST'';WKTJJ>IZ
M;;ZK9/;7,892/E/=3CJ#V-:TI\DKD3CS1L>3VR,+>X>4F.*W.Y9&/WBQY10.
M2><<>O:M3P_K5Y97T,443)%)((WC8Y1>>>3SFII/ ^JVXG,;0R! '0A]I/'*
M@8[8Z]ZQK6.Z:93]D?$9$TP(/3T9L\'%.6'PSGS<VK.)Q<))[&GKUY%?:C->
M6\R"%G"JS8!('!.#^-4EMU,2N/,0G&P2$#DDDD@'.WC\*V;?PK>ZA;>?'Y"P
M3Y,3=&5",C/MFM:Q\(2I+F[EBVJ!M\HG@YZ<C@5S8>C%3E*KT)=*I-WMN97A
MB>2/68+"":0,P\VXB9R2H'(SC@YZ<5Z'5>UL+2R+&VMXXBWWBHY/U-6*VG*+
M?NJR.VC3=.-F[E#3/W23V?\ S[R%5_W#\R_D#C\*OU2C&W6;@#^."-C]06'^
M%7:@U"BBB@ HHHH **** .0\0_\ )1O!GTOO_12T4>(?^2C>#/I??^BEHJY;
M+T_5@)X6_P"1V\:?]?5O_P"B1785Q_A;_D=O&G_7U;_^B17843W^[\@"BJ6I
M:A_9]NK)$T\\C;(84ZNW]!W)JBNGZU=?/=ZF+?//E6R<+[;CUI*.EV[&<JEG
MRI79MT5D#2[^+F+5IF/I(,THGU:T_P!? EP@ZM'U_+_ZU'+V8O:-?%%HUJ*H
MQZO:/"TC2>7L!+!AR*5GOYX]\ A@!&5$REC^(!&/UHY7U*]HGMJ7:*PI-:O=
M,D U>R"P$X^U6Q+(/J#R*V8IXIX5FBD5XV&0P/&*'%H4*D9.RW)**HRZK;QM
MM7=(?114<>MVI<)+OA8]-ZX%'*^P.K!.US2JI<ZE:6C;)91YG9%&YC^ K.N=
M2GU&];3],; 3_7W..$]AZFM&RTZWL$Q$N7/WI&Y9C[FGRI?$+G<W:&W<C75%
M;!-I>*A_B,)Q^77]*N131S)OB<,O3(I]9US)]DU6T9  MTS12#U(4E3]>"/Q
MI:/8;;CJV:-%%%2:!1110 F1G'>HPX&=J_2I<#.:J3EEG !VKC/'<TT)NQ,E
MPCMMY!Z>V:EJ@'/F JN#]XYJ4W9) 10>,DFFT2I=RU134<.H([]J=4EA14-U
M=P6</FW$@CCR%W'U/2IJ!V>X4444""BBJ']L6G]N?V/F3[7Y'GX\L[=F<?>Z
M9SVHN-1<MD7Z***!!1110!Q_Q+_Y%6'_ +"-I_Z.6NPKC_B7_P BK#_V$;3_
M -'+785;^!?/] "BBBH Y#P+_P ?'BG_ +#MQ_)*Z^N0\"_\?'BG_L.W'\DK
MKZNI\0!1114 %%%% &=?Z;+=SK-!?SVKJNWY.5/7D@_6FR:0TEQ#+]ONL1]5
MW_>^M:=% %**RE@O?-2=I(V4*ZRDDC&>1]>,_2KM%% %>:*02^?!@R8PR,<!
MQ_0^]5?MP_M(P?V=-YVP-YNP;<\Y7=],?G6E10!7@A?S&GG*F5A@!>B#T![_
M %JC/I^H/J_VN&_"0$H##L_A!R1GWYK6HH **** "BBB@ HHHH **** ,33O
M#<-AJ]SJ'FF5IV9RKC[C%B<K^#8YSTK6NK:.\M9;:8;HI5*,/4&I:* *UC86
M^FVYM[6,1P[V<(.BY.2!Z#.:SM(TW4H%MWU'4))I(HU!5" K-@AMW'S=CFMJ
MB@ HHHH CN$DDMI4AD\N5D(1\9VG'!Q69:Z3+)8W5IJ#LT$Y&V-9F8H, 'YS
M@\D$^V:UZ* "BBB@ HHHH **** .0\=?\?'A;_L.V_\ )ZZ^N0\=?\?'A;_L
M.V_\GKKZN7PH HHHJ ./^%__ "(-G_UWN?\ T?)785Q_PO\ ^1!L_P#KO<_^
MCY*["KJ?&P"BBBH **** "BBB@"E9G;?W\9_YZ+(/H4 _FIJ[5"X/V;58+@\
M1SKY#GT;JG_LP_$5?H #TKS/6;:!+V>ST^1FFDS%$EP%V(4.0,]=O4\]?>O3
M*XKQC8S7%Z)(XO, B7)V'Y1N((X&#VSGIBMZ#M*QWY=/EJV;W.>,EQ<OITDZ
MQR*T$MN\CGRT5@>O'7IW JSHU\MMJ(WR3[E :9D88)' P%XP1M&2:@TXVUS?
M7MA.XC6&'8T<KE@GH<C&XY)_.HQ%#$9HHUDEMX0!&K #:A.&X'3GU^M==DTX
MGLRC&2<&OZ?_  _ZGJEO.MS DR!@KC(W#!J2J.DW27-A'L4@Q@(>!C(';'!%
M7J\YJS/F9KEDT%4;'#W=_*.AF"_]\HH_GFK-S<):VTD\GW8U+'W]JBTZ![>Q
MC67_ %K9>3_>8Y/ZFD26JI1G9K5PO_/2!&'X%@?YBKM4-0/V>>UO>B1L8Y?9
M'P,_@P7]: +]%%% "$A1DUQ6H^)9YQ<V\=C_ */(IC&>6)/&[WYQ75:KC^R;
MLE0V(FP",C..#7DWVF!;Z"U+>9YI F>+)9%S@_+]/RS730A%W;.3$U))J,3H
MH/%]SHD0L)X(Y/LCE)6W<E0>0#TR,_I7?6UQ%=VT5S V^*50Z-C&0>AKQNY\
ME;^62'SEC=OW1EP<#MT[_7]:]6\/V<=EHMLB,[%XUD=G.26(&?I]!58B$4E)
M;LTHR;;1IT44UW6-&=V"JHR2>PKD-RI"=^L73#I'%&GX_,3^A%7:HZ6K-;-<
MN"'N7,V#U /"C_OD"KU !1110 4444 %%%% '(>(?^2C>#/I??\ HI:*/$/_
M "4;P9]+[_T4M%7+9>GZL!/"W_([>-/^OJW_ /1(KL*X_P +?\CMXT_Z^K?_
M -$BNPHGO]WY 4;Z5+6>WNI1^Z7<C/\ \\]V,,?;C'XU>!!&1R*1E5T*.H96
M&"",@BL8PW>BDM:AKBPZF$G+Q?[OJ/;M22NK=3.3<'?H;5%5[2]@O8A) X8=
MQW%6*EJQ:::NC(UN)<VC !"\ZH\@'.WFI@]S8\2_O81_'W'UJ35K5KO3W2,?
MO%(=/J*=I]VM]9)+WQAQZ&KO[ICR_O'TN3J\5Q$<8=&&""/T(KD9BFG7$PLD
MG?3O.43!3\L6>I'^?Z5MZH!91"2W5C)(P01*V-V>N/2D@:&QM39W,#+&V0Q8
M9#9ZY]:J&BN9U5SNST:ZFE:I D"FW"B-AD$=_>L[7'DF6/3X(@\L_P#$RY"#
MN:BTF=;2[?3S*'B/S0-GJ/2MRI?NRN:K]Y3ML8T6B3V:@6>H2("!N#J&R?6E
M;2;^5?WFKS X_P"6:X -;%5[F^MK129IE7VSS^5'/)L'2IQ6NB]68OVV_P!#
MO(HM1E%S93-L6XQ@H>P:IY)?[1\26\4/,-B&DD<=-Y& /YU3U2ZNM9L)UM[5
M1:(I<R3#[Q7D8_*M+P[%$FB6SQH%:10[GNS=S6CTCS/<P@W*?(G[N_W?\$U:
M***P.T****  ]*IRG$1W$YJY59UQ"5GD')X--"9"DD)^64$/U 'I3IA#E)-Y
M48QM7O4?V9O-\X8D!&!M[5%-M1OWDF">PY*U6[,[M+4OQ21LP 4J<8 -3$@#
M).![UB3W&Q(E@?.3]X4T1W?VB*7S=D8!+AN3[4^3J1[:SY4C7EFC*'*>8HY/
M P/SJ"?4XX(5E<#8Q !!SG/3I3C%%<P?.A*,!\K$\_6JVGSP7-NXAM9HHXI&
MB"2IM/R]P#V]Z6A:YVK]"[]J /S(1^-5M'LC8PSHVH7-X99VE#7#9*!OX1Z
M=J;;G4));E+F"**-9,6[*VXNOJ1VH6*"QBDD:>15+[F+/G!/;VI6B]2E*I&\
M=[F@LT;2M$LBF1 "R \C/J*?52W6$3R2!$\Y@ T@ !8=LU;J;-;E*2>J"BBB
M@84444 <?\2_^15A_P"PC:?^CEKL*X_XE_\ (JP_]A&T_P#1RUV%6_@7S_0
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M]ZZ88R/]@'K_ +QX^M7;:WBM8%AA7:@]\DGN2>Y/K699+1110 4444 %%%%
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M$Q4N=R6J6AH457LKG[7;ARACD!*R(?X6'458K)JQTIIJZ"BBB@85!/"9&1@
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MFA146,C+$XR>!^I%;%07=I!?6S6]S&)(6(+*>AP0?Z4 9NGVNAWL1-FMM-L
M#^6^[:2,C/-0Q1V]GJ]VUE/#&X**UN9 %D..!CLWO^=:&F:-9:0)19QL@E(+
M98GITZU3G\*Z9<:HNHLLBW(D\PLK=3D'N..G;% &I;74=U&63*LIVNC<,A]"
M*G/ )JAJ*_9D?48N)(8RSJ/^6J@9VGW]#V_&H+'7!?6HG2PO!\S*5V#*D'!!
MYZY% #-)U>_OKGR;K29+9-K'SMX9,@C X[\G\C5K3=5BU)IA'&R&/!^8@Y!S
M@\$X/!X/(JKIVHD6Q7[#>\2R?\LA_?;WJ+3)IK-KPR:?=@2W#2+A%.0>_!H
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M0 4444 %(0&!! (/!!I:* */]E0QMNM9);4YSB%L+_WR<C]*40:@O2^B8?\
M32#G]&%6)[F"V7=/-'$#T+L!FJXU6T;_ %9ED]TA=A^@H #;W[_>OU4?],H
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M0"[6.U+E!A&/HP_A/Z'U[5H4V2-)HFCD171QAE89!% #J*SK4O87*V$K,T+
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M/$/_ "4;P9]+[_T4M%'B'_DHW@SZ7W_HI:*N6R]/U8">%O\ D=O&G_7U;_\
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M !+_ .15A_["-I_Z.6NPJW\"^?Z %%%%0!R'@7_CX\4_]AVX_DE=?7(>!?\
MCX\4_P#8=N/Y)77U=3X@"BBBH *S5URSE8K;%[DJ2&$2DE< GI[[2 ?6M*J5
MCI5GIK2&TB\OS,;\'[QR>?KS0!"EG>2R/<O=O:O)C]U$J,% SC)(.3SR1_3-
M),NI0WD+CR[FU1?G!4"0N3@$=L $Y]>/>M2B@#"N="N+K6I;F6[8V4F%:V5V
M7*[".QQUP?ZUK6EI!8VRV]NFR)22%R3C)R>ON:GHH **** "BBB@ K,MK O8
MR6-];120&1WY;<&S(6&1CZ5IT4 5TMTLXI/LEN@+OO9 =H)/4UEQZ1=R(D%U
M+$]DX=9[9AN5@Q/'3W%;E% $<5O%!O\ *C5-[;F"C&3@#/Z"I*** "BBB@ H
MHHH *S->@U&XTX1:8T:SF123)TVCG^8%:=% &99KJPND-U(C0?O=P"@'JNSH
M?3<*S!#XEAUR26/R&LIK@%A\N0@..3U^Z!P,_4=*Z:B@ I'4.C(>C#!I:* ,
MO2] LM(D,EJ'W%-A+MN)''4]3T_#-:E%% !1110 4444 <AXZ_X^/"W_ &';
M?^3UU]<AXZ_X^/"W_8=M_P"3UU]7+X4 4445 ''_  O_ .1!L_\ KO<_^CY*
M["N/^%__ "(-G_UWN?\ T?)785=3XV 4445 !1110 4444 9]^/M5Q;V'5)"
M9)O=%QQ^)('TS6A5&V'F:I>RG^#9"OT W'_T+]*O4 59X7$$WDL<LI(3CD^V
M>F:YNQ\1&U0VBVLLDL39E5OEV ]AGJ:ZZL_5M,.HP*(IC;W$9S'*!G:?IWKD
MQ%*I\=)V:.JA5A\-573+ZG<H.",C.#U%+7':'J,.G74T=YJ3,7.'6;)8OG&<
M<X%=B"" 0<@]ZO#XB-:-UOV(KT'1E9[!111708%:_MC=6C(AVRKAXF_NN.0?
MS_2GVEP+NTBG QO7)7T/<?@>*FJCIX\N2\@SPDY*CT# -_,F@"]5'4V:2.*S
M1B'N7V$@\A,98_EQ]2*O51 ,FML3TAMP /0NQS_Z * +3#R;<B%!\B81!TX'
M KGW"#15U"*^F^W,H(;S"=TA_@V=.O&,<5TE9:6L \1RR""/?]G5MVT9R6;)
M^M;4I6O_ %\CGKP<K?=_P2Q;Z9;0*Y*>;)(,223?,S^Q)[>W2L^:RBM]1M[0
M7$T-E,K'RA(0I<8PH/4#!)P#VK<JKJ,4<VG7"R(KKY;'##/.*4*CYM7N.I2C
MRZ+;^OQ*VG$17]U:PRM+;QA2-S%O+8YRN3STP?;-:=5-,BCBTRV6-%0&)20H
MQR0.:LNZQHSNP55&23T J9N\BZ2M!7'5#=6Z7=M)!)G:XQD=1Z$>XZU4CU>)
MVC+6]Q'#*0L<SIA6)Z=\C/;(K1I2BX[E1G&6Q5TZ=[BS4RX\Y"8Y<?WE.#^?
M7\:M51MAY>J7L?\ "X28#W(*G_T 5>J2@HHHH **** "BBB@#D/$/_)1O!GT
MOO\ T4M%'B'_ )*-X,^E]_Z*6BKELO3]6 GA;_D=O&G_ %]6_P#Z)%=A7'^%
MO^1V\:?]?5O_ .B17843W^[\@&E%9E8J"R_=)'(IU%%0 4444 4;_1]/U,8O
M+6.4]G(PP^A'-<WJ7A_[%=Z=#8WES'%-/M??)NV#'!7WKLJI:G:/>696(A9X
MV$D1/3<.F?Y5I"HT[7T.>M0A--VU*']@7!/SZU?,/3<!4T/AW3XVW2+).WK,
MY/Z=*N65ZEY%G!CF7B2)N&0^_P#C5B21(D+R.J(HR68X I.<]AQI4K<R7]?,
M:?*M8"<+'$BDG P !6;H:M)'/>.,&XD+ >@_S_*JLMT_B"?[-9[A8(<RW&,"
M0C^%?4?Y^N]&BQ1JB !5& !0_=5GN$7[27,MD.HHHJ#<**** "BBB@ HHHH
M**** "J]W;-=0B-+B2 A@VZ,X/':K%% T[.Z @$8/(K(CNOM&L7=@MA,JVR(
M?.ECQ')NYPC>H[UKT47:V$U%IJ2,]RUI PA@R1RL8;;D_P J1[AX[0R,C%PN
MXQ;QG/H*T:;Y:?W%_*JYD9\C[F9EOLF;:"."4C*@H"%SUSCO4R6*27"7+I^]
M52H8]>>O%7\8'%5[/[48/],$0EW'_59QC/'6CF[#5.ZNV3)&L8PHQZ^](\4<
MI0R1HY0[E++G:?4>AIEW=V]A:2W5W,D-O$NYY'. H]Z?%+'/"DL3AXW4,K*<
M@@\@BIN:)-*ZV'T444""BBB@#C_B7_R*L/\ V$;3_P!'+785Q_Q+_P"15A_[
M"-I_Z.6NPJW\"^?Z %%%%0!R'@7_ (^/%/\ V';C^25U]<AX%_X^/%/_ &';
MC^25U]74^( HHHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BFR2+%$\C9VHI8X&>!5'3=534691$T;"..89.04?.TY]>#D=J -"BJE
MSJ-O;2>07!N2A>.'N^ >!^1_*K*,6C5BI4D D'M0 ZBLM]<MR@DM4DNT .XP
M*6*GY<#'N&S^%6K^_BTZ!9YE<QEPA91G;G@$^V<#\: +5%0VSSO&S3QA#N.T
M#KM[9]ZFH **** "BBB@ HHHH Y#QU_Q\>%O^P[;_P GKKZY#QU_Q\>%O^P[
M;_R>NOJY?"@"BBBH X_X7_\ (@V?_7>Y_P#1\E=A7'_"_P#Y$&S_ .N]S_Z/
MDKL*NI\; ****@ HHHH **** *5CQ<WZ]Q/G\T6KM44_<ZU*AZ7$0=?]Y>#^
MA6KU !1110!SGB'364B_L[!)Y.DZ( 'D''>ETK6KV1YH[K26M+:!!A]W3&/E
M.>^"*WIH4GB:)\[6ZXK*U*R^Q^'+Z*V#S.RL_P"])8L3Z_A_*N*=%TYNK!V5
MKO\ JQV0JQG!4YJ[O9?U<V 00"#D'N*6N=\-#REV/?)*[Q@B%5*[<=^>O6NB
MKHH5?:P4K6_$PK4_9S<;W"J5I_R$=0/;>@_\<%7:HZ5\]M)<\_Z1*THS_=Z+
M_P".@5J9%ZJ4'&KW@/>.(C_QZKM49?W.LP2'[L\;1'_>'S#]-U %ZJEW8+<2
M">.5X+E1M65#V]".A%6Z*:;3NB914E9F/;R:I>/.GGV\/V=_+W+&6\QL YP3
MP.1Q^M);QW.KPEKR41P!F1H("1O*D@[FZXXZ"GZE;)%/'-'+/"]Q*D4GE/MW
M9XR>#S[BM*W@CM8$AA7;&@P!6TII*Z_KN<\:;<N63T7GOV_K\RE);W=HYELG
M\V+C-M(< ?[C=OH>/I5>6ZGUBWEM;6W:)&!CEEG&-AZ$ ?Q$?E[UKR2)#&TD
MCJB*,LS'  K+T6Z@F^U(D@+F=Y I!!*D\'![4HM\KE;8<XI24+Z/H#P:C=11
MVEQ'"D2LIDF5\[PI!X7'&<?A6M116<I7-HPY>MRDG.M38[6Z9_%F_P *NU1L
M#YMS>W/\+R^6ON$&/_0MU7JDL**** "BBB@ HHHH Y#Q#_R4;P9]+[_T4M%'
MB'_DHW@SZ7W_ **6BKELO3]6 GA;_D=O&G_7U;_^B1785Q_A;_D=O&G_ %]6
M_P#Z)%=A1/?[OR ****@ HHHH **** ()[2WN2#+$K,.C="/Q'-5FT/3Y'#R
MP&8@Y'FR,X'X$XK0HIJ36S)<(O="*JHH5%"J.@ P!2T44B@HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *SM.UB+4K[4+2.WN8FLI1&[RQ[5<D9RA[BM&
MBD4FK.Z"BBBF21SV\-U \%Q$DL+C#HZAE8>A!IR(D<:QHH5% "JHP !V%.HH
M'=VL%%%% @HHHH X_P")?_(JP_\ 81M/_1RUV%<?\2_^15A_["-I_P"CEKL*
MM_ OG^@!1114 <AX%_X^/%/_ &';C^25U]<AX%_X^/%/_8=N/Y)77U=3X@"B
MBBH **** "D)"C)( ]32UG7<%Q-JEJ/-7[)L;S83_$005/X4 7S(BNJ%U#MD
MJI/)QUQ3N@S65JLM[%/"UA LT^QAM8X&W<F3^ J)H[Z,)9PW,LP>0K+))@/&
MF!RI'?F@#821)4#QNKH>C*<@TZJ>EC;IT0R3@L,GO\QJY0 F1G&1GKBF1S)*
MSA-WR-M)*D#/MZU1TFUGC\Z>[E6:X9V02#C$88E5_#)YJJ7O)+JYMU1X[4;Y
M!<QGD2!ONXSR,4 ;$T\<";I#CT &2>_ [TY'62-9$.58 @^QK,BMYFNKFZ>Z
M:6#R]J1D8 8* 6'UYJ]9?\>%O_UR7^0H GHHHH **** ,VZUNV@9HX0US+'(
M$ECA&YH\]R!_GFKT$PN+>.9591(H8*XP1GL1V-4;?1H;;5+N_660R70Q(N>
M.,8[C\.OX"F,U]I5M*S,;ZWBC++N8+-QT4GHWIDX]\]: -6N<\*RR2"<.Y(\
MJ)L'U.[)_05=BO[G58MVGA88MS*T\O+*0<$!/[P/KTQWJ*UT1]&R^ERM)N51
M)%<R%M^.X;^$\GMCV% %RYTBVNM0COWWK<Q(41T;!4'.?YU!'J4EO82I./,O
M8&$.P<&5C]PC_>X/MSZ4+KBS326EO:3O?1 >; V%$>>A9NF#@XQGZ5%)I%[-
M?Q:F]U$MY"I5(E3,6#V;N3UPW&,GCDT 6])TBWTBW,=NNWS,-( 207Q@D9]?
MZ55\32O%IL>P@!YU5@0"".3W]P*GDU9K46ZWMG+%)-+Y*[&5E+XXYR.#VR!^
M'%5;O2[_ %>TCM;R?[-&C!C+"0968>F1M4<^AS[4 :MC(TFG6TDC99HE9F/<
MX&:L=:PQ<3V,:VEXFZTB 0W,*Y& !A74@D9'4C(^E;:X*@KC&.,4 +1110 4
M444 %%%% '(>.O\ CX\+?]AVW_D]=?7(>.O^/CPM_P!AVW_D]=?5R^% %%%%
M0!Q_PO\ ^1!L_P#KO<_^CY*["N/^%_\ R(-G_P!=[G_T?)785=3XV 4445 !
M1110 4444 4]1AD>))X%W7%NWF(O][L5_$9'UQ5BWGCN;=)XFW(XR#4E9LJ2
MZ;</<P(TEK(=T\2C+(?[ZCO[C\1SG(!I44R&:.XA66%U>-AE64Y!I] !1110
M!2@TZ."X$RQ1%QG$F,-@]<^M68I"Y977:Z]1V^H]JDJK>7R6I6-$,MS(/W<*
M]6]SZ#U)J(P4?A*E-R^(BU*1I%2PA)$MQD$C^"/^)OZ#W(JZB+&BH@"JHP .
MPJM96CP;YIW$EU+@R.!P/15]%'_U^]6ZLD*K7]LUU:E8R%F4AXF/9QR/P['V
M)JS10!!9W2WELLJ@J>5=#U1AP5/T-3UGW$$MK<M>VJ%]P'GP#_EICHR_[0'Y
MCCTJW;7,-W")8'#H>/0@]P1V/M0!'=VINO(P^WRIEDZ=<=JLT44[NUA)).Y1
MU6"2>T7RD$ACD20Q$X\P*<XJ!6DO]2M9EM9H4@W%GF7:3D8V@=_7TXK5HJE.
MRL9RIWE>_;\ JIJ%R\$*QP8-S,=D(/KW8^P')^E/N[R*S0%]S.YQ'&@RSGT
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M  G5Q_T)OB;_ ,!4_P#BZ/\ A.KC_H3?$W_@*G_Q==!_;FD?]!2R_P# A/\
M&C^W-(_Z"EE_X$)_C1I_*!S_ /PG5Q_T)OB;_P !4_\ BZ/^$ZN/^A-\3?\
M@*G_ ,770?VYI'_04LO_  (3_&C^W-(_Z"EE_P"!"?XT:?R@<_\ \)U<?]";
MXF_\!4_^+H_X3JX_Z$WQ-_X"I_\ %UT']N:1_P!!2R_\"$_QH_MS2/\ H*67
M_@0G^-&G\H'/_P#"=7'_ $)OB;_P%3_XNC_A.KC_ *$WQ-_X"I_\770?VYI'
M_04LO_ A/\:/[<TC_H*67_@0G^-&G\H'/_\ "=7'_0F^)O\ P%3_ .+H_P"$
MZN/^A-\3?^ J?_%UT']N:1_T%++_ ,"$_P :/[<TC_H*67_@0G^-&G\H'/\
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MQ9B91_RTMF'_ *"V"/P)IW]JVP'SK<1GT>!Q_2KM% %(ZI 1^[CN93Z) _\
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MYZU<HH **** "BBB@ HHHH **** "BBB@#D/'7_'QX6_[#MO_)ZZ^N0\=?\
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MG9Y.=WD%WZ_[&,<=*BL+"X6[T]187::U'J#27EXRD*T.YL_/T92NT!>WH,4
M=KI^H0:E9BZMRWE%V3YA@Y5BI_4&K5<#%I\L-OI7]JZ=<S:=&]V98%B+[9&E
M)C9D')&W..#C-1PV<\2Z/'JME<W%F5NO+LMVZ6,%P8RRYR<)QGG;D4 >A45Y
MK:O=Z=X;T75].1FN)3-8F)GR3YDC>62>^U@/P)KJ-2TJYL_ \NF::9))XX @
M*MAY.07P?5AN_$T =#D8SD8]:7(QG-<%>6T'V%DT[0[J"QDNXC+YL#LH 4Y8
M0 @D9P#V)YYQ1I>BSW,.CVU[93FUBN[MGCE0J A#;-RYX7D8'3M0!WC,%0L>
M@&:KZ??PZG807MN6\J9 Z;A@X/J*RO#=K/::#-:RQ21^7/.L*/G(CWML SVQ
MC'M7,:/I=U%!I$=AIEU9:A!;RB[FE0H&RA"@MT;Y]I'ICM0!Z+D'O1D9QFN&
M\(:?/;ZE;R-%=1.EH4N=UJ8E:3*_?8L?,;.3N'8GGFH/%5I>W>LW1BL)S*@@
M^S2Q0-(S@,"S"3.(\<@@#)]Z /0,T9KSB\@6ZOO$$=O9W4NJG4$%G.BL5B.V
M,YW=% Y)Z9'K23VXN;G7$MK.[DU8ZF!:7"*VV+&S)#]% YR.^>] '<1ZQ!-(
MZ0Q7$ACNC:.4CR$8#))]%Y'-:&1G&>:XT:??"]#"VF"_\) 9R0/^67E8W?[N
M:S=)TS4UU")G6X34T:X\Z7[+M5B0VTO*6PZDE2 !Q@=,4 =U/J$%O?VEFY;S
M;K>(\#(^49.?3BI#=0"\6T,J_:&0R"//)4$ GZ9(KA]#TWR]7\/21Z3=V]Q!
M#*M_/+&0#(4 R6/WB6R<\]:TM8TZ0^+5N[>S8S2Z=+%#<K'D1S_PEF_AXSR:
M .LR#WHR!U-<1X?LRFK:4]EIUW9F&V==2>9&42.0, D_?;=D[AGCOS47C6TN
M[V_N(X["9V6RQ:RQV[2EY"22 <@1D8!SU.?;% '>45@Z]:W4N@07%O')+>V3
MQ7,<8^\[+C<OXC</QKG;#1]6&J6T,\,_V;49$U&]=C\L4BEF,7MG]V,?[)H
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M^ B?X4?\(EX<_P"@!IG_ (")_A1]<78+'QUN7U'YT;E]1^=?8O\ PB7AS_H
M:9_X")_A1_PB7AS_ * &F?\ @(G^%'UQ=@L?'6Y?4?G1N7U'YU]B_P#")>'/
M^@!IG_@(G^%'_")>'/\ H :9_P" B?X4?7%V"Q\=;E]1^=&Y?4?G7V+_ ,(E
MX<_Z &F?^ B?X4?\(EX<_P"@!IG_ (")_A1]<78+'QUN7U'YT;E]1^=?8O\
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MGB9[S38;>#>1G<JMD'TY(I=7\,7=X;I+2.*))-*2V&&"Y=7W;3CMCC/O0!T
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MMX<TK^Q= M+%CNE1,RMG.YSRQSWYK5I%W%1N #8Y ]:6@ HHHH **** ./\
MB7_R*L/_ &$;3_T<M=A7'_$O_D58?^PC:?\ HY:["K?P+Y_H 4445 '(>!?^
M/CQ3_P!AVX_DE=?7(>!?^/CQ3_V';C^25U]74^( HHHJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]DUO?Q2SW<K7P03222Y?*?=(../Y5=O-*AO]-6RN))G52C++OQ(&4@ALCOD
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M%/\ V';C^25U]<AX%_X^/%/_ &';C^25U]74^( HHHJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#D/'7_'QX6_[#MO_)ZZ^N0\=?\ 'QX6_P"P[;_R>NOJY?"@"BBB
MH X_X7_\B#9_]=[G_P!'R5V%<?\ "_\ Y$&S_P"N]S_Z/DKL*NI\; ****@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH Y#Q#_R4;P9]+[_T4M%'B'_DHW@SZ7W_ **6
MBKELO3]6 GA;_D=O&G_7U;_^B1785RVH?#_1M2U:YU*274H;FZ*F4VU_+"K$
M  <*0.@JO_PK71O^?[7?_!M/_P#%5349:W [&BN._P"%:Z-_S_:[_P"#:?\
M^*H_X5KHW_/]KO\ X-I__BJ7)'N!V-%<=_PK71O^?[7?_!M/_P#%4?\ "M=&
M_P"?[7?_  ;3_P#Q5')'N!V-%<=_PK71O^?[7?\ P;3_ /Q5'_"M=&_Y_M=_
M\&T__P 51R1[@=C17'?\*UT;_G^UW_P;3_\ Q5'_  K71O\ G^UW_P &T_\
M\51R1[@=C17'?\*UT;_G^UW_ ,&T_P#\51_PK71O^?[7?_!M/_\ %4<D>X'8
MT5QW_"M=&_Y_M=_\&T__ ,51_P *UT;_ )_M=_\ !M/_ /%4<D>X'8T5QW_"
MM=&_Y_M=_P#!M/\ _%4?\*UT;_G^UW_P;3__ !5')'N!V-%<=_PK71O^?[7?
M_!M/_P#%4?\ "M=&_P"?[7?_  ;3_P#Q5')'N!V-%<=_PK71O^?[7?\ P;3_
M /Q5'_"M=&_Y_M=_\&T__P 51R1[@=C17'?\*UT;_G^UW_P;3_\ Q5'_  K7
M1O\ G^UW_P &T_\ \51R1[@=C17'?\*UT;_G^UW_ ,&T_P#\51_PK71O^?[7
M?_!M/_\ %4<D>X'8T5QW_"M=&_Y_M=_\&T__ ,51_P *UT;_ )_M=_\ !M/_
M /%4<D>X'8T5QW_"M=&_Y_M=_P#!M/\ _%4?\*UT;_G^UW_P;3__ !5')'N!
MV-%<=_PK71O^?[7?_!M/_P#%4?\ "M=&_P"?[7?_  ;3_P#Q5')'N!V-%<=_
MPK71O^?[7?\ P;3_ /Q5'_"M=&_Y_M=_\&T__P 51R1[@=C17'?\*UT;_G^U
MW_P;3_\ Q5'_  K71O\ G^UW_P &T_\ \51R1[@=C17'?\*UT;_G^UW_ ,&T
M_P#\51_PK71O^?[7?_!M/_\ %4<D>X"_$O\ Y%6'_L(VG_HY:["N-_X5GH)D
MB>6XU>812+*J3:E,Z[E.02"V#R*[*E*R22 ****@#D/ H_?^*3_U';C^25U]
M<E<_#G1+F_NKWSM4AENI3-*+?4)8E+GJ=JL!4?\ PK71O^?[7?\ P;3_ /Q5
M:M1D[W [&BN._P"%:Z-_S_:[_P"#:?\ ^*H_X5KHW_/]KO\ X-I__BJ7)'N!
MV-%<=_PK71O^?[7?_!M/_P#%4?\ "M=&_P"?[7?_  ;3_P#Q5')'N!V-%<=_
MPK71O^?[7?\ P;3_ /Q5'_"M=&_Y_M=_\&T__P 51R1[@=C17'?\*UT;_G^U
MW_P;3_\ Q5'_  K71O\ G^UW_P &T_\ \51R1[@=C17'?\*UT;_G^UW_ ,&T
M_P#\51_PK71O^?[7?_!M/_\ %4<D>X'8T5QW_"M=&_Y_M=_\&T__ ,51_P *
MUT;_ )_M=_\ !M/_ /%4<D>X'8T5QW_"M=&_Y_M=_P#!M/\ _%4?\*UT;_G^
MUW_P;3__ !5')'N!V-%<=_PK71O^?[7?_!M/_P#%4?\ "M=&_P"?[7?_  ;3
M_P#Q5')'N!V-%<=_PK71O^?[7?\ P;3_ /Q5'_"M=&_Y_M=_\&T__P 51R1[
M@=C17'?\*UT;_G^UW_P;3_\ Q5'_  K71O\ G^UW_P &T_\ \51R1[@=C17'
M?\*UT;_G^UW_ ,&T_P#\51_PK71O^?[7?_!M/_\ %4<D>X'8T5QW_"M=&_Y_
MM=_\&T__ ,51_P *UT;_ )_M=_\ !M/_ /%4<D>X'8T5QW_"M=&_Y_M=_P#!
MM/\ _%4?\*UT;_G^UW_P;3__ !5')'N!V-%<=_PK71O^?[7?_!M/_P#%4?\
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M_P"AMU?_ +YMO_C5'F:__P!#;J__ 'S;?_&J/J\NX'K%%>3^9K__ $-NK_\
M?-M_\:H\S7_^AMU?_OFV_P#C5'U>7<#UBBO)_,U__H;=7_[YMO\ XU1YFO\
M_0VZO_WS;?\ QJCZO+N!ZQ17D_F:_P#]#;J__?-M_P#&J/,U_P#Z&W5_^^;;
M_P"-4?5Y=P/6**\G\S7_ /H;=7_[YMO_ (U1YFO_ /0VZO\ ]\VW_P :H^KR
M[@=3XA_Y*-X,^E]_Z*6BL3P_87=WXNTV^U'6M0OY+19O)6<1!5WIAON(I[#O
)16=2/+9,#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img148560552_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148560552_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #D K@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKCVU?5GNQI\5U!OC:0-<;,APJ!NGKSBNDTF[>^TJVNI  \J!B!TS0!<HHHH
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M'S5G 3<%RPQR>E %^FR?ZI_]TU3LM7LM1DDCM9@[1\L,=O7Z5;D(\I^1]TT
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M">)%'W?J/ZTI2YBJ=-0UW;+E%-CD25 \;AE/0@Y!IU2:!1110 4444 %%%%
M!1110 5'-<0VZ;YI%1?5CBDN)3# [JNY@.%]369;Z(LS?:=38W%PW.TGY$]@
M*I);LB4I7M%$W]O::3A;E6]Q4L6K6,IPMPN?2IEL;11A;:$#_<%1R:99R=;=
M![J,?RI^X3:KW1961'&58-]#3JRSHXC.;6=XC_=)R*!<WEF/])3?&.KK1RI[
M,/:27QHU*:'1CM#*3Z9JE;2B^!>1QM)^5%/;UI+G1K.Y'*LC]G1B"*5DG9CY
MFU>)1\1Z"VK10M;%8YXS][IE?2L_1/"\]OJ@O+Y(L1@A%7D9]:O-_:NBG=O-
M]9CKG[Z#^M:<&JVEQ:BXCD!7N.X^M:7FHV6J.B&/FJ;I/0NT5G_:+JX!,$>U
M>S-Q3#'JJ'<)(Y/]GI6?+YG/[3LF:=5+S48+/"N=TA^ZB\DUDW>O7$*-;>2J
M7G8,>/K5K3+2WMU^T37"37+<M(3T]A5<EE>1G[;G?+#_ (8>HU.\^8LMI&>@
MQEJD33[A6W'4)V/H>GY5.VH6:'#7,0/^]4\<B2KNC=67U!S2;?8N,(][OU(C
M(T 7SF#*3C?C&/K4]5-3*KIER6. (R<^].TZ1I=.MW;[QC&?RI6TN4G:7*6:
M***DL**** "BHY[B&VA:6>58XUY+,< 5S\NN7^JL8=!M<IT-[.,1K_NC^*@#
M4U;6K'1;;SKR8)G[B#EG/H!WKFC8ZQXQ</J'F:=H^<BV4XDF'^T>PK8TSPO;
M6EQ]MO9&O]0/)GFYV_[HZ"MV@"M8V%KIMHEM9PI#"@P%48JS110 4444 %%%
M% !1110 4444 %>>ZF]U]NU*<1RE%N%C6Y$Y409Z$KZ UZ%4!LK8I,AA0K/_
M *P$?>^M '+R>(M1CU1H(H3+#;LL<A 7]Y\N2V<Y_2I#K]]#I=QJ+O;RHRYB
M@3[\9W8&?6MXZ18&XCN#:QF6, *V.F.E":1I\<D[K:1!IP1)\OWA0!S4>OZO
M(L5NWDP2O+M\Z90 1C/0'K4,6O:D;N:<W$6'2.)4(^56) +_ $K?G\-:?*+>
M-852&)RY0#[Q]S5Q](L'^]:QD>7Y6,?P^E &'#K&ISW\.G)-;F19G22<)D.J
M@'@=CS74U5M]-L[58A#;HGE9V8'(SUJU0 4444 %%%% !1110 445G:S*\5I
M$J,5\V9(V8=E)YH 9;:%:6\EQ-Y:-/-([^:5Y&ZJDWAQC%&EO>>4?*,,I,0;
M>A.>/0^]4)=5U*.YFCM6B2.%W9@X+%P& Q^1JNWBV\_M5XX1'+&8W(CVD%2H
MSTZTP-/_ (17#"-+PBU5F=8S&"02.<MWI]WX;:>3Y;LK P0R1!!\Y7ISVK.F
MU.\D2SD&I02()'#M$I"O\I(4^]6(];OH_+M1"'F,(N$P#S&%Y'USQ0 _P[IN
MH175S-?@*AC$,2@ ':,^G7ZU<D\,Z=L<XFZ'_EJ:QK/6]1U#2KV:?RD,.V2-
MHI 2"3]T@5UVXO:[B,$IDCTXI,#-\+@+X9L%'01X'YFM>LGPS_R+=C_US_J:
MUJ "BBB@ H!!Z'-(1D$'O6/-IU[9,TVG7&X=3#,>#^-4DGU(G)QV5R32CB]U
M!!T$N<5JUS6BZG$+BY-T#%)(_P!XCY"1V!J]J^H.D:6MF=\\_"D'H/6KE!N5
MC&G5BJ7,97B._N]3D.B:1S+)Q-+V05QNJ:=<Z/?Z=8W 3YV+DYX8#^N:]/TK
M2X]-M]H^:9^9'/4FN1U>P'B3XA0V[?-;6$'[PCL6YJXS5^6.QM0FX)^UU4FM
M.WIYKN9T7E+/;^1"7+2#9&.2?;->D>6MS;JL\0^8<H><5SK:-'H5Q#=P.TD0
M<!E;^'Z5TX(8 CH:BLU*SZ&]3$.K[DM7'KW71_Y^9D7'ARSGP TL:@Y"JW J
MA/HAL9A.5:[MU^\A/(_QKIZ*QHQC1NJ:23WL<M2A">KW(+2>">V5[?&S&,#M
M[5/7/^>;/59IH!_HP8"8#MGO70 @C(Z5<HV'2GS*SW04445)J%! (P1D444
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MPHD:^4T8 5X^"*+2XFBG^R7>#)C,<@Z./\:4K2;:+IW@E&1?HHHK,V"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 W<:-QHHH -QHW&BB@ W&C<:** #<:-QHHH -QHW&BB@
MW&C<:** #<:-QHHH -QHW&BB@ W&C<:** #<:-QHHH -QHW&BB@ W&C<:**
M#<:-QHHH -QHW&BB@ W&C<:** #<:-QHHH -QHW&BB@ W&C<:** #<:-QHHH
M -QHW&BB@ W&C<:** #<:-QHHH -QHW&BB@ W&C<:** #<:-QHHH -QHW&BB
M@ W&C<:** #<:-QHHH -QHW&BB@ W&C<:** #<:-QHHH -QHW&BB@ W&C<:*
M* #<:-QHHH -QHW&BB@ W&C<:** #<:-QHHH -QHW&BB@ W&C<:** #<:-QH
=HH -QHW&BB@ W&C<:** #<:-QHHH -QHHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img148560552_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148560552_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #U J # 2(  A$! Q$!_\0
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M%N%Z'LX]:V:4HN+LPC)25T%%%%(H**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!CINH:,%-O:GTAZ'F@#*GG\F4(HW-UYZ"HY6:X8*VT-U&*+E"9
MRR$&H%Y9B6^?&!CH*M;&;W+-E<00RL6<LW3(' K5::-(][. OKFN90M$-JJV
M_L,5+<B6.UA69L!>30U=A%V1OQ7,,YQ&X)J6N>M)7DN8EAY&<DCTK<68-*4
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M(#R?4UJ-MN+1GC7!Z5@7#R6\3*JMN[8%6C*1T"W5B""&&[N,9Q2W=M%>PY#
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ML5))/9[D5I(MM<VUW'D<[9>>3VKH-2T>#5;FPN)'96LYO.0#HQ]#7,16GV"
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M%Q#!$RR((5V*4<@E>ZGU%,D\.Z8;E9S&R8(P@?"9 P#CUQ7-MJ>L-KY%NMV
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MBF04=:MUN]$OH&&0\#C]*SO!-R;KPAI[L<LL>P_@2*VYQFWE![H?Y5S7P_\
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M5[;K/ VZ-LX./0XH FHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@"Y156SU&SU!7:TN(Y@APVP]*M4@"BBB@ HHHH **** "BBB@ HHHH ****
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M,\J]Q#&7(]\4 6J*SM/UJUU&V^T(LT,7&UITV!L^F>M71/"7*"5"P&2-W.*
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M:8B:E=2/((@D2E0/)[_B::WB/48IY+ETMS8I<-#Y:@^8<+G.>E2:5>ZA=:_
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M?AL$0F+8!QUSFKM06<[7-G#.T9C:1 Q0]1[5/0 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
; %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img148560552_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148560552_5.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" UO" (# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:U.HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4$L=112$T"%HI-U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %1R5)434"8S!HIU%4B1M.
MW?6FT4FAH=3EZ4Q:6D4/W>]+NJ+<:4$T6 5NGXTQJ=4;4 +NI=WTJ&E#&J2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ&EL7HZL1U6C:K$9KIB=:)EJ2HUJ2NJ(F%%%%6(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS[>C\)(?NBA:/X:2NKH;DBT\=*8M/'2I 6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7.^'?]6OT%=(OW17KTS[6E\(E/I,"EKMZ&C)%I:1:6D4%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7\*Z5?NBN<\._P"K6NC7[HKUX;'VE-6B+3Z93U[5U]"KDBTM(.E+2+"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *:U.IK4 )11100%%%% T-:D/WA2M2'[PH*"
MBBEVF@;(FI*<U-JS/J2+3P,4U:?6;9HB.2LC4F^0UKR]ZQM2^X:YY:&<D>?>
M*6_=O7@GCUN9/QKWCQ5]QZ\$\>_>DKS:SN?,8X\,\2?ZQOK6-:_>%;'B+_7-
M]36/:_>%>)5/BJGQ'0Z>.E=+8KP*YG3VY%=/8M\HKR:IT4C5A7BIJBC/ J3=
M7F53TH;#J=2+3NP^M<+.B(]14BTQ:>M9LZ8DJFI%:H5IZM0MS0ES130U+NIL
MT1*M3+59&J=6XJ2TQ6J%C3V-02-2;'<&:FEO>HFDJ)I*D5R<M3E;I599.*>L
ME!%R]&]3JU4(Y*LQOQ5Q8)EBF-2J:*O<M$+"HVJ9A4+5DXE,:S4S=1(^VH6>
MA(S;',U,9J:S4QFJCEE(<6J-J-U)56.=R&,U025,U1N.*ZZ<3*>Q0N*P=0[U
MT%S]VL'4.]>M3B>55.9ON_UJM8_ZU?K5F^[_ %JM8_ZX5Z]$YX[GI?@S_6Q5
M]%^ ?N)]*^=?!J_OD_"OHSP"ORQ_A7MT8GU& W1[7H*_NQ^%= %^45A:"/W2
M_2M^O7@C[6'PC<&D(S3FIM="&Q56I!TIBT\=*3!"TUAS3J*0QO-.HHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !36IU-:@!****" H[T4I[4#0P]:2EI*"@HHHH&QC*:
M.E.:HFJS+J2*U/5JA4FGU!JA\C<5C:HW[MJU)&K&U1OE-831G4V/-O%WW'KY
M\\?+_K/QKZ"\6?ZMZ^?_ !Y_RU_&O,K'RN.V/"]>7,S_ %JC8)\U:>N+^^;Z
MU4L4^85XM8^/FO>-[3UZ5TEI]T5S]BNW%;UG]VO&J'131JPGI4V[BJT-3UYM
M0[XC&[U'4S5&PK$Z8H1:D5J92;\5!J3;OK2AA51IJC:ZQWJE S9JI(*L1R#(
MK#6^'K4T=^/6MHP(CN;RL*E7%8L=\,]:M1WP]:M19N:# 4SBJOVT>M,:\'K5
M<I42>0"JK@9IDEX*KM=#GFCD+L7$459CK+6\'K5B.\%<_+J6D::]*0XJFMT/
M6E^U#UJ7 LF;'-0L:B:X'K4$EQSUK/V9-B29JJ2-S39)^#S59YO>J4682+ ;
MFIXVK-\^IXYO>J<2>8TE:EW546:IEDI6L8R9)33UHW4C-3$A=U12MQ2LU02-
M6L3.6Q1NSP:YK4AG-='==#7/Z@O6O1H[GF53E[N/YC4NEQ_OJ==+\U/TO'FK
M7LTWH<\%J>K^!U_>1_6OHSP']V/Z"OG/P2W[Q/PKZ+\!M\D?TKTZ)];E^Z/8
M]%_U:_2M=AQ61HI_=K]*V&^Z*]:F?8KX2/;2KVH:A>U=2 E6I*C6GCI5@+11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8O6I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7L[#Y3R-?!*_\\_TIW_"$KQ^[_2O6O[)3^[1_9*_W:.45CR;_A"5_N?I2_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/S\L7X5[KX8^ZE=43O@=_I_3\JUH?NUE:?\ ZL5KQ=JT.R),M+2+2T %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH C:F
M T^3K3.E $JBG5&K4[=0 -3=M.^]1MH ;MJ&;@&K&VJETU &7?284URVJ2]:
MWM0DQFN6U*3+&J0&)>MN:J+#FK=Q\S&J])@+&M3JM-1?:I%I /6GTQ:?0 4X
MC-&TTM #&IAZ&I&IA6@!BK3U%)M]J<M)@&T4;12T5) FT4;12T4 %%%% ";1
M1M%+10 G%-I]-H&+NI:112T%#Z?MIJYIV30 C+2;:=DT5H@$5:=M%&VEH8";
M:-M+3MM*)<615-'43+4D?45OT-2['U%-N/NFG0FDGY%<\CGDSD_$'^K->)^.
MONR?C7M^OK^[:O%/'4?RR5RR9PU#YT\;-\\GUKRC4W_>-]:]8\<1G=(:\DU3
M/F-]:XYG!,I1MUJ;=56/O]:L*:Y6<K$D:J%Q]VKLO>J%QWI#1EWE45^]5R[;
M@U4B^_6Z-HG4^'!^^6O??AW]Z*O!/#8_?1U] ?#M?GA_"NJ#.B)]-> ?]7']
M*]J\.]$KQCP&O[N/Z5[1X>Z)79$[H'>:=_JUK7C/RBL?3ONBMF'[M:G2B5:6
MD6EH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/_5Q_2O9= Z)^%=L3KB=UIOW1]*V8?NUC:=]T5LQ]!6INB5:6D6EH*"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** $IM.IM #*3)I:55I7 5:1ONT]5ILM,#,NFP#6!J$G!K<O.]<YJ3=:I$'
M/WTF6-9<GWJO7AY-43]ZF JK4RKQ4:U*.E4 M/5:94BU(#U6G^6*1:>#0 TK
MP>M,VU-2;:I$D)ZTT]:E9:9MJM"A*D5:: ,T^LVR4)MHVTM%*Y0FVC;2T47
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M;+5IEJ-EH$0;:?MH*\TM)C0FVC;2T5-AB;:-M+118!-M&VEHHL FVC;2T46
M3;1MI:*+ %%%+MI@)2[:7;3MM0 W:*0C%.I&[58#:*7;24 +NHW4E%4BD1M4
M=/:F53&6H:L#I5:'I5K^$5S29G(RM7_U)KQ_QS_JY/I7K^L']V:\@\<?ZN3Z
M5S2..9\W>/OOR?4UXCKW^L?ZU[9X^_UDOU->):__ *QOK7-(YF8:MUIV[I42
MGDT^N=F;(IJSKGO6A)T-9UT1S68D95UU-0VZ_/4MS]XU':_>7ZUO$U1W/A5?
MWR?A7T/\./O15\\^%?\ 6K^%?0_PY!S%73$Z8GTWX%/R1?05['H)^5*\<\#_
M '4^@KV+0_NI]*ZXG7$[?3_N"M>'[M8^G_ZL5L0_=K?H:DJTM(M+4@%%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%-:@ :DHHH ?112-VH ;(:H7#5<E/%9U
MTU &1?2=:YZ^DZUL:A)UKGKR3DU2$RC-]ZH67GI4C')HVY-,D;MI5I^WZT;?
MK0 Y:D5:C6IXUS0.PJK4\:T(E3*E5<0*M.V^U*J^U+0)HB9?:HV%3MWJ,]:!
M$#+32,5,>E1M6;*2&44^BBX#**?11<!E%/HHN RBGT47 92[33J4"F@&CBG+
M2T4P"BBB@!&&.:2G4C4 -:FT^B@!E%*W6DIHI$34RGO3*8RS#TJU_"*JV]6Q
M]TUA)&$F9&L?ZLUX_P"-O]6]>PZU_JC7CWCC[LGXUSR1R29\W>/NLM>(:_\
MZYJ]N\?_ /+2O#M>_P!8U<<C)F'_ !?C3QT-0_Q4_L*P9BQLO>LRY[UH2-UK
M-N>]0)&;<=:CM?\ 6"EN.]-M/OCZUO$VB=YX5_UD5?1/PX_Y95\[>%?]9%7T
M5\.?O1?45T(Z(GTQX%Z1U[%H?W4KR#P+]Q/H*]AT/[JUUP.N)VFG_<%:T/W1
M6/8_<6M:'[M;&I86EI%I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM3J8
MQH **3=3EH =3#3Z8W]: (9&K+O&^4UH3-P:R+YN#0!A:A)UK NI/F-:VI/R
M:P9GYZT$#0W-3*N:KQM\U7(5IW -E-VU8VU&5J@&JM3QK357VJ95Z<4 2QK4
MRBHT6I5[4"8[;24ZD:K$1-TIC5*U0M4L!C=Z93FIM38H****8!1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVZ;K4I!<HW#=:;:_ZP4V8\TZS_U@^M:I&T3O?"O^N2OHSX<?\LOJ*^=/"?\
MKHZ^B_ARO^JKK@=,3Z;\#_ZN+Z"O7]#^ZM>0>!E_=Q?05[!H?W4KJB=2.RL/
MNBMB'[M9%C]T5K1_=%:FJ)EI:1:6@84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_N#Z5L1_<%;(Z"1:6D6EJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU8ONUE6/W16M']P5H=")%I:1:6J&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%1MTJ2HV%  M+2+2-0!!,U95Y)UK1N&K'O'ZT 9-[)UK(F;<:T;QJS'^]0 S
M;FI%CI8UJPJ^U "1KBGTNVC;5D@JU*JTU5Z5/&OM04/CCJS''3(TZ5;C2G8@
M%CJ58Z>J"I%CH0F1>736CJSM^M1LO!IB*K+4+K5IEJ%U]J *DB\U$RU:9/:F
M^728T5MM&VK.RAHZ0RH5I-M3M'3?+H 9MI=M/"TNWVH CY%)DTYEIM #6J-C
M4K U#)0!$Q.*8Q-.:F-0!&Q-,R:<U,HN W)IC&GMUIC=ZE@-W4;J3::<J\BE
M8!]%%%:(I$;4J4,M*HQ3'+8GA6I''%,B[5*WW:QD82,'6_\ 4FO&?'1^5Z]G
MUI?W+5XOX\;"O^-<DCED?-'Q ;F6O$->;]X_UKVSX@-\S_0UXAKK?O'KEF82
M,=6^:I1TJ"-N?QJ<=*YF9$,]9=UWK4FK+NZ:&C-F-2Z?_K*BF^]4]C_K/QK>
M)K%GHGA/_6I^%?2/PV_Y8_A7S?X3_P!<GX5](_#=?]56R-T?3W@=?W4?TKUC
M1_NK7E'@G_5QUZQHN=JUTP9TP.OLONCZ5JQ_<%9-C]T5JQ?=K9&Y*M+2+2U0
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR+KO6K/63=4D!GS?>J?3_P#6?C4$WWJFT]AYGXUT(WB>D>$?^/B.OI'X;_\
M++\*^;?"!_?)7TC\-OO1?A6T3='T[X(_U<7TKUG1ONK7D_@?_5Q?2O6='[?A
M71%&T4=;8_=%:L?05F6/W5K3C_I6R.I$JTM(M+5""BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!36[T9-)2 ;2K0U"U8"T444 %)N.X4M,9OF%2D,MPOQ3GDR*KQM3MU44(O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK?,*UH7H O*U2*U5E:I5:@"W'4J]J@BJVJT -VTY5]J=CVHH <H]JD6FK3J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&E">E6HS52+M5J,T7 G6EIJFG4D 4444P"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.:TK63D4 =-9R=*UXVX%<[9S=*UH+@;>M4A,O-35J-9 U2+5DCE:I5:H]M.
MJ1V)U:G[=U1)VJQ'0(18Z=MVFI0ORTUEH :K5(IJ%<[JE7M0 ZBBB@ HHHH
M**** "BBB@ HHI"U "T4W=2[J %HHHH **** "BBB@ IRTVG+0 C4E.:FT@)
M5[5.M0+VJ=:8"TY:;3EH T+;M6S9]JQK;M6S9]J: V+?M5H=*JV_:K0Z5#&@
M6EI%I:104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 )4$_05/5>:@"E-]VLV[K2E'!K
M.N%^4T#1B7G>L6\[UN7B]:P[SO0(P;SO63-6K?=ZR)OZT 0-WH7M0>E.5: '
M4UFH:HV:@ 9J8S4QC3: 'U&W2I*:PH @;O0M.9:;0!*BT_R\U&D@4BIUE'%
M%>2WSVJC-:^U;60U021ALTT!STT6VHXWVM6E=0\&LR1=K51+-BQN.E='8S].
M:XVTDV]ZWK&ZZ<U0(["UDSBKT?-8MA-NQ6S;G<M ,<RU$WRU99?EJO)Q4B%1
MJL1M5!6^:K<+4 60*&[4J&D:@!C4E*W6DH *93Z90 Y:6D6EH **** "BBB@
M HHHH **** "BBB@ HHHH *<M-IRT (U)2M24@)5[5.M0+VJ=:8"TY:;3EH
MT+;M6S9]JQK;M6S9]J: V+?M5H=*JV_:K0Z5#&@6EI%I:104444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 57F%6*ADH HS+6;<KUK5DK,N>] &)>=ZPKSO6]>]Z
MP+Z@#"O.]94JUKW59LJT 5-M&VI&[TV@"-NU1/UJ:HVH A9:3;4U,H 3;36%
M.W4C=Z (F[U6EEVU/-PH/O61?7&W- $\EX%[T+J '>N7OM6\O/-9W]O8;[U
M'H,>HAB.:L+<AN]<!:ZWN<?-71:?>^;CF@#7G7<M95Q'UK6C7S%JI=0\52$S
M.C?:U:=C<88<UDR+M:K%HQ!JR3M=-N-V.:Z:SDW8KBM+D^[75V$GRBI UC]T
M57FJ96^6HI><T 5>=U6834!6I8N* +T=#5'&W%.W9H 2BBB@ INVG44 (O2E
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *<M-IRT (U)3B*;2 E7M4ZU
MO:IUI@+3EIM2*M %ZV[5LV?:L:WXQ6S9]J: V+?M5H=*JV_:K0Z5#&@6EI%I
M:104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 E0R5-4,E %*;O69<]ZTKCO65<
M]Z ,>\[UBWG>MB\[UC7= &+<]ZS9_O5IW74UES4 0-4=*_6HZ "FM3J* &5$
MQJ1^]0M0 ;J6D6I56@"G=?=KF-8N-@:NIO!\IKB/$,A56JD!QVN:GY9;FN9D
MUP[CS^M2>)+DKOY[UQ<EXWF'GO4@>B:7JY>1?FKT3P]<>:%.:\5T&Z+3+S7K
MWA-]RI0!Z%9KNC7Z5'>1_*:LV"_NQ]*9??=-4B# FC^8TEM\K5-<+\U,MU^:
MF!T6F]JZJP/RBN3T_M74V/W5H UT;Y:5EW5&G]*G'2@"'RZ7&VI<"HWH 56]
MZE4U6J>.@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.
M6FTY:: 6BD:DYJ0)5[5,M0+VJ9*8$R_TIZ@4Q.E2+20%RV[5LV?:L:V[5MV?
M:I UK?M]*L?PU7A^[4_\- T*M+2+2T%!1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% "5#)4U0R4 4;CO65<]ZU;CO65<]Z ,6\[UBW=;5YWK%NZ0&/==367-6I=
M=367-3 JR5'4DE1T %(:6D:@!C?-43+4S4R@!B+TJ:F*M/QQ0!4O?NFN#\2?
M=:N\O?NFN%\2+\K4 >2>)>KUQ,F?,/UKN?$OWF^M<3)_KJ -WP_GSEKV+PDW
MRQUY!H(_>+7KWA,?*E 'ING-^Z'TIE\?E-)IY_<TMW]VJ1!CW'6FP_>%.N.M
M-M_O52 Z#35Y6NHLE^45S.F]JZ>R^Z*&!I1=JGJ%.@J4&D M,DI]-;K0!%@U
M/'40ZFID_I0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"G+3:<M "-24K4E2P)5J=%J".K"T@']*>K4RG+VH OVW:MNS[5B6W:MNS[4
M:L7058_AJO%T%6/X:!H5:6D6EH*"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $
MJ&2IJADH HW'>LJY[UJW'>LJY[T 8MYWK%NZVKSO6+=T@,>ZZFLN:M2ZZFLN
M:F!5DJ.I)*CH ***:U  U,/6E:FT +3S]T4+UIU %&]^Z:X;Q+T:NYO?NFN%
M\2-\K<T >4>)?O/7%/\ ZS\:[/Q+]YZXM_\ 6?C0!T'A_P"^OUKUWPJW"?2O
M(-!_UJUZ]X7^ZGTH ](TYOW(I]W]VHM._P!6*DNONU2(,B?[U+;?>HF^]3[=
M<M5@;NFJ>*Z:R^Z*YW35Z5TMET% %].U29%,7[M+4@2J<BD:FKVI] $8^\:E
M7M3*D6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *<M-
MIRT (U)2M25+ ECJPM5XZL+2 ?3E[4VG+VH OVW:MNS[5B6W:MNS[4 :L705
M8_AJO%T%6/X:!H5:6D6EH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*V[/M0!J1=!5C^&H8.@J;^&@8JTM(M+04%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5KVG45E6_:M2VJRD:T+=.:L"J4+=*M*U0,</O&G4BTM !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTJI-]ZK;55F6@"FU4[A>M79/EJC<-UH P=37Y6KC=87Y379:@V<URNJ1;LT
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MI:1:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ IK4ZFM0 P]:>O6F4]>M #J*** "BBB@ HHHH **** &M4,E3-4,E
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M(ZG6@$.HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% #U[5-'4*]JFCJ6!)2-2T4@!:LPU6JS#U% &E;]JTK?M6;;]JTK?M392
M-"'[M7$_I5.'[M7$_I2&2+2TBTM !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]*@9(M+2+2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IRBFT]>U
M#U6I%IBT]:E@/IRTVG+30#UJS#VJLM6H*8%^!>E:%OVJA;_>%:$% T7H?NU<
M3^E4X?NU<3^E042+2TBTM !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112$T +
M12;J-U "T444 %%%% #6IAZT]J8U #6J"2IF:H)&H I7/>L>\[UKW%9%YWH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E1M4E1M0 E.6FTY:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP=!4@*PQ3:D:F4 /C[5+MJ-*E -2P0;:<M)3J: ****8!1110 4444 %%%%
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M2M*'M0(NQU93^E5HZLI_2I9KT)%I:1:6D 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMP4$FA;_ 'A6I;]JS+?M6G;]J=P+T=6%J&/M4ZT6 >M+2+2TBPHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[:FCI&7;2J<4 2KTJ&Y^Z:E5J@N_NT <[JO^K:O-?$_\=>DZI]UJ\W\3?Q4
M>::I_KC1I?WUHU7_ %Q^M+IG^M% 'H?AO^'\*]-T/[BUYIX97YEKT[1%^5:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK4ZFM0
MP]:>O6F'K3UZT .IK4ZFM0 T?>-/6F#[QIZT +1110 UJA:IFJ%J (&JK<?>
MJU)5*9J *DQ.#65<]ZT9FZUG7/>@#'O.]8]SWK8O.]9%P,YH RYN]059F7K4
M.WVH 936[U+M]J:R^U).X%*;O562KTB\&JLBTP*].6AEI56@!U5;KO5O;56Z
M7@T <WJWW6KS?Q-U:O2M67Y6KSCQ,OWN* /-=4_UAIVD_P"L6FZFO[PT_25_
M>+0!Z1X7_AKU#1?]6OTKS+PROS)7J&B+^[7B@#=7[HJK<=:N*O3BJUPO6J0F
M5:OV?WA5+;[5>M%Y%,DZ#3^U;4/W:QM/7@5MPK\HH D/]*B:I=M-VT *E28%
M(BU)MXH ;@4]:3;3MM "44[;1MH ;13MM&V@!M%.VT;: &T4[;1MH 2GK3=M
M/6@!:*** "BBB@ HHHH **** "BBE6@!5I],H5J5@'TY:1:7 I@2)5J'[M5%
M[5<A'(IV T+<=*TX.M4+=>E:,/45# N1?TJ5>E1Q]ZD7I2 >M+2+2T%A1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,,T
MM)0 S;3EI*<.E "TUJ=36H :/O&GK3!]XT]: %HHHH :U0M4S5"U $$E4+@U
M?DK/N* *,S5GW'-7IN]49J ,JZ7K61<+UK;N%ZUDW2X- &3*M0U9F')J"@!-
MM,9:DIK4EH)%>1:K2+5QN]02+3&476A5J9EXI%6@! M5[I/EJ\JU7NE^6@#E
M-67Y6KS?Q-U>O2]67Y6KS;Q,O+4 >;ZDO[P\4[2D_>+2ZDO[PU+I2_O%H ]$
M\,+]VO4=#3]VOTKS3PO']RO4M#7Y%^E &RJ_*/I5.XXS5_;\HJC==ZI"96%7
M[5>1Q5)!DUHVB_,*9)NZ>O3BMJ'[M9%BO2M>'[M2V ]EIE2-32M4 ^/M4FVF
M1BI: $VTX+Q24X=* $VT;:=10 W;1MIU% #=M&VG44 -VT;:=10 W;2TM% !
M1110 4444 %%%% !1110 444UNM #NM/5:C7M4Z]: %'RTHYI*<M #T6KL"]
M*JQU;AZ4[@:-OQ6A;]*SK?M6C;]J3%<NQ]LU+4<=25!5QRTM(M+04%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4UJ
M &'K3UZU%_$*E6@!U-:G44 ,IPZ4M% !1110 UJA:IVJ-N] %62J,U7IN]4+
M@F@"A<=ZSYC5R=JH7#4 4KCO65<]ZT+ANM9MPU &?-UJJ_459F;K59FYH 3F
MFT_(IC-0!$]0LU/E:JDCTK /9JC5OYU&TE"MS3 M*15>Z^[3E;Y:BN6^6@#G
M-6^ZU>:^)R,/7I&KM\C5YCXH;EZ //M2;]X:GTG_ %HJEJ#?O3]:MZ*W[P4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.I%I:!!1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %%%% !1110 4444 %%%% !3)*?3)* (<"I8ZBJ6.@"2DP*6B@
MHHHH **** "HVZ4^F,U %6;[M9UQ6C-TJA.M &1<]ZR[ANM;%PM9%TG6I8&1
M<R=:RYY.O-:-XO6LJ8&@"M(W)H6F-UIR$50V2JM1R+4H(Q39.:";F?/51JOS
M+521>:!D#4E/9:0*<T (U5+IOEJVRG-5+H';0!S>K-\C5YGXH;[U>EZM]UJ\
MS\4?>>@#SG4O]::OZ'_K!5#4O]::OZ'_ *Q: /5/#/W4KTC2_P#5BO-_"_W4
MKTK2U_=K5@:#?=JI(M7&7Y:J2?>-0)B0]:U[/M61#UK7L^U62;UEVK4B_I67
M9=JU(OZ4 .:A:&ZTJK4L"6.GTU:5C30"4Y:CW4]6I@+1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !2]Z2E6I8$B]JDJ->U25,=P'44453
M<O:KUOVJBO:KUOVI :=OTK3M^U9EOTK3M^U R['4B]*CCJ1>E!0]:6D6EH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M9)3Z9)0!#NJ2-JB;K3XZ )Z*0=*6@ HHHH **** $:HV[T]J8W>@"M)5.9:N
MR52F;K0!0F6LJZCZUKRMUK.N<<T <_>1]:Q;KY370WV,&N<U!]N: ,Z:3&:A
M^T 55O+K:3S69)J.T]:5@.C6Y''-/\[-<TFI^]7+?4-W>F*QKM\U5Y$I(I]W
M>I&- RHZTS;4TE14 !%4KS[IJ[5.\^[0!R^K?=:O,O%'5J],U;[C5YGXG_CH
M \XU#_6'ZUHZ'_K%K/O_ /6_C6AHG^L% 'JOA<_*M>E:7_JQ]*\S\,?P5Z9H
M_P#JZ -)A\M4IE.ZKS?=%4IN]! V'K6O9]JR(^U:UC]ZK W[+M6I%_2LNR[5
MJ1?TH <?O"GK3&H6H8$Z]J&I(Z?5("+;4BTE*M,!:*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *<M-J1>M2P'+FGTU:=4H!U%%%4P'+VJ]
M;]JHKVJ];]J0&G;]*T[?M69;]*T[?M0,NQU(O2HXZD7I04/6EI%I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3;1MH CHJ3;1MH CHJ3;1MH CHJ3;1MH CHJ3;1MH CHJ3;1MH CHJ3;1MH
MCHJ3;1MH CHJ3;1MH CJ1>M&VEVU+ <M.IJTZD ZBBBFP'+VJ];]JHKVJ];]
MJ0&G;]*T[?M69;]*T[?M0,NQU(O2HXZD7I04/6EI%I: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&M3#UI[4P]: $J1135IZT (U0M4S5$U %>9:R[L]:U9:RKL9S0!E3-UK,NFX
M-:4Z]:R[OH: ,'4&ZU@7;98UNWPZUAW"]:L#/9=WYT"$596')J=;?VJ *)A
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5F6_2M.W[4#+L=2+TJ..I%Z4%#UI:1:6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IE/IC-0
MJTZFJ:=0 UJ8U/:F-0 E2+UJ.GJ: %:H7J;[U1NO% %62LFZZFM6;Y:R+IN3
M0!3D;FJLTGRFI)&JG-)Q0!GWK=:P;Q=V:VKINM8]Q\V: ,F:/DTU8:L24Q:
M&"'BE\D5,O:GA>1021+'BEVU,PJ)NE!1#(M5W6IY&]ZA9J *\E9.H?=-:\@K
M)U!?E- '':U]UJ\T\2?Q?6O3-;4;6KS3Q)]YJ .&F_UQ^M=%X=^\/K7/S*/,
M-=%X=7]XM 'J?AL?*E=_8?ZL5POAI?E2N^L5_=B@">J<U6G^4&J4S55A-A#]
MZM_3>U85O]ZN@TWM3L3<Z.T^Z*M55M3\HJWCB@!E3)TJ(C%/C:G8!\G:F#[Q
MJ3[U&WZ5(#EJ4=*C7Y:>M,!U%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "FM3J:U ##UIZ]:8>M/7K0 ZFM3J:U #1]XT]:8/O&GK0 M%%% #6J)
MJE:HFH KW%8FH?=-;=Q6+?CK0!S=X.:QK@ULWGWC6-=*>: *$TF,U6:6II@<
M&J;]: !I,TVCG-/5:DL9M^M'2I=M&VM$05V-)NI\BU$P-2 _=2EN*CYI: &2
M-4#-UJ9JA;O0!$U1-4K4S;0 RBI%2G>70!!MJ18ZD6'VJ9(3Z4 )#'TJ_#!3
M;>'I6E;P>U4B!L,/(K1@7;BHECQ5B/BF!.M+2*:6@ IK"G4;>* &JM3QU&J^
MU2+\M $P;BBHPU/'2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ****E@%2+4=2+2 >.E.6FCI3EJD ]:N6_;ZU36KEOV^M6!IV_2M*'
MM6;;]*TH>U2!;CJ1>E1QU(O2I970>M+2+2TAA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !36IU-:@!AZT]>M,/6GKUH =
M36IU-:@!H^\:>M,'WC3UH 6BBB@!K5$U2M434 5[BL:^^Z:V9ZQK[H: .<O5
MY-9%PO6MR\7FLN:/.:D#&FCZU2DCK8FAJI)#5 9^WVIZK4K1XIIXH 2AC36:
MF,U ",,YIA6G[J&(H AVTE/9J8S4K@1L*A9:GIK4P*Y6C94VVE"4 ,6.I5AJ
M2..K$<5 $"P>U3QV_M5F.&IUAH CAAP15V-:8B;34M4B!ZK3J91N^M,"=6J1
M>:K*U3*: )-M.5>*1:E6@!JK2X-/VFDH ;4@Z4VG#I0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%%2P"I%J.I%I /'2G+31TIRU2
M>M7+?M]:IK5RW[?6K T[?I6E#VK-M^E:4/:I MQU(O2HXZD7I4LKH/6EI%I:
M0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4UJ=36H 8>M/7K3<4]: %IK4ZFM0 T?>-/6HQ3UH =1110 UJB:I6J
M)J *]Q6%J#=:W;BL#4N] &',WS57+\&G73?,:J-)0!-NJ-FJ+SJ57J0&R+NJ
MO)#FKFW=4JP;JH#$DM<CI5=K7VKH&M1CI4,EJ* ,%K<CM430UM26PJM);XSQ
M0!E-'2>75]H:;Y- %=8ZE6&IA%4JQT[@5O)IZQU9\NG+'2 B6.I56GK'3]M
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*6DH ;3ATIM.'2@!::U.I
MK4 1TY:0]:2@"0-3JBR:>O6@ :HFJ:HVH JW%<_J?W36_<_=-8.H]Z3 YF[^
M]5"1JT;Q?F-9TG6HN S=]:>K4RG+2YA7+,;5.D@K/#8-.\XUHF,TO,%022"J
MAN#3&F-,+D\C"JTE'FFF;J=B;D;+3=E2T46$1;?I4BTVBG8+DJT[BH<FEW4F
M@YB;CVHR*AW4FXUF*Y*331R::I-. I7'S#J<O:FT#J*TB!84"I5P*@5J?NK4
M"=6IU5U:I%:@"2D]:3=]*=60"=Z=24Y:JX"T^BBF 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 444JT  %/44+3Z5@ =*?3:<M,"1>M6H
M?O563[U7+?I02S0M^U:4/:J%OVK0@H++4=2+TIL?]*E_AJ"@6EI%I: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:*
M &4X=*3;2T +36IU-:@!AZTE*>M)0 5(O6HZD7K0 M1MWJ2HV[T 5+C[IK#U
M#O6Y<?=K$OJ3 YN\7DUG3+6I>+R:RYNIJ+ 0TM)2@9I\I-@ZT;33MOM0<5:1
M1$RFHV4YJ5FIC=:L@15XHIPZ4;15 -HI2,4UC0 E)110*PC4E.HP*S8PI=IH
MIU*PF(!BEHI56E80ZBEVTE6D-#UIZTQ:D6F,<M/7I3%IZ]* )%[5(M1KVIZU
M+&#4+0:%I%$E+24M4B HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4JTE*M #UJ2FJ*=0 4JTE*M $T=7+?I5..KEOTH T[?JM:$%9]OU6
MM""I8%R.I-U1QT^D,<M+2+2T%!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU #Z5:2G5+ *<M-IRTBD244452$PHHHIB"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *5:2E6@!ZU)4:U)0 4JTE*M $T=7+?I5..KEOTH T[?J
MM:$%9]OU6M""I8%R.GTR.GT@'+2TBTM!84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %-;K2U&U $BTC4U3UI: &G
MK24K4QFH =3U-0;J>K4 2M4;"G TM %.9?E-8=^.M=!<#Y36#J'>@#F;P'<:
MSY%YK5NEY-4)*7,*Y6\NFE<5(T@7O5:2Z4=Z?.1S$U)NJB]\J]ZC;4%7O4N2
M)YC0;YJC9:I_VDN>M2Q7RMWK/VB0G(LK&:=Y)I8KE*M*ZL*GVZ$I%/R2.U,9
M2M7V -02+5JHF:<URFW%)NITBTRK4BN8*<JYH6I8UK6,KC3$5#BG;=M/X[TQ
MF%6,5:<#40;FG=ZT12'M3*=142%(<M/6D4"GK69F"U(O:F4JT 2TZF+3ZEC"
MG+2J*<.*10M%%%-$!1115 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4JTE*M #UJ2HUJ2@ I5I*5: )HZN6_2J<=7+?I0!IV_5:T(*S[?JM:$
M%2P+D=/ID=/I .6EI%I:"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(-V/FKK+#6 ZCFO#]-U@JR\UV6DZV?E&ZNZ,[FT6>L0W0D4<U*HW5RNF:F&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% #6H6G44 )3:?10 E(U.HH 93Z** (V^Z:A:IG[U
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 BTZBB@ I5I*5: )HZN6_2J<=7+?I0!IV_5:T(*S[?JM:$%2P+D=/ID=/I
M.6EI%I:"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH 2HVJ1JB8T +4BU&M2+4]0$:HFJ9JA:J 2GKVIE.7M0 ^H9
M%J:HY%I,##U1?E->>^(U^_7HNJ+\AKS_ ,0K]^N.J[(YZVQYIK"_,:Y/4.IK
MKM:&UFKCM2;K7@UJAYDC OCUKG[X;LUMWC=:R+A=RFO+G4,9,P9HSN--AC.Z
MKTMO\W2B.'VKDE*YSLLV<?2M:*'Y<U1M5VXK3C8;17-(R>I!<0C;6->0]>*Z
M&;!6LRZAW9J2&<Y,FUJ8DNTU>NH:RY<KFM$2:=O==.:TX9=RUS,$AW5L6<A.
M*L#5V;L4QX:GAY45(R5BS6)2P5-3JV>*;(M-#5S3D:1)),$55E7FK&ZH)*NC
M/4WB26K[6%=EX?N/F09KB83\PKJ=!<^8M?:8!WL>G1/7_#LVY4YKN+([HQ7G
MGAER52O0M.;]V*^ICL=J+97BH66K-12"HZED--I[4P=:UB0681Q4K=.E1PCB
MIV7Y:B0RNU"TDBTJT(H=1113("BBB@ HHHH **** "I%J.I%H 6BBB@ HHHH
M **** "BBB@ IRTVE#4 .HI-U+0 4JTE% $\=7+?I5*,U=M^E &G;]5K0@K/
MM^JUH05+ N1T^F1T^D Y:6D6EH+"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@!K5"U3-4+=: %7[U3+4%3K2Z@%0M
M4K5"W>F 4Y:C6I5[4 /'>HY*?36[T 8^I?<-<#XB7AJ] U!?D-</X@CX:O.Q
M.QA4/*]=7#/7#ZHW+5W_ (@CY>O/]87#-7RE>33/+D<[<?>-5&BW9JW-UID:
MYKS.9W.:12:VSVIGD;:U?+%031XI.1BRHHVU,LE0297-1[S7.Y&)?\S-12KN
M4U$LE2=J:8&==0YK&NH#71R1[JH36^ZM4R#$CCPU:=HI&*/L?S'BK,,.W'%4
MV!HVWW15AFXJI&VU:>TG-9&T0D.:B:G-S25S3-1E5Y).34LE4I6^8U-'XC6)
M;MVRU=?X?C+.M<EI\9D85W_ARSW;.*^YR_H>C2/0?#<9"K7?6/\ JQ7(:#;[
M57Z5V%J=JU]5'8[8EU3Q3)#0&XZTUC421J,:F4]J8.E;16AFRW#]VIVZ55A;
MWJPS?+6<AQ(7ZT+0]"T(IBT444R0HHHH **** "BBB@ J1:CJ1: %HHHH **
M** "BBB@ HHHH **** %6G4U:=0 444Y: 'QU>M^E5(OO5=A^[0!HV_:M""L
M^WZK6A!4L"Y'3Z9'3Z0#EI:1:6@L**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% "5$PJ6HVH 1:D!IJTM  S57DJ=NE0L*
M (EJ5>M,VT]>HIW D6E(.*5:1J0%"\Z5R^KKN5A7373=:Y_4EW(:Y:D;HQJ;
M'FWB"'[W%>:Z_'AFKUO7K?Y6XKS+Q%;\MQ7B5J9YDT>;ZC\K-60TV,UN:M&=
MS5STBG<:\:I1,6B99B>]3*V:IQ@U;C7BO-J1L8R0\4,O>G**&ZUYL]S%Q(6J
M)JL-4++65S.PU6-3QO4&VI%!JU(=B?S,TUJ10:=M^E=47<M1!5IQ7B@?+3))
M ,UTQC<JPV8[15"9JGEFJ()YAK=46S:,2.%"S5NZ99%W7BH+&P,C#BNRT322
M67BNJC1:9T*)K^'--QM.*]+T.SVJO%<_H>F^6!Q796,?EJ.*^GPL#LIHT5C"
MH*CDXJ3=\M0L<U[<=CL0RK4/055JQ%18LGJM-]ZK#-\M0,F:I,G<;#PU7(VJ
MLJ;:GCJ2EH34QAR:<&I&IB8RBG44$C:*=10 VBG44 -HIU% #:D6FTY: %HH
MHH **** "BBB@ HHHH *:U.HH 1:DIE/H -IH(.*=10 Z.KUO]X54CJ];_>%
M &C;]*T+<&J-OTK0@Z"I8RU&IJ3;38Z?2'8%I:1:6@84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6EVT .5J?NJ.EW4 .J1:C7K4BU2 6BBBF 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4^F4^@!U*.])2CO0!-'U%7K?M5&/J*O6_:@#5M
MNU78ZI6W:KL=2P+2?TIU-3^E.I#'+2TBTM!04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M -'WC4J]JC7[U2K5@+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4^F4^@!U*.])2CO0!-'U%7K?M5&/J*O6_:@#5MNU78ZI6W:KL
M=2P+2?TIU-3^E.I#'+2TBTM!04444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 )4;5)4;4 *M25&M24 -:HFJ5JB:@".
MI$J.I$H F6H)ONU.M03?=H Q;_O7-:AU-=+J'W37,7_>J0&1-]ZH:FD&&J-J
M9 VBBB@!&I*5J2@ IK=:=36ZT@$HHHIBZA1110 4X=*;3ATI=1BT444P'444
M4 %+24M #J?3*?0!(M2+VJ-:>M #Z;112 *5:2E6DP)5ZTZFKUIU( J1:CJ1
M:L!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "GTR
MGT .I1WI*4=Z )H^HJ];]JHQ]15ZW[4 :MMVJ['5*V[5=CJ6!:3^E.IJ?TIU
M(8Y:6D6EH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!&J)C4C5$QH >OWJDJ)6J6@!&J-A4E1M0 W;3U6FU(O6@
M!3P*JW#5:JI<#Y30!BWS<&N>O.];]\<9KG[QNM &7(OS5"PXJ:5OF-0M5(@;
MM%)3J:>M,!K4UJ<U,:@ YI*** "BBB@ HHHH$%.'2FTX=*748M%%%,!U%%%
M!2TE+0 ]:>M,6GK0 M/5J910!)S3J8K4^D@%"TX+2+3QZ4F JTZD'%+2 *D6
MHZD6J0"T444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"GTRGT .I1WI*4=Z )H^HJ];]JHQ]15ZW[4 :MMVJ['5*V[5=CJ6!:3^E.IJ
M?TIU(8Y:6D6EH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &M4+=:F:H6ZT .6IJA6IJ $J-JDJ-J $J1>M1U(O
M6@!:IW7W35RJ=U]TT 85_P!ZPKSK6[?]ZPKSK0!E2?>-1-4LGWC4352(&TT]
M:=33UI@-:F-3VIC4 )1110 4444 %%%% @IPZ4VG#I2ZC%HHHI@.HHHH *6D
MI: 'K3UIBT]: %HHHH <O6I*C6I,&D@'KVIZTQ>U/6DP'4444T 5(M1U(M"
M6BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4^F4^@
M!U*.])2CO0!-'U%7K?M5&/J*O6_:@#5MNU78ZI6W:KL7:I8RU&*?MIL=/I#L
M"TM(M+0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** &M4+=:F:H6ZT .6IJA6IJ $J-JDJ-J $J1>M1U(O6@!:IW7
MW35RJ=U]TT 85_WK"O.M;M_WK NOO&@#,D^\:B:I9/O&H6JD0)33UIU-/6F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUK]T5>C-4+;[HJ]'4L"6BBBD Y:6D6EH+"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*A:IJA:@!*D6HZD6@!S5$
MU2M434 )3U[4RGKVH =5.Y^Z:N53N?NF@#"O^]<W?=ZZ2_[US=]WIH#'F^]3
M*?-]ZF50!1110 4444 %%%% !1110 4444&84X=*;3ATI=1BT444P'4444 %
M+24M $BU*M1+4JT +1110 4444 .IRTE%2QHD6I!UJ)>HJ=::!BX-.HHIB"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G+3:<M #EIU-6
MG4 .IRTVG+0!-'6A#VK/CK0A[4 :MM]T5>CJC;?=%7HZE@2T444@'+2TBTM!
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 )4+5-4+4 )4BU'4BT .:HFJ5JB:@!*>O:F4]>U #JIW/W35RJ=S]TT
M 85_WKF[[O727_>N;ON]- 8\WWJ93YOO4RJ **** "BBB@ HHHH **** "BB
MB@S"G#I3:<.E+J,6BBBF ZBBB@ I:2EH D6I5J):E6@!:*** "BBB@!U.6FC
MI3EI#0]:F6H5J9:8V/HHHH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "G+3:<M #EIU-6G4 .IRTVG+0!-'6A#VK/CK0A[4 :MM]T5>C
MJC;?=%7HZE@2T444@'+2TBTM!84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 )4+5,U0M0 @ZU*H.*8M2CI0 C5$U2
MM434 )3U[4RGKVH =5.Z^Z:N52NONF@#"U ]:YR^[UT6I=ZYN\I(#)F^]3*D
MD^\:CK0 HHHH **** "BBB@ HHHH ****#,*<.E-IPZ4NHQ:***8#J*** "E
MI*6@"1:E6HEJ5: %HHHH *7;24^@!!3U6FCK4B@U+ 5:D6FCBG+30$E%(O2E
MI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.6FTY: '+
M3J:M.H =3EIM.6@":.M"'M6?'6A#VH U;;[HJ]'5&V^Z*O1U+ EHHHI .6EI
M%I:"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH :U1-4K5$U #U^]4E1K]ZI* &M435*U1-0 E/7M3*>O:@ :J-U]
MTU>:J5UT- &%J'>N<O*Z'4.]<[>?>-- 9<GWC4=22]ZCJ@"BBB@ HHHH ***
M* "BBB@ HHHH,PIPZ4VG#I2ZC%HHHI@.HHHH *6DI: )%J5:B6I5H 6BBB@
MI],I] #U[4]:8O:GK4L!U*M)2K30#UZ4M(O2EI@%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %.6FTY: '+3J:M.H =3EIM.6@":.M"'M6
M?'6A#VH U;;[HJ]'5&V^Z*O1U+ EHHHI .6EI%I:"PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :U1-4K5$U #U^
M]4E1K]ZI* &M435*U1-0 E/7M3*>O:@!U9]W5]ONFJ%W0!S^H'K7/7?6NAU
M'FN?O!UI(#+E[U'4DO>HZT$@HHHH&%%%% !1110 4444 %%%%!F%.'2FTX=*
M748M%%%,!U%%% !2TE+0!(M2K42U*M "T444 %/IE/H >O:GK3%[4]:E@.I5
MI*5:: >O2EI%Z4M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ IRTVG+0 Y:=35IU #J<M-IRT 31UH0]JSXZT(>U &K;?=%7HZHVWW15
MZ.I8$M%%%(!RTM(M+06%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% #6J)JE:HFH >OWJDJ-?O5)0 UJB:I6J)J $I
MZ]J93U[4 #52NNAJZU4KKH: ,#4.]<[>?>-=%J'>N;O/OFA;@S-E(S4=/E^^
M:95B04444#"BBB@ HHHH **** "BBB@S"G#I3:<.E+J,6BBBF ZBBB@ I:2E
MH D6I5J):E6@!:*** "GTRGT /7M3UIB]J>M2P'4JTE*M- /7I2TB]*6F 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Y:;3EH <M.IJT
MZ@!U.6FTY: )HZT(>U9\=:$/:@#5MONBKT=4;;[HJ]'4L"6BBBD Y:6D6EH+
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!K5$U2M434 /7[U25&OWJDH :U1-4K5$U "4]>U,IZ]J !JI770U=:J
M5UT- &!J'>N=O!\QKHM0[USMY]XT+<#*E')IE22]ZCJQ= HHHH!!1110,***
M* "BBB@ HHHH,PIPZ4VG#I2ZC%HHHI@.HHHH *6DI: )%J5:B6I5H 6BBB@
MI],I] #U[4]:8O:GK4L!U*M)2K30#UZ4M(O2EI@%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %.6FTY: '+3J:M.H =3EIM.6@":.M"'M6
M?'6A#VH U;;[HJ]'5&V^Z*O1U+ EHHHI .6EI%I:"PHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MA.*6FM0 ;J=3*?0 4444 %%%% !1110 4444 %%%% !1110 444FZ@!:***
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 (U-I]% !1110 4444 %
M%%% !1110 4444 %%%% #6I*?10 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M10 4444 %%%% !1110 4444 %%%% !1110 4Y:;10!(M.IBM3Z '4Y:;3EH
ML1_>%:%NO2L^/[PK2MNU NII0<8JY'52&K<=2RT2K2TBTM(GJ.6EI%I:"PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCZ***!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
MY:DJ-:DH =3EIM.6@"Q']X5I6W:LV/[PK2MNU NIIPU;CJI#5N.I9:)5&.:6
MD7I2TA,<M+2+2T%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !12-3: 'T444 (U,(S4E% $.WVHQBI=M-910!&U)2
MM24 %.7M3:>O6@!ZTK4@--:2@ :FU&TU1^?[T 6*<IJKYU2+(*!V+*TM0K)4
MH.:!#:94U,*\T ,I5H;K24 2+UIU1J>:>O2@!:*** &M24K4E !2,:6FGK0
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M1:***#5!11102%.6FTY:!,6G4VG4"B.6EI%I:"B1:>M,6GK0 M%%% !1110
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M10 4444 %%%% !136ZTJT +1110 4444 %%%% !1110 4444 %%%% !1110
M4UJ=36H B_BIZTAZT]>M #JC?K4E1OUH 8/O&I4Z5$/O&I4Z4 .HHHH BG^[
M6%?]ZW9_NUA7_>@#F]0K%F^]6UJ%8LWWJI"96:FTYJ;3)"BBB@ HHHH ****
M &GK2K2'K2K01U%HHHH-4%%%%!(4444"8^G4VG4"0Y:6D6EH*)%IZTQ:>M "
MT444 %%%% #ATIRTT=*<M(:'K4RU"M3+3&Q]%%%!(4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 .6I*C6I* '4Y:;3EH L1_>%:5M
MVK-C^\*TK;M0+J:<-6XZJ0U;CJ66B5>E+2+TI:0F.6EI%I:"@HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H :6XI-
MU#4S)H ?NI-WO4>[WIN[WH GW<4Y:KAJE5J '54NFPM6MU4[UOE- '/ZI+MS
M7&ZI=%=W-=1K+?*:X36)2-W- &5>WQ!/-9CZ@<]:KW\QW-S65)<'/6J2 WTU
M#WIS:E@'FN>6Z([U'->$ \U5@-V35L=Z6'5-S=:XZXU(KGFI+'4BT@YI >B6
MMSY@'-:$9+5SNCS>9BNHMH]RBH 50:FCD*U(MOQ4;1E6J;@:-I<$,*VK6ZQC
MFN6AD*M6E#<[<<T7 Z=;_:O6FMJVWO7.37VU>M9\^J$=ZM =DNKY[U,NI ]Z
MX*/53N^]5^+5..M58#KVU(>M*NI>]<BVI^]"ZI[T[ =BNHCUIW]H#UKD5U/_
M &J>NI_[5%@.K_M#WH_M >M<M_:7O3?[3_VJ5@.O741N'-6%OAZUQ:ZG[U<@
MU+..:=@.OCN@W>K4<F:YNUOMW>M>WN-W>E8#2#<4NZH%D!%+NJ; 3;J-U0[J
M7=18"?=1NJ)7IP:D _=1NINZDW>] #]U&ZF[J:6H DW4;JBW4NZ@"3<:3<:%
MYI=M "444FZ@D=NHW4S=2;O>@HDW4;JCW>]&[WH EW49%1AJ4-S0*Y)129%+
M0,1J3=2,:;DT /W4;J9DT9- $E+2#I2T %)1NHR* &;:>M&V@<4 %1M4C&HF
M:@!%[U*G2HE^]4RT +1110!!<5AZB?E-;EQ6#J;?*: .:U!NM8TK=:U=08\U
MC3-R:I QK&FTUF]Z3=[TR1]%)NHW4$BT4@-+0,**** &GK0M#&DW?6E<!]*.
MIIFZGK4C%VBC;2THYXH*&[>M 6G;:-M! N!1110 Y:6F@TNZ@"16J1:B6I5J
MD M%%%, HHHH <.E.6FCI3EI#0]:F6H5J9:8V/HHHH)"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@!RU)4:U)0 ZG+3:<M %B/[PK
M2MNU9L?WA6E;=J!=33AJW'52&K<=2RT2KTI:1>E+2$QRTM(M+04%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C4M(U #&J
M.I&J.@!E,8T]N]1M0 JFI5J%:F2@!]5+W[IJW5&^;Y30!RVM?=-<%K7>N[UA
MOE-<)K1^]5@<9J+?,:QY&Y-;&H?>-9$GWC5(!FXU5N)#M-3LU5;GE30!C7<Q
MW&I=-F.\5!=+\U,M9?):B0'I?A^3(7-=UI[ JM>4Z+J@CV\UW&EZP&V\US@=
MDJ!EJO/'UJ*VOA(HYJ>20,* *)^4U()MHIDW6J\DF* '7-S\IYK*N+@^M6)I
M,YJC)\V:TB 1W!#=:NQWAQUK,QM-/63%: :+7A]:5;L^M9^^E5J+@:BW1]:D
M6[/K66KU,K4 7_M1]:;]K/K5/=3=U &BMX?6KMO>'UK#62K4,V* .LL[SIS6
M]97>['-<5:W&,5N6-STYH Z^&;=BK*MFL>SGW 5IQM\M2!-2;J;D4V@"=6I=
M_O46?>D9J6X$^ZC=5<-3MWO56()MU-W4S=24AD@:GK4:]JF6H'8>M/\ X:8M
M+0(1J;3F[4FV@H:U)3]IINTT -I-U/VTC+00(K5(K5&JT_;MH&/HW>],I.:"
MAY:D S2J#3QQ0 S;1MJ2B@!H-#4-3&H 7=1NJ-F]Z1>U %C(I::G2G4 -:HF
MJ5JB:@ 7[U3+4*_>J9: %HHI* *]RW%8&HMP:W+GO6#J'W30!SE]_%6)-]ZM
MG4.IK&F^]0!7;K12C[QI:>Y 444Y>E( 6EHHH ***:W>@!K=J2BB@!5J5>M-
M6G+0,=2C[QI**!L=12+3UH)L)@TE/IIZT )2TE+0!(M2K42U*M4@%HHHI@%)
MNI&HH D'2G+35IRTBD/6IEJ%:F6F#'T444$A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 Y:DJ-:DH =3EIM.6@"Q']X5I6W:LV/[
MPK2MNU NIIPU;CJI#5N.I9:)5Z4M(O2EI"8Y:6D6EH*"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1J6D:@!C4VG-3: &M
MWIC+3Z* (B,4Y>U*1B@+0 N?ES6??-\M7I#69?M\IJD!S&L2?*U<+K#?,U=E
MK$GWJX?5I.33 Y?4/O&LB;O6I?-R>:RI#\U4! U03+FK06D:'(Z4 8%Y&>:R
M+B?R6KI;RW^4\5RVK1%<TF!/9ZSY+#FNOT77]S+\U>522,DE;^@WC;AS68'N
M>DZMYBKS726]QYBUYGX>NF;;S7H&E,604K 79%W53F4BM98=RU6N+>D@,:3-
M0LM7)H\5 5IHLJLM1U:=*B\OYC6A (M/\NIHX:D\GVH @5*E5:F6&I5A]JJX
M%;8::T=7?(]J#![4 4-M2QYW"I&AZTJ1[: +ENW2M>SDZ5CPJ:T+9MI% '56
M,W K9AFXZUR]G-A16I%=8[U))LK-[T>968MT/6G_ &FIL4:/G>])YB^M4/M/
MO1]I]ZH"_P"9[TX25G?:?>I%N!00:&^G;A5);BGK<<=:!EQ6IZR"L_[1CO2B
MZJ64:(EI_G>]9?VH4_[4/6D0:/G>]+Y@K-^U#UIWVH>M589H[J2J2W-2+<"F
M47%QB@X]:K+-QUI?/%38"?BAJ@\\4X2 T6$A]*JTT,#3MP%(8]:=4?F4>90
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3EI#0]:F6H5J9:8V/HHHH)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!RU)4:U)0 ZG+3:<M %B/[PK2MNU9L?WA6E;=J!=33AJW
M'52&K<=2RT2KTI:1>E+2$QRTM(M+04%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 -:FM3FIK4 -I],HH FHIJTZ@ HHHH *C:I*:U #5I:
M*1NE %2Z[US.J,>:Z*[KF]4[U2 X_5F^]7&ZHWS&NPU;^*N,U,_,:I <_==Z
MIU<NN]4ZH">'K5^'I6;$U7H6Z4V!>C7=3_LX;M3(FJPK#%2!7:S&>E,:U"]J
MN&05%-)\M2!39A#5BWU3RR.:R-0N-N>:Q)M4\MNM)@>FV.M X^:MNWO_ # .
M:\FTW6OF'S5V>CZAYFWFI [ G<M021TMM)O45)+]TT 5JL0XXJG-)MI8;GYN
MM6+8V%Q2-4,,VX4]Y.*2&AI/-/5O>JOF?,:>LU,LO*:6H(Y:D\R@@:RU"5YJ
M9I*@D>G<!>*6H/,IZR9IH:9.HJ5%-,C^:K<,>:3(;$C0U82*GQQ5;CAI"*HA
MI&AK26W]J&@XZ4 9;0FH]AK4:W]JC:W]J *&PU(L9JTMOSTJ1;?VH&55C-.V
M&K@MN.E/6W]JHHI>2:/)-7_(]J/(]JD@S_+--\LUH_9\]J/LOM0!F^6:-IK1
M^RCTIOV;VI6 H[31M-7OLWM1]F]JKH!1P:0L15YK;VJ"2U-0T,K><13EF/K2
MFW(-.6W-9V*$\PFCS&]:E6W-(UN: (O.-2+-S3'A-,VD4 78[CWJ]#<?,.:R
M%S5N%N15(#9CG]ZMPR[N]8\<AQ5ZW;I3 UHSQ3VJ*%N*F/W10 VD:AJ2@!RU
M*M1+4JT +24M)0!4N>]8.H=ZWKGO6#J'>@#F-0[UCR?>-;&H=ZQY/O&@""G4
MVG52("G+TIM.7I4@+1110 4UN].IK=Z &4444 2+4JU"O>GK0,=1110-BK2T
MBTM!(4444 %+24M $BU*M1+4JU2 6BBBF UJ*=2;: 'K3EIHZ4Y:12'K4RU"
MM3+3!CZ***"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH <M25&M24 .IRTVG+0!8C^\*TK;M6;']X5I6W:@74TX:MQU4AJW'4LM$
MJ]*6D7I2TA,<M+2+2T%!1110 4444 %%%% !1110 4444 %%%% !1110 44F
M12<T .I-U)S3=U #MU*#FH]U"MSUH EHIF[WHW>] #MU)NINZDW4 2;J6F*U
M/H **** "BBB@ HHI,B@!:*3(I"U #J*9N]Z7=0 ZBF[J4'- "T4F11D4 +1
M2;J3=0 I.*3=36;WI-WO0 _=1NIF[WHW4 2+TI:1:6@ HHHH **** "BBB@
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M 4FV@!FVG!>E+MI_% "+3J** "BBB@ HHHH **** "BBB@ HHHH *3(I:90
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M #7DYH6;YJJR25&LAW4 :T<U:-O+6!'(:U;20MB@#>A;=BK<8JC9\@5HQK0
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M;3EZT 6X/O5JVW:LF"M.U[4K@:L/:K*U6MNU6UI7*0M.6FT4ADJTM1K3QTH
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MZ $ Q2TUFVU!)<;>] $S$"HS(*J27@]:JO?>] &IYR^M F![UBG4/>G)?^]
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.6FTY: '+2TBTM
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MVVGE:;0 Y:D7M42M\M.#4 64:I5:JJM4R-0!-12#I2T %%%% !1110 5&_\
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M@ HHHH **** "BBD:@ R*,BFT4 /HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *<M-IRT .6EI%I:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IRTVG+0 Y:6D6EH
M*<M-IRT 6H>U:=KVK,A[5IVO:I8&K;=JMK52V[5;6D4A:***!CEIXZ4Q:>.E
M "T444 %%%% !1110 4444 %%%% !1110 4444 ,;O4;5(W>F4 "K4G\-,6E
M:@"M<O\ *:P+]NM;=UG!K#O5Y- &3-RU$=+(OS4P-C% #YF^4UB:@W6M2:3@
MUB7TG6@:,BX;YC42-S1<-S4<;5 B_":DD;:*K1O2S2?+6J(*E]<;0>:YO4+S
MKS6IJ$WRFN4U&;DU8%6\O,YYK-:XW=Z;=3'FJF_GK4@6U;)J=.M5835N-NE
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M*** "BBB@ I],I] #U[4]:8O:GK4L!U*M)2K30#UZ4M(O2EI@%%%% !1110
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MIVO:LR'M6G:]JE@:MMVJVM5+;M5M:12%HHHH&.6GCI3%IXZ4 +1110 4444
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M;3]M&V@8W;1MIVVC;0 W;1MIVVC;0 W;2;33]M+MH 3;2TM% !1110 4444
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M=1110,*5:2E6@!ZTM(M+0 4QJ?3&H&-I],I] V.IRTVG+022+VJ1:C7M4BT
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M+2T %,:GTQJ!C:?3*?0-CJ<M-IRT$DB]JD6HU[5(M "T444 %%%% !3Z93Z
M'KVIZTQ>U/6I8#J5:2E6F@'KTI:1>E+3 **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *<M-I5H >M+0M.VT -IR]:;3EZT 68?O5JVHZ5E
MP_>K5M*A@:MN.E6JK6W:K-!2"BBB@8Y:>.E,6GCI0 M%%% !1110 4444 %%
M%% !1110 4444 ,I,BFT4 /J"2GDU#(U $34]5IN><4]30 ^HW:G,W%5Y'H
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MK0 ]:6FTZ@ IC4^F-0,;3Z93Z!L=3EIM.6@DD7M4BU&O:I%H 6BBB@ HHHH
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M=HJK"N,VBC:*=MIRK3&*JU,@I%6GCBH 6BFLU&[WH =12;J-U K"T4FZDR:
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MQ5IP&*6B@JP4444 2+WIZTQ:>O2I98M%%.VT]P&U(M&VC;0@#=3J;MJ15IW
M3;3E6G;>**FX#E-.W4P>M+2( \TVGTNV@I#%I:7;1MIZ#$HI=M&VD E%+MI*
M "G+3=WUIRT +112;J";"T4FZC=3L(6BDW4M( HHHH'8**** L%%%% @HHHH
M ****!A3)?NT^FM0.QE7G>N?U#O707G>N;U!NM*Q)SU]W^M8UP>36Q>]36--
M]XU: K$Y-.CI3'4D<=,">&K"U JXJ5:H!^W-($HW4H:I >J"G[>*B604[S*
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MWJ&2W/I5@4O,(H\\U+);G/2H6@-0 ?:*/,IGDFCRR*; L)S4RK5=>*F63I2
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M] #U[4]:8O:GK4L!U*M)2K30#UZ4M(O2EI@%%%% !1110 4UJ=36H 2BBBD
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M&*:WWJ%H F5JFC/%5E[58CH E7I2TB]*6@ HHHH *?3*?0 ]>U/6F+VIZU+
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MP:BY%1OF@@&FI/,J)LTF34 6TDJS'(*S5?%2+/[U8&JKBAI!6<MU[TOVGWH
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MUH:C9,5?DCJ!H^M0P*VVG5)Y=*(JL@CVFC::LK#[4[R?:@"IS3U8U*8:3RZ
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M0K4ZD!$U,J5EJ-EH 2I%IFVG+WH >?NBF[J-U,)H =NHIE% %BBBB@ HHHH
M**** "FM3J:U $=-IU-H C:HF[U*U1-WH 8WK435*U1-0)D;=:2E:@#-638
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MM1-UJ!ER"YV]ZTK>[Z<U@;BM6H9L=Z"CJ+>XW8YK2MYNE<S:W'3FMBUFZ47
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M !112-0 M%-HH **913L*XK4E%%,+A13*-WO4A<?13-WO1N]Z N/HIN31N-
M7)*1J;N]Z&;WH"XM,DI=WO36-*P7*[4Y&Q2LM,^[5C+"O0\V.]5C)BH);C'>
MI86+,EQ[U6DN_>L^>\QGFJ,M[[U*0&W]L]ZKS7GR]:Q_MWO44E][U0%FZN>O
M-9-Q-DTLUT&[U3DEW&E8!)&S4+2[:<YXJM)FF!:CN/>KT,VZL-6*M5R";'>@
M#;C4-3S"*I0W0XYJPMT#WH 22W%5I+>KGG!N]-(W4 9[0^U"V_M5[R<U(L%
M%);7)'%*;7VK4CAIQA![4KBL83V]1A-I-:\UOG/%4Y;?;3&01U9C-08VT]6P
M: + ^Z:8_?Z4BO2M0!7DJ*IV6F;10 L=6HZKK5B.@"5>E+2+TI: "E6DI5H
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M%%@,.:S]JRKNRZ\5ULUO[5FW%J/2G8#C;C3=V>*RYM%W9XKN7LQZ5 ]DOI3
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MM>^]21WWS=: -O"M5::,57CO/>B2Z!S0!7E #&J^[YJ?-)NJ'- $RR=*DW5
MN:D7- $E)MI-WO2[J !5J>/I4 :I%>@+DZ]*6F+)3Z "E6FEJ<IH =112[:
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MN RBG4C4Q6&M3&I[ TQJ!D;=Z94M-H B:FD5*U)0!'MIVTTZB@!>:2GTC=*
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M*!DZGWIZMTYJ%:>#046%IZU &IZMTH EIE+N]Z2J("FLM.HJ2R%EZU$P-6&
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MT 1-3-M2E:3;[4 1[:0BI=OUII7VJRR)EIC+4S4PK^-!! 5ZTW;]:G9:B*T
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MM]JD6EVT@&;:0K3J7)H CVU&RU/3&H @9:9M]JF8<TW;0!"RTTQU8VTFWZ4
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MM3U@]JNK#3O*I,"CY'M4JQU9\NCR_:DD!$L=2*E2+'3MN* $5:D5:1:F4=*
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M*@V[:7<: +0DXIV[ZU6$E.$E*P$^[ZT*W-0>92K)S18"VA%3K5))*L)(/6I
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MDVT4 7****@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *3UI::30 QEIFWYJEI-M601[?I1M
M^E2[?:C;[5!97V4A6IV7FF,M $++3=OM4Q6F[:+@AFVC;3]M&VG<&AM%.VTC
M<5=R!E-VT_::3::E -VTC+4FVD*TP(P,4M+MI*E ,IK8IU-9:;8$;5$U3,O-
M1,M- ,INVI-M&V@!@&*6G;:-M #"M-J7;3=OM0 S;]::U/:FM5 )2-TI:".*
MD!E/5:;S3UH 6A12K2[: %IX7BD5>:D5>* $"]J<JT[;3E6@!NVC;3]M&TT
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MK'BI52GJE/V\U)0B<5,K5%3=_O0!9W4TK3%;I4E ";:*6B@5Q]%%% PHHHH
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M>J;S?SJ-IJ@"ZTU1F;BJAFJ)IJT0%MYNM5I)O>HFEJ&1J8#WF--\RH&:F[J
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MM&TT_;1MH 9M-&TT_;1MH 9M-&TT_;1MH 8HIU*RXI* "DVTM% #6I*5J2@
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MHH 913Z* (R,TFVI:3:* (J:W6I:8>M $;4E//6B@!E+S3J* "G 4BT]:JP
M!BAJ6BI A932;:FV&C8:!,AVTE3;:393L2-IZCI0%IU(!W04G%-+4;J"P:FT
MNZDJK &W=0T=2K0U,5BLT=1LE66[U&P-*X6(/+HV5+M]J-OM33%:Q&J4]4IR
MK[4Y5IW*&[:D5:-OM3MIJ; 2*!3MOM3%8BGJW%2 NTT['M30WO3MWO0 ^BF[
MJ-QH =29%-9C3=U "[J-U,W4;J '[J<M1 T]: )**** "BBB@ HHHH ****
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MAVI/+85V<GA\_P!VJSZ ?[OZ4 <K\PJ5)66MZ30S_=JM)H[+VH HK=E>]/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M] #Z*:&IU !1110 W;366I*:U $#4VGLM-VF@ #4X/3=M&V@!_F4NZHJ<.E
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M94C=*2@!5%/I%IU !1110 ZDW4M(U  K5(K5%4BT 244@Z4M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UJ=36H 8>M/7K3#U
MIZ]: '4444 %%%% "$9IC+4E-:@".FTK4E !3E[4VE6@"0-^%+NJ.B@!V13E
MJ.G+0!)12+2T %%%% !1136H 7(I:93Z "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img148560552_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148560552_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #= G # 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH *R?$][/IWAG4;RU?9/# SHV <'\:UJPO&G_(F:O\
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M>2N)R,L,_*!C@<5+5+^7\"T\0_MO[WY?YC/^%B>*/^@B/^_*?X4?\+$\4?\
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M @?A52C33MRHB$ZTHW4W]_7L5_\ A8GBC_H(C_ORG^%'_"Q/%'_01'_?E/\
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MG:JG]DZE_P! ^Z_[\M_A7T1]ID]ORH^TR>WY4UF26T27E:>\V?._]DZE_P!
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M_+?X4?V3J7_0/NO^_+?X5]$?:9/;\J/M,GM^5']I?W0_LJ/\WX'SO_9.I?\
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M3E9^2O\ JC2P?0T8/H:S?[$LO2;_ +_-_C1_8EEZ3?\ ?YO\:.:I_*OO_P"
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M!W=%8.E:M?-?6VGZA:Q1-/:">%XY"Q(& 0V>_P!*?J&JWO\ :$]AIUI%,\$
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M:CJ#"XM]/C;36E:(/YI\T 9&_'3&1]:Q[/Q/)9:9IMFAMWN&M1/)+>3%1C)
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MZ!DG_?8K=^S1^A_.F21V\*%Y&"*.I9L"CV$_Y_R_R%[2'\B_'_,Q?MU[_P!
MR3_OL4?;KT?\PR3_ +[%%SKEKN,=C ]R_3<.%'XUPWB?Q5>1WHT>Q4W^M3#Y
M+* X2$?WI6[#]36/+-_!)O[K??87M8=(+\?\S7\1_$73O"]J9M1B*M_!$K@L
MY] */"OQ"MO%T,IL-/G2>''F6\K .H/1L=P?6O.]>\"R12Z38ZE<_;?$.N7
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M/[QI_P!OVT2MY[%I//DB5(8V9L(>21[=S53_ (2^R^UCB1K-[1;E)4C)."S
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M +S?RKT*")885C4 !1@ 5P?PVL)[V*^\5:@A%[K$OG*#_P LX1Q&H_#G\:]
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MG?(&89/MQS2LP378Z!=#T:WBG3R45'3RWWR'Y4)SM&3\HSV%6;C2K&[\QIH
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M[FM3PKX'ATF1]1U"9[_5[CF>\GY9CZ#^ZOL*[$ *, 8%*]MAVON-BB2% J
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MYIWA3X0-X9U.#4HI?,NH3E6:8J/H0!R*]=HJ^65K<S)O&]^5&<&UC'^JL_\
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M^M3[5I=,O=/NVLYFMU-QM@AP[0H^-JD9X[\=LUVWDQ?\\H_^^!1Y,7_/*/\
M[X%',Q<L/,9:7*WEJDZQO&'&=D@PP^M5-$_Y!:?[S_\ H1K0^6-#P%4#/ P!
M5#1!C2H_=F(_,UC+^+'T?Z&J_AR]5^IH4445J9!1110 4444 %%%% !1110
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M&+<C8'_UCC().T=N:FEO];N;&[MI;F2.=K)C;F"V)\]BK=R/E(.!CCUKM:*
M.9>^OH-'T;_2)E65 +BY^S%W4A. 4QQD]\=O>J$^L>(#YH@+^;YDB/&;0X@4
M2!48'^+*\_CVQ7:T4 <5+K7B"WN1&(GN0KS1!5MRK.1RCGC&WMP1^-5+GQ!X
M@@T<W4DOEIY4LAE6T9F1UC#!&&!P6W<^W6O0*;+&DT3Q2HKQNI5E89!!Z@T
M<1<^)->2+9;VSS7.7<(+9MI3R-R_-T^][^U.?5/$;1LT4Q*K;RS*5M22Q5HP
MJ-D#GYGZ#I]*[9$6-%1%"JHP .@%+0!QMQK6LK;R.GFB?[4(Y(?LQQ!$2?G#
M8.[MZ]:Z?2WN9-+MGO&1KAD!D9%*J3[ \BK=% !1110 4444 %%%% !1110
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M9WN"D\7V4XME^;&#M.[HHSS7:44 5[!IWT^W:Z*&<QJ9"@(4MCG /.*L444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img148560552_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img148560552_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $( G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ J&
MYN4M8M[AF)(5449+,>@%352N_P#C_P!/';S&_P#0&IK<4G9!]HU \BQC'LUQ
MS^BT>?J'_/C#_P"!'_V-7:H:U<7EKHUW/I\/G7:1DQIMW9/T[^N.]-:NUB97
MBF[CO/U#_GQA_P# C_[&CS]0_P"?&'_P(_\ L:P=#U.>YU2**+7HM1B9&\^&
M>$031'L54 $C/!!Z>M9^B:Q)J+6XG\52I=R2LIM%MH\<,1MSL]!ZUI[)Z_\
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M=0@_M*Y&FQ-8:=,8YG\XAV4 $E5QC@'N:AU#QM':7=YY8LS;V3!91+=!)I.
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M_/Q:?]^&_P#BZ-FI?\_%I_WX;_XNL#5?&#62F:"*U^SBW6X7[3<;'F##=A%
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M"J20<]S\U44\*&V@@2RU2YMI$M5M)9%53YJ+G!P1PPR<$>M:OV6__P"@C_Y
M6C[+?_\ 01_\@+1SON'LX[<O]?>5=.\/0Z?+;N)GE$-DMEM<#YE!SD^]06GA
M=;:2T234+B:RLG\RUM7"X0C.W+ 98+GC-:/V6_\ ^@C_ .0%H^RW_P#T$?\
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M7_7S*$?AB%(EWW4TMP;R.\FN'QNE=.@] ,<8'2I+CP]%<:C+>&XD#27%O.5
M& 8N@_&K?V6__P"@C_Y 6C[+?_\ 01_\@+1SON'LX[<O]?>9W_",B)(7M;^:
M"ZAFFD2<(K<2MN92IX(Z?D*OZ-I8TBQ:V^T2W!:5Y6DEQN)8Y.<?6G?9;_\
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M;JFIWI_=S-.2LIDQ;J!"RR[5 )(!RN>_;-1ZHU^929A<>?\ 9_\ 0]BX_?\
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M4 %%%% !117.ZW,C:O;6T,\D5V=C^:SLL<2!N@'1F;[N/3K[M*X,Z*L[4?\
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M:?\ 'E;_ /7)/_014U0VG_'C;_\ 7)/_ $$5-0 4444 %%%% !1110 4444
M%%%% %FW^Z?K4U0V_P!T_6IJEFBV"BH;N[AL;62YN'V0QC+-@G'Y5%=ZC;V3
MHDID:1P65(XV=MHQDX / R/S% RW14/VJ#R(YC,BQR %68X!!Z=:4W, 0N9X
MP@;:6WC /I]: ):*C,\2R&,RH'"[BI89 ]<>E+'+',NZ*177.,J<B@!]%%07
M=U%96KW$Q.Q<?=&223@ #U)(% $]4+7_ )"^H?2+^1J>SO([V)GC#*4<QNCC
M#*PZ@U!:_P#(7U#Z1?R-,"_1112 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBF2J[Q,L;['(X;&<'Z4 /HK-T.6ZN=-2XNK@2O)G&(PH7!(_I6E0
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MCPY Z^PK07[P^M9VB?\ ()B_WY/_ $8U 79I;C_>?_OHT;C_ 'G_ .^C3:*
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M88@9QZ5K5#:?\>-O_P!<D_\ 014U$I.3NP225D%%%%(84444 %%%% !1110
M4444 6;?[I^M35#;_=/UJ:I9HM@K&E\2V(B+0^9(WF!%#(4#_O1&Q4D8.TMS
MBM@LJ@EF  ]37/6_AJ$11Q7UY)+*CLT2JP4(#+YF%XS_  J.<].,4#+H\1::
MS.HE<R+MQ'Y;;GW$A=HQDYP?RIDWB73HXI&21G94+ ;&4;MI8(21@,0.AJM;
M^%+&"19H;JX$JA1&X*97:20?N_,>2"3G.:>WA?3Y)I7>>9W<?OBS*69MNW<6
MQD<=@0.!Q0!/#XCL);>-_P!ZLKA<0>4QDY7=PN,D8!.?:M.">*ZMXYX'62*1
M0R.O0@]#62GAR!"DXO+G[5'A5N25W!0I7;]W&,$]NO-:EI:Q6-G#:P+MBA0(
M@)SP* 'R2QPIOED6-!_$QP*R+O7)K:]NK<6?$<<31.T@_>&1]@Z= #^/M6PZ
M+(NUU##T(S52YTJUNY)9)5;=)$L1(8C 5BRD>A!.<T &FWKWL,WF(J2PS-#(
M%.02.X]L$53MYX;C4=0>&19%!C4E3GG!XK2M+.*RA,<6X[F+LS'+,QZDFJ*_
M\A2__P"V7\C31,MB:BBBF01W%S%9VTMS,VV*%2[GT K#\':M%JNA[D&V2*5U
M=,],L6'Z']*U=2TVWU>R:RNO,\F0@L(WVDX/3/I61X4T*RTRU:ZM?-$DVY'#
M2$J0KD#CUXK5>S]F[_$0^;F5MCHJ***R+"BBB@ HHHH H7W_ "$-+_Z[O_Z+
M:K]9FI3Q1:IH\;R*KR3N$!/7]VW^(K3HLT(****!A1110 5F:_\ V@=%N(]+
MA,MW*/+3# ;0>K<^U:=*OWA]:<7RM,35U8Y#P##J=II<EM>VY6VSOMY-P/?#
M+U]1G\ZZZL_0_P#D"VWT;_T(UH552;J2<GU%&/*K!1114%!1110 50O/^0KI
M?^_+_P"BS5^J%Y_R%=+_ -^7_P!%F@"_1110 4C?=I:J:EJ-KI5A)>7LOE6\
M>-[[2<9..U %7PW_ ,B]9?\ 7/\ J:EO])BU":1Y9&"R6CVI4#H&8-NSZC%9
MO@W5K'4]"B2SG$K6ZA)<*1M;DXYKHJ ,23P^\DLEPU\?M<RM'+((1M*,JJ0%
MSP?E!SD\YJE+X7GF2Y5IP(5FDDMX5 R0R*HRYZ=,XQ4ET-2AUR^>Q%P99'A\
MM&3]PZB/#$MCL?<<XJFJZQ=K;&Y>]VI(I8JI5E<Q.&'W1QN*]L#/7T0R^F@7
M%[#J!U*=5DO"XVHH^0,$!/7KA/7OUJ"[\.721&UL)1Y$D7V?,F/W46_<%]3C
M+ 'TP,<9JM:RZ]###%&+D".%%17C)RHA^8GY<;M_')SP."#74:<LR:;;"XDD
MDG,:M(TN-VX@$@X]Z8%V(YES5NJD/^L%6Z3*CL%%%%(H*SM1_P"/W3_^NC_^
MBVJU!>VUS(Z03QR-&<,$;.#G%5=1_P"/W3_^NC_^BVIK<3V'4444S,*H:K]R
MS_Z_(?YU?K$\2ZI:Z9%IYN7V[[R,CZ Y)^@IQBY.R$VDKLVZ*/IS12&%%%%
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MZLBPJGJEC'J.GS6DHW1RH48>H-7** ,'PIX?3PYI"62MO()9GQC<3WK>HHH
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MISW^@VGG1!&8W \UY8D.XEY-A&[J#N/([?I2&5KW7;YK&\:)XQ-9R.&-KR)
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M )"NE_[\O_HLU?JA>?\ (5TO_?E_]%F@"_1110 4444 %%%% !1110 4444
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MJ=O97-I;R^89+J3RXPJ$@'&<D] .*MD!@0>AXJC/I<<JVB)(Z+;7 G&XERV
M1C).>]"*$L-8M]0E\N)9%S'YL9< "1,XW#GIGUP>13KS_D(:=_UT?_T6U0:9
MHO\ 9TRN;CS1%#]GA&S;M3=GGGD]!GCITJ\;.!KM;IE8RJ,*2YP.,<#./THT
M$3T444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !5!]%T^1Y'>W#&3=D%F(!8@D@9^4D@'(Q
MTJ_10!#;6L-I#Y4*;5R6.2222<DDGDFIB,T44 41JM@;@P>=AQ+Y))1@N_\
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M<"J.EV4MDET)65C+</*-OH<=?>K] "8%(Y2-&=R%51DDG  IU1W$;2VTL:;
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M1B#74.YLQ&, X4YRNX8!]AZYKK:**&[@D%%%%(84444 %%%% !1110 4444
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@[>0JZKISN%2_M68G  F4D_K5RBBLYQ4=C:G-R6I__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>asnd-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-09-03T15:57:09.8128+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://ascendispharma.com/20240630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:asnd="http://ascendispharma.com/20240630" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2023" xmlns:calc="https://xbrl.org/2023/calculation-1.1" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd" namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" namespace="http://xbrl.sec.gov/country/2023"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2022-03-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" namespace="http://fasb.org/srt/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" id="StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss">
        <link:definition>100010 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" id="StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition" id="ConsolidatedStatementsOfFinancialPosition">
        <link:definition>100030 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity" id="ConsolidatedStatementsOfChangesInEquity">
        <link:definition>100040 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements" id="ConsolidatedCashFlowStatements">
        <link:definition>100050 - Statement - Consolidated Cash Flow Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/GeneralInformation" id="GeneralInformation">
        <link:definition>100060 - Disclosure - General Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies" id="DisclosureSummaryOfMaterialAccountingPolicies">
        <link:definition>100070 - Disclosure - Summary of Material Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/SignificantAccountingJudgementsAndEstimates" id="SignificantAccountingJudgementsAndEstimates">
        <link:definition>100080 - Disclosure - Significant Accounting Judgements and Estimates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/SignificantEventsInTheReportingPeriod" id="SignificantEventsInTheReportingPeriod">
        <link:definition>100090 - Disclosure - Significant Events in the Reporting Period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/Revenue" id="Revenue">
        <link:definition>100100 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/SegmentInformation" id="SegmentInformation">
        <link:definition>100110 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPayment" id="ShareBasedPayment">
        <link:definition>100120 - Disclosure - Share-based Payment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/ShareCapital" id="ShareCapital">
        <link:definition>100130 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/TreasuryShares" id="TreasuryShares">
        <link:definition>100140 - Disclosure - Treasury Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilities" id="DisclosureFinancialAssetsAndLiabilities">
        <link:definition>100150 - Disclosure - Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>100160 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" id="DisclosureSummaryOfMaterialAccountingPoliciesPolicies">
        <link:definition>100170 - Disclosure - Summary of Material Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/RevenueTables" id="RevenueTables">
        <link:definition>100180 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentTables" id="ShareBasedPaymentTables">
        <link:definition>100190 - Disclosure - Share-based Payment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesTables" id="TreasurySharesTables">
        <link:definition>100200 - Disclosure - Treasury Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables" id="DisclosureFinancialAssetsAndLiabilitiesTables">
        <link:definition>100210 - Disclosure - Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" id="DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100220 - Disclosure - Summary of Material Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" id="DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail">
        <link:definition>100230 - Disclosure - Significant Accounting Judgements and Estimates - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail" id="DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail">
        <link:definition>100240 - Disclosure - Significant Events in the Reporting Period - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail" id="DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail">
        <link:definition>100250 - Disclosure - Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail" id="RevenueAdditionalInformationDetail">
        <link:definition>100260 - Disclosure - Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail" id="SegmentInformationAdditionalInformationDetail">
        <link:definition>100270 - Disclosure - Segment Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails" id="DisclosureSharebasedPaymentAdditionalInformationDetails">
        <link:definition>100280 - Disclosure - Share-Based Payment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail" id="ShareBasedPaymentScheduleOfWarrantActivityDetail">
        <link:definition>100290 - Disclosure - Share-based Payment - Schedule of Warrant Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail" id="DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail">
        <link:definition>100300 - Disclosure - Share-Based Payment - Summary Of Share Based Payment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/ShareCapitalAdditionalInformationDetail" id="ShareCapitalAdditionalInformationDetail">
        <link:definition>100310 - Disclosure - Share Capital - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail" id="TreasurySharesSummaryOfHoldingOfTreasurySharesDetail">
        <link:definition>100320 - Disclosure - Treasury Shares - Summary of Holding of Treasury Shares (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails" id="DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails">
        <link:definition>100330 - Disclosure - Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" id="DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
        <link:definition>100340 - Disclosure - Financial Assets and Liabilities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails" id="DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails">
        <link:definition>100350 - Disclosure - Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails" id="DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails">
        <link:definition>100360 - Disclosure - Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail" id="DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail">
        <link:definition>100370 - Disclosure - Financial Assets and Liabilities - Liquidity Risk Management (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" id="DisclosureSubsequentEventsAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/CoverPage" xlink:href="asnd-20240630.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" xlink:href="asnd-20240630.xsd#StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity" xlink:href="asnd-20240630.xsd#ConsolidatedStatementsOfChangesInEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" xlink:href="asnd-20240630.xsd#DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" xlink:href="asnd-20240630.xsd#DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail" xlink:href="asnd-20240630.xsd#DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail" xlink:href="asnd-20240630.xsd#DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail" xlink:href="asnd-20240630.xsd#RevenueAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail" xlink:href="asnd-20240630.xsd#SegmentInformationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails" xlink:href="asnd-20240630.xsd#DisclosureSharebasedPaymentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail" xlink:href="asnd-20240630.xsd#ShareBasedPaymentScheduleOfWarrantActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail" xlink:href="asnd-20240630.xsd#DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail" xlink:href="asnd-20240630.xsd#TreasurySharesSummaryOfHoldingOfTreasurySharesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails" xlink:href="asnd-20240630.xsd#DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:href="asnd-20240630.xsd#DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails" xlink:href="asnd-20240630.xsd#DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails" xlink:href="asnd-20240630.xsd#DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail" xlink:href="asnd-20240630.xsd#DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:href="asnd-20240630.xsd#DisclosureSubsequentEventsAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" xlink:href="asnd-20240630.xsd#StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition" xlink:href="asnd-20240630.xsd#ConsolidatedStatementsOfFinancialPosition" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements" xlink:href="asnd-20240630.xsd#ConsolidatedCashFlowStatements" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/GeneralInformation" xlink:href="asnd-20240630.xsd#GeneralInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies" xlink:href="asnd-20240630.xsd#DisclosureSummaryOfMaterialAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/SignificantAccountingJudgementsAndEstimates" xlink:href="asnd-20240630.xsd#SignificantAccountingJudgementsAndEstimates" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/SignificantEventsInTheReportingPeriod" xlink:href="asnd-20240630.xsd#SignificantEventsInTheReportingPeriod" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/Revenue" xlink:href="asnd-20240630.xsd#Revenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/SegmentInformation" xlink:href="asnd-20240630.xsd#SegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPayment" xlink:href="asnd-20240630.xsd#ShareBasedPayment" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/ShareCapital" xlink:href="asnd-20240630.xsd#ShareCapital" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/TreasuryShares" xlink:href="asnd-20240630.xsd#TreasuryShares" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilities" xlink:href="asnd-20240630.xsd#DisclosureFinancialAssetsAndLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/SubsequentEvents" xlink:href="asnd-20240630.xsd#SubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" xlink:href="asnd-20240630.xsd#DisclosureSummaryOfMaterialAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/RevenueTables" xlink:href="asnd-20240630.xsd#RevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentTables" xlink:href="asnd-20240630.xsd#ShareBasedPaymentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesTables" xlink:href="asnd-20240630.xsd#TreasurySharesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables" xlink:href="asnd-20240630.xsd#DisclosureFinancialAssetsAndLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20240630/taxonomy/role/ShareCapitalAdditionalInformationDetail" xlink:href="asnd-20240630.xsd#ShareCapitalAdditionalInformationDetail" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DevelopmentAndAdministrativeServices" xlink:label="asnd_DevelopmentAndAdministrativeServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="ifrs-full_PerformanceObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FairValueHierarchyCarryingAmountMember" xlink:label="asnd_FairValueHierarchyCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPaymentEndingPeriod" xlink:label="asnd_RoyaltyPaymentEndingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CollaborationPartnerOneMember" xlink:label="asnd_CollaborationPartnerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesOfNominalValue" xlink:label="asnd_TreasurySharesOfNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleDebtCurrentAbstract" xlink:label="asnd_ConvertibleDebtCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ThirdPartyInvestorsMember" xlink:label="asnd_ThirdPartyInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_OtherShortTermBorrowings" xlink:label="asnd_OtherShortTermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_InternalProfit" xlink:label="asnd_InternalProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ForeignCurrencyRiskAxis" xlink:label="asnd_ForeignCurrencyRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfInformationAboutTreasurySharesExplanatory" xlink:label="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="ifrs-full_HedgingInstrumentsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfWarrantsOutstanding" xlink:label="asnd_NumberOfWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfSharesIssuedAndOutstanding" xlink:label="asnd_NumberOfSharesIssuedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TransferOfTreasury" xlink:label="asnd_TransferOfTreasury"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock" xlink:label="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FrazierLifeSciencesOfEyconisIncMember" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SaleOfStockDomain" xlink:label="asnd_SaleOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:label="asnd_SignificantEventsInTheReportingPeriodLineitems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncomeStatementAxis" xlink:label="asnd_IncomeStatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPaymentBeginningPeriod" xlink:label="asnd_RoyaltyPaymentBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleNotesCurrent" xlink:label="asnd_ConvertibleNotesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfWarrantActivityLineItems" xlink:label="asnd_DisclosureOfWarrantActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConversionRatePerNote" xlink:label="asnd_ConversionRatePerNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RevenueFromSaleOfClinicalSupply" xlink:label="asnd_RevenueFromSaleOfClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfGeneralInformationAbstract" xlink:label="asnd_DisclosureOfGeneralInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember" xlink:label="ifrs-full_FinancialLiabilitiesTypeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember" xlink:label="ifrs-full_DerivativesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SignificantEventsInTheReportingPeriodTable" xlink:label="asnd_SignificantEventsInTheReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MinimumNumberOfCollaborationPartnerAxis" xlink:label="asnd_MinimumNumberOfCollaborationPartnerAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory" xlink:label="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowings" xlink:label="ifrs-full_ShorttermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_OtherCurrentLiabilitiesAbstract" xlink:label="asnd_OtherCurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_VestingOfSharesAxis" xlink:label="asnd_VestingOfSharesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PaymentTermOfCustomers" xlink:label="asnd_PaymentTermOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IssuedAndOutstandingSharesAmount" xlink:label="asnd_IssuedAndOutstandingSharesAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PerformanceStockUnitProgramMember" xlink:label="asnd_PerformanceStockUnitProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SaleOfStockAxis" xlink:label="asnd_SaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ProfitLossMember" xlink:label="asnd_ProfitLossMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsConditionForRedemption" xlink:label="asnd_BorrowingsConditionForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FairValueOfConvertibleNotes" xlink:label="asnd_FairValueOfConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="ifrs-full_HedgingInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory" xlink:label="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharePriceAppliedForValuation" xlink:label="asnd_SharePriceAppliedForValuation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" xlink:label="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FairValueOfRoyaltyFundingLiabilities" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CarryingAmountOfRoyaltyFundingLiabilities" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SignificantEventsInTheReportingPeriodTextBlock" xlink:label="asnd_SignificantEventsInTheReportingPeriodTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfReportableOperatingSegments" xlink:label="asnd_NumberOfReportableOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DetailsAxis" xlink:label="asnd_DetailsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentyFiveMember" xlink:label="asnd_TwoThousandAndTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfCommercialCustomers" xlink:label="asnd_NumberOfCommercialCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentyFourMember" xlink:label="asnd_TwoThousandAndTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharePriceMeasurementInputMember" xlink:label="asnd_SharePriceMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="ifrs-full_CurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentyThreeMember" xlink:label="asnd_TwoThousandAndTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="ifrs-full_OtherNoncurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FundingReceivedInExchange" xlink:label="asnd_FundingReceivedInExchange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TeijinLimitedMember" xlink:label="asnd_TeijinLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRenderingOfServices" xlink:label="ifrs-full_RevenueFromRenderingOfServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:label="asnd_SignificantEventsInTheReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ForeignCurrencyRiskDomain" xlink:label="asnd_ForeignCurrencyRiskDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentySevenMember" xlink:label="asnd_TwoThousandAndTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks" xlink:label="ifrs-full_BalancesWithBanks"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementAwardTypeMember" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DistributableEquity" xlink:label="asnd_DistributableEquity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BasicAndDilutedEarningsLossPerShares" xlink:label="asnd_BasicAndDilutedEarningsLossPerShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MarketableSecurities1" xlink:label="asnd_MarketableSecurities1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:label="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ForeignCurrencyConversionOptionMember" xlink:label="asnd_ForeignCurrencyConversionOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DetailsDomain" xlink:label="asnd_DetailsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncomeStatementMember" xlink:label="asnd_IncomeStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_UpfrontPaymentReceived" xlink:label="asnd_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsRedemptionPeriod" xlink:label="asnd_BorrowingsRedemptionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ChangesInWorkingCapitalAbstract" xlink:label="asnd_ChangesInWorkingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltiesAndMilestonesMember" xlink:label="asnd_RoyaltiesAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices" xlink:label="asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociates" xlink:label="ifrs-full_InvestmentsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AsiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asia [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within 1 to 5 years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Later than one year and not later than five years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) financing activities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Detailed Information About Marketable Securities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure detailed information about marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DevelopmentAndAdministrativeServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and administrative services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DevelopmentAndAdministrativeServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development and administrative services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale or issue of treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PerformanceObligationsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance obligations [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase/(decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings threshold percentage of sale price per share for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Threshold Percentage Of Sale Price Per Share For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings threshold percentage of sale price per share for redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueHierarchyCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueHierarchyCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy Carrying Amount [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueHierarchyCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value hierarchy carrying amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payment ending period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payment Ending Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payment ending period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationPartnerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration partner one [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationPartnerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Partner One.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proportion of ownership interest in associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RangesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ranges [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RangesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ranges [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Duration Of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Duration Of Marketable Securities Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average duration of marketable securities explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settled during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Other Equity Instruments Settled In Share Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of other equity instruments settled in share based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Settled during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested at the balance sheet date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments vested in sharebased payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average exercise price of other equity instruments vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesOfNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">June 30, 2024 (Nominal values)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesOfNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Of Nominal Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesOfNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares of nominal value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesOfNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">January 1, 2024 (Nominal values)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Other Equity Instruments Transferred In Share Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of other equity instruments transferred in share based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/(decrease) in provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">June 30, 2024 (Holding in % of total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Holding In Percentage Of Total Outstanding Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares holding in percentage of total outstanding shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">January 1, 2024 (Holding in % of total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Non Cash Consideration Regarding Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments for non cash consideration regarding revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash consideration relating to revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Inventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Inventories_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Inventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleDebtCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible debt current abstract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleDebtCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleDebtCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes, matures in April 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about financial instruments [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotionalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotionalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notional amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment arrangements [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based payment arrangements [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of operating segments [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AddressTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Address Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issued capital [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Capital [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ThirdPartyInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third party investors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ThirdPartyInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Party Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ThirdPartyInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Party Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of maturity analysis for derivative financial liabilities [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, plant and equipment at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, plant and equipment at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Europe [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other short term borrowings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Short Term Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) operating activities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments granted in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from disposal of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from sales of property, plant and equipment, classified as investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-adjusting events after reporting period [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-adjusting events after reporting period [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_InternalProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Internal profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_InternalProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal Profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_InternalProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Timing of transfer of goods or services [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of events after reporting period [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained earnings [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Borrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Borrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Borrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings (excluding lease liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TreasurySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total issued capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issued capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities at amortised cost, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at amortised cost, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of associates [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows from/(used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Risk [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Risk [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency risk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible senior notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goods or services transferred over time [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units and Performance Stock Unit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units and performance stock unit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of changes in equity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NewIFRSsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New IFRSs [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NewIFRSsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New IFRSs [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow of Royalty Funding Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of royalty funding liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Repayments of borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of borrowings, classified as financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings threshold trading days for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Threshold Trading Days For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings Threshold Trading Days For Redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Assets And Liabilities [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Financial Assets And Liabilities [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Information About Treasury Shares Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about treasury shares explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares holding in percentage transferred under stock incentive programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Holding In Percentage Transferred under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred under stock incentive programs (Holding in 1% total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MeasurementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_HedgingInstrumentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hedging instruments [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Duration Of Marketable Securities Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Duration Of Marketable Securities Noncurrent Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average duration of Marketable securities noncurrent explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goods or services transferred at point in time [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested at the balance sheet date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of other equity instruments vested in share-based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of share-based payment arrangements [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Holding of Treasury Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of treasury shares [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PerformanceObligationsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance obligations [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentPrepayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentPrepayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentPrepayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities (deferred income)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total adjustments for increase (decrease) in deferred income including contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for increase (decrease) in deferred income including contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ParValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share nominal value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ParValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of Operating Segments [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of non-adjusting events after reporting period [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfSharesIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued and outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfSharesIssuedAndOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue from external customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of operating segments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of operating segments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TransferOfTreasury_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transfer of treasury.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TransferOfTreasury_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transfer of treasury</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TransferOfTreasury_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, restricted stock unit, activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Holding Of Treasury Shares [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of holding of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales rebates and product returns in U.S. market [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Rebates And Product Returns In U.S. Market [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales rebates and product returns in U.S. market.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Purchase of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase of property, plant and equipment, classified as investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current financial marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current financial assets available-for-sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Maturity Analysis For Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity Analysis For Financial Liabilities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maturity analysis for financial liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At fair value [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, restricted stock unit, activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Liabilities at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Liabilities at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty funding liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FixedInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed interest rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FixedInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fixed interest rate [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of changes in accounting estimates [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Frazier Life Sciences of Eyconis, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Frazier Life Sciences of Eyconis, Inc. [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Frazier Life Sciences of Eyconis, Inc. [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of operating segments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of operating segments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From Issuance Of Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issue of bonds, notes and debentures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase of treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of treasury shares (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of treasury shares (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfered</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Liabilities at Fair Value Transfered</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative financial liabilities at fair value transfered.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on balances held in foreign currencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of exchange rate changes on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total selling, general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of financial liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange differences on translating foreign operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of property, plant and equipment [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of assets [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of assets [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AggregatedMeasurementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregated measurement [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserve of exchange differences on translation [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation Reserve [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from contracts with customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized as revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, award type.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share based Payment Arrangement, Award type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of income taxes (expenses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Tax income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total tax expense (income)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax expense (income)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes/(expenses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade receivables from associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of classes of share capital [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SaleOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SaleOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale Of Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodLineitems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Events In The Reporting Period LineItems</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodLineitems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant events in the reporting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of revenue [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share Based Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sharebased payment arrangement, restricted stock unit, activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deduting offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Royalty Funding Liabilities Excluding Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from royalty funding liabilities excluding offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserve of share-based payments [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Reserve [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise price of outstanding share options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RestatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Currently stated [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RestatedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Currently stated [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share based compensation costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expense from share-based payment transactions with employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings in arrears default payment start date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings In Arrears Default Payment Start Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings in arrears default payment start date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Not Included In Diluted Earnings Per Share [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilutive securities not included in diluted earnings per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparties [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at fair value, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities at fair value, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finance expenses paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance costs paid, classified as operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income statement [Axis].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial instruments [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares in entity held by entity or by its subsidiaries or associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stocks non-diluted basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial assets measured at amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets at amortised cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings, interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments for non-cash items:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to reconcile profit (loss) [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentBeginningPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payment beginning period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentBeginningPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty payment beginning period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities (excluding income tax, indirect tax, and employee related payables)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleNotesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleNotesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleNotesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleNotesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Convertible notes current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through share-based payment transactions, equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment (Note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfWarrantActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Warrant Activity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfWarrantActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Warrant Activity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfWarrantActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Warrant Activity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TopOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Top of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TopOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Top of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of summary of significant accounting policies [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of summary of significant accounting policies [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of significant accounting policies [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ordinary shares [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionRatePerNote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion rate per note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionRatePerNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Rate Per Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionRatePerNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion rate per note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit or loss [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities by category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfFinancialLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of financial liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueFromSaleOfClinicalSupply_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of clinical supply</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueFromSaleOfClinicalSupply_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Sale Of Clinical Supply</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueFromSaleOfClinicalSupply_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from sale of clinical supply.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of changes in accounting estimates [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity and liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Convertible Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible senior notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfGeneralInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of general information.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfGeneralInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of General Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of non-adjusting events after reporting period [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial liabilities at fair value through profit or loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities measured at fair value through profit or loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at fair value through profit or loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesTypeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities, type [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of financial instruments [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-adjusting events after reporting period [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-adjusting events after reporting period [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Events In The Reporting Period Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant Events In The Reporting Period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial assets [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">American depository shares [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">American depository shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CHINA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current tax assets, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Levels of fair value hierarchy [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major customers [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Major customers [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Attributable to owners of the Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive income, attributable to owners of parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MinimumNumberOfCollaborationPartnerAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum number of collaboration partner [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MinimumNumberOfCollaborationPartnerAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum Number of Collaboration Partner.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for share-based payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding received in exchange of royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding received in exchange of royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding received in exchange of royalty payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables (excluding income tax and indirect tax receivables)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested at the reporting date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_UnobservableInputsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unobservable inputs [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Derivative Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current derivative financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change to Presentation of Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of reclassifications or changes in presentation [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Duration Of Marketable Securities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Duration Of Marketable Securities Current Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average duration of marketable securities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShorttermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShorttermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to Prior Periods Estimates and Assumptions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Attributable to owners of the Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss), attributable to owners of parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Items that may be reclassified subsequently to profit or (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of vesting rights for share-based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of vesting rights for share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of vesting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for decrease (increase) in inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive income/(loss), net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income/(loss) for the period, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Not Included In Diluted Earnings Per Share [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilutive securities not Included In diluted earnings per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CounterpartiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparties [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current derivative financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of maturity analysis for derivative financial liabilities [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at June 30</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at January 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basic earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total basic earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic earnings/(loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity risk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity risk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of changes in equity [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Finance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of finance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total intangible assets and goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Intangible assets and goodwill at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Intangible assets and goodwill at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible assets and goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Significant Accounting Judgements and Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of accounting judgements and estimates [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities (deferred income)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for increase (decrease) in deferred income other than contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other current liabilities abstract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CapitalCommitmentFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capital commitment from investors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CapitalCommitmentFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital commitment from investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CapitalCommitmentFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment from investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CapitalCommitmentFromInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitment from investors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of fair value measurement of liabilities [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingOfSharesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Shares [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingOfSharesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Level 3 of fair value hierarchy [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentTermOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment Term Of Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentTermOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Term Of Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentTermOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment term of customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Diluted earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total diluted earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted earnings/(loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MajorCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customers [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MajorCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customers [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net profit/(loss) for the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net profit/(loss) for the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net profit/(loss) for the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty Pharma.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Pharma [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IssuedAndOutstandingSharesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issued and outstanding shares amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IssuedAndOutstandingSharesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issued and outstanding shares amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_UnobservableInputsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unobservable inputs [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance stock unit program member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Stock Unit Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of terms and conditions of share-based payment arrangement [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares transferred under stock incentive program nominal value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Transferred Under Stock Incentive Program Nominal Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred under stock incentive programs (Nominal values)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Categories of financial liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of summary of significant accounting policies [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of significant accounting policies [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale Of Stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProfitLossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit loss.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProfitLossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EventsAfterReportingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Events After Reporting Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EventsAfterReportingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Events after reporting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EventsAfterReportingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Events After Reporting Period [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from external customers (geographical)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of geographical areas [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsConditionForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings condition for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsConditionForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Condition For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsConditionForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings condition for redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LongtermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current portion of non-current borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LongtermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LongtermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current portion of non-current borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial instruments, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bottom of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bottom of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of convertible notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) investing activities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_HedgingInstrumentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hedging instruments [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Funding Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Royalty Funding Liabilities Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of royalty funding liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, plant and equipment [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceAppliedForValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceAppliedForValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price Applied For Valuation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceAppliedForValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share price applied for valuation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of associates [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows from/(used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiple of the purchase price were royalty payment will cease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Multiple Of Purchase Price, Were Royalty Payment Will Cease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Multiple of purchase price, were royalty payment will cease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of risks [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of risks [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of non-current financial liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classified in the statement of financial position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregated time bands [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Senior Notes and Derivative Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Convertible Notes And Derivative Liabilities [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for convertible notes and derivative liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of related parties [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Royalty Funding Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of royalty funding liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income taxes refund (paid)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income taxes paid (refund), classified as operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes received/(paid)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Trade payables, accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classes of share capital [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of share capital [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount of royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Carrying Amount of Royalty Funding Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying amount of royalty funding liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Events In the Reporting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Events In The Reporting Period [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant Events In The Reporting Period Text Block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible senior notes [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of fair value measurement of assets and liabilities [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares used for calculation (basic and diluted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Financial Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of financial borrowings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for decrease (increase) in trade and other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfReportableOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfReportableOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of reportable operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfReportableOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of reportable operating segments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of entity's revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Perentage of sale to commercial customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of changes in equity [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings, maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, award type.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Award type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Liabilities at Fair Value Remeasurement Recognized in Financial Income Or Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative financial liabilities at fair value remeasurement recognized in financial income or expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement recognized in finance (income) or expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After 5 years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Later than three years and not later than five years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DetailsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Details [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DetailsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Details.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance income received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance income received, classified as operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets by category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiple of the purchase price were royalty payment will cease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Multiple of the Purchase Price, were Royalty Payment will cease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Multiple of the purchase price, were royalty payment will cease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of equity [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of equity [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from sales or maturity of financial instruments, classified as investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Summary Of Significant Accounting Policy Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of significant accounting policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Material Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Preparation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of basis of preparation of financial statements [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of fair value measurement of liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows from/(used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfTreasurySharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfTreasurySharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of treasury shares [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two thousand and twenty five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfCommercialCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of commercial customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfCommercialCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of commercial customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfCommercialCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of commercial customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at fair value through profit or loss, category [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities measured at fair value through profit or loss [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from sale of goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of commercial products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceMeasurementInputMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price Measurement Input [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceMeasurementInputMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share price measurement input [member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Balance of equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance of equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reversal of finance income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Financial assets at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Financial assets at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Warrant Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other current receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value Hierarchy</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Summary of Fair Value Hierarchy [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of fair value hierarchy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Warrant1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Warrant1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant1 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Warrant1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of share-based payment arrangements [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of share-based payment arrangements [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. SKYTROFA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">United States Skytrofa [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. SKYTROFA [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Holding Of Treasury Shares [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of holding of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of financial position [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Addresses, Address Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherNoncurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherNoncurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other non-current receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within 1 year [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Not later than one year [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Trade Payables And Other Payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of trade payables and other payables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of changes in fair value measurement, liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in treasury shares transferred under stock incentive program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Treasury Shares Transferred Under Stock Incentive Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred under stock incentive programs (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of non-current financial assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classified in the statement of financial position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration partners and license agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration partners and license agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Partners and License Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Funding received in exchange of royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding received in exchange.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding received in exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net gains (losses) on change in fair value of derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gains (losses) on change in fair value of derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gains (losses) on change in fair value of derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings threshold consecutive trading days for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Threshold Consecutive Trading Days For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings threshold consecutive trading days for redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net gains (losses) on disposals of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gains (losses) on disposals of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reversal of (gain)/loss on disposal of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of changes in accounting estimates [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TeijinLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Teijin limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TeijinLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Teijin Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TeijinLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Teijin Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NewIFRSsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New IFRSs [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NewIFRSsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New IFRSs [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Liabilities at Fair Value Settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative financial liabilities at fair value settled.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets at amortised cost, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromRenderingOfServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rendering of services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromRenderingOfServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from rendering of services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for decrease (increase) in prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant events in the reporting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Events in the Reporting Period [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of summary of significant accounting policies [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Summary Of Significant Accounting Policies [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items representing the disclosure of summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reasonably possible decrease in unobservable input, liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of reasonably possible decrease in unobservable input, liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SharePremiumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Premium [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retrospective application and retrospective restatement [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retrospective application and retrospective restatement [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Risk [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Risk [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyRiskDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign currency risk domain.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reasonably possible increase in unobservable input, liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of reasonably possible increase in unobservable input, liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand and Twenty seven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of employee compensation costs [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of employees compensation costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical areas [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical areas [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of detailed information about financial instruments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about financial instruments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. YORVIPATH [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">United States Yorvipath [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. YORVIPATH.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BalancesWithBanks_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balances with banks</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BalancesWithBanks_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bank deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Conversion Of Convertible Senior Notes Into Number Of Ordinary Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential conversion of convertible senior notes into number of ordinary shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of cash flows [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherProvisionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other provisions [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sharebased Payment Arrangement, Award type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Award type [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">All levels of fair value hierarchy [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of interest rates [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of interest rates [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share of profit (loss) of associates accounted for using equity method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share of profit/(loss) of associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Share of profit/(loss) of associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfProvisionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of other provisions [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Multiplied to Purchase Price Minus Revenue Interest Payments Paid to Purchaser on Effective Date of Buy-out Notice As Buyout Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of general information about financial statements [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of entity's operating segments [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity's total for related parties [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">June 30, 2024 (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Treasury Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of treasury shares outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">January 1, 2024 (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DistributableEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distributable equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DistributableEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Distributable equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DistributableEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Distributable equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in derivative financial liabilities fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Derivative Financial Liabilities Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in derivative financial liabilities fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows generated from/(used in) operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BasicAndDilutedEarningsLossPerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted earnings / (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BasicAndDilutedEarningsLossPerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basic And Diluted Earnings Loss Per Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BasicAndDilutedEarningsLossPerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basic And Diluted Earnings Loss Per Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss) from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating profit/(loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecurities1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecurities1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable securities1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecurities1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share capital [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share capital [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Timing of transfer of goods or services [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of fair value measurement of liabilities [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of initial application of standards or interpretations [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">New and Amended Standards and Interpretations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New and Amended Standards and Interpretations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through transactions with owners, equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive income/(loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum additional development and regulatory milestones potentially to be received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum additional development and regulatory milestones potentially to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum additional development and regulatory milestones potentially to be received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Assets at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Assets at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Historical volatility for shares, measurement input [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyConversionOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Conversion Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyConversionOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign Currency Conversion Option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of detailed information about financial instruments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about financial instruments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DetailsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Details [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DetailsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Details</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of maturity analysis for derivative financial liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Holding Of Treasury Shares [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of holding of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income statement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Movements in Level 3 Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Movements in Level Three Fair Value Measurements [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of movements in level 3 fair value measurements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of segment revenues by destination of major customers explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of segment revenues by destination of major customers explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial liabilities at amortised cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities measured at amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at amortised cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of fair value measurement of assets [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MaturityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss) before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Profit/(loss) before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InterestRateTypesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate types [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InterestRateTypesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest rate types [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">"Right-to-use" licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licence fee income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of vesting requirements for share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsRedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings redemption period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsRedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Redemption Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsRedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings redemption period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ChangesInWorkingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in working capital:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ChangesInWorkingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes in working capital [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ChangesInWorkingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in working capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Financial Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of Financial lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue interest payment in percentage in exchange for funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue interest payment in percentage in exchange for funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange rate for percentage of revenue to royalty payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for amortisation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltiesAndMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties and milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltiesAndMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties and Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltiesAndMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties And Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical areas [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical areas [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Invoicing of various development and administrative services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Invoicing of various development and administrative services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Level 1 of fair value hierarchy [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities, category [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities, category [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables, accrued expenses and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for increase (decrease) in trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InvestmentsInAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in associates reported in separate financial statements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InvestmentsInAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment in associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of voluntary change in accounting policy [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial customers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial Customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial customers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of comprehensive income [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NorthAmericaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">North America [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NorthAmericaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">North America [Member]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" xlink:to="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DevelopmentAndAdministrativeServices" xlink:to="asnd_DevelopmentAndAdministrativeServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="ifrs-full_PerformanceObligationsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:to="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FairValueHierarchyCarryingAmountMember" xlink:to="asnd_FairValueHierarchyCarryingAmountMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPaymentEndingPeriod" xlink:to="asnd_RoyaltyPaymentEndingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CollaborationPartnerOneMember" xlink:to="asnd_CollaborationPartnerOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:to="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:to="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesOfNominalValue" xlink:to="asnd_TreasurySharesOfNominalValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:to="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForProvisions" xlink:to="ifrs-full_AdjustmentsForProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:to="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="asnd_ConvertibleDebtCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ThirdPartyInvestorsMember" xlink:to="asnd_ThirdPartyInvestorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConversionPricePerShare" xlink:to="asnd_ConversionPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_OtherShortTermBorrowings" xlink:to="asnd_OtherShortTermBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_InternalProfit" xlink:to="asnd_InternalProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_Borrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_VestingMember" xlink:to="asnd_VestingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ForeignCurrencyRiskAxis" xlink:to="asnd_ForeignCurrencyRiskAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleSeniorNotes" xlink:to="asnd_ConvertibleSeniorNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:to="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="ifrs-full_NewIFRSsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" xlink:to="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:to="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" xlink:to="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory" xlink:to="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:to="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialLiabilities" xlink:to="ifrs-full_DerivativeFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HedgingInstrumentsMember" xlink:to="ifrs-full_HedgingInstrumentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:to="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfWarrantsOutstanding" xlink:to="asnd_NumberOfWarrantsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfSharesIssuedAndOutstanding" xlink:to="asnd_NumberOfSharesIssuedAndOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TransferOfTreasury" xlink:to="asnd_TransferOfTreasury_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:to="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:to="ifrs-full_NoncurrentFinancialAssetsAvailableforsale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock" xlink:to="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentContractLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AtFairValueMember" xlink:to="ifrs-full_AtFairValueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyFundingLiabilities" xlink:to="asnd_RoyaltyFundingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixedInterestRateMember" xlink:to="ifrs-full_FixedInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FrazierLifeSciencesOfEyconisIncMember" xlink:to="asnd_FrazierLifeSciencesOfEyconisIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfTreasuryShares" xlink:to="ifrs-full_PurchaseOfTreasuryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AggregatedMeasurementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SaleOfStockDomain" xlink:to="asnd_SaleOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_SignificantEventsInTheReportingPeriodLineitems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:to="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:to="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="ifrs-full_LiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentySixMember" xlink:to="asnd_TwoThousandAndTwentySixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPaymentBeginningPeriod" xlink:to="asnd_RoyaltyPaymentBeginningPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinancialLiabilities" xlink:to="ifrs-full_OtherFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleNotesCurrent" xlink:to="asnd_ConvertibleNotesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_DisclosureOfWarrantActivityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConversionRatePerNote" xlink:to="asnd_ConversionRatePerNote_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_TypesOfFinancialLiabilitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RevenueFromSaleOfClinicalSupply" xlink:to="asnd_RevenueFromSaleOfClinicalSupply_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" xlink:to="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfGeneralInformationAbstract" xlink:to="asnd_DisclosureOfGeneralInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesTypeMember" xlink:to="ifrs-full_FinancialLiabilitiesTypeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_FinancialAssetsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativesMember" xlink:to="ifrs-full_DerivativesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="asnd_SignificantEventsInTheReportingPeriodTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AmericanDepositorySharesMember" xlink:to="asnd_AmericanDepositorySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxAssetsCurrent" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialLiabilities" xlink:to="ifrs-full_NoncurrentFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MinimumNumberOfCollaborationPartnerAxis" xlink:to="asnd_MinimumNumberOfCollaborationPartnerAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:to="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory" xlink:to="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_BorrowingsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermBorrowings" xlink:to="ifrs-full_ShorttermBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" xlink:to="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="ifrs-full_CounterpartiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiquidityRiskMember" xlink:to="ifrs-full_LiquidityRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="asnd_OtherCurrentLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CapitalCommitmentFromInvestors" xlink:to="asnd_CapitalCommitmentFromInvestors_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingOfSharesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisions" xlink:to="ifrs-full_CurrentProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PaymentTermOfCustomers" xlink:to="asnd_PaymentTermOfCustomers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="ifrs-full_MajorCustomersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPharmaMember" xlink:to="asnd_RoyaltyPharmaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IssuedAndOutstandingSharesAmount" xlink:to="asnd_IssuedAndOutstandingSharesAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_UnobservableInputsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PerformanceStockUnitProgramMember" xlink:to="asnd_PerformanceStockUnitProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:to="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SaleOfStockAxis" xlink:to="asnd_SaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ProfitLossMember" xlink:to="asnd_ProfitLossMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EventsAfterReportingPeriodMember" xlink:to="asnd_EventsAfterReportingPeriodMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:to="ifrs-full_DisclosureOfGeographicalAreasAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsConditionForRedemption" xlink:to="asnd_BorrowingsConditionForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermBorrowings" xlink:to="ifrs-full_LongtermBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FairValueOfConvertibleNotes" xlink:to="asnd_FairValueOfConvertibleNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_SummaryOfSignificantAccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssets" xlink:to="ifrs-full_NoncurrentFinancialAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory" xlink:to="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharePriceAppliedForValuation" xlink:to="asnd_SharePriceAppliedForValuation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:to="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MarketableSecuritiesExplanatory" xlink:to="asnd_MarketableSecuritiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" xlink:to="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FairValueOfRoyaltyFundingLiabilities" xlink:to="asnd_FairValueOfRoyaltyFundingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CarryingAmountOfRoyaltyFundingLiabilities" xlink:to="asnd_CarryingAmountOfRoyaltyFundingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SignificantEventsInTheReportingPeriodTextBlock" xlink:to="asnd_SignificantEventsInTheReportingPeriodTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleSeniorNotesMember" xlink:to="asnd_ConvertibleSeniorNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfReportableOperatingSegments" xlink:to="asnd_NumberOfReportableOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfEntitysRevenue" xlink:to="ifrs-full_PercentageOfEntitysRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsMaturity" xlink:to="ifrs-full_BorrowingsMaturity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DetailsAxis" xlink:to="asnd_DetailsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PerformanceStockUnitsMember" xlink:to="asnd_PerformanceStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" xlink:to="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_FinancialLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfTreasurySharesAbstract" xlink:to="asnd_DisclosureOfTreasurySharesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyFiveMember" xlink:to="asnd_TwoThousandAndTwentyFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfCommercialCustomers" xlink:to="asnd_NumberOfCommercialCustomers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyFourMember" xlink:to="asnd_TwoThousandAndTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromSaleOfGoods" xlink:to="ifrs-full_RevenueFromSaleOfGoods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharePriceMeasurementInputMember" xlink:to="asnd_SharePriceMeasurementInputMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyThreeMember" xlink:to="asnd_TwoThousandAndTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" xlink:to="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_Warrant1Member" xlink:to="asnd_Warrant1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UnitedStatesSkytrofaMember" xlink:to="asnd_UnitedStatesSkytrofaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentReceivables" xlink:to="ifrs-full_OtherNoncurrentReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:to="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:to="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FundingReceivedInExchange" xlink:to="asnd_FundingReceivedInExchange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:to="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:to="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TeijinLimitedMember" xlink:to="asnd_TeijinLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromRenderingOfServices" xlink:to="ifrs-full_RevenueFromRenderingOfServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:to="asnd_SignificantEventsInTheReportingPeriodAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RestrictedStockUnitsMember" xlink:to="asnd_RestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:to="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ForeignCurrencyRiskDomain" xlink:to="asnd_ForeignCurrencyRiskDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentySevenMember" xlink:to="asnd_TwoThousandAndTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UnitedStatesYorvipathMember" xlink:to="asnd_UnitedStatesYorvipathMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BalancesWithBanks" xlink:to="ifrs-full_BalancesWithBanks_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:to="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherProvisionsMember" xlink:to="ifrs-full_OtherProvisionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeMember" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfProvisionsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfTreasurySharesOutstanding" xlink:to="asnd_NumberOfTreasurySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DistributableEquity" xlink:to="asnd_DistributableEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BasicAndDilutedEarningsLossPerShares" xlink:to="asnd_BasicAndDilutedEarningsLossPerShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MarketableSecurities1" xlink:to="asnd_MarketableSecurities1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:to="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ForeignCurrencyConversionOptionMember" xlink:to="asnd_ForeignCurrencyConversionOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DetailsDomain" xlink:to="asnd_DetailsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncomeStatementMember" xlink:to="asnd_IncomeStatementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" xlink:to="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" xlink:to="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UpfrontPaymentReceived" xlink:to="asnd_UpfrontPaymentReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="ifrs-full_InterestRateTypesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LicenceFeeIncome" xlink:to="ifrs-full_LicenceFeeIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsRedemptionPeriod" xlink:to="asnd_BorrowingsRedemptionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="asnd_ChangesInWorkingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:to="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltiesAndMilestonesMember" xlink:to="asnd_RoyaltiesAndMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices" xlink:to="asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInAssociates" xlink:to="ifrs-full_InvestmentsInAssociates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CommercialCustomersMember" xlink:to="asnd_CommercialCustomersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BasicAndDilutedEarningsLossPerShares" xlink:label="asnd_BasicAndDilutedEarningsLossPerShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="asnd_BasicAndDilutedEarningsLossPerShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfWarrantsOutstanding" xlink:label="asnd_NumberOfWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="asnd_Warrant1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="asnd_ConvertibleSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_NumberOfWarrantsOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="ifrs-full_OrdinarySharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleDebtCurrentAbstract" xlink:label="asnd_ConvertibleDebtCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowings" xlink:label="ifrs-full_ShorttermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_OtherCurrentLiabilitiesAbstract" xlink:label="asnd_OtherCurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_OtherShortTermBorrowings" xlink:label="asnd_OtherShortTermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DistributableEquity" xlink:label="asnd_DistributableEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleNotesCurrent" xlink:label="asnd_ConvertibleNotesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociates" xlink:label="ifrs-full_InvestmentsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="ifrs-full_OtherNoncurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MarketableSecurities1" xlink:label="asnd_MarketableSecurities1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="ifrs-full_ShorttermBorrowings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="asnd_OtherShortTermBorrowings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_LongtermBorrowings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="asnd_ConvertibleDebtCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="asnd_DistributableEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentContractLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentContractLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="asnd_OtherCurrentLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="asnd_ConvertibleNotesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InvestmentsInAssociates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_DeferredTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssetsAvailableforsale" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentTaxLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentProvisions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="asnd_MarketableSecurities1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TransferOfTreasury" xlink:label="asnd_TransferOfTreasury"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_9"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_TransferOfTreasury" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_PurchaseOfTreasuryShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ChangesInWorkingCapitalAbstract" xlink:label="asnd_ChangesInWorkingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BalancesWithBanks" xlink:label="ifrs-full_BalancesWithBanks"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_9"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_FinanceIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_FinanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="asnd_ChangesInWorkingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForProvisions" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_BalancesWithBanks" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/GeneralInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfGeneralInformationAbstract" xlink:label="asnd_DisclosureOfGeneralInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfGeneralInformationAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/SignificantAccountingJudgementsAndEstimates" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/SignificantEventsInTheReportingPeriod" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:label="asnd_SignificantEventsInTheReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SignificantEventsInTheReportingPeriodTextBlock" xlink:label="asnd_SignificantEventsInTheReportingPeriodTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:to="asnd_SignificantEventsInTheReportingPeriodTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/Revenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/SegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPayment" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ShareCapital" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/TreasuryShares" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfInformationAboutTreasurySharesExplanatory" xlink:label="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfTreasurySharesAbstract" xlink:to="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/SubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory" xlink:label="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" xlink:label="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory" xlink:label="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/RevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfTreasurySharesAbstract" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock" xlink:label="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="asnd_AmericanDepositorySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="asnd_ConvertibleSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConversionPricePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConvertibleSeniorNotes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_NewIFRSsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_BorrowingsMaturity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_RangeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_CurrentProvisions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherProvisionsMember" xlink:to="asnd_SalesRebatesAndProductReturnsInUSMarketMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_OtherProvisionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_Revenue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="srt_RestatementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:label="asnd_SignificantEventsInTheReportingPeriodLineitems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SignificantEventsInTheReportingPeriodTable" xlink:label="asnd_SignificantEventsInTheReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ThirdPartyInvestorsMember" xlink:label="asnd_ThirdPartyInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:label="asnd_SignificantEventsInTheReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FrazierLifeSciencesOfEyconisIncMember" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfSharesIssuedAndOutstanding" xlink:label="asnd_NumberOfSharesIssuedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IssuedAndOutstandingSharesAmount" xlink:label="asnd_IssuedAndOutstandingSharesAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices" xlink:label="asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DevelopmentAndAdministrativeServices" xlink:label="asnd_DevelopmentAndAdministrativeServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_CapitalCommitmentFromInvestors" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="asnd_EventsAfterReportingPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="asnd_ThirdPartyInvestorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:to="asnd_SignificantEventsInTheReportingPeriodTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_RoyaltyPharmaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="asnd_FrazierLifeSciencesOfEyconisIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_UnitedStatesSkytrofaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_CounterpartiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_NumberOfSharesIssuedAndOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_MajorCustomersAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_IssuedAndOutstandingSharesAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="asnd_SignificantEventsInTheReportingPeriodLineitems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_DevelopmentAndAdministrativeServices" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_Equity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRenderingOfServices" xlink:label="ifrs-full_RevenueFromRenderingOfServices"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RevenueFromSaleOfClinicalSupply" xlink:label="asnd_RevenueFromSaleOfClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_4"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="asnd_CommercialCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:to="ifrs-full_Revenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="srt_EuropeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromRenderingOfServices" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="srt_NorthAmericaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_RevenueFromSaleOfClinicalSupply" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_MajorCustomersAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_CN" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_LicenceFeeIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="srt_AsiaMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfGeographicalAreasAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="ifrs-full_PerformanceObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltiesAndMilestonesMember" xlink:label="asnd_RoyaltiesAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PaymentTermOfCustomers" xlink:label="asnd_PaymentTermOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MinimumNumberOfCollaborationPartnerAxis" xlink:label="asnd_MinimumNumberOfCollaborationPartnerAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CollaborationPartnerOneMember" xlink:label="asnd_CollaborationPartnerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ThirdPartyInvestorsMember" xlink:label="asnd_ThirdPartyInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfCommercialCustomers" xlink:label="asnd_NumberOfCommercialCustomers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FrazierLifeSciencesOfEyconisIncMember" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TeijinLimitedMember" xlink:label="asnd_TeijinLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_UpfrontPaymentReceived" xlink:label="asnd_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_InternalProfit" xlink:label="asnd_InternalProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:label="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="asnd_RoyaltiesAndMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_PaymentTermOfCustomers" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="asnd_EventsAfterReportingPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_MinimumNumberOfCollaborationPartnerAxis" xlink:to="asnd_CollaborationPartnerOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="asnd_ThirdPartyInvestorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="asnd_CommercialCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_NumberOfCommercialCustomers" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="asnd_FrazierLifeSciencesOfEyconisIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="asnd_MinimumNumberOfCollaborationPartnerAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_PercentageOfEntitysRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="asnd_TeijinLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_CapitalCommitmentFromInvestors" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_PerformanceObligationsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_UpfrontPaymentReceived" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_CounterpartiesAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_InternalProfit" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfReportableOperatingSegments" xlink:label="asnd_NumberOfReportableOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_NumberOfReportableOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncomeStatementAxis" xlink:label="asnd_IncomeStatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncomeStatementMember" xlink:label="asnd_IncomeStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ProfitLossMember" xlink:label="asnd_ProfitLossMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PerformanceStockUnitProgramMember" xlink:label="asnd_PerformanceStockUnitProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_IncomeStatementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_IncomeStatementMember" xlink:to="asnd_ProfitLossMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfWarrantActivityLineItems" xlink:label="asnd_DisclosureOfWarrantActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_4"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_10"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="asnd_Warrant1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_DisclosureOfWarrantActivityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentyThreeMember" xlink:label="asnd_TwoThousandAndTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_VestingOfSharesAxis" xlink:label="asnd_VestingOfSharesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementAwardTypeMember" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentyFourMember" xlink:label="asnd_TwoThousandAndTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentyFiveMember" xlink:label="asnd_TwoThousandAndTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentySevenMember" xlink:label="asnd_TwoThousandAndTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFourMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_VestingOfSharesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFiveMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySixMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySevenMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ShareCapitalAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_ParValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesOfNominalValue" xlink:label="asnd_TreasurySharesOfNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesOfNominalValue" xlink:label="asnd_TreasurySharesOfNominalValue_2"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding_5"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_8"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesOfNominalValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesOfNominalValue_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_NumberOfTreasurySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_NumberOfTreasurySharesOutstanding_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_8" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="ifrs-full_CurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MarketableSecurities1" xlink:label="asnd_MarketableSecurities1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_ConvertibleSeniorNotes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentFinancialLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_TradeReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CurrentFinancialLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_CurrentFinancialAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="asnd_MarketableSecurities1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_OtherFinancialLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ForeignCurrencyRiskAxis" xlink:label="asnd_ForeignCurrencyRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ForeignCurrencyRiskDomain" xlink:label="asnd_ForeignCurrencyRiskDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="ifrs-full_HedgingInstrumentsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ForeignCurrencyConversionOptionMember" xlink:label="asnd_ForeignCurrencyConversionOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember" xlink:label="ifrs-full_DerivativesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember" xlink:label="ifrs-full_FinancialLiabilitiesTypeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SaleOfStockAxis" xlink:label="asnd_SaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SaleOfStockDomain" xlink:label="asnd_SaleOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="ifrs-full_HedgingInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DetailsAxis" xlink:label="asnd_DetailsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DetailsDomain" xlink:label="asnd_DetailsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharePriceMeasurementInputMember" xlink:label="asnd_SharePriceMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConversionRatePerNote" xlink:label="asnd_ConversionRatePerNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsRedemptionPeriod" xlink:label="asnd_BorrowingsRedemptionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsConditionForRedemption" xlink:label="asnd_BorrowingsConditionForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FairValueOfConvertibleNotes" xlink:label="asnd_FairValueOfConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharePriceAppliedForValuation" xlink:label="asnd_SharePriceAppliedForValuation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FundingReceivedInExchange" xlink:label="asnd_FundingReceivedInExchange"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPaymentBeginningPeriod" xlink:label="asnd_RoyaltyPaymentBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPaymentEndingPeriod" xlink:label="asnd_RoyaltyPaymentEndingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CarryingAmountOfRoyaltyFundingLiabilities" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FairValueOfRoyaltyFundingLiabilities" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ForeignCurrencyRiskAxis" xlink:to="asnd_ForeignCurrencyRiskDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_HedgingInstrumentsMember" xlink:to="asnd_ForeignCurrencyConversionOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember" xlink:to="asnd_AmericanDepositorySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="ifrs-full_DerivativesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesTypeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SaleOfStockAxis" xlink:to="asnd_SaleOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="asnd_ConvertibleSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DetailsAxis" xlink:to="asnd_DetailsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_RoyaltyPharmaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="asnd_ForeignCurrencyRiskAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="ifrs-full_FixedInterestRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_LiquidityRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="asnd_SharePriceMeasurementInputMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_UnitedStatesSkytrofaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="asnd_DetailsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="asnd_SaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsInArrearsDefaultPaymentStartDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionRatePerNote" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfFinancialLiabilitiesAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NotionalAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsRedemptionPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_HedgingInstrumentsAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsConditionForRedemption" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_UnobservableInputsAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdTradingDaysForRedemption" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_RangeAxis" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsMaturity" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConvertibleSeniorNotes" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FairValueOfConvertibleNotes" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_SharePriceAppliedForValuation" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchange" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchangeOfRoyaltyPayments" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentBeginningPeriod" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentEndingPeriod" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_CarryingAmountOfRoyaltyFundingLiabilities" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FairValueOfRoyaltyFundingLiabilities" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FairValueHierarchyCarryingAmountMember" xlink:label="asnd_FairValueHierarchyCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="asnd_FairValueHierarchyCarryingAmountMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="asnd_MarketableSecuritiesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_MeasurementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AtFairValueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="asnd_ConvertibleSeniorNotes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="asnd_RoyaltyFundingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_BorrowingsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ConvertibleSeniorNotes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_Borrowings" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_TradeAndOtherPayables" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_OtherFinancialLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FundingReceivedInExchange" xlink:label="asnd_FundingReceivedInExchange"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPaymentEndingPeriod" xlink:label="asnd_RoyaltyPaymentEndingPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_FundingReceivedInExchangeOfRoyaltyPayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="asnd_EventsAfterReportingPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_RoyaltyPharmaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_FundingReceivedInExchange" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_UnitedStatesYorvipathMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_RoyaltyPaymentEndingPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/CoverPage">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfWarrantsOutstanding" xlink:label="asnd_NumberOfWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="asnd_Warrant1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="asnd_ConvertibleSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_NumberOfWarrantsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="ifrs-full_OrdinarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TransferOfTreasury" xlink:label="asnd_TransferOfTreasury"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_TransferOfTreasury" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_PurchaseOfTreasuryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="asnd_AmericanDepositorySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="asnd_ConvertibleSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConversionPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_NewIFRSsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_CurrentLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_BorrowingsMaturity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_CurrentProvisions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_OtherProvisionsMember" xlink:to="asnd_SalesRebatesAndProductReturnsInUSMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_OtherProvisionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_OtherProvisionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_Revenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:label="asnd_SignificantEventsInTheReportingPeriodLineitems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SignificantEventsInTheReportingPeriodTable" xlink:label="asnd_SignificantEventsInTheReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ThirdPartyInvestorsMember" xlink:label="asnd_ThirdPartyInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FrazierLifeSciencesOfEyconisIncMember" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfSharesIssuedAndOutstanding" xlink:label="asnd_NumberOfSharesIssuedAndOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IssuedAndOutstandingSharesAmount" xlink:label="asnd_IssuedAndOutstandingSharesAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices" xlink:label="asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DevelopmentAndAdministrativeServices" xlink:label="asnd_DevelopmentAndAdministrativeServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_SignificantEventsInTheReportingPeriodTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_CapitalCommitmentFromInvestors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="asnd_EventsAfterReportingPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="asnd_ThirdPartyInvestorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_RoyaltyPharmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="asnd_FrazierLifeSciencesOfEyconisIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_UnitedStatesSkytrofaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_CounterpartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_NumberOfSharesIssuedAndOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_IssuedAndOutstandingSharesAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_DevelopmentAndAdministrativeServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_Equity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRenderingOfServices" xlink:label="ifrs-full_RevenueFromRenderingOfServices"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RevenueFromSaleOfClinicalSupply" xlink:label="asnd_RevenueFromSaleOfClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromSaleOfGoods" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="asnd_CommercialCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:to="ifrs-full_Revenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="srt_EuropeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromRenderingOfServices" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="srt_NorthAmericaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_RevenueFromSaleOfClinicalSupply" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_CN" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_LicenceFeeIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="srt_AsiaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfGeographicalAreasAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:label="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="ifrs-full_PerformanceObligationsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltiesAndMilestonesMember" xlink:label="asnd_RoyaltiesAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PaymentTermOfCustomers" xlink:label="asnd_PaymentTermOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PerformanceObligationsMember" xlink:label="ifrs-full_PerformanceObligationsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MinimumNumberOfCollaborationPartnerAxis" xlink:label="asnd_MinimumNumberOfCollaborationPartnerAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CollaborationPartnerOneMember" xlink:label="asnd_CollaborationPartnerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CollaborationPartnerOneMember" xlink:label="asnd_CollaborationPartnerOneMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ThirdPartyInvestorsMember" xlink:label="asnd_ThirdPartyInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfCommercialCustomers" xlink:label="asnd_NumberOfCommercialCustomers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FrazierLifeSciencesOfEyconisIncMember" xlink:label="asnd_FrazierLifeSciencesOfEyconisIncMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TeijinLimitedMember" xlink:label="asnd_TeijinLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CapitalCommitmentFromInvestors" xlink:label="asnd_CapitalCommitmentFromInvestors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_UpfrontPaymentReceived" xlink:label="asnd_UpfrontPaymentReceived"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_InternalProfit" xlink:label="asnd_InternalProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" xlink:label="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PerformanceObligationsMember" xlink:to="asnd_RoyaltiesAndMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_PaymentTermOfCustomers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="asnd_EventsAfterReportingPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_MinimumNumberOfCollaborationPartnerAxis" xlink:to="asnd_CollaborationPartnerOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_MinimumNumberOfCollaborationPartnerAxis" xlink:to="asnd_CollaborationPartnerOneMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="asnd_ThirdPartyInvestorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="asnd_CommercialCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_NumberOfCommercialCustomers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="asnd_FrazierLifeSciencesOfEyconisIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="asnd_MinimumNumberOfCollaborationPartnerAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_PercentageOfEntitysRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="asnd_TeijinLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_CapitalCommitmentFromInvestors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_PerformanceObligationsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_UpfrontPaymentReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_CounterpartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_InternalProfit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems" xlink:to="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfReportableOperatingSegments" xlink:label="asnd_NumberOfReportableOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_NumberOfReportableOperatingSegments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncomeStatementAxis" xlink:label="asnd_IncomeStatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncomeStatementMember" xlink:label="asnd_IncomeStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncomeStatementMember" xlink:label="asnd_IncomeStatementMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ProfitLossMember" xlink:label="asnd_ProfitLossMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PerformanceStockUnitProgramMember" xlink:label="asnd_PerformanceStockUnitProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_IncomeStatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_IncomeStatementMember" xlink:to="asnd_ProfitLossMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfWarrantActivityLineItems" xlink:label="asnd_DisclosureOfWarrantActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="asnd_Warrant1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentyThreeMember" xlink:label="asnd_TwoThousandAndTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_VestingOfSharesAxis" xlink:label="asnd_VestingOfSharesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharebasedPaymentArrangementAwardTypeMember" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentyFourMember" xlink:label="asnd_TwoThousandAndTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentyFiveMember" xlink:label="asnd_TwoThousandAndTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TwoThousandAndTwentySevenMember" xlink:label="asnd_TwoThousandAndTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_VestingOfSharesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesOfNominalValue" xlink:label="asnd_TreasurySharesOfNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesOfNominalValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_NumberOfTreasurySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesMember" xlink:label="ifrs-full_FinancialLiabilitiesMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsMember" xlink:label="ifrs-full_FinancialAssetsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="ifrs-full_CurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MarketableSecurities1" xlink:label="asnd_MarketableSecurities1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialAssetsMember" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_FinancialAssetsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_TradeReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CurrentFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_CurrentFinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="asnd_MarketableSecurities1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_OtherFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ForeignCurrencyRiskAxis" xlink:label="asnd_ForeignCurrencyRiskAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ForeignCurrencyRiskDomain" xlink:label="asnd_ForeignCurrencyRiskDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ForeignCurrencyRiskDomain" xlink:label="asnd_ForeignCurrencyRiskDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="ifrs-full_HedgingInstrumentsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ForeignCurrencyConversionOptionMember" xlink:label="asnd_ForeignCurrencyConversionOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativesMember" xlink:label="ifrs-full_DerivativesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_TypesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember" xlink:label="ifrs-full_FinancialLiabilitiesTypeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesTypeMember" xlink:label="ifrs-full_FinancialLiabilitiesTypeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SaleOfStockAxis" xlink:label="asnd_SaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SaleOfStockDomain" xlink:label="asnd_SaleOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SaleOfStockDomain" xlink:label="asnd_SaleOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="ifrs-full_HedgingInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgingInstrumentsMember" xlink:label="ifrs-full_HedgingInstrumentsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DetailsAxis" xlink:label="asnd_DetailsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DetailsDomain" xlink:label="asnd_DetailsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DetailsDomain" xlink:label="asnd_DetailsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharePriceMeasurementInputMember" xlink:label="asnd_SharePriceMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConversionRatePerNote" xlink:label="asnd_ConversionRatePerNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsRedemptionPeriod" xlink:label="asnd_BorrowingsRedemptionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsConditionForRedemption" xlink:label="asnd_BorrowingsConditionForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FairValueOfConvertibleNotes" xlink:label="asnd_FairValueOfConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_SharePriceAppliedForValuation" xlink:label="asnd_SharePriceAppliedForValuation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FundingReceivedInExchange" xlink:label="asnd_FundingReceivedInExchange"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPaymentBeginningPeriod" xlink:label="asnd_RoyaltyPaymentBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPaymentEndingPeriod" xlink:label="asnd_RoyaltyPaymentEndingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_CarryingAmountOfRoyaltyFundingLiabilities" xlink:label="asnd_CarryingAmountOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FairValueOfRoyaltyFundingLiabilities" xlink:label="asnd_FairValueOfRoyaltyFundingLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ForeignCurrencyRiskAxis" xlink:to="asnd_ForeignCurrencyRiskDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_ForeignCurrencyRiskAxis" xlink:to="asnd_ForeignCurrencyRiskDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_HedgingInstrumentsMember" xlink:to="asnd_ForeignCurrencyConversionOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EquityMember" xlink:to="asnd_AmericanDepositorySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="ifrs-full_DerivativesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesTypeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesTypeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_SaleOfStockAxis" xlink:to="asnd_SaleOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_SaleOfStockAxis" xlink:to="asnd_SaleOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="asnd_ConvertibleSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_DetailsAxis" xlink:to="asnd_DetailsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_DetailsAxis" xlink:to="asnd_DetailsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_InterestRateTypesMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_RoyaltyPharmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="asnd_ForeignCurrencyRiskAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_InterestRateTypesMember" xlink:to="ifrs-full_FixedInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_LiquidityRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="asnd_SharePriceMeasurementInputMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_UnitedStatesSkytrofaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="asnd_DetailsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="asnd_SaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsInArrearsDefaultPaymentStartDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionRatePerNote" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfFinancialLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsRedemptionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_HedgingInstrumentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsConditionForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_UnobservableInputsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdTradingDaysForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsMaturity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FairValueOfConvertibleNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_SharePriceAppliedForValuation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchangeOfRoyaltyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentBeginningPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentEndingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_CarryingAmountOfRoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FairValueOfRoyaltyFundingLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FairValueHierarchyCarryingAmountMember" xlink:label="asnd_FairValueHierarchyCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="asnd_FairValueHierarchyCarryingAmountMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="asnd_MarketableSecuritiesExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_MeasurementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AtFairValueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="asnd_RoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_BorrowingsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_Borrowings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_LeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_TradeAndOtherPayables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_OtherFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_FinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_FundingReceivedInExchange" xlink:label="asnd_FundingReceivedInExchange"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RoyaltyPaymentEndingPeriod" xlink:label="asnd_RoyaltyPaymentEndingPeriod"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_FundingReceivedInExchangeOfRoyaltyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="asnd_EventsAfterReportingPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_RoyaltyPharmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_FundingReceivedInExchange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="asnd_UnitedStatesYorvipathMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="asnd_RoyaltyPaymentEndingPeriod" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_Revenue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncome" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GrossProfit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_CostOfSales" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceCosts" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_NoncurrentLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_ConvertibleNotesCurrent" xlink:to="ifrs-full_ShorttermBorrowings" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="asnd_OtherShortTermBorrowings" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTradeReceivables" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="asnd_ConvertibleNotesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_ConvertibleNotesCurrent" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentReceivables" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="asnd_DistributableEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentPrepayments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_InvestmentsInAssociates" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_LongtermBorrowings" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="asnd_MarketableSecurities1" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentReceivables" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentFinancialAssetsAvailableforsale" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentProvisions" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_ConvertibleNotesCurrent" xlink:label="asnd_ConvertibleNotesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShorttermBorrowings" xlink:label="ifrs-full_ShorttermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_OtherShortTermBorrowings" xlink:label="asnd_OtherShortTermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_DistributableEquity" xlink:label="asnd_DistributableEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InvestmentsInAssociates" xlink:label="ifrs-full_InvestmentsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_MarketableSecurities1" xlink:label="asnd_MarketableSecurities1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="ifrs-full_OtherNoncurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentFinancialAssetsAvailableforsale" xlink:label="ifrs-full_NoncurrentFinancialAssetsAvailableforsale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_FinanceIncome" order="11" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_ProfitLoss" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_FinanceCosts" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="15" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForProvisions" order="16" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_RevenueFromRenderingOfServices" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_LicenceFeeIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Revenue" xlink:to="asnd_RevenueFromSaleOfClinicalSupply" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromRenderingOfServices" xlink:label="ifrs-full_RevenueFromRenderingOfServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20240630.xsd#asnd_RevenueFromSaleOfClinicalSupply" xlink:label="asnd_RevenueFromSaleOfClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" name="ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" name="ContractualUndiscountedCashflowOfConvertibleSeniorNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_FundingReceivedInExchange" name="FundingReceivedInExchange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_FundingReceivedInExchangeOfRoyaltyPayments" name="FundingReceivedInExchangeOfRoyaltyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_FrazierLifeSciencesOfEyconisIncMember" name="FrazierLifeSciencesOfEyconisIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IssuedAndOutstandingSharesAmount" name="IssuedAndOutstandingSharesAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ConvertibleSeniorNotesMember" name="ConvertibleSeniorNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SignificantEventsInTheReportingPeriodTable" name="SignificantEventsInTheReportingPeriodTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NumberOfWarrantsOutstanding" name="NumberOfWarrantsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_CollaborationPartnerOneMember" name="CollaborationPartnerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" name="BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfHoldingOfTreasurySharesAbstract" name="DisclosureOfHoldingOfTreasurySharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" name="DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ConvertibleSeniorNotes" name="ConvertibleSeniorNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" name="DisclosureOfSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" name="AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfWarrantActivityLineItems" name="DisclosureOfWarrantActivityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_BorrowingsInArrearsDefaultPaymentStartDate" name="BorrowingsInArrearsDefaultPaymentStartDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" name="DerivativeFinancialLiabilitiesAtFairValueTransfered" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_CapitalCommitmentFromInvestors" name="CapitalCommitmentFromInvestors" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_EventsAfterReportingPeriodMember" name="EventsAfterReportingPeriodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SummaryOfSignificantAccountingPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" name="AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices" name="InvoicingOfVariousDevelopmentAndAdministrativeServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_ProfitLossMember" name="ProfitLossMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltyPaymentBeginningPeriod" name="RoyaltyPaymentBeginningPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_FairValueHierarchyCarryingAmountMember" name="FairValueHierarchyCarryingAmountMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" name="DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_BorrowingsConditionForRedemption" name="BorrowingsConditionForRedemption" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TreasurySharesOfNominalValue" name="TreasurySharesOfNominalValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfHoldingOfTreasurySharesTable" name="DisclosureOfHoldingOfTreasurySharesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncomeStatementMember" name="IncomeStatementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_UnitedStatesSkytrofaMember" name="UnitedStatesSkytrofaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock" name="MaturityAnalysisForFinancialLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_PaymentTermOfCustomers" name="PaymentTermOfCustomers" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SharePriceMeasurementInputMember" name="SharePriceMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfTreasurySharesAbstract" name="DisclosureOfTreasurySharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" name="ContractualUndiscountedCashflowOfFinancialBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" name="MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_CollaborationPartnersAndLicenseAgreementsMember" name="CollaborationPartnersAndLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RestrictedStockUnitsMember" name="RestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" name="MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" name="WeightedAverageDurationOfMarketableSecuritiesExplanatory" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ConversionRatePerNote" name="ConversionRatePerNote" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" name="TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" name="DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" name="DisclosureOfHoldingOfTreasurySharesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TwoThousandAndTwentyFourMember" name="TwoThousandAndTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SignificantEventsInTheReportingPeriodAbstract" name="SignificantEventsInTheReportingPeriodAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" name="DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" name="PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RevenueFromSaleOfClinicalSupply" name="RevenueFromSaleOfClinicalSupply" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_IncomeStatementAxis" name="IncomeStatementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ForeignCurrencyConversionOptionMember" name="ForeignCurrencyConversionOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_Warrant1Member" name="Warrant1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_CarryingAmountOfRoyaltyFundingLiabilities" name="CarryingAmountOfRoyaltyFundingLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_TransferOfTreasury" name="TransferOfTreasury" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" name="BorrowingsThresholdConsecutiveTradingDaysForRedemption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_VestingMember" name="VestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" name="IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ForeignCurrencyRiskAxis" name="ForeignCurrencyRiskAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SignificantEventsInTheReportingPeriodTextBlock" name="SignificantEventsInTheReportingPeriodTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory" name="DisclosureOfInformationAboutTreasurySharesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TwoThousandAndTwentySixMember" name="TwoThousandAndTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PerformanceStockUnitProgramMember" name="PerformanceStockUnitProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" name="AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NumberOfCommercialCustomers" name="NumberOfCommercialCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" name="DerivativeFinancialLiabilitiesAtFairValueSettled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_PerformanceStockUnitsMember" name="PerformanceStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ConvertibleNotesCurrent" name="ConvertibleNotesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" name="MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" name="SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ConvertibleDebtCurrentAbstract" name="ConvertibleDebtCurrentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" name="DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_FairValueOfConvertibleNotes" name="FairValueOfConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementAwardTypeDomain" name="SharebasedPaymentArrangementAwardTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_CommercialCustomersMember" name="CommercialCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" name="ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ThirdPartyInvestorsMember" name="ThirdPartyInvestorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_OtherCurrentLiabilitiesAbstract" name="OtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" name="TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" name="ExchangeRateForPercentageOfRevenueToRoyaltyPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TwoThousandAndTwentySevenMember" name="TwoThousandAndTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" name="ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" name="WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DetailsDomain" name="DetailsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DetailsAxis" name="DetailsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_UpfrontPaymentReceived" name="UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" name="SharebasedPaymentArrangementRestrictedStockUnitActivityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory" name="DisclosureOfRoyaltyFundingLiabilitiesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_NumberOfReportableOperatingSegments" name="NumberOfReportableOperatingSegments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" name="DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DistributableEquity" name="DistributableEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" name="NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_NumberOfSharesIssuedAndOutstanding" name="NumberOfSharesIssuedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ShareBasedPaymentArrangementAwardTypeAxis" name="ShareBasedPaymentArrangementAwardTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltiesAndMilestonesMember" name="RoyaltiesAndMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SalesRebatesAndProductReturnsInUSMarketMember" name="SalesRebatesAndProductReturnsInUSMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ChangesInWorkingCapitalAbstract" name="ChangesInWorkingCapitalAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_MarketableSecuritiesExplanatory" name="MarketableSecuritiesExplanatory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" name="ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" name="PercentageOfVestingRightsForShareBasedPaymentArrangement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_OtherShortTermBorrowings" name="OtherShortTermBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_TeijinLimitedMember" name="TeijinLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_UnitedStatesYorvipathMember" name="UnitedStatesYorvipathMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" name="IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" name="DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SharePriceAppliedForValuation" name="SharePriceAppliedForValuation" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AmericanDepositorySharesMember" name="AmericanDepositorySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SignificantEventsInTheReportingPeriodLineitems" name="SignificantEventsInTheReportingPeriodLineitems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfEmployeeCompensationCostsAbstract" name="DisclosureOfEmployeeCompensationCostsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" name="NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_FairValueOfRoyaltyFundingLiabilities" name="FairValueOfRoyaltyFundingLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ForeignCurrencyRiskDomain" name="ForeignCurrencyRiskDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltyPharmaMember" name="RoyaltyPharmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TwoThousandAndTwentyFiveMember" name="TwoThousandAndTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ConversionPricePerShare" name="ConversionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementAwardTypeMember" name="SharebasedPaymentArrangementAwardTypeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DevelopmentAndAdministrativeServices" name="DevelopmentAndAdministrativeServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_VestingOfSharesAxis" name="VestingOfSharesAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_MinimumNumberOfCollaborationPartnerAxis" name="MinimumNumberOfCollaborationPartnerAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltyPaymentEndingPeriod" name="RoyaltyPaymentEndingPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_BasicAndDilutedEarningsLossPerShares" name="BasicAndDilutedEarningsLossPerShares" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" name="WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" name="DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" name="ContractualUndiscountedCashflowOfFinancialLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" name="TreasurySharesHoldingInPercentageOfTotalOutstandingShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TwoThousandAndTwentyThreeMember" name="TwoThousandAndTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" name="AdjustmentsForNonCashConsiderationRegardingRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_SaleOfStockAxis" name="SaleOfStockAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_BorrowingsRedemptionPeriod" name="BorrowingsRedemptionPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" name="DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" name="AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_InternalProfit" name="InternalProfit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_MarketableSecurities1" name="MarketableSecurities1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" name="DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_NumberOfTreasurySharesOutstanding" name="NumberOfTreasurySharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" name="WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfGeneralInformationAbstract" name="DisclosureOfGeneralInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" name="SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SaleOfStockDomain" name="SaleOfStockDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" name="NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_BorrowingsThresholdTradingDaysForRedemption" name="BorrowingsThresholdTradingDaysForRedemption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RoyaltyFundingLiabilities" name="RoyaltyFundingLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" name="RestrictedStockUnitsAndPerformanceStockUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700826617840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Ascendis Pharma A/S<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001612042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700826604560">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 35,998<span></span>
</td>
<td class="nump">&#8364; 47,393<span></span>
</td>
<td class="nump">&#8364; 131,892<span></span>
</td>
<td class="nump">&#8364; 80,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,465<span></span>
</td>
<td class="nump">12,929<span></span>
</td>
<td class="nump">19,034<span></span>
</td>
<td class="nump">17,551<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">24,533<span></span>
</td>
<td class="nump">34,464<span></span>
</td>
<td class="nump">112,858<span></span>
</td>
<td class="nump">63,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,478<span></span>
</td>
<td class="nump">105,021<span></span>
</td>
<td class="nump">154,165<span></span>
</td>
<td class="nump">211,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">74,312<span></span>
</td>
<td class="nump">70,281<span></span>
</td>
<td class="nump">141,095<span></span>
</td>
<td class="nump">136,820<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(133,257)<span></span>
</td>
<td class="num">(140,838)<span></span>
</td>
<td class="num">(182,402)<span></span>
</td>
<td class="num">(284,523)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) of associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,322)<span></span>
</td>
<td class="num">(7,451)<span></span>
</td>
<td class="num">(11,118)<span></span>
</td>
<td class="num">(8,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">49,052<span></span>
</td>
<td class="nump">35,761<span></span>
</td>
<td class="nump">14,395<span></span>
</td>
<td class="nump">80,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,624<span></span>
</td>
<td class="nump">9,334<span></span>
</td>
<td class="nump">58,553<span></span>
</td>
<td class="nump">18,652<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit/(loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(109,151)<span></span>
</td>
<td class="num">(121,862)<span></span>
</td>
<td class="num">(237,678)<span></span>
</td>
<td class="num">(231,478)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes/(expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(229)<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="num">(2,737)<span></span>
</td>
<td class="num">(868)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(109,380)<span></span>
</td>
<td class="num">(121,433)<span></span>
</td>
<td class="num">(240,415)<span></span>
</td>
<td class="num">(232,346)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Attributable to owners of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (109,380)<span></span>
</td>
<td class="num">&#8364; (121,433)<span></span>
</td>
<td class="num">&#8364; (240,415)<span></span>
</td>
<td class="num">&#8364; (232,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings/(loss) per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (1.91)<span></span>
</td>
<td class="num">&#8364; (2.16)<span></span>
</td>
<td class="num">&#8364; (4.21)<span></span>
</td>
<td class="num">&#8364; (4.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings/(loss) per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (1.91)<span></span>
</td>
<td class="num">&#8364; (2.16)<span></span>
</td>
<td class="num">&#8364; (4.21)<span></span>
</td>
<td class="num">&#8364; (4.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Number of shares used for calculation (basic and diluted)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">57,345,613<span></span>
</td>
<td class="nump">56,218,257<span></span>
</td>
<td class="nump">57,114,435<span></span>
</td>
<td class="nump">56,155,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (109,380)<span></span>
</td>
<td class="num">&#8364; (121,433)<span></span>
</td>
<td class="num">&#8364; (240,415)<span></span>
</td>
<td class="num">&#8364; (232,346)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be reclassified subsequently to profit or (loss):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translating foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="num">(1,016)<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="num">(1,803)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income/(loss) for the period, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15<span></span>
</td>
<td class="num">(1,016)<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="num">(1,803)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(109,365)<span></span>
</td>
<td class="num">(122,449)<span></span>
</td>
<td class="num">(240,337)<span></span>
</td>
<td class="num">(234,149)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Attributable to owners of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (109,365)<span></span>
</td>
<td class="num">&#8364; (122,449)<span></span>
</td>
<td class="num">&#8364; (240,337)<span></span>
</td>
<td class="num">&#8364; (234,149)<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and June 30, 2023, a total of </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,107,875</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,866,241</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> warrants outstanding, respectively, each carrying the right to subscribe for one ordinary share, and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">575,000</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> convertible senior notes which can potentially be converted into </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,456,785</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares, can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the periods presented. </span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700827337440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfWarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">6,107,875<span></span>
</td>
<td class="nump">6,866,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares', window );">Convertible notes</a></td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfWarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">3,456,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential conversion of convertible senior notes into number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=asnd_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=asnd_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700825904080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets</a></td>
<td class="nump">&#8364; 4,186<span></span>
</td>
<td class="nump">&#8364; 4,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">104,041<span></span>
</td>
<td class="nump">110,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociates', window );">Investment in associates</a></td>
<td class="nump">20,564<span></span>
</td>
<td class="nump">5,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentReceivables', window );">Other receivables</a></td>
<td class="nump">2,186<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">130,977<span></span>
</td>
<td class="nump">122,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">251,199<span></span>
</td>
<td class="nump">208,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">49,163<span></span>
</td>
<td class="nump">35,874<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Income tax receivables</a></td>
<td class="nump">1,841<span></span>
</td>
<td class="nump">802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">29,679<span></span>
</td>
<td class="nump">19,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepayments</a></td>
<td class="nump">36,743<span></span>
</td>
<td class="nump">38,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MarketableSecurities1', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">258,696<span></span>
</td>
<td class="nump">392,164<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">627,321<span></span>
</td>
<td class="nump">702,721<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">758,298<span></span>
</td>
<td class="nump">825,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">7,819<span></span>
</td>
<td class="nump">7,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DistributableEquity', window );">Distributable equity</a></td>
<td class="num">(328,952)<span></span>
</td>
<td class="num">(153,446)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="num">(321,133)<span></span>
</td>
<td class="num">(145,697)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Borrowings</a></td>
<td class="nump">219,052<span></span>
</td>
<td class="nump">222,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">7,644<span></span>
</td>
<td class="nump">5,830<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">231,696<span></span>
</td>
<td class="nump">234,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleDebtCurrentAbstract', window );"><strong>Convertible notes, matures in April 2028</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Borrowings</a></td>
<td class="nump">432,190<span></span>
</td>
<td class="nump">407,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">159,059<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleNotesCurrent', window );">Convertible notes current</a></td>
<td class="nump">591,249<span></span>
</td>
<td class="nump">550,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_OtherCurrentLiabilitiesAbstract', window );"><strong>Other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_OtherShortTermBorrowings', window );">Borrowings</a></td>
<td class="nump">21,397<span></span>
</td>
<td class="nump">14,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">1,293<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables and accrued expenses</a></td>
<td class="nump">99,527<span></span>
</td>
<td class="nump">94,566<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">26,411<span></span>
</td>
<td class="nump">41,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Income tax payables</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">2,299<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">106,768<span></span>
</td>
<td class="nump">32,719<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Other current liabilities</a></td>
<td class="nump">256,486<span></span>
</td>
<td class="nump">186,118<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">847,735<span></span>
</td>
<td class="nump">736,509<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,079,431<span></span>
</td>
<td class="nump">971,284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 758,298<span></span>
</td>
<td class="nump">&#8364; 825,587<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleDebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible debt current abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleDebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleNotesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleNotesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DistributableEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distributable equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DistributableEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MarketableSecurities1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MarketableSecurities1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_OtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_OtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other short term borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in associates in an entity's separate financial statements. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700827345040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share Capital [member]</div></th>
<th class="th"><div>Share Premium [member]</div></th>
<th class="th"><div>Treasury Shares [member]</div></th>
<th class="th"><div>Foreign Currency Translation Reserve [member]</div></th>
<th class="th"><div>Accumulated Deficit [member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2022</a></td>
<td class="nump">&#8364; 263,348<span></span>
</td>
<td class="nump">&#8364; 7,675<span></span>
</td>
<td class="nump">&#8364; 2,112,863<span></span>
</td>
<td class="num">&#8364; (149)<span></span>
</td>
<td class="nump">&#8364; 3,452<span></span>
</td>
<td class="num">&#8364; (1,860,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the period</a></td>
<td class="num">(232,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="num">(1,803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss)</a></td>
<td class="num">(234,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,803)<span></span>
</td>
<td class="num">(232,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment (Note 7)</a></td>
<td class="nump">33,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,568<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Capital increase</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="nump">2,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Jun. 30, 2023</a></td>
<td class="nump">64,841<span></span>
</td>
<td class="nump">7,699<span></span>
</td>
<td class="nump">2,114,913<span></span>
</td>
<td class="num">(149)<span></span>
</td>
<td class="nump">1,649<span></span>
</td>
<td class="num">(2,059,271)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2023</a></td>
<td class="num">(145,697)<span></span>
</td>
<td class="nump">7,749<span></span>
</td>
<td class="nump">2,123,074<span></span>
</td>
<td class="num">(146)<span></span>
</td>
<td class="nump">721<span></span>
</td>
<td class="num">(2,277,095)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the period</a></td>
<td class="num">(240,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(240,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss)</a></td>
<td class="num">(240,337)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="num">(240,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment (Note 7)</a></td>
<td class="nump">43,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,327<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TransferOfTreasury', window );">Transfer under stock incentive programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Capital increase</a></td>
<td class="nump">21,574<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">21,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Jun. 30, 2024</a></td>
<td class="num">&#8364; (321,133)<span></span>
</td>
<td class="nump">&#8364; 7,819<span></span>
</td>
<td class="nump">&#8364; 2,144,578<span></span>
</td>
<td class="num">&#8364; (118)<span></span>
</td>
<td class="nump">&#8364; 799<span></span>
</td>
<td class="num">&#8364; (2,474,211)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TransferOfTreasury">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transfer of treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TransferOfTreasury</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700828195920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Cash Flow Statements - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the period</a></td>
<td class="num">&#8364; (240,415)<span></span>
</td>
<td class="num">&#8364; (232,346)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Reversal of finance income</a></td>
<td class="num">(14,395)<span></span>
</td>
<td class="num">(80,374)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Reversal of finance expenses</a></td>
<td class="nump">58,553<span></span>
</td>
<td class="nump">18,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment', window );">Reversal of (gain)/loss on disposal of property, plant and equipment</a></td>
<td class="num">(91)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Reversal of income taxes (expenses)</a></td>
<td class="nump">2,737<span></span>
</td>
<td class="nump">868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AdjustmentsForNonCashConsiderationRegardingRevenue', window );">Non-cash consideration relating to revenue</a></td>
<td class="num">(25,639)<span></span>
</td>
<td class="num">(1,203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) of associates</a></td>
<td class="nump">11,118<span></span>
</td>
<td class="nump">8,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment</a></td>
<td class="nump">43,327<span></span>
</td>
<td class="nump">33,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation</a></td>
<td class="nump">8,632<span></span>
</td>
<td class="nump">8,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmortisationExpense', window );">Amortization</a></td>
<td class="nump">233<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ChangesInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Inventories</a></td>
<td class="num">(42,268)<span></span>
</td>
<td class="num">(37,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Receivables</a></td>
<td class="num">(22,747)<span></span>
</td>
<td class="num">(10,715)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepayments</a></td>
<td class="nump">1,867<span></span>
</td>
<td class="num">(12,779)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities', window );">Contract liabilities (deferred income)</a></td>
<td class="num">(840)<span></span>
</td>
<td class="num">(9,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Trade payables, accrued expenses and other payables</a></td>
<td class="num">(10,571)<span></span>
</td>
<td class="nump">9,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Increase/(decrease) in provisions</a></td>
<td class="nump">72,276<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash flows generated from/(used in) operations</a></td>
<td class="num">(158,223)<span></span>
</td>
<td class="num">(299,863)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities', window );">Finance income received</a></td>
<td class="nump">6,265<span></span>
</td>
<td class="nump">8,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities', window );">Finance expenses paid</a></td>
<td class="num">(7,714)<span></span>
</td>
<td class="num">(7,746)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes received/(paid)</a></td>
<td class="num">(3,218)<span></span>
</td>
<td class="num">(966)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flows from/(used in) operating activities</a></td>
<td class="num">(162,890)<span></span>
</td>
<td class="num">(300,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property, plant and equipment</a></td>
<td class="num">(541)<span></span>
</td>
<td class="num">(1,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Proceeds from disposal of property, plant and equipment</a></td>
<td class="nump">950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Settlement of marketable securities</a></td>
<td class="nump">7,354<span></span>
</td>
<td class="nump">259,132<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash flows from/(used in) investing activities</a></td>
<td class="nump">7,763<span></span>
</td>
<td class="nump">257,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of borrowings</a></td>
<td class="num">(5,606)<span></span>
</td>
<td class="num">(5,085)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">21,574<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows from/(used in) financing activities</a></td>
<td class="nump">15,968<span></span>
</td>
<td class="num">(3,011)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Increase/(decrease) in cash and cash equivalents</a></td>
<td class="num">(139,159)<span></span>
</td>
<td class="num">(45,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at January 1</a></td>
<td class="nump">392,164<span></span>
</td>
<td class="nump">444,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of exchange rate changes on balances held in foreign currencies</a></td>
<td class="nump">5,691<span></span>
</td>
<td class="num">(4,965)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BalancesWithBanks', window );">Bank deposits</a></td>
<td class="nump">258,696<span></span>
</td>
<td class="nump">394,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at June 30</a></td>
<td class="nump">&#8364; 258,696<span></span>
</td>
<td class="nump">&#8364; 394,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AdjustmentsForNonCashConsiderationRegardingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non cash consideration regarding revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AdjustmentsForNonCashConsiderationRegardingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BalancesWithBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash balances held at banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BalancesWithBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 98<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_98_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700834122288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfGeneralInformationAbstract', window );"><strong>Disclosure of General Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General Information</a></td>
<td class="text"><p id="notes" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">te 1&#8212;General Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Ascendis Pharma A/S, together with its subsidiaries, is applying its innovative TransCon technology platform to build a leading, fully integrated, global biopharma company focused on making a meaningful difference in patients&#8217; lives. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to Ascendis Pharma A/S and its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The address of the Company&#8217;s registered office is Tuborg Boulevard 12, DK-2900, Hellerup, Denmark.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 2, 2015, the Company completed an initial public offering which resulted in the listing of American Depositary Shares (&#8220;ADSs&#8221;), representing the Company&#8217;s ordinary shares, under the symbol &#8220;ASND&#8221; in the United States on The Nasdaq Global Select Market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) approved these unaudited condensed consolidated interim financial statements on September 3, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfGeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of general information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfGeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700824766848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract', window );"><strong>Disclosure of voluntary change in accounting policy [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory', window );">Summary of Material Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 2&#8212;Summary of Material Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Preparation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#8220;Interim Financial Reporting.&#8221; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#8220;IFRS&#8221;) have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements for the year ended December 31, 2023, and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board (the &#8220;IASB&#8221;) and as adopted by the European Union (the &#8220;EU&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting policies applied are consistent with those of the previous financial year. A description of the accounting policies is provided in the Accounting Policies section of the audited consolidated financial statements as of and for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New and Amended Standards and Interpretations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has applied amendments to paragraphs 69 to 76 of IAS 1, &#8220;Presentation of Financial Statements,&#8221; which was effective for annual reporting periods beginning on or after January 1, 2024, and must be applied retrospectively. The amendments to IAS 1 specify the requirements for classifying liabilities as current or non-current. The amendments clarify:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">What is meant by a right to defer settlement;  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That a right to defer must exist at the end of the reporting period; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That classification is unaffected by the likelihood that an entity will exercise its deferral right; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The convertible senior notes (&#8220;convertible notes&#8221;) include an embedded equity conversion option which is not deemed closely related to the financial liability and was initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since the embedded derivative is not an equity instrument under IFRS, the amendments require the convertible notes (presented as part of borrowings in the statement of financial position) and derivative liabilities, presented as non-current liabilities at December 31, 2023, to be presented as current liabilit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ies. The amendments require presentation of the convertible notes as current liabilities even though: the initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">166.34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per ADS is not met; the conversion would not require cash settlement; and, the convertible notes do not mature until </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further details, including (cash) maturity analysis are provided in Note 10, &#8220;Financial Assets and Liabilities.&#8221; On December 31, 2023, the carrying amount of convertible notes and derivative liabilities were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">407.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">143.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparative amounts have been reclassified to reflect the change to presentation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 31, 2023, lease liabilities were presented separately in the consolidated statements of financial position. At December 31, 2023, carrying amount of lease liabilities was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">84.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, for non-current liabilities and current liabilities, respectively. Since March 31, 2024, lease liabilities are presented as part of borrowings in the consolidated statements of financial position. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparative amounts have been reclassified to reflect the change in presentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, since March 31, 2024, borrowings comprise convertible notes, royalty funding liabilities, and lease liabilities. The change to presentation had no other impact on the unaudited condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The applied amendments had no other impact on the unaudited condensed consolidated interim financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other amendments apply for the first time in 2024, but do not have an impact on the unaudited condensed consolidated interim financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New International Financial Reporting Standards Not Yet Effective</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these unaudited condensed consolidated interim financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2024, the IASB issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS 18&#8221;), which replaces IAS 1, &#8220;Presentation in Financial Statements.&#8221; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Discontinued operations.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements are not expected to be affected by other new or amended standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of significant accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700868497520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgements and Estimates<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract', window );"><strong>Disclosure of voluntary change in accounting policy [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Accounting Judgements and Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 3&#8212;Significant Accounting Judgements and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In the application of the Company&#8217;s accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Judgements, estimates and assumptions applied are based on historical experience and other factors that are relevant, and which are available at the reporting date. Uncertainty concerning estimates and assumptions could result in outcomes that require a material adjustment to assets and liabilities in future periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed consolidated interim financial statements do not include all disclosures for significant accounting judgements, estimates and assumptions, that are required in the annual consolidated financial statements, and therefore should be read in conjunction with the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively. While the application of critical accounting estimates is subject to material estimation uncertainties, management&#8217;s ongoing revisions of critical accounting estimates and underlying assumptions have, except for revenue and provisions, as described below, not revealed any material impact in any of the periods presented in the unaudited condensed consolidated interim financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">There have been no other changes to the application of significant accounting judgements, or estimation uncertainties regarding accounting estimates compared to December 31, 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue and Provisions - Change in Accounting Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue includes provision for a variety of sales deductions such as prompt pay discounts, shelf stock adjustments and applicable sales rebates attributable to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangement. Provisions for sales deductions attributed to commercial arrangements are recognized when the related sales takes place and measured using the expected value method. Payable amounts for commercial arrangements are generally settled within 90-180 days from the transaction date. Provisions for unsettled sales deductions under commercial arrangements are estimated on the basis of a percentage of sales as defined by individual agreements and contracts. Further inputs to the calculations are based on payer channel mix, current contract prices under eligible programs and current inventory levels in the distribution channels. Inputs to the calculations are subject to estimation and assumptions and are based on historical experience and other factors that are relevant, and which are available at the reporting date. These estimates and assumptions are subject to material uncertainties and could result in outcomes that require a material adjustment in future periods.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue for the three months ended June 30, 2024, was negatively impacted by an adjustment to prior periods estimates and assumptions for sales deductions of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">27.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, where &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">7.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million were attributable to the three months ended March 31, 2024 and periods prior to January 1, 2024, respectively. The adjustment was primarily attributable to a different payer and rebate mix than anticipated, and which provisions for prior periods were based upon.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total provisions for the year ended, December 31, 2023 and six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">32.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">106.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700827037424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events in the Reporting Period<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SignificantEventsInTheReportingPeriodAbstract', window );"><strong>Significant Events in the Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SignificantEventsInTheReportingPeriodTextBlock', window );">Significant Events In the Reporting Period</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 4&#8212;Significant Events in the Reporting Period</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eyconis, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 29, 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, Inc. (&#8220;Eyconis&#8221;), a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s consideration for the granting of such rights, the Company received, as consideration, approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">42</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% ownership of Eyconis&#8217; on a non-diluted basis. In addition, various development and administrative services were provided to Eyconis and invoiced during the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and six months ended June 30, 2024. Further details regarding Eyconis are provided in Note 5, &#8220;Revenue.&#8221;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Equity Development</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of June 30, 2024, the unaudited condensed consolidated interim statements of financial position presented a negative balance of equity of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">321.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Under Danish corporate law, as Ascendis Pharma A/S, the parent company of the Company holds a positive balance of equity, the Company is currently not subject to legal or regulatory requirements to re-establish the balance of equity. There is no direct impact from the negative balance of equity to the liquidity and capital resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Based on its current operating plan, the Company believes that the existing capital resources as of June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, will be sufficient to meet projected cash requirements for at least twelve months from the date of this report. However, the Company's operating plan may change as a result of many factors that are currently unknown, and the Company may need to seek additional funds sooner than planned. Further details regarding borrowings including maturity analysis are provided in Note 10, &#8220;Financial Assets and Liabilities.&#8221;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SignificantEventsInTheReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant events in the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SignificantEventsInTheReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SignificantEventsInTheReportingPeriodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Events In The Reporting Period Text Block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SignificantEventsInTheReportingPeriodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700828212928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 5&#8212;Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss in the following amounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.09%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.658%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Revenue</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sale of commercial products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,895</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rendering of services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,364</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,079</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sale of clinical supply</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">254</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Licenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">869</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">589</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">35,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">47,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">131,892</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">80,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Attributable to</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial customers</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,895</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration partners and license agreements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,498</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,536</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">35,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">47,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">131,892</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">80,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Specified by timing of recognition</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recognized over time</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,364</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,079</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recognized at a point in time</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,258</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,484</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123,528</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,903</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">35,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">47,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">131,892</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">80,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Specified per geographical area</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Europe</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,082</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">North America</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,075</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Asia</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">35,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">47,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">131,892</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">80,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commercial Customers</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue to commercial customers primarily relates to sale of SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (lonapegsomatropin-tcgd), primarily in the U.S. market, which is sold to specialty pharmacies and specialty distributors. In addition, the Company began shipping SKYTROFA to customers in Germany in September 2023. In November 2023, TransCon PTH received regulatory approval in the EU and European Economic Area countries and is marketed as YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(palopegteriparatide). In August 2024, TransCon PTH received regulatory approval in the U.S. and will be marketed in the U.S. as YORVIPATH. The Company began shipping YORVIPATH to customers in Europe in the first quarter of 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the three and six months ended June 30, 2024 and 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> commercial customers, each represented more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of sales to commercial customers.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Collaboration Partners and License Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue attributable to collaboration partners and license agreements relates to Eyconis, Teijin Limited and VISEN Pharmaceuticals. Under the collaboration agreements, we provide various research and development services which are invoiced to collaboration partners. Revenue for these activities is presented as part of &#8220;Rendering of services.&#8221; Employment costs related to these activities are presented as Research and Development Costs in the consolidated statement of profit or loss.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Eyconis, Inc.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On January 29, 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophth</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">almology assets globally, together with a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received, as consideration, an equity position in the newly formed company. In addition, the Company is eligible to receive development, regulatory, and sales milestone payments, plus single digit royalties on global net sales of commercialized products, if any.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is expected to provide various research and development services, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, revenue from &#8220;Licenses&#8221; of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">25.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million relates to non-cash upfront payment through an equity position in Eyconis, which is allocated to transfer of the Company&#8217;s intellectual property (&#8220;IP&#8221;) adjusted for internal profit. Internal profit relates to the Company&#8217;s share of the non-cash upfront payment whic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">h is recognized as part of &#8220;Investment in associates&#8221; and recognized as revenue from &#8220;Licenses&#8221; as the IP is amortized in the associate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> revenue from royalties or milestones has been recognized under the Eyconis agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Teijin Limited</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 29, 2023, the Company entered into an exclusive license agreement with Teijin Limited (the &#8220;Teijin Agreement&#8221;) for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease (the &#8220;Licensed Products&#8221;) in Japan. Under the terms of the Teijin Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, with additional development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">175</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and commercial milestones. In addition, the Company is eligible to receive royalties on net sales of the Licensed Products in Japan, of up to mid-20&#8217;s percent.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further, the Company will provide clinical and commercial supply, and development services for joint activities, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At June 30, 2024, none of the Licensed Products have received marketing authorization in Japan. The Licensed Products are patent protected, where future activities do not affect their existing stand-alone functionalities. Accordingly, all three licenses have been classified as &#8220;right-to-use&#8221; licenses, with revenue recognized at a point in time, where the licensee is granted access to the IP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Development and regulatory milestones of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">175</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million are recognized as revenue when the milestone criteria specific to the Licensed Product are met. Royalty and commercial milestone income is recognized as revenue when the subsequent product sales occur.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the six months ended June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> revenue from royalties o</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">r milestones has been recognized under the Teijin Agreement.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">VISEN Pharmaceuticals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue from collaboration partners and license agreements also includes license income, rendering of services and sale of clinical supply under three licenses agreements with VISEN Pharmaceuticals, which were entered into in 2018.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700834122416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 6&#8212;Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is managed and operated as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> business unit. Accordingly, no additional information on business segments or geographical areas is disclosed apart from revenue on geographical areas as disclosed in Note 5 &#8220;Revenue.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Revenue is specified on geographical areas according to the location of the customer.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700875755504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based Payment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 7&#8212;Share-based Payment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As an incentive to the senior management, other employees, members of the Board and select consultants, Ascendis Pharma A/S has established warrant programs, a Restricted Stock Unit (&#8220;RSU&#8221;) program adopted in December 2021, and a Performance Stock Unit (&#8220;PSU&#8221;) program adopted in February 2023, which are all classified as equity-settled share-based payment transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Share-based Compensation Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Share-based compensation costs are determined using the grant date fair value and are recognized over the vesting period as research and development costs, selling, general and administrative expenses, or cost of sales. For the three and six months ended June 30, 2024 and 2023, share-based compensation costs recognized in the unaudited condensed consolidated interim statement of profit or loss were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">26.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">43.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">19.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">33.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Restricted Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs are granted by the Board to members of senior management, certain other employees and certain members of the Board (the &#8220;RSU-holders&#8221;). In addition, RSUs may be granted to select consultants.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One RSU represents a right for the RSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting, if the vesting conditions are met. RSUs granted vest over three years with 1/3 of the RSUs vesting on each anniversary date from the date of grant, and require RSU-holders to be employed, appointed as member of the Board, or retained as a consultant (the &#8220;service conditions&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Performance Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">PSUs are granted by the Board to certain members of senior management (the &#8220;PSU-holders&#8221;). In addition, PSUs may be granted to other employees, select consultants and members of the Board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">One PSU represents a right for the PSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting. PSUs vest in a manner similar to the service conditions of the RSUs. For the March 2023 PSU grant, in addition to service conditions, vesting is also contingent upon achievement of performance-based targets as determined by the Board, provided that no more than 10% of each tranche may be directly attributable to accomplishment of financial results achieved in the financial year prior to the vesting date. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For the March 2024 PSU grants, in addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%, nor will it result in additional grants. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">RSUs and PSUs generally cease to vest from the date of termination of employment or Board membership, as applicable, whereas unvested RSUs or PSUs will forfeit. The Board may at its discretion and on an individual basis decide to deviate from the vesting conditions, including deciding to accelerate vesting in the event of termination of employment or Board membership, as applicable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All RSUs and PSUs are expected to be settled at the time of vesting by treasury shares that are ADSs repurchased by the Company. The Company may at its sole discretion choose to make a cash settlement instead of delivering ADSs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">RSU and PSU Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies the number of RSUs and PSUs granted and outstanding at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.162%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.162%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.242%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Restricted Stock Units</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Performance Stock Units</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Number)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">576,625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">681,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">717,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,655</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">810,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transferred during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176,317</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,007</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,309</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,139</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1,054,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">157,841</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1,212,820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Specified by vesting year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,843</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,843</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393,254</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,478</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">456,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393,612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,478</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">457,090</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">232,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,885</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1,054,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">157,841</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1,212,820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Warrants are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to all employees, members of the Board and select consultants. Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The exercise price is fixed at the fair market value of the Company&#8217;s ordinary shares at the time of grant as determined by the Board. Vested warrants may be exercised in two or four annual exercise periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Warrant Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies the warrant activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Warrants</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Number)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,523,784</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86.38</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">197,855</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130.74</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">524,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39.85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">6,107,875</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">91.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vested at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5,088,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">86.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The exercise prices of outstanding warrants under the Company&#8217;s warrant programs range from &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">11.98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">145.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> depending on the grant dates.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700825057536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share Capital</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 8&#8212;Share Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The share capital of Ascendis Pharma A/S consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">58,231,484</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> fully paid shares at a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all in the same share class.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700827037392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Treasury Shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfTreasurySharesAbstract', window );"><strong>Disclosure of treasury shares [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfInformationAboutTreasurySharesExplanatory', window );">Treasury Shares</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 9&#8212;Treasury Shares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development in the holding of treasury shares is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.162%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.162%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.241999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nominal<br/>values</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Holding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Holding in<br/>% of total<br/>outstanding<br/>shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Number)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Treasury shares</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,093,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">881,730</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfInformationAboutTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about treasury shares explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfInformationAboutTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfTreasurySharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfTreasurySharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700825948432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 10&#8212;Financial Assets and Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies financial assets and liabilities:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,<br/>2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets by category</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade receivables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables (excluding income tax and indirect tax receivables)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,275</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">258,696</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">392,164</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">312,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">439,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">312,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">439,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">310,735</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">437,095</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">312,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">439,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities by category</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">432,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407,095</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144,547</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,566</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities (excluding income tax, indirect tax, and employee related payables)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">772,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">738,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">159,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">143,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">931,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">882,127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">219,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">222,996</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">712,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">659,131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">931,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">882,127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Convertible Senior Notes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In March 2022, the Company issued an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">575.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million of fixed rate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% convertible notes. The net proceeds from the offering of the convertible notes were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">557.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">503.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million) after deducting the initial purchasers&#8217; discounts and commissions and offering expenses. The convertible notes rank equally in right of payment with all future senior unsecured indebtedness. Unless earlier converted or redeemed, the convertible notes will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The convertible notes accrue interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their convertible notes at their option into the Company&#8217;s ordinary shares represented by ADSs, together, if applicable, with cash in lieu of any fractional ADS, at the then-applicable conversion rate. The initial conversion rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6.0118</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> ADSs per $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> principal amount of convertible notes, which represents an initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">166.34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per ADS. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The convertible notes will be optionally redeemable, in whole or in part (subject to certain limitations), at the Company&#8217;s option at any time, and from time to time, on or after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 7, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">but only if the last reported sale price per ADS exceeds </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of the conversion price on (i) each of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> trading days, whether or not consecutive, during the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2024, the carrying amount of the convertible notes was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;">432.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and the fair value was approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">412.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Fair value cannot be measured based on quoted prices in active markets or other observable input, and accordingly the fair value was measured by using an estimated market rate for an equivalent non-convertible instrument.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2023, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Agreement&#8221;) with Royalty Pharma (the &#8220;Purchaser&#8221;). The net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">146.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">136.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million) after deducting offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Under the terms of the Royalty Pharma Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Purchase Price&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">9.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty on net U.S. SKYTROFA revenue, beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">January 1, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (the &#8220;Revenue Interest Payments&#8221;). The Revenue Interest Payments to the Purchaser will cease upon reaching a multiple of the Purchase Price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.925</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">x, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">x if the Purchaser receives Revenue Interest Payments in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Royalty Pharma Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.925</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> times the Purchase Price minus the Revenue Interest Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to December 31, 2028, and the Company has paid the Purchaser Revenue Interest Payments equal to the Purchase Price as of the date of the buy-out notice, then the buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> times the Purchase Price minus the Revenue Interest Payments paid to the Purchaser as of the effective date of the buy-out notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2024, the carrying amount of the royalty funding liabilities was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">144.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, and the fair value was approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">147.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million. Fair value cannot be measured based on quoted prices in active markets or other observable input, and accordingly the fair value was measured by using an estimated market rate for an equivalent instrument.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Derivative Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value cannot be measured based on quoted prices in active markets or other observable inputs, and accordingly, derivative liabilities are measured by using the Black-Scholes option pricing model. Fair value of the option is calculated, applying the following assumptions: (1) conversion price; (2) the Company&#8217;s share price; (3) maturity of the option; (4) a risk-free interest rate equaling the effective interest rate on a U.S. government bond with the same lifetime as the maturity of the option; (5) no payment of dividends; and (6) an expected volatility using the Company&#8217;s share price </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">49.89</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">50.47</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> as of June 30, 2024 and December 31, 2023, respectively).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For additional description of fair values, refer to the following section &#8220;Fair Value Measurement.&#8221;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Sensitivity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% relative increase in volatility, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% relative decrease in volatility indicates the opposite impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Similarly, on June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% increase in the share price, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">30.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% decrease in the share price indicates the opposite impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Because of the short-term maturity for cash and cash equivalents, receivables and trade payables, their fair value approximate carrying amount. Fair value of lease liabilities are not disclosed. Fair value compared to carrying amount of marketable securities, convertible notes, royalty funding liabilities and derivative liabilities, and their level in the fair value hierarchy is summarized in the following table, where:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is based on valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Level 3 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">is based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.</span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value level</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(1-3)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,275</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,266</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">7,275</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">7,266</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">432,190</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">412,122</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407,095</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">385,410</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144,547</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">147,345</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,377</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143,975</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">576,737</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">559,467</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">545,472</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">529,385</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,059</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,059</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143,296</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143,296</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">159,059</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">159,059</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">143,296</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">143,296</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies movements in level 3 fair value measurements:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157,950</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remeasurement recognized in finance (income) or expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">159,059</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">86,385</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Maturity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the unaudited condensed consolidated statements of financial position at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Further details regarding classification of convertible notes as current liabilities in the consolidated statement of financial position are provided in Note 2, &#8220;Summary of Material Accounting Policies,&#8221; section &#8220;New and Amended Standards and Interpretations.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.42%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&lt; 1 year</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1-5 years</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&gt;5 years</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>contractual<br/>cash-flows</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">759,073</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">816,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">576,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,632</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,312</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110,746</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">133,533</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">810,705</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">83,012</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1,027,250</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">772,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700882786832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Note 11&#8212;Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In September 2024, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Yorvipath Agreement&#8221;) with Royalty Pharma (the &#8220;Purchaser&#8221;). Under the terms of the Yorvipath Agreement, Purchaser has agreed to provide the Company an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">150</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million (the &#8220;Purchase Amount&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% royalty on net U.S. YORVIPATH revenue (the &#8220;Royalty Payments&#8221;). The Royalty Payments to the Purchaser will cease upon reaching a multiple of the Purchase Amount of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">x, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">x if the Purchaser receives royalties in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">December 31, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. The Yorvipath Agreement includes certain buy-out options under various terms and conditions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No other events have occurred after the balance sheet date that would influence the evaluation of these unaudited condensed consolidated interim financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700825368608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Preparation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Basis of Preparation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#8220;Interim Financial Reporting.&#8221; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#8220;IFRS&#8221;) have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements for the year ended December 31, 2023, and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board (the &#8220;IASB&#8221;) and as adopted by the European Union (the &#8220;EU&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The accounting policies applied are consistent with those of the previous financial year. A description of the accounting policies is provided in the Accounting Policies section of the audited consolidated financial statements as of and for the year ended December 31, 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">New and Amended Standards and Interpretations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New and Amended Standards and Interpretations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has applied amendments to paragraphs 69 to 76 of IAS 1, &#8220;Presentation of Financial Statements,&#8221; which was effective for annual reporting periods beginning on or after January 1, 2024, and must be applied retrospectively. The amendments to IAS 1 specify the requirements for classifying liabilities as current or non-current. The amendments clarify:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">What is meant by a right to defer settlement;  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That a right to defer must exist at the end of the reporting period; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That classification is unaffected by the likelihood that an entity will exercise its deferral right; and </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The convertible senior notes (&#8220;convertible notes&#8221;) include an embedded equity conversion option which is not deemed closely related to the financial liability and was initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since the embedded derivative is not an equity instrument under IFRS, the amendments require the convertible notes (presented as part of borrowings in the statement of financial position) and derivative liabilities, presented as non-current liabilities at December 31, 2023, to be presented as current liabilit</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ies. The amendments require presentation of the convertible notes as current liabilities even though: the initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">166.34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> per ADS is not met; the conversion would not require cash settlement; and, the convertible notes do not mature until </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">April 1, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Further details, including (cash) maturity analysis are provided in Note 10, &#8220;Financial Assets and Liabilities.&#8221; On December 31, 2023, the carrying amount of convertible notes and derivative liabilities were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">407.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">143.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparative amounts have been reclassified to reflect the change to presentation.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 31, 2023, lease liabilities were presented separately in the consolidated statements of financial position. At December 31, 2023, carrying amount of lease liabilities was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">84.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">14.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, for non-current liabilities and current liabilities, respectively. Since March 31, 2024, lease liabilities are presented as part of borrowings in the consolidated statements of financial position. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Comparative amounts have been reclassified to reflect the change in presentation.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Accordingly, since March 31, 2024, borrowings comprise convertible notes, royalty funding liabilities, and lease liabilities. The change to presentation had no other impact on the unaudited condensed consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The applied amendments had no other impact on the unaudited condensed consolidated interim financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Other amendments apply for the first time in 2024, but do not have an impact on the unaudited condensed consolidated interim financial statements.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">New International Financial Reporting Standards Not Yet Effective</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these unaudited condensed consolidated interim financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In April 2024, the IASB issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS 18&#8221;), which replaces IAS 1, &#8220;Presentation in Financial Statements.&#8221; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Operating activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Investing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Discontinued operations.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The consolidated financial statements are not expected to be affected by other new or amended standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700825948304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory', window );">Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss in the following amounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:50.09%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.418%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:9.658%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Six Months Ended<br/>June 30,</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Revenue</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sale of commercial products</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,895</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Rendering of services</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,364</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,079</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Sale of clinical supply</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">254</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Licenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">869</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">589</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,639</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,203</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">35,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">47,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">131,892</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">80,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Attributable to</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commercial customers</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">31,389</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,895</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,888</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,446</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Collaboration partners and license agreements</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,609</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">11,498</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">34,004</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,536</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">35,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">47,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">131,892</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">80,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Specified by timing of recognition</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recognized over time</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,740</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,364</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,079</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Recognized at a point in time</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">32,258</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,484</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">123,528</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,903</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">35,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">47,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">131,892</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">80,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Specified per geographical area</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Europe</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,082</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,649</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">North America</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">29,394</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">46,758</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">122,075</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">79,828</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Asia</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,522</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,168</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,154</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total revenue</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">35,998</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">47,393</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">131,892</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">80,982</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of segment revenues by destination of major customers explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700825064320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock', window );">Summary of Share Based Payment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies the number of RSUs and PSUs granted and outstanding at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.162%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.162%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.242%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Restricted Stock Units</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Performance Stock Units</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Number)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">576,625</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">105,023</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">681,648</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">717,980</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92,655</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">810,635</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transferred during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">176,317</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,007</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,309</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,830</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">68,139</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1,054,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">157,841</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1,212,820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Specified by vesting year</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,843</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,843</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2025</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393,254</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,478</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">456,732</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2026</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">393,612</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">63,478</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">457,090</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2027</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">232,270</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,885</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">263,155</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1,054,979</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">157,841</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1,212,820</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Summary of Warrant Activity</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies the warrant activity for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">six months ended June 30, 2024:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>Warrants</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Number)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Outstanding</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,523,784</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">86.38</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Granted during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">197,855</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">130.74</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Exercised during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">524,045</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39.85</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Forfeited during the period</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">89,719</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">108.71</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">6,107,875</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">91.16</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Vested at June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">5,088,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">86.49</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased payment arrangement, restricted stock unit, activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700826760352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Treasury Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfTreasurySharesAbstract', window );"><strong>Disclosure of treasury shares [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTreasurySharesExplanatory', window );">Summary of Holding of Treasury Shares</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The development in the holding of treasury shares is as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.431%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.162%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.162%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:11.241999999999999%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nominal<br/>values</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Holding</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Holding in<br/>% of total<br/>outstanding<br/>shares</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Number)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Treasury shares</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">146</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,093,054</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1.9</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">211,324</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">118</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">881,730</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1.5</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfTreasurySharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfTreasurySharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700827325296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory', window );">Schedule of Financial Assets and Financial Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies financial assets and liabilities:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30,<br/>2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets by category</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade receivables</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49,163</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">35,874</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other receivables (excluding income tax and indirect tax receivables)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,062</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,909</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,275</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">258,696</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">392,164</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">312,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">439,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">312,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">439,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,186</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">310,735</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">437,095</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial assets</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">312,921</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">439,222</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities by category</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">432,190</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407,095</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144,547</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,377</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">98,793</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,566</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other liabilities (excluding income tax, indirect tax, and employee related payables)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">302</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">772,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">738,831</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">159,059</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">143,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">931,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">882,127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Non-current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">219,052</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">222,996</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">712,475</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">659,131</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">931,527</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">882,127</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock', window );">Summary of Fair Value Hierarchy</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.8%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:9.96%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Fair value level</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="7" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(1-3)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Marketable securities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,275</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,266</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#8212;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">7,275</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">7,266</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Convertible senior notes</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">432,190</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">412,122</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">407,095</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">385,410</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Royalty funding liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">144,547</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">147,345</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">138,377</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143,975</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">576,737</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">559,467</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">545,472</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">529,385</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,059</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">159,059</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143,296</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143,296</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">159,059</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">159,059</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">143,296</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">143,296</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="text-indent:25pt;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock', window );">Movements in Level 3 Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table specifies movements in level 3 fair value measurements:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.967%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1.16%;"></td>
        <td style="width:1%;"></td>
        <td style="width:13.357%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Derivative liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">January 1</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">143,296</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157,950</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Remeasurement recognized in finance (income) or expense</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,763</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">71,565</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">159,059</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">86,385</span></p></td>
        <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock', window );">Summary of Maturity Analysis For Financial Liabilities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the unaudited condensed consolidated statements of financial position at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.42%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.04%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:1%;"></td>
        <td style="width:8.42%;"></td>
        <td style="width:1%;"></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&lt; 1 year</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1-5 years</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&gt;5 years</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total<br/>contractual<br/>cash-flows</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Carrying<br/>amount</span></p></td>
        <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="18" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
        <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial liabilities</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
        <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">June 30, 2024</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">759,073</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">38,700</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">816,675</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">576,737</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,802</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">51,632</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">44,312</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">110,746</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,902</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#8212;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99,829</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
        <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Total financial liabilities</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">133,533</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">810,705</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">83,012</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1,027,250</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
        <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">772,468</span></p></td>
        <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Financial Assets And Liabilities [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of movements in level 3 fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity analysis for financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700827265264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 29, 2022</div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 432.2<span></span>
</td>
<td class="nump">&#8364; 407.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Non-current lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Current lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 14.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity</a></td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember', window );">American depository shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConversionPricePerShare', window );">Conversion Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items representing the disclosure of summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700825914736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgements and Estimates - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">&#8364; 106,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 106,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 32,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">35,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 47,393<span></span>
</td>
<td class="nump">131,892<span></span>
</td>
<td class="nump">&#8364; 80,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustment to Prior Periods Estimates and Assumptions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">27,100<span></span>
</td>
<td class="nump">&#8364; 19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=asnd_SalesRebatesAndProductReturnsInUSMarketMember', window );">Sales rebates and product returns in U.S. market [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">&#8364; 106,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 106,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 32,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=asnd_SalesRebatesAndProductReturnsInUSMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=asnd_SalesRebatesAndProductReturnsInUSMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700826966656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Events in the Reporting Period - Additional Information (Detail)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SignificantEventsInTheReportingPeriodLineitems', window );"><strong>Significant Events In The Reporting Period LineItems</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance of equity | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 321,133<span></span>
</td>
<td class="nump">&#8364; 145,697<span></span>
</td>
<td class="num">&#8364; (64,841)<span></span>
</td>
<td class="num">&#8364; (263,348)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=asnd_ThirdPartyInvestorsMember', window );">Third Party Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SignificantEventsInTheReportingPeriodLineitems', window );"><strong>Significant Events In The Reporting Period LineItems</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_CapitalCommitmentFromInvestors', window );">Commitment from investors | $</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Ownership percentage</a></td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_CapitalCommitmentFromInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital commitment from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_CapitalCommitmentFromInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SignificantEventsInTheReportingPeriodLineitems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant events in the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SignificantEventsInTheReportingPeriodLineitems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=asnd_ThirdPartyInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=asnd_ThirdPartyInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700827171072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue from external customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Sale of commercial products</a></td>
<td class="nump">&#8364; 31,389<span></span>
</td>
<td class="nump">&#8364; 35,895<span></span>
</td>
<td class="nump">&#8364; 97,888<span></span>
</td>
<td class="nump">&#8364; 67,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromRenderingOfServices', window );">Rendering of services</a></td>
<td class="nump">3,740<span></span>
</td>
<td class="nump">10,909<span></span>
</td>
<td class="nump">8,364<span></span>
</td>
<td class="nump">12,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RevenueFromSaleOfClinicalSupply', window );">Sale of clinical supply</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LicenceFeeIncome', window );">Licenses</a></td>
<td class="nump">869<span></span>
</td>
<td class="nump">589<span></span>
</td>
<td class="nump">25,639<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">35,998<span></span>
</td>
<td class="nump">47,393<span></span>
</td>
<td class="nump">131,892<span></span>
</td>
<td class="nump">80,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue from external customers (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">35,998<span></span>
</td>
<td class="nump">47,393<span></span>
</td>
<td class="nump">131,892<span></span>
</td>
<td class="nump">80,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember', window );">Goods or services transferred over time [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue from external customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">3,740<span></span>
</td>
<td class="nump">10,909<span></span>
</td>
<td class="nump">8,364<span></span>
</td>
<td class="nump">12,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue from external customers (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">3,740<span></span>
</td>
<td class="nump">10,909<span></span>
</td>
<td class="nump">8,364<span></span>
</td>
<td class="nump">12,079<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember', window );">Goods or services transferred at point in time [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue from external customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">32,258<span></span>
</td>
<td class="nump">36,484<span></span>
</td>
<td class="nump">123,528<span></span>
</td>
<td class="nump">68,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue from external customers (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">32,258<span></span>
</td>
<td class="nump">36,484<span></span>
</td>
<td class="nump">123,528<span></span>
</td>
<td class="nump">68,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember', window );">Commercial customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue from external customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">31,389<span></span>
</td>
<td class="nump">35,895<span></span>
</td>
<td class="nump">97,888<span></span>
</td>
<td class="nump">67,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue from external customers (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">31,389<span></span>
</td>
<td class="nump">35,895<span></span>
</td>
<td class="nump">97,888<span></span>
</td>
<td class="nump">67,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=asnd_CollaborationPartnersAndLicenseAgreementsMember', window );">Collaboration partners and license agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue from external customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">4,609<span></span>
</td>
<td class="nump">11,498<span></span>
</td>
<td class="nump">34,004<span></span>
</td>
<td class="nump">13,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue from external customers (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">4,609<span></span>
</td>
<td class="nump">11,498<span></span>
</td>
<td class="nump">34,004<span></span>
</td>
<td class="nump">13,536<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue from external customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">5,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue from external customers (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">5,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember', window );">North America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue from external customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">29,394<span></span>
</td>
<td class="nump">46,758<span></span>
</td>
<td class="nump">122,075<span></span>
</td>
<td class="nump">79,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue from external customers (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">29,394<span></span>
</td>
<td class="nump">46,758<span></span>
</td>
<td class="nump">122,075<span></span>
</td>
<td class="nump">79,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_AsiaMember', window );">Asia [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue from external customers</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">1,522<span></span>
</td>
<td class="nump">635<span></span>
</td>
<td class="nump">3,168<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue from external customers (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">&#8364; 1,522<span></span>
</td>
<td class="nump">&#8364; 635<span></span>
</td>
<td class="nump">&#8364; 3,168<span></span>
</td>
<td class="nump">&#8364; 1,154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RevenueFromSaleOfClinicalSupply">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from sale of clinical supply.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RevenueFromSaleOfClinicalSupply</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LicenceFeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from licence fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LicenceFeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromRenderingOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the rendering of services. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromRenderingOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TimingOfTransferOfGoodsOrServicesAxis=ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=asnd_CollaborationPartnersAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=asnd_CollaborationPartnersAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_AsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_AsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700827233520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Detail)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 29, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>CommercialCustomer</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>CommercialCustomer</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>CommercialCustomer</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>CommercialCustomer</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>CommercialCustomer</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=asnd_ThirdPartyInvestorsMember', window );">Third Party Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_CapitalCommitmentFromInvestors', window );">Commitment from investors</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=asnd_TeijinLimitedMember', window );">Teijin Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_UpfrontPaymentReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived', window );">Maximum additional development and regulatory milestones potentially to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=asnd_RoyaltiesAndMilestonesMember', window );">Royalties And Milestones [Member] | Third Party Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PerformanceObligationsAxis=asnd_RoyaltiesAndMilestonesMember', window );">Royalties And Milestones [Member] | Teijin Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized as revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember', window );">Commercial customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfCommercialCustomers', window );">Number of commercial customers | CommercialCustomer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember', window );">Commercial customers [Member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfEntitysRevenue', window );">Perentage of sale to commercial customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=asnd_CollaborationPartnersAndLicenseAgreementsMember', window );">Collaboration partners and license agreements [Member] | Third Party Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems', window );"><strong>Disclosure of associates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized as revenue | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_CapitalCommitmentFromInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capital commitment from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_CapitalCommitmentFromInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum additional development and regulatory milestones potentially to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfCommercialCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of commercial customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfCommercialCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_UpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_UpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfEntitysRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of the entity's revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfEntitysRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=asnd_ThirdPartyInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=asnd_ThirdPartyInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=asnd_TeijinLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=asnd_TeijinLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=asnd_RoyaltiesAndMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=asnd_RoyaltiesAndMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=asnd_CommercialCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=asnd_CollaborationPartnersAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=asnd_CollaborationPartnersAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700875210592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfReportableOperatingSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfReportableOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reportable operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfReportableOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700828034080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment - Additional Information (Details)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>kr / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Share nominal value | kr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 145.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitProgramMember', window );">Performance Stock Unit Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Description of vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">For the March 2024 PSU grants, in addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than 100%, nor will it result in additional grants. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitProgramMember', window );">Performance Stock Unit Program [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncomeStatementAxis=asnd_ProfitLossMember', window );">Profit Loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share based compensation costs | &#8364;</a></td>
<td class="nump">&#8364; 26.0<span></span>
</td>
<td class="nump">&#8364; 19.9<span></span>
</td>
<td class="nump">&#8364; 43.3<span></span>
</td>
<td class="nump">&#8364; 33.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting rights for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncomeStatementAxis=asnd_ProfitLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncomeStatementAxis=asnd_ProfitLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700827148064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment - Schedule of Warrant Activity (Detail) - Warrants [member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfWarrantActivityLineItems', window );"><strong>Disclosure Of Warrant Activity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">6,523,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the period</a></td>
<td class="nump">197,855<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised during the period</a></td>
<td class="num">(524,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the period</a></td>
<td class="num">(89,719)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">6,107,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement', window );">Vested at the balance sheet date</a></td>
<td class="nump">5,088,475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Beginning balance</a></td>
<td class="nump">&#8364; 86.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the period</a></td>
<td class="nump">130.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Exercised during the period</a></td>
<td class="nump">39.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited during the period</a></td>
<td class="nump">108.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Ending balance</a></td>
<td class="nump">91.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement', window );">Vested at the balance sheet date</a></td>
<td class="nump">&#8364; 86.49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfWarrantActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Warrant Activity [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfWarrantActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of other equity instruments vested in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of other equity instruments vested in share-based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700826631216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment - Summary Of Share Based Payment (Detail)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">576,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted</a></td>
<td class="nump">717,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement', window );">Transferred during the period</a></td>
<td class="num">(176,317)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the period</a></td>
<td class="num">(63,309)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">1,054,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">35,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">393,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">393,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">232,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">105,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted</a></td>
<td class="nump">92,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement', window );">Transferred during the period</a></td>
<td class="num">(35,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the period</a></td>
<td class="num">(4,830)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">157,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member] | 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member] | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">63,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member] | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">63,478<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member] | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">30,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">681,648<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted</a></td>
<td class="nump">810,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement', window );">Transferred during the period</a></td>
<td class="num">(211,324)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the period</a></td>
<td class="num">(68,139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">1,212,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member] | 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">35,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member] | 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">456,732<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member] | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">457,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member] | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">263,155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of other equity instruments transferred in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based payment arrangement, restricted stock unit, activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentyFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentyFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700825131952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share Capital - Additional Information (Detail)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>kr / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="nump">58,231,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Share nominal value | kr / shares</a></td>
<td class="nump">kr 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700828071680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Treasury Shares - Summary of Holding of Treasury Shares (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfHoldingOfTreasurySharesLineItems', window );"><strong>Disclosure Of Holding Of Treasury Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesOfNominalValue', window );">January 1, 2024 (Nominal values) | &#8364;</a></td>
<td class="nump">&#8364; 146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue', window );">Transferred under stock incentive programs (Nominal values) | &#8364;</a></td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesOfNominalValue', window );">June 30, 2024 (Nominal values) | &#8364;</a></td>
<td class="nump">&#8364; 118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfTreasurySharesOutstanding', window );">January 1, 2024 (Holding) | shares</a></td>
<td class="nump">1,093,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram', window );">Transferred under stock incentive programs (Holding) | shares</a></td>
<td class="num">(211,324)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfTreasurySharesOutstanding', window );">June 30, 2024 (Holding) | shares</a></td>
<td class="nump">881,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares', window );">January 1, 2024 (Holding in % of total outstanding shares)</a></td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms', window );">Transferred under stock incentive programs (Holding in 1% total outstanding shares)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares', window );">June 30, 2024 (Holding in % of total outstanding shares)</a></td>
<td class="nump">1.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfHoldingOfTreasurySharesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of holding of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfHoldingOfTreasurySharesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in treasury shares transferred under stock incentive program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfTreasurySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfTreasurySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares holding in percentage of total outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares holding in percentage transferred under stock incentive programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesOfNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesOfNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares transferred under stock incentive program nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700827078960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MarketableSecurities1', window );">Marketable securities</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 7,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">258,696<span></span>
</td>
<td class="nump">392,164<span></span>
</td>
<td class="nump">&#8364; 394,222<span></span>
</td>
<td class="nump">&#8364; 444,767<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">312,921<span></span>
</td>
<td class="nump">439,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract', window );"><strong>Classified in the statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current assets</a></td>
<td class="nump">2,186<span></span>
</td>
<td class="nump">2,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Current assets</a></td>
<td class="nump">310,735<span></span>
</td>
<td class="nump">437,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="nump">432,200<span></span>
</td>
<td class="nump">407,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">110,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">159,059<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">931,527<span></span>
</td>
<td class="nump">882,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract', window );"><strong>Classified in the statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">219,052<span></span>
</td>
<td class="nump">222,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current liabilities</a></td>
<td class="nump">712,475<span></span>
</td>
<td class="nump">659,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="nump">432,190<span></span>
</td>
<td class="nump">407,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyFundingLiabilities', window );">Royalty funding liabilities</a></td>
<td class="nump">144,547<span></span>
</td>
<td class="nump">138,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">95,902<span></span>
</td>
<td class="nump">98,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables and accrued expenses</a></td>
<td class="nump">99,527<span></span>
</td>
<td class="nump">94,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other liabilities (excluding income tax, indirect tax, and employee related payables)</a></td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities measured at amortized cost</a></td>
<td class="nump">772,468<span></span>
</td>
<td class="nump">738,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">772,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember', window );">Financial liabilities measured at fair value through profit or loss [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Financial liabilities measured at fair value through profit or loss</a></td>
<td class="nump">159,059<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">49,163<span></span>
</td>
<td class="nump">35,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables (excluding income tax and indirect tax receivables)</a></td>
<td class="nump">5,062<span></span>
</td>
<td class="nump">3,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MarketableSecurities1', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">258,696<span></span>
</td>
<td class="nump">392,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Financial assets measured at amortized cost</a></td>
<td class="nump">&#8364; 312,921<span></span>
</td>
<td class="nump">&#8364; 439,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MarketableSecurities1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MarketableSecurities1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as &#8216;an accounting mismatch&#8217;) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity&#8217;s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700822371984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Additional Information (Detail)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 29, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 29, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>XBB </div>
<div>Multiple</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>Agreement </div>
<div>Days </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>Agreement </div>
<div>Days</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 159,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 143,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 407,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FairValueOfConvertibleNotes', window );">Fair Value of Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 412,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharePriceAppliedForValuation', window );">Share price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 49.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 50.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount', window );">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount', window );">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount | XBB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_CarryingAmountOfRoyaltyFundingLiabilities', window );">Carrying amount of royalty funding liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 144,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FairValueOfRoyaltyFundingLiabilities', window );">Fair value of royalty funding liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaMember', window );">Royalty Pharma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchangeOfRoyaltyPayments', window );">Funding received in exchange of royalty payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses', window );">Net proceeds after deduting offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 136,300<span></span>
</td>
<td class="nump">$ 146,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyPaymentEndingPeriod', window );">Royalty payment ending period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaMember', window );">Royalty Pharma [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease | Multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaMember', window );">Royalty Pharma [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease | Multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesSkytrofaMember', window );">U.S. SKYTROFA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchange', window );">Funding received in exchange | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment', window );">Revenue interest payment in percentage in exchange for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyPaymentBeginningPeriod', window );">Royalty payment beginning period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Historical volatility for shares, measurement input [member] | Derivatives [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible decrease in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=asnd_SharePriceMeasurementInputMember', window );">Share Price Measurement Input [Member] | Derivatives [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue', window );">Increase decrease in derivative financial liabilities fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 30,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible decrease in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=asnd_ForeignCurrencyConversionOptionMember', window );">Foreign Currency Conversion Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue', window );">Increase decrease in derivative financial liabilities fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember', window );">American depository shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConversionPricePerShare', window );">Conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConversionRatePerNote', window );">Conversion rate per note | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsRedemptionPeriod', window );">Borrowings redemption period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">April 7, 2025<span></span>
</td>
<td class="text">April 7, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsConditionForRedemption', window );">Borrowings condition for redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">but only if the last reported sale price per ADS exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.<span></span>
</td>
<td class="text">but only if the last reported sale price per ADS exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption', window );">Borrowings threshold percentage of sale price per share for redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsThresholdTradingDaysForRedemption', window );">Borrowings threshold trading days for redemption | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption', window );">Borrowings threshold consecutive trading days for redemption | Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures', window );">Proceeds from issue of bonds, notes and debentures</a></td>
<td class="nump">&#8364; 503,300<span></span>
</td>
<td class="nump">$ 557,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity</a></td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member] | American depository shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Principal amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember', window );">Fixed interest rate [member] | Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsConditionForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings condition for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsConditionForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsRedemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings redemption period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsRedemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings threshold consecutive trading days for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings threshold percentage of sale price per share for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsThresholdTradingDaysForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings Threshold Trading Days For Redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsThresholdTradingDaysForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_CarryingAmountOfRoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_CarryingAmountOfRoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConversionRatePerNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion rate per note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConversionRatePerNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange rate for percentage of revenue to royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FairValueOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FairValueOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FairValueOfRoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FairValueOfRoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FundingReceivedInExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received in exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FundingReceivedInExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FundingReceivedInExchangeOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received in exchange of royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FundingReceivedInExchangeOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in derivative financial liabilities fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Multiple of purchase price, were royalty payment will cease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from royalty funding liabilities excluding offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyPaymentBeginningPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payment beginning period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyPaymentBeginningPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyPaymentEndingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payment ending period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyPaymentEndingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharePriceAppliedForValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price applied for valuation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharePriceAppliedForValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of bonds, notes and debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesSkytrofaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesSkytrofaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=asnd_SharePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=asnd_SharePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=asnd_ForeignCurrencyConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=asnd_ForeignCurrencyConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700910665520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets and liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="nump">&#8364; 432,200<span></span>
</td>
<td class="nump">&#8364; 407,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">159,059<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets and liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">159,059<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="nump">&#8364; 86,385<span></span>
</td>
<td class="nump">&#8364; 157,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember', window );">Carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets and liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Financial assets measured at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities measured at amortized cost</a></td>
<td class="nump">576,737<span></span>
</td>
<td class="nump">545,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Financial liabilities measured at fair value through profit or loss</a></td>
<td class="nump">159,059<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember', window );">Carrying amount [member] | Level 1 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets and liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MarketableSecuritiesExplanatory', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember', window );">Carrying amount [member] | Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets and liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="nump">432,190<span></span>
</td>
<td class="nump">407,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyFundingLiabilities', window );">Royalty funding liabilities</a></td>
<td class="nump">144,547<span></span>
</td>
<td class="nump">138,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">159,059<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets and liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Financial assets measured at amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities measured at amortized cost</a></td>
<td class="nump">559,467<span></span>
</td>
<td class="nump">529,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Financial liabilities measured at fair value through profit or loss</a></td>
<td class="nump">159,059<span></span>
</td>
<td class="nump">143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value [member] | Level 1 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets and liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MarketableSecuritiesExplanatory', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value [member] | Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems', window );"><strong>Disclosure of fair value measurement of assets and liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="nump">412,122<span></span>
</td>
<td class="nump">385,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyFundingLiabilities', window );">Royalty funding liabilities</a></td>
<td class="nump">147,345<span></span>
</td>
<td class="nump">143,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">&#8364; 159,059<span></span>
</td>
<td class="nump">&#8364; 143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MarketableSecuritiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Marketable securities explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MarketableSecuritiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as &#8216;an accounting mismatch&#8217;) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity&#8217;s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_8_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level1OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700883492704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract', window );"><strong>Reconciliation of changes in fair value measurement, liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Beginning balance</a></td>
<td class="nump">&#8364; 143,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Ending balance</a></td>
<td class="nump">159,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract', window );"><strong>Reconciliation of changes in fair value measurement, liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Beginning balance</a></td>
<td class="nump">143,296<span></span>
</td>
<td class="nump">&#8364; 157,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense', window );">Remeasurement recognized in finance (income) or expense</a></td>
<td class="nump">15,763<span></span>
</td>
<td class="num">(71,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Ending balance</a></td>
<td class="nump">&#8364; 159,059<span></span>
</td>
<td class="nump">&#8364; 86,385<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial liabilities at fair value remeasurement recognized in financial income or expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700822211584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Liquidity Risk Management (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="nump">&#8364; 432,200<span></span>
</td>
<td class="nump">&#8364; 407,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">816,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">110,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">99,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">931,527<span></span>
</td>
<td class="nump">882,127<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ContractualUndiscountedCashflowOfFinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,027,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="nump">432,190<span></span>
</td>
<td class="nump">407,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyFundingLiabilities', window );">Royalty funding liabilities</a></td>
<td class="nump">144,547<span></span>
</td>
<td class="nump">138,377<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">576,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">95,902<span></span>
</td>
<td class="nump">&#8364; 98,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">99,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other liabilities (excluding income tax, indirect tax, and employee related payables)</a></td>
<td class="nump">302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">772,468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within 1 year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">18,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">14,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">99,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">133,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Within 1 to 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">759,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">51,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">810,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">After 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">38,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">44,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">&#8364; 83,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ContractualUndiscountedCashflowOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual undiscounted cashflow of financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ContractualUndiscountedCashflowOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140700825374960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 03, 2024 </div>
<div>USD ($) </div>
<div>Multiple</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>Multiple</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaMember', window );">Royalty Pharma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchangeOfRoyaltyPayments', window );">Funding received in exchange of royalty payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyPaymentEndingPeriod', window );">Royalty payment ending period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaMember', window );">Royalty Pharma [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaMember', window );">Royalty Pharma [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=asnd_EventsAfterReportingPeriodMember', window );">Events After Reporting Period [member] | Royalty Pharma [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchangeOfRoyaltyPayments', window );">Funding received in exchange of royalty payments | $</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyPaymentEndingPeriod', window );">Royalty payment ending period</a></td>
<td class="text">Dec. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=asnd_EventsAfterReportingPeriodMember', window );">Events After Reporting Period [member] | Royalty Pharma [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease</a></td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=asnd_EventsAfterReportingPeriodMember', window );">Events After Reporting Period [member] | Royalty Pharma [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=asnd_EventsAfterReportingPeriodMember', window );">Events After Reporting Period [member] | U.S. YORVIPATH [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchange', window );">Funding received | $</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment', window );">Revenue interest payment in percentage in exchange for funding</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange rate for percentage of revenue to royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FundingReceivedInExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received in exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FundingReceivedInExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FundingReceivedInExchangeOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received in exchange of royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FundingReceivedInExchangeOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Multiple of purchase price, were royalty payment will cease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyPaymentEndingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payment ending period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyPaymentEndingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=asnd_EventsAfterReportingPeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=asnd_EventsAfterReportingPeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesYorvipathMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesYorvipathMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>51
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY:#;TGPDYZJB"8P\_ H4R$?PQF_?A''PW@$\:($'+O=GX"^;JG-#W/*X=^V
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M3,BF*#8=+2I;B.Z%QK)FFSG^2( T$_#Y2@B]ZY@7M+\FXS]02P,$%     @
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M0MW0=H42-2B_OSJ+7]/;[%6]S5_+V_GB=<*>#0O[V6.V$6HMH42O5K*2T-2
ML%$$"HS2Q:&GMV(_7RM2'KK\4J'M#O.UMYN$]P@&\M\[WA"8)_515]#;]61S
M)_39L- _O"O!"B^^S<=$R:96]W1#S-?F/BV(?L=H\6$^+9BK?EJZ7H -]P*_
ME4840[2@L?<T ][37!3(6!BZ#1$&A'+'O98(!?*0GG@\9Z)K!MB_U RPGF;
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MR@+@^U4)J]=>V &./S.Y_1]02P,$%     @ 5(DC6;YSOH[4 @  =@@  !@
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MCXD-N"2.^QAT6>7>E6@P",,8O&%+IF;.HMV3#0FUZ492W*_5'%9)AF*/4$-
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M>1#=W6WW(OFFO?Z\XU+R=?NX8BK%"FV@_K_D:CNQ?]$WJH<;].E_4$L#!!0
M   ( %2)(UE2,#MM= 4  -@>   8    >&PO=V]R:W-H965T<R]S:&5E=#4N
M>&ULM5EM;]LV$/XKA L4*=!4(D5)=NH8:&U)W8!U0=)N'X9]8&0Z%BJ)+D4E
MS;\?):NV1=&,77!?K!??/7>\YT@>3],GQK]5:TH%^%'D974]6@NQN7*<*EW3
M@E3OV(:6\I\5XP41\I$_.-6&4[)LE8K<0:X;. 7)RM%LVKZ[X;,IJT6>E?2&
M@ZHN"L*?/]*</5V/X.CGB]OL82V:%\YLNB$/](Z*KYL;+I^<'<HR*VA99:P$
MG*ZN1Q_@50*#1J&5^"NC3]7!/6B&<L_8M^;AM^7UR&T\HCE-10-!Y.61SFF>
M-TC2C^\=Z&AGLU$\O/^)'K>#EX.Y)Q6=L_SO;"G6UZ/Q""SIBM2YN&5/GV@W
M(+_!2UE>M;_@:2L;NB.0UI5@1:<L/2BR<GLE/[I '"A [X@"ZA20HH".*7B=
M@G>J NX4L*K@'U'P.P5?4<#!$86@4PA4"Y,C"F&G$+9D;:/;4K,@@LRFG#T!
MWDA+M.:FY;?5EHQD99.*=X++?S.I)V9S5E8LSY9$T"6X$_(B\TQ4@*W ?$W*
M!UJ!K 31]SH3S^ 21%]OP<7K5V,OP._?@.ZFD?BR9G5%RF4U=81TJP%WTLZ%
MCUL7T!$7OC!!<HW:W*QVMR:<@CG99%(=_%/0XI[R?S4XBU-P;C@MLKHPX40O
M#$.N!%7-GT$+6)F08C.2G&-R!I5@7G-.R_09?.&DK'+2SMU;6E'^2$WPB1G^
M0YK619VWC"_H*DLS<03-D<FTRRBTRRC4PN,C\%VN$"'!TW? @V\!<A'2Y<46
MR&^!FC7S<88"S\/CJ?-XF =#L3 (_;[00H,%(1H'7E\N&LI=0CSI"\5#(0_[
MJ"^4Z)#&@8LG>Y.] 'J[ 'K& 'Z6&]"&LU4FG(N<5=4;('<<(-84;"C/V%(7
MR2UB<.@+\I"' R641LO-MG=5;4A*KT=R7VOS;#1[_0H&[GO=O+()%MD$BVV"
M)2_'MD<SWM&,C33_*1GE(&6%]&'=[.UR4F>E?*8=[6]!*3-!+L2"_-!QCH=^
MP;&KY/O<Z,2YC-L$BVR"Q2<%([%DLL>WO^/;-_+=;G,FOG4<^[K<PX,%:VXT
M?2[+-L$BFV"Q)AP:EK5!.SYA@QV!@9' =E^_;.K>)=B0YZ9. A>?F: @U'(7
M#-SP/#]0-S>CS7.9LPD6V02+;8(E+T6V1V^XHS<TTONSDI1SLJGDJ([2<& 8
MN2%6&-4(*2(+'8[O*I6*T=USXV\3++$$UJ-IO*-I?&)Y^7M=RO+2;<M+3\?6
M>!#E (\Q5.@:2H7!1%E?%T,A65WB"52KRZ&<IKH<"L% %4HT2#)')BB$^C2?
M[.(W^87R7!N_B6XP?C )E0@.Y<)0'<]B*(0@\@:S)](:5<K86&,1*;PF&B"$
MPM"=^/H 0G=_9':M%^@=9-\=[&*HG&/F9MOG;@A6T2*K:+%5M.2$ /?I/NB0
MP/^W4._P>^FJE@%F'\ZFW29:9!4M/B$:B2V+?<;W'0QH;F'\4JG>8:H)Z'GJ
M<FDV?C;5-M$BJVBQ)B1#JO5A.SYO]VT4:.ZCG%NOP^%!'WL>&M!GM8=B%2VR
MBA9;14M>#&^?YGT;!9K[*&US="57Z+I<RM]*L/1;,ULEW<V\E1OU R>%OB]M
MLP4QMXJVL(H6P6%_!"DS,;9J,=%8O$1'CFAPWT.!YB;**8<T.#S_(^@/CFD:
ML5 Y@BWT4*Y:LYJ=/GO:V41+;*'U"=OW3*"Y::(_KF$M;\&PH>[)8Y:GMC0U
M@N$8J@<.C12"&/OJ#A3I[$(XF!T:H^HQ,=%!(1QB.0HE\YV#3W;--]\_"'_(
MR@KD="55W7>AQ.#;SZC;!\$V[5>\>R8$*]K;-25RQ6L$Y/\K)G>V[J'Y,+C[
MF#W[#U!+ P04    " !4B2-9.+*&1X4'  !1(   &    'AL+W=O<FMS:&5E
M=',O<VAE970V+GAM;+5::W/;MA+]*QAUIF//1!$!\"&ZMF9L-9FF,VT]=A^?
M81*2>$,1*@#)3G]]%Z0D2L0CSKV^^9"0U&)Y%ER<LPOD^EG(SVK%N48OZ[I1
M-Z.5UINKR405*[YFZKW8\ 9^60BY9AINY7*B-I*SLAVTKB<DBM+)FE7-:';=
M/KN7LVNQU775\'N)U':]9O++':_%\\T(CPX/'JKE2IL'D]GUABWY(]=_;.XE
MW$V.7LIJS1M5B09)OK@9W>*K>1R9 :W%GQ5_5B?7R(3R),1G<_.IO!E%!A&O
M>:&-"P;_[/B<U[7Q!#C^WCL='=]I!IY>'[Q_;(.'8)Z8XG-1_U65>G4SFHY0
MR1=L6^L'\?P3WP>4&'^%J%7[-WKN;#-X8[%56JSW@^%^737=O^QE/Q$G \"/
M>P#9#R## ;%G -T/H&V@';(VK!^99K-K*9Z1--;@S5RT<]..AFBJQGS&1RWA
MUPK&Z=E<-$K45<DT+]&<J17Z"%\6/6IX %]+*S1&'_YX0!???S>E:?S#)=I?
MH*I!OZ_$5K&F5-<3#5B,QTFQ?^]=]U[B>6^*?A&-7BGTH2EY>3Y^ C$< R&'
M0.Y(T.'/V^8]HM$[1"(2._#,7S^<!N#0X[S2UA_U^/MMPR735;/L$K72%7?.
M4N<E=GLQ:_A*;5C!;T:P2!67.SZ:??\=3J,?7"&^D;.S@.-CP''(^^Q7H)R-
M%(M*3RYJH=0E HY!>L41S$0E2E?PG<>D]6CX9C<;DSB*<7(]V9W&Y;*CA,;I
MT>X,<G*$G 0A/_ =EXK52"S0HFI84W#(ZD*LN0MLYRL]!8%CF@^Q.LRF$<UB
M-]3T"#7]9JC\!;A<N=,JM5 DTR2A ZRV%9ZF"7%#S8Y0LU=#O5B"D%Q.3#X@
MX.RR4ANQ_PER!1)#?WF'-C5K- (:0?SO;;4QK.,**;,G-L>#@&P;@MW13(_1
M3%\=39<;2+,7KM#%8?HO76"G-I",9@.TMM$TG;KAYD>X>9!V;LO_@&9TQ&W6
M7R.:<6%8O0(Z5U<NJ/E;,M ;.3N+'4>]ED5A#CI$6X"J567+P&VU47=4K 5<
M[WBS=2[PO?.S#"-)2O/!9W/981)1]Y?#)TJ,@^@?5TSR_=(XH5%XP)02106*
M[!9:;"]C^#,=PK;-IFF6>5"3'C7Y.NJQJ:1*M&%??*MW[^7T[3&E9+@D'&:4
M)KY5@7LUQD'MF_W((>',%$(^..%1Q^10,D3GL,K3W .N5TX<EL[;M9"Z^L</
M+K;9A ZYW&5$/%2.>X7$29!/YBO6+('MH-@SY;A91 7;5)K53B[!0<']5C)Y
M*V_GL?>2B\.:^ZD!JM!">BHW;*OG."8DM=:=PXYFQ%>\X%YG\=>$MN#5CCW5
M'GP.P20DBZTEY[##4792A)WCZY43AZ7S7O(](;CQV?('U8>%SK8"LLTRWZ+K
MA1('M<@T/EI";8[JBCU5=5N@HPMH +F40&6=UCNU?>_XO,2+HR%PAU5^RLKG
M74ZO<22L<;]+5G+#M.V'?P?M12&W /A0CK2%E("Z6QZ-7$$0EXA%23:LJ!QV
M.<6>W"6]UI&PUGUJ"LE!,R8PX]W5I>$84+Y=978(W)AM!<L@H],A9-N,IL23
MSJ07.A(6NK8Y7D!SK-"2-Z:V@%E?2+&>7&Q5FS&@U9M]S>'&;XO;&"=30H9<
M[C(D>0Z*Y FBUT$2UL&/9VT.5$.&0H;]]QZM+78I28?MCL,*UH(/9R^))"R)
M'P<]#N1RY49IR]XXRW \A.DT\W$PZ?61A%O(3Z<MP6$V)Q<&K9,[B*,]I,2J
MU5QF>>I#VRL:"2O:20J[$_>KVQ7$(68X)=-\2'\N0QI%./.4)*27/9(%2Q(C
MR^HU4(/J^:VUR%MY.P^ZUU(2UM+; EIC5;7MS'_3/!.'C":Q1?8NL4V(1VM)
MK[4DK+7W4A2<EUW6_6^[ ,26U3RQDN__T8;27J)I6*(?N=9UNWMJ0EPS^9EK
M(\1(\6(K_5N!MM1F-!DRF<.*)#FFGG5%>TFF84GVDT/URA5''?J<I4-Q<UB1
M)$M]FD%[@:8D2 R=9KP"9E#GOWG/]8V\G0=]LLT<%O2'0XUM4NU)2'  ,^".
MVY;J<9)&P_+):19-/?43[26=AB7]G 3X"Y=%I=K]CF<F)?-T"=31UN(DLU:%
MPRSR;;K27MYI6-[]:V+QVF2SE1PGN=4D.LQ +K%G\Y+VBD^_UL,ZZ^QVD\QP
M;7MA"'?':E^C1EV:3W,(8QB$JR-.DFGDB:*7?!KN=.<^N(AI]#-KMDQ^0=B)
MW6YN:4YP:N6/;1?'<99ZML=H+]PT+-P?%@M>M(N3OQ3M9@HRG0,J]ALKH.=/
MK#:UKD(K7IOD,ANWO%K"5]I"*PI)YLDL6ZR3U-H1=UB-XSSUK>9>TFE8TN]8
M\QF5'(2\\F2-+=0DF::Y13>V'<UC[]95W*MP'%;A<-)L&XYHY#R4BJS3)B=P
MAYT3^.3D<';-Y;(]LU:H$-M&=\>;QZ?'<_';]C1X\/P.7\V[T^W>37?8_@N3
MRZI1J.8+<!F]SP"4[,ZONQLM-NT1\)/06JS;RQ5G)9?& 'Y?"*$/-^8%Q_]%
M,/L74$L#!!0    ( %2)(UF#^S@N, 0  !()   8    >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&ULC5;;;N,V$/V5@198M(!KV8J331/;@!UW+RTV&ZR3]J'H
M R6-)"(4J9"4'?]]9RC9ZP9.T)=$O,SA.7/U=&OLHZL0/3S72KM95'G?7,6Q
MRRJLA1N:!C6=%,;6PM/2EK%K+(H\&-4J3D:CB[@64D?S:=B[L_.I:;V2&N\L
MN+:NA=TM49GM+!I'^XWOLJP\;\3S:2-*7*-_:.XLK>(#2BYKU$X:#1:+6;08
M7RTG?#]<^%/BUAU] RM)C7GDQ9=\%HV8$"K,/",(^K?!&U2*@8C&4X\9'9YD
MP^/O/?K'H)VTI,+AC5%_R=Q7L^@R@AP+T2K_W6P_8Z_GG/$RHUSX"]ON[N0\
M@JQUWM2],3&HI>[^B^?>#T<&EZ-7#)+>( F\NX<"RY7P8CZU9@N6;Q,:?P2I
MP9K(2<U!67M+IY+L_/P3:K1"P1?=!9@\-8T] ?-QG/4@RPXD>07D KX:[2L'
MO^D<\__:QT3HP"K9LUHF;P+^WNHAG(T&D(R2R1MX9P>59P'O[!6\E729,JZU
M"*: $YKA[T7JO*4<^>>4_ Y]<AJ=Z^;*-2+#642%X=!N,)J_?S>^&%V_P7UR
MX#YY"_W_1NA-D-,4;PUXA/'[=Y?).+D^Y96%RU#GTL%=)6@/%O%Z -Z4Z"NT
ME*F^ ND=573J9"Z%E>@&0-=%TZB=U&4XE5J;C>#B@WLKM+LA8(]9I8TRY0X:
M)3R_2+B0ME+E($!1>R'S 12M4CM"\%A:X3$?0*E,2BQ3:9J.4V;J1N@=%(;*
M!7,@]%H\\N,":A2:O@@%<ED4:%%G2'#0$!_4W@7M'ZY!$3LW/*47MH(E9,8V
M)E!@<VYY('3.6BOB^M0*ZPD]''ZF%H.V;0:P0DV=[G$(#UJA<T!>([HDYMF#
M81=NI4-J;4^MM.PY:D@=1<?.X-O,+QE=WW0:!V$YOMYO;_'E3NL..TROWS6M
M/6R'-QC^E-8@Z45 AW!/1$2>6Y9 Y<.\>D*]^QRAEM)U'C!%(=G)#N[;E*8%
M+$VK<"-L#N.$?/+'+\FO(RKM$V[ZIN$CII:<N8.$BW]\/CA^+L1:(0=!:'*U
M]))2H6E3)3-^%RV'?5O)K")&CAIS%Q&&4,2/3TG HJ:+&2&LL#%.>GYN34X@
MM__4>VRQ6KO>8S]S7$+1Z !P2KZQE*X,XP+, %IJA#9<=;LZI:Z^QUW?KO:1
MZ(D]D RBN?:47(ZSE]U]*UPNGN!3E^SK,,3@*SD)?1>/EPR6AAU,XE:42IDW
MEK0<)5 XW@OB\K1F0X_2#4K 5HLV#R0H.7,:N-V7,TKF?<93:&4-!8G4&?O<
M,=N:*X@9K[&A54J*S[J6#4,XU?GBHSE%,2C#-';T5JM]-[(.NX>!O^CFW(_K
MW:\%\D4IM:-.49#I:/B!YJOM)G"W\*8)4R\UGF9H^.1*1<L7Z+PPQN\7_,#A
M9]#\7U!+ P04    " !4B2-9]E'<6-,)  !S'0  &    'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;*U9ZX_;-A+_5PBW*%+ ];O.-OL =O- 4US:1;:YX'"X
M#[1$6[Q0I$I2N^O^]3<SI"3*EC<Y)%^2M<1YS_QFAKIX,/:3*X3P[+%4VEV.
M"N^K%].IRPI1<C<QE=#P9FMLR3W\M+NIJZS@.1&5:KJ8S=;3DDL]NKJ@9[?V
MZL+47DDM;BUS=5ERN[\1RCQ<CN:CYL%[N2L\/IA>751\)^Z$_U#=6O@U;;GD
MLA3:2:.9%=O+T?7\Q<T*S].!?TKQX)*_&5JR,>83_GB;7XYFJ)!0(O/(@<-_
M]^*E4 H9@1I_19ZC5B02IG\WW-^0[6#+ACOQTJB/,O?%Y>ALQ'*QY;7R[\W#
MKR+:\S/RRXQR]"]["&?7RQ'+:N=-&8E!@U+J\#]_C'Y(",YF)P@6D6!!>@=!
MI.4K[OG5A34/S.)IX(9_D*E$#<I)C4&Y\Q;>2J#S5W<A&,QLV3ONA95<L>LL
M,[7V4N_8K5$RD\)=3#T(0Y)I%AG?!,:+$XS7[)W1OG#LM<Y%WJ>?@I*MIHM&
MTYO%DPQ_J_6$+6=CMI@M5D_P6[:6+XG?\@2_5])ERKC:"C3^WB@P&3V1%5SO
M!).8,:T?*O3#GOV;;YRWD$G_&7)(D+<:EH?5]<)5/!.7(R@?)^R]&%W]\-U\
M/3M_PII5:\WJ*>Y?$\<G&0^K_;OQ@BU^^.YL,5^<?Z%H=L.=='CJUHJ*6TY5
M^6<A6*UYG4LO<I892!;MPE\."'..CZ5&MB7;2LUUAOR=AQ> #9X8>F#RTI05
MUWO&(9X5"2!""J+-@4Q 9?F"O45>FH3W];SS7.?<YFRY&C,T;3$[?QL%OVD%
MOQ>5L7A^0D?FY^REL![ #V0%B"2LT3G+V_QR3.,;I?9P*%-U'C1#K;G6-7#M
M63MHY9,FO7E_-V2)8\\:.^!$U/='5O![P39"Z,3=QC)32@_B)\3)YL!([<>H
MI/O:"+G"U"H'D0S;!EH M/^M=<!E,B&)(&75\W/'&I%?["/P/S':"VZ90-AA
MKT0FRHVP;#DGX%B.*3;H01*&[M*0S&[,'@J9%8ES/NMQ[IATKH83FSW)_6QJ
M00T8S+!G>+H)S?7=31L:T@TLSTWE.[ZO:PM-F&OV0:/#4NK7'QK:"972(61A
MW?&J4A+]")6!3I3.@[L:OQLGFA("B^^EJ5WB770E9 3T.9=965' XNDA41(3
MU=S+),.'D,#%EMQPZG+K,Q'F5.[HI2^)-9NPWV$LP./793C310*?4L# :D\Q
M<^3!!D<*GG@.J8,&WC#$KIWE%?2V]2_XX/D:M8) LGF+'+>(E3HPQK<=@MRU
MYHP;" FI]P 2Q78K:$XA V/FVP9S6 5%9D#YC=A)K?$)<H>#6S"$_<;A. !Q
M,'\54KV$&0)+K[$%K+7&54&*VL>TZ1E(EC \([<A ZWXJY8V*;-,<>?@+:J@
M)-]()3WEFH.AQ5K,+SBEC?XI_CR2 QPL,'@1'+8^9Q\+[C&!2LATCZG/F<61
M"C6",0OL<\)[14J<MU1_(M7123):/$*F,WB-%H#<)MT.W7G +)HFLQ [T C0
MC\+25:22GX22A3$Y_$0%- CPTN^AJI0"R<)F$@I+@J&DD<4PHH[G%)2>0*.Q
M,6R)">1OCGF:@V;WG!(!X0=+XQ[ZC-PHT?I[C[J!!*$"+80(GVF84.J2*IQ@
M%_6%["A#Z234@'M,0K)GGO3LVQWBE8J%=)844T#+MK&D!^A-"V6QT_6LBBH&
M(AKK38"44 #2D4ZY@!@#&D#SA 2%<"D"! @NFM+A0F<)NA2K1VK(0NJS5F1F
MI^7?U#YRS"ELQ#D809,'\@7/;[FT[)ZK6F#B)CY/4QIG_ASK#*43%N71GW5%
M^>%J:@PQNXX\DGHRM5EV+A<!];&R8(O0L82R(4^A-;ZH@Z=26="!#;*0C\!-
MUP2$H)(K. X@A";Q)2\1D/%EQEUQW.^'=77UQD'\(*^><"]9,>#'0V_[PIIZ
M5V"SV$J""@@V]F#L28B^G32&L$/L*:=W,&JYA@ ,2S5Q",UD6$@2= KT>8''
MQ6.%8PM$XT[B&\*$H6H+GAVLIQI:B*7>'_R4H%D$R.$,8,^JT WZ2FZ,A2$?
M_.Z:7MEVNLX&3/3*.(EA"//!<)J.64]&@KQ]?/9#(Q%DSD;T&1P2,]ED\H#5
MU4&S&_;" %=42=P+M![SX051QBI.T["R,E38]VR^7D^6*X1N=OWJKHE7*0!9
M#W(WP!^^;?3$?.]U$?#G^(2VN0F,N<<-$2<8&.E #Q7;ZQE,%V]J"\060@(;
M@((8!-##UO(,9?T8R -$<;7'_2?L)]V,1*O4?-8.#MV@< T)[L.@\H_.7^W>
M\8<>#"4:PZVESIQ4^G$T3J82>Q"6!LSE>G7.5K/GDSDKH:TU\-.\F:^6DV7S
M9@Q.3J<*&J-LX!W4<,EL#57;01]DGQ5;O*8)VH?]&P>M)*TF)^Q5@ T#VG>Y
MG"!^K++>F-E?)(]K#N!QL&0&?#R@"J1\XZVSU61]PHV31>?%;7]LZA<O4 T\
M/W1] +AWW$)+7;:SX+%VW![4_&E@^C]=]M7!E_H@^+T>Y08-3+3&Y<[B_'64
M]N KL^<*"G(+:'XPO8:!^<A1L8$/IB68A1###.% G*;BK/#9I7EHQ8D8>[QX
M?(V@I[9S*"QBF8A"Z?MVP]I*"V.TER6%)?JZ]@U 4ERA77Y3E7!MZV_3 S<P
MR3('(,K^)3Q[W:Y/Z$5<K6F/BVLZ3^8B#1),M#KD=&#5NP= ^_8"UR<:([KE
M#"@/#D!>'V[M'RB6D-TPU347*2BVE=7Q('H<5BS8%OWS+:Y>)N&F8GXVO)=B
MNB?7H"!S:$UM&LY;'1M@R '?>#AZ]QM*2J^M@&6S4S2Q@05.\0P0[(F5^X2$
MMGM&UN@]:_(:N6%L8/D1.V,;M(4QU!O/U?"$=CB]X@C>[;-_P(C"*4_IRP-!
M2;=JO@5@<B??1M5/TE(Z>OZ(3]-]$EUL\+(% V*" I K$XP=SW."YW%B.ZUH
MP?*C%9_V7!.V04#&W<Z*7>]V,WW4:P3)3>CXX"H4#Y8P"^U(T$^P&TL-JH*F
M1(*X'J=]1&-:GO' ..S'^S:? 7U$F/RZ/7//TD4AX#6:OD5 @XDK+<VC 9[V
M]HWXEA<PS[_H B8N/8);W$GSN'"!G.8Z]F,AH7LU=I.>32^BA+1U1B-JFJ]?
ME*X$[C6PB]"]M:;$O\-PC+:UB=).[J#C1E!>XCS[=^?2>&W6+KN?N\BS ?AP
M+<OB=H\^2NY90J<[A=,3-O319)I\""N%W='G/IP'8 0)W\3:I^T7Q>OP(:T[
M'CY'PGBQPU53B2V0SB;/?QZ%&YSFAS<5?5;;&.]-27\6@L-(C0?@_=; P!%_
MH(#V.^O5_P!02P,$%     @ 5(DC6>4R6@T>!P  /A,  !@   !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6S%6%N/VS86_BN$"_3)\74R,TUF!LBEQ29 %T'2
M;A\6?:"E8XL)1:HD98_[Z_<[)"7+$]OM;@OLRXPE\=R_\YTCW>VL^^(KHB >
M:VW\_:@*H7DQG?JBHEKZB6W(X,G:NEH&7+K-U#>.9!F%:CU=S&;7TUHJ,WJX
MB_<^N(<[VP:M#'UPPK=U+=W^-6F[NQ_-1]V-CVI3!;XQ?;AKY(8^4?BY^>!P
M->VUE*HFXY4UPM'Z?O1J_N+U%9^/!_ZE:.<'OP5'LK+V"U^\*^]',W:(-!6!
M-4C\V](;TIH5P8W?LLY1;Y(%A[\[[3_$V!'+2GIZ8_4OJ@S5_>AV)$I:RU:'
MCW;W#\KQ/&=]A=4^_A6[=/9Z.1)%ZX.MLS \J)5)_^5CSL- X'9V1F"1!1;1
M[V0H>OE6!OEPY^Q..#X-;?PCAAJEX9PR7)1/P>&I@EQX^*0V1JU5(4T0KXK"
MMB8HLQ'OVW)#R'WP0II2?.^#0@;(WTT#C++HM,@&7B<#BS,&KL6/UH3*B^]-
M2>6Q_!3.]AXO.H]?+RXJ?-^:B5C.QF(Q6UQ=T+?L,[",^I9G]+U5OM#6MXZ$
M78NMU4@!X"F*2IH-"<7(Z?/26*V*O?BW7/G@@*A?3R4DV;LZ;8^[[(5O9$'W
M([21)[>ET<.WW\RO9R\O1'/51W-U2?O?4<_+!OYI XGEM]_<+N:+E_^E-?'.
MB%"1D$V#-,K8EL@YWWICZT::?=1[\])_E7-%?@S<&YD4"^5!";^URE$I@L63
M+R0^]V;'@GJ;[('T()V&[>%Z!6Z*-@OIW)XMR)IM>?8%)RF[K95<*:T"3..X
M#$("(L8&P>2G])[#P"TXLW:V%A8JP7:V=07YR2 '%YWA3" $5LWD4@JDI%)H
M>X<$:4&/#3E%IJ HFFRL 3SK!DXYD-P6-1C'0[M*%56\+[=2:;G2^)4B=M18
M%Y-:PIV)^!F*70!U!^#=\H7AA^?]15%T"34>I,>M@506MNX2E"LBI&!IIQ"
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M-\]'PJ6O->DBV"9^(5G9$&P=?V)B@LOX )ZO+5YZ\P4;Z#^9/?P'4$L#!!0
M   ( %2)(UGHPQ9RQ04   H-   9    >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;*57VW+;-A#]E1VE3=,913?+3AI?9F3'GB23M*Z=M ^=/D#D2D0- @P
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M;[I/.Y/Q8+R9M %]0GQ/KQ40%\C!0ZQDMHQ:)U+,0H;RH1KGA8+RT&QXV4"
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M_M("/%\K<(>_( 7-9\*3?P-02P,$%     @ 5(DC6:F T2VD @  !08  !D
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M-(1CY0L/[GJ%>N<[FJR<1IKVVO>K_:.Q:'OE;WC[XMPSO>.20&!AH='PW20
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M@GR]!@" 1@Q%OX\ZLWN!ZHF)@W"V;"<^!_Z\N7_% MN;><WK*>/K$H '&:A
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M#![TUGA>P??5ZE^Z/N7U4H5LS>-_X=EPY6I7HR2/3-8U4T<0'>M%)NZHU:D
M:&8Q7M9P-H%FW(/^]T"-H #$\XX#,>=]B>I)$IG*4M-Z-6U]=804@R3>@=\4
M7),2*18(8OHU9=BBSFDFH$(=R0&S$!SP3D9Q9Q(GZE-)+LEUIE"@=[4%:YLC
MBYG4ZW@VPGF0;OO>0FZ54Q.EA$'4)4$CNW8_VC0&-)2983XT$"4SJN,6BZNB
M2;Z8K/=I, 83AA+EF573W9J9F-SV!<%-,3VH8T C-*0W#6MI/*K]F1K30UZH
M>J4G/9?0]O=-IRK8RHPY8V\SUJXB:!%9YVEDQCV-WH75B?3--777I0U4<N8V
MI<V8B#KU> ZU1A8H\@>9&FG;OHX[<YJ^,_:JZQ,A8<-? 'M+GFBK(2;/?ZYR
MS?0("4HG=+V1@4Q)2PQ*<BPW3E_1 DVG'IGMJM)JR*A.@QL(,B)I-]^>46;?
M4-I N=&RQ_4D)A6L"?99;Z$"\X!-]<S5+9-GK.'8KVJ.W5\2@O3<BEUI5G-P
MB#<D/D*7O-CD=4Z)*K![_":"=2F:]ADZP<&L.*#S'&S)D,!S&I:"W+6O&H'>
MH1:DG%TWC?1GYVIJ\OU!J_X [QJJTO08H5 U+W+\>4> .E[D>//'>-$(M_D(
M#E*84!!%JAJ,GM)E:$>S.C44LMHAE<$B#?LQ!6!@US%=V3N"76LBRMD/^)!M
M:CBPY<PA(M*X@ (9]O@X0SFY_>O?/[Q_^^H:<B#/5TA!*[&166;2"_N)@Z.@
M7CAU]ASXRO0 4&KR\\Z(K8:F/]F,U82@=9DI)I%>R^FB5% RU6!A:964<I>(
MQKA#W>FM,UM"0*S!H+(SF^.Q2?#=!+6QU2-"Z36*67Q1OD'$];<T8 7/J=G@
M*?_6Z9@X$&K-_H)VJ4PR;>H_D'@GJ4$?"!K9.@%K$@SC8+%=0F.BOQ@#JZ;C
MA3#O$\$] <>8JYFWUD)3;!K2&(F:JS$SIC*KS(?3!MIQ&1^[CK>P%P@0D_SB
MF@?3VT:@)MO_D-]C!L/GCK\3TZJ-%->U'*D5_V/> W>XBR[!-Z:$2+68 QE/
MZ]3:9\0FG6:G]=$AG0T^'%M^_C]A^*\JLX=)NP^]?L%U?'\6_,:"Z_AAEV__
M'PINO\#V]FCZM?7$UHVA7HV/B3W)#4JI(>7[/N6LJ3 %0AQW.RLC&PA_MCW5
MD4'!8L?5P_)NQ+(D]XN$1Y\N;B-:*K0\GV2A!FD>BV2@2(W.9F6IH%D259JV
M6GIUN&\&[O:TN5*58;'J"3MWID<$_HJ=N]/1=8=>F+:-O&FW-!X(@F_^E);_
M4GVZ6*,8=-L"&BDZ%32"=<$Z;$3K&U.9-SG$RW1!6='BO:T/BJ=DU[7069^K
MX6K]4*1@"B3T&44L*:V"?M<T?C[5^ 6;B0@!=SGL2![K^^<1B[!SYB]GBR7X
M!0T'LN*']*S3TB#3Z.^'V1NL$LKOC"V2/3C#*PJH.);UZ@-E,BJD\31MFK4H
M4-1S+8HN7!I7J_HPL>8I&CB_:."\-NC3L5FS%-KIHWW'.]+X&C/N%0!UF"6Q
M;-1E6(> P;V!?8<JMA6)7H93H:8TPQQ:+NJ8-GZ."DUM$%R=D2U#>MJ/!\E(
MGWV-!A/BYT0^#;JU3WL80COQQ$=BT0EQL,>KMZZ1Q<INY<8?0!"Q,D]X06%]
MJ%%_L!YLNOD,$/6^+AH!0E$Y&##_PZS<-ZZ.D0Z@?[R%/;LK=G^*A?MC'&CS
M:]8=!SM[(2)>J39SJFU>E!>T6ND2!Q6RZ-1IES4X>-/U?7"D8M6;?3W#]FQW
M2"\.DWER='Q#^E*MBLTQL(B'A8S2$141VD$Z9B[IV+F>-;8=]QB_(27'D=$2
M' B4@*XEC9]ZVF^E*.C(@$X(ZLL4^B2G:3D\:]6;0H5XPG[6PSG4:5B1SZO,
M[-F)>#I2GLEYE-7!\;ISNGQX@*67-;KVH%E)IW,T3$3;Q/6'M(<8XI!7M3PN
MR=-2!5+0G,"7(MIF\G,EC !F<:.WU,#N5=D:!X%L9B=;@-+(-<3,RC9S=V;K
M2X#&YF@-H:>W#[M?+0=I)/3^6Q)662?,;#+,9D>U;G+3@+4'YK%WO4<MX>%)
M.@C,A7=\GOXK)]J#DVWZ?SYGSE>=6S\RTO@YXQ<<]SIT^.8VQ[[,6P26CRSH
M?=D!L!]:GA\T!\'Z@'()D;RO/UX-PKD5>B$+@J7ES_'7AR"ARP)W:4&H7SUN
M'1Z1MG^_1)*O.( ],<OC]S=24,EV=R.I V8<T^K)1&-7P_7P_L:X"2;M)E$G
M5A!:R\">O!?]<$'TY@BM.@V:,UGP1W.:/B5=ZSTU]+?"N0=J&3I6@'7SM(FL
MU@"+.3F%O6ZJ5\O<1BW1Y%_5E3O>=#C719P1R,R9IED62375*8.V3WME8/PD
M>:@990RDZPH<5H,KBTDIPUKR1,9Z#=D>@JOQ4W#"Q3"=H 16A:9&YCH43;OA
M>M'%HOJ0/>(-41XYD5-L[%2]6SJ."'=*-DU'ZOT9#*!O&[E6P[AOS>5!Z@P'
MP7AT"!=IXY*P[S!/1'6TH> 'A/V-N-<5]AH2T 2WM/,%14U-UALCNT+4QT4-
MCY]\EY0@O_J E#D7@7Y [MN45\VSN0O0Y-M';B<-P-WW0>\B2_\^R!%_F3)G
MH>^?A 37T$-6LT+;9@MG;LV1GNI<,W)OQ?&M!?H%CC7WD!1]RW-<YM"]'']>
M7VHYN,UB'5]ET6?P1Q=8EDMKX2Z/<GC]VOQY]+Z$XWE6X'G0 N+8 5MXEDW2
M6;:+$A#8[0V5L6MRE[WKCZDH-OJ2)Q!)H# W(=NW[3W2:W-]LFMN+J&BRFTD
ME@*)6*.K/0N#,[-IVOPH\YV^3+G*RS)/]>-6P&8%-<#W=0Z\UC]H@O9V[?/_
M %!+ P04    " !4B2-92C>?+MH#  !:"   &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6R-5FUOVS80_BL'=2LV(+5DV<G2Q#;@)"V: 6V-I.E0#/M
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M5!=T?-/!+&I&)?E$=^%T45-]ZIW& .XH(74@350;XU_?;_98.8)>'>@;Z95
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ML 7_S)1$2TT;L+ZT:#CJ!V+0?MB]^@M02P,$%     @ 5(DC6?=.61WN P
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M::FEG"M1WS*T16OUF@L)M=#&VP%BREP(W?;P&[&EI=["LJFMBX>RO3 D49B
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M"_#]4F EZQ[, ?V_GXM_ %!+ P04    " !4B2-91+EN%2@$   ,%@  &0
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MV9S@2G,&:,&9VDF4L RRIM[57:O[%SSW;QYT A=8]% P?H,"+PC:VM,M_^W
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M/6IN"]53 ]<&ZOV:,7D8Z!ZI[]+C?P%02P,$%     @ 5(DC65?Z;\2*!P
MD#X  !D   !X;"]W;W)K<VAE971S+W-H965T,C8N>&ULM5O1<ILX%/T5C3O3
M:6=V:Y  0YIX)C'L;G?:G4S2[CYT]H$8V6:*D5?(2;M?OP([EH%K)5[?O"2
MCXZX]QY !Z'S!R&_50O.%?F^+,KJ8K!0:G4V'%;3!5^FU3NQXJ7^92;D,E5Z
M5\Z'U4KR-&L:+8LA=9Q@N$SS<C ^;XY=R_&Y6*LB+_FU)-5ZN4SECRM>B(>+
M@3MX/'"3SQ>J/C <GZ_2.;_EZLOJ6NJ]X8XERY>\K')1$LEG%X-+]RSQ_+I!
M@_@SYP_5WC:I0[D3XEN]\R&[&#CU&?&"3U5-D>I_]WS"BZ)FTN?QSY9TL.NS
M;KB__<C^2Q.\#N8NK?A$%'_EF5I<#,(!R?@L71?J1CS\QK<!-2<X%475_"4/
M6ZPS(--UI<1RVUB?P3(O-__3[]M$[#70/' #NFU NPV\ PW8M@%[;@_>MH'W
MW![\;8,F].$F]B9Q<:K2\;D4#T36:,U6;S39;UKK?.5E+91;)?6ON6ZGQC?\
MGI=K3GXFMUJ#V;K@1,S(X]$;/A7S,O^79R0OR9<R76>YTCL3469:+)NM2A1Y
MEM:'/Y2*RWQ);I7>U6I254UV+<4L5T1(\E%4%7D3<Y7FQ5O=9?+EAKQY_2ID
M@??^+=ENU#U]7HAUE999=3Y4.LCZ5(?3;4!7FX#H@8 8^21*M:A(HD\Q ]K'
M]O:!I?U0)W>78?J8X2MJ)?Q]7;XCS/F)4(=ZP/E,GM^<0>&<UGOROWMO)8/M
MY,8:/O:$W&92+ G_KN52IL56YUR"Y=X0>C!A?1\]JU;IE%\,](VRXO*>#\:O
M7[F!\Q[*-299C$F6()&UJN+MJN+9V,>WZ>:RGXJEKL(TUR5929&MIPJLR(;,
M;\CJ!]']F+DLC,Z']_NI!E!^&/EM5-Q'1:,P#-NHI(\*1IX7[%"MJ/U=U+XU
MZANNKW"9E_,Z]#JE^92#\6YH@OU(1I[3";</<IW(Z20E[J/J>UXG6H"*.J,(
MCC;811L\K\;ZAWRJ*URM5ZOB!Q2OE>C8*PZ3+ [ZF>GDKH^@O@=G;K3+W,B:
MN8]:%_I9!TICU*]GT+T0^AB_>['$?0SU ]9!)7V4%@:#HPMWT876Z#X+I<4@
M-_=E*,2PKWX_BCI7Z*2/\D8L8ITP^RB7N6%$.W'V8:$3A10.--H%&IWRZ"%O
MYES,9;I:U%?'6R@3$>9U@4D68Y(E2&2M(KF.&8\ZI^EQV_XI00(P2)$ #)0D
M@+-HTMT;?KO6<'\5(JOJL?'C X@HF9;5C$NI!]3BGDNBM#$C7Y=\><?EWV!&
MK%T<*TQ4MAB5+<%B:Q>+FF)1[-'KEA&K-IAL,2I;@L76KHTQ%JYUA/R,^P9[
MSC .0$'C.  &#.0@LL,C.=<,UUWOA1]EKM40'"U+3+88E2W!8FN7RG@,UVXR
MGI;EL]P%@ )E^2Q_ 9%99&D<AFNW&/9G6:K(2N2EJM_O//U(0_4@J&PQ*EN"
MQ=:NF?$V[@C]D6:U2T?7!I,M1F5+L-C:M3'.S#W1FKF -Z/4[PV% 5C@A5[W
MY@&X,\I\VGT9 ^"",#KD0UWCS]R7-F@NJD-#98M1V1(LMO8;;6/2Z(DFC0(F
M#5 F! .4"<! 90(XBS*I,6G4;M(FYKVHD>/73X<?7W:^8X6(RA:CLB58;.W*
M&$=&T1T9175DJ&PQ*EN"Q=:NC7%D]$1'1@%'!DPD0#!@)@& 05,) ,PRET"-
M)Z,O[<DHJB=#98M1V1(LMG:IC">C)WHR"G@R2)@ #!)F'P8*LP^S"=.X,FIW
M91-1%.F=D&GS8<8JE:JL]9B6&2DV,QLDG4N^G:^W/M5031DJ6XS*EF"QM4MF
M3!E%-V44U92ALL6H; D66[LVQI31$TT9!:;"@NZ;F@F <EVO.XL1 S#F.4[W
MC0[$QGQVZ-YA+!E]:4M&42T9*EN,RI9@L;6_JS&6C)UHR1@P(=;7)8""= G
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MP^QP*[R5D.D-^O=U'*NGD]1!N4US_C]02P,$%     @ 5(DC6=<S$&@Y @
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MKP/:'<#]O5+V'+A.&/YCZ5]02P,$%     @ 5(DC65%ZNPLR P  # H  !D
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MYL73HYA(EN;7_1.3ZO&0#R/U7 .N#ZC]*6-R.=$&J@>@_P]02P,$%     @
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M8X?J!B8\*^N_Z/YH:\U0LBLESX_.J@5Y6AS^QP]'(CH.V'["@1P=R+D.].A
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M(G9J>60/6U:43S Z%G9!,-8L.C/;<8?%F[F-DQF]A/PCK?PC9OGWAU(IHK>
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M#Z4%4!I%T53Q27O%M%^TX8:Z+E":"Z5Y4)H/I050&D715,5*7\;4^S):0_"
M^:='=I8AU(HQVTR1 ^8?-+(/I050&D715)%)P\8\8M@<>'A6B&W%L@E_&<Z9
M(CU>86X>&&N5(-31@=+<FF8T#;QA?WAI[/4)H<X-E!9 :11%4_4GG1OS-.=F
M([LQFT=)HO<,]<C."H/Z-$>*^U.8] D95J:A&(FTM*]0;P9*"Z TBJ*ITI/>
MC*F?*4.CO$CY&)CW]![3F'<!XT@\"LMKMVIFU1E9\A$P[S#6]>&*=PX;=R'E
M_.%</Y:!>C10F@NE>5":#Z4%4!I%T53E2H_&O'S1L0S4I8'27"C-@])\*"V
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M)@@%&G #8U4?@H50S4+(SD)O2[,F 7G0QT::/00 H1J T"O',L.E6?/(IOU
M:X^EK]::>I#]O&;?%!MUG-KJY^_VJ:V]U[['YS758#O57"R4GIRW)%>[HWW3
MS%#>=F77J(/A,,D5#\0QI>I#4!&NJ0C;J>@]R16;'(3#P'Q[<I"W08W7078.
M>E-NQ2;]N"Z&[=QJ[ZJOE!I^L!U^ALNMV#SX,:;M$*R#:];!KYP-[9=;2V_-
M(ZH0.^8$#HHRX\8K[/SW U^)N&.9U-MGH=T[IX'N36Q?R6]O%%\5;[5G7"F>
M%I=+JN=4Y WT]PO.U?--_J*\^F'$]']02P,$%     @ 5(DC65J/*6^Q!
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M!30$KE]0WR\8DX\W.D%U;#K]#U!+ P04    " !4B2-95]EKJX$#  "Q&
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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MW(Z?T43.R243U('L(Y#]O4&."^I>[@$".?A R#'5!;GD\GG7/3E$((=^(:]
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M4_.*\[%MNQ.WDN;MRY'VQ<[9'U!+ P04    " !4B2-90+O#+8<!  "\%P
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MX_.WY7T3<1[=<'9P6;_Z!5!+ P04    " !4B2-9_WEJDI\!   =&   $P
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M4$L! A0#%     @ 5(DC6;YSOH[4 @  =@@  !@              ("!9Q,
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( %2)(UE7R=S2
M@08  $T?   8              " @7$6  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " !4B2-94C [;70%  #8'@  &
M@($H'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ 5(DC
M63BRAD>%!P  42   !@              ("!TB(  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( %2)(UF#^S@N, 0  !()   8
M      " @8TJ  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" !4B2-9]E'<6-,)  !S'0  &               @('S+@  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 5(DC6>4R6@T>!P  /A,  !@
M             ("!_#@  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( %2)(UGHPQ9RQ04   H-   9              " @5!   !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 5(DC69Z1_V!J"@
M,AP  !D              ("!3$8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " !4B2-9J8#1+:0"   %!@  &0              @('M
M4   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( %2)(UFY
M,!3N@ D  (@8   9              " @<A3  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ 5(DC6=J.FNEE @  5@4  !D
M     ("!?UT  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %2)(UGW3ED=[@,  ,\(   9              "
M@0^   !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ 5(DC
M69#T9.0+!   8PD  !D              ("!-(0  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " !4B2-96AIUJ+,"  #!!0  &0
M        @(%VB   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( %2)(UD%W;>[7P8   <2   9              " @6"+  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 5(DC642Y;A4H!   #!8
M !D              ("!]I$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " !4B2-9#;GW,TP$  ":&   &0              @(%5E@
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( %2)(UGO]@ %
M:0,  +$/   9              " @=B:  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ 5(DC65?Z;\2*!P  D#X  !D
M ("!>)X  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " !4
MB2-9F33JGG0&  "</   &0              @($YI@  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( %2)(UFY6(;^,0(  ,0$   9
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M970S,BYX;6Q02P$"% ,4    " !4B2-947J["S(#   ,"@  &0
M    @(&:P0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M %2)(UF5WY;1/P<  *4T   9              " @0/%  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ 5(DC66Y6&!5*#@  ^)@  !D
M             ("!><P  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " !4B2-9C#?+K$8&  "7-   &0              @('ZV@  >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( %2)(UGS<.8D30,
M "4+   9              " @7?A  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ 5(DC61[8U="0!0  )"$  !D              ("!
M^^0  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " !4B2-9
M6H\I;[$$  !"'0  &0              @('"Z@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( %2)(UE7V6NK@0,  +$8   -
M      "  :KO  !X;"]S='EL97,N>&UL4$L! A0#%     @ 5(DC69>*NQS
M    $P(   L              ( !5O,  %]R96QS+RYR96QS4$L! A0#%
M  @ 5(DC6=>>\!J! P  7!H   \              ( !/_0  'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( %2)(UE N\,MAP$  +P7   :
M  "  >WW  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M %2)(UG_>6J2GP$  !T8   3              "  :SY  !;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@     O "\ P P  'S[      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>159</ContextCount>
  <ElementCount>201</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>52</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss</Role>
      <ShortName>Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Cash Flow Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements</Role>
      <ShortName>Consolidated Cash Flow Statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - General Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/GeneralInformation</Role>
      <ShortName>General Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Summary of Material Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies</Role>
      <ShortName>Summary of Material Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Significant Accounting Judgements and Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/SignificantAccountingJudgementsAndEstimates</Role>
      <ShortName>Significant Accounting Judgements and Estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Significant Events in the Reporting Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/SignificantEventsInTheReportingPeriod</Role>
      <ShortName>Significant Events in the Reporting Period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Share-based Payment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPayment</Role>
      <ShortName>Share-based Payment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Treasury Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/TreasuryShares</Role>
      <ShortName>Treasury Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilities</Role>
      <ShortName>Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Summary of Material Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Material Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20240630/taxonomy/role/Revenue</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Share-based Payment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentTables</Role>
      <ShortName>Share-based Payment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPayment</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Treasury Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesTables</Role>
      <ShortName>Treasury Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20240630/taxonomy/role/TreasuryShares</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Material Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Material Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Significant Accounting Judgements and Estimates - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail</Role>
      <ShortName>Significant Accounting Judgements and Estimates - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Significant Events in the Reporting Period - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail</Role>
      <ShortName>Significant Events in the Reporting Period - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail</Role>
      <ShortName>Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail</Role>
      <ShortName>Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Segment Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Segment Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Share-Based Payment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails</Role>
      <ShortName>Share-Based Payment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Share-based Payment - Schedule of Warrant Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail</Role>
      <ShortName>Share-based Payment - Schedule of Warrant Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Share-Based Payment - Summary Of Share Based Payment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail</Role>
      <ShortName>Share-Based Payment - Summary Of Share Based Payment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Share Capital - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/ShareCapitalAdditionalInformationDetail</Role>
      <ShortName>Share Capital - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Treasury Shares - Summary of Holding of Treasury Shares (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail</Role>
      <ShortName>Treasury Shares - Summary of Holding of Treasury Shares (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails</Role>
      <ShortName>Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Financial Assets and Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Financial Assets and Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails</Role>
      <ShortName>Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails</Role>
      <ShortName>Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Financial Assets and Liabilities - Liquidity Risk Management (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail</Role>
      <ShortName>Financial Assets and Liabilities - Liquidity Risk Management (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="asnd-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="asnd-20240630.htm">asnd-20240630.htm</File>
    <File>asnd-20240630.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img148560552_0.jpg</File>
    <File>img148560552_1.jpg</File>
    <File>img148560552_2.jpg</File>
    <File>img148560552_3.jpg</File>
    <File>img148560552_4.jpg</File>
    <File>img148560552_5.jpg</File>
    <File>img148560552_6.jpg</File>
    <File>img148560552_7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="471">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>57
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "asnd-20240630.htm": {
   "nsprefix": "asnd",
   "nsuri": "http://ascendispharma.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "asnd-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "asnd-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 142,
   "keyCustom": 59,
   "axisStandard": 22,
   "axisCustom": 4,
   "memberStandard": 26,
   "memberCustom": 25,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 159,
   "entityCount": 1,
   "segmentCount": 52,
   "elementCount": 443,
   "unitCount": 13,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 471,
    "http://xbrl.sec.gov/dei/2023": 8
   },
   "report": {
    "R1": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss",
     "longName": "100010 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)",
     "shortName": "Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical",
     "longName": "100020 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:NumberOfWarrantsOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:NumberOfWarrantsOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
     "longName": "100030 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
     "longName": "100040 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_875630a8-6b06-4d56-b547-543891791c57",
      "name": "ifrs-full:Equity",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_e6cdfa0f-6832-4fea-9068-94b3c87d8f1f",
      "name": "ifrs-full:Equity",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements",
     "longName": "100050 - Statement - Consolidated Cash Flow Statements",
     "shortName": "Consolidated Cash Flow Statements",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/GeneralInformation",
     "longName": "100060 - Disclosure - General Information",
     "shortName": "General Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies",
     "longName": "100070 - Disclosure - Summary of Material Accounting Policies",
     "shortName": "Summary of Material Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/SignificantAccountingJudgementsAndEstimates",
     "longName": "100080 - Disclosure - Significant Accounting Judgements and Estimates",
     "shortName": "Significant Accounting Judgements and Estimates",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/SignificantEventsInTheReportingPeriod",
     "longName": "100090 - Disclosure - Significant Events in the Reporting Period",
     "shortName": "Significant Events in the Reporting Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:SignificantEventsInTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:SignificantEventsInTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/Revenue",
     "longName": "100100 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/SegmentInformation",
     "longName": "100110 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPayment",
     "longName": "100120 - Disclosure - Share-based Payment",
     "shortName": "Share-based Payment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/ShareCapital",
     "longName": "100130 - Disclosure - Share Capital",
     "shortName": "Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/TreasuryShares",
     "longName": "100140 - Disclosure - Treasury Shares",
     "shortName": "Treasury Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilities",
     "longName": "100150 - Disclosure - Financial Assets and Liabilities",
     "shortName": "Financial Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/SubsequentEvents",
     "longName": "100160 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies",
     "longName": "100170 - Disclosure - Summary of Material Accounting Policies (Policies)",
     "shortName": "Summary of Material Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/RevenueTables",
     "longName": "100180 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentTables",
     "longName": "100190 - Disclosure - Share-based Payment (Tables)",
     "shortName": "Share-based Payment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesTables",
     "longName": "100200 - Disclosure - Treasury Shares (Tables)",
     "shortName": "Treasury Shares (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "ifrs-full:DisclosureOfTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables",
     "longName": "100210 - Disclosure - Financial Assets and Liabilities (Tables)",
     "shortName": "Financial Assets and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
     "longName": "100220 - Disclosure - Summary of Material Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Material Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "asnd:ConvertibleSeniorNotes",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6bc3126-0f2f-41e1-af3d-24f995e53242",
      "name": "ifrs-full:NoncurrentDerivativeFinancialLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations",
       "div",
       "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R24": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail",
     "longName": "100230 - Disclosure - Significant Accounting Judgements and Estimates - Additional Information (Detail)",
     "shortName": "Significant Accounting Judgements and Estimates - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "ifrs-full:CurrentProvisions",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_226b71fb-e2f1-440b-9ce0-1b02d378af1b",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
     "longName": "100240 - Disclosure - Significant Events in the Reporting Period - Additional Information (Detail)",
     "shortName": "Significant Events in the Reporting Period - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "ifrs-full:Equity",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1eee9ac4-42e3-4c2a-b3db-f3d552da0c91",
      "name": "ifrs-full:ProportionOfOwnershipInterestInAssociate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
     "longName": "100250 - Disclosure - Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)",
     "shortName": "Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail",
     "longName": "100260 - Disclosure - Revenue - Additional Information (Detail)",
     "shortName": "Revenue - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_1eee9ac4-42e3-4c2a-b3db-f3d552da0c91",
      "name": "asnd:CapitalCommitmentFromInvestors",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a078a24b-80df-47b2-af27-cd002780edca",
      "name": "asnd:UpfrontPaymentReceived",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail",
     "longName": "100270 - Disclosure - Segment Information - Additional Information (Detail)",
     "shortName": "Segment Information - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:NumberOfReportableOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_5a88bcad-ece2-4420-8531-9e5bb79e8880",
      "name": "asnd:NumberOfReportableOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
     "longName": "100280 - Disclosure - Share-Based Payment - Additional Information (Details)",
     "shortName": "Share-Based Payment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "U_DkkPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_32e6f681-0344-457f-8a03-21f7d9f10b40",
      "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019",
      "unitRef": "U_EurPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
     "longName": "100290 - Disclosure - Share-based Payment - Schedule of Warrant Activity (Detail)",
     "shortName": "Share-based Payment - Schedule of Warrant Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_0f31b8c9-3f3e-45ff-b2dc-b529c435f24b",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_0f31b8c9-3f3e-45ff-b2dc-b529c435f24b",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail",
     "longName": "100300 - Disclosure - Share-Based Payment - Summary Of Share Based Payment (Detail)",
     "shortName": "Share-Based Payment - Summary Of Share Based Payment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_ed967469-6caa-47a7-ad87-51a13e77b2b5",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ed967469-6caa-47a7-ad87-51a13e77b2b5",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/ShareCapitalAdditionalInformationDetail",
     "longName": "100310 - Disclosure - Share Capital - Additional Information (Detail)",
     "shortName": "Share Capital - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail",
     "longName": "100320 - Disclosure - Treasury Shares - Summary of Holding of Treasury Shares (Detail)",
     "shortName": "Treasury Shares - Summary of Holding of Treasury Shares (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_f6bc3126-0f2f-41e1-af3d-24f995e53242",
      "name": "asnd:TreasurySharesOfNominalValue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTreasurySharesExplanatory",
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f6bc3126-0f2f-41e1-af3d-24f995e53242",
      "name": "asnd:TreasurySharesOfNominalValue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTreasurySharesExplanatory",
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails",
     "longName": "100330 - Disclosure - Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Details)",
     "shortName": "Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "asnd:MarketableSecurities1",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
     "longName": "100340 - Disclosure - Financial Assets and Liabilities - Additional Information (Detail)",
     "shortName": "Financial Assets and Liabilities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "asnd:FairValueOfConvertibleNotes",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails",
     "longName": "100350 - Disclosure - Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details)",
     "shortName": "Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "asnd:ConvertibleSeniorNotes",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_756073fe-efcc-4ad7-914c-18bd04b9013e",
      "name": "ifrs-full:FinancialAssetsAtAmortisedCost",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails",
     "longName": "100360 - Disclosure - Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Details)",
     "shortName": "Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_f6bc3126-0f2f-41e1-af3d-24f995e53242",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cff9af56-3621-49bb-95fa-62e774a90dc9",
      "name": "asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
     "longName": "100370 - Disclosure - Financial Assets and Liabilities - Liquidity Risk Management (Detail)",
     "shortName": "Financial Assets and Liabilities - Liquidity Risk Management (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "asnd:ConvertibleSeniorNotes",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cf8bec94-85c6-4446-9f8d-25c797b23040",
      "name": "ifrs-full:Borrowings",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
     "longName": "100380 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_b41da24d-bd30-42f4-a704-1d5714f18704",
      "name": "asnd:FundingReceivedInExchangeOfRoyaltyPayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d66908c6-a5fa-467c-9047-36af0a5ab839",
      "name": "asnd:FundingReceivedInExchangeOfRoyaltyPayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20240630.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForAmortisationExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Adjustments for amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments",
        "label": "Adjustments for decrease (increase) in prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Adjustments for decrease (increase) in trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities (deferred income)",
        "totalLabel": "Total adjustments for increase (decrease) in deferred income including contract liabilities",
        "label": "Adjustments for increase (decrease) in deferred income including contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeOtherThanContractLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities (deferred income)",
        "label": "Adjustments for increase (decrease) in deferred income other than contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in deferred income other than contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income other than contract liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables, accrued expenses and other payables",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "asnd_AdjustmentsForNonCashConsiderationRegardingRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "AdjustmentsForNonCashConsiderationRegardingRevenue",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments For Non Cash Consideration Regarding Revenue",
        "documentation": "Adjustments for non cash consideration regarding revenue.",
        "negatedLabel": "Non-cash consideration relating to revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for provisions",
        "terseLabel": "Increase/(decrease) in provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for non-cash items:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share Based Compensation Expense",
        "terseLabel": "Share-based payment",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedMeasurementMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregated measurement [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r93"
     ]
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r103",
      "r106",
      "r107",
      "r108",
      "r109",
      "r111",
      "r116",
      "r126",
      "r175",
      "r199",
      "r201"
     ]
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r94"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmericanDepositorySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "AmericanDepositorySharesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "American depository shares [member]",
        "documentation": "American depository shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount",
        "label": "Amount Multiplied to Purchase Price Minus Revenue Interest Payments Paid to Purchaser on Effective Date of Buy-out Notice As Buyout Amount",
        "documentation": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount",
        "documentation": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Not Included In Diluted Earnings Per Share [Axis]",
        "documentation": "Antidilutive securities not included in diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Not Included In Diluted Earnings Per Share [Member]",
        "documentation": "Antidilutive securities not Included In diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "srt_AsiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "AsiaMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "periodStartLabel": "Assets at beginning of period",
        "periodEndLabel": "Assets at end of period",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r93",
      "r94",
      "r96",
      "r152",
      "r155"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value [member]",
        "label": "At fair value [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r93"
     ]
    },
    "ifrs-full_BalancesWithBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BalancesWithBanks",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balances with banks",
        "terseLabel": "Bank deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash balances held at banks."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "asnd_BasicAndDilutedEarningsLossPerShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "BasicAndDilutedEarningsLossPerShares",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted earnings / (loss) per share",
        "label": "Basic And Diluted Earnings Loss Per Shares",
        "documentation": "Basic And Diluted Earnings Loss Per Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "totalLabel": "Total basic earnings (loss) per share",
        "terseLabel": "Basic earnings/(loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings",
        "totalLabel": "Total borrowings",
        "terseLabel": "Borrowings (excluding lease liabilities)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_BorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Borrowings [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsConditionForRedemption": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "BorrowingsConditionForRedemption",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings condition for redemption",
        "label": "Borrowings Condition For Redemption",
        "documentation": "Borrowings condition for redemption."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsInArrearsDefaultPaymentStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "BorrowingsInArrearsDefaultPaymentStartDate",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings in arrears default payment start date",
        "label": "Borrowings In Arrears Default Payment Start Date",
        "documentation": "Borrowings in arrears default payment start date."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings Interest Rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "ifrs-full_BorrowingsMaturity": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BorrowingsMaturity",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, maturity"
       }
      },
      "en": {
       "role": {
        "documentation": "The maturity of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "asnd_BorrowingsRedemptionPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "BorrowingsRedemptionPeriod",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings redemption period",
        "label": "Borrowings Redemption Period",
        "documentation": "Borrowings redemption period."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "BorrowingsThresholdConsecutiveTradingDaysForRedemption",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings threshold consecutive trading days for redemption",
        "label": "Borrowings Threshold Consecutive Trading Days For Redemption",
        "documentation": "Borrowings threshold consecutive trading days for redemption."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "BorrowingsThresholdPercentageOfSalePricePerShareForRedemption",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings threshold percentage of sale price per share for redemption",
        "label": "Borrowings Threshold Percentage Of Sale Price Per Share For Redemption",
        "documentation": "Borrowings threshold percentage of sale price per share for redemption."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdTradingDaysForRedemption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "BorrowingsThresholdTradingDaysForRedemption",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings threshold trading days for redemption",
        "label": "Borrowings Threshold Trading Days For Redemption",
        "documentation": "Borrowings Threshold Trading Days For Redemption."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r111",
      "r120",
      "r187",
      "r189",
      "r226"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CN",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China [member]",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CapitalCommitmentFromInvestors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "CapitalCommitmentFromInvestors",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital commitment from investors.",
        "label": "Capital commitment from investors",
        "terseLabel": "Commitment from investors",
        "verboseLabel": "Commitment from investors"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CarryingAmountOfRoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "CarryingAmountOfRoyaltyFundingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount of royalty funding liabilities",
        "label": "Carrying Amount of Royalty Funding Liabilities",
        "documentation": "Carrying amount of royalty funding liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and cash equivalents at June 30",
        "verboseLabel": "Cash and cash equivalents",
        "totalLabel": "Total cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at January 1"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r70",
      "r89"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) financing activities",
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Cash flows from/(used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r71"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) investing activities",
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Cash flows from/(used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r71"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) operating activities",
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Cash flows from/(used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r71"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperations",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) operations",
        "label": "Cash flows from (used in) operations",
        "totalLabel": "Cash flows generated from/(used in) operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r183"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets by category",
        "label": "Categories of financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [abstract]",
        "terseLabel": "Financial liabilities by category"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [axis]",
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfNoncurrentFinancialAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of non-current financial assets [abstract]",
        "terseLabel": "Classified in the statement of financial position"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfNoncurrentFinancialLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of non-current financial liabilities [abstract]",
        "terseLabel": "Classified in the statement of financial position"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "asnd_ChangesInWorkingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ChangesInWorkingCapitalAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in working capital:",
        "label": "Changes in working capital [abstract]",
        "documentation": "Changes in working capital."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of assets [axis]",
        "label": "Classes of assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r97",
      "r105"
     ]
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfAssetsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets [member]",
        "label": "Assets [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r97",
      "r105"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r139",
      "r140",
      "r162",
      "r163"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r134",
      "r135",
      "r136"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r132",
      "r134",
      "r135",
      "r136"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r162",
      "r163"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [axis]",
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital [member]",
        "label": "Share capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "asnd_CollaborationPartnerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "CollaborationPartnerOneMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaboration partner one [Member]",
        "documentation": "Collaboration Partner One."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CollaborationPartnersAndLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "CollaborationPartnersAndLicenseAgreementsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration partners and license agreements [Member]",
        "label": "Collaboration partners and license agreements [Member]",
        "documentation": "Collaboration Partners and License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CommercialCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "CommercialCustomersMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial customers [Member]",
        "documentation": "Commercial Customers.",
        "terseLabel": "Commercial customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items that may be reclassified subsequently to profit or (loss):",
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive income/(loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r29",
      "r79",
      "r81",
      "r87",
      "r184"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Attributable to owners of the Company",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r31"
     ]
    },
    "asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ContractualUndiscountedCashflowOfConvertibleSeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes",
        "label": "Contractual Undiscounted Cashflow Of Convertible Senior Notes",
        "documentation": "Convertible senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfFinancialBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ContractualUndiscountedCashflowOfFinancialBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Contractual Undiscounted Cashflow Of Financial Borrowings",
        "documentation": "Contractual undiscounted cashflow of financial borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ContractualUndiscountedCashflowOfFinancialLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Contractual Undiscounted Cashflow Of Financial Lease Liabilities",
        "documentation": "Contractual undiscounted cashflow of Financial lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ContractualUndiscountedCashflowOfFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities",
        "label": "Contractual Undiscounted Cashflow Of Financial Liabilities",
        "documentation": "Contractual undiscounted cashflow of financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty funding liabilities",
        "label": "Contractual Undiscounted Cashflow of Royalty Funding Liabilities",
        "documentation": "Contractual undiscounted cashflow of royalty funding liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Contractual Undiscounted Cashflow Of Trade Payables And Other Payables",
        "documentation": "Contractual undiscounted cashflow of trade payables and other payables."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConversionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ConversionPricePerShare",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share",
        "label": "Conversion Price Per Share",
        "documentation": "Conversion price per share."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConversionRatePerNote": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ConversionRatePerNote",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion rate per note",
        "label": "Conversion Rate Per Note",
        "documentation": "Conversion rate per note."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleDebtCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ConvertibleDebtCurrentAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt current abstract.",
        "label": "Convertible Debt Current [Abstract]",
        "terseLabel": "Convertible notes, matures in April 2028"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleNotesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ConvertibleNotesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes current.",
        "label": "Convertible Notes Current",
        "terseLabel": "Convertible notes current",
        "totalLabel": "Convertible notes current"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ConvertibleSeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Senior Notes",
        "terseLabel": "Convertible senior notes",
        "label": "Convertible Senior Notes",
        "documentation": "Convertible senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ConvertibleSeniorNotesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Senior Notes [Member]",
        "documentation": "Convertible senior notes [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of sales",
        "terseLabel": "Cost of sales",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r37"
     ]
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ifrs-full_CounterpartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r83",
      "r184"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current contract liabilities",
        "terseLabel": "Contract liabilities",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current derivative financial liabilities",
        "terseLabel": "Derivative liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_CurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities",
        "totalLabel": "Total current financial assets",
        "label": "Current financial assets",
        "terseLabel": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_CurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current financial liabilities",
        "label": "Current financial liabilities",
        "terseLabel": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "negatedLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r85",
      "r184"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepayments",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current prepayments",
        "terseLabel": "Prepayments",
        "label": "Current prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_CurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentProvisions",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current provisions",
        "terseLabel": "Provisions",
        "label": "Current provisions",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivables",
        "label": "Current tax assets, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax liabilities",
        "terseLabel": "Income tax payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r170"
     ]
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r17",
      "r43"
     ]
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Derivative liabilities",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Liabilities at Fair Value Remeasurement Recognized in Financial Income Or Expense",
        "documentation": "Derivative financial liabilities at fair value remeasurement recognized in financial income or expense.",
        "terseLabel": "Remeasurement recognized in finance (income) or expense"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueSettled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueSettled",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled",
        "label": "Derivative Financial Liabilities at Fair Value Settled",
        "documentation": "Derivative financial liabilities at fair value settled."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueTransfered",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfered",
        "label": "Derivative Financial Liabilities at Fair Value Transfered",
        "documentation": "Derivative financial liabilities at fair value transfered."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DerivativesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r185",
      "r188",
      "r197",
      "r203"
     ]
    },
    "asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Senior Notes and Derivative Liabilities",
        "label": "Description Of Accounting Policy For Convertible Notes And Derivative Liabilities [Policy Text Block]",
        "documentation": "Description of accounting policy for convertible notes and derivative liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of initial application of standards or interpretations [text block]",
        "verboseLabel": "New and Amended Standards and Interpretations",
        "terseLabel": "New and Amended Standards and Interpretations"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of vesting requirements for share-based payment arrangement",
        "terseLabel": "Description of vesting"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "asnd_DetailsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DetailsAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details [Axis]",
        "documentation": "Details."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DetailsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DetailsDomain",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details [Domain]",
        "documentation": "Details"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DevelopmentAndAdministrativeServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DevelopmentAndAdministrativeServices",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and administrative services.",
        "label": "Development and administrative services"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "totalLabel": "Total diluted earnings (loss) per share",
        "terseLabel": "Diluted earnings/(loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57"
     ]
    },
    "asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Marketable securities",
        "label": "Disclosure Detailed Information About Marketable Securities [Text Block]",
        "documentation": "Disclosure detailed information about marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/SignificantAccountingJudgementsAndEstimates"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Accounting Judgements and Estimates",
        "label": "Disclosure of accounting judgements and estimates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Preparation",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the changes in accounting estimates."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfEmployeeCompensationCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfEmployeeCompensationCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of employee compensation costs [abstract]",
        "documentation": "Disclosure of employees compensation costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets and liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfAssetsTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of assets."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Financial Assets And Liabilities [text block]",
        "documentation": "Disclosure Of Financial Assets And Liabilities [text block]",
        "terseLabel": "Schedule of Financial Assets and Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets and Liabilities",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r134",
      "r141"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/GeneralInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Information",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "asnd_DisclosureOfGeneralInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfGeneralInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of general information.",
        "label": "Disclosure of General Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from external customers (geographical)",
        "label": "Disclosure of geographical areas [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfHoldingOfTreasurySharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Holding Of Treasury Shares [Abstract]",
        "documentation": "Disclosure of holding of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfHoldingOfTreasurySharesLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Holding Of Treasury Shares [Line Items]",
        "documentation": "Disclosure of holding of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfHoldingOfTreasurySharesTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Holding Of Treasury Shares [Table]",
        "documentation": "Disclosure of holding of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfInformationAboutTreasurySharesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfInformationAboutTreasurySharesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/TreasuryShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Shares",
        "label": "Disclosure Of Information About Treasury Shares Explanatory",
        "documentation": "Disclosure of information about treasury shares explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movements in Level 3 Fair Value Measurements",
        "label": "Disclosure of Movements in Level Three Fair Value Measurements [Table Text Block]",
        "documentation": "Disclosure of movements in level 3 fair value measurements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Warrant Activity",
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue from external customers",
        "terseLabel": "Disclosure of operating segments [line items]",
        "label": "Disclosure of operating segments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [table]",
        "label": "Disclosure of operating segments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfReclassificationsOrChangesInPresentationExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change to Presentation of Borrowings",
        "label": "Disclosure of reclassifications or changes in presentation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of reclassifications or changes in the presentation of items in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Disclosure of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfRoyaltyFundingLiabilitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Funding Liabilities",
        "label": "Disclosure Of Royalty Funding Liabilities Explanatory",
        "documentation": "Disclosure of royalty funding liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of segment revenues by destination of major customers explanatory.",
        "label": "Disclosure of segment revenues by destination of major customers explanatory",
        "terseLabel": "Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPayment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of associates [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to associates."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r55",
      "r92"
     ]
    },
    "asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfSummaryOfFairValueHierarchyTableTextBlock",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value Hierarchy",
        "label": "Disclosure of Summary of Fair Value Hierarchy [Table Text Block]",
        "documentation": "Disclosure of summary of fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of summary of significant accounting policies [abstract]",
        "documentation": "Disclosure of summary of significant accounting policies [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of summary of significant accounting policies [line items]",
        "label": "Disclosure Of Summary Of Significant Accounting Policies [line items]",
        "documentation": "Line items representing the disclosure of summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of summary of significant accounting policies [table]",
        "label": "Disclosure of summary of significant accounting policies [table]",
        "documentation": "Disclosure of summary of significant accounting policies [table]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Disclosure Of Summary Of Significant Accounting Policy Explanatory",
        "documentation": "Disclosure of summary of significant accounting policy.",
        "verboseLabel": "Summary of Material Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "asnd_DisclosureOfTreasurySharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfTreasurySharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of treasury shares.",
        "label": "Disclosure of treasury shares [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTreasurySharesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTreasurySharesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Holding of Treasury Shares",
        "label": "Disclosure of treasury shares [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of voluntary change in accounting policy [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfWarrantActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DisclosureOfWarrantActivityLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Warrant Activity [line items]",
        "label": "Disclosure Of Warrant Activity [line items]",
        "documentation": "Disclosure Of Warrant Activity [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DistributableEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "DistributableEquity",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributable equity",
        "label": "Distributable equity",
        "documentation": "Distributable equity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on balances held in foreign currencies",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Balance of equity",
        "terseLabel": "Balance of equity",
        "totalLabel": "Total equity",
        "periodStartLabel": "Equity",
        "periodEndLabel": "Equity",
        "label": "Equity",
        "verboseLabel": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r23",
      "r78",
      "r80",
      "r93",
      "r94",
      "r96"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity and liabilities",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity and liabilities",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [member]",
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EuropeMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EventsAfterReportingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "EventsAfterReportingPeriodMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After Reporting Period [Member]",
        "documentation": "Events after reporting period.",
        "terseLabel": "Events After Reporting Period [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ExchangeRateForPercentageOfRevenueToRoyaltyPayment",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue interest payment in percentage in exchange for funding",
        "terseLabel": "Revenue interest payment in percentage in exchange for funding",
        "documentation": "Exchange rate for percentage of revenue to royalty payment."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation costs",
        "label": "Expense from share-based payment transactions with employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "asnd_FairValueHierarchyCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "FairValueHierarchyCarryingAmountMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [member]",
        "label": "Fair Value Hierarchy Carrying Amount [member]",
        "documentation": "Fair value hierarchy carrying amount."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FairValueOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "FairValueOfConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Convertible Notes",
        "label": "Fair Value of Convertible Notes",
        "documentation": "Fair value of convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FairValueOfRoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "FairValueOfRoyaltyFundingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of royalty funding liabilities",
        "label": "Fair Value of Royalty Funding Liabilities",
        "documentation": "Fair value of royalty funding liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance costs",
        "verboseLabel": "Finance expenses",
        "terseLabel": "Reversal of finance expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCostsPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance expenses paid",
        "label": "Finance costs paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reversal of finance income",
        "terseLabel": "Finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncomeReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income received",
        "label": "Finance income received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]"
       }
      }
     },
     "auth_ref": [
      "r220"
     ]
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "terseLabel": "Financial assets",
        "periodStartLabel": "Financial assets at beginning of period",
        "periodEndLabel": "Financial assets at end of period",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r128",
      "r132",
      "r133",
      "r135",
      "r196"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCost",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial assets measured at amortized cost",
        "label": "Financial assets at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCostMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at amortised cost class. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_FinancialAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r117",
      "r139",
      "r140",
      "r162",
      "r163"
     ]
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCost",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial liabilities at amortised cost, Total",
        "terseLabel": "Financial liabilities measured at amortized cost",
        "label": "Financial liabilities at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at amortised cost, class [member]",
        "label": "Financial liabilities at amortised cost, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value, class [member]",
        "terseLabel": "Financial liabilities at fair value, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at fair value class. [Refer: Financial liabilities; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities at fair value through profit or loss",
        "terseLabel": "Financial liabilities measured at fair value through profit or loss",
        "label": "Financial liabilities at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as \u2018an accounting mismatch\u2019) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity\u2019s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss, category [member]",
        "terseLabel": "Financial liabilities measured at fair value through profit or loss [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesCategoryMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities, category [member]",
        "label": "Financial liabilities, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_FinancialLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r162",
      "r163"
     ]
    },
    "ifrs-full_FinancialLiabilitiesTypeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesTypeMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities, type [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated types of financial liabilities. It also represents the standard value for the 'Types of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148"
     ]
    },
    "ifrs-full_FixedInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FixedInterestRateMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed interest rate [Member]",
        "label": "Fixed interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "asnd_ForeignCurrencyConversionOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ForeignCurrencyConversionOptionMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Conversion Option [Member]",
        "documentation": "Foreign Currency Conversion Option."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ForeignCurrencyRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ForeignCurrencyRiskAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Risk [axis]",
        "label": "Foreign Currency Risk [axis]",
        "documentation": "Foreign currency risk."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ForeignCurrencyRiskDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ForeignCurrencyRiskDomain",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Risk [domain]",
        "label": "Foreign Currency Risk [domain]",
        "documentation": "Foreign currency risk domain."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FrazierLifeSciencesOfEyconisIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "FrazierLifeSciencesOfEyconisIncMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frazier Life Sciences of Eyconis, Inc.",
        "label": "Frazier Life Sciences of Eyconis, Inc. [Member]",
        "terseLabel": "Frazier Life Sciences of Eyconis, Inc. [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FundingReceivedInExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "FundingReceivedInExchange",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funding received",
        "verboseLabel": "Funding received in exchange of royalty payments",
        "documentation": "Funding received in exchange.",
        "terseLabel": "Funding received in exchange"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FundingReceivedInExchangeOfRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "FundingReceivedInExchangeOfRoyaltyPayments",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding received in exchange of royalty payments",
        "label": "Funding received in exchange of royalty payments",
        "documentation": "Funding received in exchange of royalty payments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net gains (losses) on change in fair value of derivatives",
        "terseLabel": "Gains (losses) on change in fair value of derivatives",
        "label": "Gains (losses) on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnDisposalsOfPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net gains (losses) on disposals of property, plant and equipment",
        "label": "Gains (losses) on disposals of property, plant and equipment",
        "negatedLabel": "Reversal of (gain)/loss on disposal of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [axis]",
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r174",
      "r190",
      "r194"
     ]
    },
    "ifrs-full_GeographicalAreasMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeographicalAreasMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [member]",
        "label": "Geographical areas [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r174",
      "r190",
      "r194"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodsOrServicesTransferredAtPointInTimeMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods or services transferred at point in time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GoodsOrServicesTransferredOverTimeMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods or services transferred over time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers over time. [Refer: Performance obligations satisfied over time [member]]"
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Gross profit",
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "ifrs-full_HedgingInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgingInstrumentsAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hedging instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r127"
     ]
    },
    "ifrs-full_HedgingInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HedgingInstrumentsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hedging instruments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r127"
     ]
    },
    "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HistoricalVolatilityForSharesMeasurementInputMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Historical volatility for shares, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the historical volatility for shares used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncomeStatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "IncomeStatementAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income statement [Axis].",
        "label": "Income Statement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncomeStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "IncomeStatementMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income statement.",
        "label": "Income Statement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reversal of income taxes (expenses)",
        "negatedTerseLabel": "Tax income (expense)",
        "totalLabel": "Total tax expense (income)",
        "label": "Tax expense (income)",
        "negatedLabel": "Income taxes/(expenses)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r34",
      "r40",
      "r41",
      "r42",
      "r50",
      "r91",
      "r151"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income taxes refund (paid)",
        "label": "Income taxes paid (refund), classified as operating activities",
        "negatedLabel": "Income taxes received/(paid)"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r69",
      "r178"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Increase/(decrease) in cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additions",
        "terseLabel": "Increase decrease in derivative financial liabilities fair value",
        "label": "Increase Decrease In Derivative Financial Liabilities Fair Value",
        "documentation": "Increase decrease in derivative financial liabilities fair value."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in treasury shares transferred under stock incentive program.",
        "label": "Increase Decrease In Treasury Shares Transferred Under Stock Incentive Program",
        "terseLabel": "Transferred under stock incentive programs (Holding)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based payment (Note 7)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransactionsWithOwners",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transactions with owners, equity",
        "terseLabel": "Capital increase"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transactions with owners."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total intangible assets and goodwill",
        "periodEndLabel": "Intangible assets and goodwill at end of period",
        "periodStartLabel": "Intangible assets and goodwill at beginning of period",
        "label": "Intangible assets and goodwill",
        "terseLabel": "Intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_InterestRateTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRateTypesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate types [member]",
        "label": "Interest rate types [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "asnd_InternalProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "InternalProfit",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internal profit",
        "label": "Internal Profit",
        "terseLabel": "Internal profit"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current inventories",
        "terseLabel": "Inventories",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r47",
      "r168"
     ]
    },
    "ifrs-full_InvestmentsInAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InvestmentsInAssociates",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in associates reported in separate financial statements",
        "terseLabel": "Investment in associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in associates in an entity's separate financial statements. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "asnd_InvoicingOfVariousDevelopmentAndAdministrativeServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "InvoicingOfVariousDevelopmentAndAdministrativeServices",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Invoicing of various development and administrative services.",
        "label": "Invoicing of various development and administrative services"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IssuedAndOutstandingSharesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "IssuedAndOutstandingSharesAmount",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issued and outstanding shares amount.",
        "label": "Issued and outstanding shares amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total issued capital",
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share Capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 1 to 5 years [member]",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r202"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After 5 years [member]",
        "label": "Later than three years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r202"
     ]
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liabilities",
        "totalLabel": "Total lease liabilities",
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [member]",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r94"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [member]",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r94"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Liabilities",
        "totalLabel": "Total liabilities",
        "periodStartLabel": "Liabilities at beginning of period",
        "periodEndLabel": "Liabilities at end of period",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r93",
      "r94",
      "r96",
      "r152",
      "r156"
     ]
    },
    "ifrs-full_LiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_LicenceFeeIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LicenceFeeIncome",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\"Right-to-use\" licenses",
        "label": "Licence fee income",
        "verboseLabel": "Licenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from licence fees."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_LiquidityRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiquidityRiskMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity risk [member]",
        "label": "Liquidity risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r195"
     ]
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current portion of non-current borrowings",
        "terseLabel": "Borrowings",
        "label": "Non-current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major customers [axis]",
        "label": "Major customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_MajorCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorCustomersMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customers [member]",
        "label": "Customers [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "asnd_MarketableSecurities1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "MarketableSecurities1",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable securities1",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MarketableSecuritiesExplanatory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "MarketableSecuritiesExplanatory",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities Explanatory",
        "documentation": "Marketable securities explanatory.",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "MaturityAnalysisForFinancialLiabilitiesTextBlock",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Maturity Analysis For Financial Liabilities",
        "label": "Maturity Analysis For Financial Liabilities [Text Block]",
        "documentation": "Maturity analysis for financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r103",
      "r106",
      "r107",
      "r108",
      "r109",
      "r111",
      "r116",
      "r126",
      "r138",
      "r175",
      "r199"
     ]
    },
    "asnd_MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum additional development and regulatory milestones potentially to be received.",
        "label": "Maximum additional development and regulatory milestones potentially to be received",
        "terseLabel": "Maximum additional development and regulatory milestones potentially to be received"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r93"
     ]
    },
    "asnd_MinimumNumberOfCollaborationPartnerAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "MinimumNumberOfCollaborationPartnerAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum number of collaboration partner [Axis]",
        "documentation": "Minimum Number of Collaboration Partner."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "MultipleOfPurchasePriceWereRoyaltyPaymentWillCease",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple of the purchase price were royalty payment will cease",
        "label": "Multiple Of Purchase Price, Were Royalty Payment Will Cease",
        "documentation": "Multiple of purchase price, were royalty payment will cease."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple of the purchase price were royalty payment will cease",
        "label": "Multiple of the Purchase Price, were Royalty Payment will cease",
        "documentation": "Multiple of the purchase price, were royalty payment will cease."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NewIFRSsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NewIFRSsAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New IFRSs [axis]",
        "label": "New IFRSs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_NewIFRSsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NewIFRSsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New IFRSs [member]",
        "label": "New IFRSs [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for IFRSs that have been issued but are not yet effective. It also represents the standard value for the 'New IFRSs' axis if no other member is used. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_NonadjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [member]",
        "label": "Non-adjusting events after reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r20",
      "r84",
      "r184"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current contract liabilities",
        "terseLabel": "Contract liabilities",
        "label": "Non-current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_NoncurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Liabilities",
        "terseLabel": "Derivative liabilities",
        "label": "Non-current derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current financial assets",
        "label": "Non-current financial assets",
        "terseLabel": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssetsAvailableforsale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentFinancialAssetsAvailableforsale",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current financial marketable securities",
        "terseLabel": "Marketable securities",
        "label": "Non-current financial assets available-for-sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets available-for-sale. [Refer: Financial assets available-for-sale; Non-current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "ifrs-full_NoncurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current financial liabilities",
        "label": "Non-current financial liabilities",
        "terseLabel": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r86",
      "r184"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "North America [member]",
        "label": "North America [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 1 year [member]",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r106",
      "r107",
      "r116",
      "r199",
      "r202"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "asnd_NumberOfCommercialCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "NumberOfCommercialCustomers",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of commercial customers.",
        "label": "Number of commercial customers",
        "terseLabel": "Number of commercial customers"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the period",
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "verboseLabel": "Granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r224"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised during the period",
        "terseLabel": "Vested at the reporting date",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited during the period",
        "label": "Number of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "negatedPeriodStartLabel": "Beginning balance",
        "negatedPeriodEndLabel": "Ending balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled during the period",
        "label": "Number Of Other Equity Instruments Settled In Share Based Payment Arrangement",
        "documentation": "Number of other equity instruments settled in share based payment arrangement.",
        "negatedLabel": "Settled during the period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred during the period",
        "label": "Number Of Other Equity Instruments Transferred In Share Based Payment Arrangement",
        "documentation": "Number of other equity instruments transferred in share based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested at the balance sheet date",
        "label": "Number of other equity instruments vested in share-based payment arrangement",
        "documentation": "Number of other equity instruments vested in share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfReportableOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "NumberOfReportableOperatingSegments",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "label": "Number of reportable operating segments",
        "documentation": "Number of reportable operating segments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total number of shares issued",
        "terseLabel": "Number of shares issued",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "asnd_NumberOfSharesIssuedAndOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "NumberOfSharesIssuedAndOutstanding",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued and outstanding.",
        "label": "Number of shares issued and outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfTreasurySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "NumberOfTreasurySharesOutstanding",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "June 30, 2024 (Holding)",
        "label": "Number Of Treasury Shares Outstanding",
        "documentation": "Number of treasury shares outstanding.",
        "periodStartLabel": "January 1, 2024 (Holding)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfWarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "NumberOfWarrantsOutstanding",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants outstanding.",
        "label": "Number of warrants outstanding",
        "terseLabel": "Warrants outstanding",
        "negatedLabel": "Warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r213"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "terseLabel": "Exchange differences on translating foreign operations",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r35"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "verboseLabel": "Other comprehensive income/(loss), net of tax",
        "totalLabel": "Other comprehensive income/(loss) for the period, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r173"
     ]
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current financial liabilities",
        "totalLabel": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r90"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "asnd_OtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "OtherCurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current liabilities abstract.",
        "label": "Other Current Liabilities [Abstract]",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_OtherFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial liabilities",
        "terseLabel": "Other liabilities (excluding income tax, indirect tax, and employee related payables)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_OtherNoncurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherNoncurrentReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other non-current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_OtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisionsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "terseLabel": "Other receivables (excluding income tax and indirect tax receivables)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "asnd_OtherShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "OtherShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other short term borrowings.",
        "label": "Other Short Term Borrowings",
        "terseLabel": "Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share nominal value",
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "asnd_PaymentTermOfCustomers": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "PaymentTermOfCustomers",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Term Of Customers",
        "label": "Payment Term Of Customers",
        "documentation": "Payment term of customers."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfEntitysRevenue",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of entity's revenue",
        "terseLabel": "Perentage of sale to commercial customers"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of the entity's revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reasonably possible decrease in unobservable input, liabilities",
        "label": "Percentage of reasonably possible decrease in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reasonably possible increase in unobservable input, liabilities",
        "label": "Percentage of reasonably possible increase in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "PercentageOfVestingRightsForShareBasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting rights for share-based payment arrangement.",
        "label": "Percentage of vesting rights for share-based payment arrangement",
        "terseLabel": "Percentage of vesting rights"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PerformanceObligationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PerformanceObligationsAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance obligations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_PerformanceObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PerformanceObligationsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance obligations [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "asnd_PerformanceStockUnitProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "PerformanceStockUnitProgramMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance stock unit program member.",
        "label": "Performance Stock Unit Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "PerformanceStockUnitsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Stock Units [Member]",
        "documentation": "Performance stock units."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible notes",
        "label": "Potential Conversion Of Convertible Senior Notes Into Number Of Ordinary Shares",
        "documentation": "Potential conversion of convertible senior notes into number of ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from exercise of warrants",
        "terseLabel": "Net proceeds from exercise of warrants",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssueOfBondsNotesAndDebentures",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds From Issuance Of Notes",
        "label": "Proceeds from issue of bonds, notes and debentures"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of bonds, notes and debentures."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds after deduting offering expenses",
        "label": "Proceeds From Royalty Funding Liabilities Excluding Offering Expenses",
        "documentation": "Proceeds from royalty funding liabilities excluding offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposal of property, plant and equipment",
        "label": "Proceeds from sales of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of marketable securities",
        "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "verboseLabel": "Net profit/(loss) for the period",
        "terseLabel": "Net profit/(loss) for the period",
        "totalLabel": "Net profit/(loss) for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r3",
      "r28",
      "r66",
      "r79",
      "r81",
      "r152",
      "r154",
      "r184",
      "r193"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Attributable to owners of the Company",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Profit/(loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r123",
      "r165",
      "r166",
      "r204",
      "r205"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating profit/(loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r214"
     ]
    },
    "asnd_ProfitLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ProfitLossMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit loss.",
        "label": "Profit Loss [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property, plant and equipment",
        "terseLabel": "Property, plant and equipment",
        "periodStartLabel": "Property, plant and equipment at beginning of period",
        "periodEndLabel": "Property, plant and equipment at end of period",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r44"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r45",
      "r177",
      "r192"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate",
        "terseLabel": "Ownership percentage"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r52",
      "r54",
      "r82"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property, plant and equipment",
        "negatedLabel": "Acquisition of property, plant and equipment",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfTreasuryShares",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of treasury shares",
        "negatedLabel": "Acquisition of treasury shares (Note 9)",
        "terseLabel": "Acquisition of treasury shares (Note 9)"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r111",
      "r120",
      "r187",
      "r189",
      "r226"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "terseLabel": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r111",
      "r120",
      "r187",
      "r189",
      "r226"
     ]
    },
    "ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in fair value measurement, liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of borrowings",
        "label": "Repayments of borrowings, classified as financing activities",
        "negatedLabel": "Repayment of borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r181"
     ]
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development costs",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of exchange differences on translation [member]",
        "terseLabel": "Foreign Currency Translation Reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r48",
      "r167"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of share-based payments [member]",
        "terseLabel": "Share-based Payment Reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ifrs-full_RestatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RestatedMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currently stated [member]",
        "label": "Currently stated [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r72",
      "r74",
      "r77",
      "r110",
      "r210"
     ]
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Prior Periods Estimates and Assumptions [Member]",
        "label": "Revision of Prior Period, Adjustment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RestrictedStockUnitsAndPerformanceStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "RestrictedStockUnitsAndPerformanceStockUnitMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units and Performance Stock Unit [Member]",
        "documentation": "Restricted stock units and performance stock unit."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "RestrictedStockUnitsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units.",
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Accumulated Deficit [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r167"
     ]
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retrospective application and retrospective restatement [axis]",
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r72",
      "r74",
      "r77"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenue",
        "totalLabel": "Total revenue",
        "terseLabel": "Revenue",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r88",
      "r123",
      "r150",
      "r153",
      "r157",
      "r158",
      "r160",
      "r165",
      "r166",
      "r184"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Operating Segments [abstract]",
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Recognized as revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101"
     ]
    },
    "ifrs-full_RevenueFromRenderingOfServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromRenderingOfServices",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rendering of services",
        "label": "Revenue from rendering of services"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the rendering of services. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "asnd_RevenueFromSaleOfClinicalSupply": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "RevenueFromSaleOfClinicalSupply",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of clinical supply",
        "label": "Revenue From Sale Of Clinical Supply",
        "documentation": "Revenue from sale of clinical supply."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods",
        "terseLabel": "Sale of commercial products"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "asnd_RoyaltiesAndMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "RoyaltiesAndMilestonesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties and milestones.",
        "label": "Royalties and Milestones [Member]",
        "terseLabel": "Royalties And Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "RoyaltyFundingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty funding liabilities",
        "documentation": "Royalty funding liabilities.",
        "terseLabel": "Royalty funding liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPaymentBeginningPeriod": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "RoyaltyPaymentBeginningPeriod",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment beginning period.",
        "label": "Royalty payment beginning period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPaymentEndingPeriod": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "RoyaltyPaymentEndingPeriod",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment ending period.",
        "label": "Royalty Payment Ending Period",
        "terseLabel": "Royalty payment ending period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "RoyaltyPharmaMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma.",
        "label": "Royalty Pharma [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SaleOfStockAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Of Stock [Axis]",
        "documentation": "Sale Of Stock."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SaleOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SaleOfStockDomain",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale Of Stock [Domain]",
        "documentation": "Sale Of Stock."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SaleOrIssueOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale or issue of treasury shares",
        "terseLabel": "Transfer under stock incentive programs"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "asnd_SalesRebatesAndProductReturnsInUSMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SalesRebatesAndProductReturnsInUSMarketMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales rebates and product returns in U.S. market [member]",
        "label": "Sales Rebates And Product Returns In U.S. Market [Member]",
        "documentation": "Sales rebates and product returns in U.S. market."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total selling, general and administrative expense",
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, general and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "asnd_ShareBasedPaymentArrangementAwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ShareBasedPaymentArrangementAwardTypeAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, award type.",
        "label": "Share based Payment Arrangement, Award type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share of profit (loss) of associates accounted for using equity method",
        "terseLabel": "Share of profit/(loss) of associates",
        "negatedTerseLabel": "Share of profit/(loss) of associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "asnd_SharePriceAppliedForValuation": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SharePriceAppliedForValuation",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share price",
        "label": "Share Price Applied For Valuation",
        "documentation": "Share price applied for valuation."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharePriceMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SharePriceMeasurementInputMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price Measurement Input [Member]",
        "documentation": "Share price measurement input [member]."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementAwardTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SharebasedPaymentArrangementAwardTypeDomain",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, award type.",
        "label": "Sharebased Payment Arrangement, Award type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementAwardTypeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SharebasedPaymentArrangementAwardTypeMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased Payment Arrangement, Award type",
        "label": "Sharebased Payment Arrangement, Award type [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, restricted stock unit, activity.",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, restricted stock unit, activity.",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share Based Payment",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Text Block]",
        "documentation": "Sharebased payment arrangement, restricted stock unit, activity."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangements [member]",
        "label": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares in entity held by entity or by its subsidiaries or associates",
        "terseLabel": "Common stocks non-diluted basis"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Associates [member]; Subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ifrs-full_ShorttermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShorttermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "asnd_SignificantEventsInTheReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SignificantEventsInTheReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant events in the reporting period.",
        "label": "Significant Events in the Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SignificantEventsInTheReportingPeriodLineitems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SignificantEventsInTheReportingPeriodLineitems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events In The Reporting Period LineItems",
        "documentation": "Significant events in the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SignificantEventsInTheReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SignificantEventsInTheReportingPeriodTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events In The Reporting Period Table",
        "documentation": "Significant Events In The Reporting Period."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SignificantEventsInTheReportingPeriodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SignificantEventsInTheReportingPeriodTextBlock",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/SignificantEventsInTheReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Events In the Reporting Period",
        "label": "Significant Events In The Reporting Period [Text Block]",
        "documentation": "Significant Events In The Reporting Period Text Block."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary of Significant Accounting Policies [abstract]",
        "terseLabel": "Summary of Significant Accounting Policies [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TeijinLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "TeijinLimitedMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Teijin limited.",
        "label": "Teijin Limited [Member]",
        "terseLabel": "Teijin Limited [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ThirdPartyInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "ThirdPartyInvestorsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third party investors.",
        "label": "Third Party Investors [Member]",
        "terseLabel": "Third Party Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of transfer of goods or services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of transfer of goods or services [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r111",
      "r120",
      "r187",
      "r189",
      "r226"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and accrued expenses",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r212"
     ]
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total trade and other payables",
        "terseLabel": "Trade payables",
        "label": "Trade and other payables",
        "verboseLabel": "Trade payables, accrued expenses and other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "terseLabel": "Trade payables and accrued expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_TradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "terseLabel": "Trade receivables from associate",
        "verboseLabel": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "asnd_TransferOfTreasury": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "TransferOfTreasury",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer of treasury.",
        "label": "Transfer of treasury",
        "terseLabel": "Transfer under stock incentive programs"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "TreasurySharesHoldingInPercentageOfTotalOutstandingShares",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "June 30, 2024 (Holding in % of total outstanding shares)",
        "label": "Treasury Shares Holding In Percentage Of Total Outstanding Shares",
        "documentation": "Treasury shares holding in percentage of total outstanding shares.",
        "periodStartLabel": "January 1, 2024 (Holding in % of total outstanding shares)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury shares holding in percentage transferred under stock incentive programs.",
        "label": "Treasury Shares Holding In Percentage Transferred under stock incentive programs",
        "terseLabel": "Transferred under stock incentive programs (Holding in 1% total outstanding shares)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "asnd_TreasurySharesOfNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "TreasurySharesOfNominalValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "June 30, 2024 (Nominal values)",
        "label": "Treasury Shares Of Nominal Value",
        "documentation": "Treasury shares of nominal value.",
        "periodStartLabel": "January 1, 2024 (Nominal values)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "TreasurySharesTransferredUnderStockIncentiveProgramNominalValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury shares transferred under stock incentive program nominal value.",
        "label": "Treasury Shares Transferred Under Stock Incentive Program Nominal Value",
        "terseLabel": "Transferred under stock incentive programs (Nominal values)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "TwoThousandAndTwentyFiveMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Two thousand and twenty five [Member]",
        "documentation": "Two thousand and twenty five."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "TwoThousandAndTwentyFourMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Two Thousand And Twenty four [Member]",
        "documentation": "Two thousand and twenty four."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "TwoThousandAndTwentySevenMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Twenty seven.",
        "label": "Two Thousand and Twenty seven [Member]",
        "terseLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "TwoThousandAndTwentySixMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Two Thousand And Twenty six [Member]",
        "documentation": "Two thousand and twenty six."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "TwoThousandAndTwentyThreeMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Two Thousand And Twenty Three [Member]",
        "documentation": "Two thousand and twenty three."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148"
     ]
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of interest rates [axis]",
        "label": "Types of interest rates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [axis]",
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r124",
      "r130",
      "r131"
     ]
    },
    "ifrs-full_TypesOfRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks [member]",
        "label": "Risks [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114",
      "r115",
      "r124",
      "r130",
      "r131"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "asnd_UnitedStatesSkytrofaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "UnitedStatesSkytrofaMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. SKYTROFA.",
        "label": "United States Skytrofa [member]",
        "terseLabel": "U.S. SKYTROFA [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_UnitedStatesYorvipathMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "UnitedStatesYorvipathMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. YORVIPATH [member]",
        "label": "United States Yorvipath [member]",
        "documentation": "U.S. YORVIPATH."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r223"
     ]
    },
    "ifrs-full_UnobservableInputsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r223"
     ]
    },
    "asnd_UpfrontPaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "UpfrontPaymentReceived",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment received.",
        "label": "Upfront Payment Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_VestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "VestingMember",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting",
        "label": "Vesting [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_VestingOfSharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "VestingOfSharesAxis",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Of Shares [Axis]",
        "documentation": "Vesting of shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_Warrant1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "Warrant1Member",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [member]",
        "label": "Warrant1 [member]",
        "documentation": "Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Duration Of Marketable Securities Current",
        "label": "Weighted Average Duration Of Marketable Securities Current Explanatory",
        "documentation": "Weighted average duration of marketable securities current."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Duration Of Marketable Securities",
        "label": "Weighted Average Duration Of Marketable Securities Explanatory",
        "documentation": "Weighted average duration of marketable securities explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Duration Of Marketable Securities Noncurrent",
        "label": "Weighted Average Duration Of Marketable Securities Noncurrent Explanatory",
        "documentation": "Weighted average duration of Marketable securities noncurrent explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised during the period",
        "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited during the period",
        "label": "Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the period",
        "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20240630",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/ShareBasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested at the balance sheet date",
        "label": "Weighted average exercise price of other equity instruments vested in sharebased payment arrangement",
        "documentation": "Weighted average exercise price of other equity instruments vested in share-based payment arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://ascendispharma.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares used for calculation (basic and diluted)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "41",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_41&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "98",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_98_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "130",
   "Subparagraph": "d",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "29",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "49",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B4",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "24A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B2",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B51&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2023-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2023-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_d&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>58
<FILENAME>0000950170-24-102919-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-102919-xbrl.zip
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MK$Y36+ZN:C,614' @H";CX ^!"DTH%D0(H&=1 4R27G$2-22IL!9]-TXE5>
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M0#I9CH*%GWT4T5ZL3KYOM4CGR<X<#SA9X88(!9P+.!=P+N#\T."LM&6@Z5K
M909 J[1#F@9 6Z:D"LP8JGC7)2G=5Z+0 >.R@/.]P+G4JRP5--V;3B>UFTUM
M9H;IN!K_.8J3IAJG-JSS?'P(CSDNPK#$=0K-2^)*25QYR.H53X4.TB!OA4%<
M!X.LC@I1JP,G&%068KJ.V)R5!A_&;UM9\#:]LQ-XT36/YFQ"'DO!WX*_!7\?
M#'\UI4$')!@E8"9*C"R3%AGF;; )&ZUDUT&9!\7?APW8%/PM^%OPM^#O[?<L
M4@(SSBF IX4_SA#D A5(!\>U4T1(>L&U=]^XRT/B[P/'9 K^%OPM^%OP]_9=
M$CTED?BL_Q*+N'<<6<LP(A:3:)+A)G6TR_8CX>_#AETV 7]+'<U2Z^M7V]2^
MLJ-0A7HXF\9013L9U://S:*,YBC"?!X FQ>I5R(MA>9KTV+QZG%J)OE6-C%]
M9*<=&(:4!8:<U1)Q#0J(,Z"*)!ZY$MY3'#K:2J0%]9<G.)YUEW=QLI\A_+R>
M,IM\^_U$7\%G]15Z6W7EBBT 4N">"8:H41AQ$C1RH*"AJ"1Q*4G%1.AFO"_F
MHNL!1TQVS&7;J&QLO]9B"A<!403$B@4$$2)08A+2,0%@1FN13D*BI'!RREMO
MTX5-,)>+ZO1#0!@)IK@  8%]C(A3%6&\8,H'A8DF1 F5.FKQ]O "@NZ0R\SW
M(B"*@%A[FA8!\5@"(AF"#2<H,FH0SW^<M0I)S:4PF@IC.MHHOA\"(F+.F3(.
M,4HY6!!<(^N"0%9B+B@%(8%)-^-]> '!=VBQ((J V$B:%@'Q6'D)/@KO.4>)
M)0 _ZPTR&F PX,1(%$2D>"$O;+FX6#\$!*7)2$4)PDG">*4% 4$U1]13A37&
M)N@+%M-RXWT, 4%X$1"EHJI+%'HS.W1QDBNHVHA>4\V:&-I&>3 J/QNVC2"K
M']SW0<$?JYOA*X\3\1VIS=G_!$S$U<65[63)'04G'8V;.C]]=Q+S:WR)5T,I
M*3I#"446FI>DJY)T=:TRZ!ACW&B$I6!9.>)(*YI0\F &*XREUA>25)>+O_UG
M*WECV ,*V,^QU7[.EZ(W)S]]TX/P#>J/4 /&Q4"2[:L"*#A8<+#@8&<XB#4'
M('0,B?R'QT20,8$@JBU8?X(!U%TH5ETNS+02')0#2O2 BNW;QJ+@8,'!@H.=
MX:"V FQS3I&6P@,.Z@"?)$/182RX-$Z3CIK%K4@?)(0/.-N^JJ2"@P4'"PYV
M9Q=3GI37#-G(">+*1Z0]QRAI$;UGAF!^H:/Q<D&#%>F#1(@!YY=%CPL.WAPF
MN&-HX%*&NQ@OZ$=H8 5HNLF28KL<Y!M)25C"^<@\KGI+JCZB,'L,)MZ&X18N
MWDBR;MEP"Q=O)%FW;+B%BS>2K!LUW([SQY8S$ON2>7>G.:VV$A2*P;@IE#R%
M=WE[>+^&JGJE1.UT%XR7']__VU\T)>H9W.S&%,K^3DKA],+IA=-7JNQ<VQIK
MK3SBR_#5_-7R];OU%&[MKYSSY^-1&Q>QN7'6_A3^.80#.;\^[TXRB0=QU-1?
M8O5ZY,>'L1I/JA]RY<B2++GF>%1TJ$VA9#&1RW +%V\J6;=LN(6+-Y*L6S;<
MPL4;2=:-&FXIVN[&O_$F3JNCMB_YHD=SKN#.>V(>Q4D]#B4CN%1'%YKWN/'%
M8W!SOS.X;^_;?9R]O+EP2BBGD%(Z(HZE1S92AXS!\!D;X[3J>L/+M=O4\M'%
MZJV)7!J(K!.1"URN&UQ:[:6DBJ)D:-X?S5'D,(TH>AVQMU0K>J'$YK[[4Z[=
M'I0%+@M<%K@L</GJDXE!:"(# J T 'B<(4NE0MH1K3Q6U%[4+N^[G>3:;1E9
MX++ 98'+ I>O/N&(C18D((R9S!L+<603#8A):1GE1"9[H9'%?7=_7+L='M<<
M+DO.6C<KZ.WT($Y@+9S-1JO;;+23V,%6AAM+*MJF4+($CLMP"Q=O*EFW;+B%
MBS>2K%LVW,+%&TG6C1IN+^J_>VY>MJ??5 'U>AH/FVIZ8*?5H3VN7*PFT0]M
MT]2ICC#PF6OBOV9P[O"XFHY/TM;:0JC6^MS=2H@IYN>F4+((BS+<PL6;2M8M
M&V[AXHTDZY8-MW#Q1I)UHX;;<71STRJAKIK0EU_]@1U]CE6H4XJ3./+P(N-1
M-9W849-WC1Q]SE%WF,A1-3Z*DW8[RZ9DXY1RJ$+SLBE&V13CN@(GZYC7T2-!
M3$Y!]1@YZRBRE&//@^".7M@Y?+D"IS8CY5Q[I'EWI#=Q^C9]L%\7(/_B&\:_
M'7U8(/QX=/M,K.O3^\L^0@4R"V06R+P%ORR;YWHW"'9,$*&31B1R@%-#/;)"
M$<0D2YQP;@36W11-/1P$W[+4:H#)"E-A>PK'YQFH%!,47"ZXW 6.^BAI,M$@
MB@E@8J(<:2P"TB)*'SWVVK!NJJEZHLHJO7786539 ID%,GNKRB9G-..:@S)J
M,.(:P-@H(Y&TP62@#4R2;BJT^J?*:KS"G@$]A>-[J+*E*=P#%7I]UR1N4(UB
MVZE\:K\6>5DB)(7F14?:,AWIGF7H*7@9)%7(&P9*#DD&.<HD(DEK(56P6)G5
MADP^'-CI?];#X:_Q_9FDZP_C>=GZVTDN7%\H0B5LTONE57"TX.A&X^@C]0NA
MUF$1*4.21X)X-!:LT<@0PYH(:YW!ZD)[I6X#*ZL!ZA)<N:UI=;]>) 7."YP7
M.+\MV@9G)#,L(BFR'\^XW"79:&0T]2DZ&@!85QM^>02UN(1@BEI<<+3@Z#JI
MQ8I3PAE+*'@'H"LY0PYCAF+T GN'>8@7U.)N@S2/JQ:70,W]U.)2Q-+-ZOPP
MGMIAB=R4R$V)W#RH:D5W:$;E,)ZY8=Q"Y>KR\1?UJB/U2EO&#!$1><H5XL)R
MY*3F""LO#$W$*7W!#EXN/'2)9K62O8/D@\5^OF/-3=&8"DH7E"XHW2N43D)A
MS%-"1JL$1G"BR,ID 7:5=$9)$=F%3,7E8D,/@=*4#C@W!:4+2A>4+BB].2C-
M);':LX"T8P(0ETMD)/$(-&+L&0/0H1=0>KF8T@.@=-XIB3%54+J@=$'I@M*;
M@]+:X*AB(,A'Y1&/3B/#+4.>,*.- -RS%PK8EPLH/01*,SX@19=^\!C15E7W
M7#67>]/II':SJ<W,,!U7XS]'<=*T,9^#6&7NMZ/C(A5+[*?0O*35;%E:S>-6
M-@>&;8J)HKR'.>@KC".CO$9.:$DC%82KN+*HSEFQ\&'\MA4*;],[.X$W7O.(
M3T\S9(I)6H"X '$?@9@[SA-Q$5%N'>)2. !BIE$@P5 K" GB0O5E9X&;!P7B
MAPWJ%" N0%R N #Q[;U^PB6EL4-$.P#5D'*>DW$H4:ICI-SKKNI]'AF('SAN
M4X"X '$!X@+$=VCASC 7BB/+#("J5189P@42QCHGF1?8T)6%7QX4B!\V-+,)
M0+R(P\"_F4+MQUY ['?/OO9QMT6D/+A0?ZG:DC+@H6D\1,.ZF:(XC(<QA[/@
MR4=Q<KK!4JB;HZ$]WDW#^/7\\/]GUDSK=+QX6GL&:J9V,GW6#A3EFS>[SC9Q
M6(_BA2GY]LY\1S#UUYOFJ-W))C/_;KM$?L [4OWX[!90\1TC-S,8WYG)U3?,
M[>EST1C KVYC9E7[@A=&L)BL>I1'C-HYNV:: /W(*4MFJBRXH;TGP?C[.Y[@
M6QJ/IZ/Q-,[![<V'3X0I01(!3=%GXUTKG$O*$XJ8RD0Y%=[')]77P^'NT(X^
M__PDCM#'_26#[+>:LRN#=VV@[CXA^'L]_M]GHU@Q/*@HIKRRHU"=_84-*EM-
MVXJS*U[R]F_0N02C3$9,!$5>$I!@%(AM(_?(@$U@0+*QZ.YE2MAF%';?S Y=
MG+Q-_VDGP/33YNUL"IPZ"O7H\SE!U1R \&K.2BA\@UR2 X+50*NKG>8/S@PM
M_7M&91Z<S_="V@D!.D>@R#&@-Z/).BDBM\3=1T]9.96UE /*28^H_.?)**OQ
MMV$.*AC84817^Q*'QX,J6G]0>3CQ.&^3EO,(6C4WIQ?D7;H]J&^QK30= UJ
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M%B[>5+)NU'#+_EI+I7B_'DWMZ'.;FWX[C66K"].O&O"&ZS9;3?-K:Y\WN=5
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M(BAIC<==F6*=@J*F8B#T'MLQ] @48?YY-PQ4W1H#Z[-T.2Z+JI<G"=.B8;E
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MM05=D@H'?0?TG2/7=^[,++LJ0 \L]C;6IL!U1,(:A3@6'!F>'')9]O$D539
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M-A&+(Z)9/4#<88ZLH0IAA:/@4AGL.IK>M\S16"%W5X8.E@,E-?1C!W,(@!"
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M?;TH^@1&EDN%I$Q>6:F34QLU$KM99N\:Y'X]"GOP"PL]H.;1TG.N4<SS4D<
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MQI?3>&XG>6^6E-RH6NVU?[CNO"PE[HUV<O%R^?UM7LGF=LR\T%C_:0$46SY
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M2JPD$4XCYFG,:F&BR$8ND)',>LU4<";=.>-@/<'@'_7LM.W3U%6+7WQLK<C
MM@:H!*C<"U0*$S6+1"(E4X8]$22R7"2$4WXCBLAYL8:O0B4/F%)+#=+<),2-
M)T@GGY!VGD2+M0S)'P944C(0F -< EP"7!X*7#ZU[0[S9  ; !L &P ; !L
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M^U7* ZH\ "4 Y;Y[@"1CG3 H$.41%Y(A@ZU )(;@!.$FT8XJY@\%* D>*"(
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M[3"1\@6[>:CM$Z@3V32N7K_]M(2(LYCM[&OJ6VONE'>7%-HTNUEW2&86'MQ
MIV'<7MC.LO95E9CLL'H@V=T0$TS>RJ"U0#ZR3 @>E^POPY"PM,3YO"0T7B>>
M3&8B1B<13^4[7#JDM4F9]'BVEWF,'(LMO:E6(/?WLJR,J$]39),9>;@(P.B5
M#G ]^/IDT>BMQ_Q(VMA\TA0:A3BS];"4%C6&9/%K_EB(]\\M/;9FGQU>E#RT
M-DWI,HV@2;4D>!5DNPRJO<Y&PZR-6_[M$GI7Z4<?1EO%4>$..YDT4:PUZVD3
MV&\4A]77.&GR3)CDKPX-NE4(.#.+1=I'@[@S%F6\5HA89K +21"S,0WE/G/'
MUZ"[V:U/C2>AJ;*]L;&#O-+80=PVL@NK%S</37P";,Z?'B[-]0,]=6.MP)1S
MA#4AB-O@D4X1(\\2D=10EZSJ9MK\K^/10M]YNV*.%4NNL6%'Q$ X>\$.D!A*
M5<YZ0/WIGJC)79BT(-7BV70M5V\2U_Q2616?Q-04\S0PV X[+MD-:ZKN<:3+
M;1<.PVBG6Z#^TGA9<SDNS*HK:6M7DV\WC:P7U>NM-M(6@;3E4;*I<:CP@['0
MB3(D,8M9Z$B+#"99!KD4J&:".ARZAI^_E0WJ'G T?W%S7S<0/ML'L"5OE,(H
M"IJM168B,C9K()(93KSFVA+6S>F_V>O1$_[BYG923REJTM6TJJM.E]+T=//O
MU^53ZYCZNYWXTR7N\&UX9R?7?#4W.Y3NB7S/6$+6H^T2\HG##KT5SE>"6-.M
ME+M&CJ5@85)R%39LN,P$XPL[S-9EFH_"M;3%-E-R@P,6$;ZMJE&FFN* :5L_
M+&/+BV#BK84@VU+:CT/7:ORKFUFU#]G,[U75',>F?FBV;6T[FY8MJ\J(5$^F
M&</RQ=IV)PW/S&=+-V #?Z6)P1-N^_.J!+Y?AOW5@J<M17)K>?>_YO/X_^*L
M>K=, X?:RZ=FKH)8I?RL*0A8E++9M42,4;[">,%]K?+3GN656KG"9Q>QY.$W
M>0N76?[YF]<^D-60ZY5MOS>"*"LCXTE<%AN6VZ[N=7F-YOO7.QQU4)[XG/2<
M)P*3KKFK*9\D>GM%2=%7+JO>RR%O*S!9N+^/@4W?CZHV]M+*M]F2:Q<<V]UF
M7BD7SI>\[,VS[/9S/K2EZ]=WZH%NN,,J7+&X=.'(R3C,R]4*O_O\P9/Q9&GJ
M3>=N-LXTM#VL?ST%J^2179E."BFZD*)[38_,)VX;C:0X/+XT-M E>$!V-Y#.
M=^#W2YP"Z0#I[) 8T$I"(!T@G?NC3F-.S>RW3#)%)P*R ;*YG6R*KC\NG4B*
M93!NE9YL"+_81CV]=1J^+WZ&T 1D!FL&1Y.5W9H;&T7_3;'@N"V:&E3VY&02
M3ZZT<EK_TY70SUK;I\&UOD_E@_DY[4G+D"'F;^5CR:?2?*4X_!=U(L5-WU0@
ME@\,VC*RBQ>K9P_CV"9,7E8H753K)2:M(_]9N3*>)V6ER[ZC*Q?61B9[4UOJ
M8I<=+]2=.EXLJI&BG91BL;"HA,KW6;;V^L=I/8PKLFJ><QD#:HSLR=PWB;/K
M-OB=3/#&&3_/EUNXVM-D?%9>M[*HK&W%AZM,\OR,+C;*44F*_-_++5WT*3F.
M",?GZS'F[4VA)JT3M-2$^45I8:&#M7KG-L)TD\_V4*!A>[>F&SO-/L&Q/^J
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MVGRV -@E&:^1;G.-58^9\ZL]45L7T!:QYR=U,_UY^T7;=CK_:E+&QY=XNOA
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MAW66)XN<NS8'M6Y;UFV<WJ(JZ'#BO8M>*=-Y2J6LLDUB.XNQR?S]5YM)VTP
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MDS5(_I@X4\UBFT_N7_NAM'JJB6N/UIBO5^Q\,3KUP$6_5\W20S(L/#BC4U9
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M8!.)(*R1X!B/0"GEG.9$'$T[3SSI:4'J,?4*4G5)#Q^DM$@ZL\Q!V2! >)7
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M#;>&AL;FK!5Z\TI+1#9&$0BC3D"YI5D(P;7<*$3F':/,E!(37BD0BI6MF)#
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M84Q6+<B-=F6NI(^R&IKJGC6WG^:H(E]1;$^&7%%L"R7@."(7#0F8-PQ]=RG
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MXQ0\R9QZ$RSPS%.I"IW!LQC 2V:#X#(SX9\G[?K=3S]^K?1I3S+>TZ:V>*H
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MKU]GZI*)'A&'Q]37Q>,V2;A3+E5%SSU;VXJ>6ZAKG9W.QB-1C]J R,2"2YE
M9E%%+XQ08J/9RM-1]GMBX/;).[<GN^XE\&(4IX:]'Z5_/X[&.?5KX+MV9JB=
M&?:9_V=/"2>) %4Q(O]W$BRS"FAFQBM.C0WZ*?C_$B]VRON-[6GZI!6Q]Z;%
M0W4-*CA7<-YQ+T>6E)<D@0N1@D@V@"G= DA.5BF9N&=;"J8\Q+VX(\3N8$^
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MB'4."?RCCYZNF[L5I/BU ,6'@A/O%C#QOD.)AX4>)K@0^--7C!^[O>C-(=?
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MIU;DJ4.N$GT$RWMP0ZYAL4=EF?PT&D*8C<?%-M8(V)'E?]>C#6NNEW?:<L^
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M\&BYL1O[R \+(3T->C'6L[O>,WXQHEX32A_7%;BRW)K$5).8MF9K-"=2<9O
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M.G.-N;-[N,HCHS,*<TVB.D1[ZQ%F>P966+T4RB-?/54&U&T;4.A")@+'A^5
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ML%,\<SL\PSP3S#O&,0D>Z(X5V#I+4D>W_)AS+[(,T]N("!B<,3\Q(QTL1,Q
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M7V@#\099T3*Y@TEV^I=N8S^V"UYEL?P4+MX/\;GV[',?=]F]PI>#E]3BG-5
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MQ\WS_VV^>$K22R!.I(,&_O3EW6S2^B6T=O_)RX^?@%JKLCT^T<[**D_@\5M
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M\S/$DLOBG4Q]]+=_?/E\^.;@#C4)1>K-Y]HAP9Q5=;,A4[0SX+1KKA2D$>'
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MI"&$=Q;#E7MD:C^RI!;=(>&Q' 7ZC 8ST\,?>KKK1M[\\I+^2++$'DQD/+Q
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M84[%-(0JGD4@R>,H*;FS_7R),?3W>L"]0T?IO<+-H.SXQK)'C=)6;?&-1F&
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M%/ @2>#!'8M9O4;L LD G@,P:0L11T!S,<,>S^_Z+@%H%:I(O";,:QI7,7Y
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MEK7C<-@;Y)*!C^"1_/',!P%/5P1".P'\\8UW^1SASF6OU:)5&8%';NF\:7S
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MCV0-(1=<7Q8WD[A+_2$[S:X]>%WFX!6.6LNJX5Q1<DGH3D@47V G0-1?EQA
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M.$N>HLPP] @4VSAGHJ>HU*W1X[+<A%__D:<F%'0[$=2PK<&Y:/()8"] ,,.
M/".RF 5::,U:P"315&K-E(#*X^LS\U9,,,B5I8Y5G.=2W&;EG4D=PE.N!P*+
ME$7:KU3LE"HA"P-D$0$KF[]9/8$I&GM4Y['A\IU6/F<F<YA<&E:G?@[-RILZ
M(5]&WC.5JJ(\E$6QSC31L=L'%(&6(@&L.+"+U'W5>CXI-8@'-@F"+@KB.'-T
MBY 7M5\O5*3I- *-BNM0\1-G_E+@";&KZBM83ND6@VUS=)7XB!X#@87DGRSF
M2_TXS?XMD_T<D9 MIR=A7P^0V?&,.QJ#-09OP4Q7J+!9P'\\HVZH2^TO\]17
M&>C]]NY;K6=$ZJ&#]KG&4(VA6V#H=G-)-+)I9-L,V7[/QUFL&%GQK3"QHCCO
MIA DI[D@<K[Q)3EZ\YEVWVBZ1/$)C9P:.3<-G,B$*(E!JQBAX(/8V602D>]-
MQ##R?*K8I: _DXME9>3?OF:H?;%KK!PV6[WNJ6#E<#"T^X-6M]OO=JS6< ND
M#/8?'2W+F&.M%**-<09*X:!0CBH'CZ+-8E,?^PS[M#36#&]CAJ<:7P110];-
M.:N2$#+!ZN'<:<GY$BH5%X+68/. VKD7QBOFU<SEV$/;>GUI6.TW'?L\-V3$
MJ&EERO3@DHSA&ZSKWKY4X#"#2A]\'-DTE$D7(HE,%E.^?4_IK]]PW!;ZT2?N
MC<C0-M5L2O*I8QO^-"+';TR9-W(^5R%G#(<(P.HQ&929OSZ?ZDWQ@LUZ<C>S
M?56:JV5Y:96 BBF2*PL31/(DM?(D#9PA)K+&[HOZIR&]D8Z31_QQKIDX^YP[
M*G>6^I47FPK(\$KI=D7<2OR64Z!F379)YY2R2W[AHTAVV)%(6A[B]>Y=L0E\
M;5K/O2W["K.WQ)RPK"'%YW=Y;M/UV^V6WY\\D#WNQK;EE*Q[_0Q?HL!)QXGQ
M%JB=ZLE)*;;LR\\^;FVZ>('17J?2^%,\NDGOO/I!7KL D6[.NF4+=>SW&651
M;BH_&%&)EHK+JUZ2U.F2Y#>(TH1D*W!4Y65.09A%V&-2]0NEEJ!@X5(C3!HF
M!9:N:(LYY^B3=N,Y1EYN N]&)J3 %AI).L>6HO-YZN=1DIB*B28I]Z3&@B,W
MLH0*M)+Q^: 12$0JMJS$"4!BM?&,C_\2B1FN/W-'+N@P,;9"'\\H7Q=?_^5=
MX^SCN44;I@_>?O]XU>C0WT&[<#&GA-*,98=7T;BKU"$S%/9YL0/2@8F&@U0A
MW@&N" _)F(L9LTQ.3!'=6[-A8@2P7(R':@@V%F+%RXVKG,#P@T2B(K6>4G]U
M?>: O2*J<[![:AKA[*=\)$PIV5G4;L0I)@FYLJR(TH5,.19-_3J?=899U9X[
M=Q,Y ">XPT*\;!)-/K)*AA11 (KA;?GYJEYU$T^0M]J4O5DB-_Z+2'\)8X\=
M;4JM>9F8^4=U5Z#<$<B(P2%/R]*[1-T> 8;2Z\LN9U&=-J;(L;AHV7<XE!K*
M.--0Y"QH3&3(6P"+OLG 2%0OX$S%28!M^L3?3-$#F8J' 9Q9BU\9E1Z[$3):
M>BNUT99-BVGV<6'.!35FQH>(0$+.L(K11_*)Y*R);.*1&/17G: A,7*A^=LS
MY%T!%\+$S PY!:(EL%<NTO0(U-2D4.A5^"U*T]BXH5E4"%7\-U6U**]R'0J"
M.2U3%I=P<+8 >V?*O3(R BE(5"1,*NQ!&$TDTP&GHX#[-VX4^"+D4J:C#/'+
M!*5&JHCBXL(9<AZ'R@%-5,G&A2ESC4Y2-MI /DA..^<>\^'.S=)<<5 'QNB+
M(M][W>OB_'V*.6,3=: *-.ZI!S=\\1<*!?1:8>&S&,_IL?%?Y/Z( N0+(J$Q
M?T'6ECMO55\@7K,\/)#R3A4IY[*-.('RHJ%8@,?WB#AU?<++UB<,='W"OM4G
M'$E3_!435[XK*:'ZZ&I3?R]472F"\J+TW'[-A#>EWY-VH1XK*QC2MX\J DZE
M(&/?P&F]0M$4@TID46Y97&5J=<F?JB9+%!MR9(CDQJ)W9)PJ@:M6& L'1D$\
M3T%T"@GIX?8-/Z6J11"K>:])<3 9=_C+#VZE,%=3J7]>4$_VA5*.4M_]%XY=
M\:8XGW0V%W:BU.A=WP_DS&-4_65[#1#\R^\C%5R.)B8/]-))4;E8>5WJDI2U
M2,/J,@,Q3D=HSF*+D<Q8H;X72K/2^OJ+4-NR!8?L$-OYK" .E?4N9RYG!:UB
M(HYTI*%O0\["EG@5P2+HPU ]<.0Z8A",@+P:KR.ZU=!8F>7W$RT)7;(<H$/7
M">#?R/7SF=<B0(@U^.B1F,+M*+OQEMZ!SA.R7&[=&*_$F."61A[72/@\'=K1
M-Y!QB\*@+<2*VYQ=8:+!E-=Y*8JQ5SD/72*M0(ZLURUR4>FYS:<_<>R1@X.:
M >'Q-I2H*#-ZY+'*LC4-=Z+,L$GJ4><HFK2#V:)KV>,2O4C&)[P=A=BLN8)+
M9\.<5_EXQ !TC;K/T)I6]*#S%F;> J<$=, 40IV*WR+S60 '@OT [B74DDN9
MT;4R5WDU:K ?V;28.#:AP(3T,)0$K!K#* SN:@)?;N-7L##'M_+\66HB1O29
M*S48=D%.&WK*GT*J5K$GFFCU3ZQWC)T9$N2VR&SQM41-TDN0.0@R-]"!(?21
M&$VK!H@MQ[)UE/3EIYIEX*EA$C@/1L4>4>"NGTF9Z>,T/+'@ E3,0;C?E:Y6
MX%A";5,K"IXA1H"D$7&Y0@Q5<:BF@;OW87^J[Q^F'V7]DG $B5_8G)3PLL1Y
MO$@"TAV58"?178P_B=AM%(Q@A>+K\]CM:+'V[H0'VO4SKE2^A0-C30<I:[^#
M'HA='6AVGT3C94B9!;_.QZ_]-P/C:AH@H,K='C]\;-C&[H'V[]\6\U'@_;N)
MI1Z3E4<9O1RZO'FQ0T]?[M!B%B-.YL)42L5A"L-4ESM^E>*MK&10%J6@QC&-
M8Y(/KW:5""Z%::(8;X^* BAW5,Y8-D$LXV:@TP<^/Z QMEOF(&ZNRZTB/+08
MUL2&3T0#7'4[]?/+JWD?43HM]%8MWVA) RP,@ 8%ROU7ZLX#!W.8RJX_@\G7
M(\/\^-7H$WL< *]-5HTB+VAX61I(1=FCV4:^C]11=N.4XOCDW*>_.9'L6^TM
MYB'6\#IBCIQH7S0)5(X*DWVC5^4@,-'_D2B<FM]3/E+1@9-[KF7?)P &-J7Z
M\+UAM:R\ 9!H#&2]L7-1M#P7=9-IP54H^P+QR8"GQ#+*!)OSA-'LIK$1!YXK
M[P5SSCQ*H(Q$U\I<OHEB%#X?1?#X_Z9S-C)EGW35'(E2N0K]#G&'.'N8.J<2
M.BF/K.N+'B@XHEV4(!2&604SZGY^.\,<>N5/=M2Q,M:([Z[UI$DTH#1(AX6B
M[[; B0+.X->S(*8>\=RG49J81)?(H$Q\@?EE N%\/O[+B/^5LCF6Z5*L:,RB
ML8L)&,;9^]^_O7U[;AKOO_RC44@RDLN8A50-*N9($^9S7&?E@F-<#U4/ETY6
MZE>-<]KE_93ZELKR NQ&6JV_T+;'4Y9^?&*+NM[!A;:V@I<TTC"OTJCE 1DQ
MH!<.&^&CR%><H)B6E%%132U95?&,@>V*Y"N<E[ )43>-Z[S3<9Y:+=FHZEY6
M[']6.8QLO :;"^9S42>D?D4,0A7_?OUB9T.DF\8?H7!CYVHXHKV\D@KW777:
M=;T::JX"& SFD,GI??=<2LD0*"X$5S1Q:?Y@UA>'RLC^%(1)_ /86_:!3&O#
MO08C4%MOT*-? #T;Q>,@%&%0;-U/;$ST+!?Q-=(9,^$B&5O5N7\"E+>NI2\&
M^PB!SH#?!I,)I;@ALA8:?EO4\\\^S\FRVJ]W-9*+IH9V6VD>&4D*69>7QE5%
M8J5OH!#P,Y0S]XMF873BPR#GP&@@GSCYI4HS$T#D#-7KRXB*<@/KIC<@)5("
MQ,A*JZ-6*]+(5JN&7BHB8%3.T*C4,Y1)#D=HW ;B F4.,!759:U$+XQ6LVW,
MIV\\GO5$;#6[^2="WT(V0]3F\+%'5;5PB:7G2.\3Q9(85!0?QLJ#Z6*^).50
M9SU,E[47HZJ]Z '$^Y4].-39@SI[\)E]$8]V]&VXU8H3;/.=/LH7^.3W^"AW
MX5-?W:,\BD]^=14O3;4LY]3<7MKC?E(>][/ OV$AGWH\_0M+<[T).]_<UUER
M0%82=46IKE)]DUD4I--9@= *'E FT>Z&@8I/A96@=L;P/57'4%:+R$:+-7J>
M%'K*E#!,$\!DYY$KJLX!V1 /OO[XP[#3O12F"WSP<Y;NM6LOL<:Z4\*Z)XP"
MX$/4/(%%Y'P>4];NC,\5HWQ4F"!+'*P+%8B5[D(FIB)(V[N85QA2*7$Z;V!$
M"G>9&(%@R8JGGWWY^AG=]_#W&R(G\7G1;X_^.Q'#(E>]EU)'"?'KW[^]_8@_
MIUJ%%<_0(\HOBOZ(W3GW3\#/1Q,ZQ'2.V[R)*<U>B]QY>6J7R *:!@CZG%-6
M^:CF@R_,!]?%IKJ#[K [>O"KKQ"P]T>DGO^:WXDX!C(DV0!&M$N#=\3P1!;
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MUQ9Y'6(/M8!H&I_7;W]+ *LN RJ2L*S9KKWZ,YQ4_O7Z[8=OWXT;JXG3K9:
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M&=SN..*@*.!=_OC#H-WK7/:;/0.VY,&5TX+R8ZME-RWUA4GBK,B%8S97J9!
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M#*SS.9PE,^;-887I0A/,T1$,E>/9VJ]V?)!MFZVV3O$\/KAJBCU6R';,?GV
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MH9\VN.\ 'MWA$6&%BPRE[C;$F]Y]E[(:!H^;C/,XF%2Z5<)UR_\B;&99>(1
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MX_]_^.GBY^]\_K,L@S<5H9:\,;@@FI4OSU*:&PG\XX+FA"FE81'D7BR*))A
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M.7V];+K6/H0@+69XPUKX210!Q[#0GLEI= R@+8CW22B+999Y4B@<8<JV1RA
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MID2>S8W'X9/(<2.A(^)?&Q3*$D%"2&].[3B:DCZIO0NKHH<F,@ZA@J"94AB
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MOKJ)J?WMA>STT\G5^KS5E;F@.DE6F!#SJ[,_:0<WR9G_>Y:D3 YJ7M&3Z3&
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M-3QNZ>H^HT> SV[DH;?67-C+?Y\L3UPYCQC01_-ZZ'S'P17!S??&%2#^[.#
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M0"]\9PRD_TL"L29F<W[&Z2:NAB:,D'1003G.9K&O],/EK#QO>!?B@)H"$B#
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M(F$7E&J:VH&B 444$Q0 3=C24D$5)8SL2<FDGLFRG 9E #&+$D !I1^DZ%*
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MH7^VYS_/R=G^*DWNLX>$VAP>H8J?DYE,K#@8?[W6:CE"F+?_8D7@#WOYSYC
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M'\KP'4MU0%FK8?9_SY*4W>L^Q00J&>E80LSQPZ[CY&!P\!)*9L&$-5ECW<@
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MX W %2)][^73O-XV)[>EK>.E#>P)O#<5%.V-FOY2I*^'2:'7KE##O%T-^Z/
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M6D;>#GS7)#(V@+DVRVHY05@'AG%0UT"3T"#3]A*<6!%:3XQK.A!]O6!0R2C
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M^,+ %PVF[_#:(SY#)F"!^9KTPTDXLI A9R:"-AC-]]S\@>//%&^*D ;4RKC
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M-2TV#H(!0%"ZU_$(<8"!H%*^*HLH^?^-[>3]0XB?A\QK65TU)@-"BNH;J9[
MC+7?-*<Q>2W05P1^,GCWJ@T4S<T__NNC'" E25A0@1\?H;0H,7X6GAVZ1^2.
M2SJT^@$C*T$(#H2A*\&[1>&SO$W ^J"O3JO-,_Y^ID:>M/!IPQ'(@P&R<W5S
MS25 I)Y4XJ3B=]R1#@."7M:QBJ0AA_P:$@TP(,NGL7!_8<7""9\"DE% D.-(
M:I$IK0$\_O'/JHN@X(PU>E:[#0$8D)VH6=ODKV;! " H50,O1:>%!0D$B<(3
M)?-4C7\.LN LS -GBV/X9<",OW#:CI-4N:O7Q@XYI3-D X P3S/N2'0*>-!
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M*\-?W8)Q:]Q\:YP[D%@O6YEFG5FF(]19EJLE]W&]]1/N\PB:,2OVD<$ *(9
MY_BR38Y]$&@F',@T9RXDM%S.3MJ6T85$FK=FMW;VU84$OVKP(]\2NQ!:M>9
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M.9.83L,^+B6#WP!(0IE(JY2'5&DEW'I"@,11>UYW?)U#1#P5C?=^*+@7*D
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MG2WF D@2OO=:M.GB40#1O+-<8D>A(5%WEO>-CUH3$B Z%;-Z8N!#=MD(P(A
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MF/. Q=0;7LT;*NUB,D 8GM/7IR R3<7;OT\3J9+=Q7N:YQ1M2B)</R)"?UX
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M 2+.7;"$X63C **:;U+Z9E':T!(L?)0D>\:&!HC6EGAOA/M30$!=OFPS*D
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M &3'Z47=3ZR,*I,EG#=-3:XT8M"09UIW+GF I-<5-X>YB8BIJ0<H72JJ<2L
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M(I""&W$DMEHR*X9""#K04A.E;F7;F*]"%*9_V.'Y&=YRA0$#4YA\5T!5^O-
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MF1@]%*5.9X),0\I,LU[!X&83AHNQ]O*ON;TF@K7$'**)]D187E*6W*2QD>N
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M0FX4DK^1G(%DN?@O?XCS3E@08RWOH6+?9B\PA8&_1-#)AZ6G0LJ3RD5DRO
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MX$ ")#9;H@JY2S!D,@AVN&= Q[W>.MD!1DB6GV2RD]W"F[W=4JCZ3J'ZB)_
MY_B<E=UA>4@89-<:.D"\_=IC:XT* T"O;FG-X>::SK>8II50.]M)NB0QF(G%
M<R+P13<)FVH.E/$W"EYK9!T1IGC"S+*$5L$0TR(?.?]TO!?G3 KT"(0] \PT
MLRR@%_F,.\M]OAP"WXM2V\@6[9'S5GA**LT V9#&N[/A%XUGN4DQ*=8Z:A
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M^Q:4Q@'T(]SBP_1;$' 6+0L;4QEKV'N6<N('ON^S!@&0Y$0UE+"+.!E&>0*
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M/X/(P6^>>S_D-[67# .(*.6UO[1E4M' F??!U6H*9;YKU1"\7X[SUCT @K$
M45Y,TW;V_N1G>'<*_/AXV@3^P8G6 0F1U-QJX51S:7NF8Z00M#^3/^Y!U^Y2
MK(#(><A7Z2)\/TZ$"N+BAUW),*.ZAPK&@J8M5_)B!TT4Q9.B]E*O<8S*"W B
MQ!$?H)ZH,Z-SU>F.4GN83YY&&A:36G5)Z6L>,FW:)F&I^A^JM&K<=9"+YIF\
MLH3VD,D3P9 .++.M3)Y.W62,T!@#F3;#RAB9.@"YO.) M_F0243C1="T(LW
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M"I<&ON_VN^_U?:]E]!@]^M38?T[M(^OL-=>:>^^Y[G_=_P%@*\C(RP#@G@$
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MUDBL5/=TF-LH[).;V4Q(5:$2 :2TQS)(C(6.SK=-OA/+V=C%L_U@WTCNW80
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MO1CX<%@[<6&J>MP[>GPU5:2$^"/\>!0MA=[^T842/+E8?HMP&<XQC2>QQ-2
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MONC+D-FU@Y_P.9L/WJ^M\_..;,935X"G1L<DX6YEF(>=0LE#+U1)7AN5#N'
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MY\4H-,:6@3ZB;+/^ZIC:",[<O"SSH_RMU?@[(A?("EI"FSR<GR0TII\H+[?
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MS)82-UIUX7%1,PCQ>!;=?UK/@B:8CBF?VZ+29@QOK2]BKOL-4]3.QYW2X[:
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M$!1BR)YP,WB1./PQ__^; %!+ P04    " !4B2-9<Z1FS2,H 0#'F@$ $@
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M?&1@\\%AIW1$X4@<G#,KA>M(69!$\1:CL>O 1F=_?;NM$C)11.I):OHS4%X
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M6H .X4](*V$$ &[PF' ^]7!\.E'LZ1>COS:]E5)EPIIJZ@*90I5 SR?&. 1
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M3>))G[7Q+^^1]ZDAB@-L0Y^>0,/HRHDNJNG_<J787Z266@XK6B*4GRED?4Y
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MJN.K6^0=8S,*T/"(K.&I<C+M9$"EKR#'D-0(YKQ84,=]"1%,DL!0@;&->1_
M,U@@H_^D*)KQV+O,NS!/=>,>H'</4)6X(G&/*&GTFBRM0NCIC3BU?9=SQFM$
M$60;$!ZGFOI\K&QMS;;2'/!2N1JTON](CQ+[A4E&\@!18%71+Q[LR+#:$#\;
M5'^[)JF %^?=G/,I3K,[25[[PD.M";:QLK^CM2K%LV[_3*#3IR@#&^;NDB-,
M4YI5GRJS^,?4QJ\C9J]D]7J%*HF?8!)N[.O8#]>7ZDZ4E9="RXUS]X"G& C=
M/<%[P(>P2/J! _BT+:6'Z%:]UO[K%C^/N62YF41(G5LV&4X7E<?AS79CW(V.
M03+42ZA)^A&1H<]+*G<SPAZ]VKC S!79AIJ ?7+6P>CBH,3HNF#B"I+9^IMN
MU -MAV:&QAOG*HL-1AZO?9ZM$,EFSF'!UWT+X5WD4!\'Z:[8$U95U5<VD:P7
M0=]KU4K<J"J- &2/W*-_O-)GNMG1H/X)X_$:# L:=(Z"^K>H^YXQ,<GXS&_W
M/TO2 JE3RR5CYQB&.9$W/I/<DB30FLG]C//J.[!LWQBF#6V8.1< N.,"MM]*
M%S%D^3XF>"_Q_PYU<D-+#-FFNP$F]N;JM?T>_D\B9N,B9J4 @ZSJ&DJD^)["
M!V1J&X)4.15./*PD!$T!"ZSR9DL0&DU Z";86&B^DA;;E0)=J7QD),]OA$R#
M3DE!3B0U)U]Y)QBJ0,08ZZKC]/D_]5(GNI0.E8J+*ZF%M4O''.X!;],X\H\@
M7^Y0U;[J=3J%UIJ%''GA(:W[9HQ-81H _ 49C)O?U<Q;SP>BWASU.6<QF@H,
M ]8F74^%!;-E0VRYO>H;U*5I!\VR(:@B9\3]90ZJ+2YMU;XVVC!%ZA5-B4V<
MH[(IFC9/RE(3*2)8N!-!=4[_S\_1VJ;0VKJ*/I)>ZUNWW2$B+(K/8>2$@79=
M-%3^EQ2QM=_>Q.P0"26D>GL6HR=#@%:$W_/(H_MM8R-<KR@N,VN?\BI848\X
M'I<E$PYU$.4-/_$OI)V-V0 ?G72\1SY((_^<P/&-QZXYA#:6\X\[.H!QE&C]
M36^I$(F&JXH:+F&/A"/#4A 5_L4T1KY(TN=6PM:&))=Z*RS8R"9'O_Y7(&K$
MS=5ARK+:%7#<LFW6&7X^K8 _%K],T."*T,9ZUEWQ.AF RQV9_/>6V8!Q&[93
MJZ'GI,F[V:@=3@U9J=G<17*$Q+%4F\2"Y)\"<^"M2:M*U94N;8T-_"X<W='S
MEW3JX7WH('OBQVB._0);YO5:N_NVK'N#C]SX2-:?]78(I_A)K.9+J4ZCF#CQ
M#M7"ACAC)5=HGE.*##[Z#/;90S'D<N-=&G]CV?%/JMO_E\??CX:IU2F9]2X3
MWQ_S("3_/MEW(V%R-SB>6>^L*.;UAN& F,Q(#-2_)S"RS%Q68(-D/4 :US8&
MT/E)?I$E08\3M._GEJ]P\ _9^>AMXFJK>"B=,AK$4HM'K<SV!/JJT<7T'8<<
M28_7%7(U/;1;J/D3U5A.I ;_E4&V_6B9-8SX,.79%ZA#38IQ&'1B6CW7555J
MU-2MA.<D1%,_=S9Q6!1]!7KA5%#:3/1S5SB@'CZN(@A33]037M<R(][T'5'Z
M$B% 6%3XV&/A:NY*5J1@TGF]:NJ*?_W\MI>4/<A3D2+:NS1<A]O6I(!8;! 2
M<QY:;Z=+@AHEL%G.FUFZX]Z:[[4B;.4EC\7,RC6'@]I=8L/_FAYXU)I(,3D!
M#^1Q&;?AV:@>RNWN<0,??]BPEQQVB/YA)Y"W\XG@QVGHJ)MW?LXTBO/!_/?H
M?13 ':]\J?#BDM_1/<!/JFMJ'<Z_<G,/6/;J)<RV5-$"9<1%T&N=6)AV!"O
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M'J: HM/.B4E0*>J(A1!"09=U7UUR&-X290DO\+C0=0SDI8OI&3Z6>"*3:_6
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M\V+C;?PI8?9I$9WRR&<(@4*-7?/+._, 'DQ+J> 6B"-Q/-LE:"U^1TR'=@P
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MQ*H^RQ0JK\$D/WP8.:.(X_KF6)IPZI?7D]8.\4N7R@HE!\=T[BN3ZHY&TVM
MW;!)?Z_0F2\7N?BSX?=2S*! UCN*>@"F1O+81^O*.=%GKC< ,HZHZZV$"^:<
MM'1?9Z]?WR9 04<]TW-P<A$7<F%HKXGIAFOEL'(YYSUPZ$7$KA?&0JW^A+]=
MNY.2O3YJEWA[>M)!%8&YOR/_7O/!\G)8P W@/GN@<[K)/I%54]=C.E=\C10A
M9%$\BP8Q$OH&5FHB:=XQ2V$<Y-B@FOY-;KY!-6-.;\F0)$?Z21;E'OF5!3==
M-Z1Y##YC]J^,.YNRPRG%99"B]=#$R6JE9[^\W!G@//;ZVWB[1*C)&(OZN(K&
M<T(UA;V.U:F25RMN$[AR<&88TGB$QZNI$.YE$K0V4_B&_?&>1R_)29^U4K0N
M!?&;#RN#OPEXP5Q<[P63%Z_V,T6R4V<%L^2J!.2\/9ML_&1(^Y+7,#,#O#Z&
M<?9<HN=CQM;IG%%E^<.X'0]1 ?L<8L7".4)E4V$ZM#6X1=S)Q3&-8:5!_:*8
M+<OW$>0$4INTRUM:Z,\> U&6^A4F9VHF4[E;1KP3;$(YHAD^EU:+''14DR*0
M/BJQC+5O6-<(7XFK_5I87AG<[5-4J![:6: ]-/T@WO]N+WFS@'D%]TH16+UE
MM56)>IO>/J8F$2Y>+DV0,##%U+*QE^:I5C2NZO9"'3@+IG7(D#9T/6!N_YZ4
M7$L?S8%+ORUI4Z,%2X71,I(FL\4^>SH.Q-/!'D6Q/:G_BA1EPS.2UH6_-KO-
M.Z6:F'S$,&9[4)@7PZRBN@PC2GP7T2TGP# )KQ7]%?[&EPRMREXV5B)730^.
M"4M;W8?E.B[P^0O>Y(?9/CJ13<89Z<%VY1$GF&V':M@/.2-+W-K@RHGO]4QL
M[FJ\B B1L+W;E6[@QA3H^=!M1I1(J&'^ GXR/?ES92?#^X*NA4+LE.0F?7JK
M[8# J$ '7DLHSVFN2DF@.(1R%J$D3N^Z2<6O"KL+28@9ZH#@)H(.<V+ RN77
M]:OI38,1^$NR'(!:@WDIEDL<KG4]"N?=V]<R"/?C323B^!>)!)I8WM=X$[RT
MZV;0PA1[]%&&0%NI%VW>@H7U.*_5SPXY]O6)P6%&%PKWQ_:+P>GV,8ML8G++
M53-% A'!%3>NM0HJ\Y<>*K8SCM$X07B,9 X=ZG37Z_ /-]O79LN,;N$WG(6R
M(^=HF SRF&9.3-14.TL0?5[6EHX"-F,X(  >E.,N+\),[L+(]I%?JTY+GVS:
M&&E )CYF^A.HN+^?G!#@X%X;K1;OJ>IGFYJ*,HS'0^[&$L>Q?_$1+69$A<[)
M"IU0KF#'ZJ2L>*KK;O?!!G,C?Y0YH;2A23F)[3L]+5VKFA!10<>CK+0""60P
M.>1KH2GMQ+EXGUZY>#L)OX*/V_S\R223TYZPG4F2 JT; !=@EY;<:,W1NNCL
MBOZ<;R8RG,UN(7YT@M4#<488[P).Y4*A:(.S]7K[C<[P+(>$45IA3$>)?"]+
M9]*G^3=<>%] FR.RKY19Y5#-N".'V4Y>!3::J6/R!<=:GBN:^E":XZOTDED_
MF'@%(Y4OP>QPDWZUYTH[E>Q6&9C92'<6\R*<S"Z(V;+V,_0Q+7/8%-L@2CRG
MDE H6NQG.9['(1#$ZS.GJ4SM$H]9U95 9N!VG0@0VH9+Y(2"%D>-'";[USXF
M]-MS[T].K2'L?*9BCMMDE<5NDFM(BJI"M!Q7&?ED43 C2Q*4V7%C#HP7AQ R
M:EE=%'N4L'X;[-IOL_X$II]=EF_MF$%F?MUCE&1/%\SY3K!Q-^A]@"',$+R.
M_S[Z0J-#U^YD==!!C]MKL=#>C!#[6:>/TUO/\AE<O*W,6U?Z_[]_KU:-ND"]
M<1_])'<7-2X.UJ3:CE09/;&$J7OI7SN&MS-3K13_R1<G 4MVO$.?4%='<$5,
MAMME5/MBI(H:.00\/JG&FP\Q16!@?1.:$D!CO6$Y?&#B]/MJ_DZ\1]:&DPU^
M68REMG5U1]P#YN<>?&T5O"--_7(R+$&A:> OT0KXMDG6**1>C%9M0*CTHJ1F
MLA^"595W6!9!C^;)(,8;A++#B94&3!;*42*'=GJN-C4_:9092$VIX .Q9%AR
MMXIV^O1RV!RT(2SH>&Q ^(-U*+1/L;ZN+/RH@V'I@U3T]#FT52S48QXUUV$I
M?XS4/N#+)!3LXQ7#%2:( \SU??^1SL)JI@.>G'QOM9KVUA^KN6PQ[8;#LR^9
MUXQ/]D3L:;JR0=IC02]/LHVU8<*F&5,2YO9 C/6]MA6UZ510G(+WH3J32PKY
M#B:(%W_+Z#8N@4,V+E*]4TW)$AP&)645'A9%5.VOWPQU6?%K3O /;Y-+CK#)
M9DS'\>VH&&<9TS-+X#K,J)2],W@@-!.$_N9X7%:\J;+3&!_[."(E39+7M(PZ
M+UHG[W[@2@A(=OH4#[Z\]CEQ3.Z4:MN#%AM2TZG(. :*0 ,]0_I/!N2 TT;4
M]F]Y!;OWJ?0 .VCQO83!_A+XTF"L C/<IRT@ @@5FC^].,X;]*.^M_/?7L0J
M(L,>2=7&]EF: 4/<D-]H7P4*W2["O<$W 'Z)&X!+^=GP)%\/..%%W0W@[%XI
M=MCO+P[\=&IT>EVW5W/YM/X:#B:L=P/XS)IR ^B#W@#F(-=LKK\[4^.[ >37
M/.7OVKT!N)G*J@KL!7RY 1PNUY].N0:2_'B"$^RZN8O<5W1Y YC''U:2OB+G
M%K@Z?_KU9&Y)](>_A5/F+BX_'V[]!^G_5TB'PIJBQ;FK)C+UN4AX;*^^E#C?
M %X[:+I$SMT  /K8@;>]TWUO>]/= %P)KHQN ._E7]P $K!O /6!U^RE*7-[
M-P /*\T,_=,;0 .'4:[YF3";]/G^Z\NS;RC(HJFNSO*_7IGO)P_LGKDV(@__
M J/G[PC^[@7TLR=.<=]Q3"07UB]@#0BLM;CN+GWS@I]1PN%B_>E^?:N_:/W"
M#0#AJ?QW-Q"P*7'^H#3E^J'DH^NWRM?7G-]B<"4P[[5A]]KU"M[ K_4GA:Z?
M:9)=^_QN8W![!9^!^ ;PX0JC5NI[%,P&5.9^4!G\@XG"OSC@<=:$RPU@#S6:
MCN!'E3_96.)\3;+W[)CG&PV*A75_KU+@!P-O(]MT??\_3OV/4__CU/_?.]7X
MMN)M^0DN;$$2@_D&('0+X@;P&PJ>7[W;\H]YE^Q_AWG_+IPQ.L(*#WI+DZSE
MFGC;T74_]:^J)_^'G4KWO\2N?ZNY\.]"EO\X]=_)J=_OJ>CB?JIMLY*-3O#U
MFX,-WY 9JC.C2(DNFNBE0/!LIL_#![_##N]V6%.H';3Q%S,SOYL*G15%[F[/
MQ7YI!B4(:KC&'AI%]SOB*KTDX#%Z!?([X$I]9(CB1A@$U[&:'B9N&J-KLB$5
M(S/=-L#>]>5*:M*L:AI_.T6-P).OY@$*/1)NLV.O"_<!M_UPX;Y7VFHJ/<70
M,0_-) >4V=%\Y=S=$;1\TK>BAIX"!J^/A1@S-69(\@J_*-NGU2YX%N;>RZI>
M%KF JH.JTR9;%RG)\APKI+-_=XY1'FYF7'\<:AVKA<9W+Z$Z;JI_K=3$SF_L
MM0:_4W#U63"RD?P&_KO0K)<8VOK1&$]0I/@-$(Y.3O#P<O*7<E3XN[ F#3+'
MK*>00Q'L&LHXL7G?M%^F7N@2#LN>21V]Y>0G-(:US Y=-JBT)7 ZK.&MMXD7
MIG]12WU'7CQBOES<K68_ 51!MFKL0+C#K4MTL>:7L65V[;J')/W0UKY*@V-'
M?)9M2"I<UP6!,Y+AK8H0!(%G%5+OO-(+VNWA<"4TMC#&F0P.M]OO$YBX2O-Q
M#.V8417;X"M67[KBJG4AD/:-;S7-4:5@P,HG]7YA'=JYX$X\DH;NR:@]5.)#
M!KY//"8O,3&($VEP#^Z!>B$5P.D!H5%>LB*SM.W NX0]*8\U^0CI!S,;,HV6
MQBR37604S=IZ(C*6X<MV/18G\92C3\H&GP;[0FQIWF0$<=F4>C!M$'"M\)L%
M\:!9'O%_R)ZL/0EV-GXH"SPY>)%6=:=3L*^</69A%W7BRX5M"+2SZ_(9[DEM
MLRQJ\Q*"=P,[1BSY8QM3I3@Q2=4I:1;J*WU=QAQ;K3+[&\"7H'5+RQ5T2M)$
M:/?$O(7E]%(:J]1^74SF;*,9PRYL=#D4PM=,0![K.4! )1 DP$]#7\-,*[H(
M>K,2W#EB8/<<#YA<0![KWL<NTO;Y8CH2_P5^Z8J_BC$]\=S_P]Y;AM6Q)FO#
MBY  "1;<)4@@:'"'$(('=W=WM^ )!%OX(A!<@KLL7 +!8>&R<'>7!/](LO=,
MLK-GYIR9<Z[W>]]K_^BKFZ:JGJJ[[JKN7MW]]';W1W&)^<>7^T_A;;)?!?9(
MRKN5/H!ZJ]P Z,5WO1Z9L5][7,7)1LWBO4JIZ  P\:SMYF.,-W'.*PTO;LE\
M$:,<S"@=>5S]9M30-0WI+:Z)'>DR3(I,?WWWZNK2MHL7KI]@^8709_9BZSDS
M@VHG\F7$\49I'ECM]WII,] M[4<-+.TA.6\O UZ"0O-*NN["C/AQL3D]4? ;
M/Y_H#W,?U8J#'-P6+/MX.S88OP+?$>J<:T+9HH<X,^5F]H@PT7#M.$_R@$",
M4E+=7!Q1;-!M=1H312"0-#%ZG65$"5F@Y7S1_%SIY*H]B792S*7[?>]P+I'6
MA-';>9B!!R 2.'.F=67VQQ8Z[,BJ.DQ(4Q)(^_PZ#9#AV3AZK/'S$7-74-4E
MG\!\0JGKU$M/LAN '(B@QTY_X;&?:U4W[C$NQ-YN',Q9B$RN@=^4(%#N1$M.
MS-D 9MJ%I"WC=X6WQNU#%I\HF@U[FW9'"1%ULT8FU2R,AUO'?W 5:N4.>./B
M1-];5=)"XP-RMB%_01#:U&^/"E"48#W3 K.]WCKZ)&Y6> ,@^0*O(8RI#*_Z
MRR/VFAVA[U7+AQ^/',_H;$=."8/\M[NHWCF,.SAN;6CQ&;N&2+]7V;_:>5-'
MUL/KH=@I)FO//8\_FMCC< ?9>:MUC-UARV5</7]34*K>^=2T( Q,:8LP+3T/
M/U2L\Z6;B!LSP9- _;#WN8J=V6$;JC'%/(EV-:00)YFDKCJN-33J.=R[YCZ0
M #LF:AS0W>63R9? C[5CI3DZ=^M*HSZN/B73R'+V,$:\ = UGXDLA8(U2:R5
MLTS-S/F92TKJ T:M;'97DB>MT[%+]J9?1PZ3GE)%#KVG"CO^-,QZ,:';4,.Q
M\AI[7ZA6 ;QG:$+HZ7$0V<<ALW^R4OS6\>JY&NEAX7%,F9,R13Q,%WEXW=XX
MM&R\!1JCC0$>JD_"WS0$B=@YEF$]Z"#-*,*3*29<*R9," @ %2]*%F_GHVY/
MF5D55Q+X6J'//9?]**-L=+HS?K"AL &ZIBP=[74/2(/+R&:E3%A(4]6F@M]]
MHYT*M/=^Z? >U=\F,*"PT'!$R8E6,J4"VLG!:QLYQ%07E>AR&>Z)B,S1IL(=
M/6WA<AIBLXPKG/76*KPNG\E+D-#QBJN3'F'^8#;6SH50GV"D"F3SF';-'WOW
MRL?R<\O.R[J#T_<F=BX8D^;250ZX191 P&"[@X^DB8^,]*5CP9=71(4$DEKH
MJ^==%1H6OC2UY(B!LN(/O%_;N]\ SO-&9C$;HU\>T)> IKQR;8U>@RRI.P4X
M"$D^F(XX!U4N(IY9O6+T]#9AF$2?[L+8@2<T),3O&:@WL? \I:5]5TQ>"QJ1
M7.N!ZURE2:V1T;[R6=I05P?&\LV]7AG*<&W;,W^$U+8S R:R2_3"$GS%X725
ML9 [L].K;I3?RKV\TA5NTM-!SE^]&/:BT #3O/'12(7Q^+!6V9!5EC,V*%J4
M>!R0"!=YS@1U]W3=,;\!?!K:&+\F3#X]G:4ER#&R@)0OFO;<:X8V8X3-IA0R
MR]RW %6AFY[:;^"X2Y^:"E20&4?-.7OMPMP-3<38=%?:8D2 9,]]L5NL :JR
M5J^IJ;4HV\\OP4:.?&:M)/9W%, LJELBJ*:SX;UBHH=-/].PO?"ABB!H&JK=
M;/47J0YI=U%OY=4Q 0WJ*MW=0T+@#34@=!];D:><2OWQ'@)DV*F!0]4CIJ16
M#3IY*@$@-UL;L>?D!7(6/DC+-JUUCJ3L!6'GPFHVGDE$'Q%[RL!&-R\E-#V;
MA+B&R'GPB4J\J939WC*#RK'.U9$XV6<P/X%-\.O1$F-D##$/E!\F]37D$)0+
M%I/F+3&0Q8WT]V&!-%AH;QQ.;ZEK+3(C["!EM5!1V>L:!#N#/R ;B%:7SN88
M ?QZJ@T?MI)7=^)A!J;=^1( 9:%N\EN2,9WGP*U!/!+A/R# "\0C=%JV4SMR
M]5LYZ:%UL'(S@H5"6(.816N:$2M"L5M(..")RIYDM,+MCFW.6G&(#+\86WU$
M&>J12><=PJ/PX"F_ML,F4V_4AOM86JZ&EG8( HA +6T*J6@JZ6/8=$[S4C;G
M"5>&[  8N^[:UXP.FSOLL,L\#IDL4_<-*5HU2&G:?4?S"D"6=P/X*/$9OS$&
M5'78$+:2/XWST;^=:;2,*=EUERG9/&V_/]5JAWY5@W8BK31@QJ Z]K*:4HEF
M".$T-KKX0/<@-!C4VIKP)MBTB:V\,JF@:AB5R:<5JY6Q!R(=2*+.AHRH?$T1
M**O%[N@O6Q5PJ%M23J<:1]-QUS ";LX@T8"<S7Q<&W@HUJNL$C"FAF0WLZU
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MP7FOS4<[*0N! O"J?O=,!A<66"FI=7 WO4<A3DI4/$XZ>,78K/].C7607UH
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M>X;Z;2/CFY%X88# #]:,,/]_K9MEVKYT=(OR$'B6%;#W=_DM_@NEBN%,/YZ
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M.'@TQ?/S9(N:(&[SFQJ%*&D1$>YAF_2&DH/'B</F\EJU$S/,%9'IL;H8%/<
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M)9F:':4:NAYF"J"@T[$'<CR!+;3ZXGSN*2I855.C.TRTOHU#$%RJN51EEY
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M4NTD)BQKXPN^ OTU>HKW;\\:-6DN"QRB;+GE;,M_"RJI[H"WZJ$.8B&O9]G
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M<._+;8HUH*=9B87*TX(0,B';HFL]M6%;Y$T:S'6S;.F95R<C*KXY57 ?QU7
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M<:32M:+#E\)OT20Q(N0.'!7N3HI[O)YMJ8JI=G>* >.?FZETW%%'%EX-,TC
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M>.CH>"SD1.0L_Z\?R'< "QE&$ZX #H8"@,6"@<."@70"I-!U(L#\\0#_^L#
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M9F+7>U7/M0<<*","!GM?%D M$+!.>H?/CGE_"P&FRLQ#RR2NWG+KW*AJ,T.
MS+B/$* M_=%<X#\*%2=G14I<P>7^218:;R_"O7<,)P2.MR& >D-1\AAV0U/@
MD]>4($D\>AEJYXQ+SD-Q*@^$00CP5\,7F?*^0!ALZ>KDIQY;(C1"9PWX1$8#
MI-&_4!JWNEA_"IHL9<=\0]P]\[8O2C,2 HPE,?!@$<3$5;$+_!W-/L4<J(W]
MR6:_-AEJM\ %BSGI]3D$*-6<Q+87KR!F>F!@PH, (WT%WLO#X%K2DXIF P@@
M0IT) ;P%[B8'E9>^KJZ[Y-45>GOBIN<CG4V985=+++;3;HP.((S(QX8V,7K_
MY31*ETSH8594YG=>F;B9^2&\#53O:$>9=_!EI=HSQ3 SQ*2D=OZNH[@H9TRD
M_S2N^._K=E#*2N8M7^USRF3S>N]",=/C7Q_+FOY>KH^DW8IQ4/8OG?PMD)GA
MM%OK(P_"TN(+&GS^20.%*BT>N<31URM-JJ<A*UQBO<.D_=! (+ZLK/U[R\A+
M%O)&&RRYO<%:9 0E@,I4N(8OLF/Y/F\D;B7]'5/+04,&[1\Q!D;2[P$8]2?U
MM@J@,_K\4T8JLI!6LRDGJ_$Q5DL5\U](A1KTAP=)V(K.<]=IE=.7)6,6+Z8)
M/&N*KH4E^<5TCAPWTJ4NFTJ=P9N1+]_D&T5%39<ZW/$GV&29V:JJ%SQY>IO2
M!'+FWRIW+GF)!_(@X;-4W#I\8:AV?CSYJ8.Q5[L)Q"' W62RACK@ JMROGY$
M6+YBH0P!P*)L$* ,"MK,FKE&A#+F?OE\^*_5'!NVP.0W$:>8[R:WZAHF#$+4
MPH25YUA*OJXC$4WI_)8@RH5.E?U)@QVY2D.C:L30$H\7-3'21<::\?QR N&?
MV@H=6.0]]=>@'.V8OJJ<=G3Y,Q_Y/:MJ\N%H]Q/'-/R?A.Y_J)<#-V[$ZY:B
MO'2TT?:#\/L->!]LPXM2SD]D23_UQ]D?6:[VS8Q PCO#D1VVW6;03)]%H43Y
MPGA0X*\X [FO&-WW8C@_3 -)V5F1*H:C/\WY9U/5N]-"R8K//ZO;<+7LE8+3
M1MMLQZV7-;_6S!#K?NCG5%C/7])^VPY_E<:%O1&[S#9*MX,O!LR,0HQ4-S$P
MIO")B^G51Y@<WP8=DBA6?&C*K/<%B9-="8S%!O#W!D^&?XOCEOUKEN4%];S)
M/T ?D/X[]JGZQ'X3L9;^U'5O^/W$)4[:F.KF:S]XS01A<3*3@JP&&__T,X6+
MY;M- 7 8FPHB-1UKE<@[4ESOC;Q]4E4(<*$^_4(KORO]]E5CSY3 (VYMU[2G
M@*\[,FU6: 4*;98/BLC(V(C[1R2Y=6OR$R@$%;S3F2J]"3=59[.=[\H69UR<
M_"R/CQ:@_&S@.MY%W_Z#Q8M.]]K6<I+$NGV*% WXNCA7. ;65(>QN,[&TM9J
M-PO&JMYBG-2/'*?^#6(8?$7R,]OAQ%GI7T'Y&EJM,;IW)H&E.6$V=Z*#=YGW
M(B;? H+;'^ET#A@Y!$)CS'2,%'0/\+YW)N"'U_'[3/))RYV 0<01BYN#!RQS
M\SF,^M&!XO./4T/8) _RH) #S$[.RU.BM5&[^+FW48N'W_%[=-S58\R:YJOO
M!PBP[YQKRV0R6R.,B.-#: -&F=F,A,A!VU2G<JXZ,B_4T3<:/7,3CFKB IXN
MKAR&$2M)_J":D@UB]_"D["PN6&"(0'YVXH-[&^_[L#-.-;(Y;@1J8U5;?M+<
M:Y,I# &8'(W@/>U?U2AF3([-R[+:+RW1G"[YH@^%SFEU7]Z_%W7NH0R/[N7!
MH$\]):J27;.2EY1\;9V#Q-]#VE]S68Z5$Y(MDK^@^>%.6U5;\S6)&!7)5QK3
M;J["6M1R5(OIB,*%!1VS:Y;5,L8U'XF2Q?XZU^$65,& M8GDW;OX9E9C7J$R
M4<1<WK$Y]>]GC4E4MZ:L->X8"9G9YNY>;:4=.8NFB4]G%RM#<4%1EA6Q_ IM
M7/RW!0I=RLYIM('@CO<2CCN9]ZP:X4B)+&^Z@L&4CZ\<[]O03=63KDJ_#6YN
M5!J56AGZZXKQO:US@YL+?";O,GJ87]!(G:YGD7^3:"7<S]/'=ACVU%YPL;G<
MN@>.?X)'P\(+?<(F=_R0L9R!.IBJKO)6;W((I>+XLN2>V)S6T<I];D-BFCM:
M.#Q[<X&H<CA?W2BPV,9B-4)'QBEZV/6DQA S'IXJ-9FA>YT>-+5_T;9G/)LE
M[6U%E&ZW)6J3J9>\PT_6!(HHGVP]T,-"R@K *S-\ADP6+4X6.3FE8^Z.&:),
MV*+LT80N2:FZY:KW+.=F9V9(*.^ZP:$Q.4GF@SUA4,*AU1&)6ZE!M#Z"OBM-
M='8E^PX' >]<8-D5* VOJFK,2!RK$ 6$I6=?&NWR/'E;HY-;)K$Z6S+/K.?
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M[<M7Q""PK):G9BOV+\6A"X>:.09Q&-RT #7M[2\KK7H_!'-X7RYM0P#Q/JT
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M/VMCPW>'-7EHC&U1"@'D*?XQUHPB0DB1C)X#V6KATV*DA?F_[+S(5:K8.<5
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M#N5D:@FO8W73.F)K-:IY:FJ9NJ@LOR/0V?F@OY> HUKQF**Z)GSVTO<\[CJ
M3=SE*CCWW%D,YC5AW*%L7"')W' "I;9:-JU]FGZD+!S<>0'-Q+H?3L+WF4Y
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M^-X4!"O(B<;#>260V5N<H'[T4_/ T0&G\U,/77C"%64]7Q>@EE4@6O E5:B
M#/3EI#Q]L0^\[WQ'XE7KY</)]-S,H:.X6J,+NT(:W^W3ND_3EZ,-M"N\BY)B
M=*[C?)"&[6@(%K+K3#A,1R3K!-'#8J5VKES.T\Z#T\[@P1]T&<^UL#K9"4G"
M6?'%TE_6(I-'+B&OACCW$ 3('=!)19JMU04/L(408)3TP!8DU4^ 53\G3ID<
M2XC-OB0)Y2ZXYKUSG^;:?FM+<__A@N[<S/+68$X229 O_LSS=,="ZBNVW(]G
MHL_@(Q!Q!%=0/ 'L/@/)+-><C[U[2O'7B.E0[CCS_J37\3Z1VK3; %JE,RI4
MWD4&G1^KXVB?#?'T3FI6-1*/]@:A1>QAW@XJ2]\R(H?)P_ P]D<MMDW?Y\^<
M[IC""05N4DZHI.FX:L@E[VVXV5 @O=22BIC=F^';'_D!#XM,=D&16),O-^XB
MIF1&E]BP=2<;Z!3,;F' GHR7X!O?+[: ^6$CS6)T4@F;S@<;#>"&D9:)?1?*
M<L:=1=MGS D;FJ E[JQ(EE$2I&PU[FVZD()WZXO\]CTWR9I X?'A96:9R82W
MBU$CO<-UV1<#RD<?=PC0['HW.6_A6JJKJJ=5P'<F>21Y)%MJK,;X']\C^2>F
MTC_BT5C;C'SS7B;N,6W#H6?1I@!<HV8>D'?/N.?VEG(ZVY-NPF5DP(VQ@$J:
M]*,8ZT5!K81E;HV E5,$TF)T*@Y_=]DCE>Y:PC826'2O&^Z>5;U'VJ-5/*OM
M%NPD/-#)(M8^:& Q115,)9OT$VY_5]EZ=?(2#_.K#3QM.G?AISKQ^J*/=L[&
M]J7XQ1V.&C87I4XJ-XQ)+@_($"!]K'R "D:J_W3E$DV<?7AG*HD[HAGT5H&-
M8>RI,FOL=Q>JZZU:_7$&D:J-_OV('^F<=[Y2DC3& _FO)+48?T88$SKY#.3U
M$:E(_? Q)D<^OE@?RZUNG"16RHH[Q$J+V#SQ7GDWM3:G4<3"P!R@YQ^P1R_0
ML;\Q*VD! 7A?&L*-*&Q=2US)**K//88F2:ZA?N6MD<B.N@=;(VUP%:R,'I?F
M8)QH:+9I]O;X7Y0EAFJ/'L388.(>S7,]RBHT^+^OEQZ0)>,U@L_L_BX+1U.K
M,S)'>A#FFA6CV>W#@2FR5*13,,5.>Z"R5><+^NF!2XQT"TZPWW^/3C-G.:.Q
M&+4&M^EM3-RS+S.?./\<Y[7+RR)U FPE#_KTVOD@6H/H9U7D8%QB4=62Y,JQ
M9/,=*%='Q($_^8J/!SA?L?,AQ83"3_:S^-7%XB1M*Z2^VITKI'HG]O/!-W E
M-4X]S+(()2Z!+%Q9N>!T-[';HS [<I+?Q&6'Q^%V*L;"X%5^H["@?F.CD3)"
M='0_#[NZZ>NO1 '"WS\5:912:/!RR+>DB%R%/&?FP8R/Y:1I*,;J'9W7$'<\
M#4N$D2;CD5Y/E7MUA4V[Z]*F_U%3\'^P]Y91=6W=ENC&'8+;QMW=92/!@[M#
M<'</'DB0H($$A^ >W"7!W3:V<7<([E#D7/O.^6ZKJEOOG7KMM79_K!\;EHPI
MJ\\^QNAC+B@IC(8D-$4YD@*.6XL %86K.XUL0)Y9YB4PP$:R3=/XV^I.K&^H
MO@<.$_RB0=+>1=&/D,-&M&UZ(5T=EWBY*YV10R_S04(S>AR^?O%+TMIP8TZ5
M^K.BLQ4LZ#;O/:DY79T8/W>[L/04[*&UD,<9TDO'98LX7'3"Q-#05/,**D#Z
M]UY$U03;S'B1[G&$EFI>UW"+LRAX(5=G5\;, MN])7O=*1Y]DK?3%?:L>-Y:
MTM'5(>R#SC(\KBE U>X6,RFI 7[5X$3E(B/+L[K'I9 7WB+S=^2.9QV*AG'J
MX9T%4_LGZVAG'5BIDFD^<@+>%2,Q-0)S^ D\CH7,5>";!65;XI/"7>+<=$4I
M)Q/5I])8]Z@93XAEKD/M+0B> >V?)-&3 O-?CUAPNW&QLV:J*'8"LJ&FLC<W
M ^4;'%BN\@&>9&:Q-#H,P]'BY!L@=Y?C@,^ FI7\BE31H:BH6*IW'.B5?4!/
M7-(LVGSO"<,WZTN< SREM+*,LK"D\P>+[CU\2G:&M%.'QZJZ5F=>;,/Z+.]9
M5G)@,B^K_E7;EE5ABY%OK7WWWJ4LU@%FL&B)(#A=RS*E1-G'#6UDH:Z>.F'N
MIT;0R _#+CHS7_/TV*)L])B:BX6HH1SJJ5MHZ..J$H9%WB8C.?ZC/3W<L:'"
MH1)O+3]Z<\S6&M"P$CML=]8X$6"F,5/:S,GVM'QT?&-$FJE!^*(W4)#[=K.I
M*D8W! E=TGZ4$PEHM:>[3#J1.Y6;O%8OTGT\3&OP:2*Q27HYZ@)H1==F- G:
M)":['WL&Y*0"!J<J*Z7+JZ^V#60GF229H;D_-00<4FULT[@M[A!NY+MKQJ\C
M]LTEN]#+49G@."P:4[\K ;7%(5Z3Z;VW_1*=+.U/>C^"EORS@*MVAR  1+8C
M1ERK@=> X8;I59^Z&/JI^FC@>C4U,XB\K2;R:5)!MXL@#\"N'CHK8B<ZVY7J
M7_@5NK6HC[&:][59)GZ[@(B;WH4*O-,5[A>(\'@%3O#7T'?OHU<S;S>OBSP4
M00H-4ZR6J3@:.OU#V-&9"/M2]AKXGG'&^CQMPV]E=4(&?8&O O,!EGM7S22'
MK^?+:Q< &%OM1WG1T><J/21MF96>,^I=Q"&1,]MB>)(Q\$)\'3MZ1):?+/*0
MI-+M0]10+"+VILK5LWXV6_06-4<Q1[E2GZ,P>0@@-&X4VJO Y]>!O523WY0R
M0'87.<DD&-TZ:8MLF:[,_:59J<,Y1W.?](H((?Z/&$Z]V56S<)=%&<QL",.#
MVB:#<<[B.Q52 "ZYZ9.3BG=IY;0*YI"^T65"3L3.C0ZZ,QX[Q>FWX%13H'VX
M,-G7T#BWT!_\PJ08E"5[D B\GH NO^[JP"&*QZOKHMJ!@AJ[+MHL3]@&-,HU
MG$W2!R+ \K=BB)&BFQNWD\.6=&2^;MJVP*$VT&S?=NM?A>A_#NS_A9Q-#ZW]
M\0("_RD,\D]:!4WPS=Q?M?HP1MQ)R+*1NXNXIG&V<9.3;#<7C9ES@2[$+V_X
MNWJQ!P[M?<(3EG*7G3&@SRYA$-TN/304_+<V-E/3IZ4.4"ZRI-V[G1TP;^R=
M&:+ZW7$^47DI:F'FQK2)*RB)##(C7D7=2_4,4%2-"S!'!NBX#UGG8W/63J$G
MO.F9\^>:^M5C4) 7P8CP:1I\82$ G_$?U( "*A@6&@.62(\>.O9*@Z/^0)>F
M3F"4PI[M\<P5)*\*G]W&]NW%?U DW[DPU:)K"IGW4N9V@1EO@4JMX-&7?@9H
M620N47B296<#%E8ZECLTR2X& 1C[BDCY"[<A<L-?.&'BINH/_1'$;Y#1RRT+
MKQ.$C<Y>]X,X&<'J4H).X:_C UNC$;,1_A,MRPLW_O DSQ<J^F7ECL$ZMQMT
MIMI*>-'^PD04I SJC;)*H83_4@; %/N7PHYO?H\K<;_' 5ZI"39 8I%VS3./
M6DBPA33JXLD@M3^*=U8Z$$ML4B%K:>AZ37P7X9)G8C"GCLFA*TS&XNX7*!Z4
MH==K)R7$!#S+':%[P6V8[;>+*S8-!PZXY<-JHS54W57 I!\[P>-F N4*A4AV
M3*2#-@.PJEAF$:\R\S50ITF,U$SU=6Z377$P;/5X$YAT>@;UD]X)&Z(-JZ%:
MO _=]24;PGG4D^,>R@-O&(ZORC@CF,X77W'<^BZMT]]J<:O>(H/==3'CP9S?
M?\":8^K.1J5.S$<F7+- -EB.*9O#+,*Z&!X9A>QXZE/7Q39OQUJCW<LD"\?6
M;O7V9Y0YIPH_SP^&CF,OHO?5&>HO*1WA+,SGR791; :L[$ B12=56J>_+LDN
MC]A^>BL1(@= SYO1'#F<C7'@?HA^O+VGOWH&$.F6.V5P,5&O'(;&/M4Q$R6U
M-6(J8]:#CAA^E&/5EZHJ:4_L1GEJJ>KH?_Q&>MA72E2CPG*4R[KFA@=:P94^
M,*K_]!"E?#%4OV;Z?B=+S1?J1"%9S>+\)XH_BM8A>HYW)#\<TC/ N_+F;?FT
MHN#TD4-L^MHQM1GUL"">:&97D$B8?C[+8-A1T<M4B/P=4R52P4=;U%3H?]OT
M-I&RU2YDL(O\4CA6B='.N"[@^LA(>T74^$M6RX+ R9NLK71@$$>"\AN,EQ=2
M0Q=7,UA/Z&.NMP&WPV"<$G^A F77J_@!""()5Z@<#.W$%N.MV?'G33-(DAK]
M,:F*DGFG@+"YG\HQ2O*U2?\>U4ACO3845P]CR*GIEQ-4LM3/W=6R"7@"!JLP
M/91<]6O?*P!0'6VRI4*+.C]BK^4;5?@'1JCCF=A90K2WMU.VJ)-/4!.X'(D5
M8,*%-= 3NPI;\0 ^$]FRP[=4IR?2WZI]>16 +C4\PRP=PP#LEAB&"GTW_@LM
M%=_+0B=]/Y,*LRB4Q. PA <NU84(>0E:C_CS(?I.T:Q\#7>NXDIUB4CZ(M[?
M7</_UZ(B[;_2CH9?;%F[?]3U]'OCOX":^F]0B]U,>O$X5XUO;DZ5'S\X@A*T
MC;75U_^(!52*;/).PF5TRTM+-D')70 O3W2;609]&C#[C?CBNWJKB]4.@OL1
MRHW3E$-\6G?@"M10[;NSF*/])Q8*1>NX9TX-NK:4B?K;WWM=DGX&?-%FL(.1
MWW*%8LRO:@Q.QPA@# \N*LBQ8F+FE)@8E.QC6T;M%" +?[!JYU*:*E_73\O8
M'Q/FQ,&2[UDPA0I'VA7H6U.:CD/$T_E*L[V:?/(TOXM1<DWULKJ'STK53CD=
M>U"Q<9[XH'[]N=5@3CKWZ'U1CNC$<DS-@%I*@4Q,[\KNZZ8;@M&P5_T,L%Z6
M;43#V>NV+LQY$.'T?65[G%*XL#=3P/2.,]ER)3@QF0[VNM<W%=#R@M?0G.%J
M95 (12+[ N5KF824R3SFB2<A@C-T$8Z7I3;ETHFP"<617I_)"0>+Z#G%@>FG
M*S/YH1*ZB*GZ"]]HU"PB=+YQ..2=@MWWCOVM7Z"UO0J]#NVS5LCZ1*HQHXKR
M<$E4T+ W G7Z!=4B49I\VW18.+Z,FO"\S[W>,V!,^JHB#--,ZK5*42YR"3O@
M C>R.9T(%%X(9I4D,$U0^\&1:6&Z&+P<A#=YKXVG I7+0*JW\<CB+YJ4"LFL
MLUN+*BZOK8W164_YYL;^&0&N*@F&9<Q4S::=LJF5]\"T<$SDZSS*H 8@#XLP
M%%H2*F:YS7=#7NC&O1)M)-"EL<N^>O >7@F&@S\;=I(Z4379+^W C*2G=@2:
MB0$J0'- Q7=S!VWO9J9&NJ*_3T R/C1F[JDN-L?V@UHX7[T!I.+"ZRW2,F(O
M<D*>2>;[,Y%2VW_)BC 6%%S'[]74A3 MA3U"&M[LM%GMS?H>YO1,IU-\9ENF
MY<AT"^&S:A#VR$9K'CQ%6.BHX3)U9ME"YY.5=NYX:E4C_F2P+T<V_TW'TSQN
MX?/EJ'X(XD:T6ZJB:N5H!CW[P@93?U)'*V@^&WI0Q) '\ZH8-7G!X'@P>.A=
MKC5A/\FY[A%M&\GVM^TS3"><%$W&#LIW?;"9]_*DSX //$T=*L^ 3+R5Z]N.
MF]0<!SN6Y6+OV7 0JX#J>XX$<8>HD.[+/M.;<>@]&Y\B_06#?7D5RG!9'8!"
MH']5KS^"8_O7^6^AT<"+;-0CO'WB%GQOG>JRLV)JS',G ;+@U?M0/9Z4;VTY
MM91+V4-""914<01!WE>=#Z5*_YXM$OAS_F53V.,W\<?[3?P[SGP/]K=^9?]1
M'OC7 KQ_C@HQ[K^S_YV[^3=Y&J"H@I6R+JP@Y2?E)=VM7Y:M7W-O]/$/57%F
M93$FT1G:C@P>E# *&=X)OE\8)_&/&W?H(M90$LO[9%PU\PN9'SL.=/RRUN[0
M_7MT&ZKJZK8)5'4N \H"\LZL$X[Y!_K?0D%]1<=/=[7MH:&^(E9TQ/'X%OF6
M02Y_X0NG_G%=VI.OF.?.OB!9MSK6F9T<'HD8ZXR0VA8\9FPNQAHHY_)(#V>>
M2NZ;]::4NTNX%B&L"DQ1V8':%3Z3*1.71&>:#<'FJH>$7SR8=&-/C_L/4C!@
M$4.0JFNHQD-H:18$IX+A4W2.::>@/C'X="5^B+%$9N0?1JWP6,K?F)A&OW!-
M[RO;=3/64+BS]TD04.I4J+? >_&14%G7X-CM&0 M/%T2LGX& 6<W9O)'I=-[
MPO"(NDUF9*XK\IF4N-DD5W=\+3)]:<%/3[Z-F(X8VRV<<,O'D@UE_G9*_7>K
MAHP;3O<;#?==L09:<>1!XOW<KQ#)HT/!1".Q@H:3XED7##%S+X/"G'7?<9RY
M_"%F/8B[Z&\I=$'<:0R'4#&?,5L+5?58-D1PCSLG"&?NAI?83O2!(FKG''L/
MK*3G/N2X'.CO$4FWJ.)J3TC#X47*/[X1*!3@(6%V2RUH0V;&=Q9W/],?2-9\
MG]'O;7KK=HGKN]*-:?B3IKZV*8G '%?I6]U!9E,5F-LNA?7"'1O2O[#]G8Y
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M!EBLO%_.?FI1[RJTYMPBU53:8[.%B3Z!52$&,LBORPKDDLY;&1#"^@C[UO3
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M)!> _K-45T^8>#NC^XO::O^JLPBN/T[@Y?UT<[5$J?$"SW2Q3K_NYP\1L5;
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MIP<XY2?69H$Z0\%EK4A_B1D&_!+AP;P V"E0 W?L';)NX*I$X">A%7<$T#,
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M'V__OAMS87Y)H21#'"Y]MTR+JIXK8PD'76XO_D!.I+&I:18+,GJLJ+-OHF=
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MZ/6@@<,)DQ'BR6E@,N>O^@=VN;3**E?!6%8-S*_5A5GB8U.4, [$@#)I@<\
M)"[I:]<^Y]3(/-5M+3.G^."&8QRF!)WSS-M" ZDB\>PEH_SI/1\/O!@SZNJW
M3"X<NPCD9H14Z=B&CR\67OT\WH9,PK8U^<GQF 1G^XAA^KRN_N"4DN@5V*G.
MZG 5)>Y]_<G!HJ)5]H3Z?9X4.J<,M2,Y=$!*I>3?%O,J(#1#'C97+'+N<^Z\
MFSJ(![L3#[2*T]1RP.3N<\JX><^3,?5-NSPM8X,DQ4ADFQKXR*RP>W8V1(U.
M6T@;#U0,]I$0E6E$)X\HJ:B5FL3ZB&-D5P,\^C+8U-*ZQQ=%,Z@M1=X,3\H
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MZ7H55VJO>NR%G_'[5&:I_VW?2/D<:>G=1"]MSR@,)&5P?J7'?)C^"E<[LU_
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MHP"1)['-]P+=.8?5&?*/$@HP^QE^+)$L%!H^]ND.[&=U*PK .'J= F00812
M[N0E;MWR-ZKFB^/H@#?C/C6M'((IP(<3'WED<XE4'.B[?SP*)WGK4@ .HS_-
M_6GN/VDNK.F7X[95CSDP$2XQ2]7#RZS&Y05F^3?6:\SU!:I8!.LDK,M! G]A
MC+_[=BRNN_L7!HJ=+G.@:=IAX8SFK6C'_!L#+Y\:W/Z]YDMP(=7)T'X9@L>0
MR^:?D^)/<_^7S851 #YXZ5\WF,!WDO M;]@^'X^0^X9%T"-62@8+EF@;9@V^
MHE8[1Y/@<N._3?:YJ^_^(-_]' Z=,6]F.STLY)\@%A8UN8149-4&;=[<3Z4
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MI^^WE^QOK7>MO<^^]K]S9J[[QY/G2:YY9\XQQCW&F'E>?-X O%(&*@$!""\
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M*<$>5;?5QH]7-X3&:?J)><W[ ;7/@'"J(NW.NVC.8MO\?E"QJN2F$626V?+
M+TA7#$QDY[K B_ATK4X1Q78:.Y<^2S'M=,/%$^__18N>7IIXW&Q837B;Y'[V
M6EN;K=UZR#*$GEGRZN0U,%VMQ>NAGS=O.+6Q36G9N 3&4EA<6PAE 106Y6Z1
MVX$,=PVV355XNPDG1FK>'5693SJYY6#]V,;]]%#TJQQ16V^^RL/(Y?6%6>9#
MI*BM9(AWC=WB,16OZWU$9IG=W6"S=A03]0E53[/ !,8*R#BP^0;X91:'R;=M
MY>G@@-TKA-U@$738'.5DBRZ'COE2$]KP-_%3/_?(Q?/F1!E"44*T:6F4**J)
M[(?W.62A0 =Y>+%XT%RVX1E0A11X5@UPN_")UHS7L:/[.(+5P>'VBO@VCTO%
M5O213>[3=[F253#7S441E\5[R=^V7LB!#CZ'1,A;8J$.I&D\+YI?6Y:@%=N?
M#XE5%\N4(2E=/&Y*4\SZ/7VBZW->?XO7V1%PF ( \D]2-6&";HJ=][)7Y2,4
MMW3H=_487CP#E+_G?0,%%*X+AFF19+=)2Y[?"D*NHE$>YNL2=^\,!G[>:R!3
MO.XOD_C]VDW5V<HPAR&;2:XRQ(<R7G!VSBA0:'S.XM5*H:_ATOO!"5#3?RB6
MZWDUL/?9XQ417MHH+D58,\, ULUA]BZ,O>L@@4O%L[W4'>?*9!](C&9)UWY*
M0!%F<2^Y'WZN!$Z71KKN;%$;3$POBCYL+4.$PQ@9D3JQ\F1K9>)$/PZ7HBYC
M-?(F0:=\0JVQ>^89\%$?DUZEAU,W<YZ?A %/=,2[;.V74UGR;@<[(A+?FU<!
MNW[NRPVELV<,*J+()4B1#*XG> F?+I(('N8BKSL.?G=HHOK&T&WRX/"&[02Z
M]P&DOK4[%Q#.C2YLL)'T\K( *(LD<X*:W-0Q#U<HMIPCGD"P_H;Y:THYY2Y8
M,"NFF%5L80(>FI3'>Q.OK9N.R*^L21(BQ=UC/ULQ-K->4B+Y4&=6^PW]G/@=
M[25U/7$/F_\?M9@0F0-W1: ,2I?E6)GI$K]JF;$SY5M^*IQMG:1 Q>QL+WV&
MZ3AN3R1*I+8^\()@X1$$(SK9 U-+\4_TBT](7"3K@A]A)Y949WX7_\V*DG\-
M3R%/C;&?@Y:,6OO$/9UI)QS %/B&>J=O9(R=*\J,#V[O/6.[U7.BDW-)<(YA
M5X_L*O&J+<N2]GF9%-=,;92FW3[)6P1")Y=&!C(//6)$>S7\^KMQ_;-,&WE-
M<TK58GZ^-7L>IEH3+CNRQHVA5I9)@0VFB;O58^U5YS@9;A'9^J^7!?P(>X5=
MQ91>N9(:_0I*G?E \N(U&71,>:*@ZZT<_%1%GZIK0>$IR$9^(()COQN+ XPM
M"W=E^WA/6Y>AIEMSLG!&*QY_7I,+[8^Q!![!E"1^N,T6H!W=TC3FHIVDGIPW
MD'2?G&@O2.UG2>C9YU,?? W)P%XZ,P'0Q,2ENL5&* <,3WC\D6)*Y1K2]$A6
M?S29]41QO6B66JM0?:[R-F_+'+C!H>'PI$&_WB>Y;)F6?%O*=*O%CN:5#"ER
M"/ORN^5W0*KY+=&49P"DX5X7VMOULR;+FQ;&X*\2?W?LN(*S(R(H7_5;O^32
MWM>EHN>U@IN0I-0ZA0:*MKQ;\$]85^)*U<%"FI5GHOZH^JA>23JT454:I^&(
MATBJ9ZSQ"1@BQ%*LKZ\Q_/7]*;:]': P,5-3A1=!>HBY"7WXB%316OR#V"2B
MM>QY?<4WR] #<%?3T? >FD*Z:Y?&[2U58?6<PPC)IU<NPX-?W.2/&N>:K90D
MM@P+ZXDNCM7,*2_N$KTR%2ZK%4OC/'#(D5&FLZ)ER* @3VJ=:XVQDM6P(XVY
M8:#&@6X[;JB2F%@JH\=4NJT]P?RK(41?ET;,3W+7<#0(!U;]1B!Y727,/0NC
MC8-1BLN=])JP9KBFQ. %CJ4^LVU-/\'<MF?1&ZW5/L(.Y5&A]\:S:0ML\ H9
M/,[6P#/ NTX)\/6H"U<A)V=/HY@[W1>7$I,'(Z/R.!_E?)()1UV%M<6HI_.'
M9<:[M&HNRXX60TMQW)GIZ+(T,6\[[8"<,(N5586R(Y*H2P=AFF"/!6ELH/R;
MHN$Q^XE<3D^^*H'4-[Z?"%0@W.MKXR@ERAY&?#YZF@?DT,EB&W2^7H0SE5Q]
M]B49=@';9X#Y8;%YM6;72K*A]PV_7? YSTS.*.MH+7YBRZQ>TWB=@TMWX,DB
MIT;R@XH>T.2+30M]DA]LFLNH*\;VQ\V'A4'HI<;3JJ)CU7MV%BQ^W%O]Z7:2
M(H-"Q873<G1VC!XH4;\U#3'>JW=MU?<PF*3NY'3L\G[:#Y9BB\4[:>9U>">^
MZK=QS4!ZRF"RT47/OI.FPF3QX=RE_8MCP[/R=^L![9ZEO5(7Z]N[U!JO80G+
M@:FW1HL<GYX!$@P)MI<"0]R"^4&J7$S4UZOH *L@*JB]7J":]^<,BI#?P"_R
MU6&Z\NB5A K2R"_-AN#'KA=/U-Z(3[ZKK)75VU(-U%<GQ%HME"O#ZU+*@".[
M&K^9_B?J3C-X4*+PK<U+G&,M]2U_$7$9V]+&NI2.R$8W=BOG"?7^$&$[!H0D
M5Y;*]+1X+PLYKD6$4>CK+_D3)8)[K$)I'^'>SF.-;S\^V@=-84/V.+5A8AHG
M&/U19$Q 9-%2$$/Z_#>_R")2D]:[. EPFVZ-]03[2D7AS)NBO424V6F&<]&>
MP8_WB+I!?4BL[2QS'UQUVRHD1QP@KR!D(4 9TS_:12NE,UI'UU_6B^\N7%X[
MI+]*RX\H9ZX'RE+,\X\(_A?@8.*ZPWE\DV&28I76,%*FBJ7C1..UQS0'W^H2
M%BM-ELT43]%\+!!;V4W)^Q;^QWH<%J'IAW[^0^7[U!0'?(E5MH9@../ V%4^
MAHZN@\KBIX S=JGVA/XERH%G0$W5O[?5-(UE*$<Y"> IX#0HP S*PUL7S":#
M1#L2F<![UFA37!A"_TJ6@ 7*D[]/#N176\S_0&"%B1@W>\3RHK-9[V*@KE C
M+/15$7GD=47Q,T#GCX2&>?Y+V1;S"^8S8+#%\AE@_ SXD^/\4R! ]SXZW#4>
M2+)PK(\[7J^FKXJD5&0#RA <%3&F#/95,U\T# %)0=57M.M<!UT&H+WJ6BS)
MD=L6]X!64Z]XOS0'+*T#@J0[2[F%$6.RNM*#^78S3A)N]L##=VF"D)VX3]ID
MN?-E'836<\^ A&,QDA]7O1^D*=AVATB'S@Q@6(5@;LG\JG.:Q#1JCFW$+H^&
M@B2T5Y[6-$%T]9V\:,U3],WF470V^E1W!4H7+;.,JOZ*_<L,SP#98] PP6EG
M"@W%=NC=O&T8)UUX_]8FP=[6YG=WBC32[J%[O;@&]QM5JB/S6:#T?:Y4-6-"
MM,JT4P%,7H8"7)P<!S%<Z\)JLZ14$A3YN.S40W5@[W$HOO8:9=SM0X-SIU)9
MQDX49E*=EN0;077UA=CF/$S>19.WNGZ%YZ!*;4A3G'=D<:7I(W9A!1CTT8MH
M]$>P#Q#7/]EPI,*!.$"FS)?F&4!0AJ1SX\>+'PT_#+@;H E&G[U@^2W?7@]K
M$KRT./1ZZ;$D.=F6M,VQ<3,![C#K7>JOODW>E0HS8 ;D*5>7[2R?_A@U"$0K
M7O&V[D<G4FR2)] A"_M+S2"]GX>.=[3ZQ''182%(!>(H<ZSW.'&.U*M3O$%Q
MY9_.1:6GV2$;QJ8UIZC>,U*Z-;BI<-IQ$.V,4C]=20&/Y)155'YP4!U#UH6$
M:WR;C)D7_*-;KB3>I+7.%*P'QR+/4T=6US3JE=J2/ -PBEH8&ZLMGH8Z</A]
MJ'/>>'RA- @>J/GDY%/T%(2?;-)'@-"C5.,S/47J_%N*<-:'-D;]/71;7'1[
M3%VQT]\<*5W/1BY2U"8^-V2AX1WHL7E<Q9*^OQZK:FB!\J@F,]_>3UR&HVHK
M)GZ[W^!)PNZ%";>FB=80EQ9: =9O?*YY0B\H"P*I[BP<H'.-7%\RP]CL+I3[
MH.X3M?'(KKEF"?06T25E2F)-\NE-K+66.$JV&X?$-/JG5%T+9/[.G.T3V8!#
M8).5+<T\)@,/$ZD12BA(>F]!RX>73=4[<+KW%\H1HC>"QIW+O?%VAQVJAZN3
M<]68DVA%SP 3G-%B;\H^R?D[VYG?%[Z:E_YD\,<Z@26B>;Z6 O,0![*3:PS*
MH1L3N!ABHS"BH#(6G)]U3C-=/+BF_R:9E)USY/&0/#X?_N-\&U,G7GD\6K45
MMU!BO$]SBLUJIL"RK=B7][O(DR[>KHN[@7MY<:*Z9E-]+BD2@P*D\<1Z.W>I
M:DS21-Y,5Q@Z\PD[,09ZF#2^]OI-\7V+8+H]WI+#93^4D(G\YVO=?I" I5;R
MGM;RO9UHR=RH%(-1UO?=JD.!$[>32W:Z3Z5'1^45NISU@FF4*EZC&/[L#V\)
MFELL5_>9RK)T6IO#QN:*@._5S\30%ZM4+>2"^>P3+DCV+ \D6,M&KV6S);(#
MYYG#08*U['NTB1EU@/E=C4"ZV9XHLCM5$@132=3"Z2V[L@?&=<R,43?L.*G^
ME&JF9:Z<C12K=X50=GZSOWQF,0WN!P2JJT8-9&!=X6%Z6KU$?RKAS/N+<FF2
MO&I?Q^_8XG(0GP6B<SEP5HL"^5NE^!G8#8P%D?I;J$&\FH%@2<PJ\$64I6,$
M5=EZ$V-B,@*^?^Z'XLH%)1YVP5;,PSFT_LTG@?F=H252]^K56YNK0L>F0=S0
M;_=SL7Q&%56]< HSQ;XVY^PY(Y6#:PR/^I#4U(S,E&MI',$2QMJ/N!@918Z(
M+;\"^QR8K6WBP."S'(G7]TG]>=8M7EZKO6F61V!R!T/0*Z8 6H8?[X)!X$/?
MY( 6]V$Q5A'JDM?VS$UI@NKK]#\1/:NV5DQMJHWT&KDJ/VI4 A!K2\JW4FU4
M1Q(70V?)$K(Q8<DZ<XWH;"RG=$F$J0:.SA_/8>ZC4:0)V>6GHF5F[:N!!-"O
MLWS9H9/3TR2:\K;@UYV@@"FYG3'Q>JP5.N.$HHI\1).&I&? F_:FR!<7-9-H
M Q #;RH2&%K-]("D[MKG[M.=QK=BB ?@F5\U&+8Y7*_2#3,UB6NZ$89^']EW
MZI=]DV@/.*%X\!J*DW3. P$&ZG^N#=E1.7@O-P!-F-*#9$.38W3]OV"#XW'#
MS%ZB#](O,:VU.<8\Z$L_L3:K^)8]".P))/23U"#B+OPL#>YY9]%#!&7=47JE
M.%K1@[F=UQ_"\2NH?ZM_WJI-@W)GE<?]-TVP\D+5QW,L^!@/[MB-3THRI&5'
MA%1\IC$G:$8_27$3LYX&JZFCXL .4>_O^L)9S/=ESP"/F8KZX,K@6U6 ]:]_
M*]4YZ*G_4T_QWQK=>=Z6O"FK!N.TV8\;W]B> 9K'9R ";=5":T)&&S>RJ?E3
MK)R//4MO+F-2F/-W_F29\]$R2@R7G_8<TI\.I;AWY6SV^R*_?+-W5KIO>P8<
MZXWIBQT64/5S;RW,1G%NQ@HQ*,)CS-#'IU=!8T)Y3(2)T0I/T[#Y2N_[ ._*
MZM8!OL AXO(2XJF/6U<IWO+#["0J5<OF5*BG.L%DV=3#.?O'Q%)L1@/.4I_'
MLH,([L3[3M)M@V7[B]QT.(N9A?%= 4^XJ[ V @=,);+'.1)"T(BZBNPT?Z9M
M<!>]I]0CN$VIJ9X-[;<6.DMA\>1?-6;'Q*IRS7Z=>?'*Y8 GG8]=Q9WNX\O+
MY7OA8I$Q;EPZ<SUZWRV8,8Y:^ !$.RMJ[LZ_!YA+#&.MY'%5B7.(?[9?:LN9
MT<F1*UI%U_,<:G]SH0!$?@7<C+W=)CK5%6:( $:3 8H0I_/^0R.8GL6:K?N5
M#\T\X?>L@I8<YX!!XPVY[Y)S73K;D:I!EZT3J1<T$EVJQB8M?'!L!R-WJKFX
MQI6SFF7<7$Z=$_HC!S55HNZE3M87+/2T$1J![MHF]FGIV6.HG(^[&T^>($X\
MD57JQM5ZG T^"EW1LH8Z6.G\T9/U"MW>.#?/;D^(XIFA)'U"%60#3PX[M16@
M"\!$F*X]J_,4'#JJ _K>GBA3$PZ8!)VE+#8GCS7'/J225@(]9\YBW""8^VQK
MH7XZR]I$,]M,)9V-T)NE@A17/ZJ->VA/(_DO;V"=L\;;[%= !>4"B>SX2CFW
M8D?-T&/#Y@7B]K<]&*-=K2*&D%F]+S>QI6/K;ELYI,.0KNK)3&6\:;6^RM=Z
M?D<_!R'H'?$:;$2)-=^M&AS?G7ZBS@'GWX=64\'B.F9S5E<,8B]R,>*BM0_O
M_9: 2F(ESH:QJDXNF&B1TE]/Q6:O1.VM<$-=8$9A,EX5NVC4\1SA*--E52,5
M?2=;!CW>2&:7M0?Y7O<P37UKU24RR\0_X3_MGU8EG$4V@9P"WS"=>/K0+*MA
M[\VW'5?>2S^RV7+GZJ0C1/RK0:E4'=#G8C5.>-^1^=)A3=#L7_VX-'R.BL6\
M3<DY*P?-U:7:..8D\PO%<A'@X7P-AJB!K_6TB'^5Y<O/I7#._ =_P<(PJ+AO
MU-+*;WG[T=Q]*8;\:KQ5;TX"I7TYNO,/$%B<0V19VWOZ1"44=_=)G0G&(3'+
MCXB/>\XOA20D"5\6:USPC@B]GK7O$ 2KK\D56OD/82K08(I2\FN DY!;6!C1
M4;Y__=IGHCC-L$(61A6B*US'-$G_,C'T["NE[SB+JNEV4D SBPQ27 6$<\C!
MZMW:I[6)SZP6X;\4MTB%"L321,E%D:M6LB3JDV):+82:?>YU(F,)JVPD+1'1
M>ZU3P=DYHSJ$+=2EBJ"UA#I+\E2&6WB3VI@N4X9",C6*-]R[@FN75RXQ5]U%
M.0(N'-HHR*%G4U2BY.U).->T AJ/M.0@]M*XC'_J4FQ1P$UDTLEV7]7=-?M&
M7\)4I95D*P;9%-G-J<';B5I:BAY\_Q4) )3P.7Z;UZ,Y)+G;925KR4#PLCZ'
MQQ_Q4&V^J2UM9VFI>;I3['8BOYS3S)?8XW+0X!G0Z" 9Z.A<WF&2;OMS,FT<
M5>L +D>OB,&T*]:^8Y/IM&EP4EW\T61P9?OBEO!V3#MIZ^;KK0P_7[!G&W*S
M1Y<-I[2OHWC;@([$4\IL\J16\70;2 K;4<E)]4=XCSS]CTW($,6EMMTR\XVV
MF,"6E@[=%D\KXL+L?!<AT/SOCO I2EO37-$3_ G8F%14K4UA9BUSITD$F_JA
M[[6"+=\%3X*/+PB;Y $ZM8VP*5*;SK2=Y 2K$[V#_]'!X>425Z#LO$5WK(%A
M>"]Q'!6!<R4>C^4]V9FR>[@L^5ZNZDO V:BQY;D*_-U]&.@,;PLYBEDI+-E$
M3@PN?KEK)>OPWZ&E)FGOH0 (S:01%(*-)U'>IM_K."XH05#Y:N5HI'SBYCA@
MU3': MR>KU*!6UEM_?S&?;=AIX8<;S78BUU)<AE<.Y2>N/T2?"PVZ5WI(@=M
MHT*3DYOT47(;$:8/;W^"O3375GCMBL?1",$-C6+V55<9U?M1%CXCF*Q(5&HX
MA$7_7BW4\U^<T8P;#+]DB!G$%ND6@0M&5\@'4C4X!=K;<6G2VBT%='_$DSF3
M)K:><^)<EV_--%]<<=NO& #3SSE9M27ATKP4,H_:;,&,\9NGG3QU;DKTA3@1
MIYBL%M4Z6@.HRRO3@DB_M+1!#U*_4Z@0IW?L]J,R^,=,HF@)LM/O6^QQKSX#
MJNX^GTBX<,(63F2M+GCS^,4M6EO%F7UJC=_\C-UBBE&<_L X='7R:T$%?EAO
M?+"UO(3O84TB/V6$1*&!],VPWGY>,(6O$?B.ASH=<;W$2:O/*6RH/49V *%A
M=H&W_( LO/C]_#SY6ZZ C$7WT)RR%D&,7^!?2X75GX8O^,69-%OQ>+!/\U(!
M7G0WLT4BN7SPF)PU_ND,6&I*DA+9:B^(-YV\'7V/4UPPF'3&$H+7 W]**6A(
M*DX9J+95W3R1Q>$[VA*,U6+":S63^]T=PW(@T@?P&H$;"'88<ZX"&44XR O@
MFH-)_?7 KXGA<HA?/TE%J+7.=SZ,..C$";1A[<AN<(2:D:*4$2X>>'&6V6L:
MM9^8)^E[G;2=P !3_\C&*\'ZAV6&3=]B%S<05N<]E*I-RU-WH4LD5DQ\X!3G
M&ENV-"_E'ZN5$&7Z6<:6((S8P[/C/[EPO0MYVJP5RG+E^B^WO< &A8I1+KJA
M> G^ W"*Y5PBZ^S:FX/ZE[REL<B&LT&"8X?OG;-7C$W5L8Y<?[91/,1K@H:*
MC)!7=U<?FK#1N<8^@M7 Y^\BT\D2DF^%0H;HO2E?RGGB+#;:A[H+=.(?J8+E
MD32X%A-U_-%'9I4Z9LT:WK67^?]1'W1S/YJ9"L&<7>O1>^]JU;GZ&?M%Q@R+
M 0#  2N8O*-MBM J8:A0:=.NF%2/1#"B%-3=HFUD+%M-1YT:#S'J#4-*#F'G
MF, X,BIZ^+5S(^CJ/$8RI[FG90,KI.DIU_S!FK32Q],;B:4B;^ONP%R0Q93)
MAC??HDYZY0RF)VKL9*@5[M#K(@SX,;$X4!HN?.-<X@'Q+">(;Y?ES>MOK.;8
MJ/\H_^*EZ5/Q?;+VE-)0%WJL2-_W<DUY0L:P_]B=TM&%S64P6"@N1;NZ L%K
M!#/X^O10<R[@O!ZE;IB2/,%[W[\^,JC:Z&@4&BY*/U\*0 @1*80B)4D#*)%9
M:*C^+"0IRA(=BAN+WG&B-DO/^^SI*?G>)",*S,V".6<BF<LHM+U&\PQ"PI8*
MNYN6'24F+0T>2K\%H7,E<\^=03<<MD!YLZT9L2)!P3U3$4BH83KJY%NFCR>>
MHEILOQRA'[8Q4S*V/,F<#K[4Q4%N([_AR.D=9_^LBGADH_A)PO/;H:BZ\+3&
M32>> _;'>Y6'_%NAY^_Q@AV>\>/$JC5C2V3!G6R_Z%S[L5(GK6<3J&D1;;?>
M%^Z^4.*RMCS@;\_9V+9$=R)2%>V"=:>OXB[Q>V:XI@J#A8*E^X]EQFX9B9Q,
MVVOIZ-D8XTY^TKR?R^'7-U%6VGH0N+GXUN+VME4\!CK<];/YG+^DM[[49*M9
M!,!O*?Y$*!7^HPG5NK-]%C/7:O=%%/II3XQ[' MBT/\LG6N;XE^1DU)A^/LR
M)@G%*-&\2Y+HM90*<YX7*M@\#_1F&/+E8.65$P#G1PE1B4JPO,#YI7+U#.#3
M76%]H\>V\8+:18/5J,\KL1MDY+N5Y?;Q?3?F'2F2>UPJ:+LG&JOI^Y*QT!6$
MP!3T </]MAV6\$O3F7.NIF;=J%NGJ@;J969)[D<&\/?Y/&$AH+? %TJ:I K%
M24/X.B%@[%,HV/F>-EP.;,W*.,(]U),D?;M5HHXEFZ@8[C6:0&+P$6-V7X20
M]&>5*EU%9_J/]Z-YMMU?+8KQ<[L.$.#;Y$11JW*BYBT6 +0$WFYZ6-)*+[<O
MW @T8,U75/5!:P.1G)6">CS395/13#I\(R$F3*@7'E)&0^$)=SUP0"[FMFQS
M7;?LX$(F$=:\UT"Z]:LB\D8F)1Q!!3FCF.O@]PFY*>J>[!L@.MHO!4E#LLGJ
MX'9YRV[%4=Z,'1_M%O-1W'*+8&,-/[]EUM"WY\I9[Z49B'P[CTE>^)F/0?TS
MQ7"E>W3>&Y<+\4T'X%(G%PX"V13#LOGX^ABX\5-\=DBL!6'B7#4$ZH$"A31$
M !T<3IG#LT-0LQZ:-><(O(%TYQ+;7^-E^Y_@R>\Y0CPKL #EO@[YT.0VJ]Q<
MAU:W%X90-R,H2'#76"<.S\KX(_[E"00YZ1:T9?99#?5/E2,PO\3:('XZE.+Z
MJ^**H\1>6%BM6F);R9?*\)UO*D/3IW2T>22CK 4R^YH"IQ]^Z-><Z^S,9=L>
M:[(2H@X^8'[/')4X9403GV%3^UNJ9 E+HBAI62B1P?'4.+?)_EMJ!\F0SCZT
MW3]]O*L,X+7*_@SH&)-[[-B'V#L(E)6Q0R=5,!2?=AOE#CZ4_>,$%CBZSS&V
M#2RQ%O/>/CC@:\WNA<4S(-=^=H9;T_Q+0W.($XEH=;IG+.EJ2"6?4E6LN.!3
M >,ESEI\FOB]+E#U>'+857G*J,$&RE(5E_^_,,:_-5#B!%8;YVCCSZWU69'.
M9'QU>2GXZ^U*Q!Y9ZK*_%Z@KUD>\*Y4IX]/Q">5_\!JJ'GAH1+M-UL9>0.-L
M[E1YK1# 7;U+)*9*&SB@X7VMJ+9-'<::DA^*H$,'*6"]T&M'2,M]_UW>D8-L
M.UU5'%G]7I;=G_4HXOGO)E7C;]":_"#K,3'D8G%9+D':$.=04-FP* _QIOP6
MN*L5PYMPY$\-!NS1S3>Q9!L/08B7Y >6?A=0TSB.N^LZ_5:O=$YE2.)CC&*(
M'7Z_>QK81D,5XFZ2W]",^ +UO,-+**Z+7W.@Q/Z<O<I+@P42_H)W\$H 8>1(
M6!BR:L0/3E3#(_5V-.;XZ+1QN0!S]XG0B!AMUM7/G6?*E2:NL@KX4L->2F8=
M A4)RR:G%Y5?Y/FBG 'JKA?X0/*M_H?-,I_^S*$T1>KGLO)U>^]JCVZ20J6M
M!+-7Z]GX?9YI]9DGM!DQQ-*]?E:ZA@+^_'8WDST)\O2(-%'2:S_ OQ"D 6;8
M'T*(_BFUCS/<"NEG<"T%HK:=!K(I W88YUT^+[B1'1%%&@NV-NO>]9R,_WC0
MT6LA@QO9O=AB24+DB^=E8LS:%1GL\_""">94]]Z^$/ M=>L':B;@.-[K3C1T
MXPE>)#LJL/#V/+(@9IT#F_S-I5(MZ> *.-F;*68QVQ52PY4YP3K8"[F.JL[U
MJ'VM:D9LZN_*:VJV^L=/IDXY"U/33],U(&_3V,D-WB8I8$**D!G* 50AD\C(
M49[NGI\B6KOB@OD&E>IYWY-R^$A>S^DZ^).+V9,9^=L5^4I>TH6 JG;^_J\P
MAM,RC*G')M(E6^F/CI8UP9WL0*C]8J9"1A27.221+MZR3QY28;A<>NC\RA\Q
M^0X=IN)C+9K$8'G*&F7I0'ZJXA/J%T9:VO;F[IX4<\'O.,Q@?;V;(ND;%O/F
MH1'D3<*;NOX"72"@;.I-2>!K]%>[WGZUA5 VU?^=,_?_$>C3YWQY-V'F#E14
M:2KI[?5?N4?Z P/E78S#!]GX]1 &D0OZ)$B+;39.XP@]8G7COM?7WC)#EZ<#
MQ&[L];;.0X=%=2B)VM%9=*:Y='<9S?[,8O3_9!;_"DQNO.7 ?/L+7RS6\%VC
MW://UZ-&]LL%T W1MLLEKW$D^3^6\ZMA@BKU($4#!<6S1-6BA5^&X'!WU0FX
M[A.9/Q&4.:9O9+34V'7O(:P)JB];?A-2EW!+8YOG=\5*;VAIMR;'COG*?XJ,
M0[.2+DR7!."5C\VO-L-EJL(MRIR&^GLAUN2M&45 $>GUH:'F84M#U9:#6'J<
M(C^'-2KYM]"XSFQ;V%4E"^)'C\\#2W2-'>16WECQ*;2:C;:"5 7%IK+-FOT-
M550*Y)9\N+SBR8-?:YZ@@/ Y*R,1/3U.&GE,=2W(F.I_<[SQ_S;6^F/[_WBA
M5;M5N\(0K/__XM\O"J& YZ7_!U!+ P04    " !4B2-9\UWK!,5#  !:2
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MTE[^@]H_F?WWB 7_7S'[W\3^E=<2 !T![N_+0\ &B 'N'^GS@E#_(QA@U"6
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M+-^>N5ED[FZP?FSET:M<*?!F^8=M)J3U/!D\LU>^: !KSRXQ6#'J^9" [B2
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M_7BAPUX#'?/:*N&XY#A.%5&-;V?9^B5X]]G>+"UA&HW7[*+W4Y5&ANW2:I7
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MD2GDV?CR7G'Z\"Q6?"U:[8CKH?WA^H:P@%$&?%7P/1!XXJ;>U;!M%/C-V=N
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M1X/"T2L7D]\'%4>$8\SJYTN#C]3RD55&S)5G<I0@1=Z!V5S> >'=.;*P<.R
MT+V70,WJYXDNM71FD;OKDR+@P50$<OW?#NL9?0I'1WP*QTJ.B?:.F6>5PA.K
MYKZ*O,L:"/=JZ:SH=,END;/Y7N<9,+8Z&U[?5V;4'HY>Q]+U_4T3<_=$NK\B
MV"TZ.X$I9_2X^;UO15XX^IZ#$>M!MT0!]JX (8Q64_9C[1; *HCA6!G1>WNZ
M*0+W[E\:TI6'&S&Y[ 3Z1=8+(84G:M7*Q4]A35\Q%MS\9+AQ7PFJRHBU571"
M?<F)-"(^!J(L<!QBVQMPL9_D&(=>W445E[=2'<H#*0I%A,8:=E8N@9@9)]54
MUP;I@9:?)#E0PXO_:(,DKCQN.?B#9@B[+U$UEQ&#ZZ;:Y14B$!VSTN<)9V><
M6 NJ"V_*<X0S]Z*'C#!.M0OB+3<CHW!!Q#;$#JWR$<7MEH#.HI.K_R>IKV%'
M5ZE&J1_.+D,$+SU'T+[N\246R$),V;[2C&R?3 P4CX'R[V? S,"7I-0+;OV#
M7P0L@DH_LXV'OM[9<>;A,[3&+#?/4RXIE:KA)HH49&=1J-O54.A=Q#)3V7 P
ML8IVPWZ:/:/7ZNC_[8?M%>5]^_MJU<9[").Y]VU3DT?=/S*LEBH8.Z:F?G@Q
M=,L-'B':?PPWY@IR!6Z]M-7IZER94N]D@=L@;76R.^I\KC8*E[T]+5N+Q#K+
M=#(D'X6.:D>,,'81'\BT/&1 *Q7.2G&8'FDUF,XKA5;X(6*"CC@5>:K4I,SR
MVA )98! 8I  0%"U)),0-HX#1"3-S(V@"U'].N'  )(R+<\W/2I!IRJU(YO]
M2;VV!<D*C7UH@[?J)"KMX=AL '%9(U)*\IT\I=?BB[7=EW?R"23YNA3$WMB'
M3TLX6R$&K&//V'$9GL<HF:V&-%7*98W-[]!X0H2Q_CF64LI]^=IS'XNWL78S
MP"5V5J]O/V/;8% 40F7LE6R'.] W=0I8P(3[)$">CM/I.OGMO2M*4<L)HK;X
M\KPN?1GY_LGJ_!3#._8XG#UBH+<J(NU$[HXUT& N _QY5=ZC7R6T^Y:Y 6V.
M\DHX^80]W[9U#42S)P5/KG2XW8LVYC3/EE;WC\?.49M-^.HMY[X'>^LSY#@9
M@GS3,=,6N"/6GOXPJB!6\Y9Z02SH'_P::-#MR"R0BLQ@P>V#:+J5)7N;.;$@
M-NFAJ+,S$9'NCK/C<02O(/"L=*KWA$LZ?IK012@_FCX(^>M!YFL!?EH/,E!G
M,'AYL;L<VW^UN"GLZKS78G>VX]2Q )/GRP[U-9'T0)0@>AE;/'5\=:J.7!6R
M!N+*36)/?.-;(T)MQ\XK%(>QWHVVOBZ-[JB#N2MX[JVU#3F-'!'H?YHM[JAL
M<4>:=!7,J@WDL':5466Z#>-'DK6AK TL*!W:U!A5I'V.;H\JAFU 4F4+S*E@
MZ@>B92U5>("/ZQ01;Y[T/"^(1.S(@U^ =\#72U^GHT0>8QR\>X67EN\_ZVR+
M)[.TKI/+'3_$/?"?Y<%[,;J8UH*!YJN6'QK-O<CCI L7.!O9)9R-A)$[I\BO
M>?D/V0\PLJ5/S0[X68&_+9&?!.C+?4@F>?4??8MM+]H=38R_XN@O?4&8/D6G
MPZJYFFN@$@80RVXXSAZMT:VO@\Y'BN'K/+ZXRW])79EV>A8"CG!<UAJAF)A\
M;*BU#YQL6R0N.GD&S)M=[9/WZ&6T.UW$&(WAV /A2,E\TAY,MN;FB#%GH#^M
M.5_6$/V5= P]&ZW]J_W:/S@CO<3TSZ>J@XA:UF8@/8FLZD=L+E5#@N_6A491
M+G68R>S[9,O:K6TGX:-UI@269(QY5Y<P"*E40OG-1FJ4:.X\]&?$[QZ]K)"B
M^! 7(W)MRZNM2Y6,[5,3;Y]$0(901I'["J[\M9!?CQ/EG"'EI6;!><68GGF1
M6_4^X 4>0%J\8N?6^*'[<=76]M5:V5U.0^!.X @'/. (I-KRT:X,Z+.]M,?7
MBZ]V)[L<8!G&R.;4BM*.@MFU&87$*DUV\7S4N1K'.+O#HZ9LX6I*XRC\*-">
M.!6;B5&AHE);'<:8S"SJC5#'0+E\/OL9-19] W8U_I//)_0S*AK$!VPZ$L^(
MJ^F4A%#F'396AK)]V?[$O#0(]0&NBU=(GOO]LGDOWWRH$/.J8R<$\@Q!R#SS
MZ%:E1 $F*:-78%E. %*_49PY]X#;J\#W(N5HHJ6WK]1KMOP@I.@$"C(3S(!F
M&? (^_N*EI%XQ<470GJV=:V7^LH@CGWCI*>V7?E+8P&\]NOSN%7&)&/+Y.N5
MZ>ZZ$/%(SBIX5N=0N,2./I_Y'=(6&=TC6F65<;?=VJ(]5WCA6H^C#=07G1@2
MX?B](Y;%T^PXJPXTJGH[L\00/=M8%)\JOO57U^?_@<-&0.3JU-4H(D<G Z'N
MZ).A6_WDV@<>,I\"E!\IY.;>M@& UK1H*UYY0-TH?9^6_M(XH<FT/'9*;3%M
M&=M0$[HN1-4A]U?'! W+X?.7&?H5S>^_KNY^'@9;K:ICO7O>_T=I5J/QNM][
M92S0:J"$J9A-9,MFO0%&_8Q&2CUM_5,[>7,,N=)A,X56ZPC.=7V2M/L]^DUP
M BJ#CUMFYKZT+=W='G.<'8?D%B6P=NJJ JDXMC6< 7S8XL32)S#YT6_/,?JH
M(K91#HN$ENC,Y/OI9XC+((!;8"H3;W5F.Q$#F.?=QL/8>%B[Y5L\#1IK)\PT
MM4&GT,]U';^$P  QS]KO*T4(W:%IYD/Y_JE=&]/RH1'"A)M]K/'37,/A7H9=
MYE?4%6/*C9)4Q1JZGT5^2>H:R'6AN]QT1G;8]4NDL*.[W7A']PHR;.E+[L)"
M?-WMA<C.HPVU;]78%_0LZA8N1U[+A0H\EPI'W7*CUD#LHYW5KU?'0AW;*@LG
MDQ2KU0'CZ*3J:ODD;8,@L@C4]9O7O]RP_-V!A<-9*IN$Z]XLFJ6B!?])& <>
MDDCZ28RT1#16UT4>APJ?[X40O\:VUBVQ'CSX^&H!'WF=\R7"<.E)N&TH(\:8
MPPJQ3Z@?9'QU]T,,E_5O^7Q T[@F@![XA\BU+&/)4TZ+PZ4816'J -=(CO$J
M8+2XL]K5CM,Z6EM,+%\JJ &RLF"?V'=9;@\XZJ%()D.I2F!RZ3R[D."G/O#4
MI6<#$JQYG<;_)*1RJF02VYV!3$UQR'$6YE:RCE?7#40:*>4> TBT-;-'40]'
M7K2R)D#SI-P(4/7#J>B]"),(&5+MB%B)QE.9[P0HR$]9[YT&FNYPYH&(&59G
ME46!1JCE: N';1%807$$?_ZV#T.8F"SZZ1N=A1BG$\J8*/YURB'(1\M!RMMT
M!8'L3*WONPB@N<:=-=IE #0;KM/%HP]5D:?/A:];-/>8YY7Z;5L3^DBA:Z"7
MJXE.MT(\5ZYUUR\;KH'2/*)"V3O(S_U%NZ(C.2)3YJ386XIX:<Q'C)YWB[Q>
M2[O2 UNP.BVEVS%J5UH:_9*-H,JF$2_^!_2A?W?\SQIB&3'Y\]ZCKY]F)YSN
MD@Y[WI5:W:6!RF-*N\SW!W'F2P1?IPD-Y]*:P0/V0C_WG5\;=&M#*V,B15PQ
M3H@0.&4Y_GAWHR%$,3:RNYY;18GD.ED-,(0B+^:O6+O0'>.X -3O;$?_9,B=
MJEH]5M#U^B GO$-?SM C8URI"CRZ5 TZK95#/^[;V66HT>(F&22.I*93*-UT
MR_H0A)ZI *YMSM+DWB\3\$A %%I@=>=0T78-20#'+N#>$3G)8%!!K$;:O\:1
MV.9M(J[*!4,H7ILQJCIS%$*>)78W[!A5OM:4G4F*/L!\BR+OJ$'OM0PV[]6$
MXJL=]R56XF[SKU .E?)]OU$<LTA>[I4 YZDA]L!,?6>M_I48EPS]N\'K"N*L
M9>\PX5(FX@;X.\Q 6,59\%$\%<&:6 /M2%]Q:G>ZO7!%Q(]V19&R.'UQ[]W-
M/[[2,9&S=PT$SX7R"XV/?G%C1->S$QJJ4QG^B7.S$;N"1ZUM@>"@K.-F)"(
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M%P<ALSM$PK(*GG P8ASM/3#_)5>(G05S+-J=CGW)4?(@!6O-FX7JM#%)D_%
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MNFWQL?VM,.MYS/F"PO3;YW<F'@?V[:D/ZM:FW2BES>27>CBZLT8Z#:KO?YO
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MT'N=.K"Z,:"W<9;AU=XSZ$$**NP@!U>,34L])M. W!1D?B?+XA*PBUJT/B]
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M_!>&UP9P> -'Y$O>E#:.]I '5DU#'@'R4+2;$)"]CB>L_SHO!^R?NJ,22*6
M<SR<F""Z&YE+ 96'AU92*[3N)$8.7=1I<UNYW7GK=L][;:')*+JQF0X$P5YM
MT^G3&606=5V_>&J'U[/ WX]L<O[:V_(UWWBYUZG$O9>+=XY7&^BH)SX;O+KJ
MJHF@.=\S>RI-6H,>Y\5CC#JD(0_.2_RR+I[-=#6G+]?U/#\$U-T0V!VVY/L0
MR9D.M)L:BRYL\N='N32(-E"0<:CVC(C&O6W8-4=PJTZ'K2K25I-NOJ]I(O7#
M>3VS5JI]DGD-Y\5+6?&Q?MK/R\6CRBWI4VKU<T3Z/;:BV_E0]-MFHY7/$9^J
MWW#VA%53"A_TW?2G&0X?TZ?EL1?[!$]CL1K+&\G:T<A@]$WK#Z1=Z3)WJ_^S
M.U._,@QW T[G0M[@]5_:H!\U93&W:C*"_-GP#17'7]"DF[H\PLF+"!;("X*R
M=(:]ZRLK5'Z850*BG@,FL+9$<@QY/0S0<BVG6FXN@ S( 6MTP&F(>F[>*0+=
MM6\?I]MRJ9(ADC(\J4+@&>M ],3+M&%](TXKXRL74_2##;MY5VG0W32]<(--
M670F[Z&6#M_@>O&FET@#L@3Z^Q.IJUUEERXR\P,XRURI-,BIRR6D9*F0R-N)
M\*%Y+X8T]60[.BAQ&"K[^'BF/!<4IK]V=@F93G7:;WQO#G'=A5"CB6A JF[\
M!D)'V>=6I$6ARC,@6YYV&-2@1U-OU:SX>BKHLV,',+/3FR5:]J8YHJ,QY,/;
M0<%M4OK) U\'WJB4HK()XU: 59VY0*;+,DFYF.2 H9;$<5UJ>LC@[6J,CMYE
MS<1PQB+_3D[=(<M-#*.32D9K5Q^SC5PE^^#MA5$&U6RD2I+6S+E1M5<CMCIC
MW_GH2WZ36Q578JL^/539*.BQ)26LQ1^;<M1>GRM==3_!BKYV?>Y$[_TF=XYM
M1T62XZ<OSZ8BQ_VWVUU<?_?UK?KV8B?)2(*754G?R,7X$7^MQI&-]0XB3;,B
MVFN/4YYAOA7^*FT^0?7<8<*+RFZX.D&_Y) MA*H/GOSI.?K7A%I 2A/*L/D;
M*/;43D/QC3%-1KA_7'6">SC+(>ML%GQ++LK'HD?U&E<1O9X?"WE3Q^C;Q=!/
M'@&YT%V%!FM9%G@U+V$%DLRPL@59H2M04R/NGI>@JQD.;)H:M9<%[?!P8@^+
MF:H[B3%[[/>FXW7">6&F\ZUH&!-D;(7S/-GGP$$2WM1YPG0A%9(N5!:P3,LT
M%^5(VUTI\23?*EE&(M(<(;:Z;5Y9 "C+T;#)"D(BKRT!%_87=(TY=+D$0971
M601#?+ J? 1R1:4/JOI1P^G&]U$>ZGF&5<N(/6P%T1J ,9\#QR)=2FOGR-7[
M^(XMZ.BHL*H+>BW0\</-?>T6*86:XP%7QFYCK_>:?@,Q#[Q$P>U.6._[FEFJ
M/G&\M2*Q=]!8;3!S0196DO&.U#W2*Q^E-=>:$UYE-^ZO:ZTXI'_U^30@7IOZ
M3&LXT]_TJ-K+^$OWC9<_.CMO=+F1VZ^^1R,=CE8=2&1CK<5?)[K6[-_XA?8,
MNXF=IKR)9+W\7,B?4]43=U\30[]6(YQ[CN3FOZOQ_.1V[BUFS=MY(]O5'Q..
MWK=$A5S*<)JI>SUR?>/E-\V:KVO.^^PI0[44?G(E'CIG;8FZN%85MSYCY?/>
M8=^E3=Y(E3TG@7)AS;GU+.X:Y[6,A1%7!O(OX.;I;(,U[?Q#.&1\;X4WVO:2
MK:J[ D03$_K3YR9_69055CB[Y(]V*QF_'_?:235;5GU]ZBL]CV_!@F^X7[0
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M,U-5;$?,&*K\UE35KK=&"$9[OW23YJ7C5D#\T#/<7=\:7)U:+QOVN+8Q&_&
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M;CU'N1B1)VWY\1'W_AF3GHLQ0.$WH7,!72I*ID/D8RXPD)3^&S^&_AM7<=\
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MY[+[:?-/*O9'R_H=UDW;RCSVU3B7F+\]^+9%G4((E&KNHN?V:B3<K*W^A*]
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MVEWXUB+^1^*+;=^34R+\69ZBW)@]4WYL%?_2"]P[^> :'^#+62Z,H\NFYD'
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MI %X\!^ Z51AYFFG.%VNBR"R4KC(8E/&GE L.RN6CJ7-FHL=OM3/?20(&$P
M@7Y8L)SE]][O#JC>@ ND<)NJW*L$0%P-O;9J&YI/G^IKD[A-WD,-NDW6T;2^
M__7N5*?,0-/QJ-S+>\VM'S<7\F$?EPS"]<UJUTY@[5(W^XQ]RF=U'^/L"-[G
M,^235H?:?@FT3GZO<2"[@CC:IZ#Y:?NKS0-65J*>:@4S,2D>YAB5ET.H,*:S
M&2C_C_]<A4*?1<A_""OTAFO*33Y&&^C^[V_X_/_TB8KE\5+JA65U"#SE(FM7
M(\*&+H\/]KK%=ZK-BF+"5V0,JZ74ZN1%M-WB3>)2:B%WG_7U73"+70:N2&R]
MQ;>N\S\07[K.]TF] @1+WFK(7990+/]^Y\G/ ?^W?ML\*(=C/0+7.<#9C!VL
M%,T]':J<6$]LOB)JZ&3YPP!4^<AN'WOICA<5XK![2+43W1!7IA,2(L5FW:;-
M&LCV>LC<C)SEA;R%[H?81FW7M4)8HMH<YS8DKVFCA:E.@'2XG5(#DOMK0. U
M+*)"-%"SQD@K((U;]E TX+ V/("T;1(5T:.7Z_H9 ,TR:;W5CF!9?MF(*D"\
MD%C_O,2S]>EL<=6]>X[W1DM<VG+'@P9QYMD/O#+9_AL+^;D6&"HB^XS!,GVN
MIUSB/CQ7 XEOA5.^SU&]O!ULF>I\>',(;%V9@9Q5A#<]+S3'')HE16'6QFE_
M:E$I0U,2=U92CPA\%[WR3G/O=I8 "4[+M)N$X33U_]%O6.RJ( F5+-LE,+99
MN&+$F0[<2Q_[T&\K9[;H2#<'$,EUL/44=WVO /(;*XSTK39P]:Y'S\\@7[>P
M@.&%B@+J;]?,?P3D06 U;?8XYD?(X+GP1LNL#&_7"I+N3&]*&TPY26[;!>&C
M$T'':!KMQXHFR2W9U0>?(]7\NR4_3$F=@Z48$SF/"7X^7E29-" 8UKVY_C+/
M//'\LRX>]N! D7\DYL"@^YP3CPBNR&$K6HNRRS/%E9U6-TO.K8ONM/#'P/UD
M@"@\-FN(;69^02Y[!XH\Q24;W_KT0*/=?L."N MDOP$B\)ZW:RIF3VO"Q!24
ME-]; \O+?[^*YC[:.V\4'$W9,(6:,G]R8O-=!M'ATG01<G5HZ5$1OD;FYQB-
MW>WPEI9W8SXAH(F(<[<G!#0+=JO)+D/"Y G<GID7I HU,8\%)LUJ&&<W>7A5
M>T)T%4?R-7YSGSPH?M75,@5O>KQ-&0M=BOF^FH-(I=F2U_(4[%\\Q2'//(&V
MLFD!6QX#+"9P.;60VIY4AN8[H;<PN>WT60O;-'SH KE_^JJ&@6_XG\',Q@R1
MB@ 2*X0WA!YB1BII-;.=S0<D80YDP(DQ<[=6*:3HRTW]UK^8^HENR?G[V-N<
M'YK@VL.*>5'$]O)+O&#_!C'E;)1U'^NA@!C2P*F+^MB^T"]8"6J^[-)(OF@N
M1&':(K'T""+-$ HV1\K_E:27PT*1/ ZTJ-MPXQ\HC/SM-&RP0J$ ''5BY$9.
M^ S(F/SHS9-U1=T[IV("6T^*-68UHW_M^#7>O'4T5[:_ZN4]QQCS-JM:V?Z<
M'U*,9NH]>%NZ=1 14I=#)V;,^\!V<"R>T["EJ!)'#VR[^<O,"VFYT$)SA_C0
MG$LC:&J6@3VG[Y\V[CO721M#^KW@B1JG,T9<YBP1N'J70.D%K/GY9+,K\P-$
MQ%Z!]\QSE>*>.$>1W1P$CTZQEAVU39-3_!D3GQFN\Z<SW[\+W--SW=-)W]UA
M![$XOF^4$>[_TGD(L+H8#E>:X#HADX*<2'!S-&<Q#SC@KW#=4K\E<W<O<14S
M3J5%K0$;KWE6B5/Z9$7L4S2-MBTFB<PMX)&%&&L$U_NA8*V1]C,;6G;6>Y$S
M][T%)BV.=D#3U2N8KA$%GRU"#=: I8^BL.M/=<&7]Q3U&OED?<BKD1$#>.-@
M57/=RK@W*D]B-LB8)6].2E61PEHQM79F0@(@\YHW)90S&T5O^/N3<^4_(]HZ
MQ@DXM3/QG6Q#T8/ 3([K> K\RD49[[B#*$T+[+@UA'.M#NX4&$Y3+L^\9  #
M>:'A?(Y@W9R@PG8<)<5*&9U9T.V%8_ZS5/;W;!S,G)7<29?3>5>TP9T8;6_,
MG7]QY&REPH@V_M D+K@6T5XV!&^\(;?O@E1Z0(;VS#:G/S^S_7?!@8R) QE*
M\R7IUJQLGH,M<(V\O>V_/OZ%<A;O!2D(2QO6)K.X <,,YROM""[BLB;$53SQ
MK>+()B!J/$U6Y%>2T;$S_KS>:YAZ%Q5X0G4/R9N$Z^#>2?';Q >HJ>UB"NF-
M^%5DD^.3IBA7]J2H,7[G,>+^&\6],)\T4\/<8\2T%!4SVW9K81L& RS$E#@,
M<@6>[^7^?0,W7EQB^787KL1=5*,HELO](+=[F);LK!2T73E15S0I]_2U*:&A
MN5(YOR]);'XD& 0#)VZ,EFS^M?Y7'V;H9T#R1L7U;".&B:XH43CX\-$%UBL$
M)0<[;QH-@6)'8I'FY'H1>\EH4>7,"TU]996IU!W2S3ME.Y;'-BH4K3+L0ED8
MF[5_[8A+]A*>FU(C-1Z&%ZU5]W;2<5?? %5'=+)*%,^+>D>GS#U[!2%^HSR[
M!.&\2@.7:K.M$J?![3O%W^YT_]C\)1D@E3PV<P+W\,NU9[*5VBB8E0"P,Y2[
M.D\T7 6M!1Y7;%%?5B&.N8?]F!+RO&4]8QF=LV11#!>-BVD_'+HL*WX-.!!C
MNA5VF^4JOETYUDV52](Y6K!S=J62-^OSGGL@T^N/0<!C'ZA%D)9D4_@9.'@<
MDQQVDV1E$0([^>11*L'@P#.<43EM[N-G+&K![EM>@5229B^"'3?N$="%&5G2
M;Z7T2-(;R7U\ ID04N(N3I#Z7/F04Q-"T[*K^0SX$W9M5TP%R3T^72&PTIGJ
M:U%GQ09]<* ,5@1.""9\LF.#$_J)SI?E5%[M4GP[IMA65!J1R?82ML#3CO*.
MK\B_D><(B\!+VXHTNXRW\M;6,M"""_TZL>L=S0#]F>6EFY J'0)SU,K,[(HB
ME0]LZ8[S0C(?>&3FP0^CS7[#MFXM)1GETQ6IS53RI3#]4&7;W_TCB9/4N7./
M8)VZA2V5+X'+23[S6VSXBT-/>$]\30[2(KJW!TAL48;M$&W&>,!U!L#&2GL"
M#GQ4N:P)"';O)E@.EL,8MK*BRIHDTL88-:GODK!,6.4)6['!71E7Q?[RL=?P
M'["4LR:%?B<ATMHK< ,S^B/=4N.RL:+&\K$!DN7 I3!8N+W$O(@-"[!Q@(#.
MTQYW2W:^UWAT*YS"5>^FS;F@@Y@<%HFW:13(SPAP!&R6DWZMQ><W^[ (_D8^
MEV-IGYJWK\D-/%G,2U$]&2NX0.RMAMUZ(8\2IT]?P/S:]NM5G[Q![N2-@/@7
MN16"-]0(1<FHZFV'04Z4J,$6:_/C 'M.RID1G^W,L>*$7EZT7@1T( =6V*T#
M<3JG6G'9PV0@S&/E=J2PH8VD,WAF1.]$#EO^S)S5B$JE+!(6,!Q(%MK>[K^K
M=<EKV7O-VME<3[IB4,NA;S'BKPTEGCMT'*TGM_\ @?SK" 6@<QP<9VB<)8\.
MV+FG*-R;\>U8D\G\4S&6X49%R752O\LJ-O+7CQXJ-I7]TKK]CVLW\:0C?47F
M9][K :DPG7"KI1Q#N&"_W2DR0/5]\%QL/Y%*V$%(-3><.#% VEARHURT=5KF
M%6<R  M8F$G3)#B(>.K=15S8(/CKJ5+2<I'S^V'1Z\'=X_5DH!_VX*,?]5VO
M]I8-3<3P\EYSGRNQV5RDNDK,],VR;7;C]>(;ZVL[$F"5+]Z^UYC1!Z*2[]OE
M^N "(^YU$M&"N")7'B%4RT9&.5L,)*,Y9E?O1&%^>,B;GHJV]8%^*O.NJ-#<
M(K#TI'8,D_F]T5B_P JS]OA6N";[$F,G>@T"V&V'5N^Q^JAXPM;-R608F!FS
M=R'B%;<@OU\[K>V-NH,M1.-R7.1L2?OI-RW\5\%W5HI]H^F78@!;,@($3$U#
M:6KO$;:H,(;!VADR3$#K71,^H,V2,]Y=J T@H$<+9G?FA= T;D9SCFG6[<FN
M1I9#JL+F\O JL<?+PP3/<$I6=)6>6E3%J0>$:Y4G%N_1I543J-739@"S8RG#
MK^@8Q_+&  U_@0?@&X[5@X\KRI_$L3J#L /&+.6K0[?9JP*IUX+6/2A,4AF$
MZ^D2V@0_!V9@Y_I&DEO/AWG#YQ@']RXWY=EX@8]J(C):U(UY,]IAR]L.)L'C
M'2SNPKF:]TCU.3'3Y>*1LS4?BMSR)N_Y75NA:*TAEB3%=HV6[&C?-5P7-YXT
M+?')P]=*$@'PTK#(1O(J]RB[&?/#@Y_&N;3VXSZ.ZCW%9SSDFKD=_!(1N(1Q
M)S"BP@P>YIYCII=EBU1NZ+SB\+9PYLG>ZRY8.^AM@;!%OU&HYSM?D5[+5.9]
MXT9_->@)+>22 :'(<,HU\N^%AU.<HZP DEE3SZUA\QW0D_(1N/8!G1V##FAP
M/<2XHZWT6+))5KQ_VL'CJ-YI67'XA(,'$+5D8<X#-C^D-/R[CRG;QP(AX-$[
MCY4'';MY7C<O( )O'4>J[>]\+0"3FCOY1H(QMOBY!E"RW"\2)4RR%^@C9QW1
M:ZB99 I6%_%V#E.!5S#F1["J_?[9D7CY02E1--.LGM[  R*7.$IK]7I:',4:
M=[*G(HO/W/L,*+1S89)B/%5+=*]L1[F6YI2P^#/@]1G K546*JS?9R4#G5V-
M6JS_Q?;]/ZTD*F("ML&6\"488,,2WG ]QIU6Z<L#0A+3,P.X>511 _A.\81\
M%\OM'^.&2LV84"BMC;_[>2- ,U\-OB38K$WIHS:_,\9/J;&SQ&^,X^H3-HF#
MX[L4S$B4-7,8L-\(TI\))GKPO!#@>C+9A4@5\(I0T3]O[%(-V1*I (X5P)P4
MZ9=H*^$0#142 BXB\^;Z[$MP[5?A4%';"28]C7.U+1*^;)PGOAZQY"@!&JP0
MV]<W48$&JH,';!]W$5J7M/2[OLL-.I9CA8FOD*Z+ZLE[!)LUSE4@O><E8[NA
M./T>1;QYA_/,&_<@/#1?@PR4.WX#A>.W>KOF;3RA'2;05YR"W#B62I+<W"<Z
MG%[T5CD(FA\7/(:UQL8HJH$D"?HKS7Q.[ILN\IG[@O$152G5F7I*FR.Y*L)/
M(Z&,)NP^ZP53DM[VXSB=VAGK][S__,V0PQLN%B?\E,][298+GQPSPTU>*>RG
MZE]\OH-,/X&RR@;R;BL(S+S&5R1 OZ(1 S7$WFOLD)YY<6YI3FEZC@>IGWM8
MA.4>+D' \> HSRU!E T)"L.KD):O8@Q'62_92QBJ6M]J//]@S(+.4>E08D7+
M+++(>(< !AAAPE"8,/@<A.E:VASMMHUT,&J4-F^R..G&\'%Q7<=.WW'[-RJ6
M4,&FGT725-D.(M!</J)8CB+.'L&%U1.!QMP1#-:BGGB:9)S"@8J9UW@C\$69
MK -6E>P4^((&]RYJ%MOZ,W +KD,''PICT7Y1QXHL/&K0\.7A?#G7I\:FU824
M[.I(D/ID?;CX3JA4[RZ7O*T?(FMC!8]=I\L[7%\TR\[!5U2^8"IL6W?J:8G#
MK[W=B)%#)T5D(#-$BCDP@NLW4F-OZ8%%;DX+Z1!$#'X&[OE:QQ-H[9/812G2
M %'T%AU$A\"_OM$U$T:]6BLN@-)"RW6#P"@+PU'MU]M0RK9IMAC8NFA@XFN"
M:8"I7/S:&69FH2Q6+=?-.=\V/Z.?ILX1-9ZL,J.*&A-Z0>X,T<E33-XT1ZP0
MWBG[AX='/7HSPW0NWOT+6,+?!6J"'=U0",N/!]A 4"($_:-Q<J8XMSV7 <,W
MMY$V#U?H/2SG'2].NKE^K8IUN,PY7) @?T+ 8[FY'[.7XEXK%JS028WE(UC)
M8Y'_KP3X"KZ,:6$/ <Y,@4VE<)VP9?Y#!FL<J7=Q8?.XQWYHU1"L<H.Y[T3Z
M)R9IZYZ8!%S)YK=ZGYKJB*GEM>9R8T^+@X 7KP)[KMG);5PPU1?I_REY\IZL
M^-*]7*DNR1Y][V2,><4M.8EQH-S_</@$>X^(.OT+4B5D!*L_HE=M*;)90J6[
MK=LM*S[K->0O*^DI3O88<O\AHK.DT<?ZDP#5-4PN=1A27=#0D[/2>R>J?IP#
MW,Q9"_E.H&Z*3NFX&3BAZN%:^5\5)LU\55WDQ)!/BAWT!$/EH*N(B_W&)D0P
M;N94#?].NUS@(L>*NA(H#"V(9E&/VH!(E6M=W*'B,PI&@_]6T_ '@H"Q$#,5
M#EXED\G",6FS6)UT5B=IT:48B^\F[Y)6\#P3,D0,",B+:1';M\?PCA>(;Q0W
M/PY5<0B1-GEG<81-8G8#7#O<3HQM)@IGC%_A_XM%^_>)N0(?N=7_C#^=LUL7
MEDT^QW%F#G6#AFI10YX!H_VIUQ9=7."Z6R_Y!%/P^H7'/BCEG8+(/U"T<=UO
M?@\CKJ_>\$C4WV.</0 !_2&7QL]*]ZP\NWJJK^,[*T69VV"5Y>O'VDJ_U"P-
M>T3I?;9!+F9?)W:-XP.2]YZ,^8!4LIW$SG&0X;UVMVUX#%W,LBBQV*.;W7E[
M$CM0H;^RPNR7D(BN^%;<VW<#'+FR]7%,NK3V7"7Z);A33"%L7%=?9QY-3V&+
M]NXLI:=F>X' UY$:;]0=,R>6Q(FN4H\XTKX+<42T:H7@2&^9F,WS+QN2<54\
M9QKB;X4INN,YSGYR-4M9'C_CZE=\ZXK_JWAZ9JMB/!N*9SX/J1;?O;_G&*^+
M\U/-"'P9.E["-@8OC>@5&@/H:[?6.PSRYG3Q0OR/L95_$*D<8[]B<4AAMI?"
M',-4_8-0G($S*<)^6IHD(VP"+6S?S5).Z>@N/HZ;Y.W1[$#[VIX//D6;KQ[P
M1%&XII<94N(G+FHT?QL05X)GW*H#X@IVN/>FQ 3H_? Q&7DR*'=CY)XU9_EW
MBZ\BU?-B@X]R%/+U,R#;7]ZLU:F#[:NTV]?_8*TRWL,[>P1[CLYY_ RBSQKK
MC<5-*VP^L':/6G9G43.[!1SC8@,ZALEE*$L3!DB(MGHS^'1.WQ *'<1VO'MQ
MX8K\:_P4Q)=^AJ\H W0#9H:I7-0R,&WTD -#(HH>VFHP9VR^2-..V'96$-*E
MZ'K'G"_GRP:]ZWOD%O^-Q_\)MOZ]R!2V&*E"@<"478_-$#/&'J0!A'1:MY=2
M-\$U^ /T %.#<IJ&C\=/17-?BLN**_1^JIDV QYFU01A!J!;=B<>L-U%JS#E
M;PC6Q-K-AZ$?9'!4>CZ;KDY-5B,MKV:/UED-"8%L/*_.U;L6!+PV:XO3J=VF
MN5L8@/7V"M;SK@@TJ!^U_8*5TD/(-OR7M_ZI)?G#S8T!C$A(7[ ?TCM\Z"U\
M!;)3:\1A* QONUZ\TB*ZB9[R&3A:XCMXUT&H9)VVKY_S%ORE4C>7,#O%:<G*
MHZ3-JR\-6)EV>Z1YOO1*@=)4D[\8^HVPH(_<A <.%)_5W8+),X.XS\ /6+<
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MJ/,*TIDSJB:97-6D]@7K"[4:A]6R.MYV8E!_(*=ZI!J[<'+@R\S_]!"4/Y/
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MM)[&GE^P,UH9N,M27&31AJ^U[U_FP))M:0NS.F4*(Y(N"NQ]".=LUJ[M0U8
M64&O-*1'//=R$#B,9>-Y1?#"'6/\)M,&>()/V(%3X*PE"MC61/\EZ3-S*P;0
MN8-,PZ+!3O'W3_O#?^ )#>.[O0 *8?T>V_A%30-1TM+[(<3<Z#BIG]5MV;#/
MV8BL?1[DGP$R[X+WJ7/#?GUKA<$30=*EY'&^SL_ V>' >83T[DR-5Y/)'%)R
M=9*I7Q)B8.\-HGX4H;KF2/W[CIR12@V[@'2"_#Y=NNL=%_=>X4&>0WJC'FG9
M7O-0/)N8WGU<B#]&&F+Q_5.Q]E<Y(7OWTHT]P(NR&\1M[J'W9_Q8P9_MCON"
MUK%C^0A?U'Y5W@CSC5.="WE3L+\ >(M1FOMA'(.GG51<YPRS!U!&('[0NP-]
M.7C:K<YC%1@WFB68@/N6G(W2>:>!3-Z$TK%=IQ/;&:SG7S;Z.3=3'MFU=)]J
M";.*S#2."]8DP+6<.AOBU%P=V'BV_;*)ZT6\.2;/^C'5:]&G)Y,KC-Y^A6H8
M-:N2CF<:"%U!MY1\U"UK%INY&Z^-+\]88)7WUU6#_*GI /ETXD?[^Z^5Z8'6
MO;Z* F!0(5[BM<F29I8KP7:@C&PQW39H:QTS8F* MXUS/\IH<>=@!;D' VQV
M:0N79/V0$/M$FOJVX!R9Z9H9&R2-"A2NMI+T:K\BU#QTX.N629.+50F+Q=&7
MDXN5<.;*;'#'$B^?F:_#5L18Z[H]?KC'/0PI""^Z9_K R;R^]=->LCK^,^9L
MQR9YY"&TE'7_XH;'DENBJ/+FH(9.]X;^B/-./WD>17=5O;A"L3TFW_'JR]HK
M_I=F&CC1!@85B=RARH5<^SJ8+J/,[_.UQ+9@A]JJ'D9EFRPA:LWWRD4K^L1?
MFC(\%%FS99W"_12[/3D;!#H;H'/.:#H]@16%PO"QO*KC]-RX5K0 -=?.2953
M:[?O>@X#OIZ54X477/0)V4]!?9,-*C#T;$*9Z(NL'V0B_,VAH,4JM#C@(GQ&
MO*07_IG$4UQT$9Z[TVEZ!V36JP9]5-PA)U4<5I\F\12-2L9KKJRC;W.C.1.&
MU66-,:,Y]:%9+A8DW<C!119DS_8$9#S[-3P+=@CZO5,-2XGWR$8N=YA&>.AW
M'U$B8G$,[:^:#96/U5%;7[=NO.<49=1Z^8EPZ>[QFFWBI41/129)=W=,JJHZ
M9\!CH#RR:@#GLW\8_<3-M,GD"JEF5<LX>X*"N>WBV>';99HU=H^Z=?\PRGP3
M:9PU/U5UH>7;8:S]0S3P;814@\]77UPA&1>$//A4"I#7.FD$BY5NMQC P6&A
MK[FZPH(\H*8M4<['C>/@-#T(!Q2VX_Q=3#T6F\6<>682!![ 'UP:#G<[W@L"
M?74]PKBV<0%Q0AHG0\T]M."1U^J76*6E3JD4(7K6CYWJ;(B4NC%Z7\ *!'Y>
M@%LILW,ME=KN0"95'KY T+K7D^[X[RH"?B/B 73@LU^:Z[?^:MZ=/:$3_D&-
MSUHBWX8-3<#^6OH4?FIX9F?#8,2%=X^(A%[N EP@A *AQX0WL&V?"#K_#,D$
M72)#T<<1 \[E 94TJTIM8;7VO;=QYB&$*",B$6'.!D(EPU%WN3<8+VH'2I0;
ME<LVO(MH&=TKJ3IPO=DH\D?!2<6].^#IQ>^ZJ-5A:YJ5;LS5QX7;CK/COU%2
MS?HQAZG(WJ")#4F*FXP:VUFAAZ-KKE-Q<,5:L&FGJ4GG ?$R7/P<958FKFT%
MXZ9BC?-SQC<EH:]ZA%8&G/L#J"=]PN:,GX%UQ@FW1+T)?4N1:53/BK[$/I;Q
MU7-MP7X6]J(216C>.SG*E/_-AL<\F55W>-+!)''L_?M16.3663U'/9X^SH/#
M@YQ&DZF"O@/7R^IQ=I<Y1<P<8OX=YN$:\8P8,#Z/F=O_0.]Q$?,U8L"*7,$)
MK&1[.=U\#S;.VL^ZN=NW7?D%O7PQ/FD#>3I_.8N4X)?XCDO:T(]:E#B#.P97
M)!P"LX7ON#K'KF'MXH7V5SQLO!K'F+OP)^4-\";[IOZ@R$-@)3W&K^H6\M#-
ML:J;8[QE]U[)7-J056,'QJJ^;U' 2IXQG!D=$]8CG'<EW86T*E&'2#E<GQ$R
ME@S6TD*^8MEYQ20D@T?\<<'MM]5[39X5O^TL23%R391]&OO%ZQE5=Y*)A8FR
M%9$,(.LNTE(F<WCD)&,%Z]T?\M",N"Q=UW=Q 3+)["E^F7-<N5IX;<W0Z*G%
MQTVIO1*<+G%]JP??.I)>_ Z"?A8(SZ,M_K74<)7]*B!T\D13U5-W0!_2>/04
MY&-=X*;7[/=\R9R.4'13L,L0;9TE@3&%RR:K$Y'-<AY$WA=!>J7EY5ND_0.H
M&Y!;;42?/$.3%/QWA;13"S6,0(2B1)L\G3S57LL'</9;Q(YR_?_\J;;R6NT$
M:#"*4GEZL&XC]G/&*<K,!Z/,&21.TGA5NA382+'2)$$_AUEIB+%BS]_7G]YD
MZE7F6YX6 V[T^&%JM +0()IYFV6 O<E9DYW!.AU^DGP*@-C ZL7$C[-ZAU&S
M>[TUT -=H/>M4PN _['I*=-E*]:::*QU/$2)U8.L'M3,%I&V/6/J=27@>--E
M@'.N!-<@CV0#G_:&N?+7]4ELU6:7,#'1%9?XJ!3JM4S-$XK5&X8$$_ND#WPZ
M'/_@>O$B%P]-":*O[F9S=U7"01L:_YCPZUZ;9I^&<^8'OBZ&GQ<'-2DSMC'J
M]KL2F;:+C#5^,WJP3AO /<=M@Z\^&Z4D5IO>W%8O@(\(>M??P;6FNKR=81?8
M?=/XD/_9G[Z*.?'HVQ.&486UISMN;JAMV]+@,/CX'&U(-/;N/F]H)0PL+#$]
M&9K>&+FY\NIFRM[7%&YLTYOCR"T)Y^[LYRU+2@VUVI=6?T"\,O\4\?:Q)V"G
M6)6AF"619[379RAG;_30X//J]CBM8%1'O!M QK#F*6'[9%_U59(S-?68$*?W
M(\5F2\!]Z4M&SZUJ==Q81FTOMEA5\]4%&;CEZTM9D;6E*JFT*Y"TT[S]/#)M
M\=YPU?@B2Q&3<1INHS>KBEY;/W/;AF#=;[V<;F#6SVJ_F-&NJ]H$4F]@(FR\
M=M#7Z!:YI=Q "V7H8N;TGR3;UG9S*BZ@YNZ/ZSQE1PTM.6KU"#7WS4%%&5;1
MW._2/NT@MG/A<?:F/:R'PX%776[K5V7LR0B]K?B>OM"R_-OUW:4-9<H$>KII
MB9U@#->/@0#E4BYF=[#^OJ+1B HAPN9R%LKDB\^0=@EH<LA1(#Q'9.^SC' @
M6K!%34,N_RZTAAHZ1^ROHBT0K_(@Y!;1]""K'*AM4_R+0Y N[*%_I2CY'+7X
M;H7ZPM.)Z^+A"97[%2IM>36.G(ZWU(/\@$1/EDYA1B>NB#;G),Y<ZJNX;@+(
M1'Q1,\:50)N?:+^FVYD!1"M$M]?3@<PUFE/ITC4:((^.TJY1[\0U0.\/!\\]
MO8^GXFD+)PI>=Q82BF<*_!MH"!),)/ VFNF ZK"A%WI]PF'C_(QR*NF(O _-
M0+N"Z-B^<JV'L)[B:LX ZG]Q_)>_R08CZRP/4YPJ!'N5X9L?"U>#1<15,04B
M6N>'H(BNN=2QK+>_8#))4/R&AR=K1(,BV!*YMQR;6)4(^$!PKR@A+R+IN*5I
M$D)W<74..9Z3"(; 7 S@[V79V:ZS$^<2K%P$ D5'$/1>&Y2W-0QZ[:S'Q1!]
M:N;=5L@XV1S:2@@^MALXB8"W6];[!W9;ZU@1,>(5,+\&VJ*&T@7L-=V'3("L
MP+]7!.J(($/^(,(,.N4!='@)RO@FFX,K^A^I]=/)M\SE"2&X\P_9*>?">G@N
MN/#.G>W:2//9?&\,X"?)5BX9ICJ2=(C9DI#F9YSU!Z0DW4W!R05="VK]Q@5"
MQ<XWF+W$)YD:EH%1C6^Z"U)VKR@N\JW@@"S<,2XS?,;B#'Y:HSDY425\<\@>
MB(W:VNB.1UU9)RSA4E4)/L>81D:;Q"#//,%,V?"X[LW#M41@WT6 O.,T\E.9
MB]672<[C3*-OLG>:W!(I\L6A1\87]HD2ASY_PCAMO8;NDME]_T)G0QS]TJZ%
MIU6]4OY@?ZA^2G?QD_YP1E$H8Z"VRM B%5Z9)//MD-67KW\I:'BUQX;5\2C;
MTZR'#I];U1?2!]\91]F8B)IW?336F9\5]) .2%8R9:$M'3[=-K6V9D20[@>:
MY3%D92.U#BM/R\VV^BJ4?)UWEZ\WV,?WRW;TJ(2-X'27Q'AW0NGZI<36!L$/
M%YA&2]W?=KYY/QJTMVH_AR9I-%"5U1^0@D=N#6/M"M8YF8%GXVM&\\J?8W7]
MK'A%3]07"6!Z]VPAD)!9K3[6-%Y3)\*^Z>,:+?4\Y<:=P?MZ*U;OGN.9.WSZ
MJ.6%BF6KU.2>;(?-U4?Y33.%_GW;.Q,YI?1CU_V@UQ(Z2V$;6A#0B4MGD)RR
M4=/O!?LJQOCY2 #YM.]H21__HE](S7$*D."#)/6TA<^]F4#HW'*?:?0B,LWF
M02SWVU=ZI.LB8'0A"Z0@N3JK)JZS PLZQK,]2# R O[YN!<0VCS!N=3K)U&]
MZ]H:]9ZMIKDV0^3%A=AU93AB7N83U)R? 5,WQL%1MR,&<E[!LWZ4(5I4\*B3
M9L;H)2M4S+1YI:)NZSEO$8) YM9(H0-O4)5W^&2UO;V)=HR_MGFG+9 (RHMH
M2T2C_0%$Z@@?Y;ZOVMX)DG6_:#XO;FL1AY@->K&T+H9@Y8?4-O[:7T'6GJ:4
M3$VB*[5=K\ES%.Q)JRFV#>P2VQX6S 8OBHD]XDAB&,(PD)AH<@PM$L/E-]#_
MH*%%6Y'67[BF.^DA"("CU3:=[TVD>A";N XFO06*Z,<AM(3N(,"T!H'=A;IK
MB?79"E4.;3G^:>@M7T'0-BI@7;W7KW4R4LN;V3[-U;)4B+[EU]B/,K;W5\@1
M7W%A&M'^?;;0V]),Z@FLI"W:#,XVG8\$7!G9#XE?-#KQ%3!G3;32PHVV<JIC
M:3(/B^E%&T,?&+R(#NSR+&DXAS("S0I.=C30S/(3[:<2H]A$=J46V_\!T<*
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M]Z1 #.>BW&S'@*]\-A'PYIAQ1&<YSYV GP%'5@0XAU/*)^DD.Y[K"]T<B%
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MYSQ8/"HTSV!NE.LF(?7+S^,7#IL8BU?WG+$@WS>TJZ2SNJZICEXVD)KIO._
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M1CT"O+79M%Y]:KV:MK*RZK7'B]?6.N@MZWWAD(,).:?Y%(@ R]0C2>-,@XZ
MJ6+#3-.E9X=]S@ZCYH5 WPF\.=4T]Z%1[Y.*ZV!&.K>;9J1(X@RQ>B&OV%=V
M@QB'7($$;)'K*2O@NP"TN3J?XFU.3], N406@:M+J<H$_);+/NVUWJT\D\<+
M6JU/6S<Z?;,LI;N0^Z:I]N++>L:URZ?2/A/HTEM$$#3FV]?).IO-!1[?/JY_
M*K](#39 CAU(XUR.]-HWCSR1VAHB$7=7TT7Z1M<2^2V?RL+6QO64V3INP?,>
M&,3X3=1'E56LOIN0'ES,AS]-'CI5O)^]YQ*/7=NOE_YV\2:;KG,OTLU9Q)'A
MV>]?AG;JLB]BF?@3X8.5:@\!0YBQJ<@("&U)+GC-Z$,BG/M$R6+835EJUQG/
MN"4DPUSS*DEUSI-G-=?O:HI<IU?O<3HP5+@RE9!\=AAG!QT94\:9NWS_5?H@
M*IS,M\H37%;<<V0:\I6Q3KVR$'J@%RGRI_NL=K,*>NTUHU4U^P>)13]DA$8<
MGD9H4:9LW 0V&EVQ%-IM)W0LXS3$Y2!^!N+&WMEN7K$XM$0/3[N=L E,_M86
M?QKGGALPZYEHC$>XUUTWO=67:[-&/_E;'_:*B E"6>L8Y^(I])Q%Y3MY*\1C
M0KV3\*(-X%6F_3ON*]N@FV.<A3YL7Q/W4V#*M<$PU5)PFQ7-^LM,GAH3]8I\
M0 )4/Y47P<7/.M_L.VVJ@J=<([A+@D7%MX468;FVFXNJ2$%LRY,OER+=]TS@
MQ6+/PECH_PSD+-R_&/_C#O:QA[EAEL>[:8L6(],6OLB!BQ<[ 2\.$L\+ W)L
MSL4)8 )5]2FG+*. "X^9^O+TT&9$2S2P\A"UIAI]-(YWA@Y0M(MLF3/#MNU3
MZ5>UJP;E>Q)T@Y.,G W6<C.?1#AF/B&^/6Z78!7(.3T+4O^BO&445RH.HH#%
MD_[I,R:)F(#C"3=K]Q[,T;JGZFRE;]H\NC7KQO;*,XEKNC_)"F2N1J==0^G(
MBW()I0*4,9$ZPL)7XY<M=L,5%4L1MQ57*29:CQW2\VBQ'8DZJMTOQ#/!FB_U
M,L%_6'C\EYYF[3J-J0E<AL&3:'IV$EJQ5Y4-@P05/S)-D.#+TGJF-^S=]W$@
M^8=G4,>,M4V*7<<)UBUAAYU6*%08!2R,4>;FSM\F$<'6?&__Z4/,*T:97\-X
M3=NM1ET9$ OBEC(NK&SSV*VV>@PRN@\H:G2^W9IGFZ:>*R)D7HZT>841X5=.
MZ[0V]7XBQ*RZGJ&,6$K!+:NYD^IO#C]TAI&W@01[22\G<6P&6WV<>D(A6%X7
M$CY^)C)5YO9V@N3>M9$+>NQG&L2 YJFR[0_!J"6@=*RBB_%U\^5>-<TBXT"D
MNRK@#"9?YG'_IL*^5@.<2"I7U48^O/B$D7S_L[LVBZI>O=!-ZXER^!DPC3GU
M3?,F>M/&K&M+]M?TBX^<?<.=1JW\L;'\"N[&X\>'<B[O_I%V;$+IY&FY\;@L
M\+N,PG*ZR]S773[5/QY/\P1_R'399N<CBTX[4[MXK<SKZMB$Q6YG3U!U'#L[
M)^'6OG>[7[X."^-HO -2?>LO'WN23CV_U/+\;HZ= ;)ZL1@(S^7/3/5%N-@#
MOMGT,W=-PQN)V6RF80K:6>FZ,-]W92_VQA(-D..N/'K/Y*716DA)32!?;XF#
M?SY$"3GK*9QZG';J2!+G-?H*<F-R&VH6 6DI7G<R!/KQ%%E?ET^/<X!X+%,_
MU5_F@3VS"_"1V6_:M;&-J2_TQQ@&,G6JP+RSJ+EYJ7[Y@:P>U(S\S7'T:!'T
M>(AR;DHT)P%1+X-P 3W^J'E#;&XCCCO9P/@AJNC0K$C$NE#C@J>%WLX]ZL"O
MT;6N9"B704R#\.4BR/:;HC:E2]<U2DW-D;XS5N#-CVW$0&]'S;5G[#V.2<6O
M(_*18/1:XJW21(&./DJY-,\#$?$2\YI/M#N2L3>G,#=SM@']VSR,<LNC]'CN
MY_DMC0,1\XFE([62QUWI(&M?[PVV[V("FW2@OG5O]]&2-\?IHP.RI?LR;<^V
M_/#FTTWV0 K#5&"7U4IM/%:Q<0'R#IFQ],RR-PF7.P8/%"P.UE> 9F[/D6WG
MS@K?[.RQ2(%_7]*(A[5I7&[L[>/:?Q4_X'^07:P,Q0JQ^K2]#17[&Q28Y7A^
M"CI5E:?KE^2AP3,N/HXC/)'AMF^+<*UV*IR&!BFGG&C9]6@^)CS<S]0I#:)^
MBQT8JOJ3+P..W7E+$++KT&D0]_.PC5<O*<3>74P0V39D+3/%)2'($7QG$.4K
M#(JP:=%$*X:F?3]2\DYCH> _P.IL6Z\^UQ>Z#'(JHT=*LIWI ,-3F>3IA3^)
MO_E^<($.YHHUI[A?@^@A)^F:(@Y("@EG$L/GB/8]7%/S97^;D3\J+/S%*TWW
MM:!7))U39P)?R:+-WBN&ZS."'4_E0S2V*4F9^KU:Z=@S$6H2FJ/ ?SGHPR;F
M/(3<!)(.'_IFVVS+&KN#2IL;@ZBY-TPC<MQ,P5W\)F-?S:Z<+S4[.EGZ-;%G
M2) ?-:,A?_+NL+^VO3A%46C^,T $[DI>).C\-"H<N#MZ.%--<QT8&LU?2U6U
M#$?@\,N6>_#(0M51SN95$,82RE%Z-ITAJ-F<1B+Z5U"RH6\.A+".%5=4)FIE
M,X_L&@SD(*KM 7N;SM_GP[13(J9E!5G8(*$7Y ]?(A+=8023I^?1O?K]"1\4
M=_J?<JLUSCS?5J]ES&D$WGQ&K3FC;#UJMBV^UCPQLJ:GW[F/AHB*BI-^VN8Y
M-&KQ[,:=_?PLYR>H^8EJ\+-!"2ZQBT+V6=B#,HFQ/\)O6]/=+KDN#V_$IH9^
M\57U>,7.7KR+_$DRXZS5%Y1=WGJXH_Q#+H:HV7DH<6%FBFD0TEZIZKZJ2&YR
M;U^ T(3U[J^-#&YQ?QV&-+SSG/&\EF6'"=F5(<B[SFTV$Q@MBD.?CV<=F1ZW
M2N"]\!@BR[@[E_7JA4Y\L-G%Y/TX^@7D=Z/\]9@6VCKQG/VUX)NSJ;(TE^#A
M>Z9W-83/"(]IKA%#9R.%SN9C#UQ9BOD)\#L1SE>>H"P:\@^D7.[:6_6@7J_O
M<I=7_JJ$#J>E9PFTC=%K" ]LI>VEY\1?]Y.S.<U&:_IWA.1O_C1S^W?6 EG*
M FE*VMO;UA/*%0GHAZW!!MY=ET=Y<9)>]:7/1F'+!XA%Z>879$"2((GH3=S5
MK$\\?[]ZSW+\5X(]YTVQWCT,\$&B$TUUD\U?]R!)X&]%@O60%Y&O]A71EN_B
M#+X-?1I?#"&HSKDR!U^,E0; KM\BM%ZDC5O;R/O=9I)! ,)%SE"U/E-/UT34
MJTAB&H1@>OTE-+-<2%E1TV686VQM4.%,H@O%?7&[3F*5MLDTJ=M9SF7J#[)V
M57?.90"G$MW.0*@ZN:-\!385K2VG4?R72"HW9_MZ(VKTG*9A0L3HMA#Q AVW
M!-PIHK<!G;FP%^%(UCZ-*"1PUPCSF/?UBG@>L6K'(&I.&3G/AW'^PFMT1[L^
M4N&1L$2S.%Z2\"55A7SJ\5D%[.Y=YSY^?2HQ+'BTIG]%'X_6\1K[)H.+YW50
M0P^'"+?&%FV<VQ^FU =#0U"+.LF/SK!W19.7EPQUX<7@C HB\.R[SF]V;Q!:
MQ\T51N8AB3RGKZAPX-BKY*)+T1&-\R/3P\SK97'1JXLQ$(5*38HX96KP+6;?
M/&*2AXUS_1@/E?HZLG0?/S$I?8EM==Z=Q2_QC&O=Q8N"N\O1S1871@0=W7J#
MN)IEP7J^@QI%FEH9O\$K,F<NZO8/W1/X^[M_[,==FRZ<OL/$!'^LLVZKL5II
ML\5F%YHT8WETDR!AM6F A>C1*LL93_/.-CO=DP;AG8!+3I<GL'QX;IP3;*$,
MS2</S. 1X$!V7/4;BN,U;(T3+/)3L6N<P!/C>WXB>-K<&X0G.>6+37<L9^K;
M[?L96,,)YWO1:;8U2,M67$V,TN;:S<>%5VO/*P0&X@C?3#[^"RI.ISQW$&OG
ML4%0AMFP%65:-!O,37SG%1'^CH_/89_DC>WH#S3[<3!,AQY])-=KU[%SSY39
M!8EO@Z<MAP#Z&5F[;'"!^!/A*_GGP7H%8"&1+PB]J8 A_ZI)WU0+G7E5AP90
MBQK/#>A,2)/5Z36&0R.P>^KQFK,)Q''ISK;0$SN-5$<K).VB;WQ%;V/E+_Z6
MSB&FF.'48LD9*V-$HYRUDSM])]'M-]32+N6=':. ?@A2%><MT*(" 088[??W
ME2+(M \:<C'Y?)/5V;\04_NMW:+!#,).#T%@E]A?EZ!-E_ 2NX5"R],B[0 @
MT<O.8DC^<3E#11Z'NY,Y<S06_OF/_&\\K'6\^\,EI<6RW;?&,=M!UG?M!JX9
M+G=!ZYV] 9=7[^?T?&K)-.KQW$O<V"",[W96FCIUF8<)PV==SJ]#GDBUPD0T
M-P_(=LH\AT;F;$I'VGW*X%Q,Q=U8%;Z@XP?$RJ9NFPMGGO'K'\2YMT]+[PJ_
MAY2!+N?V"R1''\8D,*Y(!E U!$E3;QF8=>!Z%>.)'?G"+5EPF^T<I./7-M9/
M3=V:6GUGG=8S+4E'$#OS^VHFLE(4L.R]*>FX%<5BS-[X]"4VW)-"(")>#[-#
M<[=R?=CS\C:<+.6MJN)H$DFW1)6D<Z'OTNO/W.]*^[M;7\8G)<RULE]E>_@A
M*?WSE-<QN8\FOA*[UBWMZ+-M:,Y<'?H*U5>\Y*M/N78D5U[\2\>>.O6[!%G)
M-X^MW_\,)!.?BY,7I: .J?X?=6\>EE3?MHTN-*V<FM3*H<'2G,L!S3'*G,4!
M 16'4M,$!3-SSFZLM*+4-(?"4E1 !M%44-,H&QS**$7 <JHL*37U-J?F>T/W
M\S[OL_?W?N_Q[&-_>Q_?_F.1:[% 37[G=5[G[[K.B]3TTC47'Q?_,]:[MS,L
M9?X79Z$HS"2E;&ZEKALRO\GJ==D2:1V)S0OF=?-"D16I^VSJ-?J3/AF>%HJ"
MOMR KZN0/(WD<,-LQ/4F+W%+XI(S^LCN%\$BVY>EV\% 4J-[.Q<1;<-H"),/
M8P^V*8[A+=]>*^><L6FM2[9[8R>D+0$9??)3O#F8L3!76SR[%(ZSD-QS=R@Y
M!2%WE1-TZ:,,,JRH#/V]T[*5!RAZF_C-?N.KB_';>%YZ>3$('J#%'UC^#E,C
MR<]^ZW=[)%^(U_:AB<K94M$TAK0*@[6AJ^,!"Q\4P+/]URH_#&"NWT/MAZS[
M=W4&C3(/0='&KAFPI@D4&D7%X^D\< G5"&H$]U-6VWD$XQTC8\(N-GV-<3F"
MP>\,]QJ>\=]''IY!0G,,$[V/U9C89JGB=HTWUE5.!R>>JOU^\5O?:G#*.E0O
M46/2M/*-"/K,(96DQ&I/]&RC%"0+@S2Q /3#4?[/ZI^,YX7O<&F,F;0K"Q#-
M(Y@5VONV+=.!N33L' ('AI(6(!JE 0\2)<B*T4ZK;>=%EG,*'.EW\GF05\V#
M99?$V9G"<VIB\33*:N%[G\[TCFD_]RRB2\4$XUIHDI@(\>FT9 @1;3/>Z-9I
MK]5V<M2O#QD\,*1)XZK5KNN(GBBU"UK"Y+5MOO*?S)%73/@-)L<F>;'!#>-X
MR^I0P<^<PM>S0DZ^#MZPT3\9\7K/4&G/,FE-9%ZM,7CWB0P$^0(%0 1F,J)R
M6,:6<WK4-P&!C"@">;U@OA.^RE/9X_9WQ,5QNL@0($N 4P[U&8/(P1MU*WO?
M%LP_\I= L*^33R#C]37/B3ZYI!Q*X%2XMND04JW+.$F'!<JD+W;MWZMMD,SW
M+Z7(*DM J_^@TZ1PNV4[=RI.]B.UWPW$V"4J%SP%0)11Z0:M R9UB(0JWQ<C
M\Y0_X$_YET]#[E\ R]WO_A)):?@W^6R9LQ/)K:0#'^8R1%X<5L988Q3C<*/\
M]*&^T1A4Q&Y4IAGZ?Q#X5<_^]NC_>YS;JD()@ YL9DDK8GYO#O]ST_=_F0GH
MWT4J4N=9]<H95#*7:;Y-6!,[1,EB2O$3+DWK"]PDV)V5ATJ=])(<_[VKJJ\[
MK&':[X E2"XPKQI!%\: ] X8U"H'?&&>?'O//U!#NBV/F_PC%8T=(!:^/8,)
M=#$$N)NP*&9:$B=]X-6?U,9X\30O4*VNWC&2YQ=[986QLFEC-Q'O#K]H^:ZT
M  GS>);]+1&YJJBC9?=?@,GQT-!(>WY("%8[=N/RRE8Q?I=@K^U"R,2,R%U,
MO7]WFA<^&C(;R0.,2[=;HP(_?& =9]_ G'2':&X8R1!>IXX&SM_786,/1D(T
M3E!_(/(;9K4-XMY-HIPP-!Z0N()*'4JM->JQYPI%1T9TZ.([VJAY1RF "O>\
M7 =^'!O@W*(TZ%D;*O\"W/U:[.(P!8CW%I.O\H,F>;MD"8/Y/A;N_#:3/8=&
MSS4394V['E3[=886OAFN1WW\"VBT;_T68%-W*%*90#);4DXJ=AL-&171%IX\
MTD@FY7U>;U!B&_STS3BIL:M";(]?"!5=LCN\&GR-^I$"W\BY??OGK4Q]629G
M\-[S<^+.X"-;9HY:_^)\"&@KR'63;]0,3-RC#-DV1_[2VO/NP\_8OE/;UZ=E
M>4]]K9<DO!* KWS[,Z:+64):E]P\"!Q<@ >$Z2!^&2ZXS$/R#MS_)@*O7'&,
MOR_!E=KZ2ZHMKW]B?M;=W;X=G)I93[A2F/D7(&H+W?M8KOF' /2I.?WZZ<1@
M]97@"Z@%Z![4:(NXKMY'*!M)!#[MND;Q:@'%;M0^F)R'1GU)[Y/O#<L:NS:#
M7ZG+K,]GZ8QI+5%.V ;.6FLT:.)J%8-9TH[T^/2C(96H2G27K>! C&9;G_Q9
MSEXU=U-7EH<IB+16HRJ:C,XQE+_NNVIJ1$!8.NQE 3,6@!*3S,B,&8> P@_:
M'V7F;OD$61">? ^%J@UZQ\@&H6XA=I41THAX8S]?XZ(E#%!(D'IW25=;F;.F
ML\F_T J#10G;5;_E)F_P?ZZ]IG)LKV$!G0&Z%;_O[WZ)PF(N6G]GMF0A*H>[
MC S04TF-5JCHH1L-7B1YK*H(51I#'CZXRI@]RHG$@DO.]AAL&2!613-:-SQ!
MF-H)/H,#$HG'5$UW/8\U%V^[BQ1<+H#77+ $O0AQ#BI=XWRJ5/TK+RH459[*
MD+W9VL,[#MV)&FUCV\\'62-9DY"MUIOE#HH;<?4J SS,:+"U/=)!R-2X:HZK
MN_Z!2!JPL$;U$SOS,>>^.W#U0:+:%&1GNS;'8^Q9/89_=H0 :#\?JC'2$ET+
MKO#(KGWBH _Q#1&>APG#XWPHP3F/YSM]M_K@4-7J%_AM;HN\40:"GTF3O94G
M^(9X:9*OA7PZF3J#W#6029,I9MUA900J0^-K%L?9K$_+RW20R=O)@.H<<LYK
M;<;(B<_Z,HW#W_U%DI.I1SZ2S+[JP8R_L3V!?7O@,=A8X5ZH0SA31Z,X_"L-
M@@S$1%U6"P]?KDE+@AQN$#"UW1H$O=J:((UNF#%"IQM6>PIXG$=%D(>;;W)I
MH.&884]G0/,,^ZA_@\O0ZG"V?S-_ :)$>4(9=AD*T-3T1EGQ!9?D5-O1PYDT
M?6=*#8,_0UHSV2[APM*:=L,%[V$?Q'M?F2Y.!)AJXL$&ODD'%O\'+AI*UI&N
MB^1#CK>(_XW>K^_.!6X>_2A;P9T+,A=QYM*?E- W]FBR%)V2*M$7"]"+G?\H
M4/&APF9)(+J!.YDDATHR+TV2VX%!D'%L)L3L=Y:_T8V+GO:2L&*2W-]5/_]T
M/OD6Y8C?QJ5+GA0LT8_:%J,-D$30].\NA8%_:__B_YTJ(B7<DB8\=^P&1(;E
M_L.RDX(!6"?_ @QJ%9>G@U."'M3:"=_WR7N-<#;P>^Z#]UF90=;=D$ \\5P2
MRYW\1J2[>"M&P]Q44PS>:&T98@W6POKJ_- C%S036)I\WIY>5)5"Z:#F0?$=
M[J&%>C"=!OU,G !OO0,^BKA[]WE:K:AU=*PLR4S,B/_ <E,7-F).32/"P3BK
M28CZS$"R4427HW/T4%9!</)1)5_Y*P?:4<Q,^AK?!<^DA(FNV(OS>ISWS-,"
MT''D_,:ZN8JEN@.P>2#NA[ WMES/\)GUH&[2N+1-599]5W#^AKCI45I^R.@]
MSH<-"TAQV=[K'8*7323^)Z?;X^W875 HLS,1Y9$]%%O;T![X3DNXW@[6$OC.
M/J!\FMGF*M..]?=5.B\;@AW_684!Q-?<K#=F#KT>L'=4E4$V6[*,S581/A8^
MB,RG>!I_^-5UNYM_.^ERUI:X !^&=0E9X6T27=$")JOR[5/[54/%X)022(*_
M*X;_A-\&W>/Z!.8,N%</6P9[FX4BZDA802*!6A(QYEA<2GN=9@/TR=^K'(<1
M7*;$L_9NG]U7IE?["K=>OR+43$:322K?W83E+EHK=>\\!!<5>6GB"W$O5Q$F
MW[5^MTTBK?/B)_':SV"F3\VM5W'$_'E^?L^KY]9G.$W4+X^2Y;\!*]]#3YGG
M$]D1@M,/1'=+G>=!9?&\T-G\$]$(DDKQ;A/_KAK+X?TI^LQ[R*$RX'://RLL
M[WM\^E.BG_;Q%_2X.?AJ=SVJ V;=S,YVULF3F&X'C*5P[1Q$^ZYMSNP2=J_#
M]!6.P+T;3%>>S>A;#<%]F?8##TJ[F\L7TX9ILE#<G6F823<WJK;8O"=&9B$D
M0<2 )LWYW1U;\DZ+D?$_==*&:;42MG2%K]&@1,7;[C<UMQ7FVU$BG!):N-#E
M%^G 2W=,Z@A2*^6^-:I%^\T223E[%^&,\W'74PZ8J#M;2(I%B*3R\MT\P-.]
MK<RS&:_]+Z5@>E- DNJHH)WVSTF%_S"^E1J,&ICK@V*HLY0>R3)GBR>AI!*I
M)]!OZ@=E3]3XFCM4Y7)TP31]W)!+F($@]Z!ND"$[MS.DD.'&5IE ZE7A.'8F
M%E$QEW8.^]DC8K&:<CLL=%N6&=;J:2_4[O7E>YSU/+W,D"UIO?T\M;:795&O
M]NI)U,UYQ/N!1\DD%9EW[B8_P!56A. OL?VZ_ <SB KW;<4[TIX1M_Z:.32T
M=?NCL"M#^Q=IQ_J[*4#:W++WZ[<U)I?"A$,AZ .?A%;\GQ(@#S9>II="G^]G
M?62_+J.$7H9.=@*)LE[+].K;W9C)^TUG_#JWO[HGA!QS.K9_O-;DZB++[5/"
M4$VPHRT\*W=YPR3,-7(F6.;%$#G8%GB1\RP=T3HS'["+TXVY@9T,4>A_@-QH
M>&,G'6EKNDK&-J44:=^64NJU1F1XU:D3JI5DVPE1*]$H"&<:J>TM]5VEJ&;W
ME+X,)Q2CLT+#:VJ3K%Y3-,\4X60,%4Z@3@[09/10FPDE-R1(!.LSZ_TI^3/@
M%<(,#!8WAU>BD_G]B(@MH^RB;Z&<74X89VV#=HPSBFS6Z]:5RS;G'STLX EW
MF5A@=R@-" 80Z*=LD ['@^5G2"R(D?'CEQ"Y!M+B93WGO^%/BO9DVON9?]4^
M-'\M@EZ$_=8^YMM$AWDB">8'LQ2AHZ*;U.N7U"O\F/Z/?/_I_%1&&W5+YTO]
M^6$S)++N_Y]ED%682'A1UQQ$61+"R"B >>(FTN%]:&QZU!L10MIM7%[NB"'?
M0 GNY+../[L5(^OX]DMM["M;$8>_5&LDE@2$N+D%N*' ZS4XX#52;K&D$'T&
M5=L(\_CA>[""YOZ@[H@OS@?<=\0:)9X;9@&1(5K1C'/^(=8H!HL'A)T7]I11
MCG<LI6\3*&LT7Z#$#=_K#RP901:=]-V9Y)G;4![;>SHT]<2/P<JIQFB+L,AQ
MBLD]O'W-8VN>^ #XB4_J<-M@0!U*_>K\V!VZY>=@"A#&-]UZ*ZWNNQ-.=5"-
M_%(M:KP]%&Q?I-JG'<7]F.T*WI5ZH7?+: A77#UA(+[3RSLQ>P"LI/(-F_+\
M71(TXN%Q^;O?NN'F;C9UPTYER0-N*N^@$(;A$J\C<%I/]'%W)+$^DP&0HTF-
M=2RK9?M!BX3HZ,A.](M471PGWJ=IT[YQO#G[Y[K$/"-& _\N60M97D'.!F:8
M X=VYN%M;KF?;N6=&'J<?7T06_O,1JT[S.F#&Z9#S&-"=;$?O]E$KU9+?^1J
MOF^\C6OM^GGY%@>P]ADX;"9+J*D=2=M0'EM5?'@?<=S>/>'S;:D7DNC&L1W@
MX'Y.3?1V<.+FIWROV",'V=A>R+87;[Z+"Z[I<>\_?&V/)OY9(?\P\EC]J3^9
MV;F&M:LK)^?7&<-;9#%$PD.O+H-![&?B53/.VN8/Q ]SINOL1755/V,5_KA.
M!&IV/T.1L\LL)\XE(H8SO(M )O1P@C#GD!EBYWE]NN=Y<I_&6FNNUS7DWN%#
M*Y10-Z5$V&HGK6+]PML1@@NLH%"(VC12_LJU#"%Z-P\92\H84'I%6COEC.4@
MCM%7%8%B9S0QUG=7&"], @H]@'YI.1^M_@7KZ 7ZQLAIB+9Q^@5N8-Y?P-B=
MHE;[1'\3L5W?:G_M%6YPWB>MQ)"BE+&E9&VG&DN0L'N_PU325:T .Q62 ^9]
MRIMW1.!53[5.4^&?VY;,1V2].T*JF+4/R4$6;G*XQ2[> 1OR+DN@SQO=(<YE
MGX_ :[>/W2KPG:6,+I'6GM3OH3V2^ESITU9@??_8KT$727%?_CV?I8EV_;T.
M-TIKQ ]*2Y<5G25+^C=Y,J_P(C44(E)0MY=6%:T_V$Q\ @/OW,IH7:]&I@=3
MK&[HJ!2EI5%J3'QU],[#L3@'P\&W+A9!8Q.JQ)?I<!.,D1O+I3?@J(6&(-'/
M@<:R"N-HFNPP$S>NYL S#]P<;R':#WCIX,TV^7R@!.5U#[%%ZS %X903%O<>
M_>)M#U]F(7)NO1<&!I@[/ER-27_U'5E?9&!?@2E3>J9>-->(S+\VXSDQ()/_
MBDO[[FCDU$LVZY/3S2E]PCP3NK?$(%"A/'2_*S+9K_$6/BY!,'63SQB@AZSJ
MH%3K$4Q!'FPV7 ).:D<EG%4-8N3G[@F3^NO)2^+@P62UWQ-%H)_ ;7R6U<W]
M3,5\5#J-QD#\*C++&_;T#BO*]074<U H?5 9VDI0Y+LJ YT\\)$DSQ P;%2?
MAA"!$D*4+7X#W>!Q=.[?[%A-BZ/K:@)$AZ749?C.!:]<8"4.79#J*<&L8U[=
M>IR]L7KQ=]$DG2<U>S%7?DXE^:UB+T7ZP2][=TBMA_L]-*[^%BNDV I1J3D*
M,S&1U1#XTW,/'NKWJNF#+,W 3)PE&%K\?S'R^U\V=/%W&^_?AB.8W[)*TTZI
MQL((U&@>90P)/7%"+%HU6\+@MTS4Y!5U2H[_3 K^JZ-KSH=JG0Y$N7$VS\.9
M$-FZMW#373W@:@3U2%&?O)P@,U;O;?J@4])V5'?;919P-$PI^LZ,$^O48/^?
ML3<$K3P@/,2:AQ#25XQ3$"=&A#M,JC/X'J-IM.KX]"#-<U[GS+^V#5K0K%&3
M>_-1XJ1UXR0ESYII^..;@I50**R'I*R89N2RU4A=G?GG$XBFB*]BN'@2:<(>
M-3JT9QR_2T!^%MVZ=[UK>U)*P-W*;P':K&X)P^9Q/!V>I\X%'7C57D9)0IV/
M3/LF=",I"4 >W=#A/*.@RL_5S)+FZIB:(T[-NR!:.([4M:]K-,S"S266-B_O
M,O5^F_G &4L0M\J-MZ/>I>^](3-$/0MS<G_==^B5*@62]?M[G]]-AXCI+&R$
M-2+7XTWW5G&KR7&8CHNX:2IHX-74V+%SY4NOO^ .[@@9O/3Q6Q9ZL'QINGQ#
MZ],:RWT.ID)$A'QC4KLPUXT7&-Q1\C,C8-,X-L;T;=M5U20HQ/)\-'V(=J,[
M_8,I^ _S.-Q<\)#20Y>P&-D&ON6?"9VGC' -7?L9MHZOC37:,TXTU*. 'B%5
M<:M,JT/,UNN$R:78CJ];Z]+=?DPZQ,@2?_',W6\&N%9/W@L;('"/4^0?=&(?
MU%P,H !QJ1GK&Y?K _X4_JE0#7XG:KH8&)#TENLI]B.FR(ZP+^/[\S!+@\]R
M[N2KC,7GIM45HJV=W%2.P['M3 7WG"F1B-PU-3%K:M4@QH/?7(]F5]X*4.O1
MJV0O,15KY7X9 E-C\XAT$59,8Y;'WFP;Q&]/OS/C^K@L<:%O=4!"G>$',0,Z
M#FC.!=P:^U(F":11+9=^Q7,AVQ[$CV^HX*)*OKV)'Z]7;9XW&W%,'QOXX7Y3
MDEA-7YT*;^ %>?:-3C^/^W&P?3LX=G@:DL^%:#].<1)1@[I9)Y'?.G!+E2ID
M32Z 2RNC31DY:I)>BNLZ]3% @@>.;_CP+;W+C  P>ZCL\_#/KKR ))+<]X-J
MQBG9&<(]XU7'+4%WU"DMW- +L)4ZGQDYC-L<886D,B3!>?!)N[^ ]/&W@G5:
MPH]+LI+X<#JE6L3J/K4N_?TN 7=JT;;4.T:6Z=YEZ'P5G/CGU-9N,,ZN/X\-
MJF^%F3',1M>A;NDJ0S;ZL?EUR@>P !@^7HJNR1XOE;;B#M"'T59],M*!*(:+
M)#GRL*=[ 42^WV4(*L"1Y(;=7 Q28)L@:R6P H%M($JPS.IW#\OY\9("&L@<
MK5]U]FH7#47%7*)MW1#&%DW#P&:T'9?:I([4C$,C!@<[==4BM N\47DW[RU9
MZ6>"LVT+:#)6J-S"&NH^TAHK!:N!H4+2T4V$4#9[[BW#S0N!"F6;V-Y0W^IL
M!/-WSE;U<P*EDJL($#VYW^)5F;,6K!_2?136[PPY6XK5=<1OQNK:$M.%^"+I
MB!\)T8S((OJR]WJ@5DG'3J7 FP[K:A%#V>WH-9)WIA8C;S77EI,S,NF'OL.K
M;$-;R00=Q1D80P+Z#_MW[D!4QS<;3+';G=TVS%1CI64[$M*-K9$V+5MC-:6>
MB1#E87?VP#)_AK1JV-/S/Z%*3:M8UU47.#:64O>'[URHW(?T#TLJB]>U1E?2
MGY1R8X^DU-[(Z,.?EV"VI>3 029F8*S#7 :"?M3N"UWP>KP&MME/(/T-I-@+
MI/]-<KMJ!C2R<J4]7,IYOU%UHQN7X4P;Y+C][R^FR)FU#TS9V/6MPHK(J&R&
MLR4([&3MY#."V>JC"G))XD6/.*&>WV$T.1,!<?S;-_,AS?2U'PBS<R8IQPD?
MDHRT/A" A>\OGS;4+F.I;5"/;KG66J/+)VLH*)G=A27N^ZE?H]"%!J2SQ>\2
M0I96TD?;)@,#;GV459A/%R4NL>S:GE]5ZI/I2F,F@/U<F&8M'DA9E# 7,[Q8
M&XN<Y,4.MZAV) W]H+;^3,P5#HX>Z#E3W!W+>^2[6IGNOD!D8?<\,_A6?OH1
M?.9ECBI(\/+JPUL9VS[F\QF3GT\8+GXX=0K4,=W<?J.U[HR#)9LTWHZ%C5AH
M5&(C[!]T H%]BZ.MXVTT[(_6;K4C'AR%U6ITPQD/0)PT:=7U\.Y 4-%77MCE
MNHES 2 &JN3JO&^0RN6=F]:QTKMSXN^V#A(_CUH]JSU'F%F\\VR-8Q'HXV;B
MF[R1'Z-,WEV_\74W?F$X3$QG>'BY\(/M,HGO-M(G1Q&UA&3.+HVDQL.W&_#2
ME&NO#,B&4B^G1O@F$H#E=N6$R(NGA2J4\:@/XGJ;:X_UMOQ:.GHDE=:TX1[>
M86-H3(BC=33'LO577\=@:<RW.ZTWSL0-,KX$K!"H>-M>9?NT2$+FIP@U<"7N
MX?Z_ (6.0;#N%6M+T"%/;F-27<4CZ]=WPS(&RWH9\F7UZ=.GC9+:X&*\X]D_
M6>)(CQG[F;[!FZG>\:.4%*N%:%,V*)_UAUK"T&6U)W4O KO!CV(WRHU"M@P&
M4,W3&)MBY3*$)MX+:'N17.<*%X@;BW6-'ZN+AXFV-BW $T/5YX*L;\3UR=F-
M(EJVQ9I#$2U)=-/*W<1GA2,+$ W1MT=&F5,C#8,*[\1U9KNBF"=ZGD"V73X^
MOK'U*S-B\/'-S*G/+^=>90AIG.0CXZ1U1]GS>WR(S;4_()K;P:F<NE871\Q(
MPSQHRU>:[! 63'KYE1DV&+A::S _Z,OE+5^9N(''MQPQP%)[IIN5(^:^]INH
MZ;#(X^,'NU\$(^_M4+J?CK>+MS2C-FO<&<Z,L4[GJI!9>3$RW[N)66^7:[I/
M:7*AK5;ZLK9NT( H(Q1O"Z;>A&N7Y6WC(;PXZ\,ZU#=#'FZ^NKGDS_KT!K6O
M6\2-=ZA?LV-DR1?\NVR8MZ=NV=0YX!16F!O"*E# 3*4@:PZ%7'G0/J@8?SHS
M-DSTY7TB1+O6&I+'"3^NUGN0=DI<[_1'NU;?:DB=P5>U,CG1IT3DZ2F@J< 3
M<7<J_0D1(!*DQBT;_E9T),P>MU)5!EGG[X/*3?]'Q1>^JA2[*B+KI8=^5=9O
MZ[2_'1#S_1P"<<6*B)+#@JZ:EO1<FFX!Q^JF8*A2<H\['L;25<UNT.D3:AO8
MD(X*'@K,IKVB2<9R=&M_]-V^50S!IWE?IO_*J4I9/60-CI8"F_W6MZ: ;@"B
M_ ]T<G6_A'?7RJ(%$Y5T_)"!1K:TJA8%>)S80JG*&GKKK H?,3E:13!0=;S)
M?L GAPD )HQEAA: =DRZJI;1]4%(,BIB0'365P*2_[V?G:NNN]\3R%;K6],5
M KO!@VEC=WXZ<?566V>.-4;-H09'I_7"%G?L/)!^"RHY@J_:9,"9?GLQQ9A
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MNC%6,*KWM_9"/QH7G,P$>X_]VWN9"M^Y'VDKDNBK1JR,KN$<_FV5]Y9A"Q4
MR]?JP:MRG<"'NVU(JT9Y-L<Z7:$FD$UL89@[PPJ33<3K+M 6?DXU@0_S([E
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M]%85?\DWW\9F7Y3E655X-I^]VDF15HBG*WD8)/<W7UWK;#KD(96-1Y=^-];
M<*0R1>G4./_;V577DDQV2%6#EQ)4DWD@%8S^0;.W^.O^=D:RVQKPGQHY]V ;
MOV&/0^;KZ<#!U=>"-W.AD="57)1,@XWEQTFOI-T) S*IF(<"A58ZDK9ZAK?#
MPQJ60P=-G:UH(5PZICIGCE?+/3PR\*H%AF6 F# :>:TW':C&H:W]BVD@J^]^
M+=,^%$6(TBL/=?+P8G4\'[_5&TG&>  W4+=\61[_T%7^+4V%RK$E"H B/^<=
MOR5RK__2G*-&G[<C;$F'#[%!DL,,F&-%&XA'42U2D"[=CAEHGH%U#.2P:C!T
MY; KI\BR^$X3R?^C_'\_ $OAM[D#C&4"'!)N0N1HP;WN]LFE;\UDA+++8F2:
M= \_"=AJ:)5/!!C] G/7 *)MCMM'67.WGXPF)Q%[S#"[:IDI:_:64=B)^NP*
M%^>=5:*K,WILYU$;NQ&[40!E!X./>"*YP@9Y>]3K!A5@V#=]5^V.N)8\Y$+%
M44YLXT<P/?6F@C28/<*CKCN?@!55V,N8*#?E5S-^["2P*@@Z/HV(SN%L3:7M
MSF<!$5!E&-$8.7);J'DQDR:[LU'9UFK2A[B=2"S0ZEM5QMA,)VCD.)-6^2JC
M\AR$,'M1-E?NHNA.6+%WK/8H\Y@ILJ!2'F]SPY+;3?$\3OZU,"OZ-I3C8#A!
MN3JROQ(4Z3R0/#/>5I;A2]O/L#T=L<\H-!!+D@<U4X)S6QF?W1%C3OXG+(D+
M#E.LQSG.#(:XUJ6=#KI "_SZ-+7. M5OC?L:*QCJ,U^L=0B *M40;MMO/L*W
MDEQ\L>09J6FM-CNFQS^#'+_+?*R!>Z5) -Z\OS);4[N'S]9MTO$N6FJ>])4#
MJ=OY/D6R46.5A2/?$%F>SW3R[06-P3<7:2A97] RP?[I\<*8SSW4CMLW!4\Y
MH:GT$N\B?$&D*DO9^KE,A3B'*;.YA;9MK'Y6V8E&[NB-.8'.V=56[U9M>?O0
M[G"8;*UQ[[YQ[J:'J/#CWD;KG/D_NL*,A'>U21/7)A@>'>E[LTYQ[QU1FW74
MXGP>#S-Z\6,[^2NFPB0]KW1=Z?KQZQJ7=N1BUM;=F882H4SXUN?O(!IK]:9N
MLX+^= A<:#@HQWJ-RB62%NBYUBB@T)61"+9U9Y";DDCR[F-,6S$9;9!-D]$N
MREVG%H6\V3\/V;K)]8HP@LH17P![N"4ODQ3*&KR#<[E3-O<D4#P<(XN(-TR=
MDTO,36OA.CHXC>%MDUI'O4<T;H<+;!,#PN^MY@(Q7\-S#3CRE82/Z4)*JS]<
M#FW2O$SS F>2E?T:"85/R_2'A)%1._.H'4AC9[T%?TO$)A<TP#2@J\>GG^NU
M+#X:',0X16Q:@3/U]&6=CT_R/%JV+96*^5\_B&C*"4G=J#^&N-/:.(?)\7<2
MG(XS&?3&.+?R(EG=WIBHUA62<OA>R_9I!YS#E'/%&-YTELJ!-/G??0H4QPS[
M?2V:N.HK8SY@)1C.!K?Y.G<9"LHR:1*J9'4#UN*12R=M)/A*,#1'5J, /8&6
M67!;N[&"X"QY7L+JG%6!R"'""1++5\^*$,IN=]:314\/79.YR;$&3?MH&ZB7
M<W8=\A<5ENK154V']AF8HZ=%U]<P?12_^'FP%1-Z7905O6FKS FP$?\4#=F$
M&"I.PG _N3M+Z:[:A7ZO49<IF4>3M6AKF#5*+ES E!;8V4FU5[O?/->+F S=
MXRCP-;I\S06JJRK7^80L0=JWSDIHME)H5SF[LX8%N$-Q["(6Y'JQ%G?*(R]L
M<6-46$I=/&PN5/=#NGC)=!'T?"REMN87AY*QDAO=,L;<[->.GO:K*"+&^C1G
ME6 0M7,M^G/(<*Y_'@;?O$NO] F&.'8L_;X61K@C*LW$?:( ]0)@?#XD9Y3E
M#A<\9<^THPWP]_>R#K^'%RM&XS6>Q2"I+6-DDJ*"4&><D4-'T&1XJIV83&"7
MOP:Y"K^%8SAPZ/,_'!K_O8K!WYYX,I+[\9*P<E25Z>YL!'PSN&-Y;  D\#\9
M\T1*FI]4Z^&UO5'Y>MF6('.^A&T[XA5.6 YA@9#LMD24U0R_,0)77!F_QP,8
M;L$=4.C/GU7H:;Y&03OM40,"#YR"P8RDY?+2?B/5_QEA/MA<6,$>2.Z3H5%V
MJ8+XQ309JSF_&3KJ!KM/UNH[++L&2T&0Y.,LN_)9@<-0HT$"4-OK9XMH]LB]
MQ@+\8J8VY]7?C2 5&':\*+&MMD]BFB,,JDGG=(XQ8+H8GC:LT!!X5NS N'D)
MQ7<2,3S7<:3UBC $F+[;48AT<V  SY+ FV1Y1PHULJJG.Q%XZD-2 >8=!3+M
MI1#'T0Y* LL:D-9\1@N&0@4O%48-#0RA0LT4\JJ-)@BBJ>$[N#<;5*Q[3TQE
ML6+,E?BU$6>?*F.[/9@F]SG8+3F&M;?[Y#T>G0LP$56\_R&T3!C'[T:AS B1
M8,!GFP5*_<N6VNOO'S ;H)U G.M^%$=;-+MT;OD<DA5M1[NM:3/J%CGJE=V$
M#*!X0" -B<BWJ(L%,!<A) QB!J^OE*!MDZ8@9;NY$-212GAFWJ(V,;9CX"2O
M,\.J164"9_0"/'R V^FVS3^I9N;J/ )Z;TPHG%+_PVR\@=IB5&X(\#ZG3D)C
M0Y:9TVH.$:JS\IZ!'S@N0W]PL%\]/=\K0!)9-=_A&X-FZDH\$R81>BW;BD#/
MGZB,"$R*63=8B>6&1<U4O 4Q0C_X',P3XXHY]\1HJ%8QX06,/8(X##,XMEL!
M"-JCF0_^ XKE*W04.MT5/;_R6!(2I\(V-6YL3 @;?3.Z\XQ/R=W+'=.MW6$_
MW[P<C#L%^EB^?>!Q0KV:\''E+K5+U+;:6-21&%!ZWRK^:6%H5<WNX3*6SP-5
MQ<J Y*<^;+\$1"!QK;&E<%-(AF"=KK10N]RS/IVEVP4]*"&S5C$RW;<6_$5>
MPGVOP6XY>,O(](IDS!4L4NVCC#L ]D[:PE3>@Z);5AB(\19UI:S(T(:MK(R<
MZ2!K3R+PE!A!9?ZDT:?]0_:$&9XGQ,A\2NG,$/8D&:?4JN_V/[V, J9W"1O&
M6-VUZ^8"-BUW^8ENMA5H?Y3MVREXE,+T>RVO'9O5(KPXA[+Z=O\[7#6/9PJ:
M\S<^>R<XTS==E'N/I,GUY=V5)\=,L:T/-O""W64CR&M0AEG\^N8UM# SB&HS
MT6N\EGU: -4&#AVS+ ^O89]ZO7>(M&H,W6M _1I-3$0&A4?3U2/AC8G>2LZK
M-&3>C54L5Z3W+AB<%I&4LR54&CD]UH",G(89_UH$-4HP7L=G+G Z(6_),"2C
M3R_.>/R66-PH^B.].)ITS?E8S5HC&\G;88#[]PG>K8QI$[=Z/FUMJ>J?[70"
M!C$3-"+;6]U+5Z]HSEEE%S,,,Q]()I(TFTNQI@.>[#X96+V'M!>5+:&&O^WU
M:["61_FW-_YMJ!DIE40K>WU0^;,#Y^ CJ_NA$BRN<K?.1*? TU2S&:O#@^CM
MW,DK@C+ZR\C&F!_H=MJH=X>=X^*Q@12_MLO )Z*Y])(S/AFZ=84Z6YVD#OJZ
M4B-/:X$Q_6]OPGWS:Q^KEKPC4@;ZVL/01("CRW@10E][7)8 OXSD7^M,Z<6:
MH[JCBY*,J$IRI_'?0Z1S!?@S;WV0M!0)K97!"G 2:C:ZQ#@4.65C,$PO;%$-
MO&:X\(59)O@+(+1YOKBN\0%LNM@AWKON&884^@PS,3@&5N@S4M/3E(]=Y]O^
MN8D7'Y8IJC,ZTOIYQ=><)6Z?,/O*L/M#%3BS=.*;B-;?I#3H\/->?\\9#,GA
M-73>O-D1,Q67]#YI._CTAYHOE<47>*'19>-\X.L49$5-N*&4!:[W:Q\L'?K2
M<O+GM_9UEQ[]H:U%2E\]I-8^T*C1^CWTE-LC,6O8;E[/AJ1\]"X<J^VNE%64
MZ!U///L4QQ[EH*NI7T^M#QCV"2M:1F$!F^ Q"G*%\9T^)0#MQYQ<H0D9SA@@
MM*KD/SCV@"1P+,WXH"(D,<,3)&"Z>[#[UH452><L7?^G5O+;.'!5%<% &F/^
M(;)<D3Q4Z_SS49*_]%2B\+JHY'=>DL"^ZJ:_P:)H&K(NES%S]Y:1+97@!;]M
MJXBV11:9GZI5#&I#LN[>)$!B782ZR.RIA\2_MVWELO]G':#5\1Q' A"E*LEX
M5IT:2DRA]OU=3"\)Y,=\9< NHY.?,%NW+$"4(WT=',I8+JC:$B>=649A=X"/
MDV];WR[3P$Q&T_!W)+/;S](2='5Y3(B,C<>,I+K:(]),?M)D93SC,2S=^C"C
M=,\_,&<E!_#A/6>9D7AP)E2UY)?0)?:(Y J5P'BBC>7%I(TS'6XLDI2.YU7&
M3$=X6DPBA@:'\.9$1\XFTZ&!PA$A>B?EA '8\IP_^YA&."IB"O(TT>\ JG%T
M:JUZ5O&-._1=5,O3@KZN5%)#\@_.JLL!I^^75!;KRY0\+8#=:B$6P[("LT1,
M]S%VF"U]-URIEBQF=1+S]J\%5\;'=@(N#<0[N#*HNW8])RCOM>KLJMO-AG]8
MR%R_370]9 !8"G>?7$!LT2C4FB4I!P9;?MULY#>TPJPRZ85H/6>JP >5:X<^
MI*A-#F53)^P#]C#0%.G.;W3EL91M1BKCCQ<ZT\'+>9[;C+:]<[;_P08] M\(
M$VXZA&P;SMU1CWE6X6.8#G^II-,>,QI 9>_B(&,\EADR\C0-!V'454DDOZJF
M,9R"R:U-26;MX.PX"-'Z(0DK\,P#];VA]E?/$5FZK>*J-XFY47E"V/AK#'&2
MW*)V*R%>1)0M(FX2(T67URZH$Y<SR)/!1,>*[YWCM'4>?QXJ-AML_^(-I16_
MV[:.8]1$6#ZB1$>@UF_+/YYTL1N<.',ZJ38#EDQH="<IZ^/NX3B5VGVX)5YM
M)S0X9Z[&$M2P.XO!SA55!M\2O-+;QEYOA63P'79?@ROK @[W"67-V7$" AL0
M>A0@R^G>THJ'OP +-<T$8BZ9M/H)&%$2QV]"I%E UC\;Q9S_(;QC6,2#J%+S
MP3 WS.(5PW8P</S):@ZRT)%#UQ$SV395'5%N.<Q[SG'@NEFA:LD!@W&\N?WG
M8N.4B0S^2%#Q"S6WAT\%H)9X^C8;5G"HVSSO9,$$YKVU'$;1[G*H9PV8*5]Y
M,S%$R39G;*E2OOY*HO>;%+\Q^3G_2X\"ML?7RN83V3N%UI%$DJWV ]HKXK.<
M+U8VS/X0^3G(1DOX:U.*\AVTOLR=O.J8*=& >\L07K\1AF7F*EL\)2ED0"W0
MS'*$Q:=%4(B&[T^,2[Z:YAX4D'(#9BP\@J8<X?K*O1333P]5L0A_W(#WF*:-
M+2ZUKC T)T\_7:]!3T#N*F\HB90\7M=,X,TAU3VZ\MY1 H,KT@%1D"%DJ:@E
M9(E>W38ZAK=$)PL2W-NHPQ"E!^0::;C82#CC0*.#BB:JL29&TH["KOV_A]M0
MJD]>$!>6N<Q1]"YI.UM=TR&G;'=!L\W&&8]G[5)$N:]1A)NV_@T!6H(B/TC=
M/SI<R_&J4M5 OTJZ.>AWT(E610B0(EFK!":<I=!D"G)6]3LAN>&ZG F8;A"X
M-B6#/TO[2+VZ<9;J=@;E18S-'(HKS/[@%#)+&6M3K,N1SO7AW\[#S<UI,-O5
MHA?F-,@=?7UJ];H_7]5M?PQ]%!">NL8_Q/5B!8AQ=5ML_;4[OS@](;@%Y:1O
M(^<2 RR?-KIACG40>!4GNF+3GZ,W:Q$O>S=LW#?>9H?=?#*_I A2LZU21X43
MX9 P\(41G+NC:K$VN#?Y'#A%MF[@[F$G)4XRT;']?CPO;/LV<OA5I?&V6XIA
M=D4XNNS8J9^'W:J)HCQ?X0<-E7IN /'3)]P*38RWLI:G#,](/IF"^2<%D*M7
M.(KS2,Q6]:RK%C#Z%DFF4!DC$X4A6G0BPX01MD!Q.HR_]Q^^ O_>]BA4.@4)
M)+D?HNKG)NA &;#A(Y*T@?RO>Z1,R#K4U20U#4&_D"PS0XZB%Z.U4TD*A;XL
M0I"AR4N:K,M86#$K=J_.[9U_7$>RR#<)P$>3]SW,!DXTJL6C/Y]4<W0/"N5,
M(0?^=YVE,&L/E-0J@<>Q^CUM*!^[Y:$DLZ1OC9'1$8S^6OS,V8H"K.'8L5M>
MD9#UW,,\PHV2RJAIY*5(:WB<<,];*$;NI#J9GOP=AB6M"4JEE=LV!N05=:&
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M&2LNOV4VIG2)1A:@!T,E$B5;NB>>SV&S (ICCT#Q_UWK@%*#!8&BJQ..']7
M!:&]@-60\G'U2WJ$-$BYGG3E_@Q:YK$)Z4NU3=5U^0L%C?U U$:DG1MC<R*O
M35$8"@*%%8V) H$$0GHQAT.DIU<T4E]WF7[M]KFFO.YR[<:PH1\P@!';W:$H
MJ>"*S>Q5P>)<8:-ZU4?QX/="3>HCC(N9ZU\/?!VG'A>5-RZF@@>VJ/,:7<6Y
M@L)D#>4VUN/^(GNTOHR>*^ ]5DLO(?H+SH862!=YU>&@@DKS80%#2YNDWF\:
MY9)0K5QD.'RK4U>^^:L\9Z@IZZ1Q'_%'@GH7++>'5D):Q7^WP/MI=B0<3'D
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M/ ,=(!\+0R+<2;;0"_RJM/")!<Y]SMV6D>E&*OB8@I4PFK<TN?B'OQIY-6P
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M,Q'27B -3_M%+L3R+F-FU8IL4I;S,BYP7#YS1DG&;E?WK' *Y))+?LW&+=N
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M,B%N9+1,7AIP=^_P)=:1_U7=ET UD6[K5I@< &U;4 F*-@B&8+ 9 LJ@T>X
M"09"0@($Q:,()L&@J*"":-06V\@@,P:!")E)5"0)"()VVXB(M) !-1'L=D !
M(ZU".$JCMXKN>]=[?=99Z]QWWEMWO>7Z8TVI2A7U?_O[]K__O<\ACPY=J!4G
MA:@<A@DI43&J/M79DEU*L3"[6*^XWK(-0=Q8;HIDKN\RTJK#QNNZ0/Y0;MK
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M?F:F7T//CT6W][JO[PNS'HH(T 3=%9DXD1L&V6L.EQPN_?9QECJ[EFOV&:A
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MF91])ZQ L*$;+5S=H"^4SQ>$.=B(T$'K;)#=M/?J"ZI/6MCJU=BX. *FX:F
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M&N?AWQ;6N)S&0[?KQL)-=:-QT(SOFC$<3.8)H?RD;-N&07[<]/!Q55/"^&=
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MR8QC*U42K<G0G.C]!V.SR6=S,!)/J/TSE0N0SX'"YLT"D#-Y7%[-^(-<1*A
M%A0:_V\. _W_UN"ZA='R*#3@"MDC3SUE^)L#H [_TZ1'LT@D-+!)6V+BB_9"
MPMS3PY9OB*P]F\N4VX"JO=G&$*[0B&N?7JGPG1!JRL2KP8?HK)'&=LPPW@@^
M*!WFV[N0X>ROF$EA ^X(6#1Y>%'5C/&;QQ\(#],"'M$<\"53P%SM3@I0_QV\
M 8W-DDS- _G7$Z++,]FE9\XZ.X21JW1%B\T"6% .MX@$K9["FV-^U*Y5&H"
M/;)[(1[NQGP9%:90_,E9T&+8/G=&R<?_478"M<^/_@-02P,$%     @ 5(DC
M6>'B"0^T4P  *V$  !(   !I;6<Q-#@U-C U-3)?-BYJ<&?4NP5<E-W6-WQ1
MHH2( @)2TM+2/0+2 H)T2I> -$B,@M30K2 -TMTY=(=T=W<WS+RC]SGG]C[/
M>\[[/,_[?<_W^RY^%VQFUEY[K?]_K;7WGFL/? *^ #R0D9"6 )"0 0 )\0/
MIP$QX.Z=.^AWT.ZBHZ/?NW<7 PL/&PL3$XOHX2,</%)B<C)28A(2"FH6.@I*
M)BH2$GJ>9TQLSSDY.<GI^(1XV059.#C9?RI!NG?O'A8F%B$V-B'[4Y*G[/_E
M"]X(X-X%9I'?HR!1 LBX2"BX2/!6@!QA)QK2KPOXVX6$C(**=@?][CT,3(1
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M:;]XBS&WT7CT:44[#Z=D,>$;&?L\RP-O[Z 1M0:"LN&R^3)Y(W;-YFV7VL.
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M?*"(P8T7DE"K;$[N3^7D$/A:U=Q]C9(;M>MV+\&5:Q\._,+VEQ*P6>$JSL[
M?FG3JT1:R_):*B4>C-J7B5I&K)GRT7B'EN>ZIE-/1VB.-33.)3IL=3\?3M/6
MPX&_CI]\U+//[<(NM^1P[)3PRC63W3WXF,102.A9UAQUR,".64W$M!7C*NJ[
MMZ>D_'^!'/8C]"CTF@>6R-%8@.Y?D!\QM20DH?[HB:'9Q*>0A)S,,_D,./#B
MNO#Z:'Y1[Z7'/SJ^T8C0>AD;G5DW>0S]74;R7W;X&7?0DK2;^4__R1Z*MQFW
M/V#=H<>>Z/UP8)(_]A9E#[K?@ZBPO[4]<'^G,?9<[)H!U'=!+@ 'C+;T3G!J
M$!6%&89/TQ"=%?A%>GCOXT/6FV(;Q5T]T;^.,P@'?J5$XZD'ZVL/@\.8YHWL
M:']*VJ9;AJ1_99^21G1TM<115:7G?SKYLA&\@QV2=K+@ ,^"^_YM9#;XA_ V
M[*;R0O&WMMH@^6_1@>@ ^O\&-CSP[QB>_%$^_J@,4WJS.']XX4+-NJ1E*68.
MC*154H0R*WYLVI[*XQKWOQ-IE2EB"49]SIC[.=CO:]5Z(N,,[!] Y(#+J&XR
M\BKFK1+O!B])[01'L*169#A]\>*>^>"P*1]G\VCFQ=OX:^DE"N2@8"]T^;G1
M?=#O&2-Y*7;-DRD@^-3:72FBAZ'B.YFVS=O@F,:.#$EK&$W9I^1*XBC;Y]0Y
M:6\CQRL_G$-_ ?/+91!BX)3;>#B@0'3<JVF=BYK-I,H30/F@L^<1<KH#%20Z
M_[0C9DFU$LJN;?2JG;OW*Q_?<J*X!\J?>"E<2X.?@28M+R<7G-%;G=]3\V!F
M]> 9X:L&%]W=^/#&5.&!=EZ/X(>@5&<<>@?#^H^-="%2A9Z_5U1Q,/V<AL?:
M?[K,)R$8DOZ?H_1_.C M7;1>04/;-+6Z#.W\*^EE.5\!1%=JU;]Z9D+TZ0A;
M7A_?-[9\C%7P/,)]VA5_[[Z)\"B^-.AJ+>O LB=F/0M/45S*"T*?C/SO[B!R
MF<PL[2Y4VXX[@I?Q!J;)IUP/!E/TXP,R8^1WC*A.\./CH4PJ?6GR@G7#3M#>
MH:83SK=7Q'VPUI*3>!@"EHO!VP#C39Y;F,UA1M^;2[5Y. "XEX&_WLX?R#&1
MBTG@I.3-[\BR2D/WC\'!Y!,QNI'@^34X0,R7 V:XA@,+Z,SD:V#GFT>RZ#\&
MO3<L>:X?]@S97-_,+TN>T<2FSY]?0MM#+)*Z&^# !5*/Y&72+!Q _7=&I,5E
M'A5"88#=(,ST'-S$6>2!32CL6PHN9JJG1=#;!^,$&VA\D(,#X/@;L[7LFUS$
MI/.1Y$^#I;TW->;_-/-^Z$/LL6$%+.\T5Q\HV\\.T- ;8"7C9F /#GB9#:IP
M7L=6^8R]11U\+OU\6+C<NBPH*GHP:F&1C@ !/[OH/\,=B_YCS&B7Z_1X2IQ1
M'.N%:Q[4-6#G&<*ZZ\N5J\L^#?LNJ*,G+:P?5S91U3/V5C'#>\.LZ80K_D__
M_@2(2V%5#WP#K*;]88PY A(V#VP3./"G@[\A]'=R^,S@ ,<U="%.7=@WB%Q,
M _JGLZ _0;)7AJF<PX'&^YJ@7MC^!6T,3DH:PG2;?Y 2^@]2249!T1YPX  E
M)O085 N[]U\T6:;_3R-'WDQ+?Y>PMJ()3Y,W\IE^3S4]Y\?7IJLX/ X#1OGM
MG(+*CU5O-?+%N4BDB6MNQP"(HX5^D=+"%7$WI8[\EM$C3M6BBI:BA5KG]:$D
MQ/!P0.Z7A48Y,IIMYEOO-D7YY54]9>! SG\Y+/[_%\>_1S'$A7HH2ENKA^I%
MNFNXU.3R"#&I]-]AI9<^:M:\S/7,&\MLM66XM6 3H]?_$01Q!V^K;3$:5W_<
MA /C7.^=)9:6E<8)GN;).I*V]QA:<=P-VR%$-;7FZ.ISCH0#!1:9-N9H9>/L
MHFS'76NR_9[OD"[>/ZLT:5PO.-61TIIK8[)%+;GFEZ6VPW<.KW@4=!^=Z^EX
MN62U,F1HI(UF>U)"4P*=,>G+X?#JIM9#<R=G3"<B6<Q,R5CLT4C"*P<\EFBS
MH,]4QBS$JYXVEV:37;=RCU\8R"X%9I1]SB/8?N^^2!ECLL;->)1%1'%UEBFV
M1"IZ2:S%R(M!$Z'#7IO0*P6B7YXJHSXX^])AJ_$@^/HK#8.4TTRW[41<W+B,
MMUQ 2"*DQ)7QH6N0S*+GAO#,H .*0Y^R162W_FNKM!!VZ@$U_:K01EQ-E:14
M<\MT\P +[MB9@:<B/DP==&1ST2G2_O1I*4U;9NE(XGBO__F^XW%^X\,Y<([(
M/)%\DH<<WI">D?F>AJ)(HBFC=Q\6+9,@C*XGF!ZFRM"&Q\Z6:]0Q>RNB"A1H
MNFSH67F;A1\\H:D\V0=BPZ>FIN+V8=N52CVF:,F5M0%Y#:-<,Y^_*Y,\Q',6
M'!);$EB#]!]IW55JOE)@F?V<WIF^KF\[C$Y:HUIA0B<M;H_K4J_KP45=J:SU
M):'@B>UM2_"$7FL:3G/)7GF"P1&IC)KZ0@6_5)74X/0'HX1T<)E+G[ JNK/X
MVTW-\F,]+?,KGSQ%SC,O%UT^S(=WD+ 3X8",9TK.'&(SKZ"?J2G.T03$.,6(
M5F%_8UB&DEYDZ#]Q$8Y2>V2<+VMH;,I7$;?F,#AD>#U&$[+ 1YXM9"F*@]?'
M'"A5I#DC/TS]P"/N77H0K'K5=IXRB9%H6%&[;SS )D]U;6ZI&06,*5ZN]&:U
MLX3[AXA@$+'C6&$NAZY&D^&[XRF1AHV\5D#](;Z0/-]:])>0",@RY:'6E(;&
ME 1SG'J>09QI[9=L.[6] HZ8Y>Q\ =8',UMQ00\FIL3/G"MDOU)_[33&>J^,
M-(.K$!WT8QBZO(]8F!:&;C"*EI[L7UR/0+>7KS!^Y-'?D(/7K/QA=%V>4O2I
MD)%&Q"_@]WN@& Z$Q:3!KN  PR!%2#)DU5$KUY\N;FY*U5=V>L(JJ&>,BRI"
MZ."Y/*[YE&JM.5I#BAOJ+H4TU9>Z %[]QJX%GJJ\C4)[1(IRV_A?P&2/)!7$
M[1^XQ+Z.:]4AY<>9UWZBI3[V)O:]5,\'%B3A\F>'^*OY$V70$A\:Z50-W6?W
M1$B^8BP+WBYZ85N:&#@HJW%8+56SS"YZ#0H/V7CV8922"+K##J[?DG>7YI63
MVNFG=#83%1A'K+XW-A9%=[YR:D.P;"-NNDD<%!<<%3& T<+)7L>>6K&*E8GJ
MO:E]VUZ<M44G52UKY*=0-4*E/DLCK*\=?ASR13@J#UU_"++L%[!27%*AGK\8
M)'.<Q+YG.AD=%EQ;/')]P"BU'7NNAFGU?:+Q.+]F1F%=SD=G%@]_RV5[*(D1
M%RIN[]1 6S5BG3_4W\]*L^O3.\ 19H@$*?G(G\B;$VE)'+QR13H3TV6C+S1V
M8A05^ZPLO,YAQ5Z2D6A\U T.7*)K(RH2-TRE;\)ET(8EWQZ_J*(FMCN(.KTW
MX7U_5?M] 8?<"N+HL_Q4'9T9S194["?^7GPFO)W45_<9&&B3>S(/"Y4M)\"=
MPM.P:M:C7*JLG#'R(YP*1 V3O<GIW'KVYN)UCKO-2/]@$YOV6W"/,\PQ&4D(
MS59S2T<VA4G5O@OKR.(ME43KP_>M."D4;QS[-*UDAB7=--+][_@N+1L^L#-2
MQK#=DK7=E?&JYXTS  525:8691RBAF\ZGWO-8FK.WGYA6?8E0J$[SGK<.LS=
M< 6>W!U4 M,9141]"=W_Z,)XPI?/U'L_(B3:QS3/@M\;,]!#F'M84]4?%.?^
MXX[$C4.[Y%CQSHT"3<S7[Y,IE6Z^Y8^ZF%?:)-A? $$1\M@(1BTE&-F'M;RV
M6^:GT8B>XG*&9&9-?POM5269BLD6@L5RS>9H-7$^Z@[$:MTC4W^J-T^R\F&H
MB-0#O[UCJ3H_/^]IR!BJ:GF(RK7R#E8U#,^ 30J1YV/1_?4>:_-"P9\YM-0-
M!\QIIGJ=?)\"RQ_=AE??.N"I<;HK<@CMMJJ&D_+W$ZZYRB8]]RY8 #83HU5U
M#%^7C>7OG<HZ>*$.9U9-HF9X(Y5]%($]O35;->2_RLR% YUD^[!JXL;20V\Y
MVJZ4<F::VKX'E5$-0VD">E3>(4N%&;.[<,!GO;:NTA>''XG:_$E,<Q@.W[[&
MF-R;V#3.E!OUJ\+>"6^84"H<L 5'RY%?C5Y!?'$NSOQ@U85'V6EP0!.JJ$+V
M67;),!,.:(\V>Y2?@'$MG=TF,D8&D)'M4+MS2\D3G.U_SF)98ZH%TW%3M+0B
MW#(X#?P\XW/9]>HAC-+5=<,.6673YBO'?;.#=OXE?%,MO'-.GR+[P1BEYOE;
M5PDYLM@SK_&'84,7/EKVOOKSR;R[%VH*W-&9VA32>58KK]=>$+.][\B^BHL0
MP.15SE,M2GY6Y/-"6'N=7!XQE]E61LCF:8OF4S9'ZF@\5@XBG8[Z1G+:IEYT
M>">7L_B5P;0-=4E;B7@P51 ][]-*&[K5%<-Z1UE#LPR9:5&,:*J[O(S-22WE
M7 X]J+66Y24?M2OLZ8.L^;;[$)K/B2LR;-/F1.S=J'EHZ=>T1;V]%AX&I7O5
M\Q^K%CC>BLZ_UF.Q9RYS#M<$[;VF,D4JL:]UYELPJ.$]">:F7PL1$IY\J!^@
M8@CPGI^FP]J'6IOU=K;UV QQ5K&"'&ZR:E B_5[7#G=,D>F5U\A^Z%FCZ-XE
M 21M]/15"QT35)L)@FV2:V*TU L>*CY IAQB"'NQE?Z\X\/FL$))B,E7YJ<:
MA#&F=]FE">D.\3K+$OCOKH0\P30;$L7,:0<,[DMX^L6Q?&RJ&2EW,V?)4UVE
M3>1;4HF2@*P223]5OLGPY1VPF/RQ'_]Z:,@TJHO"1-*0/,;N/IM:,DB>H?7*
M(^%'F((E5JJVS=S'O8Y7MPSJ%+YC^+YSU!":ZRQOP!,O'I<&3U'J]\4YUO7^
M)88Y=!\*\U9YT[+_+D),/V=V2I./KE-<%3,Q19H(.5_/-GLS_00Q\UUAFZDZ
MS->#] :?C%P\W;PJ9>\1*RN*X?X,C24MG'SYS@YCG8^NP**\TC?52U;%<OMK
M/C/U,?.NGO6(M6TG$6]7NZ4=9&RG<=W:_8FAHPT84X$_L*MU-98H%%U ;6(5
MRJ%:6">$O7,LQ6+L0UMV31V>6H!QWR^\";]8_/%;15A/X+7\T'6OQ]G8VJQ:
MT /;KO.E9.B@\+C+^&L];8T^:MU7WQ]D]LI/=BX$)8I;#(HWMH2V/! G823=
M';'"CYNB]G_Q%@F59SPT@P.&*T4^$&/9-;>G&NS3G-,^&,6GA!SDO#]6N9&Z
M@\6QF)5Q;%1=7Y6XID'EG.#E[=^O\@(%4*[Q]6*UWF-YVE!5ZO:E50WY0;I4
M6J9B4U.[N.6@^ 0A\Z)+V$LKF\Q*QTI99^.7-L^5WSXD)"&K@]2;IHL9?K V
MC)$PM(ZYL$_$6^<[Y4I!N&2Z.7]XG@T>[SC!3]&XLN'1#-@]^SD=%Z<=(+86
M7QNH+I)H+BE2(8QO@%0(_>\W"G[9!1=?N8#EQVDL_Z:HQ?"/G6_='IAOI\H<
M3W>YY<S.9M1YJ2\YJCSQ$W4*BDOL@(EJ^L,!*W T@C^]ZF-P/$^K.YCFDHH<
MACL-WHDJ>M3;H-WN\IWP?FB$G8 SY1<8L:^;[$7!/EU5XBFR]/LF,7J]VC*D
M3]Y]5H.:LU\(QQ*?E):.6I6C1KRAJ2^J5.:=>O^\"@Z4>X'YM4B1!8BLONGT
M,4S5Y3\LR9HBSUJPU\)3=$*3Q;R[\]!!TO21_#'WSGOUE= ,XTR?"#XK40L>
MT:&Q!6TQ2Y^I_&_+O%TD8[=XVEB@"XEF+6KNJ^A>!L&^%@/^*B<FN[SGX8G8
ME"ZZC"I^U_Q7:UU#2-8#A*KL%'Q$G5OLKOBU"$R-)S:XXQPVJ='.\HLJ)CHH
M@B(C/JQ$6*3K$DA]+^U/<SBKL'OL->FUJ^W%)L\N@6WSDSDG3^*0;C/WVDU8
M#TILR+3%1Z% 0UL4H7NYLH@5E=]*:?#D$&\2UJR\G:5,K@4J-O]*TN7:?'=J
MVCE1!FN(<)86SB7Z-'B<!J9BY(BOV6JH4($.<T5,LBA9J>08^ K!5U^<*NZ!
MD?>=]$KGB<9M[#B:SM;"!1E-2=3\(V70^KJUR9)HQ[!PP9/]8 XU3O I#TI5
M0JDF%R?YWN!WJHL2-I8Z9M(>;?H1EK2*JF_:0C4^TVM8]A$<(>CXS -^#_=V
M9(5N6\/NM6ZC,"3DW7^!$]QH6F%I\3//VD); O ::4X[2S6"MLW8\/CXML>)
M^#ID_%TT"2,FIG7[4'^TK!")4NV_6@]K(4)-%/^)!O[3X<5 66*WV#ARIO9V
ML8B%TX%UC7"7M]1CNRS9SH).@X)L[8OO(2TVK]FE2/ML%,4;UU</<J0-8F2S
MM?.+/KUUZ4[S!0RIJ%:IG?&I840!O=LV'O:6-G8YD2UD=\.0*K.)4#\BM5DK
MBD\0F2=/ICL?A+5CCDC-"7?GU+X@]U%1P&P?#F!UQ(P?(2@THXJB1^9N_W"_
MSC%_B[X6Y?Y\BP&-<>SKJJ^HS!C/7NHD!QDMN'>0]FG656HI8'>]"]+0K\#U
M^A &D ^5Y<04P@&*0*A+9]XV:+9G,.X'C,E#;4T#,6.F(.8\RYL<,S@P5CBB
MS ;NJ-/;8_W[E*GV<\HTJJ07V]^QP!BBP/5B9Z"R(=H!\X^]KJVY U%6F2^5
MW #S"_>1I]QLNG$SXF7E0DU"?\ </.) 8I>#.Q/J&>(ZUYR>?L=I.X-7Y/VA
M)LUM# S[DVDGH 3R7X)NW 3/%-4\?RK8^$-PLJA8!E)[9G:+LR[Y2Y"LS^>O
M(VV<O6-22BVX_37&'X*E^@;1^,Y_C/%+4"@>DXBG(LGR([U'Q#.L$-!G2 %+
M.6'[Y#O4/% (#R%7_6\#F#()V'P5X% ?*7,UBI1X/%T(WB"BNSVCOW;<OT6A
MA@,-;=:_C24[H0RSZ;F!K/L=L7;<]+)6ZL*!'^P*USN*9]OS5W>DX8 '9/:7
M*SD?$N;BT\R'+8B#F[6FFFL3)=\A(=:M:7\H\$XD[X22'W-0CQ2D!J='RCN\
M?/(U[@5 ECZ._K@#!T>V &SB3WM7KT>KI*6;^?3D/&\ WY)GCG'0ABNP-4G^
M(+AD[8F!3%\V2'QVX_-RR&F"QT&?P[[/>PLYDP@+I_VSRR4JWS?GRU?OE@]R
M@N\QK\ !G*-'W_0F]4(O$YMK?):SC(=UHH*\J%%Q9?^T^SCAD6K= 5=PQ@;'
M5B)F;;!Q<+NF)3!SJX&^QCB61ULTRJ1?7YS POQ=9[#GB;&Z\O4].,"S"A/[
M&Q;0?XW%W_C7?W,)93VZ[P*FO 'W-O\),)7VEE)PN+J_.AP@"6W,W_^-[*LZ
M1/6'D:^0#0E1(/!BS\L73X#&5M5&5L_  5RAK;;? ZR LUHE/"H^TLXMZB^A
M..K&+???"J+_&-$MU>4)+ WC)LJ=$I-4AA^7M[>ESZ87QU]%"O<S_MZY9^NH
M?FGW]L,3AC@:^DP;O1^_N4MN70\'DHV2SB?R_V(2/BC^" X\/6ZY?+P,,_G7
MD3CT-VL8P CT109P5A"L?NM/*Q2.SE0 NQD<:KWP67&R;<2/3G>!=6B60K:&
M'JJ*=,<2B6U(&FIX4L(!R'6[Y6*@:,?+H1GI[$Z<1[*C^@/)6Y;,-SPVZ>Y*
M54,CA/FG;GK"$X6 '#D6^@UZW)L4M=C9& 1WM$I:684=-P/B<A)[XEAQ]B6)
M2R_,Y__A3X'3F$ ]__+./H<8[?O"&YQ3LO+:^T5GK;1I9HW@ ?5J<O\\JH&S
M]/%9F*B*_ACF(1Q@U_O?1<U(>4S[*<]T=PF.R8HGONDO7"N5349'X #K$>.4
MV%\!>A8AZ9:UQ+=$,#;9$SQI>G96X/T;$V3$"M(RVX@P55%V#%("@X[I/P(
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MWO?N[_<^[X_]^:S/7NNS]SI[G?U=WW7.V0<]*)5C4PD6MI:5G!#;O<8;-_3
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MS=:V);.%-\H^.#0'7KO8L&PF!]EES"/3H.HU3^\N3+O>C%[U*)VIG-8S<8W
MVQJREAW?R[80KPLI?#462RY0'<Z">*@.$/!_-+IC--B#_( ]<[55LNL7#BLT
M0^=&,901=&XT//P[ONFGWLQ Q5+:_T!M+D9%DP$Y_]V&NV?9B@KH^+S@2@5(
MHPHZM0LA=R9'EYGGWW$0NOC@/I>19QY?4?=#W="]EU24/VR]>+$;/S30()F<
M2,?:V3,7_VY,)EAH,!0_2+B;T[@NURO1NL%MB=L05/Y8V.O"XU2:V($5^!#3
MV/2B;#@TO^VK^=#%M\K$_"6(T^1V6C,\F##%-G#PVJ:3%\) GWEW6=L6;VPH
M.(6SR9^M2O(8W+V.H2-WH@OJ?ZFT@6"#/:9<P@V<S:,0_K%T>6WPHSBCL=;T
MW,B@Y,:#L1@>Z4AG']\O'0&3RV%2.)DNK_R<:EW'2WKBOA8B9V+B9NVDGSA[
M&-\F_$9RBN)U>B_KR8].C$XF7AU8GTDP>'JW1_!*)W>$_L% 2ZXKZ;)9;IKM
MJ$2!S^-Q0:\Y%W>.(*$^Q,QI*L"#=[>O\(!\8>^[0/LS+HK6!*FO+H/GS40Y
M%? FW!9!/%X+MM^O0\CD/4W0DV.R?,(!FB0$KGTD<KT,*JZY.02-@W;-$L;O
MW'C/8CS10?"NG5?&E+L8^X^<.>>7>5Q<8&49MG^,"KB;MEP-5I2\N;Y'[K96
M"5M -:SFVX;@;8P^P1XX1'O4G:?<L,!YNOTRZ'^@\LG$->6; 6F.(QO);'!2
M3#A2Y/0)!OE @1%\(PP&&_!YM8C/*W;<B+7<0K]0%ISX1@5$^')Q64#!WM(7
M,,84;@<R@X]C<7;^?"ZO5+R?=2A_#AP>5C!J=[W,MN.W:S$/$I-NO@S%#P]X
MZ%X"<2\2^44I717CU1WSF" >:77+G7V-K\AE^TW6Q(-92D#(O:D#1NA/X-X\
M!.XF!.?>A4'<OCRM7-9R.7SG\0<,BO7]8.ZY@Z72BUHKRKG8VV&G1K0+3/H+
M58_GA5>%F;5+A.C(,K>A-6 (?XJIN]<:JKU"M(#D%*;]EYZ<E08"B,Q+SMM$
M'W:;O=;A[U1[C2JK>X\05U#<@<Q: Z'_N\FK:_3"7UDTM0 1S&K,Z)'("M$?
MTSU[=C"P:_X(&':1]/A>,V5QOS 'GR;M9)64\]B)FP/\L>5UR7LQ_8>.Q>W/
M7'7&^:@ DMW$ 8,T0A#\AV#'R(GZ['"@8(_/.Q"FD=Z1(,06V[O]1P)_"/Y
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M(F$C:;K5T5A,+&*5)^_@2-WF1?0? B8BVMX"T7WX594 GNOPU%#WWQJI8ZB
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M%?NW7M, -A("?/&0\ %QX/R*.2L ,V1ME<-T?C$10J0FH\B]@:*D40H#EF&
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M<L#,)_Z2N6DT3^;X,X[I]MP:L<(C<?%H(6]\OSOFO*A,.#TG__J/KC)A<FA
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MZ?$@7>57/7G=*%R)[1TVR=<'5Q.>H?#R([%Y 1Y"91XC>-HXBL^#KC>&ZV
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MY%F[R3\NOLZQ,5,,)2 C7:E :AU\O?QD')N KR$RHQ\[YIX9A1&9*+4WXT^
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M_P-02P$"% ,4    " !4B2-9_<('E2C? 0 1E!L $0              @ $
M    87-N9"TR,#(T,#8S,"YH=&U02P$"% ,4    " !4B2-9P'$=D;D( 0!=
MB1  $0              @ %7WP$ 87-N9"TR,#(T,#8S,"YX<V102P$"% ,4
M    " !4B2-9'2WB5E5"   G20  $@              @ $_Z ( :6UG,30X
M-38P-34R7S N:G!G4$L! A0#%     @ 5(DC67.D9LTC* $ QYH! !(
M         ( !Q"H# &EM9S$T.#4V,#4U,E\Q+FIP9U!+ 0(4 Q0    ( %2)
M(UGO9J?&Y)4  #N^   2              "  1=3! !I;6<Q-#@U-C U-3)?
M,BYJ<&=02P$"% ,4    " !4B2-9T4KT2F,Y   X/P  $@
M@ $KZ00 :6UG,30X-38P-34R7S,N:G!G4$L! A0#%     @ 5(DC6?-=ZP3%
M0P  6D@  !(              ( !OB(% &EM9S$T.#4V,#4U,E\T+FIP9U!+
M 0(4 Q0    ( %2)(UFNR+3$/KX! .7O @ 2              "  ;-F!0!I
M;6<Q-#@U-C U-3)?-2YJ<&=02P$"% ,4    " !4B2-9X>()#[13   K80
M$@              @ $A)0< :6UG,30X-38P-34R7S8N:G!G4$L! A0#%
M  @ 5(DC63AS&[&C/P  ETP  !(              ( !!7D' &EM9S$T.#4V
@,#4U,E\W+FIP9U!+!08     "@ * 'X"  #8N <    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>asnd-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:asnd="http://ascendispharma.com/20240630"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="asnd-20240630.xsd" xlink:type="simple"/>
    <context id="C_80565c4e-bb31-49b2-b787-63ca7487b354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_82679e63-57f7-42c8-af63-f3c54a3a76ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_84865da0-8e28-4c64-b919-2fa941621732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_875630a8-6b06-4d56-b547-543891791c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_89622b42-c78f-4d8c-aa28-7a988bd5583e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">asnd:SalesRebatesAndProductReturnsInUSMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8de101c2-a4a1-4558-b6d8-6845ebd51060">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_8ef04b98-f458-48b5-892e-fb3c6e17fd2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_8f91e2fa-63c3-4b7c-88ab-ee542b10c21b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_916a1d45-ad20-4d5e-8c65-dfd11d9b937b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_99311e47-32a5-474d-8dac-f41409c83e74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_9a1ee37c-f52e-4fe7-a481-ffe9c8b8f6b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_9f234091-2f5a-43d2-b9cb-77a8e49084d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_9fd79df1-50c6-4d41-901d-c77df4998cd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a078a24b-80df-47b2-af27-cd002780edca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-29</startDate>
            <endDate>2023-11-29</endDate>
        </period>
    </context>
    <context id="C_a15defaa-f932-466b-bc51-1a68ece7b752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_a3ac4f0f-c190-458b-a628-87ada275b688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a6a141f6-eee5-4acc-a932-da5764785d72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_a74af470-e599-4a1e-b963-cdf93c8f8ad0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a7df51f1-e149-4eba-96d2-8116875f09ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_abf9a434-e689-4daf-8c60-5e8e573deaff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_af63688c-aa98-486a-a73c-5ac60c4f9e6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_b1459f92-4bdf-48d9-b032-4c65da483b6d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b1b4d1e4-24f6-4c89-914e-0c15eb61bcdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesYorvipathMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">asnd:EventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="C_b1cd9cb9-4b1b-4fea-bbde-9d3bc31d8f4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-29</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <context id="C_b2b88484-8cd6-44b7-aec7-488f08ce60a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_b3eeeb63-6bc6-460d-8c2e-19abe3bd08c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_b41da24d-bd30-42f4-a704-1d5714f18704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_b5bd486e-1131-4c51-9d6b-ba25b8052be8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_b5e24c58-8391-46c0-963b-15580b32b822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_b745985a-29e1-4fcb-919b-47749840575a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">asnd:SalesRebatesAndProductReturnsInUSMarketMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_ba212868-8b66-4623-81ce-a65efa8cb9e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_bd7c5f8f-6386-4bcb-a667-86ed3c7b0c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">asnd:EventsAfterReportingPeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="C_be47076c-c5c2-4398-803d-95bcc128d86b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_becea9f1-8ea3-4a3f-b92c-d1e19a63174b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_bfc109b6-0267-4568-8f44-fa14915ce2e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c2fcb3f0-5af6-4d4d-b93c-dd673702d997">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c4bb41a9-9897-48ff-97d9-d9e4c2fc4102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c5bb9cca-7e70-46d1-a292-8e9d545f5c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-29</instant>
        </period>
    </context>
    <context id="C_c5d652d5-d799-43f6-903b-d2389a4f9c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c7b94f2c-5166-4906-bd69-2ea999d9fd53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_c8cfaab1-fe5c-43f9-98a6-b5e0e36fcb12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_ce698de3-cc8b-45e2-bf70-a5c86942e92e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_cf326443-9fc3-4acd-8a7b-d10a15c9c639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_cf8bec94-85c6-4446-9f8d-25c797b23040">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_cfd8955d-eb7e-4148-9713-3f97e5f71e44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_cff9af56-3621-49bb-95fa-62e774a90dc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d001d487-d74a-42b7-827b-045eca711447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:RoyaltiesAndMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d23709e8-9e0d-4985-a23d-111331fe0a1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d2e575be-2a92-4dca-9d69-cce91f677a27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_d4a58637-2055-42b3-8157-1d28bda0cf03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_d4d49cb8-932e-432f-a338-771c043ea715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d5ac3b5c-e60f-478e-83cf-eddc448b6227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_d5d1312c-4638-41e8-a0fb-c5a22dd1c28e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_d66908c6-a5fa-467c-9047-36af0a5ab839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">asnd:EventsAfterReportingPeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="C_d75b971a-1f5c-45c3-9cf0-b42af670311f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level1OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d9e73adc-e2fa-4a69-a5e0-c417bc7c2b6e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_d9f93835-5fdc-4307-9a1f-a342ff26fcd1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_da85c345-157f-4aeb-af0c-84f018bd921c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_dbce7df2-7245-4497-93d8-ee51d52959af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_dca280d3-48db-4166-b87b-1d80627ed422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_dff101ac-1dfc-4e89-bbe4-f6d1091007b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_e183e072-5783-4dae-a0cb-cb13fdbf3564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_e47ee6ea-6244-4fae-841d-df097dd0610e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_e661bb05-fc48-440a-941f-d142682c6c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:AsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_e6982966-8271-4e1c-b818-503cfb91de1c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_e6cdfa0f-6832-4fea-9068-94b3c87d8f1f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e94750b4-4124-4fd8-8705-f5583e219191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_ea6471ce-cfa4-4d71-8f75-d5e623498d8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_eb095a6e-1284-4325-9346-7b0d477b86e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_ed967469-6caa-47a7-ad87-51a13e77b2b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ee58604e-a45e-405b-aac6-1e95591f95f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_ee64b1a5-0ac7-4bae-bf54-7e5e49b1964e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-29</instant>
        </period>
    </context>
    <context id="C_eea519f3-ad46-4ee7-85b0-8608cf3c21c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f0e8016e-5734-4177-91b0-d52b46d6a142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_f6bc3126-0f2f-41e1-af3d-24f995e53242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_f87b4034-74cf-4447-b713-7401524f3969">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_f9148b7d-21b7-44df-8bda-8e6396f928c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_fb30e055-a4bd-4504-a481-e7270ff2a4d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fc29bc9d-a605-4ae9-bbea-0edd6dc89dde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_fe41fa87-a9a5-445e-889a-4a84ce27e626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_01332415-aee7-4777-a043-a57648e597b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_04baf03f-f9bb-4f2a-83ab-f0cc09cff3da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_0566eec3-61b9-4678-9b3a-a122291dbee2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_08eccbc8-30a4-467c-8814-e3da8f51a6a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0901f291-b6cf-4be5-8d74-9686996cf492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0a89dad9-4f70-4ce9-b6cb-3b23f0d335f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0be81193-83e1-496a-b2bd-963e7a3ae019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0cea65b1-8e2e-4700-abec-c50d25040dcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0d563d87-8d91-4eb6-a982-541081c3f97a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:RoyaltiesAndMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_0d721657-d4bf-491a-b07d-d4d0a337317b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0eaa7d1b-df57-4e29-a988-3e72ff479760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_0f31b8c9-3f3e-45ff-b2dc-b529c435f24b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_0fda0982-6a94-4187-a702-171d557879fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_11cc6832-e075-4630-91b6-6f66a1b43e2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_120df43c-ac40-4949-bdf1-72d7e1be8540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_12efaec8-00be-4d5b-a2c1-d97f9f8f9802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_17f53fa0-ac0d-4634-a8a3-82386070a977">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_187cae39-2542-4e99-8ed4-2163bbbdd410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_18a4bc8c-4933-49e5-bb82-fff50688e62b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1a075a8f-0d93-49ae-991b-20bf71825ac3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_1eee9ac4-42e3-4c2a-b3db-f3d552da0c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-29</startDate>
            <endDate>2024-01-29</endDate>
        </period>
    </context>
    <context id="C_1ff24599-9bec-4004-890e-f2cabcf62656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ThirdPartyInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_225597ce-7a29-4ac4-bf28-15c7db56cb1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_22691430-ca22-41f0-9568-18019e721ba9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_226b71fb-e2f1-440b-9ce0-1b02d378af1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_24e1c394-8155-4ccd-9e4a-59d9e1ec986d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_26726fd6-ee62-4142-bc95-a08f61caedc3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_276506bc-fed9-44d5-bde0-317663083ca8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_2d38989e-7833-45b0-ae39-4b7e1ff91a47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_32e6f681-0344-457f-8a03-21f7d9f10b40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_34124e79-d811-40a9-b5d7-6e45ec01b712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:TeijinLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_34afc0af-3b75-4c01-8ab1-e8ee319238ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_398210cf-1fd9-4c1e-939e-e91ca03161c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_39a0db7a-f4cf-4e59-a617-6a1e70c6bcfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_3b38ee1f-0d21-4c30-b4e6-b4a0842378c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_3d46e5dc-bcc4-472a-9b45-7da68fed384e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_44cab9aa-2fd6-48de-9166-d81f187ddff5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_44d7ff3b-a312-4758-9d5a-9853401406cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_45be4da6-fe2a-4d4e-95dc-772befc84731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TimingOfTransferOfGoodsOrServicesAxis">ifrs-full:GoodsOrServicesTransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_4875ac0d-47d5-4a79-b057-425d568f5baf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_49e1466f-2be7-41f1-9dd9-ebfd767c7ab0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_4bfef56a-6c92-4668-b539-a03819e7ccb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4c6f70b1-9efa-4bae-96b1-ae13a04d5ec3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">asnd:ForeignCurrencyConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_4d022a29-849f-49c1-8fcf-8bc1ea086dfc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_4e7c4bb8-3ee7-41bc-9070-e5a4f8998df8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_4f8a6e8b-b214-487d-a30f-ae5d8fab47d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_515c180b-f403-4c76-ab33-f262096366f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_51bb1848-afba-426b-b5e1-8227d0a04edf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_5233396e-84c8-4084-9018-ab624a6eebc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_539b6d7b-9d56-47fe-9068-c2dcb0874079">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_53d2ec13-fbb3-43f3-8664-1c7545479049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CommercialCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_5578ada0-929b-48b2-bebc-ff63e89ab5f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_567228fa-89e0-4f5f-91c5-10eec549d109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">asnd:EventsAfterReportingPeriodMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="C_58b82036-71f0-4630-b251-42c9dc52172f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_59fa5ae0-47b2-46af-9d0c-e8a4358f7f81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_5a7beea2-de57-4790-91d5-5d1200eacac6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_5a88bcad-ece2-4420-8531-9e5bb79e8880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_5a94d79c-4291-4d0a-b8bb-268dad9a101c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_5ad1bdbd-dc10-4a8c-b928-7615e2fbcdc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_5b082919-9fbb-47d2-96d1-56d15ab71d5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationPartnersAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_60329ad0-04b9-486e-902b-e170a080d6a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_607615b8-3c2e-4bf2-ae45-963ac837db9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_60e20bc2-5206-4d1b-b79b-82ec729f7143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_64ff6bf5-a7fc-4f5e-87e7-121d85ebad42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_68b6a5ee-4fe8-4f12-a551-652ec2097752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_6be2f049-eb3c-45d2-b25b-1ce6e49e5a4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_70a9c3db-ba5b-4b53-9757-db806da4769e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_73c5c8ba-1fdd-4912-bbd7-e04f001ad88b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="C_74b79d5a-c86f-4a0e-b7fd-c61544cc9d20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_755b6ff2-16af-4b77-aef3-7e63b09f7644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_756073fe-efcc-4ad7-914c-18bd04b9013e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_7c55eeb6-4f32-446b-889f-4e47524ee405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_7d3624fd-d503-4996-b6ea-8dbd9da04208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="C_7d5f46e4-3795-445e-9938-80e373d5b80d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="C_7f8c7ce5-86c4-4f44-b5a8-e85f28bd20e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="U_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_Agreement">
        <measure>asnd:Agreement</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Segment">
        <measure>asnd:Segment</measure>
    </unit>
    <unit id="U_Days">
        <measure>asnd:Days</measure>
    </unit>
    <unit id="U_XBB">
        <measure>iso4217:XBB</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_DkkPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:DKK</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_CommercialCustomer">
        <measure>asnd:CommercialCustomer</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Multiple">
        <measure>asnd:Multiple</measure>
    </unit>
    <unit id="U_EurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_98362920-f219-4adb-b411-a5a3fe50f58e">0001612042</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_7ebee0fe-bbcb-4462-81d3-e43c11577328">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentPeriodEndDate
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_7ca06285-1a8e-42b6-956d-23c8742508e2">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_305bcc60-4e3b-458d-a481-cdf96e35a5ca">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_dca34ce8-4341-49df-91ec-43789a7c6bc8">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_9ad1a90d-8cff-4b98-acea-9a4e46db3f0e">6-K</dei:DocumentType>
    <dei:DocumentFiscalYearFocus
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_1a7f23a8-94c1-406f-8456-378dbdeee588">2024</dei:DocumentFiscalYearFocus>
    <dei:EntityRegistrantName
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_7e54b22d-eced-4fb9-abc7-8fd5889dc140">Ascendis Pharma A/S</dei:EntityRegistrantName>
    <ifrs-full:Revenue
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_98dbc364-ef81-418d-86c1-ba8422eb810a"
      unitRef="U_EUR">35998000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_9f1ea7a4-3763-4312-b3d8-12895e907f51"
      unitRef="U_EUR">47393000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_3710bc06-a3ba-47cc-9ea2-6f91a79e203a"
      unitRef="U_EUR">131892000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_adb08bb3-72a9-4eff-be34-0fd7a272d99f"
      unitRef="U_EUR">80982000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_d9b81726-d120-484e-9b75-2974d9008fe2"
      unitRef="U_EUR">11465000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_cdd65880-d55f-4e25-9f7c-31e862fd43ec"
      unitRef="U_EUR">12929000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_b4de2e3b-575b-4f32-a953-203fb5229819"
      unitRef="U_EUR">19034000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_b7814773-1117-4d58-a09c-fd2c939de656"
      unitRef="U_EUR">17551000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_503b48fa-4421-472a-9882-d2c489a33187"
      unitRef="U_EUR">24533000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_c70a4b04-adb7-4397-b7bd-86c2a59d232b"
      unitRef="U_EUR">34464000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_c2b5d20f-08e5-4692-853a-5c532157f016"
      unitRef="U_EUR">112858000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_0992e5cf-b455-43e6-925d-9a0a8cb43b98"
      unitRef="U_EUR">63431000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_4ce7ec23-6cf3-45ed-92ba-4eef2d904d3c"
      unitRef="U_EUR">83478000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_f843dff4-4de0-4a37-ad54-d380b5a12d78"
      unitRef="U_EUR">105021000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_0474ab13-33bd-4409-aae6-477a1c9bb521"
      unitRef="U_EUR">154165000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_f1765de0-81e9-42a3-b35d-46a0a3106402"
      unitRef="U_EUR">211134000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_880bf0f2-147d-4dbc-9b0e-ee680f0526b7"
      unitRef="U_EUR">74312000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_dcd39260-b5ad-4ebd-8147-3bbaf8fa1441"
      unitRef="U_EUR">70281000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_90c0918c-d7b3-47f7-b2ba-bb16f9718ffd"
      unitRef="U_EUR">141095000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_5c4b6087-a8d7-4465-a221-32fc70b163af"
      unitRef="U_EUR">136820000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_445e53de-b802-4023-925b-204b45224f28"
      unitRef="U_EUR">-133257000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_33c90628-0f26-4fb7-942a-6ae9e3942539"
      unitRef="U_EUR">-140838000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_f994be03-cade-4910-bd47-38048edc4d21"
      unitRef="U_EUR">-182402000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_c03a027d-fe8a-4498-952e-2ba30414b7f9"
      unitRef="U_EUR">-284523000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_83bc2bbc-4e6c-450f-8719-3414e9a17f40"
      unitRef="U_EUR">-5322000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_fcff9022-0471-46c0-a9c8-f6f52afde1df"
      unitRef="U_EUR">-7451000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_d5335e4b-f6bc-4c66-8d8f-01e87ef9cbbb"
      unitRef="U_EUR">-11118000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_839ec1e9-d020-4774-a096-8b33518e934e"
      unitRef="U_EUR">-8677000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:FinanceIncome
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_437d35fc-678c-4834-b89a-647857d95c00"
      unitRef="U_EUR">49052000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_6697fe97-553c-4537-a4ac-6821f4f2a88b"
      unitRef="U_EUR">35761000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_895edca5-5468-45c3-a8b8-f73343d97508"
      unitRef="U_EUR">14395000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_178be397-491e-4911-9423-2fde84217078"
      unitRef="U_EUR">80374000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_7ee008f0-0e7c-489e-9130-4362f7245f87"
      unitRef="U_EUR">19624000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_5d3db34f-d2fe-4817-a50f-d24d4ce0b26c"
      unitRef="U_EUR">9334000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_d927dbd4-278e-4be6-8061-efcc25b4acba"
      unitRef="U_EUR">58553000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_a0e8d50c-e098-4fda-b6ed-ad0076d3bcb3"
      unitRef="U_EUR">18652000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_f7594020-ce76-4a44-88d8-f5d29f170602"
      unitRef="U_EUR">-109151000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_345e32ad-3d9c-4af2-9520-9c65666b22dc"
      unitRef="U_EUR">-121862000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_d501fa2e-83da-43b1-a374-69a5d5e3b0d7"
      unitRef="U_EUR">-237678000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_99959afa-b96d-4c0b-87fd-cd9b3e5a6daf"
      unitRef="U_EUR">-231478000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_7ad151a7-70ca-408e-ab99-8c3ee662087e"
      unitRef="U_EUR">229000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_0c1b3d04-89bb-47a0-b665-0c9902564342"
      unitRef="U_EUR">-429000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_8e76093a-a0c9-4256-b53f-2490cf141a3f"
      unitRef="U_EUR">2737000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_eb931759-5d3a-44ee-b368-6a6b360cc1a2"
      unitRef="U_EUR">868000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_cfd192f8-0e83-4573-8df0-52bee0245fc7"
      unitRef="U_EUR">-109380000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_8533e4ac-f5fc-4d5b-b064-a41743ee4c55"
      unitRef="U_EUR">-121433000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_b46e7905-a9ef-4e45-8fa4-dae79ce5ea02"
      unitRef="U_EUR">-240415000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_78a3339a-4e32-478b-82d0-83767d399274"
      unitRef="U_EUR">-232346000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_7c258d69-ca59-48d9-a8e7-2a8d410a0c19"
      unitRef="U_EUR">-109380000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_7c822d8d-5321-4d60-a36a-93cadaf09876"
      unitRef="U_EUR">-121433000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_57503442-4fa2-4b91-bd25-8db48b715624"
      unitRef="U_EUR">-240415000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_dc21e1cd-531a-4cb4-aa30-1a01e9f949f8"
      unitRef="U_EUR">-232346000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="2"
      id="F_7b7123d3-ba86-48ae-b983-f4e475cc20d2"
      unitRef="U_EurPerShare">-1.91</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="2"
      id="F_3fd4c353-2970-41d8-b1a0-e761bff6735d"
      unitRef="U_EurPerShare">-1.91</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="2"
      id="F_155d219f-8ef0-4eaa-8f56-f70fb7cacaf3"
      unitRef="U_EurPerShare">-2.16</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="2"
      id="F_96578553-0cee-427e-8fb4-d701811757f2"
      unitRef="U_EurPerShare">-2.16</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="2"
      id="F_1f910941-e329-4329-baa7-68465982599a"
      unitRef="U_EurPerShare">-4.21</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="2"
      id="F_e044379b-3224-4148-abd5-a60452218101"
      unitRef="U_EurPerShare">-4.21</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="2"
      id="F_5ce5cc44-f3f2-4ac9-98e2-d0f31e515fe6"
      unitRef="U_EurPerShare">-4.14</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="2"
      id="F_22f96721-0f62-46a8-a284-2c2708009d83"
      unitRef="U_EurPerShare">-4.14</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="0"
      id="F_5b333498-0653-46a4-872f-fc79e7006884"
      unitRef="U_shares">57345613</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="0"
      id="F_084333b3-53b3-4ef1-99d1-28a4da53ed19"
      unitRef="U_shares">56218257</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="0"
      id="F_8a589942-865c-4e8d-8663-eb005469b812"
      unitRef="U_shares">57114435</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="0"
      id="F_524f7c83-ae41-47ce-8c40-f85ecc391045"
      unitRef="U_shares">56155441</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLoss
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_45b757b7-778e-406c-ae2b-99006c099b87"
      unitRef="U_EUR">-109380000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_a8c66272-f922-4bb2-b02e-ec8e0ca28725"
      unitRef="U_EUR">-121433000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_9ed5816d-bb29-4f43-a267-8b187c072a87"
      unitRef="U_EUR">-240415000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_0e09851d-0036-41d4-af2d-366a32416fa2"
      unitRef="U_EUR">-232346000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_4ab3c8ec-5199-4fc0-bab2-a240c4d54b26"
      unitRef="U_EUR">15000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_b35158f8-1e43-492c-a571-363f41449508"
      unitRef="U_EUR">-1016000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_ce62f9e9-201b-4f24-805d-85e6cec0c893"
      unitRef="U_EUR">78000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_fb983484-bf90-48e9-9796-6ad988bcd361"
      unitRef="U_EUR">-1803000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_fdc6d627-c930-41f9-b236-1f88567da079"
      unitRef="U_EUR">15000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_2ab05e23-64e1-4e9a-97e3-30815aab9077"
      unitRef="U_EUR">-1016000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_db96393e-6583-49bb-9998-982cfeb2d010"
      unitRef="U_EUR">78000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_7421433f-dcb2-4643-b003-eec50cb04de7"
      unitRef="U_EUR">-1803000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_8a33915e-c247-45a4-b684-07c592f1b780"
      unitRef="U_EUR">-109365000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_f57004ff-987f-46f2-a6fa-b676b9765e31"
      unitRef="U_EUR">-122449000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_461a8c3d-8b35-4446-961c-1180c33f0321"
      unitRef="U_EUR">-240337000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_890e7ed1-ce7c-4eb8-94a3-c139895240a8"
      unitRef="U_EUR">-234149000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_d30afef2-2872-4d34-97c8-b5862e25147e"
      unitRef="U_EUR">-109365000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_4b44f1be-24ab-465b-9738-d1d92a511d59"
      unitRef="U_EUR">-122449000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_85bf780b-18bb-4df4-b69b-f228ee24c810"
      unitRef="U_EUR">-240337000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_4a304574-a392-4a7a-9145-59abb63c5092"
      unitRef="U_EUR">-234149000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <asnd:NumberOfWarrantsOutstanding
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="0"
      id="F_236e0152-c612-4210-ae4c-9b7995743eb0"
      unitRef="U_shares">6107875</asnd:NumberOfWarrantsOutstanding>
    <asnd:NumberOfWarrantsOutstanding
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="0"
      id="F_4dbc0000-8b55-4dd2-b312-32fab65e4a1b"
      unitRef="U_shares">6866241</asnd:NumberOfWarrantsOutstanding>
    <asnd:PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares
      contextRef="C_abf9a434-e689-4daf-8c60-5e8e573deaff"
      decimals="0"
      id="F_a5190953-aff8-4d00-8523-7dc220eecf74"
      unitRef="U_shares">575000</asnd:PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares>
    <asnd:NumberOfWarrantsOutstanding
      contextRef="C_64ff6bf5-a7fc-4f5e-87e7-121d85ebad42"
      decimals="0"
      id="F_a5b285fc-669d-45da-a1c4-bad41bed4f43"
      unitRef="U_shares">3456785</asnd:NumberOfWarrantsOutstanding>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_ec5dfb78-b7c7-49e7-9448-c5a264379a58"
      unitRef="U_EUR">4186000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_7e57b3a9-8415-4520-b190-e7623aa77a8b"
      unitRef="U_EUR">4419000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_6686650c-5b23-4186-b9f5-c0e5db8ed12b"
      unitRef="U_EUR">104041000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_bd576b10-7e04-442f-b95a-46b778291a84"
      unitRef="U_EUR">110634000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:InvestmentsInAssociates
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_748db188-92fe-4278-a346-3137854bce05"
      unitRef="U_EUR">20564000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:InvestmentsInAssociates
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_9dc19c89-9bf1-49f4-a7c1-5e3d7ae71023"
      unitRef="U_EUR">5686000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_14cecb2f-06cb-4fd6-aa2f-fda59e2f5320"
      unitRef="U_EUR">2186000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_233ee51a-aad9-4832-ad75-b10f6b9e9200"
      unitRef="U_EUR">2127000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:NoncurrentAssets
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_5d2ed3cf-6352-4055-913f-e9a4e6510165"
      unitRef="U_EUR">130977000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_e657ec17-8454-43a1-88d8-54894f39488b"
      unitRef="U_EUR">122866000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_9ddf6618-af50-4ec2-bf8e-597af3d5da4d"
      unitRef="U_EUR">251199000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_0dc349cc-2616-47e9-9d87-5b4ce08ffc77"
      unitRef="U_EUR">208931000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_08f8b877-cf65-4968-82cd-9199cd1f24cf"
      unitRef="U_EUR">49163000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_67abc51f-3bcb-4f46-83db-eb370da16f59"
      unitRef="U_EUR">35874000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_51322fdd-e1ab-444b-82cc-097dd46ce565"
      unitRef="U_EUR">1841000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_1967865c-c743-4421-aa13-6d4bd424ec09"
      unitRef="U_EUR">802000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:OtherCurrentReceivables
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_dfb6fdc3-41e6-4374-ad84-4fc63b348c9c"
      unitRef="U_EUR">29679000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_8c97d3a3-4fb6-4b41-860c-543a94f30be5"
      unitRef="U_EUR">19097000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_bceb0a5d-2672-4353-b448-3137cf8239e1"
      unitRef="U_EUR">36743000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_700359cb-1f36-4eea-9927-994eaeb60ffa"
      unitRef="U_EUR">38578000</ifrs-full:CurrentPrepayments>
    <asnd:MarketableSecurities1
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_10081e95-7dee-4f9c-b819-bd02f863f53c"
      unitRef="U_EUR">0</asnd:MarketableSecurities1>
    <asnd:MarketableSecurities1
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_49564e5c-380a-4e0f-8662-ab6867d57b24"
      unitRef="U_EUR">7275000</asnd:MarketableSecurities1>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_6378753c-31a0-4fe8-adab-c383c13d42cb"
      unitRef="U_EUR">258696000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_d1ea4e60-53d4-4e7d-b845-1a989bde68de"
      unitRef="U_EUR">392164000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_ed950255-5eab-44df-bc7b-ac5eb46c323e"
      unitRef="U_EUR">627321000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_44dffc56-8fa3-443c-b2a6-4e7632e6014d"
      unitRef="U_EUR">702721000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_64022296-31c9-4bc0-a13a-4bed75e0612c"
      unitRef="U_EUR">758298000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_fa26f540-87ab-4661-910d-3b5d76a9c04d"
      unitRef="U_EUR">825587000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_d37dc391-8738-4cda-bc35-a7fd02b556ba"
      unitRef="U_EUR">7819000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_4468caae-728d-4f21-84e9-903706d21fb8"
      unitRef="U_EUR">7749000</ifrs-full:IssuedCapital>
    <asnd:DistributableEquity
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_3b9f2286-8740-4dbe-b79d-a8b4d704c6b0"
      unitRef="U_EUR">-328952000</asnd:DistributableEquity>
    <asnd:DistributableEquity
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_729541c0-268c-4e4e-9f85-a9a6598f58b6"
      unitRef="U_EUR">-153446000</asnd:DistributableEquity>
    <ifrs-full:Equity
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_9aafd48e-5a97-4054-94fb-bf0f4f678b4f"
      unitRef="U_EUR">-321133000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_7a50cee2-f81a-4c0f-9457-ae618f65b38d"
      unitRef="U_EUR">-145697000</ifrs-full:Equity>
    <ifrs-full:LongtermBorrowings
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_8097d2a4-90c1-4949-9388-b3fd707c4e5a"
      unitRef="U_EUR">219052000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_3158cf98-5517-43b7-b02e-e56e57bb504c"
      unitRef="U_EUR">222996000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_2c107a77-c10e-4085-a2dd-6afe44b3d82d"
      unitRef="U_EUR">5000000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_91592c61-ac7a-4a8c-b02f-4a7d390f9fa6"
      unitRef="U_EUR">5949000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_65d873f0-2a15-4658-a406-e1d69db292e6"
      unitRef="U_EUR">7644000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_1af6c97d-a6df-4125-8a82-6404e0e630cf"
      unitRef="U_EUR">5830000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_c43442be-486a-4f81-865d-c9494312ec06"
      unitRef="U_EUR">231696000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_57f697bb-02ca-4ba1-a9e0-60565488b080"
      unitRef="U_EUR">234775000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:ShorttermBorrowings
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_ba71a074-3159-403f-a9c3-8c121f66028e"
      unitRef="U_EUR">432190000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_41aa71c5-385e-434f-96a1-ef39cddad894"
      unitRef="U_EUR">407095000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_a61611a6-0669-4796-a221-fe8d8775b222"
      unitRef="U_EUR">159059000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_10a4d01f-45ce-4892-8284-1013ef13b263"
      unitRef="U_EUR">143296000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <asnd:ConvertibleNotesCurrent
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_f033e3de-3d02-46df-9570-a8f387bb6490"
      unitRef="U_EUR">591249000</asnd:ConvertibleNotesCurrent>
    <asnd:ConvertibleNotesCurrent
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_4db275dc-86a6-4799-91c1-bcc3b23e5975"
      unitRef="U_EUR">550391000</asnd:ConvertibleNotesCurrent>
    <asnd:OtherShortTermBorrowings
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_056e797e-2c05-4db7-a993-dd344b5ce128"
      unitRef="U_EUR">21397000</asnd:OtherShortTermBorrowings>
    <asnd:OtherShortTermBorrowings
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_391a6cde-2c4a-42d1-81ef-fbe85b4890c4"
      unitRef="U_EUR">14174000</asnd:OtherShortTermBorrowings>
    <ifrs-full:CurrentContractLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_bddcbac3-ee19-4e9a-a7db-fe52df162c6a"
      unitRef="U_EUR">1293000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_d098eeb5-066d-4cdc-88c8-c4c91af0542a"
      unitRef="U_EUR">1184000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_e3075070-9217-4c64-94b6-72efde8be358"
      unitRef="U_EUR">99527000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_a783ab8c-b33f-4cb5-a0d3-db14a43cba75"
      unitRef="U_EUR">94566000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_96fdc6a5-d144-4e93-96c6-294a6fb72acb"
      unitRef="U_EUR">26411000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_612a2e7c-8e09-4c3f-917c-5f33528ebeb8"
      unitRef="U_EUR">41176000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_8f10b3a2-b96c-4713-9158-32a3bd8b8953"
      unitRef="U_EUR">1090000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_ce9e534c-d8db-4ce7-abee-d76dcf664ac1"
      unitRef="U_EUR">2299000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentProvisions
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_70af1a0e-26bc-4b04-a927-070e546790be"
      unitRef="U_EUR">106768000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_197f6a85-94fe-465c-a124-57b8fda7252c"
      unitRef="U_EUR">32719000</ifrs-full:CurrentProvisions>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_8146482c-44ef-4e73-b09f-5a8e7ca871a6"
      unitRef="U_EUR">256486000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_8bbbf781-28ad-479c-86a6-3344dba03d2e"
      unitRef="U_EUR">186118000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_5fed9d14-4a81-40dd-8b00-9c1197645472"
      unitRef="U_EUR">847735000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_74ee0fa5-ceef-4f77-8881-1d42c5515e22"
      unitRef="U_EUR">736509000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_79eca445-a392-42ea-960e-484398badb85"
      unitRef="U_EUR">1079431000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_cf9e20cb-43d0-4ec4-8a31-4e0f524a15f5"
      unitRef="U_EUR">971284000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_fc2f364c-b3c5-41e0-a467-66fc7a68fb7c"
      unitRef="U_EUR">758298000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_366def8c-0803-4cb0-945b-8ff5c883022a"
      unitRef="U_EUR">825587000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="C_539b6d7b-9d56-47fe-9068-c2dcb0874079"
      decimals="-3"
      id="F_9fc41c57-50ab-4eeb-be27-7df032cf79a2"
      unitRef="U_EUR">7749000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_18a4bc8c-4933-49e5-bb82-fff50688e62b"
      decimals="-3"
      id="F_8b0d8596-89a8-4c61-9240-5e500836ddb6"
      unitRef="U_EUR">2123074000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_34afc0af-3b75-4c01-8ab1-e8ee319238ab"
      decimals="-3"
      id="F_00ce142d-a16e-4c32-8717-5394fdfef3c1"
      unitRef="U_EUR">-146000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_60329ad0-04b9-486e-902b-e170a080d6a9"
      decimals="-3"
      id="F_cb34fba0-e86c-4cda-9404-9620f9a120c2"
      unitRef="U_EUR">721000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_11cc6832-e075-4630-91b6-6f66a1b43e2c"
      decimals="-3"
      id="F_c339653c-a4a2-41eb-9149-4ecd827dc523"
      unitRef="U_EUR">-2277095000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_6aae2350-73b0-4ae2-9bb0-c5d226bdc001"
      unitRef="U_EUR">-145697000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_8f91e2fa-63c3-4b7c-88ab-ee542b10c21b"
      decimals="-3"
      id="F_cb3ce5bb-2db1-4632-9ace-7aadc9e7a282"
      unitRef="U_EUR">-240415000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_6bc96047-4c11-42d7-963d-fec7a484d62d"
      unitRef="U_EUR">-240415000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_08eccbc8-30a4-467c-8814-e3da8f51a6a7"
      decimals="-3"
      id="F_a2b30796-42b5-4530-9e67-6812a98bb4c1"
      unitRef="U_EUR">78000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_479d5a18-f519-4d50-a88a-71288a73a0cd"
      unitRef="U_EUR">78000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_08eccbc8-30a4-467c-8814-e3da8f51a6a7"
      decimals="-3"
      id="F_994137d0-45a2-4489-ac08-1f5fa2613322"
      unitRef="U_EUR">78000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_8f91e2fa-63c3-4b7c-88ab-ee542b10c21b"
      decimals="-3"
      id="F_bce4c34e-1251-4a5d-b4e7-6839ca99272a"
      unitRef="U_EUR">-240415000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_77c5f1af-ad65-440a-a6a6-f39d0a27b5ec"
      unitRef="U_EUR">-240337000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_8f91e2fa-63c3-4b7c-88ab-ee542b10c21b"
      decimals="-3"
      id="F_0592f7a8-8532-45e6-a5c3-5dfaa6f1014c"
      unitRef="U_EUR">43327000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_ecaf0144-4186-4b78-bf4a-bfb7feb3677e"
      unitRef="U_EUR">43327000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <asnd:TransferOfTreasury
      contextRef="C_58b82036-71f0-4630-b251-42c9dc52172f"
      decimals="-3"
      id="F_f6399d61-491a-4e4b-b364-a1fb1545b658"
      unitRef="U_EUR">28000</asnd:TransferOfTreasury>
    <asnd:TransferOfTreasury
      contextRef="C_8f91e2fa-63c3-4b7c-88ab-ee542b10c21b"
      decimals="-3"
      id="F_6b31a518-b051-45af-9364-4b2f855bd7c7"
      unitRef="U_EUR">-28000</asnd:TransferOfTreasury>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_607615b8-3c2e-4bf2-ae45-963ac837db9f"
      decimals="-3"
      id="F_e8217269-1869-456e-9e9c-913b5d826261"
      unitRef="U_EUR">70000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_4d022a29-849f-49c1-8fcf-8bc1ea086dfc"
      decimals="-3"
      id="F_59e83e16-76fe-45d6-a45f-0f9e8e5e441b"
      unitRef="U_EUR">21504000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_048a55cf-c22a-4351-90f1-5dca978ebbff"
      unitRef="U_EUR">21574000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:Equity
      contextRef="C_eb095a6e-1284-4325-9346-7b0d477b86e0"
      decimals="-3"
      id="F_59c04b3d-87a8-4d77-b0cd-b2cef1a11590"
      unitRef="U_EUR">7819000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_80565c4e-bb31-49b2-b787-63ca7487b354"
      decimals="-3"
      id="F_24f5c7a1-d264-4c6e-81e5-ca47e8f2ee70"
      unitRef="U_EUR">2144578000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_68b6a5ee-4fe8-4f12-a551-652ec2097752"
      decimals="-3"
      id="F_72cbbbd7-c550-420d-9a09-0630ab0306a8"
      unitRef="U_EUR">-118000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_17f53fa0-ac0d-4634-a8a3-82386070a977"
      decimals="-3"
      id="F_ef115822-0cf1-45a6-97c3-c017b8ee8d11"
      unitRef="U_EUR">799000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_fe41fa87-a9a5-445e-889a-4a84ce27e626"
      decimals="-3"
      id="F_691a9b98-89b3-4633-8f77-01a033313daa"
      unitRef="U_EUR">-2474211000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_8d8243e4-9993-4ce7-abf8-e24865d510ae"
      unitRef="U_EUR">-321133000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_e6cdfa0f-6832-4fea-9068-94b3c87d8f1f"
      decimals="-3"
      id="F_460bc0d6-f87d-4110-b074-5fcb2d67e17c"
      unitRef="U_EUR">7675000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_dbce7df2-7245-4497-93d8-ee51d52959af"
      decimals="-3"
      id="F_31b382a9-bb13-469c-aeca-7001c89918a9"
      unitRef="U_EUR">2112863000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_a3ac4f0f-c190-458b-a628-87ada275b688"
      decimals="-3"
      id="F_822c4751-2e5a-4950-88df-5b10030e37ca"
      unitRef="U_EUR">-149000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_fb30e055-a4bd-4504-a481-e7270ff2a4d0"
      decimals="-3"
      id="F_a91a6645-aadf-4c1f-9c04-0e72b3aefd3d"
      unitRef="U_EUR">3452000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_225597ce-7a29-4ac4-bf28-15c7db56cb1a"
      decimals="-3"
      id="F_33d5b95c-77c0-4fa9-98bd-79737240fe45"
      unitRef="U_EUR">-1860493000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_875630a8-6b06-4d56-b547-543891791c57"
      decimals="-3"
      id="F_739151e3-b9c3-467c-ab38-eadd564c8378"
      unitRef="U_EUR">263348000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_a15defaa-f932-466b-bc51-1a68ece7b752"
      decimals="-3"
      id="F_b71d08c7-eaae-43b7-946b-a39ca4bc5175"
      unitRef="U_EUR">-232346000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_fdbe50e7-e444-466e-bad6-51c67a42e6b7"
      unitRef="U_EUR">-232346000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_9f234091-2f5a-43d2-b9cb-77a8e49084d4"
      decimals="-3"
      id="F_ad28e8d3-e2fa-489b-9552-f3ecf32aa2e7"
      unitRef="U_EUR">-1803000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_99fd2b31-bf5c-445d-945e-bceeb5cb0e1d"
      unitRef="U_EUR">-1803000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_9f234091-2f5a-43d2-b9cb-77a8e49084d4"
      decimals="-3"
      id="F_e16e837e-b59f-437b-9130-5331850473c0"
      unitRef="U_EUR">-1803000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_a15defaa-f932-466b-bc51-1a68ece7b752"
      decimals="-3"
      id="F_c5fecdb3-03e3-49c2-a2a6-154a303a1a4d"
      unitRef="U_EUR">-232346000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_702e98e7-7623-4b9f-bcf7-00b1f7806ac1"
      unitRef="U_EUR">-234149000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_a15defaa-f932-466b-bc51-1a68ece7b752"
      decimals="-3"
      id="F_3f803551-1191-4ac6-96b8-119c41987aaa"
      unitRef="U_EUR">33568000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_3f284b2b-4c96-405b-8e07-f60ab229ab57"
      unitRef="U_EUR">33568000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_5578ada0-929b-48b2-bebc-ff63e89ab5f2"
      decimals="-3"
      id="F_3e46ffdf-6f21-4902-8ee0-74ab0debd762"
      unitRef="U_EUR">24000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_4e7c4bb8-3ee7-41bc-9070-e5a4f8998df8"
      decimals="-3"
      id="F_b57fc59e-f854-408c-88bf-eae2e36afa82"
      unitRef="U_EUR">2050000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_25486fde-6391-4820-9417-4fdaaaaf54ce"
      unitRef="U_EUR">2074000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:Equity
      contextRef="C_c8cfaab1-fe5c-43f9-98a6-b5e0e36fcb12"
      decimals="-3"
      id="F_c5dcd651-a6d4-4d53-95e6-d0f7c9649a4b"
      unitRef="U_EUR">7699000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_5ad1bdbd-dc10-4a8c-b928-7615e2fbcdc2"
      decimals="-3"
      id="F_82556213-f429-4713-ae26-5200d7447d69"
      unitRef="U_EUR">2114913000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_7d3624fd-d503-4996-b6ea-8dbd9da04208"
      decimals="-3"
      id="F_0e3a96a5-28f0-4fa6-b8f6-c8bf6de8e73f"
      unitRef="U_EUR">-149000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_af63688c-aa98-486a-a73c-5ac60c4f9e6e"
      decimals="-3"
      id="F_2d6361b1-6957-400b-b13f-71cb8a8e4c6f"
      unitRef="U_EUR">1649000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_398210cf-1fd9-4c1e-939e-e91ca03161c0"
      decimals="-3"
      id="F_d8f00593-e0c7-4197-83bb-53840525fff0"
      unitRef="U_EUR">-2059271000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_f87b4034-74cf-4447-b713-7401524f3969"
      decimals="-3"
      id="F_b0e5ee10-858b-41d3-b67c-9403b6c9d003"
      unitRef="U_EUR">64841000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_7f6c6dc6-f450-4192-abe7-f0fd45908744"
      unitRef="U_EUR">-240415000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_652c1ada-451d-4bdd-9818-bf2b866af0e9"
      unitRef="U_EUR">-232346000</ifrs-full:ProfitLoss>
    <ifrs-full:FinanceIncome
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_0a6d1e16-72f3-4004-b840-fc34542353de"
      unitRef="U_EUR">14395000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_e5504240-8005-43a7-85d7-6b30904d70e3"
      unitRef="U_EUR">80374000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_fa050aca-0ad4-4d12-a7a5-4831ed1cbf8f"
      unitRef="U_EUR">58553000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_90980bf1-9caa-44b2-968e-cdaa2c0c4440"
      unitRef="U_EUR">18652000</ifrs-full:FinanceCosts>
    <ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_668d5afc-9514-4452-9891-2fa1e04d0def"
      unitRef="U_EUR">91000</ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_33fc0f80-dd23-4801-9919-806e640f8428"
      unitRef="U_EUR">-21000</ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_83b46eea-ba2f-4b09-ace9-0963b3c2382a"
      unitRef="U_EUR">2737000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_e5501057-57b2-40a7-bac2-bcd194f50253"
      unitRef="U_EUR">868000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <asnd:AdjustmentsForNonCashConsiderationRegardingRevenue
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_70761ef7-b344-454b-ae7b-4e72c1be3e19"
      unitRef="U_EUR">25639000</asnd:AdjustmentsForNonCashConsiderationRegardingRevenue>
    <asnd:AdjustmentsForNonCashConsiderationRegardingRevenue
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_20521aaf-6ce9-4ddc-b4a8-effa2c322875"
      unitRef="U_EUR">1203000</asnd:AdjustmentsForNonCashConsiderationRegardingRevenue>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_ef93ee45-d8d4-4668-8939-8bac0e47fe8f"
      unitRef="U_EUR">-11118000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_26326ffd-0040-4d03-ac99-68f5bb1b0ea2"
      unitRef="U_EUR">-8677000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_2c44a051-01ad-4b26-a88c-542b8feba250"
      unitRef="U_EUR">43327000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_4f79fc31-0931-40b2-9138-b2adf489a1c5"
      unitRef="U_EUR">33568000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_79b471bd-656b-476f-aaee-d30801226116"
      unitRef="U_EUR">8632000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_a6df18a4-44bc-4fbc-ae1d-efdd26f472a3"
      unitRef="U_EUR">8969000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_08c67643-8e54-4f53-b0be-bf1b2ab3ca3f"
      unitRef="U_EUR">233000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_4420d0fa-212c-4b44-9326-082486c6a76d"
      unitRef="U_EUR">222000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_dfd7536d-2550-4b06-adcb-ecaf02bdfc9a"
      unitRef="U_EUR">-42268000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_a7b1c824-acd1-4b88-9499-bd6294f2e33f"
      unitRef="U_EUR">-37246000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_0dd8aba2-a098-4a28-95fe-818d0fbaf213"
      unitRef="U_EUR">-22747000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_eff9ab59-d17c-4563-90a5-1eddb5149f22"
      unitRef="U_EUR">-10715000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_e5379d9e-6927-4610-943c-634bb46ed161"
      unitRef="U_EUR">1867000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_80a7397a-4e5a-47a6-b302-6fc80d9c0641"
      unitRef="U_EUR">-12779000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_979148be-220b-40ca-8c1e-01968b12c62b"
      unitRef="U_EUR">-840000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_1fdd8e73-7404-4d8b-8ae7-da2b4d7267bd"
      unitRef="U_EUR">-9118000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_d7e25e97-60fa-4b57-91d5-959a577024cb"
      unitRef="U_EUR">-10571000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_6a2689c0-f7cd-4c46-92fa-6dc1b7fb1aef"
      unitRef="U_EUR">9316000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_ef53d1e2-7a53-46d9-bf27-705492289901"
      unitRef="U_EUR">72276000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_947069b7-8cd5-4421-bade-223a994bcf19"
      unitRef="U_EUR">3625000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_c09a2cfd-0304-4f92-8d69-0fbd6a236aeb"
      unitRef="U_EUR">-158223000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_2c5a3b45-4fb5-4adf-a2ac-567df7bdc050"
      unitRef="U_EUR">-299863000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_4fd6f3f3-1645-4e82-86e6-5aa5432086a6"
      unitRef="U_EUR">6265000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_87ee3d6a-a2bc-4835-8406-ace6ddec1a7a"
      unitRef="U_EUR">8403000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_08508d55-5e49-4002-a4c5-735fd3da2600"
      unitRef="U_EUR">7714000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_42ea8ae3-bbd4-4882-94e3-2908d13f0927"
      unitRef="U_EUR">7746000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_ebaf1fb5-4664-4fad-8a69-13453a03c4f3"
      unitRef="U_EUR">3218000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_d32837d7-3472-40ee-847c-183ed4723df6"
      unitRef="U_EUR">966000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_1888c207-cd13-4fe9-9ef5-cdc49a6e786c"
      unitRef="U_EUR">-162890000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_8aed7a61-2d25-480c-a701-070305b2f585"
      unitRef="U_EUR">-300172000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_0659db9d-1e88-4e83-b7d8-2d096d257b23"
      unitRef="U_EUR">541000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_80814f24-7c66-4cb1-b467-d29632a2449d"
      unitRef="U_EUR">1529000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_c0f1face-a15a-4dfc-bf0d-549717c34b29"
      unitRef="U_EUR">950000</ifrs-full:ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_e23a25db-4031-4326-9051-ace8623aace5"
      unitRef="U_EUR">7354000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_273283fa-f594-4917-a222-71e320938297"
      unitRef="U_EUR">259132000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_c184583c-6bde-4d18-b630-6111b84fbdfe"
      unitRef="U_EUR">7763000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_76238698-11b3-465e-ad1c-124c5373e749"
      unitRef="U_EUR">257603000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_16eaa617-c712-4102-bcc6-caa5df1138ad"
      unitRef="U_EUR">5606000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_7d7e6ef7-e5fd-4ec3-a34f-0ef3a0f0e99e"
      unitRef="U_EUR">5085000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_6ea529bc-90d3-4386-8221-4568c26783ff"
      unitRef="U_EUR">21574000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_cbf2e55d-e28b-4f7b-ad00-0a584609c694"
      unitRef="U_EUR">2074000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_c2d0a497-6c56-4583-91ff-836c07313c4b"
      unitRef="U_EUR">15968000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_df0a64c9-34f9-46c5-abe8-9b940ad3e189"
      unitRef="U_EUR">-3011000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_cec4ed8b-92ef-4706-875f-39f3c065ab0b"
      unitRef="U_EUR">-139159000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_eb4630d9-3118-449e-bda3-09f3e15fcd19"
      unitRef="U_EUR">-45580000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_b37acba8-ce53-40cb-9be5-7ba254a9d1a3"
      unitRef="U_EUR">392164000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_875630a8-6b06-4d56-b547-543891791c57"
      decimals="-3"
      id="F_8786a2ef-4bb7-461e-888b-1348ac679e8a"
      unitRef="U_EUR">444767000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_e5aedce7-d069-44f8-89a6-9e5b085e2cfb"
      unitRef="U_EUR">5691000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_f770c00e-b640-4032-b2c7-c9ab2eb4685f"
      unitRef="U_EUR">-4965000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_dc7c7945-a3ae-4ab7-b21f-7adb96730cf5"
      unitRef="U_EUR">258696000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_f87b4034-74cf-4447-b713-7401524f3969"
      decimals="-3"
      id="F_fdfc6f2c-fad9-4510-b5ad-a71571ee2a29"
      unitRef="U_EUR">394222000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:BalancesWithBanks
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_007be83f-b1bc-43d8-b7e9-e4895a7076e9"
      unitRef="U_EUR">258696000</ifrs-full:BalancesWithBanks>
    <ifrs-full:BalancesWithBanks
      contextRef="C_f87b4034-74cf-4447-b713-7401524f3969"
      decimals="-3"
      id="F_800448db-8c6f-4170-b528-f48e01a40dd9"
      unitRef="U_EUR">394222000</ifrs-full:BalancesWithBanks>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_c8b7e0c2-0441-4493-a65c-0753c5e72494"
      unitRef="U_EUR">258696000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_f87b4034-74cf-4447-b713-7401524f3969"
      decimals="-3"
      id="F_4d9adb36-a948-4a60-a2f1-65c93a4ec761"
      unitRef="U_EUR">394222000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_da6d93fe-a7d9-4278-a059-5e5f72f3d01a">&lt;p id="notes" style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;te 1&#x2014;General Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Ascendis Pharma A/S, together with its subsidiaries, is applying its innovative TransCon technology platform to build a leading, fully integrated, global biopharma company focused on making a meaningful difference in patients&#x2019; lives. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Unless the context otherwise requires, references to the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our,&#x201d; refer to Ascendis Pharma A/S and its subsidiaries.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The address of the Company&#x2019;s registered office is Tuborg Boulevard 12, DK-2900, Hellerup, Denmark.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On February 2, 2015, the Company completed an initial public offering which resulted in the listing of American Depositary Shares (&#x201c;ADSs&#x201d;), representing the Company&#x2019;s ordinary shares, under the symbol &#x201c;ASND&#x201d; in the United States on The Nasdaq Global Select Market.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) approved these unaudited condensed consolidated interim financial statements on September 3, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_94fed202-9a8c-4631-b9cf-dee524f254f6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 2&#x2014;Summary of Material Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Preparation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#x201c;Interim Financial Reporting.&#x201d; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#x201c;IFRS&#x201d;) have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#x2019;s audited annual consolidated financial statements for the year ended December 31, 2023, and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board (the &#x201c;IASB&#x201d;) and as adopted by the European Union (the &#x201c;EU&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accounting policies applied are consistent with those of the previous financial year. A description of the accounting policies is provided in the Accounting Policies section of the audited consolidated financial statements as of and for the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New and Amended Standards and Interpretations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has applied amendments to paragraphs 69 to 76 of IAS 1, &#x201c;Presentation of Financial Statements,&#x201d; which was effective for annual reporting periods beginning on or after January 1, 2024, and must be applied retrospectively. The amendments to IAS 1 specify the requirements for classifying liabilities as current or non-current. The amendments clarify:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;What is meant by a right to defer settlement;  &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;That a right to defer must exist at the end of the reporting period; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;That classification is unaffected by the likelihood that an entity will exercise its deferral right; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The convertible senior notes (&#x201c;convertible notes&#x201d;) include an embedded equity conversion option which is not deemed closely related to the financial liability and was initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since the embedded derivative is not an equity instrument under IFRS, the amendments require the convertible notes (presented as part of borrowings in the statement of financial position) and derivative liabilities, presented as non-current liabilities at December 31, 2023, to be presented as current liabilit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ies. The amendments require presentation of the convertible notes as current liabilities even though: the initial conversion price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per ADS is not met; the conversion would not require cash settlement; and, the convertible notes do not mature until &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 1, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Further details, including (cash) maturity analysis are provided in Note 10, &#x201c;Financial Assets and Liabilities.&#x201d; On December 31, 2023, the carrying amount of convertible notes and derivative liabilities were &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comparative amounts have been reclassified to reflect the change to presentation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 31, 2023, lease liabilities were presented separately in the consolidated statements of financial position. At December 31, 2023, carrying amount of lease liabilities was &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, for non-current liabilities and current liabilities, respectively. Since March 31, 2024, lease liabilities are presented as part of borrowings in the consolidated statements of financial position. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comparative amounts have been reclassified to reflect the change in presentation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accordingly, since March 31, 2024, borrowings comprise convertible notes, royalty funding liabilities, and lease liabilities. The change to presentation had no other impact on the unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The applied amendments had no other impact on the unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other amendments apply for the first time in 2024, but do not have an impact on the unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New International Financial Reporting Standards Not Yet Effective&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2024, the IASB issued IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d; (&#x201c;IFRS 18&#x201d;), which replaces IAS 1, &#x201c;Presentation in Financial Statements.&#x201d; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Investing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements are not expected to be affected by other new or amended standards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_351ced3b-d51a-4eaf-ba8a-b94a9ff2df9b">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Basis of Preparation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#x201c;Interim Financial Reporting.&#x201d; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#x201c;IFRS&#x201d;) have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#x2019;s audited annual consolidated financial statements for the year ended December 31, 2023, and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board (the &#x201c;IASB&#x201d;) and as adopted by the European Union (the &#x201c;EU&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The accounting policies applied are consistent with those of the previous financial year. A description of the accounting policies is provided in the Accounting Policies section of the audited consolidated financial statements as of and for the year ended December 31, 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_612845fe-148b-45cf-a6ac-5379954a2ad2">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New and Amended Standards and Interpretations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has applied amendments to paragraphs 69 to 76 of IAS 1, &#x201c;Presentation of Financial Statements,&#x201d; which was effective for annual reporting periods beginning on or after January 1, 2024, and must be applied retrospectively. The amendments to IAS 1 specify the requirements for classifying liabilities as current or non-current. The amendments clarify:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;What is meant by a right to defer settlement;  &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;That a right to defer must exist at the end of the reporting period; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;That classification is unaffected by the likelihood that an entity will exercise its deferral right; and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;That only if an embedded derivative in a convertible liability is itself an equity instrument would the terms of a liability not impact its classification. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The convertible senior notes (&#x201c;convertible notes&#x201d;) include an embedded equity conversion option which is not deemed closely related to the financial liability and was initially recognized and measured separately at fair value as derivative liabilities based on the stated terms upon issuance of the convertible notes. The conversion option is classified as a foreign currency conversion option and thus not convertible into a fixed number of shares for a fixed amount of cash. Accordingly, the conversion option is subsequently recognized and measured as a derivative liability at fair value through profit or loss, with any subsequent remeasurement gains or losses recognized as part of finance income or expenses.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Since the embedded derivative is not an equity instrument under IFRS, the amendments require the convertible notes (presented as part of borrowings in the statement of financial position) and derivative liabilities, presented as non-current liabilities at December 31, 2023, to be presented as current liabilit&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;ies. The amendments require presentation of the convertible notes as current liabilities even though: the initial conversion price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per ADS is not met; the conversion would not require cash settlement; and, the convertible notes do not mature until &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 1, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Further details, including (cash) maturity analysis are provided in Note 10, &#x201c;Financial Assets and Liabilities.&#x201d; On December 31, 2023, the carrying amount of convertible notes and derivative liabilities were &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comparative amounts have been reclassified to reflect the change to presentation.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On December 31, 2023, lease liabilities were presented separately in the consolidated statements of financial position. At December 31, 2023, carrying amount of lease liabilities was &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;84.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, for non-current liabilities and current liabilities, respectively. Since March 31, 2024, lease liabilities are presented as part of borrowings in the consolidated statements of financial position. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Comparative amounts have been reclassified to reflect the change in presentation.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Accordingly, since March 31, 2024, borrowings comprise convertible notes, royalty funding liabilities, and lease liabilities. The change to presentation had no other impact on the unaudited condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The applied amendments had no other impact on the unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Other amendments apply for the first time in 2024, but do not have an impact on the unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;New International Financial Reporting Standards Not Yet Effective&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In April 2024, the IASB issued IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d; (&#x201c;IFRS 18&#x201d;), which replaces IAS 1, &#x201c;Presentation in Financial Statements.&#x201d; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Operating activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Investing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Financing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Income taxes; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The consolidated financial statements are not expected to be affected by other new or amended standards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
    <asnd:ConversionPricePerShare
      contextRef="C_26726fd6-ee62-4142-bc95-a08f61caedc3"
      decimals="2"
      id="F_c7ac5bd5-37c5-4e92-b02f-effdc9ad70c0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">166.34</asnd:ConversionPricePerShare>
    <ifrs-full:BorrowingsMaturity
      contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405"
      id="F_fca6d885-ce32-4c0a-b993-5a28531c612e">April 1, 2028</ifrs-full:BorrowingsMaturity>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-5"
      id="F_7dd0405a-8ce9-4b9a-ad77-1a390bdf5195"
      unitRef="U_EUR">407100000</asnd:ConvertibleSeniorNotes>
    <ifrs-full:NoncurrentDerivativeFinancialLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-5"
      id="F_9aa50244-0811-4adc-8fe0-c3f16292bfa7"
      unitRef="U_EUR">143300000</ifrs-full:NoncurrentDerivativeFinancialLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-5"
      id="F_90058f23-603e-4b6a-901a-8bfd28352b0d"
      unitRef="U_EUR">84600000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-5"
      id="F_dcfc9770-e525-439e-9a5a-63941c848a13"
      unitRef="U_EUR">14200000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_34ea192b-0647-4853-bb1d-09c9d40e05ba">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 3&#x2014;Significant Accounting Judgements and Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In the application of the Company&#x2019;s accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Judgements, estimates and assumptions applied are based on historical experience and other factors that are relevant, and which are available at the reporting date. Uncertainty concerning estimates and assumptions could result in outcomes that require a material adjustment to assets and liabilities in future periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The unaudited condensed consolidated interim financial statements do not include all disclosures for significant accounting judgements, estimates and assumptions, that are required in the annual consolidated financial statements, and therefore should be read in conjunction with the Company&#x2019;s audited consolidated financial statements as of and for the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively. While the application of critical accounting estimates is subject to material estimation uncertainties, management&#x2019;s ongoing revisions of critical accounting estimates and underlying assumptions have, except for revenue and provisions, as described below, not revealed any material impact in any of the periods presented in the unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;There have been no other changes to the application of significant accounting judgements, or estimation uncertainties regarding accounting estimates compared to December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Revenue and Provisions - Change in Accounting Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue includes provision for a variety of sales deductions such as prompt pay discounts, shelf stock adjustments and applicable sales rebates attributable to various commercial arrangements, managed healthcare organizations, government programs, and co-pay arrangement. Provisions for sales deductions attributed to commercial arrangements are recognized when the related sales takes place and measured using the expected value method. Payable amounts for commercial arrangements are generally settled within 90-180 days from the transaction date. Provisions for unsettled sales deductions under commercial arrangements are estimated on the basis of a percentage of sales as defined by individual agreements and contracts. Further inputs to the calculations are based on payer channel mix, current contract prices under eligible programs and current inventory levels in the distribution channels. Inputs to the calculations are subject to estimation and assumptions and are based on historical experience and other factors that are relevant, and which are available at the reporting date. These estimates and assumptions are subject to material uncertainties and could result in outcomes that require a material adjustment in future periods.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue for the three months ended June 30, 2024, was negatively impacted by an adjustment to prior periods estimates and assumptions for sales deductions of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;27.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, where &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million were attributable to the three months ended March 31, 2024 and periods prior to January 1, 2024, respectively. The adjustment was primarily attributable to a different payer and rebate mix than anticipated, and which provisions for prior periods were based upon.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Total provisions for the year ended, December 31, 2023 and six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, were &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;106.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:Revenue
      contextRef="C_226b71fb-e2f1-440b-9ce0-1b02d378af1b"
      decimals="-5"
      id="F_2d8b8809-0971-4cc2-b03c-44655f03468e"
      unitRef="U_EUR">27100000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_f9148b7d-21b7-44df-8bda-8e6396f928c6"
      decimals="-5"
      id="F_64de9b44-81b8-40c4-8e56-9486bd921213"
      unitRef="U_EUR">19500000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_74b79d5a-c86f-4a0e-b7fd-c61544cc9d20"
      decimals="-5"
      id="F_18ff54b8-98aa-4209-a986-718a2780593b"
      unitRef="U_EUR">7600000</ifrs-full:Revenue>
    <ifrs-full:CurrentProvisions
      contextRef="C_89622b42-c78f-4d8c-aa28-7a988bd5583e"
      decimals="-5"
      id="F_57a7573f-fd9b-4f54-bee5-77d9ad327cf1"
      unitRef="U_EUR">32700000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="C_b745985a-29e1-4fcb-919b-47749840575a"
      decimals="-5"
      id="F_cd2b00b3-b2a1-47c0-8359-20882df4b7dc"
      unitRef="U_EUR">106800000</ifrs-full:CurrentProvisions>
    <asnd:SignificantEventsInTheReportingPeriodTextBlock
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_b0cacb66-64a9-442b-a8d7-2b8627fda1a6">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 4&#x2014;Significant Events in the Reporting Period&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Eyconis, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 29, 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, Inc. (&#x201c;Eyconis&#x201d;), a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. A&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;s consideration for the granting of such rights, the Company received, as consideration, approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;42&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% ownership of Eyconis&#x2019; on a non-diluted basis. In addition, various development and administrative services were provided to Eyconis and invoiced during the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;three and six months ended June 30, 2024. Further details regarding Eyconis are provided in Note 5, &#x201c;Revenue.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Equity Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As of June 30, 2024, the unaudited condensed consolidated interim statements of financial position presented a negative balance of equity of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;321.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Under Danish corporate law, as Ascendis Pharma A/S, the parent company of the Company holds a positive balance of equity, the Company is currently not subject to legal or regulatory requirements to re-establish the balance of equity. There is no direct impact from the negative balance of equity to the liquidity and capital resources.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Based on its current operating plan, the Company believes that the existing capital resources as of June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, will be sufficient to meet projected cash requirements for at least twelve months from the date of this report. However, the Company's operating plan may change as a result of many factors that are currently unknown, and the Company may need to seek additional funds sooner than planned. Further details regarding borrowings including maturity analysis are provided in Note 10, &#x201c;Financial Assets and Liabilities.&#x201d;&lt;/span&gt;&lt;/p&gt;</asnd:SignificantEventsInTheReportingPeriodTextBlock>
    <asnd:CapitalCommitmentFromInvestors
      contextRef="C_1eee9ac4-42e3-4c2a-b3db-f3d552da0c91"
      decimals="-6"
      id="F_de37c6ad-8b81-4bf6-846b-d67b40c6bf31"
      unitRef="U_USD">150000000</asnd:CapitalCommitmentFromInvestors>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="C_1eee9ac4-42e3-4c2a-b3db-f3d552da0c91"
      decimals="INF"
      id="F_1f2d8ea0-3b60-4cbe-9d46-5fd2c9fc26fb"
      unitRef="U_pure">0.42</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:Equity
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-5"
      id="F_5581d3f6-891a-4d8c-ae35-d148fbe858cc"
      unitRef="U_EUR">-321100000</ifrs-full:Equity>
    <ifrs-full:DisclosureOfRevenueExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_c115d53c-edbc-4b27-b6c7-7d7fdda23a84">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 5&#x2014;Revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss in the following amounts:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.09%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.658%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sale of commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Rendering of services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sale of clinical supply&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;35,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;47,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;131,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;80,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Attributable to&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial customers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collaboration partners and license agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;35,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;47,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;131,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;80,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Specified by timing of recognition&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Recognized over time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Recognized at a point in time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;35,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;47,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;131,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;80,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Specified per geographical area&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Europe&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;North America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Asia&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;35,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;47,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;131,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;80,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Commercial Customers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue to commercial customers primarily relates to sale of SKYTROFA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (lonapegsomatropin-tcgd), primarily in the U.S. market, which is sold to specialty pharmacies and specialty distributors. In addition, the Company began shipping SKYTROFA to customers in Germany in September 2023. In November 2023, TransCon PTH received regulatory approval in the EU and European Economic Area countries and is marketed as YORVIPATH&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(palopegteriparatide). In August 2024, TransCon PTH received regulatory approval in the U.S. and will be marketed in the U.S. as YORVIPATH. The Company began shipping YORVIPATH to customers in Europe in the first quarter of 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the three and six months ended June 30, 2024 and 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; commercial customers, each represented more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of sales to commercial customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Collaboration Partners and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue attributable to collaboration partners and license agreements relates to Eyconis, Teijin Limited and VISEN Pharmaceuticals. Under the collaboration agreements, we provide various research and development services which are invoiced to collaboration partners. Revenue for these activities is presented as part of &#x201c;Rendering of services.&#x201d; Employment costs related to these activities are presented as Research and Development Costs in the consolidated statement of profit or loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Eyconis, Inc.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On January 29, 2024, the Company announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophth&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;almology assets globally, together with a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million commitment from an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received, as consideration, an equity position in the newly formed company. In addition, the Company is eligible to receive development, regulatory, and sales milestone payments, plus single digit royalties on global net sales of commercialized products, if any.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is expected to provide various research and development services, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, revenue from &#x201c;Licenses&#x201d; of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million relates to non-cash upfront payment through an equity position in Eyconis, which is allocated to transfer of the Company&#x2019;s intellectual property (&#x201c;IP&#x201d;) adjusted for internal profit. Internal profit relates to the Company&#x2019;s share of the non-cash upfront payment whic&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;h is recognized as part of &#x201c;Investment in associates&#x201d; and recognized as revenue from &#x201c;Licenses&#x201d; as the IP is amortized in the associate.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; revenue from royalties or milestones has been recognized under the Eyconis agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Teijin Limited&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On November 29, 2023, the Company entered into an exclusive license agreement with Teijin Limited (the &#x201c;Teijin Agreement&#x201d;) for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease (the &#x201c;Licensed Products&#x201d;) in Japan. Under the terms of the Teijin Agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, with additional development and regulatory milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and commercial milestones. In addition, the Company is eligible to receive royalties on net sales of the Licensed Products in Japan, of up to mid-20&#x2019;s percent.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Further, the Company will provide clinical and commercial supply, and development services for joint activities, which are subject to separate remuneration, and which will be recognized as revenue over time as rendering of services or reimbursement revenue, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;At June 30, 2024, none of the Licensed Products have received marketing authorization in Japan. The Licensed Products are patent protected, where future activities do not affect their existing stand-alone functionalities. Accordingly, all three licenses have been classified as &#x201c;right-to-use&#x201d; licenses, with revenue recognized at a point in time, where the licensee is granted access to the IP.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Development and regulatory milestones of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million are recognized as revenue when the milestone criteria specific to the Licensed Product are met. Royalty and commercial milestone income is recognized as revenue when the subsequent product sales occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the six months ended June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; revenue from royalties o&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;r milestones has been recognized under the Teijin Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;VISEN Pharmaceuticals&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue from collaboration partners and license agreements also includes license income, rendering of services and sale of clinical supply under three licenses agreements with VISEN Pharmaceuticals, which were entered into in 2018.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_ca438c0a-bed9-4a6a-a320-6473580cd2de">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss in the following amounts:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.09%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.418%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.658%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sale of commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Rendering of services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Sale of clinical supply&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;25,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,203&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;35,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;47,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;131,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;80,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Attributable to&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Commercial customers&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;31,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,895&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;97,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;67,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Collaboration partners and license agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11,498&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;34,004&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;13,536&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;35,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;47,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;131,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;80,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Specified by timing of recognition&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Recognized over time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,740&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;8,364&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;12,079&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Recognized at a point in time&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;32,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;36,484&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;123,528&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;35,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;47,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;131,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;80,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Specified per geographical area&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Europe&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,082&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,649&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;North America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;29,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;46,758&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;122,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;79,828&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Asia&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;35,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;47,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;131,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;80,982&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_603bb92e-709c-4eec-9059-9c8ed9a4f8e3"
      unitRef="U_EUR">31389000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_d56c8880-93f4-4fbe-9664-45c4b78ba2a6"
      unitRef="U_EUR">35895000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_6299e340-39e2-4536-89d8-c0b38b66e347"
      unitRef="U_EUR">97888000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_e3a7b342-caf7-4c45-8d6e-bfc0408e289e"
      unitRef="U_EUR">67446000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromRenderingOfServices
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_d4d7bd9c-9d3a-412a-a13a-f463f8192e17"
      unitRef="U_EUR">3740000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_bb2f3055-8081-4d4f-8602-8aee38e29b39"
      unitRef="U_EUR">10909000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_e74e02b9-082d-417d-9013-e6b790447f05"
      unitRef="U_EUR">8364000</ifrs-full:RevenueFromRenderingOfServices>
    <ifrs-full:RevenueFromRenderingOfServices
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_4bdd628c-dae0-4574-97bb-e8e783d55d74"
      unitRef="U_EUR">12079000</ifrs-full:RevenueFromRenderingOfServices>
    <asnd:RevenueFromSaleOfClinicalSupply
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_cacbe074-8404-4e51-a14d-20e51b544741"
      unitRef="U_EUR">1000</asnd:RevenueFromSaleOfClinicalSupply>
    <asnd:RevenueFromSaleOfClinicalSupply
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_eba61058-bfaa-4d1c-840f-9962c84c510c"
      unitRef="U_EUR">254000</asnd:RevenueFromSaleOfClinicalSupply>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_3ca87ef6-0039-4cf4-bca1-5c881c101fb4"
      unitRef="U_EUR">869000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_d43d043c-0cc5-48ea-bfe1-67da545c13cc"
      unitRef="U_EUR">589000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_56217779-677e-44db-b414-9203f1504752"
      unitRef="U_EUR">25639000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_aecbcf64-e712-4fb4-9b8b-ceb7a56d0dcf"
      unitRef="U_EUR">1203000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:Revenue
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_879af9e1-f01a-448f-bc50-edcba4fd2a02"
      unitRef="U_EUR">35998000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_a890cf5b-7de5-4d18-a7ac-1acd33d8715f"
      unitRef="U_EUR">47393000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_9a81ffcf-9138-433e-99f6-eb08c6c2ccb9"
      unitRef="U_EUR">131892000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_6ec6c79a-3faf-41f0-ac1f-bb78c152d80e"
      unitRef="U_EUR">80982000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_9fd79df1-50c6-4d41-901d-c77df4998cd3"
      decimals="-3"
      id="F_2cc12900-aa04-43da-8b8a-24106ff2abaa"
      unitRef="U_EUR">31389000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_53d2ec13-fbb3-43f3-8664-1c7545479049"
      decimals="-3"
      id="F_80484b7e-b2a7-49bc-ac22-32368b5c15db"
      unitRef="U_EUR">35895000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e94750b4-4124-4fd8-8705-f5583e219191"
      decimals="-3"
      id="F_bae8e089-eddf-44e2-a27a-5affb20bdee7"
      unitRef="U_EUR">97888000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_ee58604e-a45e-405b-aac6-1e95591f95f0"
      decimals="-3"
      id="F_2020dd1a-525a-4159-b4c1-33856d524a49"
      unitRef="U_EUR">67446000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_0a89dad9-4f70-4ce9-b6cb-3b23f0d335f1"
      decimals="-3"
      id="F_11e4b67d-2e0c-4113-a07b-2c1bd035eef6"
      unitRef="U_EUR">4609000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_5b082919-9fbb-47d2-96d1-56d15ab71d5f"
      decimals="-3"
      id="F_65b0367b-20ab-411d-b36b-3a36e820c2c5"
      unitRef="U_EUR">11498000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_cf326443-9fc3-4acd-8a7b-d10a15c9c639"
      decimals="-3"
      id="F_f83f949a-2f1e-4c08-842e-ff100d13de84"
      unitRef="U_EUR">34004000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_bfc109b6-0267-4568-8f44-fa14915ce2e1"
      decimals="-3"
      id="F_a1d8054a-362b-4ee2-a7fe-d9bba52f9798"
      unitRef="U_EUR">13536000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_bb586705-cfea-4683-9f35-c2eb57f8d2ff"
      unitRef="U_EUR">35998000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_c52f8690-15a8-4a8c-8dfb-520d6ad6b9d7"
      unitRef="U_EUR">47393000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_cd0ab485-da5d-4024-8e01-958878d8576d"
      unitRef="U_EUR">131892000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_55fd0275-b49e-4dc5-8bc0-ad06e9f4411d"
      unitRef="U_EUR">80982000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_d23709e8-9e0d-4985-a23d-111331fe0a1e"
      decimals="-3"
      id="F_0e7cc327-4eee-46bd-9243-81f7a9c80e41"
      unitRef="U_EUR">3740000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_39a0db7a-f4cf-4e59-a617-6a1e70c6bcfc"
      decimals="-3"
      id="F_74e7f2f3-69c4-4b6e-af26-d8c66dc80ca0"
      unitRef="U_EUR">10909000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_a6a141f6-eee5-4acc-a932-da5764785d72"
      decimals="-3"
      id="F_073d9472-17e8-4e15-87e2-dc8da688ffda"
      unitRef="U_EUR">8364000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_04baf03f-f9bb-4f2a-83ab-f0cc09cff3da"
      decimals="-3"
      id="F_98038a6c-657a-4542-83e6-1495decf2be7"
      unitRef="U_EUR">12079000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_22691430-ca22-41f0-9568-18019e721ba9"
      decimals="-3"
      id="F_b353522e-2665-4e38-948d-977cf9f43c26"
      unitRef="U_EUR">32258000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_ba212868-8b66-4623-81ce-a65efa8cb9e5"
      decimals="-3"
      id="F_89ff7632-6752-421d-9d7e-1391f4443755"
      unitRef="U_EUR">36484000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_ea6471ce-cfa4-4d71-8f75-d5e623498d8f"
      decimals="-3"
      id="F_ca9030bd-05d6-4d36-81a8-a6cf973b7975"
      unitRef="U_EUR">123528000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_45be4da6-fe2a-4d4e-95dc-772befc84731"
      decimals="-3"
      id="F_9799a0ac-7dc8-4cfb-b4d0-bb258b638929"
      unitRef="U_EUR">68903000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_9c37371b-9dc5-4256-b443-6df80be2f007"
      unitRef="U_EUR">35998000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_27e87f00-c365-4928-813c-2a219743c5b5"
      unitRef="U_EUR">47393000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_75ceaee0-d2ef-43a7-abeb-86dcc1dc0198"
      unitRef="U_EUR">131892000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_0e444f45-9b9e-47bd-ad3b-3da8edc8ea37"
      unitRef="U_EUR">80982000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_515c180b-f403-4c76-ab33-f262096366f4"
      decimals="-3"
      id="F_6cc79f97-5d71-4b1c-aef6-c813ff0a7275"
      unitRef="U_EUR">5082000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_755b6ff2-16af-4b77-aef3-7e63b09f7644"
      decimals="-3"
      id="F_f66412b0-ec39-49e8-b041-c1da6dda0cb7"
      unitRef="U_EUR">6649000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_4875ac0d-47d5-4a79-b057-425d568f5baf"
      decimals="-3"
      id="F_ff188f5e-5995-4410-8f90-5c386aaca90d"
      unitRef="U_EUR">29394000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_6be2f049-eb3c-45d2-b25b-1ce6e49e5a4a"
      decimals="-3"
      id="F_4ccf20ce-a2b8-4bb9-9f83-b5b00f59e1d8"
      unitRef="U_EUR">46758000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_0901f291-b6cf-4be5-8d74-9686996cf492"
      decimals="-3"
      id="F_4ac78517-13c6-4414-8dc3-2c3b27d8f9e9"
      unitRef="U_EUR">122075000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_12efaec8-00be-4d5b-a2c1-d97f9f8f9802"
      decimals="-3"
      id="F_f1594ff9-fb55-4cd1-aae9-b69b00f792dd"
      unitRef="U_EUR">79828000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e661bb05-fc48-440a-941f-d142682c6c26"
      decimals="-3"
      id="F_5be656b4-d1e8-4a59-ba52-d370b651ed30"
      unitRef="U_EUR">1522000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_cfd8955d-eb7e-4148-9713-3f97e5f71e44"
      decimals="-3"
      id="F_a09dba4d-796a-46d6-b22b-7972003518ef"
      unitRef="U_EUR">635000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_c2fcb3f0-5af6-4d4d-b93c-dd673702d997"
      decimals="-3"
      id="F_b089e65e-0192-4d7c-91e8-fe79f47eea74"
      unitRef="U_EUR">3168000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_da85c345-157f-4aeb-af0c-84f018bd921c"
      decimals="-3"
      id="F_3746a52a-bf9f-4f77-9ad3-3c2bb5fb057c"
      unitRef="U_EUR">1154000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_7538ae80-ed13-4006-b6ec-7d2ba6118c7b"
      decimals="-3"
      id="F_12b8cf28-e197-4c28-ba29-4fb0a76417d4"
      unitRef="U_EUR">35998000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_b30108dc-5bcb-44aa-bfbf-4ffa7d9f3397"
      decimals="-3"
      id="F_edfdba6b-0b5b-410f-b16d-8cd09e8d8279"
      unitRef="U_EUR">47393000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_8a3b92d2-3edb-4ee3-95b6-32b66953d3ce"
      unitRef="U_EUR">131892000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e183e072-5783-4dae-a0cb-cb13fdbf3564"
      decimals="-3"
      id="F_ee1af5a1-1010-4022-8918-f9b204c87c84"
      unitRef="U_EUR">80982000</ifrs-full:Revenue>
    <asnd:NumberOfCommercialCustomers
      contextRef="C_9fd79df1-50c6-4d41-901d-c77df4998cd3"
      decimals="0"
      id="F_04254acf-8e04-44f3-85b5-0b600845e497"
      unitRef="U_CommercialCustomer">4</asnd:NumberOfCommercialCustomers>
    <asnd:NumberOfCommercialCustomers
      contextRef="C_e94750b4-4124-4fd8-8705-f5583e219191"
      decimals="0"
      id="F_4610c87a-a4c1-4d3b-9738-7b9131dd5b62"
      unitRef="U_CommercialCustomer">4</asnd:NumberOfCommercialCustomers>
    <asnd:NumberOfCommercialCustomers
      contextRef="C_53d2ec13-fbb3-43f3-8664-1c7545479049"
      decimals="0"
      id="F_6d650873-1f88-4554-87b1-74637f84fd1c"
      unitRef="U_CommercialCustomer">4</asnd:NumberOfCommercialCustomers>
    <asnd:NumberOfCommercialCustomers
      contextRef="C_ee58604e-a45e-405b-aac6-1e95591f95f0"
      decimals="0"
      id="F_386935d2-8844-4cc9-8d66-09afb7f9dcb5"
      unitRef="U_CommercialCustomer">4</asnd:NumberOfCommercialCustomers>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="C_becea9f1-8ea3-4a3f-b92c-d1e19a63174b"
      decimals="2"
      id="F_c1058137-e6e9-4923-8d7c-1714135f2a57"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="C_be47076c-c5c2-4398-803d-95bcc128d86b"
      decimals="2"
      id="F_b246a375-e4cc-44a5-916d-245ccbb1599f"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="C_8de101c2-a4a1-4558-b6d8-6845ebd51060"
      decimals="2"
      id="F_5bdf9612-1abc-4724-a55b-31a6dc83caa3"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <ifrs-full:PercentageOfEntitysRevenue
      contextRef="C_d2e575be-2a92-4dca-9d69-cce91f677a27"
      decimals="2"
      id="F_7e1dd1a1-ed1e-418d-8046-7c8a35ff054d"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfEntitysRevenue>
    <asnd:CapitalCommitmentFromInvestors
      contextRef="C_1eee9ac4-42e3-4c2a-b3db-f3d552da0c91"
      decimals="-6"
      id="F_4e202a3c-7913-4be4-b0e7-361eeb5a71c1"
      unitRef="U_USD">150000000</asnd:CapitalCommitmentFromInvestors>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_1ff24599-9bec-4004-890e-f2cabcf62656"
      decimals="-5"
      id="F_dce02b37-cfec-4a90-b6f9-4520cc5f38db"
      unitRef="U_EUR">25600000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_0d563d87-8d91-4eb6-a982-541081c3f97a"
      decimals="INF"
      id="F_6fc30d4e-6c59-4302-9922-1a6dcd10a5c7"
      unitRef="U_USD">0</ifrs-full:RevenueFromContractsWithCustomers>
    <asnd:UpfrontPaymentReceived
      contextRef="C_a078a24b-80df-47b2-af27-cd002780edca"
      decimals="-6"
      id="F_b3ac1ef4-1df1-4366-b10c-6b7c60ea89f9"
      unitRef="U_USD">70000000</asnd:UpfrontPaymentReceived>
    <asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived
      contextRef="C_a078a24b-80df-47b2-af27-cd002780edca"
      decimals="-6"
      id="F_cd5f64b8-5a1e-41cc-9eab-6cd7b44163c9"
      unitRef="U_USD">175000000</asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived>
    <asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived
      contextRef="C_34124e79-d811-40a9-b5d7-6e45ec01b712"
      decimals="-6"
      id="F_f21235be-bd3f-468e-9d0f-dcd362a1c652"
      unitRef="U_USD">175000000</asnd:MaximumAdditionalDevelopmentAndRegulatoryMilestonesPotentiallyToBeReceived>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_d001d487-d74a-42b7-827b-045eca711447"
      decimals="INF"
      id="F_d377bfd3-7d65-4b95-9358-febb3f4193ff"
      unitRef="U_USD">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_221c7309-08ed-44df-af64-4fecc46ed0c1">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 6&#x2014;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Company is managed and operated as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; business unit. Accordingly, no additional information on business segments or geographical areas is disclosed apart from revenue on geographical areas as disclosed in Note 5 &#x201c;Revenue.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Revenue is specified on geographical areas according to the location of the customer.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <asnd:NumberOfReportableOperatingSegments
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="0"
      id="F_e7b65b04-d7d1-4860-b95f-150a4bf3157b"
      unitRef="U_Segment">1</asnd:NumberOfReportableOperatingSegments>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_df571c75-5544-4177-8ea2-2417587da809">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 7&#x2014;Share-based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;As an incentive to the senior management, other employees, members of the Board and select consultants, Ascendis Pharma A/S has established warrant programs, a Restricted Stock Unit (&#x201c;RSU&#x201d;) program adopted in December 2021, and a Performance Stock Unit (&#x201c;PSU&#x201d;) program adopted in February 2023, which are all classified as equity-settled share-based payment transactions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Share-based Compensation Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Share-based compensation costs are determined using the grant date fair value and are recognized over the vesting period as research and development costs, selling, general and administrative expenses, or cost of sales. For the three and six months ended June 30, 2024 and 2023, share-based compensation costs recognized in the unaudited condensed consolidated interim statement of profit or loss were &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;26.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;43.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;19.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;33.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Restricted Stock Unit Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs are granted by the Board to members of senior management, certain other employees and certain members of the Board (the &#x201c;RSU-holders&#x201d;). In addition, RSUs may be granted to select consultants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;One RSU represents a right for the RSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting, if the vesting conditions are met. RSUs granted vest over three years with 1/3 of the RSUs vesting on each anniversary date from the date of grant, and require RSU-holders to be employed, appointed as member of the Board, or retained as a consultant (the &#x201c;service conditions&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Performance Stock Unit Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;PSUs are granted by the Board to certain members of senior management (the &#x201c;PSU-holders&#x201d;). In addition, PSUs may be granted to other employees, select consultants and members of the Board.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;One PSU represents a right for the PSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting. PSUs vest in a manner similar to the service conditions of the RSUs. For the March 2023 PSU grant, in addition to service conditions, vesting is also contingent upon achievement of performance-based targets as determined by the Board, provided that no more than 10% of each tranche may be directly attributable to accomplishment of financial results achieved in the financial year prior to the vesting date. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For the March 2024 PSU grants, in addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%, nor will it result in additional grants. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;RSUs and PSUs generally cease to vest from the date of termination of employment or Board membership, as applicable, whereas unvested RSUs or PSUs will forfeit. The Board may at its discretion and on an individual basis decide to deviate from the vesting conditions, including deciding to accelerate vesting in the event of termination of employment or Board membership, as applicable.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;All RSUs and PSUs are expected to be settled at the time of vesting by treasury shares that are ADSs repurchased by the Company. The Company may at its sole discretion choose to make a cash settlement instead of delivering ADSs.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;RSU and PSU Activity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table specifies the number of RSUs and PSUs granted and outstanding at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;576,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;681,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;717,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;810,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Transferred during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1,054,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;157,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1,212,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Specified by vesting year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;456,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;457,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;232,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1,054,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;157,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1,212,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrant Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Warrants are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to all employees, members of the Board and select consultants. Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The exercise price is fixed at the fair market value of the Company&#x2019;s ordinary shares at the time of grant as determined by the Board. Vested warrants may be exercised in two or four annual exercise periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Warrant Activity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table specifies the warrant activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;br/&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,523,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;524,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;6,107,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;91.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Vested at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;5,088,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;86.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The exercise prices of outstanding warrants under the Company&#x2019;s warrant programs range from &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;11.98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;145.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; depending on the grant dates.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_a7df51f1-e149-4eba-96d2-8116875f09ad"
      decimals="-5"
      id="F_7f60ada7-4d17-4b61-83d3-c13b2645cb2c"
      unitRef="U_EUR">26000000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_e47ee6ea-6244-4fae-841d-df097dd0610e"
      decimals="-5"
      id="F_efdda4e1-f807-450c-b3c9-f4ef4e07802b"
      unitRef="U_EUR">43300000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_187cae39-2542-4e99-8ed4-2163bbbdd410"
      decimals="-5"
      id="F_8e37e066-d378-4761-919b-d48388e79483"
      unitRef="U_EUR">19900000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_01332415-aee7-4777-a043-a57648e597b0"
      decimals="-5"
      id="F_a511cb03-60e7-4c93-b26c-3ae406e162a3"
      unitRef="U_EUR">33600000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement
      contextRef="C_2d38989e-7833-45b0-ae39-4b7e1ff91a47"
      id="F_870c275a-7ac6-4340-bb5d-dab858cbee3b">For the March 2024 PSU grants, in addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than 100%, nor will it result in additional grants. </ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
    <asnd:PercentageOfVestingRightsForShareBasedPaymentArrangement
      contextRef="C_b2b88484-8cd6-44b7-aec7-488f08ce60a9"
      decimals="INF"
      id="F_98f4f13f-701e-476e-bb8e-78a2a10d618c"
      unitRef="U_pure">1</asnd:PercentageOfVestingRightsForShareBasedPaymentArrangement>
    <asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_a50602e9-cd71-4a1b-a83c-4446ad22c0b6">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table specifies the number of RSUs and PSUs granted and outstanding at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.242%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;576,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;105,023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;681,648&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;717,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;92,655&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;810,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Transferred during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;176,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,007&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,309&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;4,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;68,139&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1,054,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;157,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1,212,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Specified by vesting year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393,254&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;456,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;393,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;63,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;457,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;232,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;263,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1,054,979&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;157,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1,212,820&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_ed967469-6caa-47a7-ad87-51a13e77b2b5"
      decimals="0"
      id="F_c60f13ad-da26-4901-b409-804483f94432"
      unitRef="U_pure">576625</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_c5d652d5-d799-43f6-903b-d2389a4f9c48"
      decimals="0"
      id="F_c9a5fe9e-4aa1-47dc-b121-a690dcc99bbc"
      unitRef="U_pure">105023</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_ce698de3-cc8b-45e2-bf70-a5c86942e92e"
      decimals="0"
      id="F_f7935c04-218e-4706-83cb-dba8538c1bfd"
      unitRef="U_pure">681648</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_7d5f46e4-3795-445e-9938-80e373d5b80d"
      decimals="0"
      id="F_a4a44c91-22ca-483c-82a8-bc7342d2607f"
      unitRef="U_pure">717980</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_5a94d79c-4291-4d0a-b8bb-268dad9a101c"
      decimals="0"
      id="F_834831ce-2b82-4354-865b-7b066a4f43ab"
      unitRef="U_pure">92655</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_5a7beea2-de57-4790-91d5-5d1200eacac6"
      decimals="0"
      id="F_00b49ceb-2d72-4f5d-9a29-d52ddb0ae832"
      unitRef="U_pure">810635</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_7d5f46e4-3795-445e-9938-80e373d5b80d"
      decimals="0"
      id="F_70b9bc34-fe50-44bb-becf-27d120fd4873"
      unitRef="U_pure">-176317</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_5a94d79c-4291-4d0a-b8bb-268dad9a101c"
      decimals="0"
      id="F_6f1c9a15-2823-4506-a59e-06957fe82897"
      unitRef="U_pure">-35007</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_5a7beea2-de57-4790-91d5-5d1200eacac6"
      decimals="0"
      id="F_5e615e90-9305-48a1-9fc6-a27e6e21edfd"
      unitRef="U_pure">-211324</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_7d5f46e4-3795-445e-9938-80e373d5b80d"
      decimals="0"
      id="F_e61fdea3-ffdc-4d6d-98c3-9677a697d61c"
      unitRef="U_pure">63309</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_5a94d79c-4291-4d0a-b8bb-268dad9a101c"
      decimals="0"
      id="F_14360b7e-df4a-46f7-bb3e-ca34be10f6b5"
      unitRef="U_pure">4830</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_5a7beea2-de57-4790-91d5-5d1200eacac6"
      decimals="0"
      id="F_2d9fc024-25db-41c8-baec-3b742cdecd4d"
      unitRef="U_pure">68139</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_3b38ee1f-0d21-4c30-b4e6-b4a0842378c6"
      decimals="0"
      id="F_2b3acdec-d5a6-4d0c-9e7d-a97e82c4865d"
      unitRef="U_pure">1054979</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_d9f93835-5fdc-4307-9a1f-a342ff26fcd1"
      decimals="0"
      id="F_58220995-7498-4862-be32-42bb37c050cd"
      unitRef="U_pure">157841</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_d5d1312c-4638-41e8-a0fb-c5a22dd1c28e"
      decimals="0"
      id="F_dbeb3dc4-d370-4bf8-b04b-00bb48df9f3c"
      unitRef="U_pure">1212820</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_f0e8016e-5734-4177-91b0-d52b46d6a142"
      decimals="0"
      id="F_503112f0-ed65-4f84-bef5-578df9feb1bd"
      unitRef="U_pure">35843</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_d5ac3b5c-e60f-478e-83cf-eddc448b6227"
      decimals="0"
      id="F_f1b19c22-c53c-4c0e-8ff5-1d626a05f555"
      unitRef="U_pure">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_eea519f3-ad46-4ee7-85b0-8608cf3c21c0"
      decimals="0"
      id="F_c07340b8-9036-4454-96a4-64db57724239"
      unitRef="U_pure">35843</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_4f8a6e8b-b214-487d-a30f-ae5d8fab47d4"
      decimals="0"
      id="F_aef2cc4d-2c81-4cb6-affe-7521fb5d54ff"
      unitRef="U_pure">393254</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_49e1466f-2be7-41f1-9dd9-ebfd767c7ab0"
      decimals="0"
      id="F_3d987460-53da-47aa-a997-47038fdc3279"
      unitRef="U_pure">63478</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_0be81193-83e1-496a-b2bd-963e7a3ae019"
      decimals="0"
      id="F_c2543a93-932b-4b42-9f54-1aa65aececb9"
      unitRef="U_pure">456732</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_51bb1848-afba-426b-b5e1-8227d0a04edf"
      decimals="0"
      id="F_7d34d8da-29b1-45f5-8076-a26648532f5a"
      unitRef="U_pure">393612</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_c7b94f2c-5166-4906-bd69-2ea999d9fd53"
      decimals="0"
      id="F_c2943e75-a069-45be-b536-ed21c548f99c"
      unitRef="U_pure">63478</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_1a075a8f-0d93-49ae-991b-20bf71825ac3"
      decimals="0"
      id="F_de4fb3e3-3b6a-424a-87b9-c37ed7feff19"
      unitRef="U_pure">457090</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_5233396e-84c8-4084-9018-ab624a6eebc0"
      decimals="0"
      id="F_5cb7fb75-beb0-4a59-8507-2f967190066a"
      unitRef="U_pure">232270</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_c4bb41a9-9897-48ff-97d9-d9e4c2fc4102"
      decimals="0"
      id="F_8ea46ab5-8012-4282-9bf1-30618f940966"
      unitRef="U_pure">30885</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_b5e24c58-8391-46c0-963b-15580b32b822"
      decimals="0"
      id="F_704a992a-6933-4acc-a860-438262004823"
      unitRef="U_pure">263155</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_3b38ee1f-0d21-4c30-b4e6-b4a0842378c6"
      decimals="0"
      id="F_13392e19-9475-4230-a96f-ddefc3288652"
      unitRef="U_pure">1054979</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_d9f93835-5fdc-4307-9a1f-a342ff26fcd1"
      decimals="0"
      id="F_4272e50d-11b0-4ea7-98b2-adbc8959b6e2"
      unitRef="U_pure">157841</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_d5d1312c-4638-41e8-a0fb-c5a22dd1c28e"
      decimals="0"
      id="F_ed062bcf-06cb-4c7d-99e6-7c7bcbcf26f1"
      unitRef="U_pure">1212820</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:ParValuePerShare
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="0"
      id="F_c5d3c5ba-1875-480f-8f36-062d13124a0f"
      unitRef="U_DkkPerShare">1</ifrs-full:ParValuePerShare>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_3d1f079c-b3c5-48d9-9cc5-a469bf6f6278">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table specifies the warrant activity for the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;six months ended June 30, 2024:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;br/&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6,523,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;86.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Granted during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;197,855&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130.74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Exercised during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;524,045&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;39.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Forfeited during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;89,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;108.71&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;6,107,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;91.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Vested at June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;5,088,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;86.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_0f31b8c9-3f3e-45ff-b2dc-b529c435f24b"
      decimals="INF"
      id="F_a1a7129a-3efa-4bd3-a133-1c9df9423ce3"
      unitRef="U_pure">6523784</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_0f31b8c9-3f3e-45ff-b2dc-b529c435f24b"
      decimals="2"
      id="F_f96a85e8-2e1e-45d5-9fdb-7bab6d52d58d"
      unitRef="U_EurPerShare">86.38</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03"
      decimals="INF"
      id="F_9e0e919c-e250-4233-a218-4d0520f3d3f9"
      unitRef="U_pure">197855</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03"
      decimals="2"
      id="F_ac0d7dcf-0a6c-4edb-a504-d424877b292e"
      unitRef="U_EurPerShare">130.74</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03"
      decimals="INF"
      id="F_a77ea8be-cf29-4673-af66-61795dc7fe65"
      unitRef="U_pure">524045</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03"
      decimals="2"
      id="F_7fa7f8bb-ad78-4f09-aef0-f2d6db48464a"
      unitRef="U_EurPerShare">39.85</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03"
      decimals="INF"
      id="F_fb1030e0-16dd-46a5-9296-1f28b63189c7"
      unitRef="U_pure">89719</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019
      contextRef="C_c0d96e47-79ae-4b11-8a28-bcab74f24d03"
      decimals="2"
      id="F_52e6b50e-acd1-4e9c-84e6-0fe9665e3b25"
      unitRef="U_EurPerShare">108.71</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_dca280d3-48db-4166-b87b-1d80627ed422"
      decimals="INF"
      id="F_23aa26df-6096-46d4-9c2d-7d9f0a694ae1"
      unitRef="U_pure">6107875</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_dca280d3-48db-4166-b87b-1d80627ed422"
      decimals="2"
      id="F_4c878589-58e5-4d8c-a980-7f73d7aa9d70"
      unitRef="U_EurPerShare">91.16</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement
      contextRef="C_dca280d3-48db-4166-b87b-1d80627ed422"
      decimals="INF"
      id="F_137e4396-e520-4b29-98f5-16e60ca34518"
      unitRef="U_pure">5088475</asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement>
    <asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement
      contextRef="C_dca280d3-48db-4166-b87b-1d80627ed422"
      decimals="2"
      id="F_1aee1670-6090-40e1-8748-a6f0dae4a071"
      unitRef="U_EurPerShare">86.49</asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_32e6f681-0344-457f-8a03-21f7d9f10b40"
      decimals="2"
      id="F_9f63e5a2-7f1a-4276-b1ca-8169626577d1"
      unitRef="U_EurPerShare">11.98</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_73c5c8ba-1fdd-4912-bbd7-e04f001ad88b"
      decimals="2"
      id="F_b67f9313-a2c2-46a0-b631-2903fa43f4d7"
      unitRef="U_EurPerShare">145.5</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_7909469f-785d-451c-ab31-2eed86a423b9">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 8&#x2014;Share Capital&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The share capital of Ascendis Pharma A/S consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;58,231,484&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; fully paid shares at a nominal value of DKK &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, all in the same share class.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="INF"
      id="F_468fbeac-eb69-458d-8f63-8b1cfb3da616"
      unitRef="U_shares">58231484</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="0"
      id="F_2dff0aba-e057-4dc1-b646-24f639d9a238"
      unitRef="U_DkkPerShare">1</ifrs-full:ParValuePerShare>
    <asnd:DisclosureOfInformationAboutTreasurySharesExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_2e8a65c2-70a3-433b-af5a-ebe0e12439eb">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 9&#x2014;Treasury Shares&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The development in the holding of treasury shares is as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.241999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Nominal&lt;br/&gt;values&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Holding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Holding in&lt;br/&gt;% of total&lt;br/&gt;outstanding&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Treasury shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,093,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Transferred under stock incentive programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;881,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</asnd:DisclosureOfInformationAboutTreasurySharesExplanatory>
    <ifrs-full:DisclosureOfTreasurySharesExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_c9c3b362-cf4a-490c-8bbf-f8f55304b321">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The development in the holding of treasury shares is as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.431%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.162%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:11.241999999999999%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Nominal&lt;br/&gt;values&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Holding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Holding in&lt;br/&gt;% of total&lt;br/&gt;outstanding&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Treasury shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 1, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,093,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Transferred under stock incentive programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;211,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;118&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;881,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</ifrs-full:DisclosureOfTreasurySharesExplanatory>
    <asnd:TreasurySharesOfNominalValue
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_4afc5eed-d802-43f8-b9c5-d77d93370708"
      unitRef="U_EUR">146000</asnd:TreasurySharesOfNominalValue>
    <asnd:NumberOfTreasurySharesOutstanding
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="0"
      id="F_4309f52d-4362-401e-8025-5568cde89d4b"
      unitRef="U_shares">1093054</asnd:NumberOfTreasurySharesOutstanding>
    <asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="3"
      id="F_bd8b6e67-2610-4ae5-8a44-ad49810838cf"
      unitRef="U_pure">0.019</asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares>
    <asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      decimals="-3"
      id="F_e596d16c-dc2f-48fd-b4ad-01f2809aa52d"
      unitRef="U_EUR">-28000</asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue>
    <asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="0"
      id="F_d03de79a-4aee-4698-920b-e1a1bc1edeba"
      unitRef="U_shares">-211324</asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram>
    <asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="2"
      id="F_8c7408da-fc0d-49aa-9aca-8c16b03b62ab"
      unitRef="U_pure">0</asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms>
    <asnd:TreasurySharesOfNominalValue
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_010e3a82-2986-4100-a10b-dc502c291019"
      unitRef="U_EUR">118000</asnd:TreasurySharesOfNominalValue>
    <asnd:NumberOfTreasurySharesOutstanding
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="0"
      id="F_40223127-a271-4456-a6c8-ebae3aed51be"
      unitRef="U_shares">881730</asnd:NumberOfTreasurySharesOutstanding>
    <asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="3"
      id="F_f2e2dc94-aa5d-4bb0-ac85-fe76e3df21ca"
      unitRef="U_pure">0.015</asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_ee6eb23d-3494-44a3-aa55-f65c9e889631">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 10&#x2014;Financial Assets and Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table specifies financial assets and liabilities:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial assets by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Trade receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other receivables (excluding income tax and indirect tax receivables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;258,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;392,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;312,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;312,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;437,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;312,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;432,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;138,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other liabilities (excluding income tax, indirect tax, and employee related payables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;772,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;738,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;931,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;882,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;219,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;222,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;712,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;659,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;931,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;882,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Convertible Senior Notes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In March 2022, the Company issued an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;575.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million of fixed rate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% convertible notes. The net proceeds from the offering of the convertible notes were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;557.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (&#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;503.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million) after deducting the initial purchasers&#x2019; discounts and commissions and offering expenses. The convertible notes rank equally in right of payment with all future senior unsecured indebtedness. Unless earlier converted or redeemed, the convertible notes will mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 1, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The convertible notes accrue interest at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their convertible notes at their option into the Company&#x2019;s ordinary shares represented by ADSs, together, if applicable, with cash in lieu of any fractional ADS, at the then-applicable conversion rate. The initial conversion rate is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;6.0118&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; ADSs per $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; principal amount of convertible notes, which represents an initial conversion price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;166.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; per ADS. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The convertible notes will be optionally redeemable, in whole or in part (subject to certain limitations), at the Company&#x2019;s option at any time, and from time to time, on or after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;April 7, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;but only if the last reported sale price per ADS exceeds &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% of the conversion price on (i) each of at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; trading days, whether or not consecutive, during the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 30, 2024, the carrying amount of the convertible notes was &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;min-width:fit-content;color:#000000;"&gt;432.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and the fair value was approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;412.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Fair value cannot be measured based on quoted prices in active markets or other observable input, and accordingly the fair value was measured by using an estimated market rate for an equivalent non-convertible instrument.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Royalty Funding Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2023, the Company entered into a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million capped synthetic royalty funding agreement (the &#x201c;Royalty Pharma Agreement&#x201d;) with Royalty Pharma (the &#x201c;Purchaser&#x201d;). The net proceeds were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;146.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (&#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;136.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million) after deducting offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Under the terms of the Royalty Pharma Agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the &#x201c;Purchase Price&#x201d;) in exchange for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;9.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% royalty on net U.S. SKYTROFA revenue, beginning on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; (the &#x201c;Revenue Interest Payments&#x201d;). The Revenue Interest Payments to the Purchaser will cease upon reaching a multiple of the Purchase Price of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.925&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;x, or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;x if the Purchaser receives Revenue Interest Payments in that amount by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The Royalty Pharma Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.925&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; times the Purchase Price minus the Revenue Interest Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to December 31, 2028, and the Company has paid the Purchaser Revenue Interest Payments equal to the Purchase Price as of the date of the buy-out notice, then the buy-out amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; times the Purchase Price minus the Revenue Interest Payments paid to the Purchaser as of the effective date of the buy-out notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 30, 2024, the carrying amount of the royalty funding liabilities was &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million, and the fair value was approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;147.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million. Fair value cannot be measured based on quoted prices in active markets or other observable input, and accordingly the fair value was measured by using an estimated market rate for an equivalent instrument.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Derivative Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Fair value cannot be measured based on quoted prices in active markets or other observable inputs, and accordingly, derivative liabilities are measured by using the Black-Scholes option pricing model. Fair value of the option is calculated, applying the following assumptions: (1) conversion price; (2) the Company&#x2019;s share price; (3) maturity of the option; (4) a risk-free interest rate equaling the effective interest rate on a U.S. government bond with the same lifetime as the maturity of the option; (5) no payment of dividends; and (6) an expected volatility using the Company&#x2019;s share price &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49.89&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;50.47&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; as of June 30, 2024 and December 31, 2023, respectively).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;For additional description of fair values, refer to the following section &#x201c;Fair Value Measurement.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Sensitivity Analysis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;On June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, all other inputs and assumptions held constant, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% relative increase in volatility, will increase the fair value of derivative liabilities by approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and indicates a decrease in profit or loss and equity before tax. Similarly, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% relative decrease in volatility indicates the opposite impact.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Similarly, on June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;, all other inputs and assumptions held constant, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% increase in the share price, will increase the fair value of derivative liabilities by approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;30.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million and indicates a decrease in profit or loss and equity before tax. Similarly, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% decrease in the share price indicates the opposite impact.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Because of the short-term maturity for cash and cash equivalents, receivables and trade payables, their fair value approximate carrying amount. Fair value of lease liabilities are not disclosed. Fair value compared to carrying amount of marketable securities, convertible notes, royalty funding liabilities and derivative liabilities, and their level in the fair value hierarchy is summarized in the following table, where:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;is&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;is based on valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;is based on valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(1-3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;7,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;432,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;412,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;385,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;147,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;138,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;576,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;559,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;545,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;529,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table specifies movements in level 3 fair value measurements:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;157,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Remeasurement recognized in finance (income) or expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;86,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt;Maturity Analysis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the unaudited condensed consolidated statements of financial position at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; Further details regarding classification of convertible notes as current liabilities in the consolidated statement of financial position are provided in Note 2, &#x201c;Summary of Material Accounting Policies,&#x201d; section &#x201c;New and Amended Standards and Interpretations.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&amp;lt; 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1-5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&amp;gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;br/&gt;contractual&lt;br/&gt;cash-flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;759,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;816,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;576,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Trade payables, accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;133,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;810,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;83,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1,027,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;772,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_8550a9d9-76fb-42ff-9f5c-67f690702000">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table specifies financial assets and liabilities:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial assets by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Trade receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;49,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;35,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other receivables (excluding income tax and indirect tax receivables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;5,062&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;258,696&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;392,164&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;312,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;312,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,186&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;310,735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;437,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;312,921&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;439,222&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;432,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;138,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;98,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;94,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Other liabilities (excluding income tax, indirect tax, and employee related payables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;772,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;738,831&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;931,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;882,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Non-current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;219,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;222,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;712,475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;659,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;931,527&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;882,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory>
    <ifrs-full:TradeReceivables
      contextRef="C_3d46e5dc-bcc4-472a-9b45-7da68fed384e"
      decimals="-3"
      id="F_f7fd87df-52cc-4562-a616-7fe68119565e"
      unitRef="U_EUR">49163000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="C_99311e47-32a5-474d-8dac-f41409c83e74"
      decimals="-3"
      id="F_11550ed9-9c7a-4e70-8ec9-8ac5483da083"
      unitRef="U_EUR">35874000</ifrs-full:TradeReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_3d46e5dc-bcc4-472a-9b45-7da68fed384e"
      decimals="-3"
      id="F_5663040c-649e-4c74-a6cd-312855fc26f7"
      unitRef="U_EUR">5062000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_99311e47-32a5-474d-8dac-f41409c83e74"
      decimals="-3"
      id="F_435fb513-1019-424f-ba3c-bb33cb4c78ad"
      unitRef="U_EUR">3909000</ifrs-full:OtherReceivables>
    <asnd:MarketableSecurities1
      contextRef="C_99311e47-32a5-474d-8dac-f41409c83e74"
      decimals="-3"
      id="F_cf35c72a-4373-43ea-a824-98a99163c918"
      unitRef="U_EUR">7275000</asnd:MarketableSecurities1>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_3d46e5dc-bcc4-472a-9b45-7da68fed384e"
      decimals="-3"
      id="F_c1f57a57-370f-4068-9c6c-4247578c7a35"
      unitRef="U_EUR">258696000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_99311e47-32a5-474d-8dac-f41409c83e74"
      decimals="-3"
      id="F_a55f1910-d7d8-449e-8952-537b06bb78c4"
      unitRef="U_EUR">392164000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_3d46e5dc-bcc4-472a-9b45-7da68fed384e"
      decimals="-3"
      id="F_64b6863c-dc3e-4c58-9391-0cb21676d76e"
      unitRef="U_EUR">312921000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_99311e47-32a5-474d-8dac-f41409c83e74"
      decimals="-3"
      id="F_47a48f00-e64b-4933-bc10-a46645cacce5"
      unitRef="U_EUR">439222000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssets
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_d19b9dbc-fec7-47f7-80a4-8538e54303ba"
      unitRef="U_EUR">312921000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_054cd00f-9eae-4f72-b5f4-17b29d9915d8"
      unitRef="U_EUR">439222000</ifrs-full:FinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_0ba793b2-33ca-4a2f-8719-7fe143583def"
      unitRef="U_EUR">2186000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_496393e3-86d9-4436-84c4-cae065043ea3"
      unitRef="U_EUR">2127000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:CurrentFinancialAssets
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_ee0926cd-9523-449c-8d43-f0ea66c96dcb"
      unitRef="U_EUR">310735000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:CurrentFinancialAssets
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_6c3e317a-53a6-4d29-b292-ea0c0bbf57a0"
      unitRef="U_EUR">437095000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_97d91939-9aad-4d54-9b92-af5770b98f9b"
      unitRef="U_EUR">312921000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_de72fbdf-88fb-468c-b375-c493bea70237"
      unitRef="U_EUR">439222000</ifrs-full:FinancialAssets>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb"
      decimals="-3"
      id="F_510c6212-1c64-4e56-ba63-dfd05dc722ec"
      unitRef="U_EUR">432190000</asnd:ConvertibleSeniorNotes>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594"
      decimals="-3"
      id="F_9c557fc9-17af-4237-a852-f57d28b654b2"
      unitRef="U_EUR">407095000</asnd:ConvertibleSeniorNotes>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb"
      decimals="-3"
      id="F_456a6929-e3b0-4d73-8e44-15c2ff53e3ec"
      unitRef="U_EUR">144547000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594"
      decimals="-3"
      id="F_e1101d4d-7a6a-49f4-82a8-c7e61da5de90"
      unitRef="U_EUR">138377000</asnd:RoyaltyFundingLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb"
      decimals="-3"
      id="F_50baa6a1-c667-465f-9bd3-29ac20c8b5c2"
      unitRef="U_EUR">95902000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594"
      decimals="-3"
      id="F_e8ba00d9-5e48-430d-84a5-b95bcbddca65"
      unitRef="U_EUR">98793000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb"
      decimals="-3"
      id="F_95612129-43c7-4636-a8af-c9462ad49561"
      unitRef="U_EUR">99527000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594"
      decimals="-3"
      id="F_da1d15ad-d31d-4e3d-85be-c4db734348c3"
      unitRef="U_EUR">94566000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb"
      decimals="-3"
      id="F_f23ec902-027f-4900-94c7-80d99125367d"
      unitRef="U_EUR">302000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb"
      decimals="-3"
      id="F_608be36f-de9c-4b45-83ec-39026994a582"
      unitRef="U_EUR">772468000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_a76fa09e-d759-4fe5-a8a4-655f6d0c6594"
      decimals="-3"
      id="F_c1003ce9-7a92-4900-af85-88f01b3744d6"
      unitRef="U_EUR">738831000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_c2f1a640-a6c2-4852-950f-1e09064c7346"
      unitRef="U_EUR">159059000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_38454091-81da-4285-afba-81610f6027af"
      unitRef="U_EUR">143296000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_44d7ff3b-a312-4758-9d5a-9853401406cc"
      decimals="-3"
      id="F_bd265e47-3fc8-402c-8dc0-f87715df3fcc"
      unitRef="U_EUR">159059000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_0fda0982-6a94-4187-a702-171d557879fc"
      decimals="-3"
      id="F_a7039271-e737-40c3-9cec-8496475c7c1b"
      unitRef="U_EUR">143296000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_b65d0834-a024-4d7a-80a2-820cd3c66110"
      unitRef="U_EUR">931527000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_3ddaec2d-e1b5-4e4a-8df9-ef0a86a28397"
      unitRef="U_EUR">882127000</ifrs-full:FinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_d72884bc-bd6d-403f-b524-957594a4b2da"
      unitRef="U_EUR">219052000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_c1da0a35-346a-4b03-b972-887e03d9389b"
      unitRef="U_EUR">222996000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_7305639e-9902-4de5-b8ce-4889efcef82a"
      unitRef="U_EUR">712475000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_bc0f8e39-12e3-44c2-9f57-cc9061230585"
      unitRef="U_EUR">659131000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_01c5733b-885c-4258-93f7-5001781baef3"
      unitRef="U_EUR">931527000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="-3"
      id="F_f4a73b18-07f0-4391-9145-030b1f7b6fb2"
      unitRef="U_EUR">882127000</ifrs-full:FinancialLiabilities>
    <ifrs-full:NotionalAmount
      contextRef="C_ee64b1a5-0ac7-4bae-bf54-7e5e49b1964e"
      decimals="-5"
      id="F_026ff4f7-b73e-4ac6-a80e-0b25e6ada46f"
      unitRef="U_USD">575000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="C_c5bb9cca-7e70-46d1-a292-8e9d545f5c33"
      decimals="4"
      id="F_c5e445f1-6b2b-4ad6-95d5-400dc26df798"
      unitRef="U_pure">0.0225</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures
      contextRef="C_b1cd9cb9-4b1b-4fea-bbde-9d3bc31d8f4d"
      decimals="-5"
      id="F_377dc136-56a4-4b83-a2fb-038a24573caf"
      unitRef="U_USD">557900000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures
      contextRef="C_b1cd9cb9-4b1b-4fea-bbde-9d3bc31d8f4d"
      decimals="-5"
      id="F_bdce358e-42af-4d1e-ad60-39247daaad83"
      unitRef="U_EUR">503300000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <ifrs-full:BorrowingsMaturity
      contextRef="C_b1cd9cb9-4b1b-4fea-bbde-9d3bc31d8f4d"
      id="F_2e987b0c-67f8-4a2b-8862-d2f512e68cf7">April 1, 2028</ifrs-full:BorrowingsMaturity>
    <ifrs-full:BorrowingsInterestRate
      contextRef="C_120df43c-ac40-4949-bdf1-72d7e1be8540"
      decimals="4"
      id="F_4c3da444-10ca-4fe6-bbc0-e7c48fcae9f0"
      unitRef="U_pure">0.0225</ifrs-full:BorrowingsInterestRate>
    <asnd:ConversionRatePerNote
      contextRef="C_fc29bc9d-a605-4ae9-bbea-0edd6dc89dde"
      decimals="4"
      id="F_a8c864b5-e48a-4513-8605-1d4a466cb264"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.0118</asnd:ConversionRatePerNote>
    <ifrs-full:NotionalAmount
      contextRef="C_276506bc-fed9-44d5-bde0-317663083ca8"
      decimals="0"
      id="F_63da02c9-9f54-4b13-a197-1f33c3673b41"
      unitRef="U_USD">1000</ifrs-full:NotionalAmount>
    <asnd:ConversionPricePerShare
      contextRef="C_26726fd6-ee62-4142-bc95-a08f61caedc3"
      decimals="2"
      id="F_0440487c-1dff-4969-a0c2-0acb743b0fa9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">166.34</asnd:ConversionPricePerShare>
    <asnd:BorrowingsRedemptionPeriod
      contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405"
      id="F_62f47ea8-6a0c-42d4-8f60-79f2a5f506ce">April 7, 2025</asnd:BorrowingsRedemptionPeriod>
    <asnd:BorrowingsConditionForRedemption
      contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405"
      id="F_10248c2d-7a2d-4a68-b3c9-de8ee346faac">but only if the last reported sale price per ADS exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.</asnd:BorrowingsConditionForRedemption>
    <asnd:BorrowingsThresholdPercentageOfSalePricePerShareForRedemption
      contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405"
      decimals="2"
      id="F_f3267a1a-51e2-4cc8-aaff-4602ba9a20be"
      unitRef="U_pure">1.30</asnd:BorrowingsThresholdPercentageOfSalePricePerShareForRedemption>
    <asnd:BorrowingsThresholdTradingDaysForRedemption
      contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405"
      decimals="0"
      id="F_22f058de-d9e7-4ae1-ad5e-70eb56ebc18e"
      unitRef="U_Days">20</asnd:BorrowingsThresholdTradingDaysForRedemption>
    <asnd:BorrowingsThresholdConsecutiveTradingDaysForRedemption
      contextRef="C_7c55eeb6-4f32-446b-889f-4e47524ee405"
      decimals="0"
      id="F_06e0a776-7e30-4e33-b623-c68251aba831"
      unitRef="U_Agreement">30</asnd:BorrowingsThresholdConsecutiveTradingDaysForRedemption>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-5"
      id="F_fe231fb8-d28a-43bb-8743-79046dfb9e53"
      unitRef="U_EUR">432200000</asnd:ConvertibleSeniorNotes>
    <asnd:FairValueOfConvertibleNotes
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-5"
      id="F_0f09f721-8021-4145-95a4-651e0df06cc5"
      unitRef="U_EUR">412100000</asnd:FairValueOfConvertibleNotes>
    <asnd:FundingReceivedInExchangeOfRoyaltyPayments
      contextRef="C_b41da24d-bd30-42f4-a704-1d5714f18704"
      decimals="-5"
      id="F_ae853543-53eb-40f4-a661-4a8d3665ff8c"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchangeOfRoyaltyPayments>
    <asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses
      contextRef="C_8ef04b98-f458-48b5-892e-fb3c6e17fd2b"
      decimals="-5"
      id="F_d03ad2f9-9742-4e25-ad61-0b4cec2e670b"
      unitRef="U_USD">146300000</asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses>
    <asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses
      contextRef="C_8ef04b98-f458-48b5-892e-fb3c6e17fd2b"
      decimals="-5"
      id="F_87e7ece2-69cc-4e8b-84ac-98f2deb39dc4"
      unitRef="U_EUR">136300000</asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses>
    <asnd:FundingReceivedInExchange
      contextRef="C_82679e63-57f7-42c8-af63-f3c54a3a76ef"
      decimals="-5"
      id="F_5cb347ac-9dc0-4c11-bfaf-86717e875c9c"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchange>
    <asnd:ExchangeRateForPercentageOfRevenueToRoyaltyPayment
      contextRef="C_82679e63-57f7-42c8-af63-f3c54a3a76ef"
      decimals="4"
      id="F_ed3d6b36-2643-46ab-b8c5-bf5abeba26bd"
      unitRef="U_pure">0.0915</asnd:ExchangeRateForPercentageOfRevenueToRoyaltyPayment>
    <asnd:RoyaltyPaymentBeginningPeriod
      contextRef="C_82679e63-57f7-42c8-af63-f3c54a3a76ef"
      id="F_70317e4b-0935-4475-8e25-712fd9cb4615">2025-01-01</asnd:RoyaltyPaymentBeginningPeriod>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_b5bd486e-1131-4c51-9d6b-ba25b8052be8"
      decimals="3"
      id="F_e05785d9-338d-41a8-af3c-86071fce475b"
      unitRef="U_Multiple">1.925</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_dff101ac-1dfc-4e89-bbe4-f6d1091007b7"
      decimals="2"
      id="F_efd0b992-588e-4c86-9f2f-d0c4bfb2016e"
      unitRef="U_Multiple">1.65</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:RoyaltyPaymentEndingPeriod
      contextRef="C_b41da24d-bd30-42f4-a704-1d5714f18704"
      id="F_44f57d4b-43c0-4930-bb02-4aa9c56f597c">2031-12-31</asnd:RoyaltyPaymentEndingPeriod>
    <asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount
      contextRef="C_e6982966-8271-4e1c-b818-503cfb91de1c"
      decimals="3"
      id="F_9ae44f1f-be9f-4a2a-ab50-a9c6cb56949c"
      unitRef="U_XBB">1.925</asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount>
    <asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount
      contextRef="C_e6982966-8271-4e1c-b818-503cfb91de1c"
      decimals="2"
      id="F_af6c6bd8-1287-4577-8175-92372ab28383"
      unitRef="U_XBB">1.65</asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount>
    <asnd:CarryingAmountOfRoyaltyFundingLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-5"
      id="F_042612f6-e227-4306-a9dc-90b610deaca9"
      unitRef="U_EUR">144500000</asnd:CarryingAmountOfRoyaltyFundingLiabilities>
    <asnd:FairValueOfRoyaltyFundingLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-5"
      id="F_583336e0-ccc0-4599-97cd-40d3090057df"
      unitRef="U_EUR">147300000</asnd:FairValueOfRoyaltyFundingLiabilities>
    <asnd:SharePriceAppliedForValuation
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="INF"
      id="F_838b9f50-3903-4d7c-bc6b-c7bc62fd1190"
      unitRef="U_EurPerShare">49.89</asnd:SharePriceAppliedForValuation>
    <asnd:SharePriceAppliedForValuation
      contextRef="C_f6bc3126-0f2f-41e1-af3d-24f995e53242"
      decimals="INF"
      id="F_a08c5e72-fd2d-4726-a809-9a7be69ddce3"
      unitRef="U_EurPerShare">50.47</asnd:SharePriceAppliedForValuation>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="C_0d721657-d4bf-491a-b07d-d4d0a337317b"
      decimals="2"
      id="F_3cbd6228-982e-46cb-8731-b74247be4f72"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue
      contextRef="C_4c6f70b1-9efa-4bae-96b1-ae13a04d5ec3"
      decimals="-5"
      id="F_7e4da763-af5d-4159-a73c-b60ec8f95ba3"
      unitRef="U_EUR">15200000</asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="C_0d721657-d4bf-491a-b07d-d4d0a337317b"
      decimals="2"
      id="F_82f45fb9-fe32-4b89-a74c-0d8fd2cf8a3e"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="C_70a9c3db-ba5b-4b53-9757-db806da4769e"
      decimals="2"
      id="F_20fb71f4-2e3a-44e6-96c9-a144a8bbca15"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue
      contextRef="C_60e20bc2-5206-4d1b-b79b-82ec729f7143"
      decimals="-5"
      id="F_e8b67f61-e61e-4204-aabf-b197c6d360cd"
      unitRef="U_EUR">30500000</asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="C_70a9c3db-ba5b-4b53-9757-db806da4769e"
      decimals="2"
      id="F_7bc7cf52-3a39-4d3c-8ba8-ff1ef2e2920f"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_da445236-dd8f-4b3b-ad42-f9607c89c45f">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.8%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.08%;"&gt;&lt;/td&gt;
        &lt;td style="width:9.96%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="3" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Fair value level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="7" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(1-3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;7,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;7,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;7,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;432,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;412,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;407,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;385,410&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;144,547&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;147,345&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;138,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;576,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;559,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;545,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;529,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="text-indent:25pt;vertical-align:bottom;"&gt;&lt;p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock>
    <asnd:MarketableSecuritiesExplanatory
      contextRef="C_d75b971a-1f5c-45c3-9cf0-b42af670311f"
      decimals="-3"
      id="F_dcaeb48a-9f24-4dbb-80a6-c4d5ce3effa6"
      unitRef="U_EUR">7275000</asnd:MarketableSecuritiesExplanatory>
    <asnd:MarketableSecuritiesExplanatory
      contextRef="C_b3eeeb63-6bc6-460d-8c2e-19abe3bd08c0"
      decimals="-3"
      id="F_bdff43d4-b0f2-4814-9659-599ef7d01520"
      unitRef="U_EUR">7266000</asnd:MarketableSecuritiesExplanatory>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_756073fe-efcc-4ad7-914c-18bd04b9013e"
      decimals="-3"
      id="F_9ec8e1d1-4212-435c-9d83-2e8c5dc91482"
      unitRef="U_EUR">7275000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_d4d49cb8-932e-432f-a338-771c043ea715"
      decimals="-3"
      id="F_73e985e6-b789-4ada-b5c2-452f68028031"
      unitRef="U_EUR">7266000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_916a1d45-ad20-4d5e-8c65-dfd11d9b937b"
      decimals="-3"
      id="F_eb948724-06b2-402c-b582-96b022e45522"
      unitRef="U_EUR">432190000</asnd:ConvertibleSeniorNotes>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_24e1c394-8155-4ccd-9e4a-59d9e1ec986d"
      decimals="-3"
      id="F_421770e5-a7b0-451a-8372-1afa8b1099b2"
      unitRef="U_EUR">412122000</asnd:ConvertibleSeniorNotes>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_b1459f92-4bdf-48d9-b032-4c65da483b6d"
      decimals="-3"
      id="F_24cbc5b7-4e94-4247-a12a-71e1ca54cf76"
      unitRef="U_EUR">407095000</asnd:ConvertibleSeniorNotes>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_d9e73adc-e2fa-4a69-a5e0-c417bc7c2b6e"
      decimals="-3"
      id="F_9c3beec9-e4d3-4a80-a0d6-44cdcea61021"
      unitRef="U_EUR">385410000</asnd:ConvertibleSeniorNotes>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_916a1d45-ad20-4d5e-8c65-dfd11d9b937b"
      decimals="-3"
      id="F_eb94babb-ad21-471a-a35c-124935818df0"
      unitRef="U_EUR">144547000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_24e1c394-8155-4ccd-9e4a-59d9e1ec986d"
      decimals="-3"
      id="F_43619246-3d33-4dc9-be77-c9d7588eaf11"
      unitRef="U_EUR">147345000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_b1459f92-4bdf-48d9-b032-4c65da483b6d"
      decimals="-3"
      id="F_9d8739f2-0b82-458b-97f8-c2058a3a87c3"
      unitRef="U_EUR">138377000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_d9e73adc-e2fa-4a69-a5e0-c417bc7c2b6e"
      decimals="-3"
      id="F_192d5df5-93a5-4f69-8528-be6e03d13473"
      unitRef="U_EUR">143975000</asnd:RoyaltyFundingLiabilities>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_9a1ee37c-f52e-4fe7-a481-ffe9c8b8f6b1"
      decimals="-3"
      id="F_bc3fcf19-4a96-4f0a-b92f-a049d6bc04a8"
      unitRef="U_EUR">576737000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_0eaa7d1b-df57-4e29-a988-3e72ff479760"
      decimals="-3"
      id="F_a614f6ae-1af8-4283-adf4-27cee6b20161"
      unitRef="U_EUR">559467000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_756073fe-efcc-4ad7-914c-18bd04b9013e"
      decimals="-3"
      id="F_c7deea54-3af8-400e-b177-5899b5fca295"
      unitRef="U_EUR">545472000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_d4d49cb8-932e-432f-a338-771c043ea715"
      decimals="-3"
      id="F_cb2119bf-147c-44b7-8a0d-760ca357685b"
      unitRef="U_EUR">529385000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_916a1d45-ad20-4d5e-8c65-dfd11d9b937b"
      decimals="-3"
      id="F_6df4096f-b916-4a1c-b01a-c82888942fda"
      unitRef="U_EUR">159059000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_24e1c394-8155-4ccd-9e4a-59d9e1ec986d"
      decimals="-3"
      id="F_3d1a78c5-d607-4a3f-999f-2d47e05dc1d9"
      unitRef="U_EUR">159059000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_b1459f92-4bdf-48d9-b032-4c65da483b6d"
      decimals="-3"
      id="F_c692ff1d-3666-4e77-8a06-29d3d5b5e9b0"
      unitRef="U_EUR">143296000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_d9e73adc-e2fa-4a69-a5e0-c417bc7c2b6e"
      decimals="-3"
      id="F_05a30498-7f46-4868-b545-ec889d61bc4c"
      unitRef="U_EUR">143296000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_9a1ee37c-f52e-4fe7-a481-ffe9c8b8f6b1"
      decimals="-3"
      id="F_c2f362ce-60da-4a4a-89fb-41c2d387e144"
      unitRef="U_EUR">159059000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_0eaa7d1b-df57-4e29-a988-3e72ff479760"
      decimals="-3"
      id="F_602e7ae4-5879-4ef1-847e-a14b07d05b84"
      unitRef="U_EUR">159059000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_756073fe-efcc-4ad7-914c-18bd04b9013e"
      decimals="-3"
      id="F_bccf65c0-096f-4f27-9447-86daa600e374"
      unitRef="U_EUR">143296000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_d4d49cb8-932e-432f-a338-771c043ea715"
      decimals="-3"
      id="F_1f7b7d92-672d-4a8b-9d85-2cdc636bd9b3"
      unitRef="U_EUR">143296000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_66a12e92-d402-4f51-9e5f-b5ce5925f2e1">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table specifies movements in level 3 fair value measurements:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.967%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1.16%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:13.357%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;157,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Remeasurement recognized in finance (income) or expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;15,763&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;71,565&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;159,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;86,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_84865da0-8e28-4c64-b919-2fa941621732"
      decimals="-3"
      id="F_057a4418-ebfc-467e-870f-1aca9e5d651a"
      unitRef="U_EUR">143296000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_4bfef56a-6c92-4668-b539-a03819e7ccb0"
      decimals="-3"
      id="F_7ca808c0-a9d7-49da-9fe4-0cf68ce7a9e0"
      unitRef="U_EUR">157950000</ifrs-full:DerivativeFinancialLiabilities>
    <asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense
      contextRef="C_cff9af56-3621-49bb-95fa-62e774a90dc9"
      decimals="-3"
      id="F_209993cc-b612-4b18-97d3-6cf1bf784ba1"
      unitRef="U_EUR">15763000</asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense>
    <asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense
      contextRef="C_7f8c7ce5-86c4-4f44-b5a8-e85f28bd20e0"
      decimals="-3"
      id="F_2636cb5a-1b60-4878-9678-b76e5b2078bc"
      unitRef="U_EUR">-71565000</asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_59fa5ae0-47b2-46af-9d0c-e8a4358f7f81"
      decimals="-3"
      id="F_5c2020e5-0a8c-4632-86aa-f3dfce8b71c1"
      unitRef="U_EUR">159059000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_44cab9aa-2fd6-48de-9166-d81f187ddff5"
      decimals="-3"
      id="F_4615756f-e294-44a5-a020-ca4ef6a5c5dd"
      unitRef="U_EUR">86385000</ifrs-full:DerivativeFinancialLiabilities>
    <asnd:MaturityAnalysisForFinancialLiabilitiesTextBlock
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_66065812-b64b-4b44-8225-c2f882e45d41">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the unaudited condensed consolidated statements of financial position at &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;.&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.04%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
        &lt;td style="width:8.42%;"&gt;&lt;/td&gt;
        &lt;td style="width:1%;"&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&amp;lt; 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1-5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;&amp;gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total&lt;br/&gt;contractual&lt;br/&gt;cash-flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="18" style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
        &lt;td style="vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;18,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;759,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;38,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;816,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;576,737&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;14,802&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;51,632&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;44,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;110,746&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;95,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;Trade payables, accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;99,829&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;133,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;810,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;83,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;1,027,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"&gt;772,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</asnd:MaturityAnalysisForFinancialLiabilitiesTextBlock>
    <ifrs-full:Borrowings
      contextRef="C_a74af470-e599-4a1e-b963-cdf93c8f8ad0"
      decimals="-3"
      id="F_db7f052e-1be1-445e-8dfa-e46320ed4609"
      unitRef="U_EUR">18902000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_d4a58637-2055-42b3-8157-1d28bda0cf03"
      decimals="-3"
      id="F_402fda8f-b1d1-48d2-aec9-ef02e267f202"
      unitRef="U_EUR">759073000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_0566eec3-61b9-4678-9b3a-a122291dbee2"
      decimals="-3"
      id="F_51c4eb81-373d-4cfe-b344-bc05836ac77e"
      unitRef="U_EUR">38700000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_0362f06b-2086-4374-a52b-969fb5d6c252"
      unitRef="U_EUR">816675000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb"
      decimals="-3"
      id="F_d88bb79d-5c76-48d2-a5b7-06960895214a"
      unitRef="U_EUR">576737000</ifrs-full:Borrowings>
    <ifrs-full:LeaseLiabilities
      contextRef="C_a74af470-e599-4a1e-b963-cdf93c8f8ad0"
      decimals="-3"
      id="F_d028ae51-7016-454f-bf58-cf762bc37f79"
      unitRef="U_EUR">14802000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_d4a58637-2055-42b3-8157-1d28bda0cf03"
      decimals="-3"
      id="F_0469068d-c1f2-4182-a236-6ce375a4e06d"
      unitRef="U_EUR">51632000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_0566eec3-61b9-4678-9b3a-a122291dbee2"
      decimals="-3"
      id="F_ba1fb194-a04b-41f3-8a8c-a5a0cfce1879"
      unitRef="U_EUR">44312000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_116e09fe-ce08-4110-916e-b1b32f3f2927"
      unitRef="U_EUR">110746000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb"
      decimals="-3"
      id="F_722c6cf1-6afa-44b2-9ca4-5282d859acc1"
      unitRef="U_EUR">95902000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_a74af470-e599-4a1e-b963-cdf93c8f8ad0"
      decimals="-3"
      id="F_9c29c396-b5d7-4a52-8ace-ef0b601c8d31"
      unitRef="U_EUR">99829000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_d4a58637-2055-42b3-8157-1d28bda0cf03"
      decimals="-3"
      id="F_8ea05236-b6c8-44fb-9d07-87244d30ba29"
      unitRef="U_EUR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_0566eec3-61b9-4678-9b3a-a122291dbee2"
      decimals="-3"
      id="F_d1aacdf8-23ef-4c40-b1b1-e955b6967b5f"
      unitRef="U_EUR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_069a0d85-da9f-408c-9ad8-704d7bf7180f"
      unitRef="U_EUR">99829000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb"
      decimals="-3"
      id="F_1a6c844f-93e9-432d-86ea-5e44512d16ba"
      unitRef="U_EUR">99829000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:FinancialLiabilities
      contextRef="C_a74af470-e599-4a1e-b963-cdf93c8f8ad0"
      decimals="-3"
      id="F_a8d43160-e5bc-413b-9565-b06d25826373"
      unitRef="U_EUR">133533000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_d4a58637-2055-42b3-8157-1d28bda0cf03"
      decimals="-3"
      id="F_b76ca1ef-2f0d-4ed7-865f-372d9ff70344"
      unitRef="U_EUR">810705000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_0566eec3-61b9-4678-9b3a-a122291dbee2"
      decimals="-3"
      id="F_f0a242aa-e68e-4092-b04c-233bd8698f46"
      unitRef="U_EUR">83012000</ifrs-full:FinancialLiabilities>
    <asnd:ContractualUndiscountedCashflowOfFinancialLiabilities
      contextRef="C_cf8bec94-85c6-4446-9f8d-25c797b23040"
      decimals="-3"
      id="F_45873b33-f3b9-447a-8855-094e046bba02"
      unitRef="U_EUR">1027250000</asnd:ContractualUndiscountedCashflowOfFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_0cea65b1-8e2e-4700-abec-c50d25040dcb"
      decimals="-3"
      id="F_53a1d97d-24d2-4068-b93c-cfbf40c36ae0"
      unitRef="U_EUR">772468000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="C_5a88bcad-ece2-4420-8531-9e5bb79e8880"
      id="F_b5702332-9da7-440b-b26a-919982b71fec">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;Note 11&#x2014;Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;In September 2024, the Company entered into a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million capped synthetic royalty funding agreement (the &#x201c;Yorvipath Agreement&#x201d;) with Royalty Pharma (the &#x201c;Purchaser&#x201d;). Under the terms of the Yorvipath Agreement, Purchaser has agreed to provide the Company an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;150&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt; million (the &#x201c;Purchase Amount&#x201d;) in exchange for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;% royalty on net U.S. YORVIPATH revenue (the &#x201c;Royalty Payments&#x201d;). The Royalty Payments to the Purchaser will cease upon reaching a multiple of the Purchase Amount of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;x, or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;x if the Purchaser receives royalties in that amount by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;December 31, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;. The Yorvipath Agreement includes certain buy-out options under various terms and conditions.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"&gt;No other events have occurred after the balance sheet date that would influence the evaluation of these unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <asnd:FundingReceivedInExchangeOfRoyaltyPayments
      contextRef="C_d66908c6-a5fa-467c-9047-36af0a5ab839"
      decimals="-6"
      id="F_28d2d5fb-ea93-46c6-96b7-23d17824b2d4"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchangeOfRoyaltyPayments>
    <asnd:FundingReceivedInExchange
      contextRef="C_b1b4d1e4-24f6-4c89-914e-0c15eb61bcdc"
      decimals="-6"
      id="F_65032f9c-bb84-450a-9330-bd1fef8606cb"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchange>
    <asnd:ExchangeRateForPercentageOfRevenueToRoyaltyPayment
      contextRef="C_b1b4d1e4-24f6-4c89-914e-0c15eb61bcdc"
      decimals="2"
      id="F_e50e6447-1b45-44b8-98ce-dfbfb196ba48"
      unitRef="U_pure">0.03</asnd:ExchangeRateForPercentageOfRevenueToRoyaltyPayment>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_bd7c5f8f-6386-4bcb-a667-86ed3c7b0c33"
      decimals="1"
      id="F_c8c0f6ef-c6cd-405a-b8fe-dba7b7607061"
      unitRef="U_Multiple">2</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_567228fa-89e0-4f5f-91c5-10eec549d109"
      decimals="2"
      id="F_f458af5d-5c70-44c3-880d-0a40dbc5bf30"
      unitRef="U_Multiple">1.65</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:RoyaltyPaymentEndingPeriod
      contextRef="C_d66908c6-a5fa-467c-9047-36af0a5ab839"
      id="F_ee1c405c-8ffc-4356-a23d-4eb010f5ca0c">2029-12-31</asnd:RoyaltyPaymentEndingPeriod>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_5b333498-0653-46a4-872f-fc79e7006884"
          xlink:label="F_5b333498-0653-46a4-872f-fc79e7006884"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_524f7c83-ae41-47ce-8c40-f85ecc391045"
          xlink:label="F_524f7c83-ae41-47ce-8c40-f85ecc391045"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8a589942-865c-4e8d-8663-eb005469b812"
          xlink:label="F_8a589942-865c-4e8d-8663-eb005469b812"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_084333b3-53b3-4ef1-99d1-28a4da53ed19"
          xlink:label="F_084333b3-53b3-4ef1-99d1-28a4da53ed19"
          xlink:type="locator"/>
        <link:footnote id="FNT_13751f10-8ccb-4870-982f-e026f2425cce" xlink:label="FNT_13751f10-8ccb-4870-982f-e026f2425cce" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">As of </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">June 30, 2024 and June 30, 2023, a total of </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,107,875</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> and </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">6,866,241</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> warrants outstanding, respectively, each carrying the right to subscribe for one ordinary share, and </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">575,000</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> convertible senior notes which can potentially be converted into </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">3,456,785</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;"> ordinary shares, can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the periods presented. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5b333498-0653-46a4-872f-fc79e7006884"
          xlink:to="FNT_13751f10-8ccb-4870-982f-e026f2425cce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_524f7c83-ae41-47ce-8c40-f85ecc391045"
          xlink:to="FNT_13751f10-8ccb-4870-982f-e026f2425cce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8a589942-865c-4e8d-8663-eb005469b812"
          xlink:to="FNT_13751f10-8ccb-4870-982f-e026f2425cce"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_084333b3-53b3-4ef1-99d1-28a4da53ed19"
          xlink:to="FNT_13751f10-8ccb-4870-982f-e026f2425cce"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
